bio-datasets/bigbio-ner-merged · Datasets at Hugging Face

answer stringlengths 1 16.1k	id stringlengths 7 56	instruction stringlengths 106 72.6k	ner_tags list	text stringlengths 5 72.4k	tokens list	types list
Praevalenzraten, Praevalenzraten, Faehigkeiten, Testleistungen, Einkommensniveau	DerNervenarzt.80690975.ger.abstr_task2	Sentence: Mit dem Terminus " leichte kognitive Beeintraechtigung im Alter " werden kognitive Defizite bezeichnet , die ueber normale Altersbegleiterscheinungen hinausgehen , aber nicht an den Schweregrad einer dementiellen Erkrankung heranreichen . Anhand der Daten von 202 gesunden 60- bis 64jaehrigen Teilnehmern der Interdisziplinaeren Langzeitstudie fuer Erwachsene ( ILSE ) wurden die Praevalenzraten von 4 aktuellen Konzepten der leichten kognitiven Beeintraechtigung verglichen sowie Zusammenhaenge mit moeglichen soziodemographischen und psychologischen Merkmalen untersucht . Die Praevalenzraten betrugen fuer age-associated memory impairment " " 13,5% , fuer age-consistent memory impairment " " 6,5% , fuer late-life forgetfulness " 1,5% " und fuer aging associated cognitive decline " 23,5% . " Es fand sich kein Zusammenhang zwischen den subjektiven Angaben ueber nachlassende kognitive Faehigkeiten und den Ergebnissen der neuropsychologischen Testungen . Dagegen bestanden Zusammenhaenge zwischen subjektiven Beschwerden und psychologischen Variablen wie Depressivitaet und Neurotizismus sowie zwischen niedrigeren Testleistungen und soziodemographischen Variablen wie geringerem Bildungsgrad und Einkommensniveau . Der praediktive Wert der hier untersuchten Konzepte kann erst durch Langzeitstudien definitiv beurteilt werden . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Mit dem Terminus " leichte kognitive Beeintraechtigung im Alter " werden kognitive Defizite bezeichnet , die ueber normale Altersbegleiterscheinungen hinausgehen , aber nicht an den Schweregrad einer dementiellen Erkrankung heranreichen . Anhand der Daten von 202 gesunden 60- bis 64jaehrigen Teilnehmern der Interdisziplinaeren Langzeitstudie fuer Erwachsene ( ILSE ) wurden die Praevalenzraten von 4 aktuellen Konzepten der leichten kognitiven Beeintraechtigung verglichen sowie Zusammenhaenge mit moeglichen soziodemographischen und psychologischen Merkmalen untersucht . Die Praevalenzraten betrugen fuer age-associated memory impairment " " 13,5% , fuer age-consistent memory impairment " " 6,5% , fuer late-life forgetfulness " 1,5% " und fuer aging associated cognitive decline " 23,5% . " Es fand sich kein Zusammenhang zwischen den subjektiven Angaben ueber nachlassende kognitive Faehigkeiten und den Ergebnissen der neuropsychologischen Testungen . Dagegen bestanden Zusammenhaenge zwischen subjektiven Beschwerden und psychologischen Variablen wie Depressivitaet und Neurotizismus sowie zwischen niedrigeren Testleistungen und soziodemographischen Variablen wie geringerem Bildungsgrad und Einkommensniveau . Der praediktive Wert der hier untersuchten Konzepte kann erst durch Langzeitstudien definitiv beurteilt werden .	[ "Mit", "dem", "Terminus", "\"", "leichte", "kognitive", "Beeintraechtigung", "im", "Alter", "\"", "werden", "kognitive", "Defizite", "bezeichnet", ",", "die", "ueber", "normale", "Altersbegleiterscheinungen", "hinausgehen", ",", "aber", "nicht", "an", "den", "Schweregrad", "einer", "dementiellen", "Erkrankung", "heranreichen", ".", "Anhand", "der", "Daten", "von", "202", "gesunden", "60-", "bis", "64jaehrigen", "Teilnehmern", "der", "Interdisziplinaeren", "Langzeitstudie", "fuer", "Erwachsene", "(", "ILSE", ")", "wurden", "die", "Praevalenzraten", "von", "4", "aktuellen", "Konzepten", "der", "leichten", "kognitiven", "Beeintraechtigung", "verglichen", "sowie", "Zusammenhaenge", "mit", "moeglichen", "soziodemographischen", "und", "psychologischen", "Merkmalen", "untersucht", ".", "Die", "Praevalenzraten", "betrugen", "fuer", "age", "-", "associated", "memory", "impairment", "\"", "\"", "13,5", "%", ",", "fuer", "age", "-", "consistent", "memory", "impairment", "\"", "\"", "6,5", "%", ",", "fuer", "late", "-", "life", "forgetfulness", "\"", "1,5", "%", "\"", "und", "fuer", "aging", "associated", "cognitive", "decline", "\"", "23,5", "%", ".", "\"", "Es", "fand", "sich", "kein", "Zusammenhang", "zwischen", "den", "subjektiven", "Angaben", "ueber", "nachlassende", "kognitive", "Faehigkeiten", "und", "den", "Ergebnissen", "der", "neuropsychologischen", "Testungen", ".", "Dagegen", "bestanden", "Zusammenhaenge", "zwischen", "subjektiven", "Beschwerden", "und", "psychologischen", "Variablen", "wie", "Depressivitaet", "und", "Neurotizismus", "sowie", "zwischen", "niedrigeren", "Testleistungen", "und", "soziodemographischen", "Variablen", "wie", "geringerem", "Bildungsgrad", "und", "Einkommensniveau", ".", "Der", "praediktive", "Wert", "der", "hier", "untersuchten", "Konzepte", "kann", "erst", "durch", "Langzeitstudien", "definitiv", "beurteilt", "werden", "." ]	[ "umlsterm" ]
measurements is an umlsterm, hemoglobin is an umlsterm, oxygenation is an umlsterm, human is an umlsterm, cochlea is an umlsterm, round window is an umlsterm, membrane is an umlsterm, aim is an umlsterm, microlight is an umlsterm, measurements is an umlsterm, round window is an umlsterm, procedure is an umlsterm, cochlea is an umlsterm	HNO.70450372.eng.abstr_task0	Sentence: Background : Intraoperative measurements of local intracapillary hemoglobin oxygenation of the human cochlea via the round window membrane have been shown to be possible using the Erlangen microlight-guided spectrophotometer . The aim of the present study was to develop a new microlight guide suitable for measurements in the round window niche and to evaluate electrophysiologically the possible impact of the procedure on the cochlea . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]	Background : Intraoperative measurements of local intracapillary hemoglobin oxygenation of the human cochlea via the round window membrane have been shown to be possible using the Erlangen microlight-guided spectrophotometer . The aim of the present study was to develop a new microlight guide suitable for measurements in the round window niche and to evaluate electrophysiologically the possible impact of the procedure on the cochlea .	[ "Background", ":", "Intraoperative", "measurements", "of", "local", "intracapillary", "hemoglobin", "oxygenation", "of", "the", "human", "cochlea", "via", "the", "round", "window", "membrane", "have", "been", "shown", "to", "be", "possible", "using", "the", "Erlangen", "microlight", "-", "guided", "spectrophotometer", ".", "The", "aim", "of", "the", "present", "study", "was", "to", "develop", "a", "new", "microlight", "guide", "suitable", "for", "measurements", "in", "the", "round", "window", "niche", "and", "to", "evaluate", "electrophysiologically", "the", "possible", "impact", "of", "the", "procedure", "on", "the", "cochlea", "." ]	[ "umlsterm" ]
measurements is an umlsterm, hemoglobin is an umlsterm, oxygenation is an umlsterm, human is an umlsterm, cochlea is an umlsterm, round window is an umlsterm, membrane is an umlsterm, aim is an umlsterm, microlight is an umlsterm, measurements is an umlsterm, round window is an umlsterm, procedure is an umlsterm, cochlea is an umlsterm	HNO.70450372.eng.abstr_task1	Sentence: Background : Intraoperative measurements of local intracapillary hemoglobin oxygenation of the human cochlea via the round window membrane have been shown to be possible using the Erlangen microlight-guided spectrophotometer . The aim of the present study was to develop a new microlight guide suitable for measurements in the round window niche and to evaluate electrophysiologically the possible impact of the procedure on the cochlea . Instructions: please typing these entity words according to sentence: measurements, hemoglobin, oxygenation, human, cochlea, round window, membrane, aim, microlight, measurements, round window, procedure, cochlea Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]	Background : Intraoperative measurements of local intracapillary hemoglobin oxygenation of the human cochlea via the round window membrane have been shown to be possible using the Erlangen microlight-guided spectrophotometer . The aim of the present study was to develop a new microlight guide suitable for measurements in the round window niche and to evaluate electrophysiologically the possible impact of the procedure on the cochlea .	[ "Background", ":", "Intraoperative", "measurements", "of", "local", "intracapillary", "hemoglobin", "oxygenation", "of", "the", "human", "cochlea", "via", "the", "round", "window", "membrane", "have", "been", "shown", "to", "be", "possible", "using", "the", "Erlangen", "microlight", "-", "guided", "spectrophotometer", ".", "The", "aim", "of", "the", "present", "study", "was", "to", "develop", "a", "new", "microlight", "guide", "suitable", "for", "measurements", "in", "the", "round", "window", "niche", "and", "to", "evaluate", "electrophysiologically", "the", "possible", "impact", "of", "the", "procedure", "on", "the", "cochlea", "." ]	[ "umlsterm" ]
measurements, hemoglobin, oxygenation, human, cochlea, round window, membrane, aim, microlight, measurements, round window, procedure, cochlea	HNO.70450372.eng.abstr_task2	Sentence: Background : Intraoperative measurements of local intracapillary hemoglobin oxygenation of the human cochlea via the round window membrane have been shown to be possible using the Erlangen microlight-guided spectrophotometer . The aim of the present study was to develop a new microlight guide suitable for measurements in the round window niche and to evaluate electrophysiologically the possible impact of the procedure on the cochlea . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]	Background : Intraoperative measurements of local intracapillary hemoglobin oxygenation of the human cochlea via the round window membrane have been shown to be possible using the Erlangen microlight-guided spectrophotometer . The aim of the present study was to develop a new microlight guide suitable for measurements in the round window niche and to evaluate electrophysiologically the possible impact of the procedure on the cochlea .	[ "Background", ":", "Intraoperative", "measurements", "of", "local", "intracapillary", "hemoglobin", "oxygenation", "of", "the", "human", "cochlea", "via", "the", "round", "window", "membrane", "have", "been", "shown", "to", "be", "possible", "using", "the", "Erlangen", "microlight", "-", "guided", "spectrophotometer", ".", "The", "aim", "of", "the", "present", "study", "was", "to", "develop", "a", "new", "microlight", "guide", "suitable", "for", "measurements", "in", "the", "round", "window", "niche", "and", "to", "evaluate", "electrophysiologically", "the", "possible", "impact", "of", "the", "procedure", "on", "the", "cochlea", "." ]	[ "umlsterm" ]
mitogen - activated protein kinase pathways is an other_name, interleukin-8 production is an other_name, human monocytes is a cell_type, polymorphonuclear cells is a cell_type, lipopolysaccharide is a lipid, Mycoplasma fermentans membrane lipoproteins is a protein_family_or_group	52179_task0	Sentence: Involvement of mitogen-activated protein kinase pathways in interleukin-8 production by human monocytes and polymorphonuclear cells stimulated with lipopolysaccharide or Mycoplasma fermentans membrane lipoproteins. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_type, protein_family_or_group, lipid, other_name	[ "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "O", "B-cell_type", "I-cell_type", "O", "B-cell_type", "I-cell_type", "O", "O", "B-lipid", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O" ]	Involvement of mitogen-activated protein kinase pathways in interleukin-8 production by human monocytes and polymorphonuclear cells stimulated with lipopolysaccharide or Mycoplasma fermentans membrane lipoproteins.	[ "Involvement", "of", "mitogen", "-", "activated", "protein", "kinase", "pathways", "in", "interleukin-8", "production", "by", "human", "monocytes", "and", "polymorphonuclear", "cells", "stimulated", "with", "lipopolysaccharide", "or", "Mycoplasma", "fermentans", "membrane", "lipoproteins", "." ]	[ "protein_family_or_group", "other_name", "cell_line", "cell_type", "protein_molecule", "(AND other_name other_name)", "mono_cell", "other_organic_compound", "lipid", "" ]
mitogen - activated protein kinase pathways is an other_name, interleukin-8 production is an other_name, human monocytes is a cell_type, polymorphonuclear cells is a cell_type, lipopolysaccharide is a lipid, Mycoplasma fermentans membrane lipoproteins is a protein_family_or_group	52179_task1	Sentence: Involvement of mitogen-activated protein kinase pathways in interleukin-8 production by human monocytes and polymorphonuclear cells stimulated with lipopolysaccharide or Mycoplasma fermentans membrane lipoproteins. Instructions: please typing these entity words according to sentence: mitogen - activated protein kinase pathways, interleukin-8 production, human monocytes, polymorphonuclear cells, lipopolysaccharide, Mycoplasma fermentans membrane lipoproteins Options: cell_type, protein_family_or_group, lipid, other_name	[ "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "O", "B-cell_type", "I-cell_type", "O", "B-cell_type", "I-cell_type", "O", "O", "B-lipid", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O" ]	Involvement of mitogen-activated protein kinase pathways in interleukin-8 production by human monocytes and polymorphonuclear cells stimulated with lipopolysaccharide or Mycoplasma fermentans membrane lipoproteins.	[ "Involvement", "of", "mitogen", "-", "activated", "protein", "kinase", "pathways", "in", "interleukin-8", "production", "by", "human", "monocytes", "and", "polymorphonuclear", "cells", "stimulated", "with", "lipopolysaccharide", "or", "Mycoplasma", "fermentans", "membrane", "lipoproteins", "." ]	[ "protein_family_or_group", "other_name", "cell_line", "cell_type", "protein_molecule", "(AND other_name other_name)", "mono_cell", "other_organic_compound", "lipid", "" ]
mitogen - activated protein kinase pathways, interleukin-8 production, human monocytes, polymorphonuclear cells, lipopolysaccharide, Mycoplasma fermentans membrane lipoproteins	52179_task2	Sentence: Involvement of mitogen-activated protein kinase pathways in interleukin-8 production by human monocytes and polymorphonuclear cells stimulated with lipopolysaccharide or Mycoplasma fermentans membrane lipoproteins. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "O", "B-cell_type", "I-cell_type", "O", "B-cell_type", "I-cell_type", "O", "O", "B-lipid", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O" ]	Involvement of mitogen-activated protein kinase pathways in interleukin-8 production by human monocytes and polymorphonuclear cells stimulated with lipopolysaccharide or Mycoplasma fermentans membrane lipoproteins.	[ "Involvement", "of", "mitogen", "-", "activated", "protein", "kinase", "pathways", "in", "interleukin-8", "production", "by", "human", "monocytes", "and", "polymorphonuclear", "cells", "stimulated", "with", "lipopolysaccharide", "or", "Mycoplasma", "fermentans", "membrane", "lipoproteins", "." ]	[ "protein_family_or_group", "other_name", "cell_line", "cell_type", "protein_molecule", "(AND other_name other_name)", "mono_cell", "other_organic_compound", "lipid", "" ]
youth is a Participant_Age, autism spectrum disorders is a Participant_Condition, autism spectrum disorders ( ASD ) is a Participant_Condition, Project SEARCH plus ASD Supports is a Intervention_Other, employment outcomes is a Outcome_Mental, 18 - 21 is a Participant_Age, non - traditional jobs is a Outcome_Other, control is a Intervention_Control, 24 is a Participant_Sample-size, acquired employment is a Outcome_Mental, 16 is a Participant_Sample-size	60692_task0	Sentence: Competitive employment for youth with autism spectrum disorders : early results from a randomized clinical trial . For most youth with autism spectrum disorders ( ASD ) , employment upon graduation from high school or college is elusive . Employment rates are reported in many studies to be very low despite many years of intensive special education services . This paper presented the preliminary results of a randomized clinical trial of Project SEARCH plus ASD Supports on the employment outcomes for youth with ASD between the ages of 18-21 years of age . This model provides very promising results in that the employment outcomes for youth in the treatment group were much higher in non-traditional jobs with higher than minimum wage incomes than for youth in the control condition . Specifically , 21 out of 24 ( 87.5 % ) treatment group participants acquired employment while 1 of 16 ( 6.25 % ) of control group participants acquired employment . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Participant_Condition, Intervention_Control, Intervention_Other, Participant_Age, Participant_Sample-size, Outcome_Other, Outcome_Mental	[ "O", "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Competitive employment for youth with autism spectrum disorders : early results from a randomized clinical trial . For most youth with autism spectrum disorders ( ASD ) , employment upon graduation from high school or college is elusive . Employment rates are reported in many studies to be very low despite many years of intensive special education services . This paper presented the preliminary results of a randomized clinical trial of Project SEARCH plus ASD Supports on the employment outcomes for youth with ASD between the ages of 18-21 years of age . This model provides very promising results in that the employment outcomes for youth in the treatment group were much higher in non-traditional jobs with higher than minimum wage incomes than for youth in the control condition . Specifically , 21 out of 24 ( 87.5 % ) treatment group participants acquired employment while 1 of 16 ( 6.25 % ) of control group participants acquired employment .	[ "Competitive", "employment", "for", "youth", "with", "autism", "spectrum", "disorders", ":", "early", "results", "from", "a", "randomized", "clinical", "trial", ".", "For", "most", "youth", "with", "autism", "spectrum", "disorders", "(", "ASD", ")", ",", "employment", "upon", "graduation", "from", "high", "school", "or", "college", "is", "elusive", ".", "Employment", "rates", "are", "reported", "in", "many", "studies", "to", "be", "very", "low", "despite", "many", "years", "of", "intensive", "special", "education", "services", ".", "This", "paper", "presented", "the", "preliminary", "results", "of", "a", "randomized", "clinical", "trial", "of", "Project", "SEARCH", "plus", "ASD", "Supports", "on", "the", "employment", "outcomes", "for", "youth", "with", "ASD", "between", "the", "ages", "of", "18", "-", "21", "years", "of", "age", ".", "This", "model", "provides", "very", "promising", "results", "in", "that", "the", "employment", "outcomes", "for", "youth", "in", "the", "treatment", "group", "were", "much", "higher", "in", "non", "-", "traditional", "jobs", "with", "higher", "than", "minimum", "wage", "incomes", "than", "for", "youth", "in", "the", "control", "condition", ".", "Specifically", ",", "21", "out", "of", "24", "(", "87.5", "%", ")", "treatment", "group", "participants", "acquired", "employment", "while", "1", "of", "16", "(", "6.25", "%", ")", "of", "control", "group", "participants", "acquired", "employment", "." ]	[ "Participant_Condition", "Intervention_Other", "Outcome_Other", "Outcome_Mental", "Intervention_Control", "Participant_Age", "Participant_Sample-size" ]
youth is a Participant_Age, autism spectrum disorders is a Participant_Condition, autism spectrum disorders ( ASD ) is a Participant_Condition, Project SEARCH plus ASD Supports is a Intervention_Other, employment outcomes is a Outcome_Mental, 18 - 21 is a Participant_Age, non - traditional jobs is a Outcome_Other, control is a Intervention_Control, 24 is a Participant_Sample-size, acquired employment is a Outcome_Mental, 16 is a Participant_Sample-size	60692_task1	Sentence: Competitive employment for youth with autism spectrum disorders : early results from a randomized clinical trial . For most youth with autism spectrum disorders ( ASD ) , employment upon graduation from high school or college is elusive . Employment rates are reported in many studies to be very low despite many years of intensive special education services . This paper presented the preliminary results of a randomized clinical trial of Project SEARCH plus ASD Supports on the employment outcomes for youth with ASD between the ages of 18-21 years of age . This model provides very promising results in that the employment outcomes for youth in the treatment group were much higher in non-traditional jobs with higher than minimum wage incomes than for youth in the control condition . Specifically , 21 out of 24 ( 87.5 % ) treatment group participants acquired employment while 1 of 16 ( 6.25 % ) of control group participants acquired employment . Instructions: please typing these entity words according to sentence: youth, autism spectrum disorders, autism spectrum disorders ( ASD ), Project SEARCH plus ASD Supports, employment outcomes, 18 - 21, non - traditional jobs, control, 24, acquired employment, 16 Options: Participant_Condition, Intervention_Control, Intervention_Other, Participant_Age, Participant_Sample-size, Outcome_Other, Outcome_Mental	[ "O", "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Competitive employment for youth with autism spectrum disorders : early results from a randomized clinical trial . For most youth with autism spectrum disorders ( ASD ) , employment upon graduation from high school or college is elusive . Employment rates are reported in many studies to be very low despite many years of intensive special education services . This paper presented the preliminary results of a randomized clinical trial of Project SEARCH plus ASD Supports on the employment outcomes for youth with ASD between the ages of 18-21 years of age . This model provides very promising results in that the employment outcomes for youth in the treatment group were much higher in non-traditional jobs with higher than minimum wage incomes than for youth in the control condition . Specifically , 21 out of 24 ( 87.5 % ) treatment group participants acquired employment while 1 of 16 ( 6.25 % ) of control group participants acquired employment .	[ "Competitive", "employment", "for", "youth", "with", "autism", "spectrum", "disorders", ":", "early", "results", "from", "a", "randomized", "clinical", "trial", ".", "For", "most", "youth", "with", "autism", "spectrum", "disorders", "(", "ASD", ")", ",", "employment", "upon", "graduation", "from", "high", "school", "or", "college", "is", "elusive", ".", "Employment", "rates", "are", "reported", "in", "many", "studies", "to", "be", "very", "low", "despite", "many", "years", "of", "intensive", "special", "education", "services", ".", "This", "paper", "presented", "the", "preliminary", "results", "of", "a", "randomized", "clinical", "trial", "of", "Project", "SEARCH", "plus", "ASD", "Supports", "on", "the", "employment", "outcomes", "for", "youth", "with", "ASD", "between", "the", "ages", "of", "18", "-", "21", "years", "of", "age", ".", "This", "model", "provides", "very", "promising", "results", "in", "that", "the", "employment", "outcomes", "for", "youth", "in", "the", "treatment", "group", "were", "much", "higher", "in", "non", "-", "traditional", "jobs", "with", "higher", "than", "minimum", "wage", "incomes", "than", "for", "youth", "in", "the", "control", "condition", ".", "Specifically", ",", "21", "out", "of", "24", "(", "87.5", "%", ")", "treatment", "group", "participants", "acquired", "employment", "while", "1", "of", "16", "(", "6.25", "%", ")", "of", "control", "group", "participants", "acquired", "employment", "." ]	[ "Participant_Condition", "Intervention_Other", "Outcome_Other", "Outcome_Mental", "Intervention_Control", "Participant_Age", "Participant_Sample-size" ]
youth, autism spectrum disorders, autism spectrum disorders ( ASD ), Project SEARCH plus ASD Supports, employment outcomes, 18 - 21, non - traditional jobs, control, 24, acquired employment, 16	60692_task2	Sentence: Competitive employment for youth with autism spectrum disorders : early results from a randomized clinical trial . For most youth with autism spectrum disorders ( ASD ) , employment upon graduation from high school or college is elusive . Employment rates are reported in many studies to be very low despite many years of intensive special education services . This paper presented the preliminary results of a randomized clinical trial of Project SEARCH plus ASD Supports on the employment outcomes for youth with ASD between the ages of 18-21 years of age . This model provides very promising results in that the employment outcomes for youth in the treatment group were much higher in non-traditional jobs with higher than minimum wage incomes than for youth in the control condition . Specifically , 21 out of 24 ( 87.5 % ) treatment group participants acquired employment while 1 of 16 ( 6.25 % ) of control group participants acquired employment . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Competitive employment for youth with autism spectrum disorders : early results from a randomized clinical trial . For most youth with autism spectrum disorders ( ASD ) , employment upon graduation from high school or college is elusive . Employment rates are reported in many studies to be very low despite many years of intensive special education services . This paper presented the preliminary results of a randomized clinical trial of Project SEARCH plus ASD Supports on the employment outcomes for youth with ASD between the ages of 18-21 years of age . This model provides very promising results in that the employment outcomes for youth in the treatment group were much higher in non-traditional jobs with higher than minimum wage incomes than for youth in the control condition . Specifically , 21 out of 24 ( 87.5 % ) treatment group participants acquired employment while 1 of 16 ( 6.25 % ) of control group participants acquired employment .	[ "Competitive", "employment", "for", "youth", "with", "autism", "spectrum", "disorders", ":", "early", "results", "from", "a", "randomized", "clinical", "trial", ".", "For", "most", "youth", "with", "autism", "spectrum", "disorders", "(", "ASD", ")", ",", "employment", "upon", "graduation", "from", "high", "school", "or", "college", "is", "elusive", ".", "Employment", "rates", "are", "reported", "in", "many", "studies", "to", "be", "very", "low", "despite", "many", "years", "of", "intensive", "special", "education", "services", ".", "This", "paper", "presented", "the", "preliminary", "results", "of", "a", "randomized", "clinical", "trial", "of", "Project", "SEARCH", "plus", "ASD", "Supports", "on", "the", "employment", "outcomes", "for", "youth", "with", "ASD", "between", "the", "ages", "of", "18", "-", "21", "years", "of", "age", ".", "This", "model", "provides", "very", "promising", "results", "in", "that", "the", "employment", "outcomes", "for", "youth", "in", "the", "treatment", "group", "were", "much", "higher", "in", "non", "-", "traditional", "jobs", "with", "higher", "than", "minimum", "wage", "incomes", "than", "for", "youth", "in", "the", "control", "condition", ".", "Specifically", ",", "21", "out", "of", "24", "(", "87.5", "%", ")", "treatment", "group", "participants", "acquired", "employment", "while", "1", "of", "16", "(", "6.25", "%", ")", "of", "control", "group", "participants", "acquired", "employment", "." ]	[ "Participant_Condition", "Intervention_Other", "Outcome_Other", "Outcome_Mental", "Intervention_Control", "Participant_Age", "Participant_Sample-size" ]
Glutamine is a Amino_acid, glucose is a Simple_chemical, Ehrlich ascites tumour cells is a Cell, Ehrlich ascites tumour cells is a Cell, glucose is a Simple_chemical, glutamine is a Amino_acid, oxygen is a Simple_chemical, glutamine is a Amino_acid, glucose is a Simple_chemical, glucose is a Simple_chemical, glutamine is a Amino_acid, oxygen is a Simple_chemical, CO2 is a Simple_chemical, cytochromes is a Gene_or_gene_product, glucose is a Simple_chemical, Ehrlich ascites tumour cells is a Cell, Glucose is a Simple_chemical, glutamine is a Amino_acid	281_task0	Sentence: Glutamine and glucose as energy substrates for Ehrlich ascites tumour cells. Energy metabolism of freshly harvested Ehrlich ascites tumour cells in the presence of 5 mM glucose and/or 0.5 mM glutamine was studied. The rate of oxygen utilization was not altered by the addition of 0.5 mM glutamine; 5 mM glucose induced an inhibition of respiration. In the presence of both glucose and glutamine, the Crabtree effect decreased. In these conditions, the rates of oxygen uptake, the CO2 evolution and the changes in the redox states of cytochromes indicate that glucose is preferred by Ehrlich ascites tumour cells as energy substrate. Glucose decreased the rate of glutamine utilization by 34%. On the other hand, glutaminolysis did not inhibit glycolysis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Simple_chemical, Amino_acid, Gene_or_gene_product, Cell	[ "B-Amino_acid", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "B-Amino_acid", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Amino_acid", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Amino_acid", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Amino_acid", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Glutamine and glucose as energy substrates for Ehrlich ascites tumour cells. Energy metabolism of freshly harvested Ehrlich ascites tumour cells in the presence of 5 mM glucose and/or 0.5 mM glutamine was studied. The rate of oxygen utilization was not altered by the addition of 0.5 mM glutamine; 5 mM glucose induced an inhibition of respiration. In the presence of both glucose and glutamine, the Crabtree effect decreased. In these conditions, the rates of oxygen uptake, the CO2 evolution and the changes in the redox states of cytochromes indicate that glucose is preferred by Ehrlich ascites tumour cells as energy substrate. Glucose decreased the rate of glutamine utilization by 34%. On the other hand, glutaminolysis did not inhibit glycolysis.	[ "Glutamine", "and", "glucose", "as", "energy", "substrates", "for", "Ehrlich", "ascites", "tumour", "cells", ".", "\n", "Energy", "metabolism", "of", "freshly", "harvested", "Ehrlich", "ascites", "tumour", "cells", "in", "the", "presence", "of", "5", "mM", "glucose", "and", "/", "or", "0.5", "mM", "glutamine", "was", "studied", ".", "The", "rate", "of", "oxygen", "utilization", "was", "not", "altered", "by", "the", "addition", "of", "0.5", "mM", "glutamine", ";", "5", "mM", "glucose", "induced", "an", "inhibition", "of", "respiration", ".", "In", "the", "presence", "of", "both", "glucose", "and", "glutamine", ",", "the", "Crabtree", "effect", "decreased", ".", "In", "these", "conditions", ",", "the", "rates", "of", "oxygen", "uptake", ",", "the", "CO2", "evolution", "and", "the", "changes", "in", "the", "redox", "states", "of", "cytochromes", "indicate", "that", "glucose", "is", "preferred", "by", "Ehrlich", "ascites", "tumour", "cells", "as", "energy", "substrate", ".", "Glucose", "decreased", "the", "rate", "of", "glutamine", "utilization", "by", "34", "%", ".", "On", "the", "other", "hand", ",", "glutaminolysis", "did", "not", "inhibit", "glycolysis", ".", "\n" ]	[ "Cell", "Gene_or_gene_product", "Amino_acid", "Simple_chemical" ]
Glutamine is a Amino_acid, glucose is a Simple_chemical, Ehrlich ascites tumour cells is a Cell, Ehrlich ascites tumour cells is a Cell, glucose is a Simple_chemical, glutamine is a Amino_acid, oxygen is a Simple_chemical, glutamine is a Amino_acid, glucose is a Simple_chemical, glucose is a Simple_chemical, glutamine is a Amino_acid, oxygen is a Simple_chemical, CO2 is a Simple_chemical, cytochromes is a Gene_or_gene_product, glucose is a Simple_chemical, Ehrlich ascites tumour cells is a Cell, Glucose is a Simple_chemical, glutamine is a Amino_acid	281_task1	Sentence: Glutamine and glucose as energy substrates for Ehrlich ascites tumour cells. Energy metabolism of freshly harvested Ehrlich ascites tumour cells in the presence of 5 mM glucose and/or 0.5 mM glutamine was studied. The rate of oxygen utilization was not altered by the addition of 0.5 mM glutamine; 5 mM glucose induced an inhibition of respiration. In the presence of both glucose and glutamine, the Crabtree effect decreased. In these conditions, the rates of oxygen uptake, the CO2 evolution and the changes in the redox states of cytochromes indicate that glucose is preferred by Ehrlich ascites tumour cells as energy substrate. Glucose decreased the rate of glutamine utilization by 34%. On the other hand, glutaminolysis did not inhibit glycolysis. Instructions: please typing these entity words according to sentence: Glutamine, glucose, Ehrlich ascites tumour cells, Ehrlich ascites tumour cells, glucose, glutamine, oxygen, glutamine, glucose, glucose, glutamine, oxygen, CO2, cytochromes, glucose, Ehrlich ascites tumour cells, Glucose, glutamine Options: Simple_chemical, Amino_acid, Gene_or_gene_product, Cell	[ "B-Amino_acid", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "B-Amino_acid", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Amino_acid", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Amino_acid", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Amino_acid", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Glutamine and glucose as energy substrates for Ehrlich ascites tumour cells. Energy metabolism of freshly harvested Ehrlich ascites tumour cells in the presence of 5 mM glucose and/or 0.5 mM glutamine was studied. The rate of oxygen utilization was not altered by the addition of 0.5 mM glutamine; 5 mM glucose induced an inhibition of respiration. In the presence of both glucose and glutamine, the Crabtree effect decreased. In these conditions, the rates of oxygen uptake, the CO2 evolution and the changes in the redox states of cytochromes indicate that glucose is preferred by Ehrlich ascites tumour cells as energy substrate. Glucose decreased the rate of glutamine utilization by 34%. On the other hand, glutaminolysis did not inhibit glycolysis.	[ "Glutamine", "and", "glucose", "as", "energy", "substrates", "for", "Ehrlich", "ascites", "tumour", "cells", ".", "\n", "Energy", "metabolism", "of", "freshly", "harvested", "Ehrlich", "ascites", "tumour", "cells", "in", "the", "presence", "of", "5", "mM", "glucose", "and", "/", "or", "0.5", "mM", "glutamine", "was", "studied", ".", "The", "rate", "of", "oxygen", "utilization", "was", "not", "altered", "by", "the", "addition", "of", "0.5", "mM", "glutamine", ";", "5", "mM", "glucose", "induced", "an", "inhibition", "of", "respiration", ".", "In", "the", "presence", "of", "both", "glucose", "and", "glutamine", ",", "the", "Crabtree", "effect", "decreased", ".", "In", "these", "conditions", ",", "the", "rates", "of", "oxygen", "uptake", ",", "the", "CO2", "evolution", "and", "the", "changes", "in", "the", "redox", "states", "of", "cytochromes", "indicate", "that", "glucose", "is", "preferred", "by", "Ehrlich", "ascites", "tumour", "cells", "as", "energy", "substrate", ".", "Glucose", "decreased", "the", "rate", "of", "glutamine", "utilization", "by", "34", "%", ".", "On", "the", "other", "hand", ",", "glutaminolysis", "did", "not", "inhibit", "glycolysis", ".", "\n" ]	[ "Cell", "Gene_or_gene_product", "Amino_acid", "Simple_chemical" ]
Glutamine, glucose, Ehrlich ascites tumour cells, Ehrlich ascites tumour cells, glucose, glutamine, oxygen, glutamine, glucose, glucose, glutamine, oxygen, CO2, cytochromes, glucose, Ehrlich ascites tumour cells, Glucose, glutamine	281_task2	Sentence: Glutamine and glucose as energy substrates for Ehrlich ascites tumour cells. Energy metabolism of freshly harvested Ehrlich ascites tumour cells in the presence of 5 mM glucose and/or 0.5 mM glutamine was studied. The rate of oxygen utilization was not altered by the addition of 0.5 mM glutamine; 5 mM glucose induced an inhibition of respiration. In the presence of both glucose and glutamine, the Crabtree effect decreased. In these conditions, the rates of oxygen uptake, the CO2 evolution and the changes in the redox states of cytochromes indicate that glucose is preferred by Ehrlich ascites tumour cells as energy substrate. Glucose decreased the rate of glutamine utilization by 34%. On the other hand, glutaminolysis did not inhibit glycolysis. Instructions: please extract entity words from the input sentence	[ "B-Amino_acid", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "B-Amino_acid", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Amino_acid", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Amino_acid", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Amino_acid", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Glutamine and glucose as energy substrates for Ehrlich ascites tumour cells. Energy metabolism of freshly harvested Ehrlich ascites tumour cells in the presence of 5 mM glucose and/or 0.5 mM glutamine was studied. The rate of oxygen utilization was not altered by the addition of 0.5 mM glutamine; 5 mM glucose induced an inhibition of respiration. In the presence of both glucose and glutamine, the Crabtree effect decreased. In these conditions, the rates of oxygen uptake, the CO2 evolution and the changes in the redox states of cytochromes indicate that glucose is preferred by Ehrlich ascites tumour cells as energy substrate. Glucose decreased the rate of glutamine utilization by 34%. On the other hand, glutaminolysis did not inhibit glycolysis.	[ "Glutamine", "and", "glucose", "as", "energy", "substrates", "for", "Ehrlich", "ascites", "tumour", "cells", ".", "\n", "Energy", "metabolism", "of", "freshly", "harvested", "Ehrlich", "ascites", "tumour", "cells", "in", "the", "presence", "of", "5", "mM", "glucose", "and", "/", "or", "0.5", "mM", "glutamine", "was", "studied", ".", "The", "rate", "of", "oxygen", "utilization", "was", "not", "altered", "by", "the", "addition", "of", "0.5", "mM", "glutamine", ";", "5", "mM", "glucose", "induced", "an", "inhibition", "of", "respiration", ".", "In", "the", "presence", "of", "both", "glucose", "and", "glutamine", ",", "the", "Crabtree", "effect", "decreased", ".", "In", "these", "conditions", ",", "the", "rates", "of", "oxygen", "uptake", ",", "the", "CO2", "evolution", "and", "the", "changes", "in", "the", "redox", "states", "of", "cytochromes", "indicate", "that", "glucose", "is", "preferred", "by", "Ehrlich", "ascites", "tumour", "cells", "as", "energy", "substrate", ".", "Glucose", "decreased", "the", "rate", "of", "glutamine", "utilization", "by", "34", "%", ".", "On", "the", "other", "hand", ",", "glutaminolysis", "did", "not", "inhibit", "glycolysis", ".", "\n" ]	[ "Cell", "Gene_or_gene_product", "Amino_acid", "Simple_chemical" ]
Antofine is a CHEMICAL, connexin43 is a GENE-Y, protein kinase Cβ is a GENE-Y	23403203_task0	Sentence: Antofine-induced connexin43 gap junction disassembly in rat astrocytes involves protein kinase Cβ. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL	[ "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O" ]	Antofine-induced connexin43 gap junction disassembly in rat astrocytes involves protein kinase Cβ.	[ "Antofine", "-", "induced", "connexin43", "gap", "junction", "disassembly", "in", "rat", "astrocytes", "involves", "protein", "kinase", "Cβ", "." ]	[ "CHEMICAL", "GENE-N", "GENE-Y" ]
Antofine is a CHEMICAL, connexin43 is a GENE-Y, protein kinase Cβ is a GENE-Y	23403203_task1	Sentence: Antofine-induced connexin43 gap junction disassembly in rat astrocytes involves protein kinase Cβ. Instructions: please typing these entity words according to sentence: Antofine, connexin43, protein kinase Cβ Options: GENE-Y, CHEMICAL	[ "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O" ]	Antofine-induced connexin43 gap junction disassembly in rat astrocytes involves protein kinase Cβ.	[ "Antofine", "-", "induced", "connexin43", "gap", "junction", "disassembly", "in", "rat", "astrocytes", "involves", "protein", "kinase", "Cβ", "." ]	[ "CHEMICAL", "GENE-N", "GENE-Y" ]
Antofine, connexin43, protein kinase Cβ	23403203_task2	Sentence: Antofine-induced connexin43 gap junction disassembly in rat astrocytes involves protein kinase Cβ. Instructions: please extract entity words from the input sentence	[ "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O" ]	Antofine-induced connexin43 gap junction disassembly in rat astrocytes involves protein kinase Cβ.	[ "Antofine", "-", "induced", "connexin43", "gap", "junction", "disassembly", "in", "rat", "astrocytes", "involves", "protein", "kinase", "Cβ", "." ]	[ "CHEMICAL", "GENE-N", "GENE-Y" ]
primary prevention program is a Intervention_Educational, adolescents is a Participant_Age, school - based primary prevention psychological program is a Intervention_Educational, distress - coping is a Outcome_Mental, " gatekeepers " with regard to self - destructive behavior of peers is a Outcome_Mental, face validity and social validity is a Outcome_Mental, Two hundred and thirty - seven is a Participant_Sample-size, attitudes , emotions , knowledge and awareness of distress coping skills is a Outcome_Mental, cognitive - behavioral , school - based prevention program is a Intervention_Educational	85443_task0	Sentence: Coping with distress and self harm : the impact of a primary prevention program among adolescents . The effectiveness of a school-based primary prevention psychological program is assessed in the present study . The program was designed to ( a ) improve students ' distress-coping , ( b ) prepare them as " gatekeepers " with regard to self-destructive behavior of peers and ( c ) assess the program 's face validity and social validity . The program was primarily based on cognitive-behavioral modification principles , procedures and techniques . Two hundred and thirty-seven students , drawn from six homeroom grade eight classes were randomly assigned to experimental and control ( no intervention ) conditions . The program consisted of seven units passed during twelve weekly one-hour sessions . Overall , the program had a positive effect on attitudes , emotions , knowledge and awareness of distress coping skills . In addition , it had some degree of face validity and social validity from the students ' vantage point . These results lend support to the feasibility of a cognitive-behavioral , school-based prevention program for students ' distress-coping enhancement . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Educational, Participant_Age, Participant_Sample-size, Outcome_Mental	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O" ]	Coping with distress and self harm : the impact of a primary prevention program among adolescents . The effectiveness of a school-based primary prevention psychological program is assessed in the present study . The program was designed to ( a ) improve students ' distress-coping , ( b ) prepare them as " gatekeepers " with regard to self-destructive behavior of peers and ( c ) assess the program 's face validity and social validity . The program was primarily based on cognitive-behavioral modification principles , procedures and techniques . Two hundred and thirty-seven students , drawn from six homeroom grade eight classes were randomly assigned to experimental and control ( no intervention ) conditions . The program consisted of seven units passed during twelve weekly one-hour sessions . Overall , the program had a positive effect on attitudes , emotions , knowledge and awareness of distress coping skills . In addition , it had some degree of face validity and social validity from the students ' vantage point . These results lend support to the feasibility of a cognitive-behavioral , school-based prevention program for students ' distress-coping enhancement .	[ "Coping", "with", "distress", "and", "self", "harm", ":", "the", "impact", "of", "a", "primary", "prevention", "program", "among", "adolescents", ".", "The", "effectiveness", "of", "a", "school", "-", "based", "primary", "prevention", "psychological", "program", "is", "assessed", "in", "the", "present", "study", ".", "The", "program", "was", "designed", "to", "(", "a", ")", "improve", "students", "'", "distress", "-", "coping", ",", "(", "b", ")", "prepare", "them", "as", "\"", "gatekeepers", "\"", "with", "regard", "to", "self", "-", "destructive", "behavior", "of", "peers", "and", "(", "c", ")", "assess", "the", "program", "'", "s", "face", "validity", "and", "social", "validity", ".", "The", "program", "was", "primarily", "based", "on", "cognitive", "-", "behavioral", "modification", "principles", ",", "procedures", "and", "techniques", ".", "Two", "hundred", "and", "thirty", "-", "seven", "students", ",", "drawn", "from", "six", "homeroom", "grade", "eight", "classes", "were", "randomly", "assigned", "to", "experimental", "and", "control", "(", "no", "intervention", ")", "conditions", ".", "The", "program", "consisted", "of", "seven", "units", "passed", "during", "twelve", "weekly", "one", "-", "hour", "sessions", ".", "Overall", ",", "the", "program", "had", "a", "positive", "effect", "on", "attitudes", ",", "emotions", ",", "knowledge", "and", "awareness", "of", "distress", "coping", "skills", ".", "In", "addition", ",", "it", "had", "some", "degree", "of", "face", "validity", "and", "social", "validity", "from", "the", "students", "'", "vantage", "point", ".", "These", "results", "lend", "support", "to", "the", "feasibility", "of", "a", "cognitive", "-", "behavioral", ",", "school", "-", "based", "prevention", "program", "for", "students", "'", "distress", "-", "coping", "enhancement", "." ]	[ "Outcome_Mental", "Intervention_Educational", "Participant_Sample-size", "Participant_Age" ]
primary prevention program is a Intervention_Educational, adolescents is a Participant_Age, school - based primary prevention psychological program is a Intervention_Educational, distress - coping is a Outcome_Mental, " gatekeepers " with regard to self - destructive behavior of peers is a Outcome_Mental, face validity and social validity is a Outcome_Mental, Two hundred and thirty - seven is a Participant_Sample-size, attitudes , emotions , knowledge and awareness of distress coping skills is a Outcome_Mental, cognitive - behavioral , school - based prevention program is a Intervention_Educational	85443_task1	Sentence: Coping with distress and self harm : the impact of a primary prevention program among adolescents . The effectiveness of a school-based primary prevention psychological program is assessed in the present study . The program was designed to ( a ) improve students ' distress-coping , ( b ) prepare them as " gatekeepers " with regard to self-destructive behavior of peers and ( c ) assess the program 's face validity and social validity . The program was primarily based on cognitive-behavioral modification principles , procedures and techniques . Two hundred and thirty-seven students , drawn from six homeroom grade eight classes were randomly assigned to experimental and control ( no intervention ) conditions . The program consisted of seven units passed during twelve weekly one-hour sessions . Overall , the program had a positive effect on attitudes , emotions , knowledge and awareness of distress coping skills . In addition , it had some degree of face validity and social validity from the students ' vantage point . These results lend support to the feasibility of a cognitive-behavioral , school-based prevention program for students ' distress-coping enhancement . Instructions: please typing these entity words according to sentence: primary prevention program, adolescents, school - based primary prevention psychological program, distress - coping, " gatekeepers " with regard to self - destructive behavior of peers, face validity and social validity, Two hundred and thirty - seven, attitudes , emotions , knowledge and awareness of distress coping skills, cognitive - behavioral , school - based prevention program Options: Intervention_Educational, Participant_Age, Participant_Sample-size, Outcome_Mental	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O" ]	Coping with distress and self harm : the impact of a primary prevention program among adolescents . The effectiveness of a school-based primary prevention psychological program is assessed in the present study . The program was designed to ( a ) improve students ' distress-coping , ( b ) prepare them as " gatekeepers " with regard to self-destructive behavior of peers and ( c ) assess the program 's face validity and social validity . The program was primarily based on cognitive-behavioral modification principles , procedures and techniques . Two hundred and thirty-seven students , drawn from six homeroom grade eight classes were randomly assigned to experimental and control ( no intervention ) conditions . The program consisted of seven units passed during twelve weekly one-hour sessions . Overall , the program had a positive effect on attitudes , emotions , knowledge and awareness of distress coping skills . In addition , it had some degree of face validity and social validity from the students ' vantage point . These results lend support to the feasibility of a cognitive-behavioral , school-based prevention program for students ' distress-coping enhancement .	[ "Coping", "with", "distress", "and", "self", "harm", ":", "the", "impact", "of", "a", "primary", "prevention", "program", "among", "adolescents", ".", "The", "effectiveness", "of", "a", "school", "-", "based", "primary", "prevention", "psychological", "program", "is", "assessed", "in", "the", "present", "study", ".", "The", "program", "was", "designed", "to", "(", "a", ")", "improve", "students", "'", "distress", "-", "coping", ",", "(", "b", ")", "prepare", "them", "as", "\"", "gatekeepers", "\"", "with", "regard", "to", "self", "-", "destructive", "behavior", "of", "peers", "and", "(", "c", ")", "assess", "the", "program", "'", "s", "face", "validity", "and", "social", "validity", ".", "The", "program", "was", "primarily", "based", "on", "cognitive", "-", "behavioral", "modification", "principles", ",", "procedures", "and", "techniques", ".", "Two", "hundred", "and", "thirty", "-", "seven", "students", ",", "drawn", "from", "six", "homeroom", "grade", "eight", "classes", "were", "randomly", "assigned", "to", "experimental", "and", "control", "(", "no", "intervention", ")", "conditions", ".", "The", "program", "consisted", "of", "seven", "units", "passed", "during", "twelve", "weekly", "one", "-", "hour", "sessions", ".", "Overall", ",", "the", "program", "had", "a", "positive", "effect", "on", "attitudes", ",", "emotions", ",", "knowledge", "and", "awareness", "of", "distress", "coping", "skills", ".", "In", "addition", ",", "it", "had", "some", "degree", "of", "face", "validity", "and", "social", "validity", "from", "the", "students", "'", "vantage", "point", ".", "These", "results", "lend", "support", "to", "the", "feasibility", "of", "a", "cognitive", "-", "behavioral", ",", "school", "-", "based", "prevention", "program", "for", "students", "'", "distress", "-", "coping", "enhancement", "." ]	[ "Outcome_Mental", "Intervention_Educational", "Participant_Sample-size", "Participant_Age" ]
primary prevention program, adolescents, school - based primary prevention psychological program, distress - coping, " gatekeepers " with regard to self - destructive behavior of peers, face validity and social validity, Two hundred and thirty - seven, attitudes , emotions , knowledge and awareness of distress coping skills, cognitive - behavioral , school - based prevention program	85443_task2	Sentence: Coping with distress and self harm : the impact of a primary prevention program among adolescents . The effectiveness of a school-based primary prevention psychological program is assessed in the present study . The program was designed to ( a ) improve students ' distress-coping , ( b ) prepare them as " gatekeepers " with regard to self-destructive behavior of peers and ( c ) assess the program 's face validity and social validity . The program was primarily based on cognitive-behavioral modification principles , procedures and techniques . Two hundred and thirty-seven students , drawn from six homeroom grade eight classes were randomly assigned to experimental and control ( no intervention ) conditions . The program consisted of seven units passed during twelve weekly one-hour sessions . Overall , the program had a positive effect on attitudes , emotions , knowledge and awareness of distress coping skills . In addition , it had some degree of face validity and social validity from the students ' vantage point . These results lend support to the feasibility of a cognitive-behavioral , school-based prevention program for students ' distress-coping enhancement . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O" ]	Coping with distress and self harm : the impact of a primary prevention program among adolescents . The effectiveness of a school-based primary prevention psychological program is assessed in the present study . The program was designed to ( a ) improve students ' distress-coping , ( b ) prepare them as " gatekeepers " with regard to self-destructive behavior of peers and ( c ) assess the program 's face validity and social validity . The program was primarily based on cognitive-behavioral modification principles , procedures and techniques . Two hundred and thirty-seven students , drawn from six homeroom grade eight classes were randomly assigned to experimental and control ( no intervention ) conditions . The program consisted of seven units passed during twelve weekly one-hour sessions . Overall , the program had a positive effect on attitudes , emotions , knowledge and awareness of distress coping skills . In addition , it had some degree of face validity and social validity from the students ' vantage point . These results lend support to the feasibility of a cognitive-behavioral , school-based prevention program for students ' distress-coping enhancement .	[ "Coping", "with", "distress", "and", "self", "harm", ":", "the", "impact", "of", "a", "primary", "prevention", "program", "among", "adolescents", ".", "The", "effectiveness", "of", "a", "school", "-", "based", "primary", "prevention", "psychological", "program", "is", "assessed", "in", "the", "present", "study", ".", "The", "program", "was", "designed", "to", "(", "a", ")", "improve", "students", "'", "distress", "-", "coping", ",", "(", "b", ")", "prepare", "them", "as", "\"", "gatekeepers", "\"", "with", "regard", "to", "self", "-", "destructive", "behavior", "of", "peers", "and", "(", "c", ")", "assess", "the", "program", "'", "s", "face", "validity", "and", "social", "validity", ".", "The", "program", "was", "primarily", "based", "on", "cognitive", "-", "behavioral", "modification", "principles", ",", "procedures", "and", "techniques", ".", "Two", "hundred", "and", "thirty", "-", "seven", "students", ",", "drawn", "from", "six", "homeroom", "grade", "eight", "classes", "were", "randomly", "assigned", "to", "experimental", "and", "control", "(", "no", "intervention", ")", "conditions", ".", "The", "program", "consisted", "of", "seven", "units", "passed", "during", "twelve", "weekly", "one", "-", "hour", "sessions", ".", "Overall", ",", "the", "program", "had", "a", "positive", "effect", "on", "attitudes", ",", "emotions", ",", "knowledge", "and", "awareness", "of", "distress", "coping", "skills", ".", "In", "addition", ",", "it", "had", "some", "degree", "of", "face", "validity", "and", "social", "validity", "from", "the", "students", "'", "vantage", "point", ".", "These", "results", "lend", "support", "to", "the", "feasibility", "of", "a", "cognitive", "-", "behavioral", ",", "school", "-", "based", "prevention", "program", "for", "students", "'", "distress", "-", "coping", "enhancement", "." ]	[ "Outcome_Mental", "Intervention_Educational", "Participant_Sample-size", "Participant_Age" ]
profilin is a Individual_protein, actin is a Individual_protein	347_task0	Sentence: High levels of profilin suppress the lethality caused by overproduction of actin in yeast cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein	[ "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O" ]	High levels of profilin suppress the lethality caused by overproduction of actin in yeast cells.	[ "High", "levels", "of", "profilin", "suppress", "the", "lethality", "caused", "by", "overproduction", "of", "actin", "in", "yeast", "cells", "." ]	[ "Individual_protein" ]
profilin is a Individual_protein, actin is a Individual_protein	347_task1	Sentence: High levels of profilin suppress the lethality caused by overproduction of actin in yeast cells. Instructions: please typing these entity words according to sentence: profilin, actin Options: Individual_protein	[ "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O" ]	High levels of profilin suppress the lethality caused by overproduction of actin in yeast cells.	[ "High", "levels", "of", "profilin", "suppress", "the", "lethality", "caused", "by", "overproduction", "of", "actin", "in", "yeast", "cells", "." ]	[ "Individual_protein" ]
profilin, actin	347_task2	Sentence: High levels of profilin suppress the lethality caused by overproduction of actin in yeast cells. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O" ]	High levels of profilin suppress the lethality caused by overproduction of actin in yeast cells.	[ "High", "levels", "of", "profilin", "suppress", "the", "lethality", "caused", "by", "overproduction", "of", "actin", "in", "yeast", "cells", "." ]	[ "Individual_protein" ]
Fragebogenaktion is an umlsterm, Gesellschaft is an umlsterm, Pneumologie is an umlsterm, Aerzten is an umlsterm, Intensivbettenzahl is an umlsterm, Intensivbetten is an umlsterm, Betten is an umlsterm, Universitaetskliniken is an umlsterm, Lungenkliniken is an umlsterm, Universitaetskliniken is an umlsterm, Intensivbetten is an umlsterm, selbst is an umlsterm, Lungenkliniken is an umlsterm, Intensivstationen is an umlsterm, Deutschland is an umlsterm, Intensivbetten is an umlsterm, Deutschland is an umlsterm, Pneumologie is an umlsterm, Krankenhaeusern is an umlsterm, Intensivmedizin is an umlsterm	IntensiveMedizin.90360190.ger.abstr_task0	Sentence: Im Rahmen einer Fragebogenaktion wurde der Stand der Intensiv-Versorgung an Kliniken mit in der Deutschen Gesellschaft fuer Pneumologie ( DGP ) organisierten Pneumologen untersucht . Dazu wurden saemtliche eingetragenen Mitglieder der DGP zur Situation an der Klinik , an der sie arbeiten , befragt . Von mehr als 1600 angeschriebenen Aerzten antworteten 240 , die 145 verschiedene Kliniken repraesentieren ( Ruecklaufquote 14,4% ) . : Analysiert wurden die Anzahl und Art der Einrichtungen , die pneumologische Gesamt- und Intensivbettenzahl und das pneumologisch-intensivmedizinische Leistungsspektrum . Auch wenn der Anteil pneumologischer Intensivbetten an der Gesamtzahl pneumologischer Betten an Universitaetskliniken genau so hoch liegt wie an Lungenkliniken , finden sich weder an Universitaetskliniken ( 8% ) noch an Versorgungskrankenhaeusern ( 2% ) eine akzeptable Anzahl pneumologisch verantworteter Intensivbetten , und selbst an Lungenkliniken ( 50% ) wird nur ein Teil der Intensivstationen durch Pneumologen geleitet . Pneumologen haben in Deutschland bezogen auf die Gesamtzahl der internistischen Intensivbetten so gut wie nichts mit der Intensiv-Versorgung zu tun . Das in Deutschland bestehende Defizit in der Praesenz von Pneumologie an Universitaetsklinika und an den anderen Krankenhaeusern spiegelt sich - im Gegensatz zu anderen Laendern - in besonderer Weise in der internistischen Intensivmedizin wider . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Im Rahmen einer Fragebogenaktion wurde der Stand der Intensiv-Versorgung an Kliniken mit in der Deutschen Gesellschaft fuer Pneumologie ( DGP ) organisierten Pneumologen untersucht . Dazu wurden saemtliche eingetragenen Mitglieder der DGP zur Situation an der Klinik , an der sie arbeiten , befragt . Von mehr als 1600 angeschriebenen Aerzten antworteten 240 , die 145 verschiedene Kliniken repraesentieren ( Ruecklaufquote 14,4% ) . : Analysiert wurden die Anzahl und Art der Einrichtungen , die pneumologische Gesamt- und Intensivbettenzahl und das pneumologisch-intensivmedizinische Leistungsspektrum . Auch wenn der Anteil pneumologischer Intensivbetten an der Gesamtzahl pneumologischer Betten an Universitaetskliniken genau so hoch liegt wie an Lungenkliniken , finden sich weder an Universitaetskliniken ( 8% ) noch an Versorgungskrankenhaeusern ( 2% ) eine akzeptable Anzahl pneumologisch verantworteter Intensivbetten , und selbst an Lungenkliniken ( 50% ) wird nur ein Teil der Intensivstationen durch Pneumologen geleitet . Pneumologen haben in Deutschland bezogen auf die Gesamtzahl der internistischen Intensivbetten so gut wie nichts mit der Intensiv-Versorgung zu tun . Das in Deutschland bestehende Defizit in der Praesenz von Pneumologie an Universitaetsklinika und an den anderen Krankenhaeusern spiegelt sich - im Gegensatz zu anderen Laendern - in besonderer Weise in der internistischen Intensivmedizin wider .	[ "Im", "Rahmen", "einer", "Fragebogenaktion", "wurde", "der", "Stand", "der", "Intensiv", "-", "Versorgung", "an", "Kliniken", "mit", "in", "der", "Deutschen", "Gesellschaft", "fuer", "Pneumologie", "(", "DGP", ")", "organisierten", "Pneumologen", "untersucht", ".", "Dazu", "wurden", "saemtliche", "eingetragenen", "Mitglieder", "der", "DGP", "zur", "Situation", "an", "der", "Klinik", ",", "an", "der", "sie", "arbeiten", ",", "befragt", ".", "Von", "mehr", "als", "1600", "angeschriebenen", "Aerzten", "antworteten", "240", ",", "die", "145", "verschiedene", "Kliniken", "repraesentieren", "(", "Ruecklaufquote", "14,4", "%", ")", ".", ":", "Analysiert", "wurden", "die", "Anzahl", "und", "Art", "der", "Einrichtungen", ",", "die", "pneumologische", "Gesamt-", "und", "Intensivbettenzahl", "und", "das", "pneumologisch", "-", "intensivmedizinische", "Leistungsspektrum", ".", "Auch", "wenn", "der", "Anteil", "pneumologischer", "Intensivbetten", "an", "der", "Gesamtzahl", "pneumologischer", "Betten", "an", "Universitaetskliniken", "genau", "so", "hoch", "liegt", "wie", "an", "Lungenkliniken", ",", "finden", "sich", "weder", "an", "Universitaetskliniken", "(", "8", "%", ")", "noch", "an", "Versorgungskrankenhaeusern", "(", "2", "%", ")", "eine", "akzeptable", "Anzahl", "pneumologisch", "verantworteter", "Intensivbetten", ",", "und", "selbst", "an", "Lungenkliniken", "(", "50", "%", ")", "wird", "nur", "ein", "Teil", "der", "Intensivstationen", "durch", "Pneumologen", "geleitet", ".", "Pneumologen", "haben", "in", "Deutschland", "bezogen", "auf", "die", "Gesamtzahl", "der", "internistischen", "Intensivbetten", "so", "gut", "wie", "nichts", "mit", "der", "Intensiv", "-", "Versorgung", "zu", "tun", ".", "Das", "in", "Deutschland", "bestehende", "Defizit", "in", "der", "Praesenz", "von", "Pneumologie", "an", "Universitaetsklinika", "und", "an", "den", "anderen", "Krankenhaeusern", "spiegelt", "sich", "-", "im", "Gegensatz", "zu", "anderen", "Laendern", "-", "in", "besonderer", "Weise", "in", "der", "internistischen", "Intensivmedizin", "wider", "." ]	[ "umlsterm" ]
Fragebogenaktion is an umlsterm, Gesellschaft is an umlsterm, Pneumologie is an umlsterm, Aerzten is an umlsterm, Intensivbettenzahl is an umlsterm, Intensivbetten is an umlsterm, Betten is an umlsterm, Universitaetskliniken is an umlsterm, Lungenkliniken is an umlsterm, Universitaetskliniken is an umlsterm, Intensivbetten is an umlsterm, selbst is an umlsterm, Lungenkliniken is an umlsterm, Intensivstationen is an umlsterm, Deutschland is an umlsterm, Intensivbetten is an umlsterm, Deutschland is an umlsterm, Pneumologie is an umlsterm, Krankenhaeusern is an umlsterm, Intensivmedizin is an umlsterm	IntensiveMedizin.90360190.ger.abstr_task1	Sentence: Im Rahmen einer Fragebogenaktion wurde der Stand der Intensiv-Versorgung an Kliniken mit in der Deutschen Gesellschaft fuer Pneumologie ( DGP ) organisierten Pneumologen untersucht . Dazu wurden saemtliche eingetragenen Mitglieder der DGP zur Situation an der Klinik , an der sie arbeiten , befragt . Von mehr als 1600 angeschriebenen Aerzten antworteten 240 , die 145 verschiedene Kliniken repraesentieren ( Ruecklaufquote 14,4% ) . : Analysiert wurden die Anzahl und Art der Einrichtungen , die pneumologische Gesamt- und Intensivbettenzahl und das pneumologisch-intensivmedizinische Leistungsspektrum . Auch wenn der Anteil pneumologischer Intensivbetten an der Gesamtzahl pneumologischer Betten an Universitaetskliniken genau so hoch liegt wie an Lungenkliniken , finden sich weder an Universitaetskliniken ( 8% ) noch an Versorgungskrankenhaeusern ( 2% ) eine akzeptable Anzahl pneumologisch verantworteter Intensivbetten , und selbst an Lungenkliniken ( 50% ) wird nur ein Teil der Intensivstationen durch Pneumologen geleitet . Pneumologen haben in Deutschland bezogen auf die Gesamtzahl der internistischen Intensivbetten so gut wie nichts mit der Intensiv-Versorgung zu tun . Das in Deutschland bestehende Defizit in der Praesenz von Pneumologie an Universitaetsklinika und an den anderen Krankenhaeusern spiegelt sich - im Gegensatz zu anderen Laendern - in besonderer Weise in der internistischen Intensivmedizin wider . Instructions: please typing these entity words according to sentence: Fragebogenaktion, Gesellschaft, Pneumologie, Aerzten, Intensivbettenzahl, Intensivbetten, Betten, Universitaetskliniken, Lungenkliniken, Universitaetskliniken, Intensivbetten, selbst, Lungenkliniken, Intensivstationen, Deutschland, Intensivbetten, Deutschland, Pneumologie, Krankenhaeusern, Intensivmedizin Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Im Rahmen einer Fragebogenaktion wurde der Stand der Intensiv-Versorgung an Kliniken mit in der Deutschen Gesellschaft fuer Pneumologie ( DGP ) organisierten Pneumologen untersucht . Dazu wurden saemtliche eingetragenen Mitglieder der DGP zur Situation an der Klinik , an der sie arbeiten , befragt . Von mehr als 1600 angeschriebenen Aerzten antworteten 240 , die 145 verschiedene Kliniken repraesentieren ( Ruecklaufquote 14,4% ) . : Analysiert wurden die Anzahl und Art der Einrichtungen , die pneumologische Gesamt- und Intensivbettenzahl und das pneumologisch-intensivmedizinische Leistungsspektrum . Auch wenn der Anteil pneumologischer Intensivbetten an der Gesamtzahl pneumologischer Betten an Universitaetskliniken genau so hoch liegt wie an Lungenkliniken , finden sich weder an Universitaetskliniken ( 8% ) noch an Versorgungskrankenhaeusern ( 2% ) eine akzeptable Anzahl pneumologisch verantworteter Intensivbetten , und selbst an Lungenkliniken ( 50% ) wird nur ein Teil der Intensivstationen durch Pneumologen geleitet . Pneumologen haben in Deutschland bezogen auf die Gesamtzahl der internistischen Intensivbetten so gut wie nichts mit der Intensiv-Versorgung zu tun . Das in Deutschland bestehende Defizit in der Praesenz von Pneumologie an Universitaetsklinika und an den anderen Krankenhaeusern spiegelt sich - im Gegensatz zu anderen Laendern - in besonderer Weise in der internistischen Intensivmedizin wider .	[ "Im", "Rahmen", "einer", "Fragebogenaktion", "wurde", "der", "Stand", "der", "Intensiv", "-", "Versorgung", "an", "Kliniken", "mit", "in", "der", "Deutschen", "Gesellschaft", "fuer", "Pneumologie", "(", "DGP", ")", "organisierten", "Pneumologen", "untersucht", ".", "Dazu", "wurden", "saemtliche", "eingetragenen", "Mitglieder", "der", "DGP", "zur", "Situation", "an", "der", "Klinik", ",", "an", "der", "sie", "arbeiten", ",", "befragt", ".", "Von", "mehr", "als", "1600", "angeschriebenen", "Aerzten", "antworteten", "240", ",", "die", "145", "verschiedene", "Kliniken", "repraesentieren", "(", "Ruecklaufquote", "14,4", "%", ")", ".", ":", "Analysiert", "wurden", "die", "Anzahl", "und", "Art", "der", "Einrichtungen", ",", "die", "pneumologische", "Gesamt-", "und", "Intensivbettenzahl", "und", "das", "pneumologisch", "-", "intensivmedizinische", "Leistungsspektrum", ".", "Auch", "wenn", "der", "Anteil", "pneumologischer", "Intensivbetten", "an", "der", "Gesamtzahl", "pneumologischer", "Betten", "an", "Universitaetskliniken", "genau", "so", "hoch", "liegt", "wie", "an", "Lungenkliniken", ",", "finden", "sich", "weder", "an", "Universitaetskliniken", "(", "8", "%", ")", "noch", "an", "Versorgungskrankenhaeusern", "(", "2", "%", ")", "eine", "akzeptable", "Anzahl", "pneumologisch", "verantworteter", "Intensivbetten", ",", "und", "selbst", "an", "Lungenkliniken", "(", "50", "%", ")", "wird", "nur", "ein", "Teil", "der", "Intensivstationen", "durch", "Pneumologen", "geleitet", ".", "Pneumologen", "haben", "in", "Deutschland", "bezogen", "auf", "die", "Gesamtzahl", "der", "internistischen", "Intensivbetten", "so", "gut", "wie", "nichts", "mit", "der", "Intensiv", "-", "Versorgung", "zu", "tun", ".", "Das", "in", "Deutschland", "bestehende", "Defizit", "in", "der", "Praesenz", "von", "Pneumologie", "an", "Universitaetsklinika", "und", "an", "den", "anderen", "Krankenhaeusern", "spiegelt", "sich", "-", "im", "Gegensatz", "zu", "anderen", "Laendern", "-", "in", "besonderer", "Weise", "in", "der", "internistischen", "Intensivmedizin", "wider", "." ]	[ "umlsterm" ]
Fragebogenaktion, Gesellschaft, Pneumologie, Aerzten, Intensivbettenzahl, Intensivbetten, Betten, Universitaetskliniken, Lungenkliniken, Universitaetskliniken, Intensivbetten, selbst, Lungenkliniken, Intensivstationen, Deutschland, Intensivbetten, Deutschland, Pneumologie, Krankenhaeusern, Intensivmedizin	IntensiveMedizin.90360190.ger.abstr_task2	Sentence: Im Rahmen einer Fragebogenaktion wurde der Stand der Intensiv-Versorgung an Kliniken mit in der Deutschen Gesellschaft fuer Pneumologie ( DGP ) organisierten Pneumologen untersucht . Dazu wurden saemtliche eingetragenen Mitglieder der DGP zur Situation an der Klinik , an der sie arbeiten , befragt . Von mehr als 1600 angeschriebenen Aerzten antworteten 240 , die 145 verschiedene Kliniken repraesentieren ( Ruecklaufquote 14,4% ) . : Analysiert wurden die Anzahl und Art der Einrichtungen , die pneumologische Gesamt- und Intensivbettenzahl und das pneumologisch-intensivmedizinische Leistungsspektrum . Auch wenn der Anteil pneumologischer Intensivbetten an der Gesamtzahl pneumologischer Betten an Universitaetskliniken genau so hoch liegt wie an Lungenkliniken , finden sich weder an Universitaetskliniken ( 8% ) noch an Versorgungskrankenhaeusern ( 2% ) eine akzeptable Anzahl pneumologisch verantworteter Intensivbetten , und selbst an Lungenkliniken ( 50% ) wird nur ein Teil der Intensivstationen durch Pneumologen geleitet . Pneumologen haben in Deutschland bezogen auf die Gesamtzahl der internistischen Intensivbetten so gut wie nichts mit der Intensiv-Versorgung zu tun . Das in Deutschland bestehende Defizit in der Praesenz von Pneumologie an Universitaetsklinika und an den anderen Krankenhaeusern spiegelt sich - im Gegensatz zu anderen Laendern - in besonderer Weise in der internistischen Intensivmedizin wider . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Im Rahmen einer Fragebogenaktion wurde der Stand der Intensiv-Versorgung an Kliniken mit in der Deutschen Gesellschaft fuer Pneumologie ( DGP ) organisierten Pneumologen untersucht . Dazu wurden saemtliche eingetragenen Mitglieder der DGP zur Situation an der Klinik , an der sie arbeiten , befragt . Von mehr als 1600 angeschriebenen Aerzten antworteten 240 , die 145 verschiedene Kliniken repraesentieren ( Ruecklaufquote 14,4% ) . : Analysiert wurden die Anzahl und Art der Einrichtungen , die pneumologische Gesamt- und Intensivbettenzahl und das pneumologisch-intensivmedizinische Leistungsspektrum . Auch wenn der Anteil pneumologischer Intensivbetten an der Gesamtzahl pneumologischer Betten an Universitaetskliniken genau so hoch liegt wie an Lungenkliniken , finden sich weder an Universitaetskliniken ( 8% ) noch an Versorgungskrankenhaeusern ( 2% ) eine akzeptable Anzahl pneumologisch verantworteter Intensivbetten , und selbst an Lungenkliniken ( 50% ) wird nur ein Teil der Intensivstationen durch Pneumologen geleitet . Pneumologen haben in Deutschland bezogen auf die Gesamtzahl der internistischen Intensivbetten so gut wie nichts mit der Intensiv-Versorgung zu tun . Das in Deutschland bestehende Defizit in der Praesenz von Pneumologie an Universitaetsklinika und an den anderen Krankenhaeusern spiegelt sich - im Gegensatz zu anderen Laendern - in besonderer Weise in der internistischen Intensivmedizin wider .	[ "Im", "Rahmen", "einer", "Fragebogenaktion", "wurde", "der", "Stand", "der", "Intensiv", "-", "Versorgung", "an", "Kliniken", "mit", "in", "der", "Deutschen", "Gesellschaft", "fuer", "Pneumologie", "(", "DGP", ")", "organisierten", "Pneumologen", "untersucht", ".", "Dazu", "wurden", "saemtliche", "eingetragenen", "Mitglieder", "der", "DGP", "zur", "Situation", "an", "der", "Klinik", ",", "an", "der", "sie", "arbeiten", ",", "befragt", ".", "Von", "mehr", "als", "1600", "angeschriebenen", "Aerzten", "antworteten", "240", ",", "die", "145", "verschiedene", "Kliniken", "repraesentieren", "(", "Ruecklaufquote", "14,4", "%", ")", ".", ":", "Analysiert", "wurden", "die", "Anzahl", "und", "Art", "der", "Einrichtungen", ",", "die", "pneumologische", "Gesamt-", "und", "Intensivbettenzahl", "und", "das", "pneumologisch", "-", "intensivmedizinische", "Leistungsspektrum", ".", "Auch", "wenn", "der", "Anteil", "pneumologischer", "Intensivbetten", "an", "der", "Gesamtzahl", "pneumologischer", "Betten", "an", "Universitaetskliniken", "genau", "so", "hoch", "liegt", "wie", "an", "Lungenkliniken", ",", "finden", "sich", "weder", "an", "Universitaetskliniken", "(", "8", "%", ")", "noch", "an", "Versorgungskrankenhaeusern", "(", "2", "%", ")", "eine", "akzeptable", "Anzahl", "pneumologisch", "verantworteter", "Intensivbetten", ",", "und", "selbst", "an", "Lungenkliniken", "(", "50", "%", ")", "wird", "nur", "ein", "Teil", "der", "Intensivstationen", "durch", "Pneumologen", "geleitet", ".", "Pneumologen", "haben", "in", "Deutschland", "bezogen", "auf", "die", "Gesamtzahl", "der", "internistischen", "Intensivbetten", "so", "gut", "wie", "nichts", "mit", "der", "Intensiv", "-", "Versorgung", "zu", "tun", ".", "Das", "in", "Deutschland", "bestehende", "Defizit", "in", "der", "Praesenz", "von", "Pneumologie", "an", "Universitaetsklinika", "und", "an", "den", "anderen", "Krankenhaeusern", "spiegelt", "sich", "-", "im", "Gegensatz", "zu", "anderen", "Laendern", "-", "in", "besonderer", "Weise", "in", "der", "internistischen", "Intensivmedizin", "wider", "." ]	[ "umlsterm" ]
liver cancer cell Bel-7402 ] is a Cell, liver cancer cell Bel-7402 is a Cell, cell is a Cell, tumor is a Cancer, Bel-7402 is a Cell, Bel-7402 is a Cell, chromatin is a Cellular_component, cell is a Cell, tumor cell is a Cell	PMID-11255762_task0	Sentence: [Study of fungus polysaccharides compounds (FPC) in inducing the apoptosis of liver cancer cell Bel-7402]. To observe the influence of fungus polysaccharides compounds (FPC) in inducing human liver cancer cell Bel-7402 apoptosis in cell cultivating in vitro, the authors analyzed tumor inhibitive gene P53 expression in Bel-7402 apoptosis by applying double immuno-marker. The result showed that the multilevel of FPC could all apparently induce Bel-7402 apoptosis. With the enhancement of FPC concentration, the authors observed chromatin condensation in some phases companying with the characteristic apoptosis. In the meantime, it could also greatly reduce the G1 and S, with obviously dose-response relationship. The percentage of cell apoptosis increased with the enhancing of concentration. In the high-level group the authors found typical DNA ladder eletrophoresis stripe. The result showed that the mechanism of the FPC antineoplastic effect had an intimate relation with its induction to apoptosis and that the result of FPC inducing tumor cell apoptosis had the character of P53 independence. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Cancer, Cellular_component, Cell	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	[Study of fungus polysaccharides compounds (FPC) in inducing the apoptosis of liver cancer cell Bel-7402]. To observe the influence of fungus polysaccharides compounds (FPC) in inducing human liver cancer cell Bel-7402 apoptosis in cell cultivating in vitro, the authors analyzed tumor inhibitive gene P53 expression in Bel-7402 apoptosis by applying double immuno-marker. The result showed that the multilevel of FPC could all apparently induce Bel-7402 apoptosis. With the enhancement of FPC concentration, the authors observed chromatin condensation in some phases companying with the characteristic apoptosis. In the meantime, it could also greatly reduce the G1 and S, with obviously dose-response relationship. The percentage of cell apoptosis increased with the enhancing of concentration. In the high-level group the authors found typical DNA ladder eletrophoresis stripe. The result showed that the mechanism of the FPC antineoplastic effect had an intimate relation with its induction to apoptosis and that the result of FPC inducing tumor cell apoptosis had the character of P53 independence.	[ "[", "Study", "of", "fungus", "polysaccharides", "compounds", "(", "FPC", ")", "in", "inducing", "the", "apoptosis", "of", "liver", "cancer", "cell", "Bel-7402", "]", ".", "\n", "To", "observe", "the", "influence", "of", "fungus", "polysaccharides", "compounds", "(", "FPC", ")", "in", "inducing", "human", "liver", "cancer", "cell", "Bel-7402", "apoptosis", "in", "cell", "cultivating", "in", "vitro", ",", "the", "authors", "analyzed", "tumor", "inhibitive", "gene", "P53", "expression", "in", "Bel-7402", "apoptosis", "by", "applying", "double", "immuno", "-", "marker", ".", "The", "result", "showed", "that", "the", "multilevel", "of", "FPC", "could", "all", "apparently", "induce", "Bel-7402", "apoptosis", ".", "With", "the", "enhancement", "of", "FPC", "concentration", ",", "the", "authors", "observed", "chromatin", "condensation", "in", "some", "phases", "companying", "with", "the", "characteristic", "apoptosis", ".", "In", "the", "meantime", ",", "it", "could", "also", "greatly", "reduce", "the", "G1", "and", "S", ",", "with", "obviously", "dose", "-", "response", "relationship", ".", "The", "percentage", "of", "cell", "apoptosis", "increased", "with", "the", "enhancing", "of", "concentration", ".", "In", "the", "high", "-", "level", "group", "the", "authors", "found", "typical", "DNA", "ladder", "eletrophoresis", "stripe", ".", "The", "result", "showed", "that", "the", "mechanism", "of", "the", "FPC", "antineoplastic", "effect", "had", "an", "intimate", "relation", "with", "its", "induction", "to", "apoptosis", "and", "that", "the", "result", "of", "FPC", "inducing", "tumor", "cell", "apoptosis", "had", "the", "character", "of", "P53", "independence", ".", "\n" ]	[ "Cell", "Cancer", "Cellular_component" ]
liver cancer cell Bel-7402 ] is a Cell, liver cancer cell Bel-7402 is a Cell, cell is a Cell, tumor is a Cancer, Bel-7402 is a Cell, Bel-7402 is a Cell, chromatin is a Cellular_component, cell is a Cell, tumor cell is a Cell	PMID-11255762_task1	Sentence: [Study of fungus polysaccharides compounds (FPC) in inducing the apoptosis of liver cancer cell Bel-7402]. To observe the influence of fungus polysaccharides compounds (FPC) in inducing human liver cancer cell Bel-7402 apoptosis in cell cultivating in vitro, the authors analyzed tumor inhibitive gene P53 expression in Bel-7402 apoptosis by applying double immuno-marker. The result showed that the multilevel of FPC could all apparently induce Bel-7402 apoptosis. With the enhancement of FPC concentration, the authors observed chromatin condensation in some phases companying with the characteristic apoptosis. In the meantime, it could also greatly reduce the G1 and S, with obviously dose-response relationship. The percentage of cell apoptosis increased with the enhancing of concentration. In the high-level group the authors found typical DNA ladder eletrophoresis stripe. The result showed that the mechanism of the FPC antineoplastic effect had an intimate relation with its induction to apoptosis and that the result of FPC inducing tumor cell apoptosis had the character of P53 independence. Instructions: please typing these entity words according to sentence: liver cancer cell Bel-7402 ], liver cancer cell Bel-7402, cell, tumor, Bel-7402, Bel-7402, chromatin, cell, tumor cell Options: Cancer, Cellular_component, Cell	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	[Study of fungus polysaccharides compounds (FPC) in inducing the apoptosis of liver cancer cell Bel-7402]. To observe the influence of fungus polysaccharides compounds (FPC) in inducing human liver cancer cell Bel-7402 apoptosis in cell cultivating in vitro, the authors analyzed tumor inhibitive gene P53 expression in Bel-7402 apoptosis by applying double immuno-marker. The result showed that the multilevel of FPC could all apparently induce Bel-7402 apoptosis. With the enhancement of FPC concentration, the authors observed chromatin condensation in some phases companying with the characteristic apoptosis. In the meantime, it could also greatly reduce the G1 and S, with obviously dose-response relationship. The percentage of cell apoptosis increased with the enhancing of concentration. In the high-level group the authors found typical DNA ladder eletrophoresis stripe. The result showed that the mechanism of the FPC antineoplastic effect had an intimate relation with its induction to apoptosis and that the result of FPC inducing tumor cell apoptosis had the character of P53 independence.	[ "[", "Study", "of", "fungus", "polysaccharides", "compounds", "(", "FPC", ")", "in", "inducing", "the", "apoptosis", "of", "liver", "cancer", "cell", "Bel-7402", "]", ".", "\n", "To", "observe", "the", "influence", "of", "fungus", "polysaccharides", "compounds", "(", "FPC", ")", "in", "inducing", "human", "liver", "cancer", "cell", "Bel-7402", "apoptosis", "in", "cell", "cultivating", "in", "vitro", ",", "the", "authors", "analyzed", "tumor", "inhibitive", "gene", "P53", "expression", "in", "Bel-7402", "apoptosis", "by", "applying", "double", "immuno", "-", "marker", ".", "The", "result", "showed", "that", "the", "multilevel", "of", "FPC", "could", "all", "apparently", "induce", "Bel-7402", "apoptosis", ".", "With", "the", "enhancement", "of", "FPC", "concentration", ",", "the", "authors", "observed", "chromatin", "condensation", "in", "some", "phases", "companying", "with", "the", "characteristic", "apoptosis", ".", "In", "the", "meantime", ",", "it", "could", "also", "greatly", "reduce", "the", "G1", "and", "S", ",", "with", "obviously", "dose", "-", "response", "relationship", ".", "The", "percentage", "of", "cell", "apoptosis", "increased", "with", "the", "enhancing", "of", "concentration", ".", "In", "the", "high", "-", "level", "group", "the", "authors", "found", "typical", "DNA", "ladder", "eletrophoresis", "stripe", ".", "The", "result", "showed", "that", "the", "mechanism", "of", "the", "FPC", "antineoplastic", "effect", "had", "an", "intimate", "relation", "with", "its", "induction", "to", "apoptosis", "and", "that", "the", "result", "of", "FPC", "inducing", "tumor", "cell", "apoptosis", "had", "the", "character", "of", "P53", "independence", ".", "\n" ]	[ "Cell", "Cancer", "Cellular_component" ]
liver cancer cell Bel-7402 ], liver cancer cell Bel-7402, cell, tumor, Bel-7402, Bel-7402, chromatin, cell, tumor cell	PMID-11255762_task2	Sentence: [Study of fungus polysaccharides compounds (FPC) in inducing the apoptosis of liver cancer cell Bel-7402]. To observe the influence of fungus polysaccharides compounds (FPC) in inducing human liver cancer cell Bel-7402 apoptosis in cell cultivating in vitro, the authors analyzed tumor inhibitive gene P53 expression in Bel-7402 apoptosis by applying double immuno-marker. The result showed that the multilevel of FPC could all apparently induce Bel-7402 apoptosis. With the enhancement of FPC concentration, the authors observed chromatin condensation in some phases companying with the characteristic apoptosis. In the meantime, it could also greatly reduce the G1 and S, with obviously dose-response relationship. The percentage of cell apoptosis increased with the enhancing of concentration. In the high-level group the authors found typical DNA ladder eletrophoresis stripe. The result showed that the mechanism of the FPC antineoplastic effect had an intimate relation with its induction to apoptosis and that the result of FPC inducing tumor cell apoptosis had the character of P53 independence. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	[Study of fungus polysaccharides compounds (FPC) in inducing the apoptosis of liver cancer cell Bel-7402]. To observe the influence of fungus polysaccharides compounds (FPC) in inducing human liver cancer cell Bel-7402 apoptosis in cell cultivating in vitro, the authors analyzed tumor inhibitive gene P53 expression in Bel-7402 apoptosis by applying double immuno-marker. The result showed that the multilevel of FPC could all apparently induce Bel-7402 apoptosis. With the enhancement of FPC concentration, the authors observed chromatin condensation in some phases companying with the characteristic apoptosis. In the meantime, it could also greatly reduce the G1 and S, with obviously dose-response relationship. The percentage of cell apoptosis increased with the enhancing of concentration. In the high-level group the authors found typical DNA ladder eletrophoresis stripe. The result showed that the mechanism of the FPC antineoplastic effect had an intimate relation with its induction to apoptosis and that the result of FPC inducing tumor cell apoptosis had the character of P53 independence.	[ "[", "Study", "of", "fungus", "polysaccharides", "compounds", "(", "FPC", ")", "in", "inducing", "the", "apoptosis", "of", "liver", "cancer", "cell", "Bel-7402", "]", ".", "\n", "To", "observe", "the", "influence", "of", "fungus", "polysaccharides", "compounds", "(", "FPC", ")", "in", "inducing", "human", "liver", "cancer", "cell", "Bel-7402", "apoptosis", "in", "cell", "cultivating", "in", "vitro", ",", "the", "authors", "analyzed", "tumor", "inhibitive", "gene", "P53", "expression", "in", "Bel-7402", "apoptosis", "by", "applying", "double", "immuno", "-", "marker", ".", "The", "result", "showed", "that", "the", "multilevel", "of", "FPC", "could", "all", "apparently", "induce", "Bel-7402", "apoptosis", ".", "With", "the", "enhancement", "of", "FPC", "concentration", ",", "the", "authors", "observed", "chromatin", "condensation", "in", "some", "phases", "companying", "with", "the", "characteristic", "apoptosis", ".", "In", "the", "meantime", ",", "it", "could", "also", "greatly", "reduce", "the", "G1", "and", "S", ",", "with", "obviously", "dose", "-", "response", "relationship", ".", "The", "percentage", "of", "cell", "apoptosis", "increased", "with", "the", "enhancing", "of", "concentration", ".", "In", "the", "high", "-", "level", "group", "the", "authors", "found", "typical", "DNA", "ladder", "eletrophoresis", "stripe", ".", "The", "result", "showed", "that", "the", "mechanism", "of", "the", "FPC", "antineoplastic", "effect", "had", "an", "intimate", "relation", "with", "its", "induction", "to", "apoptosis", "and", "that", "the", "result", "of", "FPC", "inducing", "tumor", "cell", "apoptosis", "had", "the", "character", "of", "P53", "independence", ".", "\n" ]	[ "Cell", "Cancer", "Cellular_component" ]
Salmonella typhimurium is a Microorganism, Escherichia coli is a Microorganism	4_task0	Sentence: A new purification method for overproduced proteins sensitive to endogenous proteases. Proteolysisis a major problem in purification of overproduced proteins for structural studies. We developed a new method to avoid proteolysis of the products even in cases where popular protease inhibitors do not work effectively. When we cloned FlgF, a flagellar rod protein, from Salmonella typhimurium and overproduced it in Escherichia coli, FlgF was highly susceptible to cleavage by endogenous proteases after cell disruption even in the presence of various protease inhibitors. However, FlgF was not digested when the cells were disrupted in the presence of urea, which allowed us to develop the following new purification procedure. After cell disruption in the presence of urea and removal of the cell debris, the supernatant was passed through tandem-connected cation- and anion-exchange columns. Proteases were trapped in the cation-exchange column, and protease-free FlgF was eluted from the disconnected anion-exchange column. This gave a stable full-length product suitable for crystallization trials. The key procedures are cell disruption in the presence of urea and linked ion-exchange chromatography to quickly remove proteases as well as urea. This fast and simple method can be applied to purification of other overproduced proteins that are very sensitive to proteolysis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Microorganism	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A new purification method for overproduced proteins sensitive to endogenous proteases. Proteolysisis a major problem in purification of overproduced proteins for structural studies. We developed a new method to avoid proteolysis of the products even in cases where popular protease inhibitors do not work effectively. When we cloned FlgF, a flagellar rod protein, from Salmonella typhimurium and overproduced it in Escherichia coli, FlgF was highly susceptible to cleavage by endogenous proteases after cell disruption even in the presence of various protease inhibitors. However, FlgF was not digested when the cells were disrupted in the presence of urea, which allowed us to develop the following new purification procedure. After cell disruption in the presence of urea and removal of the cell debris, the supernatant was passed through tandem-connected cation- and anion-exchange columns. Proteases were trapped in the cation-exchange column, and protease-free FlgF was eluted from the disconnected anion-exchange column. This gave a stable full-length product suitable for crystallization trials. The key procedures are cell disruption in the presence of urea and linked ion-exchange chromatography to quickly remove proteases as well as urea. This fast and simple method can be applied to purification of other overproduced proteins that are very sensitive to proteolysis.	[ "A", "new", "purification", "method", "for", "overproduced", "proteins", "sensitive", "to", "endogenous", "proteases", ".", "Proteolysisis", "a", "major", "problem", "in", "purification", "of", "overproduced", "proteins", "for", "structural", "studies", ".", "We", "developed", "a", "new", "method", "to", "avoid", "proteolysis", "of", "the", "products", "even", "in", "cases", "where", "popular", "protease", "inhibitors", "do", "not", "work", "effectively", ".", "When", "we", "cloned", "FlgF", ",", "a", "flagellar", "rod", "protein", ",", "from", "Salmonella", "typhimurium", "and", "overproduced", "it", "in", "Escherichia", "coli", ",", "FlgF", "was", "highly", "susceptible", "to", "cleavage", "by", "endogenous", "proteases", "after", "cell", "disruption", "even", "in", "the", "presence", "of", "various", "protease", "inhibitors", ".", "However", ",", "FlgF", "was", "not", "digested", "when", "the", "cells", "were", "disrupted", "in", "the", "presence", "of", "urea", ",", "which", "allowed", "us", "to", "develop", "the", "following", "new", "purification", "procedure", ".", "After", "cell", "disruption", "in", "the", "presence", "of", "urea", "and", "removal", "of", "the", "cell", "debris", ",", "the", "supernatant", "was", "passed", "through", "tandem", "-", "connected", "cation-", "and", "anion", "-", "exchange", "columns", ".", "Proteases", "were", "trapped", "in", "the", "cation", "-", "exchange", "column", ",", "and", "protease", "-", "free", "FlgF", "was", "eluted", "from", "the", "disconnected", "anion", "-", "exchange", "column", ".", "This", "gave", "a", "stable", "full", "-", "length", "product", "suitable", "for", "crystallization", "trials", ".", "The", "key", "procedures", "are", "cell", "disruption", "in", "the", "presence", "of", "urea", "and", "linked", "ion", "-", "exchange", "chromatography", "to", "quickly", "remove", "proteases", "as", "well", "as", "urea", ".", "This", "fast", "and", "simple", "method", "can", "be", "applied", "to", "purification", "of", "other", "overproduced", "proteins", "that", "are", "very", "sensitive", "to", "proteolysis", ".", " " ]	[ "Microorganism" ]
Salmonella typhimurium is a Microorganism, Escherichia coli is a Microorganism	4_task1	Sentence: A new purification method for overproduced proteins sensitive to endogenous proteases. Proteolysisis a major problem in purification of overproduced proteins for structural studies. We developed a new method to avoid proteolysis of the products even in cases where popular protease inhibitors do not work effectively. When we cloned FlgF, a flagellar rod protein, from Salmonella typhimurium and overproduced it in Escherichia coli, FlgF was highly susceptible to cleavage by endogenous proteases after cell disruption even in the presence of various protease inhibitors. However, FlgF was not digested when the cells were disrupted in the presence of urea, which allowed us to develop the following new purification procedure. After cell disruption in the presence of urea and removal of the cell debris, the supernatant was passed through tandem-connected cation- and anion-exchange columns. Proteases were trapped in the cation-exchange column, and protease-free FlgF was eluted from the disconnected anion-exchange column. This gave a stable full-length product suitable for crystallization trials. The key procedures are cell disruption in the presence of urea and linked ion-exchange chromatography to quickly remove proteases as well as urea. This fast and simple method can be applied to purification of other overproduced proteins that are very sensitive to proteolysis. Instructions: please typing these entity words according to sentence: Salmonella typhimurium, Escherichia coli Options: Microorganism	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A new purification method for overproduced proteins sensitive to endogenous proteases. Proteolysisis a major problem in purification of overproduced proteins for structural studies. We developed a new method to avoid proteolysis of the products even in cases where popular protease inhibitors do not work effectively. When we cloned FlgF, a flagellar rod protein, from Salmonella typhimurium and overproduced it in Escherichia coli, FlgF was highly susceptible to cleavage by endogenous proteases after cell disruption even in the presence of various protease inhibitors. However, FlgF was not digested when the cells were disrupted in the presence of urea, which allowed us to develop the following new purification procedure. After cell disruption in the presence of urea and removal of the cell debris, the supernatant was passed through tandem-connected cation- and anion-exchange columns. Proteases were trapped in the cation-exchange column, and protease-free FlgF was eluted from the disconnected anion-exchange column. This gave a stable full-length product suitable for crystallization trials. The key procedures are cell disruption in the presence of urea and linked ion-exchange chromatography to quickly remove proteases as well as urea. This fast and simple method can be applied to purification of other overproduced proteins that are very sensitive to proteolysis.	[ "A", "new", "purification", "method", "for", "overproduced", "proteins", "sensitive", "to", "endogenous", "proteases", ".", "Proteolysisis", "a", "major", "problem", "in", "purification", "of", "overproduced", "proteins", "for", "structural", "studies", ".", "We", "developed", "a", "new", "method", "to", "avoid", "proteolysis", "of", "the", "products", "even", "in", "cases", "where", "popular", "protease", "inhibitors", "do", "not", "work", "effectively", ".", "When", "we", "cloned", "FlgF", ",", "a", "flagellar", "rod", "protein", ",", "from", "Salmonella", "typhimurium", "and", "overproduced", "it", "in", "Escherichia", "coli", ",", "FlgF", "was", "highly", "susceptible", "to", "cleavage", "by", "endogenous", "proteases", "after", "cell", "disruption", "even", "in", "the", "presence", "of", "various", "protease", "inhibitors", ".", "However", ",", "FlgF", "was", "not", "digested", "when", "the", "cells", "were", "disrupted", "in", "the", "presence", "of", "urea", ",", "which", "allowed", "us", "to", "develop", "the", "following", "new", "purification", "procedure", ".", "After", "cell", "disruption", "in", "the", "presence", "of", "urea", "and", "removal", "of", "the", "cell", "debris", ",", "the", "supernatant", "was", "passed", "through", "tandem", "-", "connected", "cation-", "and", "anion", "-", "exchange", "columns", ".", "Proteases", "were", "trapped", "in", "the", "cation", "-", "exchange", "column", ",", "and", "protease", "-", "free", "FlgF", "was", "eluted", "from", "the", "disconnected", "anion", "-", "exchange", "column", ".", "This", "gave", "a", "stable", "full", "-", "length", "product", "suitable", "for", "crystallization", "trials", ".", "The", "key", "procedures", "are", "cell", "disruption", "in", "the", "presence", "of", "urea", "and", "linked", "ion", "-", "exchange", "chromatography", "to", "quickly", "remove", "proteases", "as", "well", "as", "urea", ".", "This", "fast", "and", "simple", "method", "can", "be", "applied", "to", "purification", "of", "other", "overproduced", "proteins", "that", "are", "very", "sensitive", "to", "proteolysis", ".", " " ]	[ "Microorganism" ]
Salmonella typhimurium, Escherichia coli	4_task2	Sentence: A new purification method for overproduced proteins sensitive to endogenous proteases. Proteolysisis a major problem in purification of overproduced proteins for structural studies. We developed a new method to avoid proteolysis of the products even in cases where popular protease inhibitors do not work effectively. When we cloned FlgF, a flagellar rod protein, from Salmonella typhimurium and overproduced it in Escherichia coli, FlgF was highly susceptible to cleavage by endogenous proteases after cell disruption even in the presence of various protease inhibitors. However, FlgF was not digested when the cells were disrupted in the presence of urea, which allowed us to develop the following new purification procedure. After cell disruption in the presence of urea and removal of the cell debris, the supernatant was passed through tandem-connected cation- and anion-exchange columns. Proteases were trapped in the cation-exchange column, and protease-free FlgF was eluted from the disconnected anion-exchange column. This gave a stable full-length product suitable for crystallization trials. The key procedures are cell disruption in the presence of urea and linked ion-exchange chromatography to quickly remove proteases as well as urea. This fast and simple method can be applied to purification of other overproduced proteins that are very sensitive to proteolysis. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A new purification method for overproduced proteins sensitive to endogenous proteases. Proteolysisis a major problem in purification of overproduced proteins for structural studies. We developed a new method to avoid proteolysis of the products even in cases where popular protease inhibitors do not work effectively. When we cloned FlgF, a flagellar rod protein, from Salmonella typhimurium and overproduced it in Escherichia coli, FlgF was highly susceptible to cleavage by endogenous proteases after cell disruption even in the presence of various protease inhibitors. However, FlgF was not digested when the cells were disrupted in the presence of urea, which allowed us to develop the following new purification procedure. After cell disruption in the presence of urea and removal of the cell debris, the supernatant was passed through tandem-connected cation- and anion-exchange columns. Proteases were trapped in the cation-exchange column, and protease-free FlgF was eluted from the disconnected anion-exchange column. This gave a stable full-length product suitable for crystallization trials. The key procedures are cell disruption in the presence of urea and linked ion-exchange chromatography to quickly remove proteases as well as urea. This fast and simple method can be applied to purification of other overproduced proteins that are very sensitive to proteolysis.	[ "A", "new", "purification", "method", "for", "overproduced", "proteins", "sensitive", "to", "endogenous", "proteases", ".", "Proteolysisis", "a", "major", "problem", "in", "purification", "of", "overproduced", "proteins", "for", "structural", "studies", ".", "We", "developed", "a", "new", "method", "to", "avoid", "proteolysis", "of", "the", "products", "even", "in", "cases", "where", "popular", "protease", "inhibitors", "do", "not", "work", "effectively", ".", "When", "we", "cloned", "FlgF", ",", "a", "flagellar", "rod", "protein", ",", "from", "Salmonella", "typhimurium", "and", "overproduced", "it", "in", "Escherichia", "coli", ",", "FlgF", "was", "highly", "susceptible", "to", "cleavage", "by", "endogenous", "proteases", "after", "cell", "disruption", "even", "in", "the", "presence", "of", "various", "protease", "inhibitors", ".", "However", ",", "FlgF", "was", "not", "digested", "when", "the", "cells", "were", "disrupted", "in", "the", "presence", "of", "urea", ",", "which", "allowed", "us", "to", "develop", "the", "following", "new", "purification", "procedure", ".", "After", "cell", "disruption", "in", "the", "presence", "of", "urea", "and", "removal", "of", "the", "cell", "debris", ",", "the", "supernatant", "was", "passed", "through", "tandem", "-", "connected", "cation-", "and", "anion", "-", "exchange", "columns", ".", "Proteases", "were", "trapped", "in", "the", "cation", "-", "exchange", "column", ",", "and", "protease", "-", "free", "FlgF", "was", "eluted", "from", "the", "disconnected", "anion", "-", "exchange", "column", ".", "This", "gave", "a", "stable", "full", "-", "length", "product", "suitable", "for", "crystallization", "trials", ".", "The", "key", "procedures", "are", "cell", "disruption", "in", "the", "presence", "of", "urea", "and", "linked", "ion", "-", "exchange", "chromatography", "to", "quickly", "remove", "proteases", "as", "well", "as", "urea", ".", "This", "fast", "and", "simple", "method", "can", "be", "applied", "to", "purification", "of", "other", "overproduced", "proteins", "that", "are", "very", "sensitive", "to", "proteolysis", ".", " " ]	[ "Microorganism" ]
Gesichtshaelfte is an umlsterm, Patienten is an umlsterm, wachsende is an umlsterm, Tumoren is an umlsterm, Schilddruesenlaborparameter is an umlsterm, antinukleaere Antikoerper is an umlsterm, Kontaktallergien is an umlsterm, Angiosarkom is an umlsterm, Therapie is an umlsterm, Radiotherapie is an umlsterm, rezidivfreies is an umlsterm	DerHautarzt.00510419.ger.abstr_task0	Sentence: Kutane Angiosarkome entwickeln sich am Kapillitium und der oberen Gesichtshaelfte aelterer Patienten als schnell wachsende , roetlich-livide Infiltrate und Knoten , die bluten und exulzerieren koennen . Die Tumoren sind aggressiv , rezidivieren haeufig und metastasieren haematogen und lymphogen . Wir berichten ueber eine 48jaehrige Patientin mit einer einseitigen Lidschwellung als Erstmanifestation eines kutanen Angiosarkoms . Trotz der ungewoehnlichen Klinik und zunaechst nicht-Malignom-verdaechtiger Befunde wie pathologische Schilddruesenlaborparameter , antinukleaere Antikoerper und multiple Kontaktallergien wurde ein hochdifferenziertes Angiosarkom bioptisch gesichert . Nach radikaler chirurgischer Therapie und postoperativer Radiotherapie konnte in einem Nachbeobachtungszeitraum von 26 Monaten ein rezidivfreies Ergebnis ohne Anhaltspunkt fuer Metastasierung erzielt werden . Das Fallbeispiel soll veranschaulichen , dass bei einseitigen Lid- bzw. Periorbitalschwellungen differential-diagnostisch immer ein neoplastischer Prozess in Erwaegung gezogen werden sollte . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Kutane Angiosarkome entwickeln sich am Kapillitium und der oberen Gesichtshaelfte aelterer Patienten als schnell wachsende , roetlich-livide Infiltrate und Knoten , die bluten und exulzerieren koennen . Die Tumoren sind aggressiv , rezidivieren haeufig und metastasieren haematogen und lymphogen . Wir berichten ueber eine 48jaehrige Patientin mit einer einseitigen Lidschwellung als Erstmanifestation eines kutanen Angiosarkoms . Trotz der ungewoehnlichen Klinik und zunaechst nicht-Malignom-verdaechtiger Befunde wie pathologische Schilddruesenlaborparameter , antinukleaere Antikoerper und multiple Kontaktallergien wurde ein hochdifferenziertes Angiosarkom bioptisch gesichert . Nach radikaler chirurgischer Therapie und postoperativer Radiotherapie konnte in einem Nachbeobachtungszeitraum von 26 Monaten ein rezidivfreies Ergebnis ohne Anhaltspunkt fuer Metastasierung erzielt werden . Das Fallbeispiel soll veranschaulichen , dass bei einseitigen Lid- bzw. Periorbitalschwellungen differential-diagnostisch immer ein neoplastischer Prozess in Erwaegung gezogen werden sollte .	[ "Kutane", "Angiosarkome", "entwickeln", "sich", "am", "Kapillitium", "und", "der", "oberen", "Gesichtshaelfte", "aelterer", "Patienten", "als", "schnell", "wachsende", ",", "roetlich", "-", "livide", "Infiltrate", "und", "Knoten", ",", "die", "bluten", "und", "exulzerieren", "koennen", ".", "Die", "Tumoren", "sind", "aggressiv", ",", "rezidivieren", "haeufig", "und", "metastasieren", "haematogen", "und", "lymphogen", ".", "Wir", "berichten", "ueber", "eine", "48jaehrige", "Patientin", "mit", "einer", "einseitigen", "Lidschwellung", "als", "Erstmanifestation", "eines", "kutanen", "Angiosarkoms", ".", "Trotz", "der", "ungewoehnlichen", "Klinik", "und", "zunaechst", "nicht", "-", "Malignom", "-", "verdaechtiger", "Befunde", "wie", "pathologische", "Schilddruesenlaborparameter", ",", "antinukleaere", "Antikoerper", "und", "multiple", "Kontaktallergien", "wurde", "ein", "hochdifferenziertes", "Angiosarkom", "bioptisch", "gesichert", ".", "Nach", "radikaler", "chirurgischer", "Therapie", "und", "postoperativer", "Radiotherapie", "konnte", "in", "einem", "Nachbeobachtungszeitraum", "von", "26", "Monaten", "ein", "rezidivfreies", "Ergebnis", "ohne", "Anhaltspunkt", "fuer", "Metastasierung", "erzielt", "werden", ".", "Das", "Fallbeispiel", "soll", "veranschaulichen", ",", "dass", "bei", "einseitigen", "Lid-", "bzw", ".", "Periorbitalschwellungen", "differential", "-", "diagnostisch", "immer", "ein", "neoplastischer", "Prozess", "in", "Erwaegung", "gezogen", "werden", "sollte", "." ]	[ "umlsterm" ]
Gesichtshaelfte is an umlsterm, Patienten is an umlsterm, wachsende is an umlsterm, Tumoren is an umlsterm, Schilddruesenlaborparameter is an umlsterm, antinukleaere Antikoerper is an umlsterm, Kontaktallergien is an umlsterm, Angiosarkom is an umlsterm, Therapie is an umlsterm, Radiotherapie is an umlsterm, rezidivfreies is an umlsterm	DerHautarzt.00510419.ger.abstr_task1	Sentence: Kutane Angiosarkome entwickeln sich am Kapillitium und der oberen Gesichtshaelfte aelterer Patienten als schnell wachsende , roetlich-livide Infiltrate und Knoten , die bluten und exulzerieren koennen . Die Tumoren sind aggressiv , rezidivieren haeufig und metastasieren haematogen und lymphogen . Wir berichten ueber eine 48jaehrige Patientin mit einer einseitigen Lidschwellung als Erstmanifestation eines kutanen Angiosarkoms . Trotz der ungewoehnlichen Klinik und zunaechst nicht-Malignom-verdaechtiger Befunde wie pathologische Schilddruesenlaborparameter , antinukleaere Antikoerper und multiple Kontaktallergien wurde ein hochdifferenziertes Angiosarkom bioptisch gesichert . Nach radikaler chirurgischer Therapie und postoperativer Radiotherapie konnte in einem Nachbeobachtungszeitraum von 26 Monaten ein rezidivfreies Ergebnis ohne Anhaltspunkt fuer Metastasierung erzielt werden . Das Fallbeispiel soll veranschaulichen , dass bei einseitigen Lid- bzw. Periorbitalschwellungen differential-diagnostisch immer ein neoplastischer Prozess in Erwaegung gezogen werden sollte . Instructions: please typing these entity words according to sentence: Gesichtshaelfte, Patienten, wachsende, Tumoren, Schilddruesenlaborparameter, antinukleaere Antikoerper, Kontaktallergien, Angiosarkom, Therapie, Radiotherapie, rezidivfreies Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Kutane Angiosarkome entwickeln sich am Kapillitium und der oberen Gesichtshaelfte aelterer Patienten als schnell wachsende , roetlich-livide Infiltrate und Knoten , die bluten und exulzerieren koennen . Die Tumoren sind aggressiv , rezidivieren haeufig und metastasieren haematogen und lymphogen . Wir berichten ueber eine 48jaehrige Patientin mit einer einseitigen Lidschwellung als Erstmanifestation eines kutanen Angiosarkoms . Trotz der ungewoehnlichen Klinik und zunaechst nicht-Malignom-verdaechtiger Befunde wie pathologische Schilddruesenlaborparameter , antinukleaere Antikoerper und multiple Kontaktallergien wurde ein hochdifferenziertes Angiosarkom bioptisch gesichert . Nach radikaler chirurgischer Therapie und postoperativer Radiotherapie konnte in einem Nachbeobachtungszeitraum von 26 Monaten ein rezidivfreies Ergebnis ohne Anhaltspunkt fuer Metastasierung erzielt werden . Das Fallbeispiel soll veranschaulichen , dass bei einseitigen Lid- bzw. Periorbitalschwellungen differential-diagnostisch immer ein neoplastischer Prozess in Erwaegung gezogen werden sollte .	[ "Kutane", "Angiosarkome", "entwickeln", "sich", "am", "Kapillitium", "und", "der", "oberen", "Gesichtshaelfte", "aelterer", "Patienten", "als", "schnell", "wachsende", ",", "roetlich", "-", "livide", "Infiltrate", "und", "Knoten", ",", "die", "bluten", "und", "exulzerieren", "koennen", ".", "Die", "Tumoren", "sind", "aggressiv", ",", "rezidivieren", "haeufig", "und", "metastasieren", "haematogen", "und", "lymphogen", ".", "Wir", "berichten", "ueber", "eine", "48jaehrige", "Patientin", "mit", "einer", "einseitigen", "Lidschwellung", "als", "Erstmanifestation", "eines", "kutanen", "Angiosarkoms", ".", "Trotz", "der", "ungewoehnlichen", "Klinik", "und", "zunaechst", "nicht", "-", "Malignom", "-", "verdaechtiger", "Befunde", "wie", "pathologische", "Schilddruesenlaborparameter", ",", "antinukleaere", "Antikoerper", "und", "multiple", "Kontaktallergien", "wurde", "ein", "hochdifferenziertes", "Angiosarkom", "bioptisch", "gesichert", ".", "Nach", "radikaler", "chirurgischer", "Therapie", "und", "postoperativer", "Radiotherapie", "konnte", "in", "einem", "Nachbeobachtungszeitraum", "von", "26", "Monaten", "ein", "rezidivfreies", "Ergebnis", "ohne", "Anhaltspunkt", "fuer", "Metastasierung", "erzielt", "werden", ".", "Das", "Fallbeispiel", "soll", "veranschaulichen", ",", "dass", "bei", "einseitigen", "Lid-", "bzw", ".", "Periorbitalschwellungen", "differential", "-", "diagnostisch", "immer", "ein", "neoplastischer", "Prozess", "in", "Erwaegung", "gezogen", "werden", "sollte", "." ]	[ "umlsterm" ]
Gesichtshaelfte, Patienten, wachsende, Tumoren, Schilddruesenlaborparameter, antinukleaere Antikoerper, Kontaktallergien, Angiosarkom, Therapie, Radiotherapie, rezidivfreies	DerHautarzt.00510419.ger.abstr_task2	Sentence: Kutane Angiosarkome entwickeln sich am Kapillitium und der oberen Gesichtshaelfte aelterer Patienten als schnell wachsende , roetlich-livide Infiltrate und Knoten , die bluten und exulzerieren koennen . Die Tumoren sind aggressiv , rezidivieren haeufig und metastasieren haematogen und lymphogen . Wir berichten ueber eine 48jaehrige Patientin mit einer einseitigen Lidschwellung als Erstmanifestation eines kutanen Angiosarkoms . Trotz der ungewoehnlichen Klinik und zunaechst nicht-Malignom-verdaechtiger Befunde wie pathologische Schilddruesenlaborparameter , antinukleaere Antikoerper und multiple Kontaktallergien wurde ein hochdifferenziertes Angiosarkom bioptisch gesichert . Nach radikaler chirurgischer Therapie und postoperativer Radiotherapie konnte in einem Nachbeobachtungszeitraum von 26 Monaten ein rezidivfreies Ergebnis ohne Anhaltspunkt fuer Metastasierung erzielt werden . Das Fallbeispiel soll veranschaulichen , dass bei einseitigen Lid- bzw. Periorbitalschwellungen differential-diagnostisch immer ein neoplastischer Prozess in Erwaegung gezogen werden sollte . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Kutane Angiosarkome entwickeln sich am Kapillitium und der oberen Gesichtshaelfte aelterer Patienten als schnell wachsende , roetlich-livide Infiltrate und Knoten , die bluten und exulzerieren koennen . Die Tumoren sind aggressiv , rezidivieren haeufig und metastasieren haematogen und lymphogen . Wir berichten ueber eine 48jaehrige Patientin mit einer einseitigen Lidschwellung als Erstmanifestation eines kutanen Angiosarkoms . Trotz der ungewoehnlichen Klinik und zunaechst nicht-Malignom-verdaechtiger Befunde wie pathologische Schilddruesenlaborparameter , antinukleaere Antikoerper und multiple Kontaktallergien wurde ein hochdifferenziertes Angiosarkom bioptisch gesichert . Nach radikaler chirurgischer Therapie und postoperativer Radiotherapie konnte in einem Nachbeobachtungszeitraum von 26 Monaten ein rezidivfreies Ergebnis ohne Anhaltspunkt fuer Metastasierung erzielt werden . Das Fallbeispiel soll veranschaulichen , dass bei einseitigen Lid- bzw. Periorbitalschwellungen differential-diagnostisch immer ein neoplastischer Prozess in Erwaegung gezogen werden sollte .	[ "Kutane", "Angiosarkome", "entwickeln", "sich", "am", "Kapillitium", "und", "der", "oberen", "Gesichtshaelfte", "aelterer", "Patienten", "als", "schnell", "wachsende", ",", "roetlich", "-", "livide", "Infiltrate", "und", "Knoten", ",", "die", "bluten", "und", "exulzerieren", "koennen", ".", "Die", "Tumoren", "sind", "aggressiv", ",", "rezidivieren", "haeufig", "und", "metastasieren", "haematogen", "und", "lymphogen", ".", "Wir", "berichten", "ueber", "eine", "48jaehrige", "Patientin", "mit", "einer", "einseitigen", "Lidschwellung", "als", "Erstmanifestation", "eines", "kutanen", "Angiosarkoms", ".", "Trotz", "der", "ungewoehnlichen", "Klinik", "und", "zunaechst", "nicht", "-", "Malignom", "-", "verdaechtiger", "Befunde", "wie", "pathologische", "Schilddruesenlaborparameter", ",", "antinukleaere", "Antikoerper", "und", "multiple", "Kontaktallergien", "wurde", "ein", "hochdifferenziertes", "Angiosarkom", "bioptisch", "gesichert", ".", "Nach", "radikaler", "chirurgischer", "Therapie", "und", "postoperativer", "Radiotherapie", "konnte", "in", "einem", "Nachbeobachtungszeitraum", "von", "26", "Monaten", "ein", "rezidivfreies", "Ergebnis", "ohne", "Anhaltspunkt", "fuer", "Metastasierung", "erzielt", "werden", ".", "Das", "Fallbeispiel", "soll", "veranschaulichen", ",", "dass", "bei", "einseitigen", "Lid-", "bzw", ".", "Periorbitalschwellungen", "differential", "-", "diagnostisch", "immer", "ein", "neoplastischer", "Prozess", "in", "Erwaegung", "gezogen", "werden", "sollte", "." ]	[ "umlsterm" ]
p27Kip1 is a Protein, p27Kip1 is a Protein, p27Kip1 is a Protein, p27Kip1 is a Protein, p27Kip1 is a Protein, p27Kip1 is a Protein, Sp1 is a Protein, Myb is a Protein, p27Kip1 is a Protein	653_task0	Sentence: Characterization of the murine cyclin-dependent kinase inhibitor gene p27Kip1. The cyclin-dependent kinase inhibitor p27Kip1 plays an important role in regulating cell-cycle progression. p27Kip1 directly inhibits the catalytic activity of cyclin/cdks (cyclin-dependent kinase) complexes and/or interferes physically with cyclin/cdks activation by CAK. Interestingly, the expression level of p27Kip1 mRNA was maximal in resting Go T-cells and rapidly declined following anti-CD3 activation. We report here the cloning of p27Kip1 gene from murine genomic DNA and the functional analysis of the promoter of the p27Kip1 gene. The gene consists of at least three exons and spans more than 5.6 kb of DNA. Primer extension and nuclease S1 protection analysis revealed two major transcription initiation sites. The promoter region lacked a TATA box but contained potential binding sites for the transcriptional factors including two Sp1, CRE, Myb and NFkB located at positions -153, -178, -286, -875, and -1011, respectively. To analyze the regulatory mechanisms controlling p27Kip1 gene expression, we characterized the 5'-flanking region from nt -1609 to +178. The -326 to -615 region contained positive regulatory elements. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Characterization of the murine cyclin-dependent kinase inhibitor gene p27Kip1. The cyclin-dependent kinase inhibitor p27Kip1 plays an important role in regulating cell-cycle progression. p27Kip1 directly inhibits the catalytic activity of cyclin/cdks (cyclin-dependent kinase) complexes and/or interferes physically with cyclin/cdks activation by CAK. Interestingly, the expression level of p27Kip1 mRNA was maximal in resting Go T-cells and rapidly declined following anti-CD3 activation. We report here the cloning of p27Kip1 gene from murine genomic DNA and the functional analysis of the promoter of the p27Kip1 gene. The gene consists of at least three exons and spans more than 5.6 kb of DNA. Primer extension and nuclease S1 protection analysis revealed two major transcription initiation sites. The promoter region lacked a TATA box but contained potential binding sites for the transcriptional factors including two Sp1, CRE, Myb and NFkB located at positions -153, -178, -286, -875, and -1011, respectively. To analyze the regulatory mechanisms controlling p27Kip1 gene expression, we characterized the 5'-flanking region from nt -1609 to +178. The -326 to -615 region contained positive regulatory elements.	[ "Characterization", "of", "the", "murine", "cyclin", "-", "dependent", "kinase", "inhibitor", "gene", "p27Kip1", ".", "\n", "The", "cyclin", "-", "dependent", "kinase", "inhibitor", "p27Kip1", "plays", "an", "important", "role", "in", "regulating", "cell", "-", "cycle", "progression", ".", "p27Kip1", "directly", "inhibits", "the", "catalytic", "activity", "of", "cyclin", "/", "cdks", "(", "cyclin", "-", "dependent", "kinase", ")", "complexes", "and", "/", "or", "interferes", "physically", "with", "cyclin", "/", "cdks", "activation", "by", "CAK", ".", "Interestingly", ",", "the", "expression", "level", "of", "p27Kip1", "mRNA", "was", "maximal", "in", "resting", "Go", "T", "-", "cells", "and", "rapidly", "declined", "following", "anti", "-", "CD3", "activation", ".", "We", "report", "here", "the", "cloning", "of", "p27Kip1", "gene", "from", "murine", "genomic", "DNA", "and", "the", "functional", "analysis", "of", "the", "promoter", "of", "the", "p27Kip1", "gene", ".", "The", "gene", "consists", "of", "at", "least", "three", "exons", "and", "spans", "more", "than", "5.6", "kb", "of", "DNA", ".", "Primer", "extension", "and", "nuclease", "S1", "protection", "analysis", "revealed", "two", "major", "transcription", "initiation", "sites", ".", "The", "promoter", "region", "lacked", "a", "TATA", "box", "but", "contained", "potential", "binding", "sites", "for", "the", "transcriptional", "factors", "including", "two", "Sp1", ",", "CRE", ",", "Myb", "and", "NFkB", "located", "at", "positions", "-153", ",", "-178", ",", "-286", ",", "-875", ",", "and", "-1011", ",", "respectively", ".", "To", "analyze", "the", "regulatory", "mechanisms", "controlling", "p27Kip1", "gene", "expression", ",", "we", "characterized", "the", "5'-flanking", "region", "from", "nt", "-1609", "to", "+178", ".", "The", "-326", "to", "-615", "region", "contained", "positive", "regulatory", "elements", "." ]	[ "Protein" ]
p27Kip1 is a Protein, p27Kip1 is a Protein, p27Kip1 is a Protein, p27Kip1 is a Protein, p27Kip1 is a Protein, p27Kip1 is a Protein, Sp1 is a Protein, Myb is a Protein, p27Kip1 is a Protein	653_task1	Sentence: Characterization of the murine cyclin-dependent kinase inhibitor gene p27Kip1. The cyclin-dependent kinase inhibitor p27Kip1 plays an important role in regulating cell-cycle progression. p27Kip1 directly inhibits the catalytic activity of cyclin/cdks (cyclin-dependent kinase) complexes and/or interferes physically with cyclin/cdks activation by CAK. Interestingly, the expression level of p27Kip1 mRNA was maximal in resting Go T-cells and rapidly declined following anti-CD3 activation. We report here the cloning of p27Kip1 gene from murine genomic DNA and the functional analysis of the promoter of the p27Kip1 gene. The gene consists of at least three exons and spans more than 5.6 kb of DNA. Primer extension and nuclease S1 protection analysis revealed two major transcription initiation sites. The promoter region lacked a TATA box but contained potential binding sites for the transcriptional factors including two Sp1, CRE, Myb and NFkB located at positions -153, -178, -286, -875, and -1011, respectively. To analyze the regulatory mechanisms controlling p27Kip1 gene expression, we characterized the 5'-flanking region from nt -1609 to +178. The -326 to -615 region contained positive regulatory elements. Instructions: please typing these entity words according to sentence: p27Kip1, p27Kip1, p27Kip1, p27Kip1, p27Kip1, p27Kip1, Sp1, Myb, p27Kip1 Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Characterization of the murine cyclin-dependent kinase inhibitor gene p27Kip1. The cyclin-dependent kinase inhibitor p27Kip1 plays an important role in regulating cell-cycle progression. p27Kip1 directly inhibits the catalytic activity of cyclin/cdks (cyclin-dependent kinase) complexes and/or interferes physically with cyclin/cdks activation by CAK. Interestingly, the expression level of p27Kip1 mRNA was maximal in resting Go T-cells and rapidly declined following anti-CD3 activation. We report here the cloning of p27Kip1 gene from murine genomic DNA and the functional analysis of the promoter of the p27Kip1 gene. The gene consists of at least three exons and spans more than 5.6 kb of DNA. Primer extension and nuclease S1 protection analysis revealed two major transcription initiation sites. The promoter region lacked a TATA box but contained potential binding sites for the transcriptional factors including two Sp1, CRE, Myb and NFkB located at positions -153, -178, -286, -875, and -1011, respectively. To analyze the regulatory mechanisms controlling p27Kip1 gene expression, we characterized the 5'-flanking region from nt -1609 to +178. The -326 to -615 region contained positive regulatory elements.	[ "Characterization", "of", "the", "murine", "cyclin", "-", "dependent", "kinase", "inhibitor", "gene", "p27Kip1", ".", "\n", "The", "cyclin", "-", "dependent", "kinase", "inhibitor", "p27Kip1", "plays", "an", "important", "role", "in", "regulating", "cell", "-", "cycle", "progression", ".", "p27Kip1", "directly", "inhibits", "the", "catalytic", "activity", "of", "cyclin", "/", "cdks", "(", "cyclin", "-", "dependent", "kinase", ")", "complexes", "and", "/", "or", "interferes", "physically", "with", "cyclin", "/", "cdks", "activation", "by", "CAK", ".", "Interestingly", ",", "the", "expression", "level", "of", "p27Kip1", "mRNA", "was", "maximal", "in", "resting", "Go", "T", "-", "cells", "and", "rapidly", "declined", "following", "anti", "-", "CD3", "activation", ".", "We", "report", "here", "the", "cloning", "of", "p27Kip1", "gene", "from", "murine", "genomic", "DNA", "and", "the", "functional", "analysis", "of", "the", "promoter", "of", "the", "p27Kip1", "gene", ".", "The", "gene", "consists", "of", "at", "least", "three", "exons", "and", "spans", "more", "than", "5.6", "kb", "of", "DNA", ".", "Primer", "extension", "and", "nuclease", "S1", "protection", "analysis", "revealed", "two", "major", "transcription", "initiation", "sites", ".", "The", "promoter", "region", "lacked", "a", "TATA", "box", "but", "contained", "potential", "binding", "sites", "for", "the", "transcriptional", "factors", "including", "two", "Sp1", ",", "CRE", ",", "Myb", "and", "NFkB", "located", "at", "positions", "-153", ",", "-178", ",", "-286", ",", "-875", ",", "and", "-1011", ",", "respectively", ".", "To", "analyze", "the", "regulatory", "mechanisms", "controlling", "p27Kip1", "gene", "expression", ",", "we", "characterized", "the", "5'-flanking", "region", "from", "nt", "-1609", "to", "+178", ".", "The", "-326", "to", "-615", "region", "contained", "positive", "regulatory", "elements", "." ]	[ "Protein" ]
p27Kip1, p27Kip1, p27Kip1, p27Kip1, p27Kip1, p27Kip1, Sp1, Myb, p27Kip1	653_task2	Sentence: Characterization of the murine cyclin-dependent kinase inhibitor gene p27Kip1. The cyclin-dependent kinase inhibitor p27Kip1 plays an important role in regulating cell-cycle progression. p27Kip1 directly inhibits the catalytic activity of cyclin/cdks (cyclin-dependent kinase) complexes and/or interferes physically with cyclin/cdks activation by CAK. Interestingly, the expression level of p27Kip1 mRNA was maximal in resting Go T-cells and rapidly declined following anti-CD3 activation. We report here the cloning of p27Kip1 gene from murine genomic DNA and the functional analysis of the promoter of the p27Kip1 gene. The gene consists of at least three exons and spans more than 5.6 kb of DNA. Primer extension and nuclease S1 protection analysis revealed two major transcription initiation sites. The promoter region lacked a TATA box but contained potential binding sites for the transcriptional factors including two Sp1, CRE, Myb and NFkB located at positions -153, -178, -286, -875, and -1011, respectively. To analyze the regulatory mechanisms controlling p27Kip1 gene expression, we characterized the 5'-flanking region from nt -1609 to +178. The -326 to -615 region contained positive regulatory elements. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Characterization of the murine cyclin-dependent kinase inhibitor gene p27Kip1. The cyclin-dependent kinase inhibitor p27Kip1 plays an important role in regulating cell-cycle progression. p27Kip1 directly inhibits the catalytic activity of cyclin/cdks (cyclin-dependent kinase) complexes and/or interferes physically with cyclin/cdks activation by CAK. Interestingly, the expression level of p27Kip1 mRNA was maximal in resting Go T-cells and rapidly declined following anti-CD3 activation. We report here the cloning of p27Kip1 gene from murine genomic DNA and the functional analysis of the promoter of the p27Kip1 gene. The gene consists of at least three exons and spans more than 5.6 kb of DNA. Primer extension and nuclease S1 protection analysis revealed two major transcription initiation sites. The promoter region lacked a TATA box but contained potential binding sites for the transcriptional factors including two Sp1, CRE, Myb and NFkB located at positions -153, -178, -286, -875, and -1011, respectively. To analyze the regulatory mechanisms controlling p27Kip1 gene expression, we characterized the 5'-flanking region from nt -1609 to +178. The -326 to -615 region contained positive regulatory elements.	[ "Characterization", "of", "the", "murine", "cyclin", "-", "dependent", "kinase", "inhibitor", "gene", "p27Kip1", ".", "\n", "The", "cyclin", "-", "dependent", "kinase", "inhibitor", "p27Kip1", "plays", "an", "important", "role", "in", "regulating", "cell", "-", "cycle", "progression", ".", "p27Kip1", "directly", "inhibits", "the", "catalytic", "activity", "of", "cyclin", "/", "cdks", "(", "cyclin", "-", "dependent", "kinase", ")", "complexes", "and", "/", "or", "interferes", "physically", "with", "cyclin", "/", "cdks", "activation", "by", "CAK", ".", "Interestingly", ",", "the", "expression", "level", "of", "p27Kip1", "mRNA", "was", "maximal", "in", "resting", "Go", "T", "-", "cells", "and", "rapidly", "declined", "following", "anti", "-", "CD3", "activation", ".", "We", "report", "here", "the", "cloning", "of", "p27Kip1", "gene", "from", "murine", "genomic", "DNA", "and", "the", "functional", "analysis", "of", "the", "promoter", "of", "the", "p27Kip1", "gene", ".", "The", "gene", "consists", "of", "at", "least", "three", "exons", "and", "spans", "more", "than", "5.6", "kb", "of", "DNA", ".", "Primer", "extension", "and", "nuclease", "S1", "protection", "analysis", "revealed", "two", "major", "transcription", "initiation", "sites", ".", "The", "promoter", "region", "lacked", "a", "TATA", "box", "but", "contained", "potential", "binding", "sites", "for", "the", "transcriptional", "factors", "including", "two", "Sp1", ",", "CRE", ",", "Myb", "and", "NFkB", "located", "at", "positions", "-153", ",", "-178", ",", "-286", ",", "-875", ",", "and", "-1011", ",", "respectively", ".", "To", "analyze", "the", "regulatory", "mechanisms", "controlling", "p27Kip1", "gene", "expression", ",", "we", "characterized", "the", "5'-flanking", "region", "from", "nt", "-1609", "to", "+178", ".", "The", "-326", "to", "-615", "region", "contained", "positive", "regulatory", "elements", "." ]	[ "Protein" ]
p75 tumor necrosis factor receptor is a Protein, p75TNF - R is a Protein, lymphotoxin alpha is a Protein, p75 tumor necrosis factor receptor is a Protein, p75TNF - R is a Protein, p75TNF - R is a Protein, NF - kappaB is a Entity, lymphotoxin alpha is a Protein, p55TNF - R is a Protein, human TNF transgene is a Entity, p75TNF - R is a Protein	341_task0	Sentence: A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNF-R. Despite overwhelming evidence that enhanced production of the p75 tumor necrosis factor receptor (p75TNF-R) accompanies development of specific human inflammatory pathologies such as multi-organ failure during sepsis, inflammatory liver disease, pancreatitis, respiratory distress syndrome, or AIDS, the function of this receptor remains poorly defined in vivo. We show here that at levels relevant to human disease, production of the human p75TNF-R in transgenic mice results in a severe inflammatory syndrome involving mainly the pancreas, liver, kidney, and lung, and characterized by constitutively increased NF-kappaB activity in the peripheral blood mononuclear cell compartment. This process is shown to evolve independently of the presence of TNF, lymphotoxin alpha, or the p55TNF-R, although coexpression of a human TNF transgene accelerated pathology. These results establish an independent role for enhanced p75TNF-R production in the pathogenesis of inflammatory disease and implicate the direct involvement of this receptor in a wide range of human inflammatory pathologies. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNF-R. Despite overwhelming evidence that enhanced production of the p75 tumor necrosis factor receptor (p75TNF-R) accompanies development of specific human inflammatory pathologies such as multi-organ failure during sepsis, inflammatory liver disease, pancreatitis, respiratory distress syndrome, or AIDS, the function of this receptor remains poorly defined in vivo. We show here that at levels relevant to human disease, production of the human p75TNF-R in transgenic mice results in a severe inflammatory syndrome involving mainly the pancreas, liver, kidney, and lung, and characterized by constitutively increased NF-kappaB activity in the peripheral blood mononuclear cell compartment. This process is shown to evolve independently of the presence of TNF, lymphotoxin alpha, or the p55TNF-R, although coexpression of a human TNF transgene accelerated pathology. These results establish an independent role for enhanced p75TNF-R production in the pathogenesis of inflammatory disease and implicate the direct involvement of this receptor in a wide range of human inflammatory pathologies.	[ "A", "critical", "role", "of", "the", "p75", "tumor", "necrosis", "factor", "receptor", "(", "p75TNF", "-", "R", ")", "in", "organ", "inflammation", "independent", "of", "TNF", ",", "lymphotoxin", "alpha", ",", "or", "the", "p55TNF", "-", "R.", "\n", "Despite", "overwhelming", "evidence", "that", "enhanced", "production", "of", "the", "p75", "tumor", "necrosis", "factor", "receptor", "(", "p75TNF", "-", "R", ")", "accompanies", "development", "of", "specific", "human", "inflammatory", "pathologies", "such", "as", "multi", "-", "organ", "failure", "during", "sepsis", ",", "inflammatory", "liver", "disease", ",", "pancreatitis", ",", "respiratory", "distress", "syndrome", ",", "or", "AIDS", ",", "the", "function", "of", "this", "receptor", "remains", "poorly", "defined", "in", "vivo", ".", "We", "show", "here", "that", "at", "levels", "relevant", "to", "human", "disease", ",", "production", "of", "the", "human", "p75TNF", "-", "R", "in", "transgenic", "mice", "results", "in", "a", "severe", "inflammatory", "syndrome", "involving", "mainly", "the", "pancreas", ",", "liver", ",", "kidney", ",", "and", "lung", ",", "and", "characterized", "by", "constitutively", "increased", "NF", "-", "kappaB", "activity", "in", "the", "peripheral", "blood", "mononuclear", "cell", "compartment", ".", "This", "process", "is", "shown", "to", "evolve", "independently", "of", "the", "presence", "of", "TNF", ",", "lymphotoxin", "alpha", ",", "or", "the", "p55TNF", "-", "R", ",", "although", "coexpression", "of", "a", "human", "TNF", "transgene", "accelerated", "pathology", ".", "These", "results", "establish", "an", "independent", "role", "for", "enhanced", "p75TNF", "-", "R", "production", "in", "the", "pathogenesis", "of", "inflammatory", "disease", "and", "implicate", "the", "direct", "involvement", "of", "this", "receptor", "in", "a", "wide", "range", "of", "human", "inflammatory", "pathologies", ".", "\n" ]	[ "Protein", "Entity" ]
p75 tumor necrosis factor receptor is a Protein, p75TNF - R is a Protein, lymphotoxin alpha is a Protein, p75 tumor necrosis factor receptor is a Protein, p75TNF - R is a Protein, p75TNF - R is a Protein, NF - kappaB is a Entity, lymphotoxin alpha is a Protein, p55TNF - R is a Protein, human TNF transgene is a Entity, p75TNF - R is a Protein	341_task1	Sentence: A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNF-R. Despite overwhelming evidence that enhanced production of the p75 tumor necrosis factor receptor (p75TNF-R) accompanies development of specific human inflammatory pathologies such as multi-organ failure during sepsis, inflammatory liver disease, pancreatitis, respiratory distress syndrome, or AIDS, the function of this receptor remains poorly defined in vivo. We show here that at levels relevant to human disease, production of the human p75TNF-R in transgenic mice results in a severe inflammatory syndrome involving mainly the pancreas, liver, kidney, and lung, and characterized by constitutively increased NF-kappaB activity in the peripheral blood mononuclear cell compartment. This process is shown to evolve independently of the presence of TNF, lymphotoxin alpha, or the p55TNF-R, although coexpression of a human TNF transgene accelerated pathology. These results establish an independent role for enhanced p75TNF-R production in the pathogenesis of inflammatory disease and implicate the direct involvement of this receptor in a wide range of human inflammatory pathologies. Instructions: please typing these entity words according to sentence: p75 tumor necrosis factor receptor, p75TNF - R, lymphotoxin alpha, p75 tumor necrosis factor receptor, p75TNF - R, p75TNF - R, NF - kappaB, lymphotoxin alpha, p55TNF - R, human TNF transgene, p75TNF - R Options: Entity, Protein	[ "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNF-R. Despite overwhelming evidence that enhanced production of the p75 tumor necrosis factor receptor (p75TNF-R) accompanies development of specific human inflammatory pathologies such as multi-organ failure during sepsis, inflammatory liver disease, pancreatitis, respiratory distress syndrome, or AIDS, the function of this receptor remains poorly defined in vivo. We show here that at levels relevant to human disease, production of the human p75TNF-R in transgenic mice results in a severe inflammatory syndrome involving mainly the pancreas, liver, kidney, and lung, and characterized by constitutively increased NF-kappaB activity in the peripheral blood mononuclear cell compartment. This process is shown to evolve independently of the presence of TNF, lymphotoxin alpha, or the p55TNF-R, although coexpression of a human TNF transgene accelerated pathology. These results establish an independent role for enhanced p75TNF-R production in the pathogenesis of inflammatory disease and implicate the direct involvement of this receptor in a wide range of human inflammatory pathologies.	[ "A", "critical", "role", "of", "the", "p75", "tumor", "necrosis", "factor", "receptor", "(", "p75TNF", "-", "R", ")", "in", "organ", "inflammation", "independent", "of", "TNF", ",", "lymphotoxin", "alpha", ",", "or", "the", "p55TNF", "-", "R.", "\n", "Despite", "overwhelming", "evidence", "that", "enhanced", "production", "of", "the", "p75", "tumor", "necrosis", "factor", "receptor", "(", "p75TNF", "-", "R", ")", "accompanies", "development", "of", "specific", "human", "inflammatory", "pathologies", "such", "as", "multi", "-", "organ", "failure", "during", "sepsis", ",", "inflammatory", "liver", "disease", ",", "pancreatitis", ",", "respiratory", "distress", "syndrome", ",", "or", "AIDS", ",", "the", "function", "of", "this", "receptor", "remains", "poorly", "defined", "in", "vivo", ".", "We", "show", "here", "that", "at", "levels", "relevant", "to", "human", "disease", ",", "production", "of", "the", "human", "p75TNF", "-", "R", "in", "transgenic", "mice", "results", "in", "a", "severe", "inflammatory", "syndrome", "involving", "mainly", "the", "pancreas", ",", "liver", ",", "kidney", ",", "and", "lung", ",", "and", "characterized", "by", "constitutively", "increased", "NF", "-", "kappaB", "activity", "in", "the", "peripheral", "blood", "mononuclear", "cell", "compartment", ".", "This", "process", "is", "shown", "to", "evolve", "independently", "of", "the", "presence", "of", "TNF", ",", "lymphotoxin", "alpha", ",", "or", "the", "p55TNF", "-", "R", ",", "although", "coexpression", "of", "a", "human", "TNF", "transgene", "accelerated", "pathology", ".", "These", "results", "establish", "an", "independent", "role", "for", "enhanced", "p75TNF", "-", "R", "production", "in", "the", "pathogenesis", "of", "inflammatory", "disease", "and", "implicate", "the", "direct", "involvement", "of", "this", "receptor", "in", "a", "wide", "range", "of", "human", "inflammatory", "pathologies", ".", "\n" ]	[ "Protein", "Entity" ]
p75 tumor necrosis factor receptor, p75TNF - R, lymphotoxin alpha, p75 tumor necrosis factor receptor, p75TNF - R, p75TNF - R, NF - kappaB, lymphotoxin alpha, p55TNF - R, human TNF transgene, p75TNF - R	341_task2	Sentence: A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNF-R. Despite overwhelming evidence that enhanced production of the p75 tumor necrosis factor receptor (p75TNF-R) accompanies development of specific human inflammatory pathologies such as multi-organ failure during sepsis, inflammatory liver disease, pancreatitis, respiratory distress syndrome, or AIDS, the function of this receptor remains poorly defined in vivo. We show here that at levels relevant to human disease, production of the human p75TNF-R in transgenic mice results in a severe inflammatory syndrome involving mainly the pancreas, liver, kidney, and lung, and characterized by constitutively increased NF-kappaB activity in the peripheral blood mononuclear cell compartment. This process is shown to evolve independently of the presence of TNF, lymphotoxin alpha, or the p55TNF-R, although coexpression of a human TNF transgene accelerated pathology. These results establish an independent role for enhanced p75TNF-R production in the pathogenesis of inflammatory disease and implicate the direct involvement of this receptor in a wide range of human inflammatory pathologies. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNF-R. Despite overwhelming evidence that enhanced production of the p75 tumor necrosis factor receptor (p75TNF-R) accompanies development of specific human inflammatory pathologies such as multi-organ failure during sepsis, inflammatory liver disease, pancreatitis, respiratory distress syndrome, or AIDS, the function of this receptor remains poorly defined in vivo. We show here that at levels relevant to human disease, production of the human p75TNF-R in transgenic mice results in a severe inflammatory syndrome involving mainly the pancreas, liver, kidney, and lung, and characterized by constitutively increased NF-kappaB activity in the peripheral blood mononuclear cell compartment. This process is shown to evolve independently of the presence of TNF, lymphotoxin alpha, or the p55TNF-R, although coexpression of a human TNF transgene accelerated pathology. These results establish an independent role for enhanced p75TNF-R production in the pathogenesis of inflammatory disease and implicate the direct involvement of this receptor in a wide range of human inflammatory pathologies.	[ "A", "critical", "role", "of", "the", "p75", "tumor", "necrosis", "factor", "receptor", "(", "p75TNF", "-", "R", ")", "in", "organ", "inflammation", "independent", "of", "TNF", ",", "lymphotoxin", "alpha", ",", "or", "the", "p55TNF", "-", "R.", "\n", "Despite", "overwhelming", "evidence", "that", "enhanced", "production", "of", "the", "p75", "tumor", "necrosis", "factor", "receptor", "(", "p75TNF", "-", "R", ")", "accompanies", "development", "of", "specific", "human", "inflammatory", "pathologies", "such", "as", "multi", "-", "organ", "failure", "during", "sepsis", ",", "inflammatory", "liver", "disease", ",", "pancreatitis", ",", "respiratory", "distress", "syndrome", ",", "or", "AIDS", ",", "the", "function", "of", "this", "receptor", "remains", "poorly", "defined", "in", "vivo", ".", "We", "show", "here", "that", "at", "levels", "relevant", "to", "human", "disease", ",", "production", "of", "the", "human", "p75TNF", "-", "R", "in", "transgenic", "mice", "results", "in", "a", "severe", "inflammatory", "syndrome", "involving", "mainly", "the", "pancreas", ",", "liver", ",", "kidney", ",", "and", "lung", ",", "and", "characterized", "by", "constitutively", "increased", "NF", "-", "kappaB", "activity", "in", "the", "peripheral", "blood", "mononuclear", "cell", "compartment", ".", "This", "process", "is", "shown", "to", "evolve", "independently", "of", "the", "presence", "of", "TNF", ",", "lymphotoxin", "alpha", ",", "or", "the", "p55TNF", "-", "R", ",", "although", "coexpression", "of", "a", "human", "TNF", "transgene", "accelerated", "pathology", ".", "These", "results", "establish", "an", "independent", "role", "for", "enhanced", "p75TNF", "-", "R", "production", "in", "the", "pathogenesis", "of", "inflammatory", "disease", "and", "implicate", "the", "direct", "involvement", "of", "this", "receptor", "in", "a", "wide", "range", "of", "human", "inflammatory", "pathologies", ".", "\n" ]	[ "Protein", "Entity" ]
Acyl - CoA synthetase isoforms 1 , 4 , and 5 is a GENE-N, acyl - CoA synthetase is a GENE-N, ACS is a GENE-N, acyl - CoAs is a CHEMICAL, ACSs is a GENE-N, ACS1 is a GENE-Y, ACS4 is a GENE-Y, ACS5 is a GENE-Y, ACS1 is a GENE-Y, ACS4 is a GENE-Y, ACS5 is a GENE-Y, N - ethylmaleimide is a CHEMICAL, ACS4 is a GENE-Y, ACS is a GENE-N, Troglitazone is a CHEMICAL, ACS4 is a GENE-Y, ACS is a GENE-N, Triacsin C is a CHEMICAL, ACS1 is a GENE-Y, ACS4 is a GENE-Y, ACS is a GENE-N, triacsin is a CHEMICAL, ACS is a GENE-N, ACS1 is a GENE-Y, ACS4 is a GENE-Y, ACS5 is a GENE-Y, ACS4 is a GENE-Y, ACS5 is a GENE-Y, sucrose is a CHEMICAL, ACS1 is a GENE-Y, ACS4 is a GENE-Y, ACS1 is a GENE-Y, ACS4 is a GENE-Y, triacylglycerol is a CHEMICAL, acyl - CoAs is a CHEMICAL, ACS is a GENE-N	8550_task0	Sentence: Acyl-CoA synthetase isoforms 1, 4, and 5 are present in different subcellular membranes in rat liver and can be inhibited independently. Inhibition studies have suggested that acyl-CoA synthetase (ACS, EC ) isoforms might regulate the use of acyl-CoAs by different metabolic pathways. In order to determine whether the subcellular locations differed for each of the three ACSs present in liver and whether these isoforms were regulated independently, non-cross-reacting peptide antibodies were raised against ACS1, ACS4, and ACS5. ACS1 was identified in endoplasmic reticulum, mitochondria-associated membrane (MAM), and cytosol, but not in mitochondria. ACS4 was present primarily in MAM, and the 76-kDa ACS5 protein was located in mitochondrial membrane. Consistent with these locations, N-ethylmaleimide, an inhibitor of ACS4, inhibited ACS activity 47% in MAM and 28% in endoplasmic reticulum. Troglitazone, a second ACS4 inhibitor, inhibited ACS activity <10% in microsomes and mitochondria and 45% in MAM. Triacsin C, a competitive inhibitor of both ACS1 and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria. ACS1, ACS4, and ACS5 were regulated independently by fasting and re-feeding. Fasting rats for 48 h resulted in a decrease in ACS4 protein, and an increase in ACS5. Re-feeding normal chow or a high sucrose diet for 24 h after a 48-h fast increased both ACS1 and ACS4 protein expression 1.5-2.0-fold, consistent with inhibition studies. These results suggest that ACS1 and ACS4 may be linked to triacylglycerol synthesis. Taken together, the data suggest that acyl-CoAs may be functionally channeled to specific metabolic pathways through different ACS isoforms in unique subcellular locations. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N, CHEMICAL	[ "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O" ]	Acyl-CoA synthetase isoforms 1, 4, and 5 are present in different subcellular membranes in rat liver and can be inhibited independently. Inhibition studies have suggested that acyl-CoA synthetase (ACS, EC ) isoforms might regulate the use of acyl-CoAs by different metabolic pathways. In order to determine whether the subcellular locations differed for each of the three ACSs present in liver and whether these isoforms were regulated independently, non-cross-reacting peptide antibodies were raised against ACS1, ACS4, and ACS5. ACS1 was identified in endoplasmic reticulum, mitochondria-associated membrane (MAM), and cytosol, but not in mitochondria. ACS4 was present primarily in MAM, and the 76-kDa ACS5 protein was located in mitochondrial membrane. Consistent with these locations, N-ethylmaleimide, an inhibitor of ACS4, inhibited ACS activity 47% in MAM and 28% in endoplasmic reticulum. Troglitazone, a second ACS4 inhibitor, inhibited ACS activity <10% in microsomes and mitochondria and 45% in MAM. Triacsin C, a competitive inhibitor of both ACS1 and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria. ACS1, ACS4, and ACS5 were regulated independently by fasting and re-feeding. Fasting rats for 48 h resulted in a decrease in ACS4 protein, and an increase in ACS5. Re-feeding normal chow or a high sucrose diet for 24 h after a 48-h fast increased both ACS1 and ACS4 protein expression 1.5-2.0-fold, consistent with inhibition studies. These results suggest that ACS1 and ACS4 may be linked to triacylglycerol synthesis. Taken together, the data suggest that acyl-CoAs may be functionally channeled to specific metabolic pathways through different ACS isoforms in unique subcellular locations.	[ "Acyl", "-", "CoA", "synthetase", "isoforms", "1", ",", "4", ",", "and", "5", "are", "present", "in", "different", "subcellular", "membranes", "in", "rat", "liver", "and", "can", "be", "inhibited", "independently", ".", "\n", "Inhibition", "studies", "have", "suggested", "that", "acyl", "-", "CoA", "synthetase", "(", "ACS", ",", "EC", ")", "isoforms", "might", "regulate", "the", "use", "of", "acyl", "-", "CoAs", "by", "different", "metabolic", "pathways", ".", "In", "order", "to", "determine", "whether", "the", "subcellular", "locations", "differed", "for", "each", "of", "the", "three", "ACSs", "present", "in", "liver", "and", "whether", "these", "isoforms", "were", "regulated", "independently", ",", "non", "-", "cross", "-", "reacting", "peptide", "antibodies", "were", "raised", "against", "ACS1", ",", "ACS4", ",", "and", "ACS5", ".", "ACS1", "was", "identified", "in", "endoplasmic", "reticulum", ",", "mitochondria", "-", "associated", "membrane", "(", "MAM", ")", ",", "and", "cytosol", ",", "but", "not", "in", "mitochondria", ".", "ACS4", "was", "present", "primarily", "in", "MAM", ",", "and", "the", "76-kDa", "ACS5", "protein", "was", "located", "in", "mitochondrial", "membrane", ".", "Consistent", "with", "these", "locations", ",", "N", "-", "ethylmaleimide", ",", "an", "inhibitor", "of", "ACS4", ",", "inhibited", "ACS", "activity", "47", "%", "in", "MAM", "and", "28", "%", "in", "endoplasmic", "reticulum", ".", "Troglitazone", ",", "a", "second", "ACS4", "inhibitor", ",", "inhibited", "ACS", "activity", "<", "10", "%", "in", "microsomes", "and", "mitochondria", "and", "45", "%", "in", "MAM", ".", "Triacsin", "C", ",", "a", "competitive", "inhibitor", "of", "both", "ACS1", "and", "ACS4", ",", "inhibited", "ACS", "activity", "similarly", "in", "endoplasmic", "reticulum", ",", "MAM", ",", "and", "mitochondria", ",", "suggesting", "that", "a", "hitherto", "unidentified", "triacsin", "-", "sensitive", "ACS", "is", "present", "in", "mitochondria", ".", "ACS1", ",", "ACS4", ",", "and", "ACS5", "were", "regulated", "independently", "by", "fasting", "and", "re", "-", "feeding", ".", "Fasting", "rats", "for", "48", "h", "resulted", "in", "a", "decrease", "in", "ACS4", "protein", ",", "and", "an", "increase", "in", "ACS5", ".", "Re", "-", "feeding", "normal", "chow", "or", "a", "high", "sucrose", "diet", "for", "24", "h", "after", "a", "48-h", "fast", "increased", "both", "ACS1", "and", "ACS4", "protein", "expression", "1.5", "-", "2.0-fold", ",", "consistent", "with", "inhibition", "studies", ".", "These", "results", "suggest", "that", "ACS1", "and", "ACS4", "may", "be", "linked", "to", "triacylglycerol", "synthesis", ".", "Taken", "together", ",", "the", "data", "suggest", "that", "acyl", "-", "CoAs", "may", "be", "functionally", "channeled", "to", "specific", "metabolic", "pathways", "through", "different", "ACS", "isoforms", "in", "unique", "subcellular", "locations", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
Acyl - CoA synthetase isoforms 1 , 4 , and 5 is a GENE-N, acyl - CoA synthetase is a GENE-N, ACS is a GENE-N, acyl - CoAs is a CHEMICAL, ACSs is a GENE-N, ACS1 is a GENE-Y, ACS4 is a GENE-Y, ACS5 is a GENE-Y, ACS1 is a GENE-Y, ACS4 is a GENE-Y, ACS5 is a GENE-Y, N - ethylmaleimide is a CHEMICAL, ACS4 is a GENE-Y, ACS is a GENE-N, Troglitazone is a CHEMICAL, ACS4 is a GENE-Y, ACS is a GENE-N, Triacsin C is a CHEMICAL, ACS1 is a GENE-Y, ACS4 is a GENE-Y, ACS is a GENE-N, triacsin is a CHEMICAL, ACS is a GENE-N, ACS1 is a GENE-Y, ACS4 is a GENE-Y, ACS5 is a GENE-Y, ACS4 is a GENE-Y, ACS5 is a GENE-Y, sucrose is a CHEMICAL, ACS1 is a GENE-Y, ACS4 is a GENE-Y, ACS1 is a GENE-Y, ACS4 is a GENE-Y, triacylglycerol is a CHEMICAL, acyl - CoAs is a CHEMICAL, ACS is a GENE-N	8550_task1	Sentence: Acyl-CoA synthetase isoforms 1, 4, and 5 are present in different subcellular membranes in rat liver and can be inhibited independently. Inhibition studies have suggested that acyl-CoA synthetase (ACS, EC ) isoforms might regulate the use of acyl-CoAs by different metabolic pathways. In order to determine whether the subcellular locations differed for each of the three ACSs present in liver and whether these isoforms were regulated independently, non-cross-reacting peptide antibodies were raised against ACS1, ACS4, and ACS5. ACS1 was identified in endoplasmic reticulum, mitochondria-associated membrane (MAM), and cytosol, but not in mitochondria. ACS4 was present primarily in MAM, and the 76-kDa ACS5 protein was located in mitochondrial membrane. Consistent with these locations, N-ethylmaleimide, an inhibitor of ACS4, inhibited ACS activity 47% in MAM and 28% in endoplasmic reticulum. Troglitazone, a second ACS4 inhibitor, inhibited ACS activity <10% in microsomes and mitochondria and 45% in MAM. Triacsin C, a competitive inhibitor of both ACS1 and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria. ACS1, ACS4, and ACS5 were regulated independently by fasting and re-feeding. Fasting rats for 48 h resulted in a decrease in ACS4 protein, and an increase in ACS5. Re-feeding normal chow or a high sucrose diet for 24 h after a 48-h fast increased both ACS1 and ACS4 protein expression 1.5-2.0-fold, consistent with inhibition studies. These results suggest that ACS1 and ACS4 may be linked to triacylglycerol synthesis. Taken together, the data suggest that acyl-CoAs may be functionally channeled to specific metabolic pathways through different ACS isoforms in unique subcellular locations. Instructions: please typing these entity words according to sentence: Acyl - CoA synthetase isoforms 1 , 4 , and 5, acyl - CoA synthetase, ACS, acyl - CoAs, ACSs, ACS1, ACS4, ACS5, ACS1, ACS4, ACS5, N - ethylmaleimide, ACS4, ACS, Troglitazone, ACS4, ACS, Triacsin C, ACS1, ACS4, ACS, triacsin, ACS, ACS1, ACS4, ACS5, ACS4, ACS5, sucrose, ACS1, ACS4, ACS1, ACS4, triacylglycerol, acyl - CoAs, ACS Options: GENE-Y, GENE-N, CHEMICAL	[ "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O" ]	Acyl-CoA synthetase isoforms 1, 4, and 5 are present in different subcellular membranes in rat liver and can be inhibited independently. Inhibition studies have suggested that acyl-CoA synthetase (ACS, EC ) isoforms might regulate the use of acyl-CoAs by different metabolic pathways. In order to determine whether the subcellular locations differed for each of the three ACSs present in liver and whether these isoforms were regulated independently, non-cross-reacting peptide antibodies were raised against ACS1, ACS4, and ACS5. ACS1 was identified in endoplasmic reticulum, mitochondria-associated membrane (MAM), and cytosol, but not in mitochondria. ACS4 was present primarily in MAM, and the 76-kDa ACS5 protein was located in mitochondrial membrane. Consistent with these locations, N-ethylmaleimide, an inhibitor of ACS4, inhibited ACS activity 47% in MAM and 28% in endoplasmic reticulum. Troglitazone, a second ACS4 inhibitor, inhibited ACS activity <10% in microsomes and mitochondria and 45% in MAM. Triacsin C, a competitive inhibitor of both ACS1 and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria. ACS1, ACS4, and ACS5 were regulated independently by fasting and re-feeding. Fasting rats for 48 h resulted in a decrease in ACS4 protein, and an increase in ACS5. Re-feeding normal chow or a high sucrose diet for 24 h after a 48-h fast increased both ACS1 and ACS4 protein expression 1.5-2.0-fold, consistent with inhibition studies. These results suggest that ACS1 and ACS4 may be linked to triacylglycerol synthesis. Taken together, the data suggest that acyl-CoAs may be functionally channeled to specific metabolic pathways through different ACS isoforms in unique subcellular locations.	[ "Acyl", "-", "CoA", "synthetase", "isoforms", "1", ",", "4", ",", "and", "5", "are", "present", "in", "different", "subcellular", "membranes", "in", "rat", "liver", "and", "can", "be", "inhibited", "independently", ".", "\n", "Inhibition", "studies", "have", "suggested", "that", "acyl", "-", "CoA", "synthetase", "(", "ACS", ",", "EC", ")", "isoforms", "might", "regulate", "the", "use", "of", "acyl", "-", "CoAs", "by", "different", "metabolic", "pathways", ".", "In", "order", "to", "determine", "whether", "the", "subcellular", "locations", "differed", "for", "each", "of", "the", "three", "ACSs", "present", "in", "liver", "and", "whether", "these", "isoforms", "were", "regulated", "independently", ",", "non", "-", "cross", "-", "reacting", "peptide", "antibodies", "were", "raised", "against", "ACS1", ",", "ACS4", ",", "and", "ACS5", ".", "ACS1", "was", "identified", "in", "endoplasmic", "reticulum", ",", "mitochondria", "-", "associated", "membrane", "(", "MAM", ")", ",", "and", "cytosol", ",", "but", "not", "in", "mitochondria", ".", "ACS4", "was", "present", "primarily", "in", "MAM", ",", "and", "the", "76-kDa", "ACS5", "protein", "was", "located", "in", "mitochondrial", "membrane", ".", "Consistent", "with", "these", "locations", ",", "N", "-", "ethylmaleimide", ",", "an", "inhibitor", "of", "ACS4", ",", "inhibited", "ACS", "activity", "47", "%", "in", "MAM", "and", "28", "%", "in", "endoplasmic", "reticulum", ".", "Troglitazone", ",", "a", "second", "ACS4", "inhibitor", ",", "inhibited", "ACS", "activity", "<", "10", "%", "in", "microsomes", "and", "mitochondria", "and", "45", "%", "in", "MAM", ".", "Triacsin", "C", ",", "a", "competitive", "inhibitor", "of", "both", "ACS1", "and", "ACS4", ",", "inhibited", "ACS", "activity", "similarly", "in", "endoplasmic", "reticulum", ",", "MAM", ",", "and", "mitochondria", ",", "suggesting", "that", "a", "hitherto", "unidentified", "triacsin", "-", "sensitive", "ACS", "is", "present", "in", "mitochondria", ".", "ACS1", ",", "ACS4", ",", "and", "ACS5", "were", "regulated", "independently", "by", "fasting", "and", "re", "-", "feeding", ".", "Fasting", "rats", "for", "48", "h", "resulted", "in", "a", "decrease", "in", "ACS4", "protein", ",", "and", "an", "increase", "in", "ACS5", ".", "Re", "-", "feeding", "normal", "chow", "or", "a", "high", "sucrose", "diet", "for", "24", "h", "after", "a", "48-h", "fast", "increased", "both", "ACS1", "and", "ACS4", "protein", "expression", "1.5", "-", "2.0-fold", ",", "consistent", "with", "inhibition", "studies", ".", "These", "results", "suggest", "that", "ACS1", "and", "ACS4", "may", "be", "linked", "to", "triacylglycerol", "synthesis", ".", "Taken", "together", ",", "the", "data", "suggest", "that", "acyl", "-", "CoAs", "may", "be", "functionally", "channeled", "to", "specific", "metabolic", "pathways", "through", "different", "ACS", "isoforms", "in", "unique", "subcellular", "locations", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
Acyl - CoA synthetase isoforms 1 , 4 , and 5, acyl - CoA synthetase, ACS, acyl - CoAs, ACSs, ACS1, ACS4, ACS5, ACS1, ACS4, ACS5, N - ethylmaleimide, ACS4, ACS, Troglitazone, ACS4, ACS, Triacsin C, ACS1, ACS4, ACS, triacsin, ACS, ACS1, ACS4, ACS5, ACS4, ACS5, sucrose, ACS1, ACS4, ACS1, ACS4, triacylglycerol, acyl - CoAs, ACS	8550_task2	Sentence: Acyl-CoA synthetase isoforms 1, 4, and 5 are present in different subcellular membranes in rat liver and can be inhibited independently. Inhibition studies have suggested that acyl-CoA synthetase (ACS, EC ) isoforms might regulate the use of acyl-CoAs by different metabolic pathways. In order to determine whether the subcellular locations differed for each of the three ACSs present in liver and whether these isoforms were regulated independently, non-cross-reacting peptide antibodies were raised against ACS1, ACS4, and ACS5. ACS1 was identified in endoplasmic reticulum, mitochondria-associated membrane (MAM), and cytosol, but not in mitochondria. ACS4 was present primarily in MAM, and the 76-kDa ACS5 protein was located in mitochondrial membrane. Consistent with these locations, N-ethylmaleimide, an inhibitor of ACS4, inhibited ACS activity 47% in MAM and 28% in endoplasmic reticulum. Troglitazone, a second ACS4 inhibitor, inhibited ACS activity <10% in microsomes and mitochondria and 45% in MAM. Triacsin C, a competitive inhibitor of both ACS1 and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria. ACS1, ACS4, and ACS5 were regulated independently by fasting and re-feeding. Fasting rats for 48 h resulted in a decrease in ACS4 protein, and an increase in ACS5. Re-feeding normal chow or a high sucrose diet for 24 h after a 48-h fast increased both ACS1 and ACS4 protein expression 1.5-2.0-fold, consistent with inhibition studies. These results suggest that ACS1 and ACS4 may be linked to triacylglycerol synthesis. Taken together, the data suggest that acyl-CoAs may be functionally channeled to specific metabolic pathways through different ACS isoforms in unique subcellular locations. Instructions: please extract entity words from the input sentence	[ "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O" ]	Acyl-CoA synthetase isoforms 1, 4, and 5 are present in different subcellular membranes in rat liver and can be inhibited independently. Inhibition studies have suggested that acyl-CoA synthetase (ACS, EC ) isoforms might regulate the use of acyl-CoAs by different metabolic pathways. In order to determine whether the subcellular locations differed for each of the three ACSs present in liver and whether these isoforms were regulated independently, non-cross-reacting peptide antibodies were raised against ACS1, ACS4, and ACS5. ACS1 was identified in endoplasmic reticulum, mitochondria-associated membrane (MAM), and cytosol, but not in mitochondria. ACS4 was present primarily in MAM, and the 76-kDa ACS5 protein was located in mitochondrial membrane. Consistent with these locations, N-ethylmaleimide, an inhibitor of ACS4, inhibited ACS activity 47% in MAM and 28% in endoplasmic reticulum. Troglitazone, a second ACS4 inhibitor, inhibited ACS activity <10% in microsomes and mitochondria and 45% in MAM. Triacsin C, a competitive inhibitor of both ACS1 and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria. ACS1, ACS4, and ACS5 were regulated independently by fasting and re-feeding. Fasting rats for 48 h resulted in a decrease in ACS4 protein, and an increase in ACS5. Re-feeding normal chow or a high sucrose diet for 24 h after a 48-h fast increased both ACS1 and ACS4 protein expression 1.5-2.0-fold, consistent with inhibition studies. These results suggest that ACS1 and ACS4 may be linked to triacylglycerol synthesis. Taken together, the data suggest that acyl-CoAs may be functionally channeled to specific metabolic pathways through different ACS isoforms in unique subcellular locations.	[ "Acyl", "-", "CoA", "synthetase", "isoforms", "1", ",", "4", ",", "and", "5", "are", "present", "in", "different", "subcellular", "membranes", "in", "rat", "liver", "and", "can", "be", "inhibited", "independently", ".", "\n", "Inhibition", "studies", "have", "suggested", "that", "acyl", "-", "CoA", "synthetase", "(", "ACS", ",", "EC", ")", "isoforms", "might", "regulate", "the", "use", "of", "acyl", "-", "CoAs", "by", "different", "metabolic", "pathways", ".", "In", "order", "to", "determine", "whether", "the", "subcellular", "locations", "differed", "for", "each", "of", "the", "three", "ACSs", "present", "in", "liver", "and", "whether", "these", "isoforms", "were", "regulated", "independently", ",", "non", "-", "cross", "-", "reacting", "peptide", "antibodies", "were", "raised", "against", "ACS1", ",", "ACS4", ",", "and", "ACS5", ".", "ACS1", "was", "identified", "in", "endoplasmic", "reticulum", ",", "mitochondria", "-", "associated", "membrane", "(", "MAM", ")", ",", "and", "cytosol", ",", "but", "not", "in", "mitochondria", ".", "ACS4", "was", "present", "primarily", "in", "MAM", ",", "and", "the", "76-kDa", "ACS5", "protein", "was", "located", "in", "mitochondrial", "membrane", ".", "Consistent", "with", "these", "locations", ",", "N", "-", "ethylmaleimide", ",", "an", "inhibitor", "of", "ACS4", ",", "inhibited", "ACS", "activity", "47", "%", "in", "MAM", "and", "28", "%", "in", "endoplasmic", "reticulum", ".", "Troglitazone", ",", "a", "second", "ACS4", "inhibitor", ",", "inhibited", "ACS", "activity", "<", "10", "%", "in", "microsomes", "and", "mitochondria", "and", "45", "%", "in", "MAM", ".", "Triacsin", "C", ",", "a", "competitive", "inhibitor", "of", "both", "ACS1", "and", "ACS4", ",", "inhibited", "ACS", "activity", "similarly", "in", "endoplasmic", "reticulum", ",", "MAM", ",", "and", "mitochondria", ",", "suggesting", "that", "a", "hitherto", "unidentified", "triacsin", "-", "sensitive", "ACS", "is", "present", "in", "mitochondria", ".", "ACS1", ",", "ACS4", ",", "and", "ACS5", "were", "regulated", "independently", "by", "fasting", "and", "re", "-", "feeding", ".", "Fasting", "rats", "for", "48", "h", "resulted", "in", "a", "decrease", "in", "ACS4", "protein", ",", "and", "an", "increase", "in", "ACS5", ".", "Re", "-", "feeding", "normal", "chow", "or", "a", "high", "sucrose", "diet", "for", "24", "h", "after", "a", "48-h", "fast", "increased", "both", "ACS1", "and", "ACS4", "protein", "expression", "1.5", "-", "2.0-fold", ",", "consistent", "with", "inhibition", "studies", ".", "These", "results", "suggest", "that", "ACS1", "and", "ACS4", "may", "be", "linked", "to", "triacylglycerol", "synthesis", ".", "Taken", "together", ",", "the", "data", "suggest", "that", "acyl", "-", "CoAs", "may", "be", "functionally", "channeled", "to", "specific", "metabolic", "pathways", "through", "different", "ACS", "isoforms", "in", "unique", "subcellular", "locations", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
use is an umlsterm, non - biologic is an umlsterm, head is an umlsterm, neck is an umlsterm, surgery is an umlsterm, tissue compatibility is an umlsterm, epithelial cells is an umlsterm, mesenchymatic is an umlsterm, cells is an umlsterm, human is an umlsterm, fibroblasts is an umlsterm, keratinocytes is an umlsterm, oral mucosa is an umlsterm, cell culture is an umlsterm, tissue culture is an umlsterm, keratinocyte is an umlsterm, flaps is an umlsterm, histology is an umlsterm, scanning electron microscopy is an umlsterm, Cellulose - ester is an umlsterm, polyglactin is an umlsterm, fibroblasts is an umlsterm, keratinocytes is an umlsterm, cell cultures is an umlsterm, tissue culture is an umlsterm, flaps is an umlsterm, keratinocytes is an umlsterm, polytetrafluor - ethylene is an umlsterm, fibroblasts is an umlsterm, keratinocytes is an umlsterm, cell culture is an umlsterm, cell is an umlsterm, tissue culture is an umlsterm, flaps is an umlsterm, mesenchymatic is an umlsterm, cell is an umlsterm, tissue cultures is an umlsterm, growth is an umlsterm, non - biologic is an umlsterm, implants is an umlsterm, method is an umlsterm, development is an umlsterm, non - biologic is an umlsterm, implantation is an umlsterm	HNO.00480430.eng.abstr_task0	Sentence: Successful use of non-biologic implants in reconstructive head and neck surgery is dependent on tissue compatibility and epithelization . This is true not only for epithelial cells , but also for mesenchymatic cells . Therefore we tested several substrates with human fibroblasts or keratinocytes from the oral mucosa in cell culture . In tissue culture keratinocyte outgrowth from small mucosal flaps onto the surface was observed . Preparations were evaluated by histology and scanning electron microscopy . Cellulose-ester , polyvinylidene-difluoride and polyglactin developed monolayers of fibroblasts and keratinocytes in cell cultures . In tissue culture mucosal flaps showed good adherence to the surface of these materials and a fine outgrowth of keratinocytes . Expanded polytetrafluor-ethylene ( ePTFE ) was partially covered by a layer of fibroblasts and keratinocytes in cell culture , but cell adherence was not sufficient . In tissue culture the mucosal flaps failed to attach on ePTFE . These results illustrate that the mesenchymatic and epithelial component of cell and tissue cultures show different qualities of cellular adherence and growth on the surface of non-biologic implants . We propose our method for the development of an in-vitro model for the epithelization of non-biologic implantation materials . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O" ]	Successful use of non-biologic implants in reconstructive head and neck surgery is dependent on tissue compatibility and epithelization . This is true not only for epithelial cells , but also for mesenchymatic cells . Therefore we tested several substrates with human fibroblasts or keratinocytes from the oral mucosa in cell culture . In tissue culture keratinocyte outgrowth from small mucosal flaps onto the surface was observed . Preparations were evaluated by histology and scanning electron microscopy . Cellulose-ester , polyvinylidene-difluoride and polyglactin developed monolayers of fibroblasts and keratinocytes in cell cultures . In tissue culture mucosal flaps showed good adherence to the surface of these materials and a fine outgrowth of keratinocytes . Expanded polytetrafluor-ethylene ( ePTFE ) was partially covered by a layer of fibroblasts and keratinocytes in cell culture , but cell adherence was not sufficient . In tissue culture the mucosal flaps failed to attach on ePTFE . These results illustrate that the mesenchymatic and epithelial component of cell and tissue cultures show different qualities of cellular adherence and growth on the surface of non-biologic implants . We propose our method for the development of an in-vitro model for the epithelization of non-biologic implantation materials .	[ "Successful", "use", "of", "non", "-", "biologic", "implants", "in", "reconstructive", "head", "and", "neck", "surgery", "is", "dependent", "on", "tissue", "compatibility", "and", "epithelization", ".", "This", "is", "true", "not", "only", "for", "epithelial", "cells", ",", "but", "also", "for", "mesenchymatic", "cells", ".", "Therefore", "we", "tested", "several", "substrates", "with", "human", "fibroblasts", "or", "keratinocytes", "from", "the", "oral", "mucosa", "in", "cell", "culture", ".", "In", "tissue", "culture", "keratinocyte", "outgrowth", "from", "small", "mucosal", "flaps", "onto", "the", "surface", "was", "observed", ".", "Preparations", "were", "evaluated", "by", "histology", "and", "scanning", "electron", "microscopy", ".", "Cellulose", "-", "ester", ",", "polyvinylidene", "-", "difluoride", "and", "polyglactin", "developed", "monolayers", "of", "fibroblasts", "and", "keratinocytes", "in", "cell", "cultures", ".", "In", "tissue", "culture", "mucosal", "flaps", "showed", "good", "adherence", "to", "the", "surface", "of", "these", "materials", "and", "a", "fine", "outgrowth", "of", "keratinocytes", ".", "Expanded", "polytetrafluor", "-", "ethylene", "(", "ePTFE", ")", "was", "partially", "covered", "by", "a", "layer", "of", "fibroblasts", "and", "keratinocytes", "in", "cell", "culture", ",", "but", "cell", "adherence", "was", "not", "sufficient", ".", "In", "tissue", "culture", "the", "mucosal", "flaps", "failed", "to", "attach", "on", "ePTFE", ".", "These", "results", "illustrate", "that", "the", "mesenchymatic", "and", "epithelial", "component", "of", "cell", "and", "tissue", "cultures", "show", "different", "qualities", "of", "cellular", "adherence", "and", "growth", "on", "the", "surface", "of", "non", "-", "biologic", "implants", ".", "We", "propose", "our", "method", "for", "the", "development", "of", "an", "in", "-", "vitro", "model", "for", "the", "epithelization", "of", "non", "-", "biologic", "implantation", "materials", "." ]	[ "umlsterm" ]
use is an umlsterm, non - biologic is an umlsterm, head is an umlsterm, neck is an umlsterm, surgery is an umlsterm, tissue compatibility is an umlsterm, epithelial cells is an umlsterm, mesenchymatic is an umlsterm, cells is an umlsterm, human is an umlsterm, fibroblasts is an umlsterm, keratinocytes is an umlsterm, oral mucosa is an umlsterm, cell culture is an umlsterm, tissue culture is an umlsterm, keratinocyte is an umlsterm, flaps is an umlsterm, histology is an umlsterm, scanning electron microscopy is an umlsterm, Cellulose - ester is an umlsterm, polyglactin is an umlsterm, fibroblasts is an umlsterm, keratinocytes is an umlsterm, cell cultures is an umlsterm, tissue culture is an umlsterm, flaps is an umlsterm, keratinocytes is an umlsterm, polytetrafluor - ethylene is an umlsterm, fibroblasts is an umlsterm, keratinocytes is an umlsterm, cell culture is an umlsterm, cell is an umlsterm, tissue culture is an umlsterm, flaps is an umlsterm, mesenchymatic is an umlsterm, cell is an umlsterm, tissue cultures is an umlsterm, growth is an umlsterm, non - biologic is an umlsterm, implants is an umlsterm, method is an umlsterm, development is an umlsterm, non - biologic is an umlsterm, implantation is an umlsterm	HNO.00480430.eng.abstr_task1	Sentence: Successful use of non-biologic implants in reconstructive head and neck surgery is dependent on tissue compatibility and epithelization . This is true not only for epithelial cells , but also for mesenchymatic cells . Therefore we tested several substrates with human fibroblasts or keratinocytes from the oral mucosa in cell culture . In tissue culture keratinocyte outgrowth from small mucosal flaps onto the surface was observed . Preparations were evaluated by histology and scanning electron microscopy . Cellulose-ester , polyvinylidene-difluoride and polyglactin developed monolayers of fibroblasts and keratinocytes in cell cultures . In tissue culture mucosal flaps showed good adherence to the surface of these materials and a fine outgrowth of keratinocytes . Expanded polytetrafluor-ethylene ( ePTFE ) was partially covered by a layer of fibroblasts and keratinocytes in cell culture , but cell adherence was not sufficient . In tissue culture the mucosal flaps failed to attach on ePTFE . These results illustrate that the mesenchymatic and epithelial component of cell and tissue cultures show different qualities of cellular adherence and growth on the surface of non-biologic implants . We propose our method for the development of an in-vitro model for the epithelization of non-biologic implantation materials . Instructions: please typing these entity words according to sentence: use, non - biologic, head, neck, surgery, tissue compatibility, epithelial cells, mesenchymatic, cells, human, fibroblasts, keratinocytes, oral mucosa, cell culture, tissue culture, keratinocyte, flaps, histology, scanning electron microscopy, Cellulose - ester, polyglactin, fibroblasts, keratinocytes, cell cultures, tissue culture, flaps, keratinocytes, polytetrafluor - ethylene, fibroblasts, keratinocytes, cell culture, cell, tissue culture, flaps, mesenchymatic, cell, tissue cultures, growth, non - biologic, implants, method, development, non - biologic, implantation Options: umlsterm	[ "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O" ]	Successful use of non-biologic implants in reconstructive head and neck surgery is dependent on tissue compatibility and epithelization . This is true not only for epithelial cells , but also for mesenchymatic cells . Therefore we tested several substrates with human fibroblasts or keratinocytes from the oral mucosa in cell culture . In tissue culture keratinocyte outgrowth from small mucosal flaps onto the surface was observed . Preparations were evaluated by histology and scanning electron microscopy . Cellulose-ester , polyvinylidene-difluoride and polyglactin developed monolayers of fibroblasts and keratinocytes in cell cultures . In tissue culture mucosal flaps showed good adherence to the surface of these materials and a fine outgrowth of keratinocytes . Expanded polytetrafluor-ethylene ( ePTFE ) was partially covered by a layer of fibroblasts and keratinocytes in cell culture , but cell adherence was not sufficient . In tissue culture the mucosal flaps failed to attach on ePTFE . These results illustrate that the mesenchymatic and epithelial component of cell and tissue cultures show different qualities of cellular adherence and growth on the surface of non-biologic implants . We propose our method for the development of an in-vitro model for the epithelization of non-biologic implantation materials .	[ "Successful", "use", "of", "non", "-", "biologic", "implants", "in", "reconstructive", "head", "and", "neck", "surgery", "is", "dependent", "on", "tissue", "compatibility", "and", "epithelization", ".", "This", "is", "true", "not", "only", "for", "epithelial", "cells", ",", "but", "also", "for", "mesenchymatic", "cells", ".", "Therefore", "we", "tested", "several", "substrates", "with", "human", "fibroblasts", "or", "keratinocytes", "from", "the", "oral", "mucosa", "in", "cell", "culture", ".", "In", "tissue", "culture", "keratinocyte", "outgrowth", "from", "small", "mucosal", "flaps", "onto", "the", "surface", "was", "observed", ".", "Preparations", "were", "evaluated", "by", "histology", "and", "scanning", "electron", "microscopy", ".", "Cellulose", "-", "ester", ",", "polyvinylidene", "-", "difluoride", "and", "polyglactin", "developed", "monolayers", "of", "fibroblasts", "and", "keratinocytes", "in", "cell", "cultures", ".", "In", "tissue", "culture", "mucosal", "flaps", "showed", "good", "adherence", "to", "the", "surface", "of", "these", "materials", "and", "a", "fine", "outgrowth", "of", "keratinocytes", ".", "Expanded", "polytetrafluor", "-", "ethylene", "(", "ePTFE", ")", "was", "partially", "covered", "by", "a", "layer", "of", "fibroblasts", "and", "keratinocytes", "in", "cell", "culture", ",", "but", "cell", "adherence", "was", "not", "sufficient", ".", "In", "tissue", "culture", "the", "mucosal", "flaps", "failed", "to", "attach", "on", "ePTFE", ".", "These", "results", "illustrate", "that", "the", "mesenchymatic", "and", "epithelial", "component", "of", "cell", "and", "tissue", "cultures", "show", "different", "qualities", "of", "cellular", "adherence", "and", "growth", "on", "the", "surface", "of", "non", "-", "biologic", "implants", ".", "We", "propose", "our", "method", "for", "the", "development", "of", "an", "in", "-", "vitro", "model", "for", "the", "epithelization", "of", "non", "-", "biologic", "implantation", "materials", "." ]	[ "umlsterm" ]
use, non - biologic, head, neck, surgery, tissue compatibility, epithelial cells, mesenchymatic, cells, human, fibroblasts, keratinocytes, oral mucosa, cell culture, tissue culture, keratinocyte, flaps, histology, scanning electron microscopy, Cellulose - ester, polyglactin, fibroblasts, keratinocytes, cell cultures, tissue culture, flaps, keratinocytes, polytetrafluor - ethylene, fibroblasts, keratinocytes, cell culture, cell, tissue culture, flaps, mesenchymatic, cell, tissue cultures, growth, non - biologic, implants, method, development, non - biologic, implantation	HNO.00480430.eng.abstr_task2	Sentence: Successful use of non-biologic implants in reconstructive head and neck surgery is dependent on tissue compatibility and epithelization . This is true not only for epithelial cells , but also for mesenchymatic cells . Therefore we tested several substrates with human fibroblasts or keratinocytes from the oral mucosa in cell culture . In tissue culture keratinocyte outgrowth from small mucosal flaps onto the surface was observed . Preparations were evaluated by histology and scanning electron microscopy . Cellulose-ester , polyvinylidene-difluoride and polyglactin developed monolayers of fibroblasts and keratinocytes in cell cultures . In tissue culture mucosal flaps showed good adherence to the surface of these materials and a fine outgrowth of keratinocytes . Expanded polytetrafluor-ethylene ( ePTFE ) was partially covered by a layer of fibroblasts and keratinocytes in cell culture , but cell adherence was not sufficient . In tissue culture the mucosal flaps failed to attach on ePTFE . These results illustrate that the mesenchymatic and epithelial component of cell and tissue cultures show different qualities of cellular adherence and growth on the surface of non-biologic implants . We propose our method for the development of an in-vitro model for the epithelization of non-biologic implantation materials . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O" ]	Successful use of non-biologic implants in reconstructive head and neck surgery is dependent on tissue compatibility and epithelization . This is true not only for epithelial cells , but also for mesenchymatic cells . Therefore we tested several substrates with human fibroblasts or keratinocytes from the oral mucosa in cell culture . In tissue culture keratinocyte outgrowth from small mucosal flaps onto the surface was observed . Preparations were evaluated by histology and scanning electron microscopy . Cellulose-ester , polyvinylidene-difluoride and polyglactin developed monolayers of fibroblasts and keratinocytes in cell cultures . In tissue culture mucosal flaps showed good adherence to the surface of these materials and a fine outgrowth of keratinocytes . Expanded polytetrafluor-ethylene ( ePTFE ) was partially covered by a layer of fibroblasts and keratinocytes in cell culture , but cell adherence was not sufficient . In tissue culture the mucosal flaps failed to attach on ePTFE . These results illustrate that the mesenchymatic and epithelial component of cell and tissue cultures show different qualities of cellular adherence and growth on the surface of non-biologic implants . We propose our method for the development of an in-vitro model for the epithelization of non-biologic implantation materials .	[ "Successful", "use", "of", "non", "-", "biologic", "implants", "in", "reconstructive", "head", "and", "neck", "surgery", "is", "dependent", "on", "tissue", "compatibility", "and", "epithelization", ".", "This", "is", "true", "not", "only", "for", "epithelial", "cells", ",", "but", "also", "for", "mesenchymatic", "cells", ".", "Therefore", "we", "tested", "several", "substrates", "with", "human", "fibroblasts", "or", "keratinocytes", "from", "the", "oral", "mucosa", "in", "cell", "culture", ".", "In", "tissue", "culture", "keratinocyte", "outgrowth", "from", "small", "mucosal", "flaps", "onto", "the", "surface", "was", "observed", ".", "Preparations", "were", "evaluated", "by", "histology", "and", "scanning", "electron", "microscopy", ".", "Cellulose", "-", "ester", ",", "polyvinylidene", "-", "difluoride", "and", "polyglactin", "developed", "monolayers", "of", "fibroblasts", "and", "keratinocytes", "in", "cell", "cultures", ".", "In", "tissue", "culture", "mucosal", "flaps", "showed", "good", "adherence", "to", "the", "surface", "of", "these", "materials", "and", "a", "fine", "outgrowth", "of", "keratinocytes", ".", "Expanded", "polytetrafluor", "-", "ethylene", "(", "ePTFE", ")", "was", "partially", "covered", "by", "a", "layer", "of", "fibroblasts", "and", "keratinocytes", "in", "cell", "culture", ",", "but", "cell", "adherence", "was", "not", "sufficient", ".", "In", "tissue", "culture", "the", "mucosal", "flaps", "failed", "to", "attach", "on", "ePTFE", ".", "These", "results", "illustrate", "that", "the", "mesenchymatic", "and", "epithelial", "component", "of", "cell", "and", "tissue", "cultures", "show", "different", "qualities", "of", "cellular", "adherence", "and", "growth", "on", "the", "surface", "of", "non", "-", "biologic", "implants", ".", "We", "propose", "our", "method", "for", "the", "development", "of", "an", "in", "-", "vitro", "model", "for", "the", "epithelization", "of", "non", "-", "biologic", "implantation", "materials", "." ]	[ "umlsterm" ]
interleukin-1alpha is a Protein, promoter is a Entity, Tax is a Protein, interleukin-1alpha is a Protein, IL-1alpha is a Protein, IL-1alpha is a Protein, IL-1alpha is a Protein, IL-1alpha is a Protein, IL-1alpha is a Protein, chloramphenicol acetyltransferase is a Protein, CAT is a Protein, IL-1alpha is a Protein, Tax is a Protein, IL-1alpha is a Protein, Tax is a Protein, IL-1alpha is a Protein, CAT is a Protein, p65 is a Protein, p50 is a Protein, IL-1alpha is a Protein, IL-1alpha is a Protein, IL-1alpha is a Protein, promoter is a Entity, Tax is a Protein, Tax is a Protein, IL-1alpha is a Protein, IL-1alpha is a Protein	8605359_task0	Sentence: Transactivation of the interleukin-1alpha promoter by human T-cell leukemia virus type I and type II Tax proteins. Human T-cell leukemia virus type I (HTLV-I)-infected T-cell lines constitutively produce high levels of interleukin-1alpha (IL-1alpha). To analyze the mechanisms that lead to the expression of IL-1alpha in HTLV-I-infected cell lines, we studied regulatory regions of the human IL-1alpha promoter involved in activation of the IL-1alpha gene. IL-1alpha promoter constructs drive transcription of the chloramphenicol acetyltransferase (CAT) reporter gene in HTLV-I-positive MT-2 cells, which constitutively produce IL-1alpha. In a cotransfection assay, the Tax protein of both HTLV-I and HTLV-II specifically activated transcription from the IL-1alpha promoter in an uninfected Jurkat cell line. A mutant Tax protein deficient in transactivation of genes by the nuclear factor (NF)-kappaB pathway was unable to induce transcriptional activity of IL-1alpha promoter-CAT constructs, but was rescued by exogenous provision of p65/p50 NF-kappaB. We found that two IL-1alpha kappaB-like sites (positions -1,065 to -1,056 and +646 to +655) specifically formed a complex with NF-kappaB-containing nuclear extract from MT-2 cells and that NF-kappaB bound with higher affinity to the 3' NF-kappaB binding site than to the 5' NF-kappaB site. Moreover, deletion of either 5' or 3' NF-kappaB sites reduced IL-1alpha promoter activity in MT-2 cells and transactivation of the IL-1alpha promoter by exogenous NF-kappaB and Tax in Jurkat cells. These data suggest a general role for Tax induction of IL-1alpha gene transcription by the NF-kappaB pathway. Expression of IL-1alpha by HTLV-I productively infected cells may be important in the hypercalcemia, osteolytic bone lesions, neutrophilia, elevation of C-reactive protein, and fever frequently seen in patients with HTLV-I-induced adult T-cell leukemia/lymphoma. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Transactivation of the interleukin-1alpha promoter by human T-cell leukemia virus type I and type II Tax proteins. Human T-cell leukemia virus type I (HTLV-I)-infected T-cell lines constitutively produce high levels of interleukin-1alpha (IL-1alpha). To analyze the mechanisms that lead to the expression of IL-1alpha in HTLV-I-infected cell lines, we studied regulatory regions of the human IL-1alpha promoter involved in activation of the IL-1alpha gene. IL-1alpha promoter constructs drive transcription of the chloramphenicol acetyltransferase (CAT) reporter gene in HTLV-I-positive MT-2 cells, which constitutively produce IL-1alpha. In a cotransfection assay, the Tax protein of both HTLV-I and HTLV-II specifically activated transcription from the IL-1alpha promoter in an uninfected Jurkat cell line. A mutant Tax protein deficient in transactivation of genes by the nuclear factor (NF)-kappaB pathway was unable to induce transcriptional activity of IL-1alpha promoter-CAT constructs, but was rescued by exogenous provision of p65/p50 NF-kappaB. We found that two IL-1alpha kappaB-like sites (positions -1,065 to -1,056 and +646 to +655) specifically formed a complex with NF-kappaB-containing nuclear extract from MT-2 cells and that NF-kappaB bound with higher affinity to the 3' NF-kappaB binding site than to the 5' NF-kappaB site. Moreover, deletion of either 5' or 3' NF-kappaB sites reduced IL-1alpha promoter activity in MT-2 cells and transactivation of the IL-1alpha promoter by exogenous NF-kappaB and Tax in Jurkat cells. These data suggest a general role for Tax induction of IL-1alpha gene transcription by the NF-kappaB pathway. Expression of IL-1alpha by HTLV-I productively infected cells may be important in the hypercalcemia, osteolytic bone lesions, neutrophilia, elevation of C-reactive protein, and fever frequently seen in patients with HTLV-I-induced adult T-cell leukemia/lymphoma.	[ "Transactivation", "of", "the", "interleukin-1alpha", "promoter", "by", "human", "T", "-", "cell", "leukemia", "virus", "type", "I", "and", "type", "II", "Tax", "proteins", ".", "\n", "Human", "T", "-", "cell", "leukemia", "virus", "type", "I", "(", "HTLV", "-", "I)-infected", "T", "-", "cell", "lines", "constitutively", "produce", "high", "levels", "of", "interleukin-1alpha", "(", "IL-1alpha", ")", ".", "To", "analyze", "the", "mechanisms", "that", "lead", "to", "the", "expression", "of", "IL-1alpha", "in", "HTLV", "-", "I", "-", "infected", "cell", "lines", ",", "we", "studied", "regulatory", "regions", "of", "the", "human", "IL-1alpha", "promoter", "involved", "in", "activation", "of", "the", "IL-1alpha", "gene", ".", "IL-1alpha", "promoter", "constructs", "drive", "transcription", "of", "the", "chloramphenicol", "acetyltransferase", "(", "CAT", ")", "reporter", "gene", "in", "HTLV", "-", "I", "-", "positive", "MT-2", "cells", ",", "which", "constitutively", "produce", "IL-1alpha", ".", "In", "a", "cotransfection", "assay", ",", "the", "Tax", "protein", "of", "both", "HTLV", "-", "I", "and", "HTLV", "-", "II", "specifically", "activated", "transcription", "from", "the", "IL-1alpha", "promoter", "in", "an", "uninfected", "Jurkat", "cell", "line", ".", "A", "mutant", "Tax", "protein", "deficient", "in", "transactivation", "of", "genes", "by", "the", "nuclear", "factor", "(", "NF)-kappaB", "pathway", "was", "unable", "to", "induce", "transcriptional", "activity", "of", "IL-1alpha", "promoter", "-", "CAT", "constructs", ",", "but", "was", "rescued", "by", "exogenous", "provision", "of", "p65", "/", "p50", "NF", "-", "kappaB.", "We", "found", "that", "two", "IL-1alpha", "kappaB", "-", "like", "sites", "(", "positions", "-1,065", "to", "-1,056", "and", "+646", "to", "+655", ")", "specifically", "formed", "a", "complex", "with", "NF", "-", "kappaB", "-", "containing", "nuclear", "extract", "from", "MT-2", "cells", "and", "that", "NF", "-", "kappaB", "bound", "with", "higher", "affinity", "to", "the", "3", "'", "NF", "-", "kappaB", "binding", "site", "than", "to", "the", "5", "'", "NF", "-", "kappaB", "site", ".", "Moreover", ",", "deletion", "of", "either", "5", "'", "or", "3", "'", "NF", "-", "kappaB", "sites", "reduced", "IL-1alpha", "promoter", "activity", "in", "MT-2", "cells", "and", "transactivation", "of", "the", "IL-1alpha", "promoter", "by", "exogenous", "NF", "-", "kappaB", "and", "Tax", "in", "Jurkat", "cells", ".", "These", "data", "suggest", "a", "general", "role", "for", "Tax", "induction", "of", "IL-1alpha", "gene", "transcription", "by", "the", "NF", "-", "kappaB", "pathway", ".", "Expression", "of", "IL-1alpha", "by", "HTLV", "-", "I", "productively", "infected", "cells", "may", "be", "important", "in", "the", "hypercalcemia", ",", "osteolytic", "bone", "lesions", ",", "neutrophilia", ",", "elevation", "of", "C", "-", "reactive", "protein", ",", "and", "fever", "frequently", "seen", "in", "patients", "with", "HTLV", "-", "I", "-", "induced", "adult", "T", "-", "cell", "leukemia", "/", "lymphoma", "." ]	[ "Protein", "Entity" ]
interleukin-1alpha is a Protein, promoter is a Entity, Tax is a Protein, interleukin-1alpha is a Protein, IL-1alpha is a Protein, IL-1alpha is a Protein, IL-1alpha is a Protein, IL-1alpha is a Protein, IL-1alpha is a Protein, chloramphenicol acetyltransferase is a Protein, CAT is a Protein, IL-1alpha is a Protein, Tax is a Protein, IL-1alpha is a Protein, Tax is a Protein, IL-1alpha is a Protein, CAT is a Protein, p65 is a Protein, p50 is a Protein, IL-1alpha is a Protein, IL-1alpha is a Protein, IL-1alpha is a Protein, promoter is a Entity, Tax is a Protein, Tax is a Protein, IL-1alpha is a Protein, IL-1alpha is a Protein	8605359_task1	Sentence: Transactivation of the interleukin-1alpha promoter by human T-cell leukemia virus type I and type II Tax proteins. Human T-cell leukemia virus type I (HTLV-I)-infected T-cell lines constitutively produce high levels of interleukin-1alpha (IL-1alpha). To analyze the mechanisms that lead to the expression of IL-1alpha in HTLV-I-infected cell lines, we studied regulatory regions of the human IL-1alpha promoter involved in activation of the IL-1alpha gene. IL-1alpha promoter constructs drive transcription of the chloramphenicol acetyltransferase (CAT) reporter gene in HTLV-I-positive MT-2 cells, which constitutively produce IL-1alpha. In a cotransfection assay, the Tax protein of both HTLV-I and HTLV-II specifically activated transcription from the IL-1alpha promoter in an uninfected Jurkat cell line. A mutant Tax protein deficient in transactivation of genes by the nuclear factor (NF)-kappaB pathway was unable to induce transcriptional activity of IL-1alpha promoter-CAT constructs, but was rescued by exogenous provision of p65/p50 NF-kappaB. We found that two IL-1alpha kappaB-like sites (positions -1,065 to -1,056 and +646 to +655) specifically formed a complex with NF-kappaB-containing nuclear extract from MT-2 cells and that NF-kappaB bound with higher affinity to the 3' NF-kappaB binding site than to the 5' NF-kappaB site. Moreover, deletion of either 5' or 3' NF-kappaB sites reduced IL-1alpha promoter activity in MT-2 cells and transactivation of the IL-1alpha promoter by exogenous NF-kappaB and Tax in Jurkat cells. These data suggest a general role for Tax induction of IL-1alpha gene transcription by the NF-kappaB pathway. Expression of IL-1alpha by HTLV-I productively infected cells may be important in the hypercalcemia, osteolytic bone lesions, neutrophilia, elevation of C-reactive protein, and fever frequently seen in patients with HTLV-I-induced adult T-cell leukemia/lymphoma. Instructions: please typing these entity words according to sentence: interleukin-1alpha, promoter, Tax, interleukin-1alpha, IL-1alpha, IL-1alpha, IL-1alpha, IL-1alpha, IL-1alpha, chloramphenicol acetyltransferase, CAT, IL-1alpha, Tax, IL-1alpha, Tax, IL-1alpha, CAT, p65, p50, IL-1alpha, IL-1alpha, IL-1alpha, promoter, Tax, Tax, IL-1alpha, IL-1alpha Options: Entity, Protein	[ "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Transactivation of the interleukin-1alpha promoter by human T-cell leukemia virus type I and type II Tax proteins. Human T-cell leukemia virus type I (HTLV-I)-infected T-cell lines constitutively produce high levels of interleukin-1alpha (IL-1alpha). To analyze the mechanisms that lead to the expression of IL-1alpha in HTLV-I-infected cell lines, we studied regulatory regions of the human IL-1alpha promoter involved in activation of the IL-1alpha gene. IL-1alpha promoter constructs drive transcription of the chloramphenicol acetyltransferase (CAT) reporter gene in HTLV-I-positive MT-2 cells, which constitutively produce IL-1alpha. In a cotransfection assay, the Tax protein of both HTLV-I and HTLV-II specifically activated transcription from the IL-1alpha promoter in an uninfected Jurkat cell line. A mutant Tax protein deficient in transactivation of genes by the nuclear factor (NF)-kappaB pathway was unable to induce transcriptional activity of IL-1alpha promoter-CAT constructs, but was rescued by exogenous provision of p65/p50 NF-kappaB. We found that two IL-1alpha kappaB-like sites (positions -1,065 to -1,056 and +646 to +655) specifically formed a complex with NF-kappaB-containing nuclear extract from MT-2 cells and that NF-kappaB bound with higher affinity to the 3' NF-kappaB binding site than to the 5' NF-kappaB site. Moreover, deletion of either 5' or 3' NF-kappaB sites reduced IL-1alpha promoter activity in MT-2 cells and transactivation of the IL-1alpha promoter by exogenous NF-kappaB and Tax in Jurkat cells. These data suggest a general role for Tax induction of IL-1alpha gene transcription by the NF-kappaB pathway. Expression of IL-1alpha by HTLV-I productively infected cells may be important in the hypercalcemia, osteolytic bone lesions, neutrophilia, elevation of C-reactive protein, and fever frequently seen in patients with HTLV-I-induced adult T-cell leukemia/lymphoma.	[ "Transactivation", "of", "the", "interleukin-1alpha", "promoter", "by", "human", "T", "-", "cell", "leukemia", "virus", "type", "I", "and", "type", "II", "Tax", "proteins", ".", "\n", "Human", "T", "-", "cell", "leukemia", "virus", "type", "I", "(", "HTLV", "-", "I)-infected", "T", "-", "cell", "lines", "constitutively", "produce", "high", "levels", "of", "interleukin-1alpha", "(", "IL-1alpha", ")", ".", "To", "analyze", "the", "mechanisms", "that", "lead", "to", "the", "expression", "of", "IL-1alpha", "in", "HTLV", "-", "I", "-", "infected", "cell", "lines", ",", "we", "studied", "regulatory", "regions", "of", "the", "human", "IL-1alpha", "promoter", "involved", "in", "activation", "of", "the", "IL-1alpha", "gene", ".", "IL-1alpha", "promoter", "constructs", "drive", "transcription", "of", "the", "chloramphenicol", "acetyltransferase", "(", "CAT", ")", "reporter", "gene", "in", "HTLV", "-", "I", "-", "positive", "MT-2", "cells", ",", "which", "constitutively", "produce", "IL-1alpha", ".", "In", "a", "cotransfection", "assay", ",", "the", "Tax", "protein", "of", "both", "HTLV", "-", "I", "and", "HTLV", "-", "II", "specifically", "activated", "transcription", "from", "the", "IL-1alpha", "promoter", "in", "an", "uninfected", "Jurkat", "cell", "line", ".", "A", "mutant", "Tax", "protein", "deficient", "in", "transactivation", "of", "genes", "by", "the", "nuclear", "factor", "(", "NF)-kappaB", "pathway", "was", "unable", "to", "induce", "transcriptional", "activity", "of", "IL-1alpha", "promoter", "-", "CAT", "constructs", ",", "but", "was", "rescued", "by", "exogenous", "provision", "of", "p65", "/", "p50", "NF", "-", "kappaB.", "We", "found", "that", "two", "IL-1alpha", "kappaB", "-", "like", "sites", "(", "positions", "-1,065", "to", "-1,056", "and", "+646", "to", "+655", ")", "specifically", "formed", "a", "complex", "with", "NF", "-", "kappaB", "-", "containing", "nuclear", "extract", "from", "MT-2", "cells", "and", "that", "NF", "-", "kappaB", "bound", "with", "higher", "affinity", "to", "the", "3", "'", "NF", "-", "kappaB", "binding", "site", "than", "to", "the", "5", "'", "NF", "-", "kappaB", "site", ".", "Moreover", ",", "deletion", "of", "either", "5", "'", "or", "3", "'", "NF", "-", "kappaB", "sites", "reduced", "IL-1alpha", "promoter", "activity", "in", "MT-2", "cells", "and", "transactivation", "of", "the", "IL-1alpha", "promoter", "by", "exogenous", "NF", "-", "kappaB", "and", "Tax", "in", "Jurkat", "cells", ".", "These", "data", "suggest", "a", "general", "role", "for", "Tax", "induction", "of", "IL-1alpha", "gene", "transcription", "by", "the", "NF", "-", "kappaB", "pathway", ".", "Expression", "of", "IL-1alpha", "by", "HTLV", "-", "I", "productively", "infected", "cells", "may", "be", "important", "in", "the", "hypercalcemia", ",", "osteolytic", "bone", "lesions", ",", "neutrophilia", ",", "elevation", "of", "C", "-", "reactive", "protein", ",", "and", "fever", "frequently", "seen", "in", "patients", "with", "HTLV", "-", "I", "-", "induced", "adult", "T", "-", "cell", "leukemia", "/", "lymphoma", "." ]	[ "Protein", "Entity" ]
interleukin-1alpha, promoter, Tax, interleukin-1alpha, IL-1alpha, IL-1alpha, IL-1alpha, IL-1alpha, IL-1alpha, chloramphenicol acetyltransferase, CAT, IL-1alpha, Tax, IL-1alpha, Tax, IL-1alpha, CAT, p65, p50, IL-1alpha, IL-1alpha, IL-1alpha, promoter, Tax, Tax, IL-1alpha, IL-1alpha	8605359_task2	Sentence: Transactivation of the interleukin-1alpha promoter by human T-cell leukemia virus type I and type II Tax proteins. Human T-cell leukemia virus type I (HTLV-I)-infected T-cell lines constitutively produce high levels of interleukin-1alpha (IL-1alpha). To analyze the mechanisms that lead to the expression of IL-1alpha in HTLV-I-infected cell lines, we studied regulatory regions of the human IL-1alpha promoter involved in activation of the IL-1alpha gene. IL-1alpha promoter constructs drive transcription of the chloramphenicol acetyltransferase (CAT) reporter gene in HTLV-I-positive MT-2 cells, which constitutively produce IL-1alpha. In a cotransfection assay, the Tax protein of both HTLV-I and HTLV-II specifically activated transcription from the IL-1alpha promoter in an uninfected Jurkat cell line. A mutant Tax protein deficient in transactivation of genes by the nuclear factor (NF)-kappaB pathway was unable to induce transcriptional activity of IL-1alpha promoter-CAT constructs, but was rescued by exogenous provision of p65/p50 NF-kappaB. We found that two IL-1alpha kappaB-like sites (positions -1,065 to -1,056 and +646 to +655) specifically formed a complex with NF-kappaB-containing nuclear extract from MT-2 cells and that NF-kappaB bound with higher affinity to the 3' NF-kappaB binding site than to the 5' NF-kappaB site. Moreover, deletion of either 5' or 3' NF-kappaB sites reduced IL-1alpha promoter activity in MT-2 cells and transactivation of the IL-1alpha promoter by exogenous NF-kappaB and Tax in Jurkat cells. These data suggest a general role for Tax induction of IL-1alpha gene transcription by the NF-kappaB pathway. Expression of IL-1alpha by HTLV-I productively infected cells may be important in the hypercalcemia, osteolytic bone lesions, neutrophilia, elevation of C-reactive protein, and fever frequently seen in patients with HTLV-I-induced adult T-cell leukemia/lymphoma. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Transactivation of the interleukin-1alpha promoter by human T-cell leukemia virus type I and type II Tax proteins. Human T-cell leukemia virus type I (HTLV-I)-infected T-cell lines constitutively produce high levels of interleukin-1alpha (IL-1alpha). To analyze the mechanisms that lead to the expression of IL-1alpha in HTLV-I-infected cell lines, we studied regulatory regions of the human IL-1alpha promoter involved in activation of the IL-1alpha gene. IL-1alpha promoter constructs drive transcription of the chloramphenicol acetyltransferase (CAT) reporter gene in HTLV-I-positive MT-2 cells, which constitutively produce IL-1alpha. In a cotransfection assay, the Tax protein of both HTLV-I and HTLV-II specifically activated transcription from the IL-1alpha promoter in an uninfected Jurkat cell line. A mutant Tax protein deficient in transactivation of genes by the nuclear factor (NF)-kappaB pathway was unable to induce transcriptional activity of IL-1alpha promoter-CAT constructs, but was rescued by exogenous provision of p65/p50 NF-kappaB. We found that two IL-1alpha kappaB-like sites (positions -1,065 to -1,056 and +646 to +655) specifically formed a complex with NF-kappaB-containing nuclear extract from MT-2 cells and that NF-kappaB bound with higher affinity to the 3' NF-kappaB binding site than to the 5' NF-kappaB site. Moreover, deletion of either 5' or 3' NF-kappaB sites reduced IL-1alpha promoter activity in MT-2 cells and transactivation of the IL-1alpha promoter by exogenous NF-kappaB and Tax in Jurkat cells. These data suggest a general role for Tax induction of IL-1alpha gene transcription by the NF-kappaB pathway. Expression of IL-1alpha by HTLV-I productively infected cells may be important in the hypercalcemia, osteolytic bone lesions, neutrophilia, elevation of C-reactive protein, and fever frequently seen in patients with HTLV-I-induced adult T-cell leukemia/lymphoma.	[ "Transactivation", "of", "the", "interleukin-1alpha", "promoter", "by", "human", "T", "-", "cell", "leukemia", "virus", "type", "I", "and", "type", "II", "Tax", "proteins", ".", "\n", "Human", "T", "-", "cell", "leukemia", "virus", "type", "I", "(", "HTLV", "-", "I)-infected", "T", "-", "cell", "lines", "constitutively", "produce", "high", "levels", "of", "interleukin-1alpha", "(", "IL-1alpha", ")", ".", "To", "analyze", "the", "mechanisms", "that", "lead", "to", "the", "expression", "of", "IL-1alpha", "in", "HTLV", "-", "I", "-", "infected", "cell", "lines", ",", "we", "studied", "regulatory", "regions", "of", "the", "human", "IL-1alpha", "promoter", "involved", "in", "activation", "of", "the", "IL-1alpha", "gene", ".", "IL-1alpha", "promoter", "constructs", "drive", "transcription", "of", "the", "chloramphenicol", "acetyltransferase", "(", "CAT", ")", "reporter", "gene", "in", "HTLV", "-", "I", "-", "positive", "MT-2", "cells", ",", "which", "constitutively", "produce", "IL-1alpha", ".", "In", "a", "cotransfection", "assay", ",", "the", "Tax", "protein", "of", "both", "HTLV", "-", "I", "and", "HTLV", "-", "II", "specifically", "activated", "transcription", "from", "the", "IL-1alpha", "promoter", "in", "an", "uninfected", "Jurkat", "cell", "line", ".", "A", "mutant", "Tax", "protein", "deficient", "in", "transactivation", "of", "genes", "by", "the", "nuclear", "factor", "(", "NF)-kappaB", "pathway", "was", "unable", "to", "induce", "transcriptional", "activity", "of", "IL-1alpha", "promoter", "-", "CAT", "constructs", ",", "but", "was", "rescued", "by", "exogenous", "provision", "of", "p65", "/", "p50", "NF", "-", "kappaB.", "We", "found", "that", "two", "IL-1alpha", "kappaB", "-", "like", "sites", "(", "positions", "-1,065", "to", "-1,056", "and", "+646", "to", "+655", ")", "specifically", "formed", "a", "complex", "with", "NF", "-", "kappaB", "-", "containing", "nuclear", "extract", "from", "MT-2", "cells", "and", "that", "NF", "-", "kappaB", "bound", "with", "higher", "affinity", "to", "the", "3", "'", "NF", "-", "kappaB", "binding", "site", "than", "to", "the", "5", "'", "NF", "-", "kappaB", "site", ".", "Moreover", ",", "deletion", "of", "either", "5", "'", "or", "3", "'", "NF", "-", "kappaB", "sites", "reduced", "IL-1alpha", "promoter", "activity", "in", "MT-2", "cells", "and", "transactivation", "of", "the", "IL-1alpha", "promoter", "by", "exogenous", "NF", "-", "kappaB", "and", "Tax", "in", "Jurkat", "cells", ".", "These", "data", "suggest", "a", "general", "role", "for", "Tax", "induction", "of", "IL-1alpha", "gene", "transcription", "by", "the", "NF", "-", "kappaB", "pathway", ".", "Expression", "of", "IL-1alpha", "by", "HTLV", "-", "I", "productively", "infected", "cells", "may", "be", "important", "in", "the", "hypercalcemia", ",", "osteolytic", "bone", "lesions", ",", "neutrophilia", ",", "elevation", "of", "C", "-", "reactive", "protein", ",", "and", "fever", "frequently", "seen", "in", "patients", "with", "HTLV", "-", "I", "-", "induced", "adult", "T", "-", "cell", "leukemia", "/", "lymphoma", "." ]	[ "Protein", "Entity" ]
cyclooxygenase is a GENE-N, ketorolac tromethamine is a CHEMICAL, bromfenac sodium is a CHEMICAL, cyclooxygenase is a GENE-N, COX is a GENE-N, ketorolac tromethamine is a CHEMICAL, ketorolac is a CHEMICAL, bromfenac sodium is a CHEMICAL, bromfenac is a CHEMICAL, Cyclooxygenase is a GENE-N, prostaglandin E(2 ) is a CHEMICAL, PGE(2 ) is a CHEMICAL, human recombinant COX-1 is a GENE-Y, COX-2 is a GENE-Y, arachidonic acid is a CHEMICAL, ( + /- ) ketorolac is a CHEMICAL, Acular LS is a CHEMICAL, bromfenac is a CHEMICAL, Xibrom is a CHEMICAL, PGE(2 ) is a CHEMICAL, fluorescein isothiocyanate is a CHEMICAL, PGE(2 ) is a CHEMICAL, Ketorolac is a CHEMICAL, COX-1 is a GENE-Y, COX-2 is a GENE-Y, bromfenac is a CHEMICAL, COX-2 is a GENE-Y, COX-1 is a GENE-Y, FITC is a CHEMICAL, PGE(2 ) is a CHEMICAL, FITC is a CHEMICAL, bromfenac is a CHEMICAL, ketorolac is a CHEMICAL, Ketorolac is a CHEMICAL, COX-1 is a GENE-Y, bromfenac is a CHEMICAL, COX-2 is a GENE-Y, COX-1 is a GENE-Y, ketorolac is a CHEMICAL, bromfenac is a CHEMICAL, bromfenac is a CHEMICAL	19386_task0	Sentence: Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. OBJECTIVE: To compare the cyclooxygenase (COX) activity and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs (NSAIDs) ketorolac tromethamine (ketorolac) and bromfenac sodium (bromfenac). METHODS: Cyclooxygenase activity and selectivity was determined in vitro by measuring prostaglandin E(2) (PGE(2)) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid. Anti-inflammatory effects were evaluated in a rabbit model in which an ocular inflammatory response was induced by intravenous injection of 10 microg/kg lipopolysaccharide (LPS). In study animals, one eye was treated with 50 microL (+/-) ketorolac 0.4% (Acular LS) or bromfenac 0.09% (Xibrom) and the other eye with 50 microL buffered saline. In control animals, both eyes were treated with vehicle. All animals were treated twice: 2 hours and 1 hour before LPS. MAIN OUTCOME MEASURES: PGE(2) production in vitro, measured by enzyme immunoassay; fluorescein isothiocyanate (FITC)-dextran leakage into the anterior chamber, measured by fluorophotometry; aqueous PGE(2) levels in vivo, measured by ELISA immunoassay. RESULTS: Ketorolac was six times more active against COX-1 (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM). In the animal model, both drugs resulted in nearly complete inhibition of FITC-dextran leakage and PGE(2) production in the anterior chamber of treated eyes. There was also a 79% inhibition (p < 0.001) of FITC-dextran leakage in the contralateral eyes of bromfenac-treated rabbits, and a 22.5% inhibition (not statistically significant) in the contralateral eyes of ketorolac-treated rabbits. CONCLUSIONS: Ketorolac is relatively COX-1 selective while bromfenac is potently selective for COX-2 over COX-1. In the animal model, both ketorolac 0.4% and bromfenac 0.09% demonstrated maximal anti-inflammatory activity in treated eyes. Only bromfenac 0.09% had a significant effect on the contralateral eye, suggesting possible systemic absorption of this drug. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N, CHEMICAL	[ "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. OBJECTIVE: To compare the cyclooxygenase (COX) activity and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs (NSAIDs) ketorolac tromethamine (ketorolac) and bromfenac sodium (bromfenac). METHODS: Cyclooxygenase activity and selectivity was determined in vitro by measuring prostaglandin E(2) (PGE(2)) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid. Anti-inflammatory effects were evaluated in a rabbit model in which an ocular inflammatory response was induced by intravenous injection of 10 microg/kg lipopolysaccharide (LPS). In study animals, one eye was treated with 50 microL (+/-) ketorolac 0.4% (Acular LS) or bromfenac 0.09% (Xibrom) and the other eye with 50 microL buffered saline. In control animals, both eyes were treated with vehicle. All animals were treated twice: 2 hours and 1 hour before LPS. MAIN OUTCOME MEASURES: PGE(2) production in vitro, measured by enzyme immunoassay; fluorescein isothiocyanate (FITC)-dextran leakage into the anterior chamber, measured by fluorophotometry; aqueous PGE(2) levels in vivo, measured by ELISA immunoassay. RESULTS: Ketorolac was six times more active against COX-1 (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM). In the animal model, both drugs resulted in nearly complete inhibition of FITC-dextran leakage and PGE(2) production in the anterior chamber of treated eyes. There was also a 79% inhibition (p < 0.001) of FITC-dextran leakage in the contralateral eyes of bromfenac-treated rabbits, and a 22.5% inhibition (not statistically significant) in the contralateral eyes of ketorolac-treated rabbits. CONCLUSIONS: Ketorolac is relatively COX-1 selective while bromfenac is potently selective for COX-2 over COX-1. In the animal model, both ketorolac 0.4% and bromfenac 0.09% demonstrated maximal anti-inflammatory activity in treated eyes. Only bromfenac 0.09% had a significant effect on the contralateral eye, suggesting possible systemic absorption of this drug.	[ "Comparison", "of", "cyclooxygenase", "inhibitory", "activity", "and", "ocular", "anti", "-", "inflammatory", "effects", "of", "ketorolac", "tromethamine", "and", "bromfenac", "sodium", ".", "\n", "OBJECTIVE", ":", "To", "compare", "the", "cyclooxygenase", "(", "COX", ")", "activity", "and", "anti", "-", "inflammatory", "effects", "of", "the", "nonsteroidal", "anti", "-", "inflammatory", "drugs", "(", "NSAIDs", ")", "ketorolac", "tromethamine", "(", "ketorolac", ")", "and", "bromfenac", "sodium", "(", "bromfenac", ")", ".", "METHODS", ":", "Cyclooxygenase", "activity", "and", "selectivity", "was", "determined", "in", "vitro", "by", "measuring", "prostaglandin", "E(2", ")", "(", "PGE(2", ")", ")", "production", "following", "incubation", "of", "varying", "concentrations", "of", "NSAID", "with", "human", "recombinant", "COX-1", "or", "COX-2", "and", "arachidonic", "acid", ".", "Anti", "-", "inflammatory", "effects", "were", "evaluated", "in", "a", "rabbit", "model", "in", "which", "an", "ocular", "inflammatory", "response", "was", "induced", "by", "intravenous", "injection", "of", "10", "microg", "/", "kg", "lipopolysaccharide", "(", "LPS", ")", ".", "In", "study", "animals", ",", "one", "eye", "was", "treated", "with", "50", "microL", "(", "+", "/-", ")", "ketorolac", "0.4", "%", "(", "Acular", "LS", ")", "or", "bromfenac", "0.09", "%", "(", "Xibrom", ")", "and", "the", "other", "eye", "with", "50", "microL", "buffered", "saline", ".", "In", "control", "animals", ",", "both", "eyes", "were", "treated", "with", "vehicle", ".", "All", "animals", "were", "treated", "twice", ":", "2", "hours", "and", "1", "hour", "before", "LPS", ".", "MAIN", "OUTCOME", "MEASURES", ":", "PGE(2", ")", "production", "in", "vitro", ",", "measured", "by", "enzyme", "immunoassay", ";", "fluorescein", "isothiocyanate", "(", "FITC)-dextran", "leakage", "into", "the", "anterior", "chamber", ",", "measured", "by", "fluorophotometry", ";", "aqueous", "PGE(2", ")", "levels", "in", "vivo", ",", "measured", "by", "ELISA", "immunoassay", ".", "RESULTS", ":", "Ketorolac", "was", "six", "times", "more", "active", "against", "COX-1", "(", "IC(50", ")", "=", "0.02", "microM", ")", "than", "COX-2", "(", "IC(50", ")", "=", "0.12", "microM", ")", "while", "bromfenac", "was", "approximately", "32", "times", "more", "active", "against", "COX-2", "(", "IC(50", ")", "=", "0.0066", "microM", ")", "than", "COX-1", "(", "IC(50", ")", "=", "0.210", "microM", ")", ".", "In", "the", "animal", "model", ",", "both", "drugs", "resulted", "in", "nearly", "complete", "inhibition", "of", "FITC", "-", "dextran", "leakage", "and", "PGE(2", ")", "production", "in", "the", "anterior", "chamber", "of", "treated", "eyes", ".", "There", "was", "also", "a", "79", "%", "inhibition", "(", "p", "<", "0.001", ")", "of", "FITC", "-", "dextran", "leakage", "in", "the", "contralateral", "eyes", "of", "bromfenac", "-", "treated", "rabbits", ",", "and", "a", "22.5", "%", "inhibition", "(", "not", "statistically", "significant", ")", "in", "the", "contralateral", "eyes", "of", "ketorolac", "-", "treated", "rabbits", ".", "CONCLUSIONS", ":", "Ketorolac", "is", "relatively", "COX-1", "selective", "while", "bromfenac", "is", "potently", "selective", "for", "COX-2", "over", "COX-1", ".", "In", "the", "animal", "model", ",", "both", "ketorolac", "0.4", "%", "and", "bromfenac", "0.09", "%", "demonstrated", "maximal", "anti", "-", "inflammatory", "activity", "in", "treated", "eyes", ".", "Only", "bromfenac", "0.09", "%", "had", "a", "significant", "effect", "on", "the", "contralateral", "eye", ",", "suggesting", "possible", "systemic", "absorption", "of", "this", "drug", "." ]	[ "CHEMICAL", "GENE-Y", "GENE-N" ]
cyclooxygenase is a GENE-N, ketorolac tromethamine is a CHEMICAL, bromfenac sodium is a CHEMICAL, cyclooxygenase is a GENE-N, COX is a GENE-N, ketorolac tromethamine is a CHEMICAL, ketorolac is a CHEMICAL, bromfenac sodium is a CHEMICAL, bromfenac is a CHEMICAL, Cyclooxygenase is a GENE-N, prostaglandin E(2 ) is a CHEMICAL, PGE(2 ) is a CHEMICAL, human recombinant COX-1 is a GENE-Y, COX-2 is a GENE-Y, arachidonic acid is a CHEMICAL, ( + /- ) ketorolac is a CHEMICAL, Acular LS is a CHEMICAL, bromfenac is a CHEMICAL, Xibrom is a CHEMICAL, PGE(2 ) is a CHEMICAL, fluorescein isothiocyanate is a CHEMICAL, PGE(2 ) is a CHEMICAL, Ketorolac is a CHEMICAL, COX-1 is a GENE-Y, COX-2 is a GENE-Y, bromfenac is a CHEMICAL, COX-2 is a GENE-Y, COX-1 is a GENE-Y, FITC is a CHEMICAL, PGE(2 ) is a CHEMICAL, FITC is a CHEMICAL, bromfenac is a CHEMICAL, ketorolac is a CHEMICAL, Ketorolac is a CHEMICAL, COX-1 is a GENE-Y, bromfenac is a CHEMICAL, COX-2 is a GENE-Y, COX-1 is a GENE-Y, ketorolac is a CHEMICAL, bromfenac is a CHEMICAL, bromfenac is a CHEMICAL	19386_task1	Sentence: Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. OBJECTIVE: To compare the cyclooxygenase (COX) activity and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs (NSAIDs) ketorolac tromethamine (ketorolac) and bromfenac sodium (bromfenac). METHODS: Cyclooxygenase activity and selectivity was determined in vitro by measuring prostaglandin E(2) (PGE(2)) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid. Anti-inflammatory effects were evaluated in a rabbit model in which an ocular inflammatory response was induced by intravenous injection of 10 microg/kg lipopolysaccharide (LPS). In study animals, one eye was treated with 50 microL (+/-) ketorolac 0.4% (Acular LS) or bromfenac 0.09% (Xibrom) and the other eye with 50 microL buffered saline. In control animals, both eyes were treated with vehicle. All animals were treated twice: 2 hours and 1 hour before LPS. MAIN OUTCOME MEASURES: PGE(2) production in vitro, measured by enzyme immunoassay; fluorescein isothiocyanate (FITC)-dextran leakage into the anterior chamber, measured by fluorophotometry; aqueous PGE(2) levels in vivo, measured by ELISA immunoassay. RESULTS: Ketorolac was six times more active against COX-1 (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM). In the animal model, both drugs resulted in nearly complete inhibition of FITC-dextran leakage and PGE(2) production in the anterior chamber of treated eyes. There was also a 79% inhibition (p < 0.001) of FITC-dextran leakage in the contralateral eyes of bromfenac-treated rabbits, and a 22.5% inhibition (not statistically significant) in the contralateral eyes of ketorolac-treated rabbits. CONCLUSIONS: Ketorolac is relatively COX-1 selective while bromfenac is potently selective for COX-2 over COX-1. In the animal model, both ketorolac 0.4% and bromfenac 0.09% demonstrated maximal anti-inflammatory activity in treated eyes. Only bromfenac 0.09% had a significant effect on the contralateral eye, suggesting possible systemic absorption of this drug. Instructions: please typing these entity words according to sentence: cyclooxygenase, ketorolac tromethamine, bromfenac sodium, cyclooxygenase, COX, ketorolac tromethamine, ketorolac, bromfenac sodium, bromfenac, Cyclooxygenase, prostaglandin E(2 ), PGE(2 ), human recombinant COX-1, COX-2, arachidonic acid, ( + /- ) ketorolac, Acular LS, bromfenac, Xibrom, PGE(2 ), fluorescein isothiocyanate, PGE(2 ), Ketorolac, COX-1, COX-2, bromfenac, COX-2, COX-1, FITC, PGE(2 ), FITC, bromfenac, ketorolac, Ketorolac, COX-1, bromfenac, COX-2, COX-1, ketorolac, bromfenac, bromfenac Options: GENE-Y, GENE-N, CHEMICAL	[ "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. OBJECTIVE: To compare the cyclooxygenase (COX) activity and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs (NSAIDs) ketorolac tromethamine (ketorolac) and bromfenac sodium (bromfenac). METHODS: Cyclooxygenase activity and selectivity was determined in vitro by measuring prostaglandin E(2) (PGE(2)) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid. Anti-inflammatory effects were evaluated in a rabbit model in which an ocular inflammatory response was induced by intravenous injection of 10 microg/kg lipopolysaccharide (LPS). In study animals, one eye was treated with 50 microL (+/-) ketorolac 0.4% (Acular LS) or bromfenac 0.09% (Xibrom) and the other eye with 50 microL buffered saline. In control animals, both eyes were treated with vehicle. All animals were treated twice: 2 hours and 1 hour before LPS. MAIN OUTCOME MEASURES: PGE(2) production in vitro, measured by enzyme immunoassay; fluorescein isothiocyanate (FITC)-dextran leakage into the anterior chamber, measured by fluorophotometry; aqueous PGE(2) levels in vivo, measured by ELISA immunoassay. RESULTS: Ketorolac was six times more active against COX-1 (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM). In the animal model, both drugs resulted in nearly complete inhibition of FITC-dextran leakage and PGE(2) production in the anterior chamber of treated eyes. There was also a 79% inhibition (p < 0.001) of FITC-dextran leakage in the contralateral eyes of bromfenac-treated rabbits, and a 22.5% inhibition (not statistically significant) in the contralateral eyes of ketorolac-treated rabbits. CONCLUSIONS: Ketorolac is relatively COX-1 selective while bromfenac is potently selective for COX-2 over COX-1. In the animal model, both ketorolac 0.4% and bromfenac 0.09% demonstrated maximal anti-inflammatory activity in treated eyes. Only bromfenac 0.09% had a significant effect on the contralateral eye, suggesting possible systemic absorption of this drug.	[ "Comparison", "of", "cyclooxygenase", "inhibitory", "activity", "and", "ocular", "anti", "-", "inflammatory", "effects", "of", "ketorolac", "tromethamine", "and", "bromfenac", "sodium", ".", "\n", "OBJECTIVE", ":", "To", "compare", "the", "cyclooxygenase", "(", "COX", ")", "activity", "and", "anti", "-", "inflammatory", "effects", "of", "the", "nonsteroidal", "anti", "-", "inflammatory", "drugs", "(", "NSAIDs", ")", "ketorolac", "tromethamine", "(", "ketorolac", ")", "and", "bromfenac", "sodium", "(", "bromfenac", ")", ".", "METHODS", ":", "Cyclooxygenase", "activity", "and", "selectivity", "was", "determined", "in", "vitro", "by", "measuring", "prostaglandin", "E(2", ")", "(", "PGE(2", ")", ")", "production", "following", "incubation", "of", "varying", "concentrations", "of", "NSAID", "with", "human", "recombinant", "COX-1", "or", "COX-2", "and", "arachidonic", "acid", ".", "Anti", "-", "inflammatory", "effects", "were", "evaluated", "in", "a", "rabbit", "model", "in", "which", "an", "ocular", "inflammatory", "response", "was", "induced", "by", "intravenous", "injection", "of", "10", "microg", "/", "kg", "lipopolysaccharide", "(", "LPS", ")", ".", "In", "study", "animals", ",", "one", "eye", "was", "treated", "with", "50", "microL", "(", "+", "/-", ")", "ketorolac", "0.4", "%", "(", "Acular", "LS", ")", "or", "bromfenac", "0.09", "%", "(", "Xibrom", ")", "and", "the", "other", "eye", "with", "50", "microL", "buffered", "saline", ".", "In", "control", "animals", ",", "both", "eyes", "were", "treated", "with", "vehicle", ".", "All", "animals", "were", "treated", "twice", ":", "2", "hours", "and", "1", "hour", "before", "LPS", ".", "MAIN", "OUTCOME", "MEASURES", ":", "PGE(2", ")", "production", "in", "vitro", ",", "measured", "by", "enzyme", "immunoassay", ";", "fluorescein", "isothiocyanate", "(", "FITC)-dextran", "leakage", "into", "the", "anterior", "chamber", ",", "measured", "by", "fluorophotometry", ";", "aqueous", "PGE(2", ")", "levels", "in", "vivo", ",", "measured", "by", "ELISA", "immunoassay", ".", "RESULTS", ":", "Ketorolac", "was", "six", "times", "more", "active", "against", "COX-1", "(", "IC(50", ")", "=", "0.02", "microM", ")", "than", "COX-2", "(", "IC(50", ")", "=", "0.12", "microM", ")", "while", "bromfenac", "was", "approximately", "32", "times", "more", "active", "against", "COX-2", "(", "IC(50", ")", "=", "0.0066", "microM", ")", "than", "COX-1", "(", "IC(50", ")", "=", "0.210", "microM", ")", ".", "In", "the", "animal", "model", ",", "both", "drugs", "resulted", "in", "nearly", "complete", "inhibition", "of", "FITC", "-", "dextran", "leakage", "and", "PGE(2", ")", "production", "in", "the", "anterior", "chamber", "of", "treated", "eyes", ".", "There", "was", "also", "a", "79", "%", "inhibition", "(", "p", "<", "0.001", ")", "of", "FITC", "-", "dextran", "leakage", "in", "the", "contralateral", "eyes", "of", "bromfenac", "-", "treated", "rabbits", ",", "and", "a", "22.5", "%", "inhibition", "(", "not", "statistically", "significant", ")", "in", "the", "contralateral", "eyes", "of", "ketorolac", "-", "treated", "rabbits", ".", "CONCLUSIONS", ":", "Ketorolac", "is", "relatively", "COX-1", "selective", "while", "bromfenac", "is", "potently", "selective", "for", "COX-2", "over", "COX-1", ".", "In", "the", "animal", "model", ",", "both", "ketorolac", "0.4", "%", "and", "bromfenac", "0.09", "%", "demonstrated", "maximal", "anti", "-", "inflammatory", "activity", "in", "treated", "eyes", ".", "Only", "bromfenac", "0.09", "%", "had", "a", "significant", "effect", "on", "the", "contralateral", "eye", ",", "suggesting", "possible", "systemic", "absorption", "of", "this", "drug", "." ]	[ "CHEMICAL", "GENE-Y", "GENE-N" ]
cyclooxygenase, ketorolac tromethamine, bromfenac sodium, cyclooxygenase, COX, ketorolac tromethamine, ketorolac, bromfenac sodium, bromfenac, Cyclooxygenase, prostaglandin E(2 ), PGE(2 ), human recombinant COX-1, COX-2, arachidonic acid, ( + /- ) ketorolac, Acular LS, bromfenac, Xibrom, PGE(2 ), fluorescein isothiocyanate, PGE(2 ), Ketorolac, COX-1, COX-2, bromfenac, COX-2, COX-1, FITC, PGE(2 ), FITC, bromfenac, ketorolac, Ketorolac, COX-1, bromfenac, COX-2, COX-1, ketorolac, bromfenac, bromfenac	19386_task2	Sentence: Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. OBJECTIVE: To compare the cyclooxygenase (COX) activity and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs (NSAIDs) ketorolac tromethamine (ketorolac) and bromfenac sodium (bromfenac). METHODS: Cyclooxygenase activity and selectivity was determined in vitro by measuring prostaglandin E(2) (PGE(2)) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid. Anti-inflammatory effects were evaluated in a rabbit model in which an ocular inflammatory response was induced by intravenous injection of 10 microg/kg lipopolysaccharide (LPS). In study animals, one eye was treated with 50 microL (+/-) ketorolac 0.4% (Acular LS) or bromfenac 0.09% (Xibrom) and the other eye with 50 microL buffered saline. In control animals, both eyes were treated with vehicle. All animals were treated twice: 2 hours and 1 hour before LPS. MAIN OUTCOME MEASURES: PGE(2) production in vitro, measured by enzyme immunoassay; fluorescein isothiocyanate (FITC)-dextran leakage into the anterior chamber, measured by fluorophotometry; aqueous PGE(2) levels in vivo, measured by ELISA immunoassay. RESULTS: Ketorolac was six times more active against COX-1 (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM). In the animal model, both drugs resulted in nearly complete inhibition of FITC-dextran leakage and PGE(2) production in the anterior chamber of treated eyes. There was also a 79% inhibition (p < 0.001) of FITC-dextran leakage in the contralateral eyes of bromfenac-treated rabbits, and a 22.5% inhibition (not statistically significant) in the contralateral eyes of ketorolac-treated rabbits. CONCLUSIONS: Ketorolac is relatively COX-1 selective while bromfenac is potently selective for COX-2 over COX-1. In the animal model, both ketorolac 0.4% and bromfenac 0.09% demonstrated maximal anti-inflammatory activity in treated eyes. Only bromfenac 0.09% had a significant effect on the contralateral eye, suggesting possible systemic absorption of this drug. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. OBJECTIVE: To compare the cyclooxygenase (COX) activity and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs (NSAIDs) ketorolac tromethamine (ketorolac) and bromfenac sodium (bromfenac). METHODS: Cyclooxygenase activity and selectivity was determined in vitro by measuring prostaglandin E(2) (PGE(2)) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid. Anti-inflammatory effects were evaluated in a rabbit model in which an ocular inflammatory response was induced by intravenous injection of 10 microg/kg lipopolysaccharide (LPS). In study animals, one eye was treated with 50 microL (+/-) ketorolac 0.4% (Acular LS) or bromfenac 0.09% (Xibrom) and the other eye with 50 microL buffered saline. In control animals, both eyes were treated with vehicle. All animals were treated twice: 2 hours and 1 hour before LPS. MAIN OUTCOME MEASURES: PGE(2) production in vitro, measured by enzyme immunoassay; fluorescein isothiocyanate (FITC)-dextran leakage into the anterior chamber, measured by fluorophotometry; aqueous PGE(2) levels in vivo, measured by ELISA immunoassay. RESULTS: Ketorolac was six times more active against COX-1 (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM). In the animal model, both drugs resulted in nearly complete inhibition of FITC-dextran leakage and PGE(2) production in the anterior chamber of treated eyes. There was also a 79% inhibition (p < 0.001) of FITC-dextran leakage in the contralateral eyes of bromfenac-treated rabbits, and a 22.5% inhibition (not statistically significant) in the contralateral eyes of ketorolac-treated rabbits. CONCLUSIONS: Ketorolac is relatively COX-1 selective while bromfenac is potently selective for COX-2 over COX-1. In the animal model, both ketorolac 0.4% and bromfenac 0.09% demonstrated maximal anti-inflammatory activity in treated eyes. Only bromfenac 0.09% had a significant effect on the contralateral eye, suggesting possible systemic absorption of this drug.	[ "Comparison", "of", "cyclooxygenase", "inhibitory", "activity", "and", "ocular", "anti", "-", "inflammatory", "effects", "of", "ketorolac", "tromethamine", "and", "bromfenac", "sodium", ".", "\n", "OBJECTIVE", ":", "To", "compare", "the", "cyclooxygenase", "(", "COX", ")", "activity", "and", "anti", "-", "inflammatory", "effects", "of", "the", "nonsteroidal", "anti", "-", "inflammatory", "drugs", "(", "NSAIDs", ")", "ketorolac", "tromethamine", "(", "ketorolac", ")", "and", "bromfenac", "sodium", "(", "bromfenac", ")", ".", "METHODS", ":", "Cyclooxygenase", "activity", "and", "selectivity", "was", "determined", "in", "vitro", "by", "measuring", "prostaglandin", "E(2", ")", "(", "PGE(2", ")", ")", "production", "following", "incubation", "of", "varying", "concentrations", "of", "NSAID", "with", "human", "recombinant", "COX-1", "or", "COX-2", "and", "arachidonic", "acid", ".", "Anti", "-", "inflammatory", "effects", "were", "evaluated", "in", "a", "rabbit", "model", "in", "which", "an", "ocular", "inflammatory", "response", "was", "induced", "by", "intravenous", "injection", "of", "10", "microg", "/", "kg", "lipopolysaccharide", "(", "LPS", ")", ".", "In", "study", "animals", ",", "one", "eye", "was", "treated", "with", "50", "microL", "(", "+", "/-", ")", "ketorolac", "0.4", "%", "(", "Acular", "LS", ")", "or", "bromfenac", "0.09", "%", "(", "Xibrom", ")", "and", "the", "other", "eye", "with", "50", "microL", "buffered", "saline", ".", "In", "control", "animals", ",", "both", "eyes", "were", "treated", "with", "vehicle", ".", "All", "animals", "were", "treated", "twice", ":", "2", "hours", "and", "1", "hour", "before", "LPS", ".", "MAIN", "OUTCOME", "MEASURES", ":", "PGE(2", ")", "production", "in", "vitro", ",", "measured", "by", "enzyme", "immunoassay", ";", "fluorescein", "isothiocyanate", "(", "FITC)-dextran", "leakage", "into", "the", "anterior", "chamber", ",", "measured", "by", "fluorophotometry", ";", "aqueous", "PGE(2", ")", "levels", "in", "vivo", ",", "measured", "by", "ELISA", "immunoassay", ".", "RESULTS", ":", "Ketorolac", "was", "six", "times", "more", "active", "against", "COX-1", "(", "IC(50", ")", "=", "0.02", "microM", ")", "than", "COX-2", "(", "IC(50", ")", "=", "0.12", "microM", ")", "while", "bromfenac", "was", "approximately", "32", "times", "more", "active", "against", "COX-2", "(", "IC(50", ")", "=", "0.0066", "microM", ")", "than", "COX-1", "(", "IC(50", ")", "=", "0.210", "microM", ")", ".", "In", "the", "animal", "model", ",", "both", "drugs", "resulted", "in", "nearly", "complete", "inhibition", "of", "FITC", "-", "dextran", "leakage", "and", "PGE(2", ")", "production", "in", "the", "anterior", "chamber", "of", "treated", "eyes", ".", "There", "was", "also", "a", "79", "%", "inhibition", "(", "p", "<", "0.001", ")", "of", "FITC", "-", "dextran", "leakage", "in", "the", "contralateral", "eyes", "of", "bromfenac", "-", "treated", "rabbits", ",", "and", "a", "22.5", "%", "inhibition", "(", "not", "statistically", "significant", ")", "in", "the", "contralateral", "eyes", "of", "ketorolac", "-", "treated", "rabbits", ".", "CONCLUSIONS", ":", "Ketorolac", "is", "relatively", "COX-1", "selective", "while", "bromfenac", "is", "potently", "selective", "for", "COX-2", "over", "COX-1", ".", "In", "the", "animal", "model", ",", "both", "ketorolac", "0.4", "%", "and", "bromfenac", "0.09", "%", "demonstrated", "maximal", "anti", "-", "inflammatory", "activity", "in", "treated", "eyes", ".", "Only", "bromfenac", "0.09", "%", "had", "a", "significant", "effect", "on", "the", "contralateral", "eye", ",", "suggesting", "possible", "systemic", "absorption", "of", "this", "drug", "." ]	[ "CHEMICAL", "GENE-Y", "GENE-N" ]
O - linked N - acetylglucosaminyltransferase is a Protein, O - linked N - acetylglucosaminyltransferase is a Protein, OGT is a Protein, OGT is a Protein, O - GlcNAcase is a Protein, O - GlcNAcase is a Protein	293_task0	Sentence: Glucose deprivation stimulates O-GlcNAc modification of proteins through up-regulation of O-linked N-acetylglucosaminyltransferase. O-Linked N-acetylglucosamine (O-GlcNAc) is a post-translational modification of proteins that functions as a nutrient sensing mechanism. Here we report on regulation of O-GlcNAcylation over a broad range of glucose concentrations. We have discovered a significant induction of O-GlcNAc modification of a limited number of proteins under conditions of glucose deprivation. Beginning 12 h after treatment, glucose-deprived human hepatocellular carcinoma (HepG2) cells demonstrate a 7.8-fold increase in total O-GlcNAc modification compared with cells cultured in normal glucose (5 mm; p = 0.008). Some of the targets of glucose deprivation-induced O-GlcNAcylation are distinct from those modified in response to high glucose (20 mm) or glucosamine (10 mm) treatment, suggesting differential targeting with glucose deprivation and glucose excess. O-GlcNAcylation of glycogen synthase is significantly increased with glucose deprivation, and this O-GlcNAc increase contributes to a 60% decrease (p = 0.004) in glycogen synthase activity. Increased O-GlcNAc modification is not mediated by increased UDP-GlcNAc, the rate-limiting substrate for O-GlcNAcylation. Rather, the mRNA for nucleocytoplasmic O-linked N-acetylglucosaminyltransferase (OGT) increases 3.4-fold within 6 h of glucose deprivation (p = 0.006). Within 12 h, OGT protein increases 1.7-fold (p = 0.01) compared with normal glucose-treated cells. In addition, 12-h glucose deprivation leads to a 49% decrease in O-GlcNAcase protein levels (p = 0.03). We conclude that increased O-GlcNAc modification stimulated by glucose deprivation results from increased OGT and decreased O-GlcNAcase levels and that these changes affect cell metabolism, thus inactivating glycogen synthase. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Glucose deprivation stimulates O-GlcNAc modification of proteins through up-regulation of O-linked N-acetylglucosaminyltransferase. O-Linked N-acetylglucosamine (O-GlcNAc) is a post-translational modification of proteins that functions as a nutrient sensing mechanism. Here we report on regulation of O-GlcNAcylation over a broad range of glucose concentrations. We have discovered a significant induction of O-GlcNAc modification of a limited number of proteins under conditions of glucose deprivation. Beginning 12 h after treatment, glucose-deprived human hepatocellular carcinoma (HepG2) cells demonstrate a 7.8-fold increase in total O-GlcNAc modification compared with cells cultured in normal glucose (5 mm; p = 0.008). Some of the targets of glucose deprivation-induced O-GlcNAcylation are distinct from those modified in response to high glucose (20 mm) or glucosamine (10 mm) treatment, suggesting differential targeting with glucose deprivation and glucose excess. O-GlcNAcylation of glycogen synthase is significantly increased with glucose deprivation, and this O-GlcNAc increase contributes to a 60% decrease (p = 0.004) in glycogen synthase activity. Increased O-GlcNAc modification is not mediated by increased UDP-GlcNAc, the rate-limiting substrate for O-GlcNAcylation. Rather, the mRNA for nucleocytoplasmic O-linked N-acetylglucosaminyltransferase (OGT) increases 3.4-fold within 6 h of glucose deprivation (p = 0.006). Within 12 h, OGT protein increases 1.7-fold (p = 0.01) compared with normal glucose-treated cells. In addition, 12-h glucose deprivation leads to a 49% decrease in O-GlcNAcase protein levels (p = 0.03). We conclude that increased O-GlcNAc modification stimulated by glucose deprivation results from increased OGT and decreased O-GlcNAcase levels and that these changes affect cell metabolism, thus inactivating glycogen synthase.	[ "Glucose", "deprivation", "stimulates", "O", "-", "GlcNAc", "modification", "of", "proteins", "through", "up", "-", "regulation", "of", "O", "-", "linked", "N", "-", "acetylglucosaminyltransferase", ".", "\n", "O", "-", "Linked", "N", "-", "acetylglucosamine", "(", "O", "-", "GlcNAc", ")", "is", "a", "post", "-", "translational", "modification", "of", "proteins", "that", "functions", "as", "a", "nutrient", "sensing", "mechanism", ".", "Here", "we", "report", "on", "regulation", "of", "O", "-", "GlcNAcylation", "over", "a", "broad", "range", "of", "glucose", "concentrations", ".", "We", "have", "discovered", "a", "significant", "induction", "of", "O", "-", "GlcNAc", "modification", "of", "a", "limited", "number", "of", "proteins", "under", "conditions", "of", "glucose", "deprivation", ".", "Beginning", "12", "h", "after", "treatment", ",", "glucose", "-", "deprived", "human", "hepatocellular", "carcinoma", "(", "HepG2", ")", "cells", "demonstrate", "a", "7.8-fold", "increase", "in", "total", "O", "-", "GlcNAc", "modification", "compared", "with", "cells", "cultured", "in", "normal", "glucose", "(", "5", "mm", ";", "p", "=", "0.008", ")", ".", "Some", "of", "the", "targets", "of", "glucose", "deprivation", "-", "induced", "O", "-", "GlcNAcylation", "are", "distinct", "from", "those", "modified", "in", "response", "to", "high", "glucose", "(", "20", "mm", ")", "or", "glucosamine", "(", "10", "mm", ")", "treatment", ",", "suggesting", "differential", "targeting", "with", "glucose", "deprivation", "and", "glucose", "excess", ".", "O", "-", "GlcNAcylation", "of", "glycogen", "synthase", "is", "significantly", "increased", "with", "glucose", "deprivation", ",", "and", "this", "O", "-", "GlcNAc", "increase", "contributes", "to", "a", "60", "%", "decrease", "(", "p", "=", "0.004", ")", "in", "glycogen", "synthase", "activity", ".", "Increased", "O", "-", "GlcNAc", "modification", "is", "not", "mediated", "by", "increased", "UDP", "-", "GlcNAc", ",", "the", "rate", "-", "limiting", "substrate", "for", "O", "-", "GlcNAcylation", ".", "Rather", ",", "the", "mRNA", "for", "nucleocytoplasmic", "O", "-", "linked", "N", "-", "acetylglucosaminyltransferase", "(", "OGT", ")", "increases", "3.4-fold", "within", "6", "h", "of", "glucose", "deprivation", "(", "p", "=", "0.006", ")", ".", "Within", "12", "h", ",", "OGT", "protein", "increases", "1.7-fold", "(", "p", "=", "0.01", ")", "compared", "with", "normal", "glucose", "-", "treated", "cells", ".", "In", "addition", ",", "12-h", "glucose", "deprivation", "leads", "to", "a", "49", "%", "decrease", "in", "O", "-", "GlcNAcase", "protein", "levels", "(", "p", "=", "0.03", ")", ".", "We", "conclude", "that", "increased", "O", "-", "GlcNAc", "modification", "stimulated", "by", "glucose", "deprivation", "results", "from", "increased", "OGT", "and", "decreased", "O", "-", "GlcNAcase", "levels", "and", "that", "these", "changes", "affect", "cell", "metabolism", ",", "thus", "inactivating", "glycogen", "synthase", ".", "\n" ]	[ "Protein" ]
O - linked N - acetylglucosaminyltransferase is a Protein, O - linked N - acetylglucosaminyltransferase is a Protein, OGT is a Protein, OGT is a Protein, O - GlcNAcase is a Protein, O - GlcNAcase is a Protein	293_task1	Sentence: Glucose deprivation stimulates O-GlcNAc modification of proteins through up-regulation of O-linked N-acetylglucosaminyltransferase. O-Linked N-acetylglucosamine (O-GlcNAc) is a post-translational modification of proteins that functions as a nutrient sensing mechanism. Here we report on regulation of O-GlcNAcylation over a broad range of glucose concentrations. We have discovered a significant induction of O-GlcNAc modification of a limited number of proteins under conditions of glucose deprivation. Beginning 12 h after treatment, glucose-deprived human hepatocellular carcinoma (HepG2) cells demonstrate a 7.8-fold increase in total O-GlcNAc modification compared with cells cultured in normal glucose (5 mm; p = 0.008). Some of the targets of glucose deprivation-induced O-GlcNAcylation are distinct from those modified in response to high glucose (20 mm) or glucosamine (10 mm) treatment, suggesting differential targeting with glucose deprivation and glucose excess. O-GlcNAcylation of glycogen synthase is significantly increased with glucose deprivation, and this O-GlcNAc increase contributes to a 60% decrease (p = 0.004) in glycogen synthase activity. Increased O-GlcNAc modification is not mediated by increased UDP-GlcNAc, the rate-limiting substrate for O-GlcNAcylation. Rather, the mRNA for nucleocytoplasmic O-linked N-acetylglucosaminyltransferase (OGT) increases 3.4-fold within 6 h of glucose deprivation (p = 0.006). Within 12 h, OGT protein increases 1.7-fold (p = 0.01) compared with normal glucose-treated cells. In addition, 12-h glucose deprivation leads to a 49% decrease in O-GlcNAcase protein levels (p = 0.03). We conclude that increased O-GlcNAc modification stimulated by glucose deprivation results from increased OGT and decreased O-GlcNAcase levels and that these changes affect cell metabolism, thus inactivating glycogen synthase. Instructions: please typing these entity words according to sentence: O - linked N - acetylglucosaminyltransferase, O - linked N - acetylglucosaminyltransferase, OGT, OGT, O - GlcNAcase, O - GlcNAcase Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Glucose deprivation stimulates O-GlcNAc modification of proteins through up-regulation of O-linked N-acetylglucosaminyltransferase. O-Linked N-acetylglucosamine (O-GlcNAc) is a post-translational modification of proteins that functions as a nutrient sensing mechanism. Here we report on regulation of O-GlcNAcylation over a broad range of glucose concentrations. We have discovered a significant induction of O-GlcNAc modification of a limited number of proteins under conditions of glucose deprivation. Beginning 12 h after treatment, glucose-deprived human hepatocellular carcinoma (HepG2) cells demonstrate a 7.8-fold increase in total O-GlcNAc modification compared with cells cultured in normal glucose (5 mm; p = 0.008). Some of the targets of glucose deprivation-induced O-GlcNAcylation are distinct from those modified in response to high glucose (20 mm) or glucosamine (10 mm) treatment, suggesting differential targeting with glucose deprivation and glucose excess. O-GlcNAcylation of glycogen synthase is significantly increased with glucose deprivation, and this O-GlcNAc increase contributes to a 60% decrease (p = 0.004) in glycogen synthase activity. Increased O-GlcNAc modification is not mediated by increased UDP-GlcNAc, the rate-limiting substrate for O-GlcNAcylation. Rather, the mRNA for nucleocytoplasmic O-linked N-acetylglucosaminyltransferase (OGT) increases 3.4-fold within 6 h of glucose deprivation (p = 0.006). Within 12 h, OGT protein increases 1.7-fold (p = 0.01) compared with normal glucose-treated cells. In addition, 12-h glucose deprivation leads to a 49% decrease in O-GlcNAcase protein levels (p = 0.03). We conclude that increased O-GlcNAc modification stimulated by glucose deprivation results from increased OGT and decreased O-GlcNAcase levels and that these changes affect cell metabolism, thus inactivating glycogen synthase.	[ "Glucose", "deprivation", "stimulates", "O", "-", "GlcNAc", "modification", "of", "proteins", "through", "up", "-", "regulation", "of", "O", "-", "linked", "N", "-", "acetylglucosaminyltransferase", ".", "\n", "O", "-", "Linked", "N", "-", "acetylglucosamine", "(", "O", "-", "GlcNAc", ")", "is", "a", "post", "-", "translational", "modification", "of", "proteins", "that", "functions", "as", "a", "nutrient", "sensing", "mechanism", ".", "Here", "we", "report", "on", "regulation", "of", "O", "-", "GlcNAcylation", "over", "a", "broad", "range", "of", "glucose", "concentrations", ".", "We", "have", "discovered", "a", "significant", "induction", "of", "O", "-", "GlcNAc", "modification", "of", "a", "limited", "number", "of", "proteins", "under", "conditions", "of", "glucose", "deprivation", ".", "Beginning", "12", "h", "after", "treatment", ",", "glucose", "-", "deprived", "human", "hepatocellular", "carcinoma", "(", "HepG2", ")", "cells", "demonstrate", "a", "7.8-fold", "increase", "in", "total", "O", "-", "GlcNAc", "modification", "compared", "with", "cells", "cultured", "in", "normal", "glucose", "(", "5", "mm", ";", "p", "=", "0.008", ")", ".", "Some", "of", "the", "targets", "of", "glucose", "deprivation", "-", "induced", "O", "-", "GlcNAcylation", "are", "distinct", "from", "those", "modified", "in", "response", "to", "high", "glucose", "(", "20", "mm", ")", "or", "glucosamine", "(", "10", "mm", ")", "treatment", ",", "suggesting", "differential", "targeting", "with", "glucose", "deprivation", "and", "glucose", "excess", ".", "O", "-", "GlcNAcylation", "of", "glycogen", "synthase", "is", "significantly", "increased", "with", "glucose", "deprivation", ",", "and", "this", "O", "-", "GlcNAc", "increase", "contributes", "to", "a", "60", "%", "decrease", "(", "p", "=", "0.004", ")", "in", "glycogen", "synthase", "activity", ".", "Increased", "O", "-", "GlcNAc", "modification", "is", "not", "mediated", "by", "increased", "UDP", "-", "GlcNAc", ",", "the", "rate", "-", "limiting", "substrate", "for", "O", "-", "GlcNAcylation", ".", "Rather", ",", "the", "mRNA", "for", "nucleocytoplasmic", "O", "-", "linked", "N", "-", "acetylglucosaminyltransferase", "(", "OGT", ")", "increases", "3.4-fold", "within", "6", "h", "of", "glucose", "deprivation", "(", "p", "=", "0.006", ")", ".", "Within", "12", "h", ",", "OGT", "protein", "increases", "1.7-fold", "(", "p", "=", "0.01", ")", "compared", "with", "normal", "glucose", "-", "treated", "cells", ".", "In", "addition", ",", "12-h", "glucose", "deprivation", "leads", "to", "a", "49", "%", "decrease", "in", "O", "-", "GlcNAcase", "protein", "levels", "(", "p", "=", "0.03", ")", ".", "We", "conclude", "that", "increased", "O", "-", "GlcNAc", "modification", "stimulated", "by", "glucose", "deprivation", "results", "from", "increased", "OGT", "and", "decreased", "O", "-", "GlcNAcase", "levels", "and", "that", "these", "changes", "affect", "cell", "metabolism", ",", "thus", "inactivating", "glycogen", "synthase", ".", "\n" ]	[ "Protein" ]
O - linked N - acetylglucosaminyltransferase, O - linked N - acetylglucosaminyltransferase, OGT, OGT, O - GlcNAcase, O - GlcNAcase	293_task2	Sentence: Glucose deprivation stimulates O-GlcNAc modification of proteins through up-regulation of O-linked N-acetylglucosaminyltransferase. O-Linked N-acetylglucosamine (O-GlcNAc) is a post-translational modification of proteins that functions as a nutrient sensing mechanism. Here we report on regulation of O-GlcNAcylation over a broad range of glucose concentrations. We have discovered a significant induction of O-GlcNAc modification of a limited number of proteins under conditions of glucose deprivation. Beginning 12 h after treatment, glucose-deprived human hepatocellular carcinoma (HepG2) cells demonstrate a 7.8-fold increase in total O-GlcNAc modification compared with cells cultured in normal glucose (5 mm; p = 0.008). Some of the targets of glucose deprivation-induced O-GlcNAcylation are distinct from those modified in response to high glucose (20 mm) or glucosamine (10 mm) treatment, suggesting differential targeting with glucose deprivation and glucose excess. O-GlcNAcylation of glycogen synthase is significantly increased with glucose deprivation, and this O-GlcNAc increase contributes to a 60% decrease (p = 0.004) in glycogen synthase activity. Increased O-GlcNAc modification is not mediated by increased UDP-GlcNAc, the rate-limiting substrate for O-GlcNAcylation. Rather, the mRNA for nucleocytoplasmic O-linked N-acetylglucosaminyltransferase (OGT) increases 3.4-fold within 6 h of glucose deprivation (p = 0.006). Within 12 h, OGT protein increases 1.7-fold (p = 0.01) compared with normal glucose-treated cells. In addition, 12-h glucose deprivation leads to a 49% decrease in O-GlcNAcase protein levels (p = 0.03). We conclude that increased O-GlcNAc modification stimulated by glucose deprivation results from increased OGT and decreased O-GlcNAcase levels and that these changes affect cell metabolism, thus inactivating glycogen synthase. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Glucose deprivation stimulates O-GlcNAc modification of proteins through up-regulation of O-linked N-acetylglucosaminyltransferase. O-Linked N-acetylglucosamine (O-GlcNAc) is a post-translational modification of proteins that functions as a nutrient sensing mechanism. Here we report on regulation of O-GlcNAcylation over a broad range of glucose concentrations. We have discovered a significant induction of O-GlcNAc modification of a limited number of proteins under conditions of glucose deprivation. Beginning 12 h after treatment, glucose-deprived human hepatocellular carcinoma (HepG2) cells demonstrate a 7.8-fold increase in total O-GlcNAc modification compared with cells cultured in normal glucose (5 mm; p = 0.008). Some of the targets of glucose deprivation-induced O-GlcNAcylation are distinct from those modified in response to high glucose (20 mm) or glucosamine (10 mm) treatment, suggesting differential targeting with glucose deprivation and glucose excess. O-GlcNAcylation of glycogen synthase is significantly increased with glucose deprivation, and this O-GlcNAc increase contributes to a 60% decrease (p = 0.004) in glycogen synthase activity. Increased O-GlcNAc modification is not mediated by increased UDP-GlcNAc, the rate-limiting substrate for O-GlcNAcylation. Rather, the mRNA for nucleocytoplasmic O-linked N-acetylglucosaminyltransferase (OGT) increases 3.4-fold within 6 h of glucose deprivation (p = 0.006). Within 12 h, OGT protein increases 1.7-fold (p = 0.01) compared with normal glucose-treated cells. In addition, 12-h glucose deprivation leads to a 49% decrease in O-GlcNAcase protein levels (p = 0.03). We conclude that increased O-GlcNAc modification stimulated by glucose deprivation results from increased OGT and decreased O-GlcNAcase levels and that these changes affect cell metabolism, thus inactivating glycogen synthase.	[ "Glucose", "deprivation", "stimulates", "O", "-", "GlcNAc", "modification", "of", "proteins", "through", "up", "-", "regulation", "of", "O", "-", "linked", "N", "-", "acetylglucosaminyltransferase", ".", "\n", "O", "-", "Linked", "N", "-", "acetylglucosamine", "(", "O", "-", "GlcNAc", ")", "is", "a", "post", "-", "translational", "modification", "of", "proteins", "that", "functions", "as", "a", "nutrient", "sensing", "mechanism", ".", "Here", "we", "report", "on", "regulation", "of", "O", "-", "GlcNAcylation", "over", "a", "broad", "range", "of", "glucose", "concentrations", ".", "We", "have", "discovered", "a", "significant", "induction", "of", "O", "-", "GlcNAc", "modification", "of", "a", "limited", "number", "of", "proteins", "under", "conditions", "of", "glucose", "deprivation", ".", "Beginning", "12", "h", "after", "treatment", ",", "glucose", "-", "deprived", "human", "hepatocellular", "carcinoma", "(", "HepG2", ")", "cells", "demonstrate", "a", "7.8-fold", "increase", "in", "total", "O", "-", "GlcNAc", "modification", "compared", "with", "cells", "cultured", "in", "normal", "glucose", "(", "5", "mm", ";", "p", "=", "0.008", ")", ".", "Some", "of", "the", "targets", "of", "glucose", "deprivation", "-", "induced", "O", "-", "GlcNAcylation", "are", "distinct", "from", "those", "modified", "in", "response", "to", "high", "glucose", "(", "20", "mm", ")", "or", "glucosamine", "(", "10", "mm", ")", "treatment", ",", "suggesting", "differential", "targeting", "with", "glucose", "deprivation", "and", "glucose", "excess", ".", "O", "-", "GlcNAcylation", "of", "glycogen", "synthase", "is", "significantly", "increased", "with", "glucose", "deprivation", ",", "and", "this", "O", "-", "GlcNAc", "increase", "contributes", "to", "a", "60", "%", "decrease", "(", "p", "=", "0.004", ")", "in", "glycogen", "synthase", "activity", ".", "Increased", "O", "-", "GlcNAc", "modification", "is", "not", "mediated", "by", "increased", "UDP", "-", "GlcNAc", ",", "the", "rate", "-", "limiting", "substrate", "for", "O", "-", "GlcNAcylation", ".", "Rather", ",", "the", "mRNA", "for", "nucleocytoplasmic", "O", "-", "linked", "N", "-", "acetylglucosaminyltransferase", "(", "OGT", ")", "increases", "3.4-fold", "within", "6", "h", "of", "glucose", "deprivation", "(", "p", "=", "0.006", ")", ".", "Within", "12", "h", ",", "OGT", "protein", "increases", "1.7-fold", "(", "p", "=", "0.01", ")", "compared", "with", "normal", "glucose", "-", "treated", "cells", ".", "In", "addition", ",", "12-h", "glucose", "deprivation", "leads", "to", "a", "49", "%", "decrease", "in", "O", "-", "GlcNAcase", "protein", "levels", "(", "p", "=", "0.03", ")", ".", "We", "conclude", "that", "increased", "O", "-", "GlcNAc", "modification", "stimulated", "by", "glucose", "deprivation", "results", "from", "increased", "OGT", "and", "decreased", "O", "-", "GlcNAcase", "levels", "and", "that", "these", "changes", "affect", "cell", "metabolism", ",", "thus", "inactivating", "glycogen", "synthase", ".", "\n" ]	[ "Protein" ]
knowledge gain is a Outcome_Mental, structured is a Intervention_Other, student - directed learning is a Intervention_Educational, Health is a Participant_Condition, students is a Participant_Age, versus is a Intervention_Educational, 138 is a Participant_Sample-size, structured learning is a Intervention_Other, Pre- and post - course tests is a Outcome_Other, 129 is a Participant_Sample-size, gain in knowledge is a Outcome_Mental, pre - course scores is a Outcome_Mental, post - course scores is a Outcome_Mental, Knowledge gain is a Outcome_Mental	26561_task0	Sentence: Greater knowledge gain with structured than student-directed learning in Child Health : cluster randomized trial . The aim of this study was to detect a difference in knowledge gain between students receiving structured versus student-directed learning for the two-week Child Health outpatient module . A total of 138 phase 3 ( year 4 ) medical students in 10 two-week paediatric outpatient blocks at the Department of Child Health , University of Dundee , Scotland , were randomized to student-directed or structured learning between January and December 2002 . Pre- and post-course tests were administered at the start and the end of the attachment ; 129 students sat both tests . Results are presented as mean scores with standard deviations or 95 % confidence intervals ( CI ) in parentheses . The primary outcome measure was gain in knowledge of the Child Health core curriculum that is covered in the outpatient setting . Although pre-course scores were similar ( student-directed 25.3 ( 7.3 ) ; structured 24.8 ( 7.5 ) ) the structured approach resulted in higher post-course scores in comparison with the student-directed approach ( student-directed 41.8 ( 9.4 ) ; structured 53.8 ( 8.8 ) ; p < 0.01 ) . Knowledge gain showed significant differences between the two learning approaches ( student-directed 16.5 ( 3.7 ) ; structured 29.1 ( 3.8 ) , difference = 12.6 ( 95 % CI 11.3 to 13.9 ) ) . Low pre-course scores or gender did not affect knowledge gain . In the Child Health outpatient setting , the 'traditional ' structured approach led to significantly greater knowledge gain in comparison with the 'novel ' student-directed approach . The findings emphasize the importance of careful evaluation of novel medical education strategies before their implementation in medical schools , and the need for further research to define the effective methods for delivering medical education in Child Health . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Participant_Condition, Intervention_Educational, Intervention_Other, Participant_Age, Participant_Sample-size, Outcome_Other, Outcome_Mental	[ "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Intervention_Other", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "O", "B-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Greater knowledge gain with structured than student-directed learning in Child Health : cluster randomized trial . The aim of this study was to detect a difference in knowledge gain between students receiving structured versus student-directed learning for the two-week Child Health outpatient module . A total of 138 phase 3 ( year 4 ) medical students in 10 two-week paediatric outpatient blocks at the Department of Child Health , University of Dundee , Scotland , were randomized to student-directed or structured learning between January and December 2002 . Pre- and post-course tests were administered at the start and the end of the attachment ; 129 students sat both tests . Results are presented as mean scores with standard deviations or 95 % confidence intervals ( CI ) in parentheses . The primary outcome measure was gain in knowledge of the Child Health core curriculum that is covered in the outpatient setting . Although pre-course scores were similar ( student-directed 25.3 ( 7.3 ) ; structured 24.8 ( 7.5 ) ) the structured approach resulted in higher post-course scores in comparison with the student-directed approach ( student-directed 41.8 ( 9.4 ) ; structured 53.8 ( 8.8 ) ; p < 0.01 ) . Knowledge gain showed significant differences between the two learning approaches ( student-directed 16.5 ( 3.7 ) ; structured 29.1 ( 3.8 ) , difference = 12.6 ( 95 % CI 11.3 to 13.9 ) ) . Low pre-course scores or gender did not affect knowledge gain . In the Child Health outpatient setting , the 'traditional ' structured approach led to significantly greater knowledge gain in comparison with the 'novel ' student-directed approach . The findings emphasize the importance of careful evaluation of novel medical education strategies before their implementation in medical schools , and the need for further research to define the effective methods for delivering medical education in Child Health .	[ "Greater", "knowledge", "gain", "with", "structured", "than", "student", "-", "directed", "learning", "in", "Child", "Health", ":", "cluster", "randomized", "trial", ".", "The", "aim", "of", "this", "study", "was", "to", "detect", "a", "difference", "in", "knowledge", "gain", "between", "students", "receiving", "structured", "versus", "student", "-", "directed", "learning", "for", "the", "two", "-", "week", "Child", "Health", "outpatient", "module", ".", "A", "total", "of", "138", "phase", "3", "(", "year", "4", ")", "medical", "students", "in", "10", "two", "-", "week", "paediatric", "outpatient", "blocks", "at", "the", "Department", "of", "Child", "Health", ",", "University", "of", "Dundee", ",", "Scotland", ",", "were", "randomized", "to", "student", "-", "directed", "or", "structured", "learning", "between", "January", "and", "December", "2002", ".", "Pre-", "and", "post", "-", "course", "tests", "were", "administered", "at", "the", "start", "and", "the", "end", "of", "the", "attachment", ";", "129", "students", "sat", "both", "tests", ".", "Results", "are", "presented", "as", "mean", "scores", "with", "standard", "deviations", "or", "95", "%", "confidence", "intervals", "(", "CI", ")", "in", "parentheses", ".", "The", "primary", "outcome", "measure", "was", "gain", "in", "knowledge", "of", "the", "Child", "Health", "core", "curriculum", "that", "is", "covered", "in", "the", "outpatient", "setting", ".", "Although", "pre", "-", "course", "scores", "were", "similar", "(", "student", "-", "directed", "25.3", "(", "7.3", ")", ";", "structured", "24.8", "(", "7.5", ")", ")", "the", "structured", "approach", "resulted", "in", "higher", "post", "-", "course", "scores", "in", "comparison", "with", "the", "student", "-", "directed", "approach", "(", "student", "-", "directed", "41.8", "(", "9.4", ")", ";", "structured", "53.8", "(", "8.8", ")", ";", "p", "<", "0.01", ")", ".", "Knowledge", "gain", "showed", "significant", "differences", "between", "the", "two", "learning", "approaches", "(", "student", "-", "directed", "16.5", "(", "3.7", ")", ";", "structured", "29.1", "(", "3.8", ")", ",", "difference", "=", "12.6", "(", "95", "%", "CI", "11.3", "to", "13.9", ")", ")", ".", "Low", "pre", "-", "course", "scores", "or", "gender", "did", "not", "affect", "knowledge", "gain", ".", "In", "the", "Child", "Health", "outpatient", "setting", ",", "the", "'", "traditional", "'", "structured", "approach", "led", "to", "significantly", "greater", "knowledge", "gain", "in", "comparison", "with", "the", "'", "novel", "'", "student", "-", "directed", "approach", ".", "The", "findings", "emphasize", "the", "importance", "of", "careful", "evaluation", "of", "novel", "medical", "education", "strategies", "before", "their", "implementation", "in", "medical", "schools", ",", "and", "the", "need", "for", "further", "research", "to", "define", "the", "effective", "methods", "for", "delivering", "medical", "education", "in", "Child", "Health", "." ]	[ "Outcome_Other", "Intervention_Educational", "Intervention_Other", "Outcome_Mental", "Intervention_Control", "Participant_Age", "Participant_Condition", "Participant_Sample-size" ]
knowledge gain is a Outcome_Mental, structured is a Intervention_Other, student - directed learning is a Intervention_Educational, Health is a Participant_Condition, students is a Participant_Age, versus is a Intervention_Educational, 138 is a Participant_Sample-size, structured learning is a Intervention_Other, Pre- and post - course tests is a Outcome_Other, 129 is a Participant_Sample-size, gain in knowledge is a Outcome_Mental, pre - course scores is a Outcome_Mental, post - course scores is a Outcome_Mental, Knowledge gain is a Outcome_Mental	26561_task1	Sentence: Greater knowledge gain with structured than student-directed learning in Child Health : cluster randomized trial . The aim of this study was to detect a difference in knowledge gain between students receiving structured versus student-directed learning for the two-week Child Health outpatient module . A total of 138 phase 3 ( year 4 ) medical students in 10 two-week paediatric outpatient blocks at the Department of Child Health , University of Dundee , Scotland , were randomized to student-directed or structured learning between January and December 2002 . Pre- and post-course tests were administered at the start and the end of the attachment ; 129 students sat both tests . Results are presented as mean scores with standard deviations or 95 % confidence intervals ( CI ) in parentheses . The primary outcome measure was gain in knowledge of the Child Health core curriculum that is covered in the outpatient setting . Although pre-course scores were similar ( student-directed 25.3 ( 7.3 ) ; structured 24.8 ( 7.5 ) ) the structured approach resulted in higher post-course scores in comparison with the student-directed approach ( student-directed 41.8 ( 9.4 ) ; structured 53.8 ( 8.8 ) ; p < 0.01 ) . Knowledge gain showed significant differences between the two learning approaches ( student-directed 16.5 ( 3.7 ) ; structured 29.1 ( 3.8 ) , difference = 12.6 ( 95 % CI 11.3 to 13.9 ) ) . Low pre-course scores or gender did not affect knowledge gain . In the Child Health outpatient setting , the 'traditional ' structured approach led to significantly greater knowledge gain in comparison with the 'novel ' student-directed approach . The findings emphasize the importance of careful evaluation of novel medical education strategies before their implementation in medical schools , and the need for further research to define the effective methods for delivering medical education in Child Health . Instructions: please typing these entity words according to sentence: knowledge gain, structured, student - directed learning, Health, students, versus, 138, structured learning, Pre- and post - course tests, 129, gain in knowledge, pre - course scores, post - course scores, Knowledge gain Options: Participant_Condition, Intervention_Educational, Intervention_Other, Participant_Age, Participant_Sample-size, Outcome_Other, Outcome_Mental	[ "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Intervention_Other", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "O", "B-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Greater knowledge gain with structured than student-directed learning in Child Health : cluster randomized trial . The aim of this study was to detect a difference in knowledge gain between students receiving structured versus student-directed learning for the two-week Child Health outpatient module . A total of 138 phase 3 ( year 4 ) medical students in 10 two-week paediatric outpatient blocks at the Department of Child Health , University of Dundee , Scotland , were randomized to student-directed or structured learning between January and December 2002 . Pre- and post-course tests were administered at the start and the end of the attachment ; 129 students sat both tests . Results are presented as mean scores with standard deviations or 95 % confidence intervals ( CI ) in parentheses . The primary outcome measure was gain in knowledge of the Child Health core curriculum that is covered in the outpatient setting . Although pre-course scores were similar ( student-directed 25.3 ( 7.3 ) ; structured 24.8 ( 7.5 ) ) the structured approach resulted in higher post-course scores in comparison with the student-directed approach ( student-directed 41.8 ( 9.4 ) ; structured 53.8 ( 8.8 ) ; p < 0.01 ) . Knowledge gain showed significant differences between the two learning approaches ( student-directed 16.5 ( 3.7 ) ; structured 29.1 ( 3.8 ) , difference = 12.6 ( 95 % CI 11.3 to 13.9 ) ) . Low pre-course scores or gender did not affect knowledge gain . In the Child Health outpatient setting , the 'traditional ' structured approach led to significantly greater knowledge gain in comparison with the 'novel ' student-directed approach . The findings emphasize the importance of careful evaluation of novel medical education strategies before their implementation in medical schools , and the need for further research to define the effective methods for delivering medical education in Child Health .	[ "Greater", "knowledge", "gain", "with", "structured", "than", "student", "-", "directed", "learning", "in", "Child", "Health", ":", "cluster", "randomized", "trial", ".", "The", "aim", "of", "this", "study", "was", "to", "detect", "a", "difference", "in", "knowledge", "gain", "between", "students", "receiving", "structured", "versus", "student", "-", "directed", "learning", "for", "the", "two", "-", "week", "Child", "Health", "outpatient", "module", ".", "A", "total", "of", "138", "phase", "3", "(", "year", "4", ")", "medical", "students", "in", "10", "two", "-", "week", "paediatric", "outpatient", "blocks", "at", "the", "Department", "of", "Child", "Health", ",", "University", "of", "Dundee", ",", "Scotland", ",", "were", "randomized", "to", "student", "-", "directed", "or", "structured", "learning", "between", "January", "and", "December", "2002", ".", "Pre-", "and", "post", "-", "course", "tests", "were", "administered", "at", "the", "start", "and", "the", "end", "of", "the", "attachment", ";", "129", "students", "sat", "both", "tests", ".", "Results", "are", "presented", "as", "mean", "scores", "with", "standard", "deviations", "or", "95", "%", "confidence", "intervals", "(", "CI", ")", "in", "parentheses", ".", "The", "primary", "outcome", "measure", "was", "gain", "in", "knowledge", "of", "the", "Child", "Health", "core", "curriculum", "that", "is", "covered", "in", "the", "outpatient", "setting", ".", "Although", "pre", "-", "course", "scores", "were", "similar", "(", "student", "-", "directed", "25.3", "(", "7.3", ")", ";", "structured", "24.8", "(", "7.5", ")", ")", "the", "structured", "approach", "resulted", "in", "higher", "post", "-", "course", "scores", "in", "comparison", "with", "the", "student", "-", "directed", "approach", "(", "student", "-", "directed", "41.8", "(", "9.4", ")", ";", "structured", "53.8", "(", "8.8", ")", ";", "p", "<", "0.01", ")", ".", "Knowledge", "gain", "showed", "significant", "differences", "between", "the", "two", "learning", "approaches", "(", "student", "-", "directed", "16.5", "(", "3.7", ")", ";", "structured", "29.1", "(", "3.8", ")", ",", "difference", "=", "12.6", "(", "95", "%", "CI", "11.3", "to", "13.9", ")", ")", ".", "Low", "pre", "-", "course", "scores", "or", "gender", "did", "not", "affect", "knowledge", "gain", ".", "In", "the", "Child", "Health", "outpatient", "setting", ",", "the", "'", "traditional", "'", "structured", "approach", "led", "to", "significantly", "greater", "knowledge", "gain", "in", "comparison", "with", "the", "'", "novel", "'", "student", "-", "directed", "approach", ".", "The", "findings", "emphasize", "the", "importance", "of", "careful", "evaluation", "of", "novel", "medical", "education", "strategies", "before", "their", "implementation", "in", "medical", "schools", ",", "and", "the", "need", "for", "further", "research", "to", "define", "the", "effective", "methods", "for", "delivering", "medical", "education", "in", "Child", "Health", "." ]	[ "Outcome_Other", "Intervention_Educational", "Intervention_Other", "Outcome_Mental", "Intervention_Control", "Participant_Age", "Participant_Condition", "Participant_Sample-size" ]
knowledge gain, structured, student - directed learning, Health, students, versus, 138, structured learning, Pre- and post - course tests, 129, gain in knowledge, pre - course scores, post - course scores, Knowledge gain	26561_task2	Sentence: Greater knowledge gain with structured than student-directed learning in Child Health : cluster randomized trial . The aim of this study was to detect a difference in knowledge gain between students receiving structured versus student-directed learning for the two-week Child Health outpatient module . A total of 138 phase 3 ( year 4 ) medical students in 10 two-week paediatric outpatient blocks at the Department of Child Health , University of Dundee , Scotland , were randomized to student-directed or structured learning between January and December 2002 . Pre- and post-course tests were administered at the start and the end of the attachment ; 129 students sat both tests . Results are presented as mean scores with standard deviations or 95 % confidence intervals ( CI ) in parentheses . The primary outcome measure was gain in knowledge of the Child Health core curriculum that is covered in the outpatient setting . Although pre-course scores were similar ( student-directed 25.3 ( 7.3 ) ; structured 24.8 ( 7.5 ) ) the structured approach resulted in higher post-course scores in comparison with the student-directed approach ( student-directed 41.8 ( 9.4 ) ; structured 53.8 ( 8.8 ) ; p < 0.01 ) . Knowledge gain showed significant differences between the two learning approaches ( student-directed 16.5 ( 3.7 ) ; structured 29.1 ( 3.8 ) , difference = 12.6 ( 95 % CI 11.3 to 13.9 ) ) . Low pre-course scores or gender did not affect knowledge gain . In the Child Health outpatient setting , the 'traditional ' structured approach led to significantly greater knowledge gain in comparison with the 'novel ' student-directed approach . The findings emphasize the importance of careful evaluation of novel medical education strategies before their implementation in medical schools , and the need for further research to define the effective methods for delivering medical education in Child Health . Instructions: please extract entity words from the input sentence	[ "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Intervention_Other", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "O", "B-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Greater knowledge gain with structured than student-directed learning in Child Health : cluster randomized trial . The aim of this study was to detect a difference in knowledge gain between students receiving structured versus student-directed learning for the two-week Child Health outpatient module . A total of 138 phase 3 ( year 4 ) medical students in 10 two-week paediatric outpatient blocks at the Department of Child Health , University of Dundee , Scotland , were randomized to student-directed or structured learning between January and December 2002 . Pre- and post-course tests were administered at the start and the end of the attachment ; 129 students sat both tests . Results are presented as mean scores with standard deviations or 95 % confidence intervals ( CI ) in parentheses . The primary outcome measure was gain in knowledge of the Child Health core curriculum that is covered in the outpatient setting . Although pre-course scores were similar ( student-directed 25.3 ( 7.3 ) ; structured 24.8 ( 7.5 ) ) the structured approach resulted in higher post-course scores in comparison with the student-directed approach ( student-directed 41.8 ( 9.4 ) ; structured 53.8 ( 8.8 ) ; p < 0.01 ) . Knowledge gain showed significant differences between the two learning approaches ( student-directed 16.5 ( 3.7 ) ; structured 29.1 ( 3.8 ) , difference = 12.6 ( 95 % CI 11.3 to 13.9 ) ) . Low pre-course scores or gender did not affect knowledge gain . In the Child Health outpatient setting , the 'traditional ' structured approach led to significantly greater knowledge gain in comparison with the 'novel ' student-directed approach . The findings emphasize the importance of careful evaluation of novel medical education strategies before their implementation in medical schools , and the need for further research to define the effective methods for delivering medical education in Child Health .	[ "Greater", "knowledge", "gain", "with", "structured", "than", "student", "-", "directed", "learning", "in", "Child", "Health", ":", "cluster", "randomized", "trial", ".", "The", "aim", "of", "this", "study", "was", "to", "detect", "a", "difference", "in", "knowledge", "gain", "between", "students", "receiving", "structured", "versus", "student", "-", "directed", "learning", "for", "the", "two", "-", "week", "Child", "Health", "outpatient", "module", ".", "A", "total", "of", "138", "phase", "3", "(", "year", "4", ")", "medical", "students", "in", "10", "two", "-", "week", "paediatric", "outpatient", "blocks", "at", "the", "Department", "of", "Child", "Health", ",", "University", "of", "Dundee", ",", "Scotland", ",", "were", "randomized", "to", "student", "-", "directed", "or", "structured", "learning", "between", "January", "and", "December", "2002", ".", "Pre-", "and", "post", "-", "course", "tests", "were", "administered", "at", "the", "start", "and", "the", "end", "of", "the", "attachment", ";", "129", "students", "sat", "both", "tests", ".", "Results", "are", "presented", "as", "mean", "scores", "with", "standard", "deviations", "or", "95", "%", "confidence", "intervals", "(", "CI", ")", "in", "parentheses", ".", "The", "primary", "outcome", "measure", "was", "gain", "in", "knowledge", "of", "the", "Child", "Health", "core", "curriculum", "that", "is", "covered", "in", "the", "outpatient", "setting", ".", "Although", "pre", "-", "course", "scores", "were", "similar", "(", "student", "-", "directed", "25.3", "(", "7.3", ")", ";", "structured", "24.8", "(", "7.5", ")", ")", "the", "structured", "approach", "resulted", "in", "higher", "post", "-", "course", "scores", "in", "comparison", "with", "the", "student", "-", "directed", "approach", "(", "student", "-", "directed", "41.8", "(", "9.4", ")", ";", "structured", "53.8", "(", "8.8", ")", ";", "p", "<", "0.01", ")", ".", "Knowledge", "gain", "showed", "significant", "differences", "between", "the", "two", "learning", "approaches", "(", "student", "-", "directed", "16.5", "(", "3.7", ")", ";", "structured", "29.1", "(", "3.8", ")", ",", "difference", "=", "12.6", "(", "95", "%", "CI", "11.3", "to", "13.9", ")", ")", ".", "Low", "pre", "-", "course", "scores", "or", "gender", "did", "not", "affect", "knowledge", "gain", ".", "In", "the", "Child", "Health", "outpatient", "setting", ",", "the", "'", "traditional", "'", "structured", "approach", "led", "to", "significantly", "greater", "knowledge", "gain", "in", "comparison", "with", "the", "'", "novel", "'", "student", "-", "directed", "approach", ".", "The", "findings", "emphasize", "the", "importance", "of", "careful", "evaluation", "of", "novel", "medical", "education", "strategies", "before", "their", "implementation", "in", "medical", "schools", ",", "and", "the", "need", "for", "further", "research", "to", "define", "the", "effective", "methods", "for", "delivering", "medical", "education", "in", "Child", "Health", "." ]	[ "Outcome_Other", "Intervention_Educational", "Intervention_Other", "Outcome_Mental", "Intervention_Control", "Participant_Age", "Participant_Condition", "Participant_Sample-size" ]
aconitine is a CHEMICAL, cytochrome P450 3A is a GENE-N, buspirone is a CHEMICAL, paclitaxel is a CHEMICAL, Aconitine is a CHEMICAL, CYP3A is a GENE-N, CYP3A is a GENE-N, buspirone is a CHEMICAL, buspirone is a CHEMICAL, CYP3A is a GENE-N, buspirone is a CHEMICAL, Buspirone is a CHEMICAL, 1-(2-pyrimidinyl)piperazine is a CHEMICAL, 6'-hydroxybuspirone is a CHEMICAL, CYP3A is a GENE-N, 1-(2-pyrimidinyl)piperazine is a CHEMICAL, 6'-hydroxybuspirone is a CHEMICAL, CYP3A is a GENE-N, CYP3A is a GENE-N, CYP3A is a GENE-N	10737_task0	Sentence: The exposure of highly toxic aconitine does not significantly impact the activity and expression of cytochrome P450 3A in rats determined by a novel ultra performance liquid chromatography-tandem mass spectrometric method of a specific probe buspirone. Aconitum species are widely used to treat rheumatism, cardiovascular diseases, and tumors in China and other Asian countries. The herbs are always used with drugs such as paclitaxel. Aconitine (AC) is one of the main bioactive/high-toxic alkaloids of Aconitum roots. AC is metabolized by cytochrome P450 (CYP) 3A. However, whether AC inhibits/induces CYP3A, which causes drug-drug interaction (DDI) is unclear. Our study aims to explore the potent effects of AC, as a marker component of Aconitum, on CYP3A using the probe buspirone in rats. The effects of oral AC on pharmacokinetics of buspirone were evaluated. CYP3A activity and protein levels in rat liver microsomes pretreated with oral AC were also measured using in vitro buspirone metabolism and Western blot. Buspirone and its major metabolites 1-(2-pyrimidinyl)piperazine and 6'-hydroxybuspirone were determined using a newly validated UPLC-MS/MS method. Single dose and 7-day AC administration at 0.125mg/kg had no effect on CYP3A activity since no change in the formation of 1-(2-pyrimidinyl)piperazine and 6'-hydroxybuspirone. CYP3A activity and protein levels in liver microsomes were also not affected by 7-day AC pretreatment at 0.125mg/kg. Therefore, AC neither inhibits nor induces CYP3A in rats, indicating AC does not cause CYP3A-related DDI in the liver. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, CHEMICAL	[ "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O" ]	The exposure of highly toxic aconitine does not significantly impact the activity and expression of cytochrome P450 3A in rats determined by a novel ultra performance liquid chromatography-tandem mass spectrometric method of a specific probe buspirone. Aconitum species are widely used to treat rheumatism, cardiovascular diseases, and tumors in China and other Asian countries. The herbs are always used with drugs such as paclitaxel. Aconitine (AC) is one of the main bioactive/high-toxic alkaloids of Aconitum roots. AC is metabolized by cytochrome P450 (CYP) 3A. However, whether AC inhibits/induces CYP3A, which causes drug-drug interaction (DDI) is unclear. Our study aims to explore the potent effects of AC, as a marker component of Aconitum, on CYP3A using the probe buspirone in rats. The effects of oral AC on pharmacokinetics of buspirone were evaluated. CYP3A activity and protein levels in rat liver microsomes pretreated with oral AC were also measured using in vitro buspirone metabolism and Western blot. Buspirone and its major metabolites 1-(2-pyrimidinyl)piperazine and 6'-hydroxybuspirone were determined using a newly validated UPLC-MS/MS method. Single dose and 7-day AC administration at 0.125mg/kg had no effect on CYP3A activity since no change in the formation of 1-(2-pyrimidinyl)piperazine and 6'-hydroxybuspirone. CYP3A activity and protein levels in liver microsomes were also not affected by 7-day AC pretreatment at 0.125mg/kg. Therefore, AC neither inhibits nor induces CYP3A in rats, indicating AC does not cause CYP3A-related DDI in the liver.	[ "The", "exposure", "of", "highly", "toxic", "aconitine", "does", "not", "significantly", "impact", "the", "activity", "and", "expression", "of", "cytochrome", "P450", "3A", "in", "rats", "determined", "by", "a", "novel", "ultra", "performance", "liquid", "chromatography", "-", "tandem", "mass", "spectrometric", "method", "of", "a", "specific", "probe", "buspirone", ".", "\n", "Aconitum", "species", "are", "widely", "used", "to", "treat", "rheumatism", ",", "cardiovascular", "diseases", ",", "and", "tumors", "in", "China", "and", "other", "Asian", "countries", ".", "The", "herbs", "are", "always", "used", "with", "drugs", "such", "as", "paclitaxel", ".", "Aconitine", "(", "AC", ")", "is", "one", "of", "the", "main", "bioactive", "/", "high", "-", "toxic", "alkaloids", "of", "Aconitum", "roots", ".", "AC", "is", "metabolized", "by", "cytochrome", "P450", "(", "CYP", ")", "3A.", "However", ",", "whether", "AC", "inhibits", "/", "induces", "CYP3A", ",", "which", "causes", "drug", "-", "drug", "interaction", "(", "DDI", ")", "is", "unclear", ".", "Our", "study", "aims", "to", "explore", "the", "potent", "effects", "of", "AC", ",", "as", "a", "marker", "component", "of", "Aconitum", ",", "on", "CYP3A", "using", "the", "probe", "buspirone", "in", "rats", ".", "The", "effects", "of", "oral", "AC", "on", "pharmacokinetics", "of", "buspirone", "were", "evaluated", ".", "CYP3A", "activity", "and", "protein", "levels", "in", "rat", "liver", "microsomes", "pretreated", "with", "oral", "AC", "were", "also", "measured", "using", "in", "vitro", "buspirone", "metabolism", "and", "Western", "blot", ".", "Buspirone", "and", "its", "major", "metabolites", "1-(2-pyrimidinyl)piperazine", "and", "6'-hydroxybuspirone", "were", "determined", "using", "a", "newly", "validated", "UPLC", "-", "MS", "/", "MS", "method", ".", "Single", "dose", "and", "7-day", "AC", "administration", "at", "0.125mg", "/", "kg", "had", "no", "effect", "on", "CYP3A", "activity", "since", "no", "change", "in", "the", "formation", "of", "1-(2-pyrimidinyl)piperazine", "and", "6'-hydroxybuspirone", ".", "CYP3A", "activity", "and", "protein", "levels", "in", "liver", "microsomes", "were", "also", "not", "affected", "by", "7-day", "AC", "pretreatment", "at", "0.125mg", "/", "kg", ".", "Therefore", ",", "AC", "neither", "inhibits", "nor", "induces", "CYP3A", "in", "rats", ",", "indicating", "AC", "does", "not", "cause", "CYP3A", "-", "related", "DDI", "in", "the", "liver", "." ]	[ "CHEMICAL", "GENE-N" ]
aconitine is a CHEMICAL, cytochrome P450 3A is a GENE-N, buspirone is a CHEMICAL, paclitaxel is a CHEMICAL, Aconitine is a CHEMICAL, CYP3A is a GENE-N, CYP3A is a GENE-N, buspirone is a CHEMICAL, buspirone is a CHEMICAL, CYP3A is a GENE-N, buspirone is a CHEMICAL, Buspirone is a CHEMICAL, 1-(2-pyrimidinyl)piperazine is a CHEMICAL, 6'-hydroxybuspirone is a CHEMICAL, CYP3A is a GENE-N, 1-(2-pyrimidinyl)piperazine is a CHEMICAL, 6'-hydroxybuspirone is a CHEMICAL, CYP3A is a GENE-N, CYP3A is a GENE-N, CYP3A is a GENE-N	10737_task1	Sentence: The exposure of highly toxic aconitine does not significantly impact the activity and expression of cytochrome P450 3A in rats determined by a novel ultra performance liquid chromatography-tandem mass spectrometric method of a specific probe buspirone. Aconitum species are widely used to treat rheumatism, cardiovascular diseases, and tumors in China and other Asian countries. The herbs are always used with drugs such as paclitaxel. Aconitine (AC) is one of the main bioactive/high-toxic alkaloids of Aconitum roots. AC is metabolized by cytochrome P450 (CYP) 3A. However, whether AC inhibits/induces CYP3A, which causes drug-drug interaction (DDI) is unclear. Our study aims to explore the potent effects of AC, as a marker component of Aconitum, on CYP3A using the probe buspirone in rats. The effects of oral AC on pharmacokinetics of buspirone were evaluated. CYP3A activity and protein levels in rat liver microsomes pretreated with oral AC were also measured using in vitro buspirone metabolism and Western blot. Buspirone and its major metabolites 1-(2-pyrimidinyl)piperazine and 6'-hydroxybuspirone were determined using a newly validated UPLC-MS/MS method. Single dose and 7-day AC administration at 0.125mg/kg had no effect on CYP3A activity since no change in the formation of 1-(2-pyrimidinyl)piperazine and 6'-hydroxybuspirone. CYP3A activity and protein levels in liver microsomes were also not affected by 7-day AC pretreatment at 0.125mg/kg. Therefore, AC neither inhibits nor induces CYP3A in rats, indicating AC does not cause CYP3A-related DDI in the liver. Instructions: please typing these entity words according to sentence: aconitine, cytochrome P450 3A, buspirone, paclitaxel, Aconitine, CYP3A, CYP3A, buspirone, buspirone, CYP3A, buspirone, Buspirone, 1-(2-pyrimidinyl)piperazine, 6'-hydroxybuspirone, CYP3A, 1-(2-pyrimidinyl)piperazine, 6'-hydroxybuspirone, CYP3A, CYP3A, CYP3A Options: GENE-N, CHEMICAL	[ "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O" ]	The exposure of highly toxic aconitine does not significantly impact the activity and expression of cytochrome P450 3A in rats determined by a novel ultra performance liquid chromatography-tandem mass spectrometric method of a specific probe buspirone. Aconitum species are widely used to treat rheumatism, cardiovascular diseases, and tumors in China and other Asian countries. The herbs are always used with drugs such as paclitaxel. Aconitine (AC) is one of the main bioactive/high-toxic alkaloids of Aconitum roots. AC is metabolized by cytochrome P450 (CYP) 3A. However, whether AC inhibits/induces CYP3A, which causes drug-drug interaction (DDI) is unclear. Our study aims to explore the potent effects of AC, as a marker component of Aconitum, on CYP3A using the probe buspirone in rats. The effects of oral AC on pharmacokinetics of buspirone were evaluated. CYP3A activity and protein levels in rat liver microsomes pretreated with oral AC were also measured using in vitro buspirone metabolism and Western blot. Buspirone and its major metabolites 1-(2-pyrimidinyl)piperazine and 6'-hydroxybuspirone were determined using a newly validated UPLC-MS/MS method. Single dose and 7-day AC administration at 0.125mg/kg had no effect on CYP3A activity since no change in the formation of 1-(2-pyrimidinyl)piperazine and 6'-hydroxybuspirone. CYP3A activity and protein levels in liver microsomes were also not affected by 7-day AC pretreatment at 0.125mg/kg. Therefore, AC neither inhibits nor induces CYP3A in rats, indicating AC does not cause CYP3A-related DDI in the liver.	[ "The", "exposure", "of", "highly", "toxic", "aconitine", "does", "not", "significantly", "impact", "the", "activity", "and", "expression", "of", "cytochrome", "P450", "3A", "in", "rats", "determined", "by", "a", "novel", "ultra", "performance", "liquid", "chromatography", "-", "tandem", "mass", "spectrometric", "method", "of", "a", "specific", "probe", "buspirone", ".", "\n", "Aconitum", "species", "are", "widely", "used", "to", "treat", "rheumatism", ",", "cardiovascular", "diseases", ",", "and", "tumors", "in", "China", "and", "other", "Asian", "countries", ".", "The", "herbs", "are", "always", "used", "with", "drugs", "such", "as", "paclitaxel", ".", "Aconitine", "(", "AC", ")", "is", "one", "of", "the", "main", "bioactive", "/", "high", "-", "toxic", "alkaloids", "of", "Aconitum", "roots", ".", "AC", "is", "metabolized", "by", "cytochrome", "P450", "(", "CYP", ")", "3A.", "However", ",", "whether", "AC", "inhibits", "/", "induces", "CYP3A", ",", "which", "causes", "drug", "-", "drug", "interaction", "(", "DDI", ")", "is", "unclear", ".", "Our", "study", "aims", "to", "explore", "the", "potent", "effects", "of", "AC", ",", "as", "a", "marker", "component", "of", "Aconitum", ",", "on", "CYP3A", "using", "the", "probe", "buspirone", "in", "rats", ".", "The", "effects", "of", "oral", "AC", "on", "pharmacokinetics", "of", "buspirone", "were", "evaluated", ".", "CYP3A", "activity", "and", "protein", "levels", "in", "rat", "liver", "microsomes", "pretreated", "with", "oral", "AC", "were", "also", "measured", "using", "in", "vitro", "buspirone", "metabolism", "and", "Western", "blot", ".", "Buspirone", "and", "its", "major", "metabolites", "1-(2-pyrimidinyl)piperazine", "and", "6'-hydroxybuspirone", "were", "determined", "using", "a", "newly", "validated", "UPLC", "-", "MS", "/", "MS", "method", ".", "Single", "dose", "and", "7-day", "AC", "administration", "at", "0.125mg", "/", "kg", "had", "no", "effect", "on", "CYP3A", "activity", "since", "no", "change", "in", "the", "formation", "of", "1-(2-pyrimidinyl)piperazine", "and", "6'-hydroxybuspirone", ".", "CYP3A", "activity", "and", "protein", "levels", "in", "liver", "microsomes", "were", "also", "not", "affected", "by", "7-day", "AC", "pretreatment", "at", "0.125mg", "/", "kg", ".", "Therefore", ",", "AC", "neither", "inhibits", "nor", "induces", "CYP3A", "in", "rats", ",", "indicating", "AC", "does", "not", "cause", "CYP3A", "-", "related", "DDI", "in", "the", "liver", "." ]	[ "CHEMICAL", "GENE-N" ]
aconitine, cytochrome P450 3A, buspirone, paclitaxel, Aconitine, CYP3A, CYP3A, buspirone, buspirone, CYP3A, buspirone, Buspirone, 1-(2-pyrimidinyl)piperazine, 6'-hydroxybuspirone, CYP3A, 1-(2-pyrimidinyl)piperazine, 6'-hydroxybuspirone, CYP3A, CYP3A, CYP3A	10737_task2	Sentence: The exposure of highly toxic aconitine does not significantly impact the activity and expression of cytochrome P450 3A in rats determined by a novel ultra performance liquid chromatography-tandem mass spectrometric method of a specific probe buspirone. Aconitum species are widely used to treat rheumatism, cardiovascular diseases, and tumors in China and other Asian countries. The herbs are always used with drugs such as paclitaxel. Aconitine (AC) is one of the main bioactive/high-toxic alkaloids of Aconitum roots. AC is metabolized by cytochrome P450 (CYP) 3A. However, whether AC inhibits/induces CYP3A, which causes drug-drug interaction (DDI) is unclear. Our study aims to explore the potent effects of AC, as a marker component of Aconitum, on CYP3A using the probe buspirone in rats. The effects of oral AC on pharmacokinetics of buspirone were evaluated. CYP3A activity and protein levels in rat liver microsomes pretreated with oral AC were also measured using in vitro buspirone metabolism and Western blot. Buspirone and its major metabolites 1-(2-pyrimidinyl)piperazine and 6'-hydroxybuspirone were determined using a newly validated UPLC-MS/MS method. Single dose and 7-day AC administration at 0.125mg/kg had no effect on CYP3A activity since no change in the formation of 1-(2-pyrimidinyl)piperazine and 6'-hydroxybuspirone. CYP3A activity and protein levels in liver microsomes were also not affected by 7-day AC pretreatment at 0.125mg/kg. Therefore, AC neither inhibits nor induces CYP3A in rats, indicating AC does not cause CYP3A-related DDI in the liver. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O" ]	The exposure of highly toxic aconitine does not significantly impact the activity and expression of cytochrome P450 3A in rats determined by a novel ultra performance liquid chromatography-tandem mass spectrometric method of a specific probe buspirone. Aconitum species are widely used to treat rheumatism, cardiovascular diseases, and tumors in China and other Asian countries. The herbs are always used with drugs such as paclitaxel. Aconitine (AC) is one of the main bioactive/high-toxic alkaloids of Aconitum roots. AC is metabolized by cytochrome P450 (CYP) 3A. However, whether AC inhibits/induces CYP3A, which causes drug-drug interaction (DDI) is unclear. Our study aims to explore the potent effects of AC, as a marker component of Aconitum, on CYP3A using the probe buspirone in rats. The effects of oral AC on pharmacokinetics of buspirone were evaluated. CYP3A activity and protein levels in rat liver microsomes pretreated with oral AC were also measured using in vitro buspirone metabolism and Western blot. Buspirone and its major metabolites 1-(2-pyrimidinyl)piperazine and 6'-hydroxybuspirone were determined using a newly validated UPLC-MS/MS method. Single dose and 7-day AC administration at 0.125mg/kg had no effect on CYP3A activity since no change in the formation of 1-(2-pyrimidinyl)piperazine and 6'-hydroxybuspirone. CYP3A activity and protein levels in liver microsomes were also not affected by 7-day AC pretreatment at 0.125mg/kg. Therefore, AC neither inhibits nor induces CYP3A in rats, indicating AC does not cause CYP3A-related DDI in the liver.	[ "The", "exposure", "of", "highly", "toxic", "aconitine", "does", "not", "significantly", "impact", "the", "activity", "and", "expression", "of", "cytochrome", "P450", "3A", "in", "rats", "determined", "by", "a", "novel", "ultra", "performance", "liquid", "chromatography", "-", "tandem", "mass", "spectrometric", "method", "of", "a", "specific", "probe", "buspirone", ".", "\n", "Aconitum", "species", "are", "widely", "used", "to", "treat", "rheumatism", ",", "cardiovascular", "diseases", ",", "and", "tumors", "in", "China", "and", "other", "Asian", "countries", ".", "The", "herbs", "are", "always", "used", "with", "drugs", "such", "as", "paclitaxel", ".", "Aconitine", "(", "AC", ")", "is", "one", "of", "the", "main", "bioactive", "/", "high", "-", "toxic", "alkaloids", "of", "Aconitum", "roots", ".", "AC", "is", "metabolized", "by", "cytochrome", "P450", "(", "CYP", ")", "3A.", "However", ",", "whether", "AC", "inhibits", "/", "induces", "CYP3A", ",", "which", "causes", "drug", "-", "drug", "interaction", "(", "DDI", ")", "is", "unclear", ".", "Our", "study", "aims", "to", "explore", "the", "potent", "effects", "of", "AC", ",", "as", "a", "marker", "component", "of", "Aconitum", ",", "on", "CYP3A", "using", "the", "probe", "buspirone", "in", "rats", ".", "The", "effects", "of", "oral", "AC", "on", "pharmacokinetics", "of", "buspirone", "were", "evaluated", ".", "CYP3A", "activity", "and", "protein", "levels", "in", "rat", "liver", "microsomes", "pretreated", "with", "oral", "AC", "were", "also", "measured", "using", "in", "vitro", "buspirone", "metabolism", "and", "Western", "blot", ".", "Buspirone", "and", "its", "major", "metabolites", "1-(2-pyrimidinyl)piperazine", "and", "6'-hydroxybuspirone", "were", "determined", "using", "a", "newly", "validated", "UPLC", "-", "MS", "/", "MS", "method", ".", "Single", "dose", "and", "7-day", "AC", "administration", "at", "0.125mg", "/", "kg", "had", "no", "effect", "on", "CYP3A", "activity", "since", "no", "change", "in", "the", "formation", "of", "1-(2-pyrimidinyl)piperazine", "and", "6'-hydroxybuspirone", ".", "CYP3A", "activity", "and", "protein", "levels", "in", "liver", "microsomes", "were", "also", "not", "affected", "by", "7-day", "AC", "pretreatment", "at", "0.125mg", "/", "kg", ".", "Therefore", ",", "AC", "neither", "inhibits", "nor", "induces", "CYP3A", "in", "rats", ",", "indicating", "AC", "does", "not", "cause", "CYP3A", "-", "related", "DDI", "in", "the", "liver", "." ]	[ "CHEMICAL", "GENE-N" ]
Ezequiel is a NOMBRE_SUJETO_ASISTENCIA, Lopez Pereira is a NOMBRE_SUJETO_ASISTENCIA, 7856544 is a ID_SUJETO_ASISTENCIA, 78 45678567 05 is a ID_ASEGURAMIENTO, Madrid is a TERRITORIO, 28029 is a TERRITORIO, 23/08/1957 is a FECHAS, España is a PAIS, 60 años is a EDAD_SUJETO_ASISTENCIA, 29/12/2017 is a FECHAS, Luis Roberto León is a NOMBRE_PERSONAL_SANITARIO, 28 28 57103 is a ID_TITULACION_PERSONAL_SANITARIO, varón is a SEXO_SUJETO_ASISTENCIA, 60 años is a EDAD_SUJETO_ASISTENCIA, 1995 is a FECHAS, Hermano mayor is a FAMILIARES_SUJETO_ASISTENCIA, 65 años is a FAMILIARES_SUJETO_ASISTENCIA, Hermano menor is a FAMILIARES_SUJETO_ASISTENCIA, 58 años is a FAMILIARES_SUJETO_ASISTENCIA, Hermana is a FAMILIARES_SUJETO_ASISTENCIA, 55 años is a FAMILIARES_SUJETO_ASISTENCIA, Tío materno is a FAMILIARES_SUJETO_ASISTENCIA, 60 años is a FAMILIARES_SUJETO_ASISTENCIA, hijo varón is a FAMILIARES_SUJETO_ASISTENCIA, Madre is a FAMILIARES_SUJETO_ASISTENCIA, dos primos hermanos is a FAMILIARES_SUJETO_ASISTENCIA, 67 años is a FAMILIARES_SUJETO_ASISTENCIA, 62 años is a FAMILIARES_SUJETO_ASISTENCIA, Luis Roberto León is a NOMBRE_PERSONAL_SANITARIO, lleon@intramed.com is a CORREO_ELECTRONICO	111_task0	Sentence: Datos del paciente. Nombre: Ezequiel. Apellidos: Lopez Pereira. NHC: 7856544. NASS: 78 45678567 05. Domicilio: C/ Vinuesa, 4, 6 A. Localidad/ Provincia: Madrid. CP: 28029. Datos asistenciales. Fecha de nacimiento: 23/08/1957. País de nacimiento: España. Edad: 60 años Sexo: H. Fecha de Ingreso: 29/12/2017. Médico: Luis Roberto León NºCol: 28 28 57103. Informe clínico del paciente: Paciente varón de 60 años, con síndrome de Alport, microhematuria y proteinuria de 4 g/día, creatinina de 2 mg/dl, urea 123 mg/dl, pérdida moderada de la audición, hipertensión arterial tratada con enalapril 20 mg, obesidad con IMC = 36,26 (P 120 kg, h 1,81 m), glucemias en ayunas alteradas (menor a 126 mg/dl), Hb glucosilada normal, dislipidemia e hiperuricemia en tratamiento. Ex-fumador de un paquete al día. Normotiroideo. Biopsia renal (realizada en 1995): MO (12 glomérulos) esclerosis focal y segmentaria glomerular en evolución a glomerulopatía esclerosante, IF con Ig M de leve intensidad en mesangio e IgA y M en cilindros tubulares. ME 2 glomérulos. MB capilar con engrosamiento irregular y desdoblamiento focal de la lámina densa. Podocitos con fusión total de pedicelos. En un sector, borramiento de la estructura glomerular con depósito de abundante material amorfo, electrón denso. Las alteraciones de la lámina densa son compatibles con enfermedad de Alport, el resto de los hallazgos con glomerulonefritis esclerosante focal. Ecografía renal: RD 95,6 x 52 x 53, RI 99 x 51 x 52. Doppler renal sin alteraciones. Se indica dieta baja en proteínas, hipocalórica y se agrega al tratamiento losartán en dosis de 75 mg/día (máxima tolerada por el paciente). Se observa reducción muy leve de proteinuria a 3,6 g/día. Se realiza cirugía de by-pass gástrico, y presenta en su evolución disminución de 35 kg en total, llegando a IMC de 25,6. Control nefrológico: creatinina 1,56 mg/dl, proteinuria 0,3 g/día, urea 65 mg/dl y normotensión con enalapril 5 mg/d; se mantiene dosis mínima de hipolipemiantes, normouricemia y normoglucemias. Antecedentes familiares: Hermano mayor de 65 años con nefropatía e hipoacusia neurosensorial bilateral y síndrome de Alport. Hermano menor de 58 años también con nefropatía e hipoacusia y síndrome de Alport. Hermana de 55 años de edad con nefropatía sin hipoacusia. Tío materno fallecido a los 60 años de edad por nefropatía de causa no aclarada y sin hipoacusia, que además ha tenido un hijo varón y una nieta con nefropatía sin hipoacusia. Madre con nefropatía desde la infancia con posible síndrome de Alport. Según comenta, dos primos hermanos de 67 años y 62 años de edad respectivamente, con diagnóstico clínico de hemocromatosis hereditaria. Tres años después de la cirugía, la buena evolución del paciente está relacionada con el cumplimento del tratamiento (dieta), ejercicio aeróbico y apoyo clínico-psicológico. Responsable clínico: Dr. Luis Roberto León, Email: lleon@intramed.com Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, FAMILIARES_SUJETO_ASISTENCIA, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Datos del paciente. Nombre: Ezequiel. Apellidos: Lopez Pereira. NHC: 7856544. NASS: 78 45678567 05. Domicilio: C/ Vinuesa, 4, 6 A. Localidad/ Provincia: Madrid. CP: 28029. Datos asistenciales. Fecha de nacimiento: 23/08/1957. País de nacimiento: España. Edad: 60 años Sexo: H. Fecha de Ingreso: 29/12/2017. Médico: Luis Roberto León NºCol: 28 28 57103. Informe clínico del paciente: Paciente varón de 60 años, con síndrome de Alport, microhematuria y proteinuria de 4 g/día, creatinina de 2 mg/dl, urea 123 mg/dl, pérdida moderada de la audición, hipertensión arterial tratada con enalapril 20 mg, obesidad con IMC = 36,26 (P 120 kg, h 1,81 m), glucemias en ayunas alteradas (menor a 126 mg/dl), Hb glucosilada normal, dislipidemia e hiperuricemia en tratamiento. Ex-fumador de un paquete al día. Normotiroideo. Biopsia renal (realizada en 1995): MO (12 glomérulos) esclerosis focal y segmentaria glomerular en evolución a glomerulopatía esclerosante, IF con Ig M de leve intensidad en mesangio e IgA y M en cilindros tubulares. ME 2 glomérulos. MB capilar con engrosamiento irregular y desdoblamiento focal de la lámina densa. Podocitos con fusión total de pedicelos. En un sector, borramiento de la estructura glomerular con depósito de abundante material amorfo, electrón denso. Las alteraciones de la lámina densa son compatibles con enfermedad de Alport, el resto de los hallazgos con glomerulonefritis esclerosante focal. Ecografía renal: RD 95,6 x 52 x 53, RI 99 x 51 x 52. Doppler renal sin alteraciones. Se indica dieta baja en proteínas, hipocalórica y se agrega al tratamiento losartán en dosis de 75 mg/día (máxima tolerada por el paciente). Se observa reducción muy leve de proteinuria a 3,6 g/día. Se realiza cirugía de by-pass gástrico, y presenta en su evolución disminución de 35 kg en total, llegando a IMC de 25,6. Control nefrológico: creatinina 1,56 mg/dl, proteinuria 0,3 g/día, urea 65 mg/dl y normotensión con enalapril 5 mg/d; se mantiene dosis mínima de hipolipemiantes, normouricemia y normoglucemias. Antecedentes familiares: Hermano mayor de 65 años con nefropatía e hipoacusia neurosensorial bilateral y síndrome de Alport. Hermano menor de 58 años también con nefropatía e hipoacusia y síndrome de Alport. Hermana de 55 años de edad con nefropatía sin hipoacusia. Tío materno fallecido a los 60 años de edad por nefropatía de causa no aclarada y sin hipoacusia, que además ha tenido un hijo varón y una nieta con nefropatía sin hipoacusia. Madre con nefropatía desde la infancia con posible síndrome de Alport. Según comenta, dos primos hermanos de 67 años y 62 años de edad respectivamente, con diagnóstico clínico de hemocromatosis hereditaria. Tres años después de la cirugía, la buena evolución del paciente está relacionada con el cumplimento del tratamiento (dieta), ejercicio aeróbico y apoyo clínico-psicológico. Responsable clínico: Dr. Luis Roberto León, Email: lleon@intramed.com	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Ezequiel", ".", "\n", "Apellidos", ":", "Lopez", "Pereira", ".", "\n", "NHC", ":", "7856544", ".", "\n", "NASS", ":", "78", "45678567", "05", ".", "\n", "Domicilio", ":", "C/", "Vinuesa", ",", "4", ",", "6", "A.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "28029", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "23/08/1957", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "60", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "29/12/2017", ".", "\n", "Médico", ":", "Luis", "Roberto", "León", " ", "NºCol", ":", "28", "28", "57103", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Paciente", "varón", "de", "60", "años", ",", "con", "síndrome", "de", "Alport", ",", "microhematuria", "y", "proteinuria", "de", "4", "g", "/", "día", ",", "creatinina", "de", "2", "mg", "/", "dl", ",", "urea", "123", "mg", "/", "dl", ",", "pérdida", "moderada", "de", "la", "audición", ",", "hipertensión", "arterial", "tratada", "con", "enalapril", "20", "mg", ",", "obesidad", "con", "IMC", "=", "36,26", "(", "P", "120", "kg", ",", "h", "1,81", "m", ")", ",", "glucemias", "en", "ayunas", "alteradas", "(", "menor", "a", "126", "mg", "/", "dl", ")", ",", "Hb", "glucosilada", "normal", ",", "dislipidemia", "e", "hiperuricemia", "en", "tratamiento", ".", "Ex", "-", "fumador", "de", "un", "paquete", "al", "día", ".", "Normotiroideo", ".", "Biopsia", "renal", "(", "realizada", "en", "1995", "):", "MO", "(", "12", "glomérulos", ")", "esclerosis", "focal", "y", "segmentaria", "glomerular", "en", "evolución", "a", "glomerulopatía", "esclerosante", ",", "IF", "con", "Ig", "M", "de", "leve", "intensidad", "en", "mesangio", "e", "IgA", "y", "M", "en", "cilindros", "tubulares", ".", "ME", "2", "glomérulos", ".", "MB", "capilar", "con", "engrosamiento", "irregular", "y", "desdoblamiento", "focal", "de", "la", "lámina", "densa", ".", "Podocitos", "con", "fusión", "total", "de", "pedicelos", ".", "En", "un", "sector", ",", "borramiento", "de", "la", "estructura", "glomerular", "con", "depósito", "de", "abundante", "material", "amorfo", ",", "electrón", "denso", ".", "Las", "alteraciones", "de", "la", "lámina", "densa", "son", "compatibles", "con", "enfermedad", "de", "Alport", ",", "el", "resto", "de", "los", "hallazgos", "con", "glomerulonefritis", "esclerosante", "focal", ".", "Ecografía", "renal", ":", "RD", "95,6", "x", "52", "x", "53", ",", "RI", "99", "x", "51", "x", "52", ".", "Doppler", "renal", "sin", "alteraciones", ".", "\n", "Se", "indica", "dieta", "baja", "en", "proteínas", ",", "hipocalórica", "y", "se", "agrega", "al", "tratamiento", "losartán", "en", "dosis", "de", "75", "mg", "/", "día", "(", "máxima", "tolerada", "por", "el", "paciente", ")", ".", "Se", "observa", "reducción", "muy", "leve", "de", "proteinuria", "a", "3,6", "g", "/", "día", ".", "Se", "realiza", "cirugía", "de", "by", "-", "pass", "gástrico", ",", "y", "presenta", "en", "su", "evolución", "disminución", "de", "35", "kg", "en", "total", ",", "llegando", "a", "IMC", "de", "25,6", ".", "Control", "nefrológico", ":", "creatinina", "1,56", "mg", "/", "dl", ",", "proteinuria", "0,3", "g", "/", "día", ",", "urea", "65", "mg", "/", "dl", "y", "normotensión", "con", "enalapril", "5", "mg", "/", "d", ";", "se", "mantiene", "dosis", "mínima", "de", "hipolipemiantes", ",", "normouricemia", "y", "normoglucemias", ".", "\n", "Antecedentes", "familiares", ":", "\n", "Hermano", "mayor", "de", "65", "años", "con", "nefropatía", "e", "hipoacusia", "neurosensorial", "bilateral", "y", "síndrome", "de", "Alport", ".", "\n", "Hermano", "menor", "de", "58", "años", "también", "con", "nefropatía", "e", "hipoacusia", "y", "síndrome", "de", "Alport", ".", "\n", "Hermana", "de", "55", "años", "de", "edad", "con", "nefropatía", "sin", "hipoacusia", ".", "\n", "Tío", "materno", "fallecido", "a", "los", "60", "años", "de", "edad", "por", "nefropatía", "de", "causa", "no", "aclarada", "y", "sin", "hipoacusia", ",", "que", "además", "ha", "tenido", "un", "hijo", "varón", "y", "una", "nieta", "con", "nefropatía", "sin", "hipoacusia", ".", "\n", "Madre", "con", "nefropatía", "desde", "la", "infancia", "con", "posible", "síndrome", "de", "Alport", ".", "\n", "Según", "comenta", ",", "dos", "primos", "hermanos", "de", "67", "años", "y", "62", "años", "de", "edad", "respectivamente", ",", "con", "diagnóstico", "clínico", "de", "hemocromatosis", "hereditaria", ".", "\n", "Tres", "años", "después", "de", "la", "cirugía", ",", "la", "buena", "evolución", "del", "paciente", "está", "relacionada", "con", "el", "cumplimento", "del", "tratamiento", "(", "dieta", ")", ",", "ejercicio", "aeróbico", "y", "apoyo", "clínico", "-", "psicológico", ".", "\n", "Responsable", "clínico", ":", "Dr", ".", "Luis", "Roberto", "León", ",", "Email", ":", "lleon@intramed.com", "\n" ]	[ "FAMILIARES_SUJETO_ASISTENCIA", "CORREO_ELECTRONICO", "CALLE", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]
Ezequiel is a NOMBRE_SUJETO_ASISTENCIA, Lopez Pereira is a NOMBRE_SUJETO_ASISTENCIA, 7856544 is a ID_SUJETO_ASISTENCIA, 78 45678567 05 is a ID_ASEGURAMIENTO, Madrid is a TERRITORIO, 28029 is a TERRITORIO, 23/08/1957 is a FECHAS, España is a PAIS, 60 años is a EDAD_SUJETO_ASISTENCIA, 29/12/2017 is a FECHAS, Luis Roberto León is a NOMBRE_PERSONAL_SANITARIO, 28 28 57103 is a ID_TITULACION_PERSONAL_SANITARIO, varón is a SEXO_SUJETO_ASISTENCIA, 60 años is a EDAD_SUJETO_ASISTENCIA, 1995 is a FECHAS, Hermano mayor is a FAMILIARES_SUJETO_ASISTENCIA, 65 años is a FAMILIARES_SUJETO_ASISTENCIA, Hermano menor is a FAMILIARES_SUJETO_ASISTENCIA, 58 años is a FAMILIARES_SUJETO_ASISTENCIA, Hermana is a FAMILIARES_SUJETO_ASISTENCIA, 55 años is a FAMILIARES_SUJETO_ASISTENCIA, Tío materno is a FAMILIARES_SUJETO_ASISTENCIA, 60 años is a FAMILIARES_SUJETO_ASISTENCIA, hijo varón is a FAMILIARES_SUJETO_ASISTENCIA, Madre is a FAMILIARES_SUJETO_ASISTENCIA, dos primos hermanos is a FAMILIARES_SUJETO_ASISTENCIA, 67 años is a FAMILIARES_SUJETO_ASISTENCIA, 62 años is a FAMILIARES_SUJETO_ASISTENCIA, Luis Roberto León is a NOMBRE_PERSONAL_SANITARIO, lleon@intramed.com is a CORREO_ELECTRONICO	111_task1	Sentence: Datos del paciente. Nombre: Ezequiel. Apellidos: Lopez Pereira. NHC: 7856544. NASS: 78 45678567 05. Domicilio: C/ Vinuesa, 4, 6 A. Localidad/ Provincia: Madrid. CP: 28029. Datos asistenciales. Fecha de nacimiento: 23/08/1957. País de nacimiento: España. Edad: 60 años Sexo: H. Fecha de Ingreso: 29/12/2017. Médico: Luis Roberto León NºCol: 28 28 57103. Informe clínico del paciente: Paciente varón de 60 años, con síndrome de Alport, microhematuria y proteinuria de 4 g/día, creatinina de 2 mg/dl, urea 123 mg/dl, pérdida moderada de la audición, hipertensión arterial tratada con enalapril 20 mg, obesidad con IMC = 36,26 (P 120 kg, h 1,81 m), glucemias en ayunas alteradas (menor a 126 mg/dl), Hb glucosilada normal, dislipidemia e hiperuricemia en tratamiento. Ex-fumador de un paquete al día. Normotiroideo. Biopsia renal (realizada en 1995): MO (12 glomérulos) esclerosis focal y segmentaria glomerular en evolución a glomerulopatía esclerosante, IF con Ig M de leve intensidad en mesangio e IgA y M en cilindros tubulares. ME 2 glomérulos. MB capilar con engrosamiento irregular y desdoblamiento focal de la lámina densa. Podocitos con fusión total de pedicelos. En un sector, borramiento de la estructura glomerular con depósito de abundante material amorfo, electrón denso. Las alteraciones de la lámina densa son compatibles con enfermedad de Alport, el resto de los hallazgos con glomerulonefritis esclerosante focal. Ecografía renal: RD 95,6 x 52 x 53, RI 99 x 51 x 52. Doppler renal sin alteraciones. Se indica dieta baja en proteínas, hipocalórica y se agrega al tratamiento losartán en dosis de 75 mg/día (máxima tolerada por el paciente). Se observa reducción muy leve de proteinuria a 3,6 g/día. Se realiza cirugía de by-pass gástrico, y presenta en su evolución disminución de 35 kg en total, llegando a IMC de 25,6. Control nefrológico: creatinina 1,56 mg/dl, proteinuria 0,3 g/día, urea 65 mg/dl y normotensión con enalapril 5 mg/d; se mantiene dosis mínima de hipolipemiantes, normouricemia y normoglucemias. Antecedentes familiares: Hermano mayor de 65 años con nefropatía e hipoacusia neurosensorial bilateral y síndrome de Alport. Hermano menor de 58 años también con nefropatía e hipoacusia y síndrome de Alport. Hermana de 55 años de edad con nefropatía sin hipoacusia. Tío materno fallecido a los 60 años de edad por nefropatía de causa no aclarada y sin hipoacusia, que además ha tenido un hijo varón y una nieta con nefropatía sin hipoacusia. Madre con nefropatía desde la infancia con posible síndrome de Alport. Según comenta, dos primos hermanos de 67 años y 62 años de edad respectivamente, con diagnóstico clínico de hemocromatosis hereditaria. Tres años después de la cirugía, la buena evolución del paciente está relacionada con el cumplimento del tratamiento (dieta), ejercicio aeróbico y apoyo clínico-psicológico. Responsable clínico: Dr. Luis Roberto León, Email: lleon@intramed.com Instructions: please typing these entity words according to sentence: Ezequiel, Lopez Pereira, 7856544, 78 45678567 05, Madrid, 28029, 23/08/1957, España, 60 años, 29/12/2017, Luis Roberto León, 28 28 57103, varón, 60 años, 1995, Hermano mayor, 65 años, Hermano menor, 58 años, Hermana, 55 años, Tío materno, 60 años, hijo varón, Madre, dos primos hermanos, 67 años, 62 años, Luis Roberto León, lleon@intramed.com Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, FAMILIARES_SUJETO_ASISTENCIA, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Datos del paciente. Nombre: Ezequiel. Apellidos: Lopez Pereira. NHC: 7856544. NASS: 78 45678567 05. Domicilio: C/ Vinuesa, 4, 6 A. Localidad/ Provincia: Madrid. CP: 28029. Datos asistenciales. Fecha de nacimiento: 23/08/1957. País de nacimiento: España. Edad: 60 años Sexo: H. Fecha de Ingreso: 29/12/2017. Médico: Luis Roberto León NºCol: 28 28 57103. Informe clínico del paciente: Paciente varón de 60 años, con síndrome de Alport, microhematuria y proteinuria de 4 g/día, creatinina de 2 mg/dl, urea 123 mg/dl, pérdida moderada de la audición, hipertensión arterial tratada con enalapril 20 mg, obesidad con IMC = 36,26 (P 120 kg, h 1,81 m), glucemias en ayunas alteradas (menor a 126 mg/dl), Hb glucosilada normal, dislipidemia e hiperuricemia en tratamiento. Ex-fumador de un paquete al día. Normotiroideo. Biopsia renal (realizada en 1995): MO (12 glomérulos) esclerosis focal y segmentaria glomerular en evolución a glomerulopatía esclerosante, IF con Ig M de leve intensidad en mesangio e IgA y M en cilindros tubulares. ME 2 glomérulos. MB capilar con engrosamiento irregular y desdoblamiento focal de la lámina densa. Podocitos con fusión total de pedicelos. En un sector, borramiento de la estructura glomerular con depósito de abundante material amorfo, electrón denso. Las alteraciones de la lámina densa son compatibles con enfermedad de Alport, el resto de los hallazgos con glomerulonefritis esclerosante focal. Ecografía renal: RD 95,6 x 52 x 53, RI 99 x 51 x 52. Doppler renal sin alteraciones. Se indica dieta baja en proteínas, hipocalórica y se agrega al tratamiento losartán en dosis de 75 mg/día (máxima tolerada por el paciente). Se observa reducción muy leve de proteinuria a 3,6 g/día. Se realiza cirugía de by-pass gástrico, y presenta en su evolución disminución de 35 kg en total, llegando a IMC de 25,6. Control nefrológico: creatinina 1,56 mg/dl, proteinuria 0,3 g/día, urea 65 mg/dl y normotensión con enalapril 5 mg/d; se mantiene dosis mínima de hipolipemiantes, normouricemia y normoglucemias. Antecedentes familiares: Hermano mayor de 65 años con nefropatía e hipoacusia neurosensorial bilateral y síndrome de Alport. Hermano menor de 58 años también con nefropatía e hipoacusia y síndrome de Alport. Hermana de 55 años de edad con nefropatía sin hipoacusia. Tío materno fallecido a los 60 años de edad por nefropatía de causa no aclarada y sin hipoacusia, que además ha tenido un hijo varón y una nieta con nefropatía sin hipoacusia. Madre con nefropatía desde la infancia con posible síndrome de Alport. Según comenta, dos primos hermanos de 67 años y 62 años de edad respectivamente, con diagnóstico clínico de hemocromatosis hereditaria. Tres años después de la cirugía, la buena evolución del paciente está relacionada con el cumplimento del tratamiento (dieta), ejercicio aeróbico y apoyo clínico-psicológico. Responsable clínico: Dr. Luis Roberto León, Email: lleon@intramed.com	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Ezequiel", ".", "\n", "Apellidos", ":", "Lopez", "Pereira", ".", "\n", "NHC", ":", "7856544", ".", "\n", "NASS", ":", "78", "45678567", "05", ".", "\n", "Domicilio", ":", "C/", "Vinuesa", ",", "4", ",", "6", "A.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "28029", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "23/08/1957", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "60", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "29/12/2017", ".", "\n", "Médico", ":", "Luis", "Roberto", "León", " ", "NºCol", ":", "28", "28", "57103", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Paciente", "varón", "de", "60", "años", ",", "con", "síndrome", "de", "Alport", ",", "microhematuria", "y", "proteinuria", "de", "4", "g", "/", "día", ",", "creatinina", "de", "2", "mg", "/", "dl", ",", "urea", "123", "mg", "/", "dl", ",", "pérdida", "moderada", "de", "la", "audición", ",", "hipertensión", "arterial", "tratada", "con", "enalapril", "20", "mg", ",", "obesidad", "con", "IMC", "=", "36,26", "(", "P", "120", "kg", ",", "h", "1,81", "m", ")", ",", "glucemias", "en", "ayunas", "alteradas", "(", "menor", "a", "126", "mg", "/", "dl", ")", ",", "Hb", "glucosilada", "normal", ",", "dislipidemia", "e", "hiperuricemia", "en", "tratamiento", ".", "Ex", "-", "fumador", "de", "un", "paquete", "al", "día", ".", "Normotiroideo", ".", "Biopsia", "renal", "(", "realizada", "en", "1995", "):", "MO", "(", "12", "glomérulos", ")", "esclerosis", "focal", "y", "segmentaria", "glomerular", "en", "evolución", "a", "glomerulopatía", "esclerosante", ",", "IF", "con", "Ig", "M", "de", "leve", "intensidad", "en", "mesangio", "e", "IgA", "y", "M", "en", "cilindros", "tubulares", ".", "ME", "2", "glomérulos", ".", "MB", "capilar", "con", "engrosamiento", "irregular", "y", "desdoblamiento", "focal", "de", "la", "lámina", "densa", ".", "Podocitos", "con", "fusión", "total", "de", "pedicelos", ".", "En", "un", "sector", ",", "borramiento", "de", "la", "estructura", "glomerular", "con", "depósito", "de", "abundante", "material", "amorfo", ",", "electrón", "denso", ".", "Las", "alteraciones", "de", "la", "lámina", "densa", "son", "compatibles", "con", "enfermedad", "de", "Alport", ",", "el", "resto", "de", "los", "hallazgos", "con", "glomerulonefritis", "esclerosante", "focal", ".", "Ecografía", "renal", ":", "RD", "95,6", "x", "52", "x", "53", ",", "RI", "99", "x", "51", "x", "52", ".", "Doppler", "renal", "sin", "alteraciones", ".", "\n", "Se", "indica", "dieta", "baja", "en", "proteínas", ",", "hipocalórica", "y", "se", "agrega", "al", "tratamiento", "losartán", "en", "dosis", "de", "75", "mg", "/", "día", "(", "máxima", "tolerada", "por", "el", "paciente", ")", ".", "Se", "observa", "reducción", "muy", "leve", "de", "proteinuria", "a", "3,6", "g", "/", "día", ".", "Se", "realiza", "cirugía", "de", "by", "-", "pass", "gástrico", ",", "y", "presenta", "en", "su", "evolución", "disminución", "de", "35", "kg", "en", "total", ",", "llegando", "a", "IMC", "de", "25,6", ".", "Control", "nefrológico", ":", "creatinina", "1,56", "mg", "/", "dl", ",", "proteinuria", "0,3", "g", "/", "día", ",", "urea", "65", "mg", "/", "dl", "y", "normotensión", "con", "enalapril", "5", "mg", "/", "d", ";", "se", "mantiene", "dosis", "mínima", "de", "hipolipemiantes", ",", "normouricemia", "y", "normoglucemias", ".", "\n", "Antecedentes", "familiares", ":", "\n", "Hermano", "mayor", "de", "65", "años", "con", "nefropatía", "e", "hipoacusia", "neurosensorial", "bilateral", "y", "síndrome", "de", "Alport", ".", "\n", "Hermano", "menor", "de", "58", "años", "también", "con", "nefropatía", "e", "hipoacusia", "y", "síndrome", "de", "Alport", ".", "\n", "Hermana", "de", "55", "años", "de", "edad", "con", "nefropatía", "sin", "hipoacusia", ".", "\n", "Tío", "materno", "fallecido", "a", "los", "60", "años", "de", "edad", "por", "nefropatía", "de", "causa", "no", "aclarada", "y", "sin", "hipoacusia", ",", "que", "además", "ha", "tenido", "un", "hijo", "varón", "y", "una", "nieta", "con", "nefropatía", "sin", "hipoacusia", ".", "\n", "Madre", "con", "nefropatía", "desde", "la", "infancia", "con", "posible", "síndrome", "de", "Alport", ".", "\n", "Según", "comenta", ",", "dos", "primos", "hermanos", "de", "67", "años", "y", "62", "años", "de", "edad", "respectivamente", ",", "con", "diagnóstico", "clínico", "de", "hemocromatosis", "hereditaria", ".", "\n", "Tres", "años", "después", "de", "la", "cirugía", ",", "la", "buena", "evolución", "del", "paciente", "está", "relacionada", "con", "el", "cumplimento", "del", "tratamiento", "(", "dieta", ")", ",", "ejercicio", "aeróbico", "y", "apoyo", "clínico", "-", "psicológico", ".", "\n", "Responsable", "clínico", ":", "Dr", ".", "Luis", "Roberto", "León", ",", "Email", ":", "lleon@intramed.com", "\n" ]	[ "FAMILIARES_SUJETO_ASISTENCIA", "CORREO_ELECTRONICO", "CALLE", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]
Ezequiel, Lopez Pereira, 7856544, 78 45678567 05, Madrid, 28029, 23/08/1957, España, 60 años, 29/12/2017, Luis Roberto León, 28 28 57103, varón, 60 años, 1995, Hermano mayor, 65 años, Hermano menor, 58 años, Hermana, 55 años, Tío materno, 60 años, hijo varón, Madre, dos primos hermanos, 67 años, 62 años, Luis Roberto León, lleon@intramed.com	111_task2	Sentence: Datos del paciente. Nombre: Ezequiel. Apellidos: Lopez Pereira. NHC: 7856544. NASS: 78 45678567 05. Domicilio: C/ Vinuesa, 4, 6 A. Localidad/ Provincia: Madrid. CP: 28029. Datos asistenciales. Fecha de nacimiento: 23/08/1957. País de nacimiento: España. Edad: 60 años Sexo: H. Fecha de Ingreso: 29/12/2017. Médico: Luis Roberto León NºCol: 28 28 57103. Informe clínico del paciente: Paciente varón de 60 años, con síndrome de Alport, microhematuria y proteinuria de 4 g/día, creatinina de 2 mg/dl, urea 123 mg/dl, pérdida moderada de la audición, hipertensión arterial tratada con enalapril 20 mg, obesidad con IMC = 36,26 (P 120 kg, h 1,81 m), glucemias en ayunas alteradas (menor a 126 mg/dl), Hb glucosilada normal, dislipidemia e hiperuricemia en tratamiento. Ex-fumador de un paquete al día. Normotiroideo. Biopsia renal (realizada en 1995): MO (12 glomérulos) esclerosis focal y segmentaria glomerular en evolución a glomerulopatía esclerosante, IF con Ig M de leve intensidad en mesangio e IgA y M en cilindros tubulares. ME 2 glomérulos. MB capilar con engrosamiento irregular y desdoblamiento focal de la lámina densa. Podocitos con fusión total de pedicelos. En un sector, borramiento de la estructura glomerular con depósito de abundante material amorfo, electrón denso. Las alteraciones de la lámina densa son compatibles con enfermedad de Alport, el resto de los hallazgos con glomerulonefritis esclerosante focal. Ecografía renal: RD 95,6 x 52 x 53, RI 99 x 51 x 52. Doppler renal sin alteraciones. Se indica dieta baja en proteínas, hipocalórica y se agrega al tratamiento losartán en dosis de 75 mg/día (máxima tolerada por el paciente). Se observa reducción muy leve de proteinuria a 3,6 g/día. Se realiza cirugía de by-pass gástrico, y presenta en su evolución disminución de 35 kg en total, llegando a IMC de 25,6. Control nefrológico: creatinina 1,56 mg/dl, proteinuria 0,3 g/día, urea 65 mg/dl y normotensión con enalapril 5 mg/d; se mantiene dosis mínima de hipolipemiantes, normouricemia y normoglucemias. Antecedentes familiares: Hermano mayor de 65 años con nefropatía e hipoacusia neurosensorial bilateral y síndrome de Alport. Hermano menor de 58 años también con nefropatía e hipoacusia y síndrome de Alport. Hermana de 55 años de edad con nefropatía sin hipoacusia. Tío materno fallecido a los 60 años de edad por nefropatía de causa no aclarada y sin hipoacusia, que además ha tenido un hijo varón y una nieta con nefropatía sin hipoacusia. Madre con nefropatía desde la infancia con posible síndrome de Alport. Según comenta, dos primos hermanos de 67 años y 62 años de edad respectivamente, con diagnóstico clínico de hemocromatosis hereditaria. Tres años después de la cirugía, la buena evolución del paciente está relacionada con el cumplimento del tratamiento (dieta), ejercicio aeróbico y apoyo clínico-psicológico. Responsable clínico: Dr. Luis Roberto León, Email: lleon@intramed.com Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Datos del paciente. Nombre: Ezequiel. Apellidos: Lopez Pereira. NHC: 7856544. NASS: 78 45678567 05. Domicilio: C/ Vinuesa, 4, 6 A. Localidad/ Provincia: Madrid. CP: 28029. Datos asistenciales. Fecha de nacimiento: 23/08/1957. País de nacimiento: España. Edad: 60 años Sexo: H. Fecha de Ingreso: 29/12/2017. Médico: Luis Roberto León NºCol: 28 28 57103. Informe clínico del paciente: Paciente varón de 60 años, con síndrome de Alport, microhematuria y proteinuria de 4 g/día, creatinina de 2 mg/dl, urea 123 mg/dl, pérdida moderada de la audición, hipertensión arterial tratada con enalapril 20 mg, obesidad con IMC = 36,26 (P 120 kg, h 1,81 m), glucemias en ayunas alteradas (menor a 126 mg/dl), Hb glucosilada normal, dislipidemia e hiperuricemia en tratamiento. Ex-fumador de un paquete al día. Normotiroideo. Biopsia renal (realizada en 1995): MO (12 glomérulos) esclerosis focal y segmentaria glomerular en evolución a glomerulopatía esclerosante, IF con Ig M de leve intensidad en mesangio e IgA y M en cilindros tubulares. ME 2 glomérulos. MB capilar con engrosamiento irregular y desdoblamiento focal de la lámina densa. Podocitos con fusión total de pedicelos. En un sector, borramiento de la estructura glomerular con depósito de abundante material amorfo, electrón denso. Las alteraciones de la lámina densa son compatibles con enfermedad de Alport, el resto de los hallazgos con glomerulonefritis esclerosante focal. Ecografía renal: RD 95,6 x 52 x 53, RI 99 x 51 x 52. Doppler renal sin alteraciones. Se indica dieta baja en proteínas, hipocalórica y se agrega al tratamiento losartán en dosis de 75 mg/día (máxima tolerada por el paciente). Se observa reducción muy leve de proteinuria a 3,6 g/día. Se realiza cirugía de by-pass gástrico, y presenta en su evolución disminución de 35 kg en total, llegando a IMC de 25,6. Control nefrológico: creatinina 1,56 mg/dl, proteinuria 0,3 g/día, urea 65 mg/dl y normotensión con enalapril 5 mg/d; se mantiene dosis mínima de hipolipemiantes, normouricemia y normoglucemias. Antecedentes familiares: Hermano mayor de 65 años con nefropatía e hipoacusia neurosensorial bilateral y síndrome de Alport. Hermano menor de 58 años también con nefropatía e hipoacusia y síndrome de Alport. Hermana de 55 años de edad con nefropatía sin hipoacusia. Tío materno fallecido a los 60 años de edad por nefropatía de causa no aclarada y sin hipoacusia, que además ha tenido un hijo varón y una nieta con nefropatía sin hipoacusia. Madre con nefropatía desde la infancia con posible síndrome de Alport. Según comenta, dos primos hermanos de 67 años y 62 años de edad respectivamente, con diagnóstico clínico de hemocromatosis hereditaria. Tres años después de la cirugía, la buena evolución del paciente está relacionada con el cumplimento del tratamiento (dieta), ejercicio aeróbico y apoyo clínico-psicológico. Responsable clínico: Dr. Luis Roberto León, Email: lleon@intramed.com	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Ezequiel", ".", "\n", "Apellidos", ":", "Lopez", "Pereira", ".", "\n", "NHC", ":", "7856544", ".", "\n", "NASS", ":", "78", "45678567", "05", ".", "\n", "Domicilio", ":", "C/", "Vinuesa", ",", "4", ",", "6", "A.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "28029", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "23/08/1957", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "60", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "29/12/2017", ".", "\n", "Médico", ":", "Luis", "Roberto", "León", " ", "NºCol", ":", "28", "28", "57103", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Paciente", "varón", "de", "60", "años", ",", "con", "síndrome", "de", "Alport", ",", "microhematuria", "y", "proteinuria", "de", "4", "g", "/", "día", ",", "creatinina", "de", "2", "mg", "/", "dl", ",", "urea", "123", "mg", "/", "dl", ",", "pérdida", "moderada", "de", "la", "audición", ",", "hipertensión", "arterial", "tratada", "con", "enalapril", "20", "mg", ",", "obesidad", "con", "IMC", "=", "36,26", "(", "P", "120", "kg", ",", "h", "1,81", "m", ")", ",", "glucemias", "en", "ayunas", "alteradas", "(", "menor", "a", "126", "mg", "/", "dl", ")", ",", "Hb", "glucosilada", "normal", ",", "dislipidemia", "e", "hiperuricemia", "en", "tratamiento", ".", "Ex", "-", "fumador", "de", "un", "paquete", "al", "día", ".", "Normotiroideo", ".", "Biopsia", "renal", "(", "realizada", "en", "1995", "):", "MO", "(", "12", "glomérulos", ")", "esclerosis", "focal", "y", "segmentaria", "glomerular", "en", "evolución", "a", "glomerulopatía", "esclerosante", ",", "IF", "con", "Ig", "M", "de", "leve", "intensidad", "en", "mesangio", "e", "IgA", "y", "M", "en", "cilindros", "tubulares", ".", "ME", "2", "glomérulos", ".", "MB", "capilar", "con", "engrosamiento", "irregular", "y", "desdoblamiento", "focal", "de", "la", "lámina", "densa", ".", "Podocitos", "con", "fusión", "total", "de", "pedicelos", ".", "En", "un", "sector", ",", "borramiento", "de", "la", "estructura", "glomerular", "con", "depósito", "de", "abundante", "material", "amorfo", ",", "electrón", "denso", ".", "Las", "alteraciones", "de", "la", "lámina", "densa", "son", "compatibles", "con", "enfermedad", "de", "Alport", ",", "el", "resto", "de", "los", "hallazgos", "con", "glomerulonefritis", "esclerosante", "focal", ".", "Ecografía", "renal", ":", "RD", "95,6", "x", "52", "x", "53", ",", "RI", "99", "x", "51", "x", "52", ".", "Doppler", "renal", "sin", "alteraciones", ".", "\n", "Se", "indica", "dieta", "baja", "en", "proteínas", ",", "hipocalórica", "y", "se", "agrega", "al", "tratamiento", "losartán", "en", "dosis", "de", "75", "mg", "/", "día", "(", "máxima", "tolerada", "por", "el", "paciente", ")", ".", "Se", "observa", "reducción", "muy", "leve", "de", "proteinuria", "a", "3,6", "g", "/", "día", ".", "Se", "realiza", "cirugía", "de", "by", "-", "pass", "gástrico", ",", "y", "presenta", "en", "su", "evolución", "disminución", "de", "35", "kg", "en", "total", ",", "llegando", "a", "IMC", "de", "25,6", ".", "Control", "nefrológico", ":", "creatinina", "1,56", "mg", "/", "dl", ",", "proteinuria", "0,3", "g", "/", "día", ",", "urea", "65", "mg", "/", "dl", "y", "normotensión", "con", "enalapril", "5", "mg", "/", "d", ";", "se", "mantiene", "dosis", "mínima", "de", "hipolipemiantes", ",", "normouricemia", "y", "normoglucemias", ".", "\n", "Antecedentes", "familiares", ":", "\n", "Hermano", "mayor", "de", "65", "años", "con", "nefropatía", "e", "hipoacusia", "neurosensorial", "bilateral", "y", "síndrome", "de", "Alport", ".", "\n", "Hermano", "menor", "de", "58", "años", "también", "con", "nefropatía", "e", "hipoacusia", "y", "síndrome", "de", "Alport", ".", "\n", "Hermana", "de", "55", "años", "de", "edad", "con", "nefropatía", "sin", "hipoacusia", ".", "\n", "Tío", "materno", "fallecido", "a", "los", "60", "años", "de", "edad", "por", "nefropatía", "de", "causa", "no", "aclarada", "y", "sin", "hipoacusia", ",", "que", "además", "ha", "tenido", "un", "hijo", "varón", "y", "una", "nieta", "con", "nefropatía", "sin", "hipoacusia", ".", "\n", "Madre", "con", "nefropatía", "desde", "la", "infancia", "con", "posible", "síndrome", "de", "Alport", ".", "\n", "Según", "comenta", ",", "dos", "primos", "hermanos", "de", "67", "años", "y", "62", "años", "de", "edad", "respectivamente", ",", "con", "diagnóstico", "clínico", "de", "hemocromatosis", "hereditaria", ".", "\n", "Tres", "años", "después", "de", "la", "cirugía", ",", "la", "buena", "evolución", "del", "paciente", "está", "relacionada", "con", "el", "cumplimento", "del", "tratamiento", "(", "dieta", ")", ",", "ejercicio", "aeróbico", "y", "apoyo", "clínico", "-", "psicológico", ".", "\n", "Responsable", "clínico", ":", "Dr", ".", "Luis", "Roberto", "León", ",", "Email", ":", "lleon@intramed.com", "\n" ]	[ "FAMILIARES_SUJETO_ASISTENCIA", "CORREO_ELECTRONICO", "CALLE", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]
Symptomatic treatment is a Intervention_Physical, combination chemotherapy is a Intervention_Pharmacological, patients with extensive non - small cell lung cancer . is a Participant_Condition, 87 is a Participant_Sample-size, patients with inoperable , extensive non - small cell lung cancer ( NSCLC ) is a Participant_Condition, combination chemotherapy ( cisplatin is a Intervention_Pharmacological, etoposide is a Intervention_Pharmacological, symptomatic treatment is a Intervention_Physical, survival time is a Outcome_Mortality, Three long - term survivors is a Outcome_Mortality	35790_task0	Sentence: Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer . In a randomized clinical trial , 87 patients with inoperable , extensive non-small cell lung cancer ( NSCLC ) were randomized to receive either combination chemotherapy ( cisplatin at 70 mg/m2 intravenously [ i.v . ] on day 1 and etoposide at 100 mg/m2 i.v . on day 1 and 200 mg/m2 orally on days 2 and 3 ) or symptomatic treatment . No statistically significant differences in survival time were found between the two treatment techniques . A major problem in the interpretation of the results was the use of semicurative radiation therapy ( 3000 to 4200 cGy ) to the primary tumor and mediastinum , which was given with symptomatic intent . Three long-term survivors were seen in the latter group . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Outcome_Mortality, Participant_Sample-size	[ "B-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O" ]	Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer . In a randomized clinical trial , 87 patients with inoperable , extensive non-small cell lung cancer ( NSCLC ) were randomized to receive either combination chemotherapy ( cisplatin at 70 mg/m2 intravenously [ i.v . ] on day 1 and etoposide at 100 mg/m2 i.v . on day 1 and 200 mg/m2 orally on days 2 and 3 ) or symptomatic treatment . No statistically significant differences in survival time were found between the two treatment techniques . A major problem in the interpretation of the results was the use of semicurative radiation therapy ( 3000 to 4200 cGy ) to the primary tumor and mediastinum , which was given with symptomatic intent . Three long-term survivors were seen in the latter group .	[ "Symptomatic", "treatment", "versus", "combination", "chemotherapy", "for", "patients", "with", "extensive", "non", "-", "small", "cell", "lung", "cancer", ".", "In", "a", "randomized", "clinical", "trial", ",", "87", "patients", "with", "inoperable", ",", "extensive", "non", "-", "small", "cell", "lung", "cancer", "(", "NSCLC", ")", "were", "randomized", "to", "receive", "either", "combination", "chemotherapy", "(", "cisplatin", "at", "70", "mg", "/", "m2", "intravenously", "[", "i.v", ".", "]", "on", "day", "1", "and", "etoposide", "at", "100", "mg", "/", "m2", "i.v", ".", "on", "day", "1", "and", "200", "mg", "/", "m2", "orally", "on", "days", "2", "and", "3", ")", "or", "symptomatic", "treatment", ".", "No", "statistically", "significant", "differences", "in", "survival", "time", "were", "found", "between", "the", "two", "treatment", "techniques", ".", "A", "major", "problem", "in", "the", "interpretation", "of", "the", "results", "was", "the", "use", "of", "semicurative", "radiation", "therapy", "(", "3000", "to", "4200", "cGy", ")", "to", "the", "primary", "tumor", "and", "mediastinum", ",", "which", "was", "given", "with", "symptomatic", "intent", ".", "Three", "long", "-", "term", "survivors", "were", "seen", "in", "the", "latter", "group", "." ]	[ "Participant_Condition", "Intervention_Pharmacological", "Outcome_Mortality", "Intervention_Physical", "Participant_Sample-size" ]
Symptomatic treatment is a Intervention_Physical, combination chemotherapy is a Intervention_Pharmacological, patients with extensive non - small cell lung cancer . is a Participant_Condition, 87 is a Participant_Sample-size, patients with inoperable , extensive non - small cell lung cancer ( NSCLC ) is a Participant_Condition, combination chemotherapy ( cisplatin is a Intervention_Pharmacological, etoposide is a Intervention_Pharmacological, symptomatic treatment is a Intervention_Physical, survival time is a Outcome_Mortality, Three long - term survivors is a Outcome_Mortality	35790_task1	Sentence: Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer . In a randomized clinical trial , 87 patients with inoperable , extensive non-small cell lung cancer ( NSCLC ) were randomized to receive either combination chemotherapy ( cisplatin at 70 mg/m2 intravenously [ i.v . ] on day 1 and etoposide at 100 mg/m2 i.v . on day 1 and 200 mg/m2 orally on days 2 and 3 ) or symptomatic treatment . No statistically significant differences in survival time were found between the two treatment techniques . A major problem in the interpretation of the results was the use of semicurative radiation therapy ( 3000 to 4200 cGy ) to the primary tumor and mediastinum , which was given with symptomatic intent . Three long-term survivors were seen in the latter group . Instructions: please typing these entity words according to sentence: Symptomatic treatment, combination chemotherapy, patients with extensive non - small cell lung cancer ., 87, patients with inoperable , extensive non - small cell lung cancer ( NSCLC ), combination chemotherapy ( cisplatin, etoposide, symptomatic treatment, survival time, Three long - term survivors Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Outcome_Mortality, Participant_Sample-size	[ "B-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O" ]	Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer . In a randomized clinical trial , 87 patients with inoperable , extensive non-small cell lung cancer ( NSCLC ) were randomized to receive either combination chemotherapy ( cisplatin at 70 mg/m2 intravenously [ i.v . ] on day 1 and etoposide at 100 mg/m2 i.v . on day 1 and 200 mg/m2 orally on days 2 and 3 ) or symptomatic treatment . No statistically significant differences in survival time were found between the two treatment techniques . A major problem in the interpretation of the results was the use of semicurative radiation therapy ( 3000 to 4200 cGy ) to the primary tumor and mediastinum , which was given with symptomatic intent . Three long-term survivors were seen in the latter group .	[ "Symptomatic", "treatment", "versus", "combination", "chemotherapy", "for", "patients", "with", "extensive", "non", "-", "small", "cell", "lung", "cancer", ".", "In", "a", "randomized", "clinical", "trial", ",", "87", "patients", "with", "inoperable", ",", "extensive", "non", "-", "small", "cell", "lung", "cancer", "(", "NSCLC", ")", "were", "randomized", "to", "receive", "either", "combination", "chemotherapy", "(", "cisplatin", "at", "70", "mg", "/", "m2", "intravenously", "[", "i.v", ".", "]", "on", "day", "1", "and", "etoposide", "at", "100", "mg", "/", "m2", "i.v", ".", "on", "day", "1", "and", "200", "mg", "/", "m2", "orally", "on", "days", "2", "and", "3", ")", "or", "symptomatic", "treatment", ".", "No", "statistically", "significant", "differences", "in", "survival", "time", "were", "found", "between", "the", "two", "treatment", "techniques", ".", "A", "major", "problem", "in", "the", "interpretation", "of", "the", "results", "was", "the", "use", "of", "semicurative", "radiation", "therapy", "(", "3000", "to", "4200", "cGy", ")", "to", "the", "primary", "tumor", "and", "mediastinum", ",", "which", "was", "given", "with", "symptomatic", "intent", ".", "Three", "long", "-", "term", "survivors", "were", "seen", "in", "the", "latter", "group", "." ]	[ "Participant_Condition", "Intervention_Pharmacological", "Outcome_Mortality", "Intervention_Physical", "Participant_Sample-size" ]
Symptomatic treatment, combination chemotherapy, patients with extensive non - small cell lung cancer ., 87, patients with inoperable , extensive non - small cell lung cancer ( NSCLC ), combination chemotherapy ( cisplatin, etoposide, symptomatic treatment, survival time, Three long - term survivors	35790_task2	Sentence: Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer . In a randomized clinical trial , 87 patients with inoperable , extensive non-small cell lung cancer ( NSCLC ) were randomized to receive either combination chemotherapy ( cisplatin at 70 mg/m2 intravenously [ i.v . ] on day 1 and etoposide at 100 mg/m2 i.v . on day 1 and 200 mg/m2 orally on days 2 and 3 ) or symptomatic treatment . No statistically significant differences in survival time were found between the two treatment techniques . A major problem in the interpretation of the results was the use of semicurative radiation therapy ( 3000 to 4200 cGy ) to the primary tumor and mediastinum , which was given with symptomatic intent . Three long-term survivors were seen in the latter group . Instructions: please extract entity words from the input sentence	[ "B-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O" ]	Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer . In a randomized clinical trial , 87 patients with inoperable , extensive non-small cell lung cancer ( NSCLC ) were randomized to receive either combination chemotherapy ( cisplatin at 70 mg/m2 intravenously [ i.v . ] on day 1 and etoposide at 100 mg/m2 i.v . on day 1 and 200 mg/m2 orally on days 2 and 3 ) or symptomatic treatment . No statistically significant differences in survival time were found between the two treatment techniques . A major problem in the interpretation of the results was the use of semicurative radiation therapy ( 3000 to 4200 cGy ) to the primary tumor and mediastinum , which was given with symptomatic intent . Three long-term survivors were seen in the latter group .	[ "Symptomatic", "treatment", "versus", "combination", "chemotherapy", "for", "patients", "with", "extensive", "non", "-", "small", "cell", "lung", "cancer", ".", "In", "a", "randomized", "clinical", "trial", ",", "87", "patients", "with", "inoperable", ",", "extensive", "non", "-", "small", "cell", "lung", "cancer", "(", "NSCLC", ")", "were", "randomized", "to", "receive", "either", "combination", "chemotherapy", "(", "cisplatin", "at", "70", "mg", "/", "m2", "intravenously", "[", "i.v", ".", "]", "on", "day", "1", "and", "etoposide", "at", "100", "mg", "/", "m2", "i.v", ".", "on", "day", "1", "and", "200", "mg", "/", "m2", "orally", "on", "days", "2", "and", "3", ")", "or", "symptomatic", "treatment", ".", "No", "statistically", "significant", "differences", "in", "survival", "time", "were", "found", "between", "the", "two", "treatment", "techniques", ".", "A", "major", "problem", "in", "the", "interpretation", "of", "the", "results", "was", "the", "use", "of", "semicurative", "radiation", "therapy", "(", "3000", "to", "4200", "cGy", ")", "to", "the", "primary", "tumor", "and", "mediastinum", ",", "which", "was", "given", "with", "symptomatic", "intent", ".", "Three", "long", "-", "term", "survivors", "were", "seen", "in", "the", "latter", "group", "." ]	[ "Participant_Condition", "Intervention_Pharmacological", "Outcome_Mortality", "Intervention_Physical", "Participant_Sample-size" ]
progesterone is a compound, low - density lipoprotein receptor is a protein, VLDLR is a protein, low - density lipoprotein receptor is a protein, SR - BI is a protein	DS.d1451_task0	Sentence: The use of lipoproteins as a substrate for progesterone synthesis remains unclear, and the expression of lipoprotein receptors (very-low-density lipoprotein receptor (VLDLR), low-density lipoprotein receptor (LDLR), and scavenger receptor-BI (SR-BI 12 h) has not been characterized. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "I-protein", "O", "B-protein", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O" ]	The use of lipoproteins as a substrate for progesterone synthesis remains unclear, and the expression of lipoprotein receptors (very-low-density lipoprotein receptor (VLDLR), low-density lipoprotein receptor (LDLR), and scavenger receptor-BI (SR-BI 12 h) has not been characterized.	[ "The", "use", "of", "lipoproteins", "as", "a", "substrate", "for", "progesterone", "synthesis", "remains", "unclear", ",", "and", "the", "expression", "of", "lipoprotein", "receptors", "(", "very", "-", "low", "-", "density", "lipoprotein", "receptor", "(", "VLDLR", ")", ",", "low", "-", "density", "lipoprotein", "receptor", "(", "LDLR", ")", ",", "and", "scavenger", "receptor", "-", "BI", "(", "SR", "-", "BI", "12", "h", ")", "has", "not", "been", "characterized", "." ]	[ "protein", "compound" ]
progesterone is a compound, low - density lipoprotein receptor is a protein, VLDLR is a protein, low - density lipoprotein receptor is a protein, SR - BI is a protein	DS.d1451_task1	Sentence: The use of lipoproteins as a substrate for progesterone synthesis remains unclear, and the expression of lipoprotein receptors (very-low-density lipoprotein receptor (VLDLR), low-density lipoprotein receptor (LDLR), and scavenger receptor-BI (SR-BI 12 h) has not been characterized. Instructions: please typing these entity words according to sentence: progesterone, low - density lipoprotein receptor, VLDLR, low - density lipoprotein receptor, SR - BI Options: compound, protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "I-protein", "O", "B-protein", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O" ]	The use of lipoproteins as a substrate for progesterone synthesis remains unclear, and the expression of lipoprotein receptors (very-low-density lipoprotein receptor (VLDLR), low-density lipoprotein receptor (LDLR), and scavenger receptor-BI (SR-BI 12 h) has not been characterized.	[ "The", "use", "of", "lipoproteins", "as", "a", "substrate", "for", "progesterone", "synthesis", "remains", "unclear", ",", "and", "the", "expression", "of", "lipoprotein", "receptors", "(", "very", "-", "low", "-", "density", "lipoprotein", "receptor", "(", "VLDLR", ")", ",", "low", "-", "density", "lipoprotein", "receptor", "(", "LDLR", ")", ",", "and", "scavenger", "receptor", "-", "BI", "(", "SR", "-", "BI", "12", "h", ")", "has", "not", "been", "characterized", "." ]	[ "protein", "compound" ]
progesterone, low - density lipoprotein receptor, VLDLR, low - density lipoprotein receptor, SR - BI	DS.d1451_task2	Sentence: The use of lipoproteins as a substrate for progesterone synthesis remains unclear, and the expression of lipoprotein receptors (very-low-density lipoprotein receptor (VLDLR), low-density lipoprotein receptor (LDLR), and scavenger receptor-BI (SR-BI 12 h) has not been characterized. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "I-protein", "O", "B-protein", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O" ]	The use of lipoproteins as a substrate for progesterone synthesis remains unclear, and the expression of lipoprotein receptors (very-low-density lipoprotein receptor (VLDLR), low-density lipoprotein receptor (LDLR), and scavenger receptor-BI (SR-BI 12 h) has not been characterized.	[ "The", "use", "of", "lipoproteins", "as", "a", "substrate", "for", "progesterone", "synthesis", "remains", "unclear", ",", "and", "the", "expression", "of", "lipoprotein", "receptors", "(", "very", "-", "low", "-", "density", "lipoprotein", "receptor", "(", "VLDLR", ")", ",", "low", "-", "density", "lipoprotein", "receptor", "(", "LDLR", ")", ",", "and", "scavenger", "receptor", "-", "BI", "(", "SR", "-", "BI", "12", "h", ")", "has", "not", "been", "characterized", "." ]	[ "protein", "compound" ]
lysine - rich histones is a Protein, lysine - rich histone is a Protein, histone is a Protein, NH2 terminus is a Entity, histone is a Protein, lysine - rich histone is a Protein, lysine - rich is a Protein, arginine - rich histones is a Protein, lysine - rich histones is a Protein	2_task0	Sentence: Amino acid sequence and sequence variability of the amino-terminal regions of lysine-rich histones. The amino acid sequence has been determined for the first 72 residues of a lysine-rich histone from rabbit thymus. These are the residues contained in a fragment released from the histone by treatment with N-bromosuccinimide. Peptides derived by tryptic, thermolysin, and chymotryptic digestion of this 72-residue fragment were used to reconstruct the total sequence. Analysis of the sequence revealed some unusual aspects of the structure of the fragment, which comprises about one-third of the histone molecule. Thirty of the first 40 residues are accounted for by lysine, alanine, and proline; this portion of the fragment includes sequences of 4,2, and 3 consecutive basic residues. The last 32 residues contain all the hydrophobic amino acids (valine, isoleucine, leucine, tyrosine) of the fragment but have few basic residues and no prolines. The NH2 terminus of the histone is acetylated. Comparison of the sequence of the NH2-terminal half of this lysine-rich histone with the entire sequences of the slightly lysine-rich and arginine-rich histones shows that all three have similar characteristics, that is, an NH2-terminal region rich in basic amino acids and a COOH-terminal portion rich in hydrophobic residues. Tryptic peptides from the NH2-terminal N-bromosuccinimide fragment of two other thymus lysine-rich histones have been isolated. These peptides (with partial sequences) were aligned by direct identity or analogy with the complete amino acid sequence of the NH2-terminal N-bromosuccinimide fragment of the lysine-rich histone studied previously. It was found that there were from 7 to 14 amino acid differences between fractions. One of the amino acid interchanges eliminates a major phosphorylation site. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Amino acid sequence and sequence variability of the amino-terminal regions of lysine-rich histones. The amino acid sequence has been determined for the first 72 residues of a lysine-rich histone from rabbit thymus. These are the residues contained in a fragment released from the histone by treatment with N-bromosuccinimide. Peptides derived by tryptic, thermolysin, and chymotryptic digestion of this 72-residue fragment were used to reconstruct the total sequence. Analysis of the sequence revealed some unusual aspects of the structure of the fragment, which comprises about one-third of the histone molecule. Thirty of the first 40 residues are accounted for by lysine, alanine, and proline; this portion of the fragment includes sequences of 4,2, and 3 consecutive basic residues. The last 32 residues contain all the hydrophobic amino acids (valine, isoleucine, leucine, tyrosine) of the fragment but have few basic residues and no prolines. The NH2 terminus of the histone is acetylated. Comparison of the sequence of the NH2-terminal half of this lysine-rich histone with the entire sequences of the slightly lysine-rich and arginine-rich histones shows that all three have similar characteristics, that is, an NH2-terminal region rich in basic amino acids and a COOH-terminal portion rich in hydrophobic residues. Tryptic peptides from the NH2-terminal N-bromosuccinimide fragment of two other thymus lysine-rich histones have been isolated. These peptides (with partial sequences) were aligned by direct identity or analogy with the complete amino acid sequence of the NH2-terminal N-bromosuccinimide fragment of the lysine-rich histone studied previously. It was found that there were from 7 to 14 amino acid differences between fractions. One of the amino acid interchanges eliminates a major phosphorylation site.	[ "Amino", "acid", "sequence", "and", "sequence", "variability", "of", "the", "amino", "-", "terminal", "regions", "of", "lysine", "-", "rich", "histones", ".", "\n", "The", "amino", "acid", "sequence", "has", "been", "determined", "for", "the", "first", "72", "residues", "of", "a", "lysine", "-", "rich", "histone", "from", "rabbit", "thymus", ".", "These", "are", "the", "residues", "contained", "in", "a", "fragment", "released", "from", "the", "histone", "by", "treatment", "with", "N", "-", "bromosuccinimide", ".", "Peptides", "derived", "by", "tryptic", ",", "thermolysin", ",", "and", "chymotryptic", "digestion", "of", "this", "72-residue", "fragment", "were", "used", "to", "reconstruct", "the", "total", "sequence", ".", "Analysis", "of", "the", "sequence", "revealed", "some", "unusual", "aspects", "of", "the", "structure", "of", "the", "fragment", ",", "which", "comprises", "about", "one", "-", "third", "of", "the", "histone", "molecule", ".", "Thirty", "of", "the", "first", "40", "residues", "are", "accounted", "for", "by", "lysine", ",", "alanine", ",", "and", "proline", ";", "this", "portion", "of", "the", "fragment", "includes", "sequences", "of", "4,2", ",", "and", "3", "consecutive", "basic", "residues", ".", "The", "last", "32", "residues", "contain", "all", "the", "hydrophobic", "amino", "acids", "(", "valine", ",", "isoleucine", ",", "leucine", ",", "tyrosine", ")", "of", "the", "fragment", "but", "have", "few", "basic", "residues", "and", "no", "prolines", ".", "The", "NH2", "terminus", "of", "the", "histone", "is", "acetylated", ".", "Comparison", "of", "the", "sequence", "of", "the", "NH2-terminal", "half", "of", "this", "lysine", "-", "rich", "histone", "with", "the", "entire", "sequences", "of", "the", "slightly", "lysine", "-", "rich", "and", "arginine", "-", "rich", "histones", "shows", "that", "all", "three", "have", "similar", "characteristics", ",", "that", "is", ",", "an", "NH2-terminal", "region", "rich", "in", "basic", "amino", "acids", "and", "a", "COOH", "-", "terminal", "portion", "rich", "in", "hydrophobic", "residues", ".", "Tryptic", "peptides", "from", "the", "NH2-terminal", "N", "-", "bromosuccinimide", "fragment", "of", "two", "other", "thymus", "lysine", "-", "rich", "histones", "have", "been", "isolated", ".", "These", "peptides", "(", "with", "partial", "sequences", ")", "were", "aligned", "by", "direct", "identity", "or", "analogy", "with", "the", "complete", "amino", "acid", "sequence", "of", "the", "NH2-terminal", "N", "-", "bromosuccinimide", "fragment", "of", "the", "lysine", "-", "rich", "histone", "studied", "previously", ".", "It", "was", "found", "that", "there", "were", "from", "7", "to", "14", "amino", "acid", "differences", "between", "fractions", ".", "One", "of", "the", "amino", "acid", "interchanges", "eliminates", "a", "major", "phosphorylation", "site", "." ]	[ "Protein", "Entity" ]
lysine - rich histones is a Protein, lysine - rich histone is a Protein, histone is a Protein, NH2 terminus is a Entity, histone is a Protein, lysine - rich histone is a Protein, lysine - rich is a Protein, arginine - rich histones is a Protein, lysine - rich histones is a Protein	2_task1	Sentence: Amino acid sequence and sequence variability of the amino-terminal regions of lysine-rich histones. The amino acid sequence has been determined for the first 72 residues of a lysine-rich histone from rabbit thymus. These are the residues contained in a fragment released from the histone by treatment with N-bromosuccinimide. Peptides derived by tryptic, thermolysin, and chymotryptic digestion of this 72-residue fragment were used to reconstruct the total sequence. Analysis of the sequence revealed some unusual aspects of the structure of the fragment, which comprises about one-third of the histone molecule. Thirty of the first 40 residues are accounted for by lysine, alanine, and proline; this portion of the fragment includes sequences of 4,2, and 3 consecutive basic residues. The last 32 residues contain all the hydrophobic amino acids (valine, isoleucine, leucine, tyrosine) of the fragment but have few basic residues and no prolines. The NH2 terminus of the histone is acetylated. Comparison of the sequence of the NH2-terminal half of this lysine-rich histone with the entire sequences of the slightly lysine-rich and arginine-rich histones shows that all three have similar characteristics, that is, an NH2-terminal region rich in basic amino acids and a COOH-terminal portion rich in hydrophobic residues. Tryptic peptides from the NH2-terminal N-bromosuccinimide fragment of two other thymus lysine-rich histones have been isolated. These peptides (with partial sequences) were aligned by direct identity or analogy with the complete amino acid sequence of the NH2-terminal N-bromosuccinimide fragment of the lysine-rich histone studied previously. It was found that there were from 7 to 14 amino acid differences between fractions. One of the amino acid interchanges eliminates a major phosphorylation site. Instructions: please typing these entity words according to sentence: lysine - rich histones, lysine - rich histone, histone, NH2 terminus, histone, lysine - rich histone, lysine - rich, arginine - rich histones, lysine - rich histones Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Amino acid sequence and sequence variability of the amino-terminal regions of lysine-rich histones. The amino acid sequence has been determined for the first 72 residues of a lysine-rich histone from rabbit thymus. These are the residues contained in a fragment released from the histone by treatment with N-bromosuccinimide. Peptides derived by tryptic, thermolysin, and chymotryptic digestion of this 72-residue fragment were used to reconstruct the total sequence. Analysis of the sequence revealed some unusual aspects of the structure of the fragment, which comprises about one-third of the histone molecule. Thirty of the first 40 residues are accounted for by lysine, alanine, and proline; this portion of the fragment includes sequences of 4,2, and 3 consecutive basic residues. The last 32 residues contain all the hydrophobic amino acids (valine, isoleucine, leucine, tyrosine) of the fragment but have few basic residues and no prolines. The NH2 terminus of the histone is acetylated. Comparison of the sequence of the NH2-terminal half of this lysine-rich histone with the entire sequences of the slightly lysine-rich and arginine-rich histones shows that all three have similar characteristics, that is, an NH2-terminal region rich in basic amino acids and a COOH-terminal portion rich in hydrophobic residues. Tryptic peptides from the NH2-terminal N-bromosuccinimide fragment of two other thymus lysine-rich histones have been isolated. These peptides (with partial sequences) were aligned by direct identity or analogy with the complete amino acid sequence of the NH2-terminal N-bromosuccinimide fragment of the lysine-rich histone studied previously. It was found that there were from 7 to 14 amino acid differences between fractions. One of the amino acid interchanges eliminates a major phosphorylation site.	[ "Amino", "acid", "sequence", "and", "sequence", "variability", "of", "the", "amino", "-", "terminal", "regions", "of", "lysine", "-", "rich", "histones", ".", "\n", "The", "amino", "acid", "sequence", "has", "been", "determined", "for", "the", "first", "72", "residues", "of", "a", "lysine", "-", "rich", "histone", "from", "rabbit", "thymus", ".", "These", "are", "the", "residues", "contained", "in", "a", "fragment", "released", "from", "the", "histone", "by", "treatment", "with", "N", "-", "bromosuccinimide", ".", "Peptides", "derived", "by", "tryptic", ",", "thermolysin", ",", "and", "chymotryptic", "digestion", "of", "this", "72-residue", "fragment", "were", "used", "to", "reconstruct", "the", "total", "sequence", ".", "Analysis", "of", "the", "sequence", "revealed", "some", "unusual", "aspects", "of", "the", "structure", "of", "the", "fragment", ",", "which", "comprises", "about", "one", "-", "third", "of", "the", "histone", "molecule", ".", "Thirty", "of", "the", "first", "40", "residues", "are", "accounted", "for", "by", "lysine", ",", "alanine", ",", "and", "proline", ";", "this", "portion", "of", "the", "fragment", "includes", "sequences", "of", "4,2", ",", "and", "3", "consecutive", "basic", "residues", ".", "The", "last", "32", "residues", "contain", "all", "the", "hydrophobic", "amino", "acids", "(", "valine", ",", "isoleucine", ",", "leucine", ",", "tyrosine", ")", "of", "the", "fragment", "but", "have", "few", "basic", "residues", "and", "no", "prolines", ".", "The", "NH2", "terminus", "of", "the", "histone", "is", "acetylated", ".", "Comparison", "of", "the", "sequence", "of", "the", "NH2-terminal", "half", "of", "this", "lysine", "-", "rich", "histone", "with", "the", "entire", "sequences", "of", "the", "slightly", "lysine", "-", "rich", "and", "arginine", "-", "rich", "histones", "shows", "that", "all", "three", "have", "similar", "characteristics", ",", "that", "is", ",", "an", "NH2-terminal", "region", "rich", "in", "basic", "amino", "acids", "and", "a", "COOH", "-", "terminal", "portion", "rich", "in", "hydrophobic", "residues", ".", "Tryptic", "peptides", "from", "the", "NH2-terminal", "N", "-", "bromosuccinimide", "fragment", "of", "two", "other", "thymus", "lysine", "-", "rich", "histones", "have", "been", "isolated", ".", "These", "peptides", "(", "with", "partial", "sequences", ")", "were", "aligned", "by", "direct", "identity", "or", "analogy", "with", "the", "complete", "amino", "acid", "sequence", "of", "the", "NH2-terminal", "N", "-", "bromosuccinimide", "fragment", "of", "the", "lysine", "-", "rich", "histone", "studied", "previously", ".", "It", "was", "found", "that", "there", "were", "from", "7", "to", "14", "amino", "acid", "differences", "between", "fractions", ".", "One", "of", "the", "amino", "acid", "interchanges", "eliminates", "a", "major", "phosphorylation", "site", "." ]	[ "Protein", "Entity" ]
lysine - rich histones, lysine - rich histone, histone, NH2 terminus, histone, lysine - rich histone, lysine - rich, arginine - rich histones, lysine - rich histones	2_task2	Sentence: Amino acid sequence and sequence variability of the amino-terminal regions of lysine-rich histones. The amino acid sequence has been determined for the first 72 residues of a lysine-rich histone from rabbit thymus. These are the residues contained in a fragment released from the histone by treatment with N-bromosuccinimide. Peptides derived by tryptic, thermolysin, and chymotryptic digestion of this 72-residue fragment were used to reconstruct the total sequence. Analysis of the sequence revealed some unusual aspects of the structure of the fragment, which comprises about one-third of the histone molecule. Thirty of the first 40 residues are accounted for by lysine, alanine, and proline; this portion of the fragment includes sequences of 4,2, and 3 consecutive basic residues. The last 32 residues contain all the hydrophobic amino acids (valine, isoleucine, leucine, tyrosine) of the fragment but have few basic residues and no prolines. The NH2 terminus of the histone is acetylated. Comparison of the sequence of the NH2-terminal half of this lysine-rich histone with the entire sequences of the slightly lysine-rich and arginine-rich histones shows that all three have similar characteristics, that is, an NH2-terminal region rich in basic amino acids and a COOH-terminal portion rich in hydrophobic residues. Tryptic peptides from the NH2-terminal N-bromosuccinimide fragment of two other thymus lysine-rich histones have been isolated. These peptides (with partial sequences) were aligned by direct identity or analogy with the complete amino acid sequence of the NH2-terminal N-bromosuccinimide fragment of the lysine-rich histone studied previously. It was found that there were from 7 to 14 amino acid differences between fractions. One of the amino acid interchanges eliminates a major phosphorylation site. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Amino acid sequence and sequence variability of the amino-terminal regions of lysine-rich histones. The amino acid sequence has been determined for the first 72 residues of a lysine-rich histone from rabbit thymus. These are the residues contained in a fragment released from the histone by treatment with N-bromosuccinimide. Peptides derived by tryptic, thermolysin, and chymotryptic digestion of this 72-residue fragment were used to reconstruct the total sequence. Analysis of the sequence revealed some unusual aspects of the structure of the fragment, which comprises about one-third of the histone molecule. Thirty of the first 40 residues are accounted for by lysine, alanine, and proline; this portion of the fragment includes sequences of 4,2, and 3 consecutive basic residues. The last 32 residues contain all the hydrophobic amino acids (valine, isoleucine, leucine, tyrosine) of the fragment but have few basic residues and no prolines. The NH2 terminus of the histone is acetylated. Comparison of the sequence of the NH2-terminal half of this lysine-rich histone with the entire sequences of the slightly lysine-rich and arginine-rich histones shows that all three have similar characteristics, that is, an NH2-terminal region rich in basic amino acids and a COOH-terminal portion rich in hydrophobic residues. Tryptic peptides from the NH2-terminal N-bromosuccinimide fragment of two other thymus lysine-rich histones have been isolated. These peptides (with partial sequences) were aligned by direct identity or analogy with the complete amino acid sequence of the NH2-terminal N-bromosuccinimide fragment of the lysine-rich histone studied previously. It was found that there were from 7 to 14 amino acid differences between fractions. One of the amino acid interchanges eliminates a major phosphorylation site.	[ "Amino", "acid", "sequence", "and", "sequence", "variability", "of", "the", "amino", "-", "terminal", "regions", "of", "lysine", "-", "rich", "histones", ".", "\n", "The", "amino", "acid", "sequence", "has", "been", "determined", "for", "the", "first", "72", "residues", "of", "a", "lysine", "-", "rich", "histone", "from", "rabbit", "thymus", ".", "These", "are", "the", "residues", "contained", "in", "a", "fragment", "released", "from", "the", "histone", "by", "treatment", "with", "N", "-", "bromosuccinimide", ".", "Peptides", "derived", "by", "tryptic", ",", "thermolysin", ",", "and", "chymotryptic", "digestion", "of", "this", "72-residue", "fragment", "were", "used", "to", "reconstruct", "the", "total", "sequence", ".", "Analysis", "of", "the", "sequence", "revealed", "some", "unusual", "aspects", "of", "the", "structure", "of", "the", "fragment", ",", "which", "comprises", "about", "one", "-", "third", "of", "the", "histone", "molecule", ".", "Thirty", "of", "the", "first", "40", "residues", "are", "accounted", "for", "by", "lysine", ",", "alanine", ",", "and", "proline", ";", "this", "portion", "of", "the", "fragment", "includes", "sequences", "of", "4,2", ",", "and", "3", "consecutive", "basic", "residues", ".", "The", "last", "32", "residues", "contain", "all", "the", "hydrophobic", "amino", "acids", "(", "valine", ",", "isoleucine", ",", "leucine", ",", "tyrosine", ")", "of", "the", "fragment", "but", "have", "few", "basic", "residues", "and", "no", "prolines", ".", "The", "NH2", "terminus", "of", "the", "histone", "is", "acetylated", ".", "Comparison", "of", "the", "sequence", "of", "the", "NH2-terminal", "half", "of", "this", "lysine", "-", "rich", "histone", "with", "the", "entire", "sequences", "of", "the", "slightly", "lysine", "-", "rich", "and", "arginine", "-", "rich", "histones", "shows", "that", "all", "three", "have", "similar", "characteristics", ",", "that", "is", ",", "an", "NH2-terminal", "region", "rich", "in", "basic", "amino", "acids", "and", "a", "COOH", "-", "terminal", "portion", "rich", "in", "hydrophobic", "residues", ".", "Tryptic", "peptides", "from", "the", "NH2-terminal", "N", "-", "bromosuccinimide", "fragment", "of", "two", "other", "thymus", "lysine", "-", "rich", "histones", "have", "been", "isolated", ".", "These", "peptides", "(", "with", "partial", "sequences", ")", "were", "aligned", "by", "direct", "identity", "or", "analogy", "with", "the", "complete", "amino", "acid", "sequence", "of", "the", "NH2-terminal", "N", "-", "bromosuccinimide", "fragment", "of", "the", "lysine", "-", "rich", "histone", "studied", "previously", ".", "It", "was", "found", "that", "there", "were", "from", "7", "to", "14", "amino", "acid", "differences", "between", "fractions", ".", "One", "of", "the", "amino", "acid", "interchanges", "eliminates", "a", "major", "phosphorylation", "site", "." ]	[ "Protein", "Entity" ]
tRNA is a RNA, HisRS - like is a protein-domain, eIF2alpha is a protein	1.0alpha7.train.646_task0	Sentence: Accordingly, it was proposed that binding of uncharged tRNA to the HisRS-like domain stimulates the ability of the kinase domain to phosphorylate eIF2alpha ( 51). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: RNA, protein-domain, protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-RNA", "O", "O", "O", "B-protein-domain", "I-protein-domain", "I-protein-domain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O" ]	Accordingly, it was proposed that binding of uncharged tRNA to the HisRS-like domain stimulates the ability of the kinase domain to phosphorylate eIF2alpha ( 51).	[ " ", "Accordingly", ",", "it", "was", "proposed", "that", "binding", "of", "uncharged", " ", "tRNA", "to", "the", " ", "HisRS", "-", "like", "domain", "stimulates", "the", "ability", "of", "the", "kinase", "domain", "to", "phosphorylate", " ", "eIF2alpha", "(", "51", ")", ".", " " ]	[ "protein-domain", "protein", "RNA" ]
tRNA is a RNA, HisRS - like is a protein-domain, eIF2alpha is a protein	1.0alpha7.train.646_task1	Sentence: Accordingly, it was proposed that binding of uncharged tRNA to the HisRS-like domain stimulates the ability of the kinase domain to phosphorylate eIF2alpha ( 51). Instructions: please typing these entity words according to sentence: tRNA, HisRS - like, eIF2alpha Options: RNA, protein-domain, protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-RNA", "O", "O", "O", "B-protein-domain", "I-protein-domain", "I-protein-domain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O" ]	Accordingly, it was proposed that binding of uncharged tRNA to the HisRS-like domain stimulates the ability of the kinase domain to phosphorylate eIF2alpha ( 51).	[ " ", "Accordingly", ",", "it", "was", "proposed", "that", "binding", "of", "uncharged", " ", "tRNA", "to", "the", " ", "HisRS", "-", "like", "domain", "stimulates", "the", "ability", "of", "the", "kinase", "domain", "to", "phosphorylate", " ", "eIF2alpha", "(", "51", ")", ".", " " ]	[ "protein-domain", "protein", "RNA" ]
tRNA, HisRS - like, eIF2alpha	1.0alpha7.train.646_task2	Sentence: Accordingly, it was proposed that binding of uncharged tRNA to the HisRS-like domain stimulates the ability of the kinase domain to phosphorylate eIF2alpha ( 51). Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-RNA", "O", "O", "O", "B-protein-domain", "I-protein-domain", "I-protein-domain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O" ]	Accordingly, it was proposed that binding of uncharged tRNA to the HisRS-like domain stimulates the ability of the kinase domain to phosphorylate eIF2alpha ( 51).	[ " ", "Accordingly", ",", "it", "was", "proposed", "that", "binding", "of", "uncharged", " ", "tRNA", "to", "the", " ", "HisRS", "-", "like", "domain", "stimulates", "the", "ability", "of", "the", "kinase", "domain", "to", "phosphorylate", " ", "eIF2alpha", "(", "51", ")", ".", " " ]	[ "protein-domain", "protein", "RNA" ]
ubiquitin is a protein, methamphetamine is a compound	DS.d1022_task0	Sentence: Quinone formation is closely linked to other representative hypotheses such as mitochondrial dysfunction, inflammation, oxidative stress, and dysfunction of the ubiquitin-proteasome system, in the pathogenesis of neurodegenerative diseases such as Parkinson's disease and methamphetamine-induced neurotoxicity. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O" ]	Quinone formation is closely linked to other representative hypotheses such as mitochondrial dysfunction, inflammation, oxidative stress, and dysfunction of the ubiquitin-proteasome system, in the pathogenesis of neurodegenerative diseases such as Parkinson's disease and methamphetamine-induced neurotoxicity.	[ "Quinone", "formation", "is", "closely", "linked", "to", "other", "representative", "hypotheses", "such", "as", "mitochondrial", "dysfunction", ",", "inflammation", ",", "oxidative", "stress", ",", "and", "dysfunction", "of", "the", "ubiquitin", "-", "proteasome", "system", ",", "in", "the", "pathogenesis", "of", "neurodegenerative", "diseases", "such", "as", "Parkinson", "'s", "disease", "and", "methamphetamine", "-", "induced", "neurotoxicity", "." ]	[ "compound", "protein" ]
ubiquitin is a protein, methamphetamine is a compound	DS.d1022_task1	Sentence: Quinone formation is closely linked to other representative hypotheses such as mitochondrial dysfunction, inflammation, oxidative stress, and dysfunction of the ubiquitin-proteasome system, in the pathogenesis of neurodegenerative diseases such as Parkinson's disease and methamphetamine-induced neurotoxicity. Instructions: please typing these entity words according to sentence: ubiquitin, methamphetamine Options: compound, protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O" ]	Quinone formation is closely linked to other representative hypotheses such as mitochondrial dysfunction, inflammation, oxidative stress, and dysfunction of the ubiquitin-proteasome system, in the pathogenesis of neurodegenerative diseases such as Parkinson's disease and methamphetamine-induced neurotoxicity.	[ "Quinone", "formation", "is", "closely", "linked", "to", "other", "representative", "hypotheses", "such", "as", "mitochondrial", "dysfunction", ",", "inflammation", ",", "oxidative", "stress", ",", "and", "dysfunction", "of", "the", "ubiquitin", "-", "proteasome", "system", ",", "in", "the", "pathogenesis", "of", "neurodegenerative", "diseases", "such", "as", "Parkinson", "'s", "disease", "and", "methamphetamine", "-", "induced", "neurotoxicity", "." ]	[ "compound", "protein" ]
ubiquitin, methamphetamine	DS.d1022_task2	Sentence: Quinone formation is closely linked to other representative hypotheses such as mitochondrial dysfunction, inflammation, oxidative stress, and dysfunction of the ubiquitin-proteasome system, in the pathogenesis of neurodegenerative diseases such as Parkinson's disease and methamphetamine-induced neurotoxicity. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O" ]	Quinone formation is closely linked to other representative hypotheses such as mitochondrial dysfunction, inflammation, oxidative stress, and dysfunction of the ubiquitin-proteasome system, in the pathogenesis of neurodegenerative diseases such as Parkinson's disease and methamphetamine-induced neurotoxicity.	[ "Quinone", "formation", "is", "closely", "linked", "to", "other", "representative", "hypotheses", "such", "as", "mitochondrial", "dysfunction", ",", "inflammation", ",", "oxidative", "stress", ",", "and", "dysfunction", "of", "the", "ubiquitin", "-", "proteasome", "system", ",", "in", "the", "pathogenesis", "of", "neurodegenerative", "diseases", "such", "as", "Parkinson", "'s", "disease", "and", "methamphetamine", "-", "induced", "neurotoxicity", "." ]	[ "compound", "protein" ]
microRNA is a Non-Specific_miRNAs, modulate adenoviral protein expression is a Relation_Trigger, tumor is a Diseases	4501_task0	Sentence: Additionally, several research groups have established that inserting microRNA (miRNA)-targeted sequences into the adenoviral genome can modulate adenoviral protein expression to confer tissue and tumor selectivity. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Relation_Trigger, Diseases, Non-Specific_miRNAs	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Non-Specific_miRNAs", "O", "O", "O", "O", "O", "O", "O", "O", "B-Relation_Trigger", "I-Relation_Trigger", "I-Relation_Trigger", "I-Relation_Trigger", "O", "O", "O", "O", "B-Diseases", "O", "O" ]	Additionally, several research groups have established that inserting microRNA (miRNA)-targeted sequences into the adenoviral genome can modulate adenoviral protein expression to confer tissue and tumor selectivity.	[ "Additionally", ",", "several", "research", "groups", "have", "established", "that", "inserting", "microRNA", "(", "miRNA)-targeted", "sequences", "into", "the", "adenoviral", "genome", "can", "modulate", "adenoviral", "protein", "expression", "to", "confer", "tissue", "and", "tumor", "selectivity", "." ]	[ "Relation_Trigger", "Diseases", "Non-Specific_miRNAs", "Genes/Proteins" ]
microRNA is a Non-Specific_miRNAs, modulate adenoviral protein expression is a Relation_Trigger, tumor is a Diseases	4501_task1	Sentence: Additionally, several research groups have established that inserting microRNA (miRNA)-targeted sequences into the adenoviral genome can modulate adenoviral protein expression to confer tissue and tumor selectivity. Instructions: please typing these entity words according to sentence: microRNA, modulate adenoviral protein expression, tumor Options: Relation_Trigger, Diseases, Non-Specific_miRNAs	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Non-Specific_miRNAs", "O", "O", "O", "O", "O", "O", "O", "O", "B-Relation_Trigger", "I-Relation_Trigger", "I-Relation_Trigger", "I-Relation_Trigger", "O", "O", "O", "O", "B-Diseases", "O", "O" ]	Additionally, several research groups have established that inserting microRNA (miRNA)-targeted sequences into the adenoviral genome can modulate adenoviral protein expression to confer tissue and tumor selectivity.	[ "Additionally", ",", "several", "research", "groups", "have", "established", "that", "inserting", "microRNA", "(", "miRNA)-targeted", "sequences", "into", "the", "adenoviral", "genome", "can", "modulate", "adenoviral", "protein", "expression", "to", "confer", "tissue", "and", "tumor", "selectivity", "." ]	[ "Relation_Trigger", "Diseases", "Non-Specific_miRNAs", "Genes/Proteins" ]
microRNA, modulate adenoviral protein expression, tumor	4501_task2	Sentence: Additionally, several research groups have established that inserting microRNA (miRNA)-targeted sequences into the adenoviral genome can modulate adenoviral protein expression to confer tissue and tumor selectivity. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Non-Specific_miRNAs", "O", "O", "O", "O", "O", "O", "O", "O", "B-Relation_Trigger", "I-Relation_Trigger", "I-Relation_Trigger", "I-Relation_Trigger", "O", "O", "O", "O", "B-Diseases", "O", "O" ]	Additionally, several research groups have established that inserting microRNA (miRNA)-targeted sequences into the adenoviral genome can modulate adenoviral protein expression to confer tissue and tumor selectivity.	[ "Additionally", ",", "several", "research", "groups", "have", "established", "that", "inserting", "microRNA", "(", "miRNA)-targeted", "sequences", "into", "the", "adenoviral", "genome", "can", "modulate", "adenoviral", "protein", "expression", "to", "confer", "tissue", "and", "tumor", "selectivity", "." ]	[ "Relation_Trigger", "Diseases", "Non-Specific_miRNAs", "Genes/Proteins" ]
sialic acid is a compound, peroxidase is a protein	DS.d1286_task0	Sentence: After 2 and 6 weeks of treatment, parotid gland was removed and total protein and sialic acid (free and total) concentration and amylase and peroxidase activities were determined. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O" ]	After 2 and 6 weeks of treatment, parotid gland was removed and total protein and sialic acid (free and total) concentration and amylase and peroxidase activities were determined.	[ "After", "2", "and", "6", "weeks", "of", "treatment", ",", "parotid", "gland", "was", "removed", "and", "total", "protein", "and", "sialic", "acid", "(", "free", "and", "total", ")", "concentration", "and", "amylase", "and", "peroxidase", "activities", "were", "determined", "." ]	[ "compound", "protein" ]
sialic acid is a compound, peroxidase is a protein	DS.d1286_task1	Sentence: After 2 and 6 weeks of treatment, parotid gland was removed and total protein and sialic acid (free and total) concentration and amylase and peroxidase activities were determined. Instructions: please typing these entity words according to sentence: sialic acid, peroxidase Options: compound, protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O" ]	After 2 and 6 weeks of treatment, parotid gland was removed and total protein and sialic acid (free and total) concentration and amylase and peroxidase activities were determined.	[ "After", "2", "and", "6", "weeks", "of", "treatment", ",", "parotid", "gland", "was", "removed", "and", "total", "protein", "and", "sialic", "acid", "(", "free", "and", "total", ")", "concentration", "and", "amylase", "and", "peroxidase", "activities", "were", "determined", "." ]	[ "compound", "protein" ]
sialic acid, peroxidase	DS.d1286_task2	Sentence: After 2 and 6 weeks of treatment, parotid gland was removed and total protein and sialic acid (free and total) concentration and amylase and peroxidase activities were determined. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O" ]	After 2 and 6 weeks of treatment, parotid gland was removed and total protein and sialic acid (free and total) concentration and amylase and peroxidase activities were determined.	[ "After", "2", "and", "6", "weeks", "of", "treatment", ",", "parotid", "gland", "was", "removed", "and", "total", "protein", "and", "sialic", "acid", "(", "free", "and", "total", ")", "concentration", "and", "amylase", "and", "peroxidase", "activities", "were", "determined", "." ]	[ "compound", "protein" ]
4-Hydroxyphenylpyruvate dioxygenase is a Protein, 4-Hydroxyphenylpyruvate dioxygenase is a Protein, HPPD is a Protein, HPPD is a Protein, HPPD is a Protein, HPPD is a Protein, HPPD is a Protein, HPPD is a Protein, HPPD is a Protein	141_task0	Sentence: 4-Hydroxyphenylpyruvate dioxygenase. 4-Hydroxyphenylpyruvate dioxygenase (HPPD) is an Fe(II)-dependent, non-heme oxygenase that catalyzes the conversion of 4-hydroxyphenylpyruvate to homogentisate. This reaction involves decarboxylation, substituent migration and aromatic oxygenation in a single catalytic cycle. HPPD is a member of the alpha-keto acid dependent oxygenases that typically require an alpha-keto acid (almost exclusively alpha-ketoglutarate) and molecular oxygen to either oxygenate or oxidize a third molecule. As an exception in this class of enzymes HPPD has only two substrates, does not use alpha-ketoglutarate, and incorporates both atoms of dioxygen into the aromatic product, homogentisate. The tertiary structure of the enzyme would suggest that its mechanism converged with that of other alpha-keto acid enzymes from an extradiol dioxygenase progenitor. The transformation catalyzed by HPPD has both agricultural and therapeutic significance. HPPD catalyzes the second step in the pathway for the catabolism of tyrosine, that is common to essentially all aerobic forms of life. In plants this pathway has an anabolic branch from homogentisate that forms essential isoprenoid redox cofactors such as plastoquinone and tocopherol. Naturally occurring multi-ketone molecules act as allelopathic agents by inhibiting HPPD and preventing the production of homogentisate and hence required redox cofactors. This has been the basis for the development of a range of very effective herbicides that are currently used commercially. In humans, deficiencies of specific enzymes of the tyrosine catabolism pathway give rise to a number of severe metabolic disorders. Interestingly, HPPD inhibitor/herbicide molecules act also as therapeutic agents for a number of debilitating and lethal inborn defects in tyrosine catabolism by preventing the accumulation of toxic metabolites. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "B-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	4-Hydroxyphenylpyruvate dioxygenase. 4-Hydroxyphenylpyruvate dioxygenase (HPPD) is an Fe(II)-dependent, non-heme oxygenase that catalyzes the conversion of 4-hydroxyphenylpyruvate to homogentisate. This reaction involves decarboxylation, substituent migration and aromatic oxygenation in a single catalytic cycle. HPPD is a member of the alpha-keto acid dependent oxygenases that typically require an alpha-keto acid (almost exclusively alpha-ketoglutarate) and molecular oxygen to either oxygenate or oxidize a third molecule. As an exception in this class of enzymes HPPD has only two substrates, does not use alpha-ketoglutarate, and incorporates both atoms of dioxygen into the aromatic product, homogentisate. The tertiary structure of the enzyme would suggest that its mechanism converged with that of other alpha-keto acid enzymes from an extradiol dioxygenase progenitor. The transformation catalyzed by HPPD has both agricultural and therapeutic significance. HPPD catalyzes the second step in the pathway for the catabolism of tyrosine, that is common to essentially all aerobic forms of life. In plants this pathway has an anabolic branch from homogentisate that forms essential isoprenoid redox cofactors such as plastoquinone and tocopherol. Naturally occurring multi-ketone molecules act as allelopathic agents by inhibiting HPPD and preventing the production of homogentisate and hence required redox cofactors. This has been the basis for the development of a range of very effective herbicides that are currently used commercially. In humans, deficiencies of specific enzymes of the tyrosine catabolism pathway give rise to a number of severe metabolic disorders. Interestingly, HPPD inhibitor/herbicide molecules act also as therapeutic agents for a number of debilitating and lethal inborn defects in tyrosine catabolism by preventing the accumulation of toxic metabolites.	[ "4-Hydroxyphenylpyruvate", "dioxygenase", ".", "\n", "4-Hydroxyphenylpyruvate", "dioxygenase", "(", "HPPD", ")", "is", "an", "Fe(II)-dependent", ",", "non", "-", "heme", "oxygenase", "that", "catalyzes", "the", "conversion", "of", "4-hydroxyphenylpyruvate", "to", "homogentisate", ".", "This", "reaction", "involves", "decarboxylation", ",", "substituent", "migration", "and", "aromatic", "oxygenation", "in", "a", "single", "catalytic", "cycle", ".", "HPPD", "is", "a", "member", "of", "the", "alpha", "-", "keto", "acid", "dependent", "oxygenases", "that", "typically", "require", "an", "alpha", "-", "keto", "acid", "(", "almost", "exclusively", "alpha", "-", "ketoglutarate", ")", "and", "molecular", "oxygen", "to", "either", "oxygenate", "or", "oxidize", "a", "third", "molecule", ".", "As", "an", "exception", "in", "this", "class", "of", "enzymes", "HPPD", "has", "only", "two", "substrates", ",", "does", "not", "use", "alpha", "-", "ketoglutarate", ",", "and", "incorporates", "both", "atoms", "of", "dioxygen", "into", "the", "aromatic", "product", ",", "homogentisate", ".", "The", "tertiary", "structure", "of", "the", "enzyme", "would", "suggest", "that", "its", "mechanism", "converged", "with", "that", "of", "other", "alpha", "-", "keto", "acid", "enzymes", "from", "an", "extradiol", "dioxygenase", "progenitor", ".", "The", "transformation", "catalyzed", "by", "HPPD", "has", "both", "agricultural", "and", "therapeutic", "significance", ".", "HPPD", "catalyzes", "the", "second", "step", "in", "the", "pathway", "for", "the", "catabolism", "of", "tyrosine", ",", "that", "is", "common", "to", "essentially", "all", "aerobic", "forms", "of", "life", ".", "In", "plants", "this", "pathway", "has", "an", "anabolic", "branch", "from", "homogentisate", "that", "forms", "essential", "isoprenoid", "redox", "cofactors", "such", "as", "plastoquinone", "and", "tocopherol", ".", "Naturally", "occurring", "multi", "-", "ketone", "molecules", "act", "as", "allelopathic", "agents", "by", "inhibiting", "HPPD", "and", "preventing", "the", "production", "of", "homogentisate", "and", "hence", "required", "redox", "cofactors", ".", "This", "has", "been", "the", "basis", "for", "the", "development", "of", "a", "range", "of", "very", "effective", "herbicides", "that", "are", "currently", "used", "commercially", ".", "In", "humans", ",", "deficiencies", "of", "specific", "enzymes", "of", "the", "tyrosine", "catabolism", "pathway", "give", "rise", "to", "a", "number", "of", "severe", "metabolic", "disorders", ".", "Interestingly", ",", "HPPD", "inhibitor", "/", "herbicide", "molecules", "act", "also", "as", "therapeutic", "agents", "for", "a", "number", "of", "debilitating", "and", "lethal", "inborn", "defects", "in", "tyrosine", "catabolism", "by", "preventing", "the", "accumulation", "of", "toxic", "metabolites", ".", "\n" ]	[ "Protein" ]
4-Hydroxyphenylpyruvate dioxygenase is a Protein, 4-Hydroxyphenylpyruvate dioxygenase is a Protein, HPPD is a Protein, HPPD is a Protein, HPPD is a Protein, HPPD is a Protein, HPPD is a Protein, HPPD is a Protein, HPPD is a Protein	141_task1	Sentence: 4-Hydroxyphenylpyruvate dioxygenase. 4-Hydroxyphenylpyruvate dioxygenase (HPPD) is an Fe(II)-dependent, non-heme oxygenase that catalyzes the conversion of 4-hydroxyphenylpyruvate to homogentisate. This reaction involves decarboxylation, substituent migration and aromatic oxygenation in a single catalytic cycle. HPPD is a member of the alpha-keto acid dependent oxygenases that typically require an alpha-keto acid (almost exclusively alpha-ketoglutarate) and molecular oxygen to either oxygenate or oxidize a third molecule. As an exception in this class of enzymes HPPD has only two substrates, does not use alpha-ketoglutarate, and incorporates both atoms of dioxygen into the aromatic product, homogentisate. The tertiary structure of the enzyme would suggest that its mechanism converged with that of other alpha-keto acid enzymes from an extradiol dioxygenase progenitor. The transformation catalyzed by HPPD has both agricultural and therapeutic significance. HPPD catalyzes the second step in the pathway for the catabolism of tyrosine, that is common to essentially all aerobic forms of life. In plants this pathway has an anabolic branch from homogentisate that forms essential isoprenoid redox cofactors such as plastoquinone and tocopherol. Naturally occurring multi-ketone molecules act as allelopathic agents by inhibiting HPPD and preventing the production of homogentisate and hence required redox cofactors. This has been the basis for the development of a range of very effective herbicides that are currently used commercially. In humans, deficiencies of specific enzymes of the tyrosine catabolism pathway give rise to a number of severe metabolic disorders. Interestingly, HPPD inhibitor/herbicide molecules act also as therapeutic agents for a number of debilitating and lethal inborn defects in tyrosine catabolism by preventing the accumulation of toxic metabolites. Instructions: please typing these entity words according to sentence: 4-Hydroxyphenylpyruvate dioxygenase, 4-Hydroxyphenylpyruvate dioxygenase, HPPD, HPPD, HPPD, HPPD, HPPD, HPPD, HPPD Options: Protein	[ "B-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	4-Hydroxyphenylpyruvate dioxygenase. 4-Hydroxyphenylpyruvate dioxygenase (HPPD) is an Fe(II)-dependent, non-heme oxygenase that catalyzes the conversion of 4-hydroxyphenylpyruvate to homogentisate. This reaction involves decarboxylation, substituent migration and aromatic oxygenation in a single catalytic cycle. HPPD is a member of the alpha-keto acid dependent oxygenases that typically require an alpha-keto acid (almost exclusively alpha-ketoglutarate) and molecular oxygen to either oxygenate or oxidize a third molecule. As an exception in this class of enzymes HPPD has only two substrates, does not use alpha-ketoglutarate, and incorporates both atoms of dioxygen into the aromatic product, homogentisate. The tertiary structure of the enzyme would suggest that its mechanism converged with that of other alpha-keto acid enzymes from an extradiol dioxygenase progenitor. The transformation catalyzed by HPPD has both agricultural and therapeutic significance. HPPD catalyzes the second step in the pathway for the catabolism of tyrosine, that is common to essentially all aerobic forms of life. In plants this pathway has an anabolic branch from homogentisate that forms essential isoprenoid redox cofactors such as plastoquinone and tocopherol. Naturally occurring multi-ketone molecules act as allelopathic agents by inhibiting HPPD and preventing the production of homogentisate and hence required redox cofactors. This has been the basis for the development of a range of very effective herbicides that are currently used commercially. In humans, deficiencies of specific enzymes of the tyrosine catabolism pathway give rise to a number of severe metabolic disorders. Interestingly, HPPD inhibitor/herbicide molecules act also as therapeutic agents for a number of debilitating and lethal inborn defects in tyrosine catabolism by preventing the accumulation of toxic metabolites.	[ "4-Hydroxyphenylpyruvate", "dioxygenase", ".", "\n", "4-Hydroxyphenylpyruvate", "dioxygenase", "(", "HPPD", ")", "is", "an", "Fe(II)-dependent", ",", "non", "-", "heme", "oxygenase", "that", "catalyzes", "the", "conversion", "of", "4-hydroxyphenylpyruvate", "to", "homogentisate", ".", "This", "reaction", "involves", "decarboxylation", ",", "substituent", "migration", "and", "aromatic", "oxygenation", "in", "a", "single", "catalytic", "cycle", ".", "HPPD", "is", "a", "member", "of", "the", "alpha", "-", "keto", "acid", "dependent", "oxygenases", "that", "typically", "require", "an", "alpha", "-", "keto", "acid", "(", "almost", "exclusively", "alpha", "-", "ketoglutarate", ")", "and", "molecular", "oxygen", "to", "either", "oxygenate", "or", "oxidize", "a", "third", "molecule", ".", "As", "an", "exception", "in", "this", "class", "of", "enzymes", "HPPD", "has", "only", "two", "substrates", ",", "does", "not", "use", "alpha", "-", "ketoglutarate", ",", "and", "incorporates", "both", "atoms", "of", "dioxygen", "into", "the", "aromatic", "product", ",", "homogentisate", ".", "The", "tertiary", "structure", "of", "the", "enzyme", "would", "suggest", "that", "its", "mechanism", "converged", "with", "that", "of", "other", "alpha", "-", "keto", "acid", "enzymes", "from", "an", "extradiol", "dioxygenase", "progenitor", ".", "The", "transformation", "catalyzed", "by", "HPPD", "has", "both", "agricultural", "and", "therapeutic", "significance", ".", "HPPD", "catalyzes", "the", "second", "step", "in", "the", "pathway", "for", "the", "catabolism", "of", "tyrosine", ",", "that", "is", "common", "to", "essentially", "all", "aerobic", "forms", "of", "life", ".", "In", "plants", "this", "pathway", "has", "an", "anabolic", "branch", "from", "homogentisate", "that", "forms", "essential", "isoprenoid", "redox", "cofactors", "such", "as", "plastoquinone", "and", "tocopherol", ".", "Naturally", "occurring", "multi", "-", "ketone", "molecules", "act", "as", "allelopathic", "agents", "by", "inhibiting", "HPPD", "and", "preventing", "the", "production", "of", "homogentisate", "and", "hence", "required", "redox", "cofactors", ".", "This", "has", "been", "the", "basis", "for", "the", "development", "of", "a", "range", "of", "very", "effective", "herbicides", "that", "are", "currently", "used", "commercially", ".", "In", "humans", ",", "deficiencies", "of", "specific", "enzymes", "of", "the", "tyrosine", "catabolism", "pathway", "give", "rise", "to", "a", "number", "of", "severe", "metabolic", "disorders", ".", "Interestingly", ",", "HPPD", "inhibitor", "/", "herbicide", "molecules", "act", "also", "as", "therapeutic", "agents", "for", "a", "number", "of", "debilitating", "and", "lethal", "inborn", "defects", "in", "tyrosine", "catabolism", "by", "preventing", "the", "accumulation", "of", "toxic", "metabolites", ".", "\n" ]	[ "Protein" ]
4-Hydroxyphenylpyruvate dioxygenase, 4-Hydroxyphenylpyruvate dioxygenase, HPPD, HPPD, HPPD, HPPD, HPPD, HPPD, HPPD	141_task2	Sentence: 4-Hydroxyphenylpyruvate dioxygenase. 4-Hydroxyphenylpyruvate dioxygenase (HPPD) is an Fe(II)-dependent, non-heme oxygenase that catalyzes the conversion of 4-hydroxyphenylpyruvate to homogentisate. This reaction involves decarboxylation, substituent migration and aromatic oxygenation in a single catalytic cycle. HPPD is a member of the alpha-keto acid dependent oxygenases that typically require an alpha-keto acid (almost exclusively alpha-ketoglutarate) and molecular oxygen to either oxygenate or oxidize a third molecule. As an exception in this class of enzymes HPPD has only two substrates, does not use alpha-ketoglutarate, and incorporates both atoms of dioxygen into the aromatic product, homogentisate. The tertiary structure of the enzyme would suggest that its mechanism converged with that of other alpha-keto acid enzymes from an extradiol dioxygenase progenitor. The transformation catalyzed by HPPD has both agricultural and therapeutic significance. HPPD catalyzes the second step in the pathway for the catabolism of tyrosine, that is common to essentially all aerobic forms of life. In plants this pathway has an anabolic branch from homogentisate that forms essential isoprenoid redox cofactors such as plastoquinone and tocopherol. Naturally occurring multi-ketone molecules act as allelopathic agents by inhibiting HPPD and preventing the production of homogentisate and hence required redox cofactors. This has been the basis for the development of a range of very effective herbicides that are currently used commercially. In humans, deficiencies of specific enzymes of the tyrosine catabolism pathway give rise to a number of severe metabolic disorders. Interestingly, HPPD inhibitor/herbicide molecules act also as therapeutic agents for a number of debilitating and lethal inborn defects in tyrosine catabolism by preventing the accumulation of toxic metabolites. Instructions: please extract entity words from the input sentence	[ "B-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	4-Hydroxyphenylpyruvate dioxygenase. 4-Hydroxyphenylpyruvate dioxygenase (HPPD) is an Fe(II)-dependent, non-heme oxygenase that catalyzes the conversion of 4-hydroxyphenylpyruvate to homogentisate. This reaction involves decarboxylation, substituent migration and aromatic oxygenation in a single catalytic cycle. HPPD is a member of the alpha-keto acid dependent oxygenases that typically require an alpha-keto acid (almost exclusively alpha-ketoglutarate) and molecular oxygen to either oxygenate or oxidize a third molecule. As an exception in this class of enzymes HPPD has only two substrates, does not use alpha-ketoglutarate, and incorporates both atoms of dioxygen into the aromatic product, homogentisate. The tertiary structure of the enzyme would suggest that its mechanism converged with that of other alpha-keto acid enzymes from an extradiol dioxygenase progenitor. The transformation catalyzed by HPPD has both agricultural and therapeutic significance. HPPD catalyzes the second step in the pathway for the catabolism of tyrosine, that is common to essentially all aerobic forms of life. In plants this pathway has an anabolic branch from homogentisate that forms essential isoprenoid redox cofactors such as plastoquinone and tocopherol. Naturally occurring multi-ketone molecules act as allelopathic agents by inhibiting HPPD and preventing the production of homogentisate and hence required redox cofactors. This has been the basis for the development of a range of very effective herbicides that are currently used commercially. In humans, deficiencies of specific enzymes of the tyrosine catabolism pathway give rise to a number of severe metabolic disorders. Interestingly, HPPD inhibitor/herbicide molecules act also as therapeutic agents for a number of debilitating and lethal inborn defects in tyrosine catabolism by preventing the accumulation of toxic metabolites.	[ "4-Hydroxyphenylpyruvate", "dioxygenase", ".", "\n", "4-Hydroxyphenylpyruvate", "dioxygenase", "(", "HPPD", ")", "is", "an", "Fe(II)-dependent", ",", "non", "-", "heme", "oxygenase", "that", "catalyzes", "the", "conversion", "of", "4-hydroxyphenylpyruvate", "to", "homogentisate", ".", "This", "reaction", "involves", "decarboxylation", ",", "substituent", "migration", "and", "aromatic", "oxygenation", "in", "a", "single", "catalytic", "cycle", ".", "HPPD", "is", "a", "member", "of", "the", "alpha", "-", "keto", "acid", "dependent", "oxygenases", "that", "typically", "require", "an", "alpha", "-", "keto", "acid", "(", "almost", "exclusively", "alpha", "-", "ketoglutarate", ")", "and", "molecular", "oxygen", "to", "either", "oxygenate", "or", "oxidize", "a", "third", "molecule", ".", "As", "an", "exception", "in", "this", "class", "of", "enzymes", "HPPD", "has", "only", "two", "substrates", ",", "does", "not", "use", "alpha", "-", "ketoglutarate", ",", "and", "incorporates", "both", "atoms", "of", "dioxygen", "into", "the", "aromatic", "product", ",", "homogentisate", ".", "The", "tertiary", "structure", "of", "the", "enzyme", "would", "suggest", "that", "its", "mechanism", "converged", "with", "that", "of", "other", "alpha", "-", "keto", "acid", "enzymes", "from", "an", "extradiol", "dioxygenase", "progenitor", ".", "The", "transformation", "catalyzed", "by", "HPPD", "has", "both", "agricultural", "and", "therapeutic", "significance", ".", "HPPD", "catalyzes", "the", "second", "step", "in", "the", "pathway", "for", "the", "catabolism", "of", "tyrosine", ",", "that", "is", "common", "to", "essentially", "all", "aerobic", "forms", "of", "life", ".", "In", "plants", "this", "pathway", "has", "an", "anabolic", "branch", "from", "homogentisate", "that", "forms", "essential", "isoprenoid", "redox", "cofactors", "such", "as", "plastoquinone", "and", "tocopherol", ".", "Naturally", "occurring", "multi", "-", "ketone", "molecules", "act", "as", "allelopathic", "agents", "by", "inhibiting", "HPPD", "and", "preventing", "the", "production", "of", "homogentisate", "and", "hence", "required", "redox", "cofactors", ".", "This", "has", "been", "the", "basis", "for", "the", "development", "of", "a", "range", "of", "very", "effective", "herbicides", "that", "are", "currently", "used", "commercially", ".", "In", "humans", ",", "deficiencies", "of", "specific", "enzymes", "of", "the", "tyrosine", "catabolism", "pathway", "give", "rise", "to", "a", "number", "of", "severe", "metabolic", "disorders", ".", "Interestingly", ",", "HPPD", "inhibitor", "/", "herbicide", "molecules", "act", "also", "as", "therapeutic", "agents", "for", "a", "number", "of", "debilitating", "and", "lethal", "inborn", "defects", "in", "tyrosine", "catabolism", "by", "preventing", "the", "accumulation", "of", "toxic", "metabolites", ".", "\n" ]	[ "Protein" ]
Diagnostik is an umlsterm, Interviewtechnik is an umlsterm, Selbsterleben is an umlsterm, Psychotherapiemotivation is an umlsterm, Diagnostik is an umlsterm, Erstinterview is an umlsterm	Psychotherapeut.60410297.ger.abstr_task0	Sentence: Auf der Grundlage der bisherigen Modelle zur psychodynamischen Diagnostik und der psychoanalytischen Interviewtechnik sowie den theoretischen Konzepten der fuenf Achsen der OPD-Diagnostik wird eine psychodynamisch-diagnostische Untersuchung konzeptualisiert . Die Untersuchung ist in fuenf Phasen strukturiert : Eroeffnung Ermittlung , von Beziehungsepisoden , von Selbsterleben , von Objekterleben und der Psychotherapiemotivation sowie Behandlungsvoraussetzungen und Einsichtsfaehigkeit . Die syndromale Diagnostik nach ICD 10 wird in einer abschliessenden Phase ermittelt . Die entwickelte psychodynamisch-diagnostische Untersuchung kann als Erstinterview oder auch in spaeteren Phasen eingesetzt werden . Sie wird ueber die OPD-Diagnostik hinaus auch zur klinischen Anwendung empfohlen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Auf der Grundlage der bisherigen Modelle zur psychodynamischen Diagnostik und der psychoanalytischen Interviewtechnik sowie den theoretischen Konzepten der fuenf Achsen der OPD-Diagnostik wird eine psychodynamisch-diagnostische Untersuchung konzeptualisiert . Die Untersuchung ist in fuenf Phasen strukturiert : Eroeffnung Ermittlung , von Beziehungsepisoden , von Selbsterleben , von Objekterleben und der Psychotherapiemotivation sowie Behandlungsvoraussetzungen und Einsichtsfaehigkeit . Die syndromale Diagnostik nach ICD 10 wird in einer abschliessenden Phase ermittelt . Die entwickelte psychodynamisch-diagnostische Untersuchung kann als Erstinterview oder auch in spaeteren Phasen eingesetzt werden . Sie wird ueber die OPD-Diagnostik hinaus auch zur klinischen Anwendung empfohlen .	[ "Auf", "der", "Grundlage", "der", "bisherigen", "Modelle", "zur", "psychodynamischen", "Diagnostik", "und", "der", "psychoanalytischen", "Interviewtechnik", "sowie", "den", "theoretischen", "Konzepten", "der", "fuenf", "Achsen", "der", "OPD", "-", "Diagnostik", "wird", "eine", "psychodynamisch", "-", "diagnostische", "Untersuchung", "konzeptualisiert", ".", "Die", "Untersuchung", "ist", "in", "fuenf", "Phasen", "strukturiert", ":", "Eroeffnung", "Ermittlung", ",", "von", "Beziehungsepisoden", ",", "von", "Selbsterleben", ",", "von", "Objekterleben", "und", "der", "Psychotherapiemotivation", "sowie", "Behandlungsvoraussetzungen", "und", "Einsichtsfaehigkeit", ".", "Die", "syndromale", "Diagnostik", "nach", "ICD", "10", "wird", "in", "einer", "abschliessenden", "Phase", "ermittelt", ".", "Die", "entwickelte", "psychodynamisch", "-", "diagnostische", "Untersuchung", "kann", "als", "Erstinterview", "oder", "auch", "in", "spaeteren", "Phasen", "eingesetzt", "werden", ".", "Sie", "wird", "ueber", "die", "OPD", "-", "Diagnostik", "hinaus", "auch", "zur", "klinischen", "Anwendung", "empfohlen", "." ]	[ "umlsterm" ]
Diagnostik is an umlsterm, Interviewtechnik is an umlsterm, Selbsterleben is an umlsterm, Psychotherapiemotivation is an umlsterm, Diagnostik is an umlsterm, Erstinterview is an umlsterm	Psychotherapeut.60410297.ger.abstr_task1	Sentence: Auf der Grundlage der bisherigen Modelle zur psychodynamischen Diagnostik und der psychoanalytischen Interviewtechnik sowie den theoretischen Konzepten der fuenf Achsen der OPD-Diagnostik wird eine psychodynamisch-diagnostische Untersuchung konzeptualisiert . Die Untersuchung ist in fuenf Phasen strukturiert : Eroeffnung Ermittlung , von Beziehungsepisoden , von Selbsterleben , von Objekterleben und der Psychotherapiemotivation sowie Behandlungsvoraussetzungen und Einsichtsfaehigkeit . Die syndromale Diagnostik nach ICD 10 wird in einer abschliessenden Phase ermittelt . Die entwickelte psychodynamisch-diagnostische Untersuchung kann als Erstinterview oder auch in spaeteren Phasen eingesetzt werden . Sie wird ueber die OPD-Diagnostik hinaus auch zur klinischen Anwendung empfohlen . Instructions: please typing these entity words according to sentence: Diagnostik, Interviewtechnik, Selbsterleben, Psychotherapiemotivation, Diagnostik, Erstinterview Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Auf der Grundlage der bisherigen Modelle zur psychodynamischen Diagnostik und der psychoanalytischen Interviewtechnik sowie den theoretischen Konzepten der fuenf Achsen der OPD-Diagnostik wird eine psychodynamisch-diagnostische Untersuchung konzeptualisiert . Die Untersuchung ist in fuenf Phasen strukturiert : Eroeffnung Ermittlung , von Beziehungsepisoden , von Selbsterleben , von Objekterleben und der Psychotherapiemotivation sowie Behandlungsvoraussetzungen und Einsichtsfaehigkeit . Die syndromale Diagnostik nach ICD 10 wird in einer abschliessenden Phase ermittelt . Die entwickelte psychodynamisch-diagnostische Untersuchung kann als Erstinterview oder auch in spaeteren Phasen eingesetzt werden . Sie wird ueber die OPD-Diagnostik hinaus auch zur klinischen Anwendung empfohlen .	[ "Auf", "der", "Grundlage", "der", "bisherigen", "Modelle", "zur", "psychodynamischen", "Diagnostik", "und", "der", "psychoanalytischen", "Interviewtechnik", "sowie", "den", "theoretischen", "Konzepten", "der", "fuenf", "Achsen", "der", "OPD", "-", "Diagnostik", "wird", "eine", "psychodynamisch", "-", "diagnostische", "Untersuchung", "konzeptualisiert", ".", "Die", "Untersuchung", "ist", "in", "fuenf", "Phasen", "strukturiert", ":", "Eroeffnung", "Ermittlung", ",", "von", "Beziehungsepisoden", ",", "von", "Selbsterleben", ",", "von", "Objekterleben", "und", "der", "Psychotherapiemotivation", "sowie", "Behandlungsvoraussetzungen", "und", "Einsichtsfaehigkeit", ".", "Die", "syndromale", "Diagnostik", "nach", "ICD", "10", "wird", "in", "einer", "abschliessenden", "Phase", "ermittelt", ".", "Die", "entwickelte", "psychodynamisch", "-", "diagnostische", "Untersuchung", "kann", "als", "Erstinterview", "oder", "auch", "in", "spaeteren", "Phasen", "eingesetzt", "werden", ".", "Sie", "wird", "ueber", "die", "OPD", "-", "Diagnostik", "hinaus", "auch", "zur", "klinischen", "Anwendung", "empfohlen", "." ]	[ "umlsterm" ]
Diagnostik, Interviewtechnik, Selbsterleben, Psychotherapiemotivation, Diagnostik, Erstinterview	Psychotherapeut.60410297.ger.abstr_task2	Sentence: Auf der Grundlage der bisherigen Modelle zur psychodynamischen Diagnostik und der psychoanalytischen Interviewtechnik sowie den theoretischen Konzepten der fuenf Achsen der OPD-Diagnostik wird eine psychodynamisch-diagnostische Untersuchung konzeptualisiert . Die Untersuchung ist in fuenf Phasen strukturiert : Eroeffnung Ermittlung , von Beziehungsepisoden , von Selbsterleben , von Objekterleben und der Psychotherapiemotivation sowie Behandlungsvoraussetzungen und Einsichtsfaehigkeit . Die syndromale Diagnostik nach ICD 10 wird in einer abschliessenden Phase ermittelt . Die entwickelte psychodynamisch-diagnostische Untersuchung kann als Erstinterview oder auch in spaeteren Phasen eingesetzt werden . Sie wird ueber die OPD-Diagnostik hinaus auch zur klinischen Anwendung empfohlen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Auf der Grundlage der bisherigen Modelle zur psychodynamischen Diagnostik und der psychoanalytischen Interviewtechnik sowie den theoretischen Konzepten der fuenf Achsen der OPD-Diagnostik wird eine psychodynamisch-diagnostische Untersuchung konzeptualisiert . Die Untersuchung ist in fuenf Phasen strukturiert : Eroeffnung Ermittlung , von Beziehungsepisoden , von Selbsterleben , von Objekterleben und der Psychotherapiemotivation sowie Behandlungsvoraussetzungen und Einsichtsfaehigkeit . Die syndromale Diagnostik nach ICD 10 wird in einer abschliessenden Phase ermittelt . Die entwickelte psychodynamisch-diagnostische Untersuchung kann als Erstinterview oder auch in spaeteren Phasen eingesetzt werden . Sie wird ueber die OPD-Diagnostik hinaus auch zur klinischen Anwendung empfohlen .	[ "Auf", "der", "Grundlage", "der", "bisherigen", "Modelle", "zur", "psychodynamischen", "Diagnostik", "und", "der", "psychoanalytischen", "Interviewtechnik", "sowie", "den", "theoretischen", "Konzepten", "der", "fuenf", "Achsen", "der", "OPD", "-", "Diagnostik", "wird", "eine", "psychodynamisch", "-", "diagnostische", "Untersuchung", "konzeptualisiert", ".", "Die", "Untersuchung", "ist", "in", "fuenf", "Phasen", "strukturiert", ":", "Eroeffnung", "Ermittlung", ",", "von", "Beziehungsepisoden", ",", "von", "Selbsterleben", ",", "von", "Objekterleben", "und", "der", "Psychotherapiemotivation", "sowie", "Behandlungsvoraussetzungen", "und", "Einsichtsfaehigkeit", ".", "Die", "syndromale", "Diagnostik", "nach", "ICD", "10", "wird", "in", "einer", "abschliessenden", "Phase", "ermittelt", ".", "Die", "entwickelte", "psychodynamisch", "-", "diagnostische", "Untersuchung", "kann", "als", "Erstinterview", "oder", "auch", "in", "spaeteren", "Phasen", "eingesetzt", "werden", ".", "Sie", "wird", "ueber", "die", "OPD", "-", "Diagnostik", "hinaus", "auch", "zur", "klinischen", "Anwendung", "empfohlen", "." ]	[ "umlsterm" ]
B - domain deleted recombinant factor VIII preparations is a Intervention_Pharmacological, bioequivalent is a Outcome_Other, BDDrFVIII formulations ( one reconstituted with 5 mL of sterile water , the other reconstituted with 4 mL sodium chloride 0.9 % USP ) is a Intervention_Pharmacological, full - length FVIII preparation ( Hemofil M ) is a Intervention_Control, haemophilia A is a Participant_Condition, blood samples is a Outcome_Physical, FVIII preparations is a Intervention_Pharmacological, Plasma FVIII activity is a Outcome_Physical, time curves is a Outcome_Other, maximum plasma concentration ( Cmax ) and the area under plasma concentration vs . time curves ( AUCs is a Outcome_Physical, ratio of geometric means for Cmax and AUCs is a Outcome_Physical	21167_task0	Sentence: B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate : a randomized , three-way crossover study . BACKGROUND Deletion of the B-domain of recombinant blood coagulation factor VIII ( BDDrFVIII ) increases the manufacturing yield of the product but does not impair in vitro or in vivo functionality . BDDrFVIII ( ReFacto ) has been developed with the additional benefit of being formulated without human albumin . OBJECTIVE The primary objective of this three-way crossover-design study was to compare the pharmacokinetic ( PK ) parameters of two BDDrFVIII formulations ( one reconstituted with 5 mL of sterile water , the other reconstituted with 4 mL sodium chloride 0.9 % USP ) with those of a plasma-derived , full-length FVIII preparation ( Hemofil M ) in patients with haemophilia A to determine bioequivalence . METHODS A series of blood samples were collected over a period of 48 h after i.v . administration of each of the FVIII preparations . Plasma FVIII activity was determined using a validated chromogenic substrate assay . Plasma FVIII activity vs. time curves was characterized for a standard set of PK parameter estimates . Two parameter estimates , the maximum plasma concentration ( Cmax ) and the area under plasma concentration vs. time curves ( AUCs ) , were used to evaluate bioequivalence . The two preparations were considered bioequivalent if the 90 % confidence intervals for the ratio of geometric means for Cmax and AUCs fell within the bioequivalence window of 80 % to 125 % . RESULTS/CONCLUSION Results show that each BDDrFVIII formulation is bioequivalent to Hemofil M and the two formulations of BDDrFVIII are bioequivalent to each other . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Outcome_Other	[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate : a randomized , three-way crossover study . BACKGROUND Deletion of the B-domain of recombinant blood coagulation factor VIII ( BDDrFVIII ) increases the manufacturing yield of the product but does not impair in vitro or in vivo functionality . BDDrFVIII ( ReFacto ) has been developed with the additional benefit of being formulated without human albumin . OBJECTIVE The primary objective of this three-way crossover-design study was to compare the pharmacokinetic ( PK ) parameters of two BDDrFVIII formulations ( one reconstituted with 5 mL of sterile water , the other reconstituted with 4 mL sodium chloride 0.9 % USP ) with those of a plasma-derived , full-length FVIII preparation ( Hemofil M ) in patients with haemophilia A to determine bioequivalence . METHODS A series of blood samples were collected over a period of 48 h after i.v . administration of each of the FVIII preparations . Plasma FVIII activity was determined using a validated chromogenic substrate assay . Plasma FVIII activity vs. time curves was characterized for a standard set of PK parameter estimates . Two parameter estimates , the maximum plasma concentration ( Cmax ) and the area under plasma concentration vs. time curves ( AUCs ) , were used to evaluate bioequivalence . The two preparations were considered bioequivalent if the 90 % confidence intervals for the ratio of geometric means for Cmax and AUCs fell within the bioequivalence window of 80 % to 125 % . RESULTS/CONCLUSION Results show that each BDDrFVIII formulation is bioequivalent to Hemofil M and the two formulations of BDDrFVIII are bioequivalent to each other .	[ "B", "-", "domain", "deleted", "recombinant", "factor", "VIII", "preparations", "are", "bioequivalent", "to", "a", "monoclonal", "antibody", "purified", "plasma", "-", "derived", "factor", "VIII", "concentrate", ":", "a", "randomized", ",", "three", "-", "way", "crossover", "study", ".", "BACKGROUND", "Deletion", "of", "the", "B", "-", "domain", "of", "recombinant", "blood", "coagulation", "factor", "VIII", "(", "BDDrFVIII", ")", "increases", "the", "manufacturing", "yield", "of", "the", "product", "but", "does", "not", "impair", "in", "vitro", "or", "in", "vivo", "functionality", ".", "BDDrFVIII", "(", "ReFacto", ")", "has", "been", "developed", "with", "the", "additional", "benefit", "of", "being", "formulated", "without", "human", "albumin", ".", "OBJECTIVE", "The", "primary", "objective", "of", "this", "three", "-", "way", "crossover", "-", "design", "study", "was", "to", "compare", "the", "pharmacokinetic", "(", "PK", ")", "parameters", "of", "two", "BDDrFVIII", "formulations", "(", "one", "reconstituted", "with", "5", "mL", "of", "sterile", "water", ",", "the", "other", "reconstituted", "with", "4", "mL", "sodium", "chloride", "0.9", "%", "USP", ")", "with", "those", "of", "a", "plasma", "-", "derived", ",", "full", "-", "length", "FVIII", "preparation", "(", "Hemofil", "M", ")", "in", "patients", "with", "haemophilia", "A", "to", "determine", "bioequivalence", ".", "METHODS", "A", "series", "of", "blood", "samples", "were", "collected", "over", "a", "period", "of", "48", "h", "after", "i.v", ".", "administration", "of", "each", "of", "the", "FVIII", "preparations", ".", "Plasma", "FVIII", "activity", "was", "determined", "using", "a", "validated", "chromogenic", "substrate", "assay", ".", "Plasma", "FVIII", "activity", "vs", ".", "time", "curves", "was", "characterized", "for", "a", "standard", "set", "of", "PK", "parameter", "estimates", ".", "Two", "parameter", "estimates", ",", "the", "maximum", "plasma", "concentration", "(", "Cmax", ")", "and", "the", "area", "under", "plasma", "concentration", "vs", ".", "time", "curves", "(", "AUCs", ")", ",", "were", "used", "to", "evaluate", "bioequivalence", ".", "The", "two", "preparations", "were", "considered", "bioequivalent", "if", "the", "90", "%", "confidence", "intervals", "for", "the", "ratio", "of", "geometric", "means", "for", "Cmax", "and", "AUCs", "fell", "within", "the", "bioequivalence", "window", "of", "80", "%", "to", "125", "%", ".", "RESULTS", "/", "CONCLUSION", "Results", "show", "that", "each", "BDDrFVIII", "formulation", "is", "bioequivalent", "to", "Hemofil", "M", "and", "the", "two", "formulations", "of", "BDDrFVIII", "are", "bioequivalent", "to", "each", "other", "." ]	[ "Intervention_Pharmacological", "Outcome_Physical", "Intervention_Control", "Outcome_Other", "Participant_Condition" ]
B - domain deleted recombinant factor VIII preparations is a Intervention_Pharmacological, bioequivalent is a Outcome_Other, BDDrFVIII formulations ( one reconstituted with 5 mL of sterile water , the other reconstituted with 4 mL sodium chloride 0.9 % USP ) is a Intervention_Pharmacological, full - length FVIII preparation ( Hemofil M ) is a Intervention_Control, haemophilia A is a Participant_Condition, blood samples is a Outcome_Physical, FVIII preparations is a Intervention_Pharmacological, Plasma FVIII activity is a Outcome_Physical, time curves is a Outcome_Other, maximum plasma concentration ( Cmax ) and the area under plasma concentration vs . time curves ( AUCs is a Outcome_Physical, ratio of geometric means for Cmax and AUCs is a Outcome_Physical	21167_task1	Sentence: B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate : a randomized , three-way crossover study . BACKGROUND Deletion of the B-domain of recombinant blood coagulation factor VIII ( BDDrFVIII ) increases the manufacturing yield of the product but does not impair in vitro or in vivo functionality . BDDrFVIII ( ReFacto ) has been developed with the additional benefit of being formulated without human albumin . OBJECTIVE The primary objective of this three-way crossover-design study was to compare the pharmacokinetic ( PK ) parameters of two BDDrFVIII formulations ( one reconstituted with 5 mL of sterile water , the other reconstituted with 4 mL sodium chloride 0.9 % USP ) with those of a plasma-derived , full-length FVIII preparation ( Hemofil M ) in patients with haemophilia A to determine bioequivalence . METHODS A series of blood samples were collected over a period of 48 h after i.v . administration of each of the FVIII preparations . Plasma FVIII activity was determined using a validated chromogenic substrate assay . Plasma FVIII activity vs. time curves was characterized for a standard set of PK parameter estimates . Two parameter estimates , the maximum plasma concentration ( Cmax ) and the area under plasma concentration vs. time curves ( AUCs ) , were used to evaluate bioequivalence . The two preparations were considered bioequivalent if the 90 % confidence intervals for the ratio of geometric means for Cmax and AUCs fell within the bioequivalence window of 80 % to 125 % . RESULTS/CONCLUSION Results show that each BDDrFVIII formulation is bioequivalent to Hemofil M and the two formulations of BDDrFVIII are bioequivalent to each other . Instructions: please typing these entity words according to sentence: B - domain deleted recombinant factor VIII preparations, bioequivalent, BDDrFVIII formulations ( one reconstituted with 5 mL of sterile water , the other reconstituted with 4 mL sodium chloride 0.9 % USP ), full - length FVIII preparation ( Hemofil M ), haemophilia A, blood samples, FVIII preparations, Plasma FVIII activity, time curves, maximum plasma concentration ( Cmax ) and the area under plasma concentration vs . time curves ( AUCs, ratio of geometric means for Cmax and AUCs Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Outcome_Other	[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate : a randomized , three-way crossover study . BACKGROUND Deletion of the B-domain of recombinant blood coagulation factor VIII ( BDDrFVIII ) increases the manufacturing yield of the product but does not impair in vitro or in vivo functionality . BDDrFVIII ( ReFacto ) has been developed with the additional benefit of being formulated without human albumin . OBJECTIVE The primary objective of this three-way crossover-design study was to compare the pharmacokinetic ( PK ) parameters of two BDDrFVIII formulations ( one reconstituted with 5 mL of sterile water , the other reconstituted with 4 mL sodium chloride 0.9 % USP ) with those of a plasma-derived , full-length FVIII preparation ( Hemofil M ) in patients with haemophilia A to determine bioequivalence . METHODS A series of blood samples were collected over a period of 48 h after i.v . administration of each of the FVIII preparations . Plasma FVIII activity was determined using a validated chromogenic substrate assay . Plasma FVIII activity vs. time curves was characterized for a standard set of PK parameter estimates . Two parameter estimates , the maximum plasma concentration ( Cmax ) and the area under plasma concentration vs. time curves ( AUCs ) , were used to evaluate bioequivalence . The two preparations were considered bioequivalent if the 90 % confidence intervals for the ratio of geometric means for Cmax and AUCs fell within the bioequivalence window of 80 % to 125 % . RESULTS/CONCLUSION Results show that each BDDrFVIII formulation is bioequivalent to Hemofil M and the two formulations of BDDrFVIII are bioequivalent to each other .	[ "B", "-", "domain", "deleted", "recombinant", "factor", "VIII", "preparations", "are", "bioequivalent", "to", "a", "monoclonal", "antibody", "purified", "plasma", "-", "derived", "factor", "VIII", "concentrate", ":", "a", "randomized", ",", "three", "-", "way", "crossover", "study", ".", "BACKGROUND", "Deletion", "of", "the", "B", "-", "domain", "of", "recombinant", "blood", "coagulation", "factor", "VIII", "(", "BDDrFVIII", ")", "increases", "the", "manufacturing", "yield", "of", "the", "product", "but", "does", "not", "impair", "in", "vitro", "or", "in", "vivo", "functionality", ".", "BDDrFVIII", "(", "ReFacto", ")", "has", "been", "developed", "with", "the", "additional", "benefit", "of", "being", "formulated", "without", "human", "albumin", ".", "OBJECTIVE", "The", "primary", "objective", "of", "this", "three", "-", "way", "crossover", "-", "design", "study", "was", "to", "compare", "the", "pharmacokinetic", "(", "PK", ")", "parameters", "of", "two", "BDDrFVIII", "formulations", "(", "one", "reconstituted", "with", "5", "mL", "of", "sterile", "water", ",", "the", "other", "reconstituted", "with", "4", "mL", "sodium", "chloride", "0.9", "%", "USP", ")", "with", "those", "of", "a", "plasma", "-", "derived", ",", "full", "-", "length", "FVIII", "preparation", "(", "Hemofil", "M", ")", "in", "patients", "with", "haemophilia", "A", "to", "determine", "bioequivalence", ".", "METHODS", "A", "series", "of", "blood", "samples", "were", "collected", "over", "a", "period", "of", "48", "h", "after", "i.v", ".", "administration", "of", "each", "of", "the", "FVIII", "preparations", ".", "Plasma", "FVIII", "activity", "was", "determined", "using", "a", "validated", "chromogenic", "substrate", "assay", ".", "Plasma", "FVIII", "activity", "vs", ".", "time", "curves", "was", "characterized", "for", "a", "standard", "set", "of", "PK", "parameter", "estimates", ".", "Two", "parameter", "estimates", ",", "the", "maximum", "plasma", "concentration", "(", "Cmax", ")", "and", "the", "area", "under", "plasma", "concentration", "vs", ".", "time", "curves", "(", "AUCs", ")", ",", "were", "used", "to", "evaluate", "bioequivalence", ".", "The", "two", "preparations", "were", "considered", "bioequivalent", "if", "the", "90", "%", "confidence", "intervals", "for", "the", "ratio", "of", "geometric", "means", "for", "Cmax", "and", "AUCs", "fell", "within", "the", "bioequivalence", "window", "of", "80", "%", "to", "125", "%", ".", "RESULTS", "/", "CONCLUSION", "Results", "show", "that", "each", "BDDrFVIII", "formulation", "is", "bioequivalent", "to", "Hemofil", "M", "and", "the", "two", "formulations", "of", "BDDrFVIII", "are", "bioequivalent", "to", "each", "other", "." ]	[ "Intervention_Pharmacological", "Outcome_Physical", "Intervention_Control", "Outcome_Other", "Participant_Condition" ]
B - domain deleted recombinant factor VIII preparations, bioequivalent, BDDrFVIII formulations ( one reconstituted with 5 mL of sterile water , the other reconstituted with 4 mL sodium chloride 0.9 % USP ), full - length FVIII preparation ( Hemofil M ), haemophilia A, blood samples, FVIII preparations, Plasma FVIII activity, time curves, maximum plasma concentration ( Cmax ) and the area under plasma concentration vs . time curves ( AUCs, ratio of geometric means for Cmax and AUCs	21167_task2	Sentence: B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate : a randomized , three-way crossover study . BACKGROUND Deletion of the B-domain of recombinant blood coagulation factor VIII ( BDDrFVIII ) increases the manufacturing yield of the product but does not impair in vitro or in vivo functionality . BDDrFVIII ( ReFacto ) has been developed with the additional benefit of being formulated without human albumin . OBJECTIVE The primary objective of this three-way crossover-design study was to compare the pharmacokinetic ( PK ) parameters of two BDDrFVIII formulations ( one reconstituted with 5 mL of sterile water , the other reconstituted with 4 mL sodium chloride 0.9 % USP ) with those of a plasma-derived , full-length FVIII preparation ( Hemofil M ) in patients with haemophilia A to determine bioequivalence . METHODS A series of blood samples were collected over a period of 48 h after i.v . administration of each of the FVIII preparations . Plasma FVIII activity was determined using a validated chromogenic substrate assay . Plasma FVIII activity vs. time curves was characterized for a standard set of PK parameter estimates . Two parameter estimates , the maximum plasma concentration ( Cmax ) and the area under plasma concentration vs. time curves ( AUCs ) , were used to evaluate bioequivalence . The two preparations were considered bioequivalent if the 90 % confidence intervals for the ratio of geometric means for Cmax and AUCs fell within the bioequivalence window of 80 % to 125 % . RESULTS/CONCLUSION Results show that each BDDrFVIII formulation is bioequivalent to Hemofil M and the two formulations of BDDrFVIII are bioequivalent to each other . Instructions: please extract entity words from the input sentence	[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate : a randomized , three-way crossover study . BACKGROUND Deletion of the B-domain of recombinant blood coagulation factor VIII ( BDDrFVIII ) increases the manufacturing yield of the product but does not impair in vitro or in vivo functionality . BDDrFVIII ( ReFacto ) has been developed with the additional benefit of being formulated without human albumin . OBJECTIVE The primary objective of this three-way crossover-design study was to compare the pharmacokinetic ( PK ) parameters of two BDDrFVIII formulations ( one reconstituted with 5 mL of sterile water , the other reconstituted with 4 mL sodium chloride 0.9 % USP ) with those of a plasma-derived , full-length FVIII preparation ( Hemofil M ) in patients with haemophilia A to determine bioequivalence . METHODS A series of blood samples were collected over a period of 48 h after i.v . administration of each of the FVIII preparations . Plasma FVIII activity was determined using a validated chromogenic substrate assay . Plasma FVIII activity vs. time curves was characterized for a standard set of PK parameter estimates . Two parameter estimates , the maximum plasma concentration ( Cmax ) and the area under plasma concentration vs. time curves ( AUCs ) , were used to evaluate bioequivalence . The two preparations were considered bioequivalent if the 90 % confidence intervals for the ratio of geometric means for Cmax and AUCs fell within the bioequivalence window of 80 % to 125 % . RESULTS/CONCLUSION Results show that each BDDrFVIII formulation is bioequivalent to Hemofil M and the two formulations of BDDrFVIII are bioequivalent to each other .	[ "B", "-", "domain", "deleted", "recombinant", "factor", "VIII", "preparations", "are", "bioequivalent", "to", "a", "monoclonal", "antibody", "purified", "plasma", "-", "derived", "factor", "VIII", "concentrate", ":", "a", "randomized", ",", "three", "-", "way", "crossover", "study", ".", "BACKGROUND", "Deletion", "of", "the", "B", "-", "domain", "of", "recombinant", "blood", "coagulation", "factor", "VIII", "(", "BDDrFVIII", ")", "increases", "the", "manufacturing", "yield", "of", "the", "product", "but", "does", "not", "impair", "in", "vitro", "or", "in", "vivo", "functionality", ".", "BDDrFVIII", "(", "ReFacto", ")", "has", "been", "developed", "with", "the", "additional", "benefit", "of", "being", "formulated", "without", "human", "albumin", ".", "OBJECTIVE", "The", "primary", "objective", "of", "this", "three", "-", "way", "crossover", "-", "design", "study", "was", "to", "compare", "the", "pharmacokinetic", "(", "PK", ")", "parameters", "of", "two", "BDDrFVIII", "formulations", "(", "one", "reconstituted", "with", "5", "mL", "of", "sterile", "water", ",", "the", "other", "reconstituted", "with", "4", "mL", "sodium", "chloride", "0.9", "%", "USP", ")", "with", "those", "of", "a", "plasma", "-", "derived", ",", "full", "-", "length", "FVIII", "preparation", "(", "Hemofil", "M", ")", "in", "patients", "with", "haemophilia", "A", "to", "determine", "bioequivalence", ".", "METHODS", "A", "series", "of", "blood", "samples", "were", "collected", "over", "a", "period", "of", "48", "h", "after", "i.v", ".", "administration", "of", "each", "of", "the", "FVIII", "preparations", ".", "Plasma", "FVIII", "activity", "was", "determined", "using", "a", "validated", "chromogenic", "substrate", "assay", ".", "Plasma", "FVIII", "activity", "vs", ".", "time", "curves", "was", "characterized", "for", "a", "standard", "set", "of", "PK", "parameter", "estimates", ".", "Two", "parameter", "estimates", ",", "the", "maximum", "plasma", "concentration", "(", "Cmax", ")", "and", "the", "area", "under", "plasma", "concentration", "vs", ".", "time", "curves", "(", "AUCs", ")", ",", "were", "used", "to", "evaluate", "bioequivalence", ".", "The", "two", "preparations", "were", "considered", "bioequivalent", "if", "the", "90", "%", "confidence", "intervals", "for", "the", "ratio", "of", "geometric", "means", "for", "Cmax", "and", "AUCs", "fell", "within", "the", "bioequivalence", "window", "of", "80", "%", "to", "125", "%", ".", "RESULTS", "/", "CONCLUSION", "Results", "show", "that", "each", "BDDrFVIII", "formulation", "is", "bioequivalent", "to", "Hemofil", "M", "and", "the", "two", "formulations", "of", "BDDrFVIII", "are", "bioequivalent", "to", "each", "other", "." ]	[ "Intervention_Pharmacological", "Outcome_Physical", "Intervention_Control", "Outcome_Other", "Participant_Condition" ]
E - cadherin is a Individual_protein, alpha - catenin is a Individual_protein, beta - catenin is a Individual_protein	133_task0	Sentence: These results suggest that the dysfunction of E-cadherin in these cell lines is due primarily to its failure to interact with alpha-catenin, and that this defect results from the mutation in beta-catenin. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein	[ "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O" ]	These results suggest that the dysfunction of E-cadherin in these cell lines is due primarily to its failure to interact with alpha-catenin, and that this defect results from the mutation in beta-catenin.	[ "These", "results", "suggest", "that", "the", "dysfunction", "of", "E", "-", "cadherin", "in", "these", "cell", "lines", "is", "due", "primarily", "to", "its", "failure", "to", "interact", "with", "alpha", "-", "catenin", ",", "and", "that", "this", "defect", "results", "from", "the", "mutation", "in", "beta", "-", "catenin", "." ]	[ "Individual_protein" ]
E - cadherin is a Individual_protein, alpha - catenin is a Individual_protein, beta - catenin is a Individual_protein	133_task1	Sentence: These results suggest that the dysfunction of E-cadherin in these cell lines is due primarily to its failure to interact with alpha-catenin, and that this defect results from the mutation in beta-catenin. Instructions: please typing these entity words according to sentence: E - cadherin, alpha - catenin, beta - catenin Options: Individual_protein	[ "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O" ]	These results suggest that the dysfunction of E-cadherin in these cell lines is due primarily to its failure to interact with alpha-catenin, and that this defect results from the mutation in beta-catenin.	[ "These", "results", "suggest", "that", "the", "dysfunction", "of", "E", "-", "cadherin", "in", "these", "cell", "lines", "is", "due", "primarily", "to", "its", "failure", "to", "interact", "with", "alpha", "-", "catenin", ",", "and", "that", "this", "defect", "results", "from", "the", "mutation", "in", "beta", "-", "catenin", "." ]	[ "Individual_protein" ]
E - cadherin, alpha - catenin, beta - catenin	133_task2	Sentence: These results suggest that the dysfunction of E-cadherin in these cell lines is due primarily to its failure to interact with alpha-catenin, and that this defect results from the mutation in beta-catenin. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O" ]	These results suggest that the dysfunction of E-cadherin in these cell lines is due primarily to its failure to interact with alpha-catenin, and that this defect results from the mutation in beta-catenin.	[ "These", "results", "suggest", "that", "the", "dysfunction", "of", "E", "-", "cadherin", "in", "these", "cell", "lines", "is", "due", "primarily", "to", "its", "failure", "to", "interact", "with", "alpha", "-", "catenin", ",", "and", "that", "this", "defect", "results", "from", "the", "mutation", "in", "beta", "-", "catenin", "." ]	[ "Individual_protein" ]
Stat3 is a protein_molecule, ligand - induced , tyrosine - phosphorylated docking sites is a protein_domain_or_region, interleukin-10 receptor intracellular domain is a protein_domain_or_region	20598_task0	Sentence: Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein_domain_or_region, protein_molecule	[ "B-protein_molecule", "O", "O", "O", "O", "B-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "O", "O", "B-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "O" ]	Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain.	[ "Stat3", "recruitment", "by", "two", "distinct", "ligand", "-", "induced", ",", "tyrosine", "-", "phosphorylated", "docking", "sites", "in", "the", "interleukin-10", "receptor", "intracellular", "domain", "." ]	[ "protein_molecule", "protein_domain_or_region", "other_name", "peptide", "protein_complex", "protein_family_or_group", "amino_acid_monomer", "cell_line" ]
Stat3 is a protein_molecule, ligand - induced , tyrosine - phosphorylated docking sites is a protein_domain_or_region, interleukin-10 receptor intracellular domain is a protein_domain_or_region	20598_task1	Sentence: Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. Instructions: please typing these entity words according to sentence: Stat3, ligand - induced , tyrosine - phosphorylated docking sites, interleukin-10 receptor intracellular domain Options: protein_domain_or_region, protein_molecule	[ "B-protein_molecule", "O", "O", "O", "O", "B-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "O", "O", "B-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "O" ]	Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain.	[ "Stat3", "recruitment", "by", "two", "distinct", "ligand", "-", "induced", ",", "tyrosine", "-", "phosphorylated", "docking", "sites", "in", "the", "interleukin-10", "receptor", "intracellular", "domain", "." ]	[ "protein_molecule", "protein_domain_or_region", "other_name", "peptide", "protein_complex", "protein_family_or_group", "amino_acid_monomer", "cell_line" ]
Stat3, ligand - induced , tyrosine - phosphorylated docking sites, interleukin-10 receptor intracellular domain	20598_task2	Sentence: Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. Instructions: please extract entity words from the input sentence	[ "B-protein_molecule", "O", "O", "O", "O", "B-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "O", "O", "B-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "O" ]	Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain.	[ "Stat3", "recruitment", "by", "two", "distinct", "ligand", "-", "induced", ",", "tyrosine", "-", "phosphorylated", "docking", "sites", "in", "the", "interleukin-10", "receptor", "intracellular", "domain", "." ]	[ "protein_molecule", "protein_domain_or_region", "other_name", "peptide", "protein_complex", "protein_family_or_group", "amino_acid_monomer", "cell_line" ]

Praevalenzraten, Praevalenzraten, Faehigkeiten, Testleistungen, Einkommensniveau

DerNervenarzt.80690975.ger.abstr_task2

Sentence: Mit dem Terminus " leichte kognitive Beeintraechtigung im Alter " werden kognitive Defizite bezeichnet , die ueber normale Altersbegleiterscheinungen hinausgehen , aber nicht an den Schweregrad einer dementiellen Erkrankung heranreichen . Anhand der Daten von 202 gesunden 60- bis 64jaehrigen Teilnehmern der Interdisziplinaeren Langzeitstudie fuer Erwachsene ( ILSE ) wurden die Praevalenzraten von 4 aktuellen Konzepten der leichten kognitiven Beeintraechtigung verglichen sowie Zusammenhaenge mit moeglichen soziodemographischen und psychologischen Merkmalen untersucht . Die Praevalenzraten betrugen fuer age-associated memory impairment " " 13,5% , fuer age-consistent memory impairment " " 6,5% , fuer late-life forgetfulness " 1,5% " und fuer aging associated cognitive decline " 23,5% . " Es fand sich kein Zusammenhang zwischen den subjektiven Angaben ueber nachlassende kognitive Faehigkeiten und den Ergebnissen der neuropsychologischen Testungen . Dagegen bestanden Zusammenhaenge zwischen subjektiven Beschwerden und psychologischen Variablen wie Depressivitaet und Neurotizismus sowie zwischen niedrigeren Testleistungen und soziodemographischen Variablen wie geringerem Bildungsgrad und Einkommensniveau . Der praediktive Wert der hier untersuchten Konzepte kann erst durch Langzeitstudien definitiv beurteilt werden . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Mit dem Terminus " leichte kognitive Beeintraechtigung im Alter " werden kognitive Defizite bezeichnet , die ueber normale Altersbegleiterscheinungen hinausgehen , aber nicht an den Schweregrad einer dementiellen Erkrankung heranreichen . Anhand der Daten von 202 gesunden 60- bis 64jaehrigen Teilnehmern der Interdisziplinaeren Langzeitstudie fuer Erwachsene ( ILSE ) wurden die Praevalenzraten von 4 aktuellen Konzepten der leichten kognitiven Beeintraechtigung verglichen sowie Zusammenhaenge mit moeglichen soziodemographischen und psychologischen Merkmalen untersucht . Die Praevalenzraten betrugen fuer age-associated memory impairment " " 13,5% , fuer age-consistent memory impairment " " 6,5% , fuer late-life forgetfulness " 1,5% " und fuer aging associated cognitive decline " 23,5% . " Es fand sich kein Zusammenhang zwischen den subjektiven Angaben ueber nachlassende kognitive Faehigkeiten und den Ergebnissen der neuropsychologischen Testungen . Dagegen bestanden Zusammenhaenge zwischen subjektiven Beschwerden und psychologischen Variablen wie Depressivitaet und Neurotizismus sowie zwischen niedrigeren Testleistungen und soziodemographischen Variablen wie geringerem Bildungsgrad und Einkommensniveau . Der praediktive Wert der hier untersuchten Konzepte kann erst durch Langzeitstudien definitiv beurteilt werden .

[ "Mit", "dem", "Terminus", "\"", "leichte", "kognitive", "Beeintraechtigung", "im", "Alter", "\"", "werden", "kognitive", "Defizite", "bezeichnet", ",", "die", "ueber", "normale", "Altersbegleiterscheinungen", "hinausgehen", ",", "aber", "nicht", "an", "den", "Schweregrad", "einer", "dementiellen", "Erkrankung", "heranreichen", ".", "Anhand", "der", "Daten", "von", "202", "gesunden", "60-", "bis", "64jaehrigen", "Teilnehmern", "der", "Interdisziplinaeren", "Langzeitstudie", "fuer", "Erwachsene", "(", "ILSE", ")", "wurden", "die", "Praevalenzraten", "von", "4", "aktuellen", "Konzepten", "der", "leichten", "kognitiven", "Beeintraechtigung", "verglichen", "sowie", "Zusammenhaenge", "mit", "moeglichen", "soziodemographischen", "und", "psychologischen", "Merkmalen", "untersucht", ".", "Die", "Praevalenzraten", "betrugen", "fuer", "age", "-", "associated", "memory", "impairment", "\"", "\"", "13,5", "%", ",", "fuer", "age", "-", "consistent", "memory", "impairment", "\"", "\"", "6,5", "%", ",", "fuer", "late", "-", "life", "forgetfulness", "\"", "1,5", "%", "\"", "und", "fuer", "aging", "associated", "cognitive", "decline", "\"", "23,5", "%", ".", "\"", "Es", "fand", "sich", "kein", "Zusammenhang", "zwischen", "den", "subjektiven", "Angaben", "ueber", "nachlassende", "kognitive", "Faehigkeiten", "und", "den", "Ergebnissen", "der", "neuropsychologischen", "Testungen", ".", "Dagegen", "bestanden", "Zusammenhaenge", "zwischen", "subjektiven", "Beschwerden", "und", "psychologischen", "Variablen", "wie", "Depressivitaet", "und", "Neurotizismus", "sowie", "zwischen", "niedrigeren", "Testleistungen", "und", "soziodemographischen", "Variablen", "wie", "geringerem", "Bildungsgrad", "und", "Einkommensniveau", ".", "Der", "praediktive", "Wert", "der", "hier", "untersuchten", "Konzepte", "kann", "erst", "durch", "Langzeitstudien", "definitiv", "beurteilt", "werden", "." ]

[ "umlsterm" ]

measurements is an umlsterm, hemoglobin is an umlsterm, oxygenation is an umlsterm, human is an umlsterm, cochlea is an umlsterm, round window is an umlsterm, membrane is an umlsterm, aim is an umlsterm, microlight is an umlsterm, measurements is an umlsterm, round window is an umlsterm, procedure is an umlsterm, cochlea is an umlsterm

HNO.70450372.eng.abstr_task0

Sentence: Background : Intraoperative measurements of local intracapillary hemoglobin oxygenation of the human cochlea via the round window membrane have been shown to be possible using the Erlangen microlight-guided spectrophotometer . The aim of the present study was to develop a new microlight guide suitable for measurements in the round window niche and to evaluate electrophysiologically the possible impact of the procedure on the cochlea . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]

Background : Intraoperative measurements of local intracapillary hemoglobin oxygenation of the human cochlea via the round window membrane have been shown to be possible using the Erlangen microlight-guided spectrophotometer . The aim of the present study was to develop a new microlight guide suitable for measurements in the round window niche and to evaluate electrophysiologically the possible impact of the procedure on the cochlea .

[ "Background", ":", "Intraoperative", "measurements", "of", "local", "intracapillary", "hemoglobin", "oxygenation", "of", "the", "human", "cochlea", "via", "the", "round", "window", "membrane", "have", "been", "shown", "to", "be", "possible", "using", "the", "Erlangen", "microlight", "-", "guided", "spectrophotometer", ".", "The", "aim", "of", "the", "present", "study", "was", "to", "develop", "a", "new", "microlight", "guide", "suitable", "for", "measurements", "in", "the", "round", "window", "niche", "and", "to", "evaluate", "electrophysiologically", "the", "possible", "impact", "of", "the", "procedure", "on", "the", "cochlea", "." ]

[ "umlsterm" ]

measurements is an umlsterm, hemoglobin is an umlsterm, oxygenation is an umlsterm, human is an umlsterm, cochlea is an umlsterm, round window is an umlsterm, membrane is an umlsterm, aim is an umlsterm, microlight is an umlsterm, measurements is an umlsterm, round window is an umlsterm, procedure is an umlsterm, cochlea is an umlsterm

HNO.70450372.eng.abstr_task1

Sentence: Background : Intraoperative measurements of local intracapillary hemoglobin oxygenation of the human cochlea via the round window membrane have been shown to be possible using the Erlangen microlight-guided spectrophotometer . The aim of the present study was to develop a new microlight guide suitable for measurements in the round window niche and to evaluate electrophysiologically the possible impact of the procedure on the cochlea . Instructions: please typing these entity words according to sentence: measurements, hemoglobin, oxygenation, human, cochlea, round window, membrane, aim, microlight, measurements, round window, procedure, cochlea Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]

Background : Intraoperative measurements of local intracapillary hemoglobin oxygenation of the human cochlea via the round window membrane have been shown to be possible using the Erlangen microlight-guided spectrophotometer . The aim of the present study was to develop a new microlight guide suitable for measurements in the round window niche and to evaluate electrophysiologically the possible impact of the procedure on the cochlea .

[ "Background", ":", "Intraoperative", "measurements", "of", "local", "intracapillary", "hemoglobin", "oxygenation", "of", "the", "human", "cochlea", "via", "the", "round", "window", "membrane", "have", "been", "shown", "to", "be", "possible", "using", "the", "Erlangen", "microlight", "-", "guided", "spectrophotometer", ".", "The", "aim", "of", "the", "present", "study", "was", "to", "develop", "a", "new", "microlight", "guide", "suitable", "for", "measurements", "in", "the", "round", "window", "niche", "and", "to", "evaluate", "electrophysiologically", "the", "possible", "impact", "of", "the", "procedure", "on", "the", "cochlea", "." ]

[ "umlsterm" ]

measurements, hemoglobin, oxygenation, human, cochlea, round window, membrane, aim, microlight, measurements, round window, procedure, cochlea

HNO.70450372.eng.abstr_task2

Sentence: Background : Intraoperative measurements of local intracapillary hemoglobin oxygenation of the human cochlea via the round window membrane have been shown to be possible using the Erlangen microlight-guided spectrophotometer . The aim of the present study was to develop a new microlight guide suitable for measurements in the round window niche and to evaluate electrophysiologically the possible impact of the procedure on the cochlea . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]

Background : Intraoperative measurements of local intracapillary hemoglobin oxygenation of the human cochlea via the round window membrane have been shown to be possible using the Erlangen microlight-guided spectrophotometer . The aim of the present study was to develop a new microlight guide suitable for measurements in the round window niche and to evaluate electrophysiologically the possible impact of the procedure on the cochlea .

[ "Background", ":", "Intraoperative", "measurements", "of", "local", "intracapillary", "hemoglobin", "oxygenation", "of", "the", "human", "cochlea", "via", "the", "round", "window", "membrane", "have", "been", "shown", "to", "be", "possible", "using", "the", "Erlangen", "microlight", "-", "guided", "spectrophotometer", ".", "The", "aim", "of", "the", "present", "study", "was", "to", "develop", "a", "new", "microlight", "guide", "suitable", "for", "measurements", "in", "the", "round", "window", "niche", "and", "to", "evaluate", "electrophysiologically", "the", "possible", "impact", "of", "the", "procedure", "on", "the", "cochlea", "." ]

[ "umlsterm" ]

mitogen - activated protein kinase pathways is an other_name, interleukin-8 production is an other_name, human monocytes is a cell_type, polymorphonuclear cells is a cell_type, lipopolysaccharide is a lipid, Mycoplasma fermentans membrane lipoproteins is a protein_family_or_group

52179_task0

Sentence: Involvement of mitogen-activated protein kinase pathways in interleukin-8 production by human monocytes and polymorphonuclear cells stimulated with lipopolysaccharide or Mycoplasma fermentans membrane lipoproteins. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_type, protein_family_or_group, lipid, other_name

[ "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "O", "B-cell_type", "I-cell_type", "O", "B-cell_type", "I-cell_type", "O", "O", "B-lipid", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O" ]

Involvement of mitogen-activated protein kinase pathways in interleukin-8 production by human monocytes and polymorphonuclear cells stimulated with lipopolysaccharide or Mycoplasma fermentans membrane lipoproteins.

[ "Involvement", "of", "mitogen", "-", "activated", "protein", "kinase", "pathways", "in", "interleukin-8", "production", "by", "human", "monocytes", "and", "polymorphonuclear", "cells", "stimulated", "with", "lipopolysaccharide", "or", "Mycoplasma", "fermentans", "membrane", "lipoproteins", "." ]

[ "protein_family_or_group", "other_name", "cell_line", "cell_type", "protein_molecule", "(AND other_name other_name)", "mono_cell", "other_organic_compound", "lipid", "" ]

mitogen - activated protein kinase pathways is an other_name, interleukin-8 production is an other_name, human monocytes is a cell_type, polymorphonuclear cells is a cell_type, lipopolysaccharide is a lipid, Mycoplasma fermentans membrane lipoproteins is a protein_family_or_group

52179_task1

Sentence: Involvement of mitogen-activated protein kinase pathways in interleukin-8 production by human monocytes and polymorphonuclear cells stimulated with lipopolysaccharide or Mycoplasma fermentans membrane lipoproteins. Instructions: please typing these entity words according to sentence: mitogen - activated protein kinase pathways, interleukin-8 production, human monocytes, polymorphonuclear cells, lipopolysaccharide, Mycoplasma fermentans membrane lipoproteins Options: cell_type, protein_family_or_group, lipid, other_name

[ "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "O", "B-cell_type", "I-cell_type", "O", "B-cell_type", "I-cell_type", "O", "O", "B-lipid", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O" ]

Involvement of mitogen-activated protein kinase pathways in interleukin-8 production by human monocytes and polymorphonuclear cells stimulated with lipopolysaccharide or Mycoplasma fermentans membrane lipoproteins.

[ "Involvement", "of", "mitogen", "-", "activated", "protein", "kinase", "pathways", "in", "interleukin-8", "production", "by", "human", "monocytes", "and", "polymorphonuclear", "cells", "stimulated", "with", "lipopolysaccharide", "or", "Mycoplasma", "fermentans", "membrane", "lipoproteins", "." ]

[ "protein_family_or_group", "other_name", "cell_line", "cell_type", "protein_molecule", "(AND other_name other_name)", "mono_cell", "other_organic_compound", "lipid", "" ]

mitogen - activated protein kinase pathways, interleukin-8 production, human monocytes, polymorphonuclear cells, lipopolysaccharide, Mycoplasma fermentans membrane lipoproteins

52179_task2

Sentence: Involvement of mitogen-activated protein kinase pathways in interleukin-8 production by human monocytes and polymorphonuclear cells stimulated with lipopolysaccharide or Mycoplasma fermentans membrane lipoproteins. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "O", "B-cell_type", "I-cell_type", "O", "B-cell_type", "I-cell_type", "O", "O", "B-lipid", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O" ]

Involvement of mitogen-activated protein kinase pathways in interleukin-8 production by human monocytes and polymorphonuclear cells stimulated with lipopolysaccharide or Mycoplasma fermentans membrane lipoproteins.

[ "Involvement", "of", "mitogen", "-", "activated", "protein", "kinase", "pathways", "in", "interleukin-8", "production", "by", "human", "monocytes", "and", "polymorphonuclear", "cells", "stimulated", "with", "lipopolysaccharide", "or", "Mycoplasma", "fermentans", "membrane", "lipoproteins", "." ]

[ "protein_family_or_group", "other_name", "cell_line", "cell_type", "protein_molecule", "(AND other_name other_name)", "mono_cell", "other_organic_compound", "lipid", "" ]

youth is a Participant_Age, autism spectrum disorders is a Participant_Condition, autism spectrum disorders ( ASD ) is a Participant_Condition, Project SEARCH plus ASD Supports is a Intervention_Other, employment outcomes is a Outcome_Mental, 18 - 21 is a Participant_Age, non - traditional jobs is a Outcome_Other, control is a Intervention_Control, 24 is a Participant_Sample-size, acquired employment is a Outcome_Mental, 16 is a Participant_Sample-size

60692_task0

Sentence: Competitive employment for youth with autism spectrum disorders : early results from a randomized clinical trial . For most youth with autism spectrum disorders ( ASD ) , employment upon graduation from high school or college is elusive . Employment rates are reported in many studies to be very low despite many years of intensive special education services . This paper presented the preliminary results of a randomized clinical trial of Project SEARCH plus ASD Supports on the employment outcomes for youth with ASD between the ages of 18-21 years of age . This model provides very promising results in that the employment outcomes for youth in the treatment group were much higher in non-traditional jobs with higher than minimum wage incomes than for youth in the control condition . Specifically , 21 out of 24 ( 87.5 % ) treatment group participants acquired employment while 1 of 16 ( 6.25 % ) of control group participants acquired employment . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Participant_Condition, Intervention_Control, Intervention_Other, Participant_Age, Participant_Sample-size, Outcome_Other, Outcome_Mental

[ "O", "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Competitive employment for youth with autism spectrum disorders : early results from a randomized clinical trial . For most youth with autism spectrum disorders ( ASD ) , employment upon graduation from high school or college is elusive . Employment rates are reported in many studies to be very low despite many years of intensive special education services . This paper presented the preliminary results of a randomized clinical trial of Project SEARCH plus ASD Supports on the employment outcomes for youth with ASD between the ages of 18-21 years of age . This model provides very promising results in that the employment outcomes for youth in the treatment group were much higher in non-traditional jobs with higher than minimum wage incomes than for youth in the control condition . Specifically , 21 out of 24 ( 87.5 % ) treatment group participants acquired employment while 1 of 16 ( 6.25 % ) of control group participants acquired employment .

[ "Competitive", "employment", "for", "youth", "with", "autism", "spectrum", "disorders", ":", "early", "results", "from", "a", "randomized", "clinical", "trial", ".", "For", "most", "youth", "with", "autism", "spectrum", "disorders", "(", "ASD", ")", ",", "employment", "upon", "graduation", "from", "high", "school", "or", "college", "is", "elusive", ".", "Employment", "rates", "are", "reported", "in", "many", "studies", "to", "be", "very", "low", "despite", "many", "years", "of", "intensive", "special", "education", "services", ".", "This", "paper", "presented", "the", "preliminary", "results", "of", "a", "randomized", "clinical", "trial", "of", "Project", "SEARCH", "plus", "ASD", "Supports", "on", "the", "employment", "outcomes", "for", "youth", "with", "ASD", "between", "the", "ages", "of", "18", "-", "21", "years", "of", "age", ".", "This", "model", "provides", "very", "promising", "results", "in", "that", "the", "employment", "outcomes", "for", "youth", "in", "the", "treatment", "group", "were", "much", "higher", "in", "non", "-", "traditional", "jobs", "with", "higher", "than", "minimum", "wage", "incomes", "than", "for", "youth", "in", "the", "control", "condition", ".", "Specifically", ",", "21", "out", "of", "24", "(", "87.5", "%", ")", "treatment", "group", "participants", "acquired", "employment", "while", "1", "of", "16", "(", "6.25", "%", ")", "of", "control", "group", "participants", "acquired", "employment", "." ]

[ "Participant_Condition", "Intervention_Other", "Outcome_Other", "Outcome_Mental", "Intervention_Control", "Participant_Age", "Participant_Sample-size" ]

youth is a Participant_Age, autism spectrum disorders is a Participant_Condition, autism spectrum disorders ( ASD ) is a Participant_Condition, Project SEARCH plus ASD Supports is a Intervention_Other, employment outcomes is a Outcome_Mental, 18 - 21 is a Participant_Age, non - traditional jobs is a Outcome_Other, control is a Intervention_Control, 24 is a Participant_Sample-size, acquired employment is a Outcome_Mental, 16 is a Participant_Sample-size

60692_task1

Sentence: Competitive employment for youth with autism spectrum disorders : early results from a randomized clinical trial . For most youth with autism spectrum disorders ( ASD ) , employment upon graduation from high school or college is elusive . Employment rates are reported in many studies to be very low despite many years of intensive special education services . This paper presented the preliminary results of a randomized clinical trial of Project SEARCH plus ASD Supports on the employment outcomes for youth with ASD between the ages of 18-21 years of age . This model provides very promising results in that the employment outcomes for youth in the treatment group were much higher in non-traditional jobs with higher than minimum wage incomes than for youth in the control condition . Specifically , 21 out of 24 ( 87.5 % ) treatment group participants acquired employment while 1 of 16 ( 6.25 % ) of control group participants acquired employment . Instructions: please typing these entity words according to sentence: youth, autism spectrum disorders, autism spectrum disorders ( ASD ), Project SEARCH plus ASD Supports, employment outcomes, 18 - 21, non - traditional jobs, control, 24, acquired employment, 16 Options: Participant_Condition, Intervention_Control, Intervention_Other, Participant_Age, Participant_Sample-size, Outcome_Other, Outcome_Mental

[ "O", "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Competitive employment for youth with autism spectrum disorders : early results from a randomized clinical trial . For most youth with autism spectrum disorders ( ASD ) , employment upon graduation from high school or college is elusive . Employment rates are reported in many studies to be very low despite many years of intensive special education services . This paper presented the preliminary results of a randomized clinical trial of Project SEARCH plus ASD Supports on the employment outcomes for youth with ASD between the ages of 18-21 years of age . This model provides very promising results in that the employment outcomes for youth in the treatment group were much higher in non-traditional jobs with higher than minimum wage incomes than for youth in the control condition . Specifically , 21 out of 24 ( 87.5 % ) treatment group participants acquired employment while 1 of 16 ( 6.25 % ) of control group participants acquired employment .

[ "Competitive", "employment", "for", "youth", "with", "autism", "spectrum", "disorders", ":", "early", "results", "from", "a", "randomized", "clinical", "trial", ".", "For", "most", "youth", "with", "autism", "spectrum", "disorders", "(", "ASD", ")", ",", "employment", "upon", "graduation", "from", "high", "school", "or", "college", "is", "elusive", ".", "Employment", "rates", "are", "reported", "in", "many", "studies", "to", "be", "very", "low", "despite", "many", "years", "of", "intensive", "special", "education", "services", ".", "This", "paper", "presented", "the", "preliminary", "results", "of", "a", "randomized", "clinical", "trial", "of", "Project", "SEARCH", "plus", "ASD", "Supports", "on", "the", "employment", "outcomes", "for", "youth", "with", "ASD", "between", "the", "ages", "of", "18", "-", "21", "years", "of", "age", ".", "This", "model", "provides", "very", "promising", "results", "in", "that", "the", "employment", "outcomes", "for", "youth", "in", "the", "treatment", "group", "were", "much", "higher", "in", "non", "-", "traditional", "jobs", "with", "higher", "than", "minimum", "wage", "incomes", "than", "for", "youth", "in", "the", "control", "condition", ".", "Specifically", ",", "21", "out", "of", "24", "(", "87.5", "%", ")", "treatment", "group", "participants", "acquired", "employment", "while", "1", "of", "16", "(", "6.25", "%", ")", "of", "control", "group", "participants", "acquired", "employment", "." ]

[ "Participant_Condition", "Intervention_Other", "Outcome_Other", "Outcome_Mental", "Intervention_Control", "Participant_Age", "Participant_Sample-size" ]

youth, autism spectrum disorders, autism spectrum disorders ( ASD ), Project SEARCH plus ASD Supports, employment outcomes, 18 - 21, non - traditional jobs, control, 24, acquired employment, 16

60692_task2

Sentence: Competitive employment for youth with autism spectrum disorders : early results from a randomized clinical trial . For most youth with autism spectrum disorders ( ASD ) , employment upon graduation from high school or college is elusive . Employment rates are reported in many studies to be very low despite many years of intensive special education services . This paper presented the preliminary results of a randomized clinical trial of Project SEARCH plus ASD Supports on the employment outcomes for youth with ASD between the ages of 18-21 years of age . This model provides very promising results in that the employment outcomes for youth in the treatment group were much higher in non-traditional jobs with higher than minimum wage incomes than for youth in the control condition . Specifically , 21 out of 24 ( 87.5 % ) treatment group participants acquired employment while 1 of 16 ( 6.25 % ) of control group participants acquired employment . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Competitive employment for youth with autism spectrum disorders : early results from a randomized clinical trial . For most youth with autism spectrum disorders ( ASD ) , employment upon graduation from high school or college is elusive . Employment rates are reported in many studies to be very low despite many years of intensive special education services . This paper presented the preliminary results of a randomized clinical trial of Project SEARCH plus ASD Supports on the employment outcomes for youth with ASD between the ages of 18-21 years of age . This model provides very promising results in that the employment outcomes for youth in the treatment group were much higher in non-traditional jobs with higher than minimum wage incomes than for youth in the control condition . Specifically , 21 out of 24 ( 87.5 % ) treatment group participants acquired employment while 1 of 16 ( 6.25 % ) of control group participants acquired employment .

[ "Competitive", "employment", "for", "youth", "with", "autism", "spectrum", "disorders", ":", "early", "results", "from", "a", "randomized", "clinical", "trial", ".", "For", "most", "youth", "with", "autism", "spectrum", "disorders", "(", "ASD", ")", ",", "employment", "upon", "graduation", "from", "high", "school", "or", "college", "is", "elusive", ".", "Employment", "rates", "are", "reported", "in", "many", "studies", "to", "be", "very", "low", "despite", "many", "years", "of", "intensive", "special", "education", "services", ".", "This", "paper", "presented", "the", "preliminary", "results", "of", "a", "randomized", "clinical", "trial", "of", "Project", "SEARCH", "plus", "ASD", "Supports", "on", "the", "employment", "outcomes", "for", "youth", "with", "ASD", "between", "the", "ages", "of", "18", "-", "21", "years", "of", "age", ".", "This", "model", "provides", "very", "promising", "results", "in", "that", "the", "employment", "outcomes", "for", "youth", "in", "the", "treatment", "group", "were", "much", "higher", "in", "non", "-", "traditional", "jobs", "with", "higher", "than", "minimum", "wage", "incomes", "than", "for", "youth", "in", "the", "control", "condition", ".", "Specifically", ",", "21", "out", "of", "24", "(", "87.5", "%", ")", "treatment", "group", "participants", "acquired", "employment", "while", "1", "of", "16", "(", "6.25", "%", ")", "of", "control", "group", "participants", "acquired", "employment", "." ]

[ "Participant_Condition", "Intervention_Other", "Outcome_Other", "Outcome_Mental", "Intervention_Control", "Participant_Age", "Participant_Sample-size" ]

Glutamine is a Amino_acid, glucose is a Simple_chemical, Ehrlich ascites tumour cells is a Cell, Ehrlich ascites tumour cells is a Cell, glucose is a Simple_chemical, glutamine is a Amino_acid, oxygen is a Simple_chemical, glutamine is a Amino_acid, glucose is a Simple_chemical, glucose is a Simple_chemical, glutamine is a Amino_acid, oxygen is a Simple_chemical, CO2 is a Simple_chemical, cytochromes is a Gene_or_gene_product, glucose is a Simple_chemical, Ehrlich ascites tumour cells is a Cell, Glucose is a Simple_chemical, glutamine is a Amino_acid

281_task0

Sentence: Glutamine and glucose as energy substrates for Ehrlich ascites tumour cells. Energy metabolism of freshly harvested Ehrlich ascites tumour cells in the presence of 5 mM glucose and/or 0.5 mM glutamine was studied. The rate of oxygen utilization was not altered by the addition of 0.5 mM glutamine; 5 mM glucose induced an inhibition of respiration. In the presence of both glucose and glutamine, the Crabtree effect decreased. In these conditions, the rates of oxygen uptake, the CO2 evolution and the changes in the redox states of cytochromes indicate that glucose is preferred by Ehrlich ascites tumour cells as energy substrate. Glucose decreased the rate of glutamine utilization by 34%. On the other hand, glutaminolysis did not inhibit glycolysis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Simple_chemical, Amino_acid, Gene_or_gene_product, Cell

[ "B-Amino_acid", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "B-Amino_acid", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Amino_acid", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Amino_acid", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Amino_acid", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Glutamine and glucose as energy substrates for Ehrlich ascites tumour cells. Energy metabolism of freshly harvested Ehrlich ascites tumour cells in the presence of 5 mM glucose and/or 0.5 mM glutamine was studied. The rate of oxygen utilization was not altered by the addition of 0.5 mM glutamine; 5 mM glucose induced an inhibition of respiration. In the presence of both glucose and glutamine, the Crabtree effect decreased. In these conditions, the rates of oxygen uptake, the CO2 evolution and the changes in the redox states of cytochromes indicate that glucose is preferred by Ehrlich ascites tumour cells as energy substrate. Glucose decreased the rate of glutamine utilization by 34%. On the other hand, glutaminolysis did not inhibit glycolysis.

[ "Glutamine", "and", "glucose", "as", "energy", "substrates", "for", "Ehrlich", "ascites", "tumour", "cells", ".", "\n", "Energy", "metabolism", "of", "freshly", "harvested", "Ehrlich", "ascites", "tumour", "cells", "in", "the", "presence", "of", "5", "mM", "glucose", "and", "/", "or", "0.5", "mM", "glutamine", "was", "studied", ".", "The", "rate", "of", "oxygen", "utilization", "was", "not", "altered", "by", "the", "addition", "of", "0.5", "mM", "glutamine", ";", "5", "mM", "glucose", "induced", "an", "inhibition", "of", "respiration", ".", "In", "the", "presence", "of", "both", "glucose", "and", "glutamine", ",", "the", "Crabtree", "effect", "decreased", ".", "In", "these", "conditions", ",", "the", "rates", "of", "oxygen", "uptake", ",", "the", "CO2", "evolution", "and", "the", "changes", "in", "the", "redox", "states", "of", "cytochromes", "indicate", "that", "glucose", "is", "preferred", "by", "Ehrlich", "ascites", "tumour", "cells", "as", "energy", "substrate", ".", "Glucose", "decreased", "the", "rate", "of", "glutamine", "utilization", "by", "34", "%", ".", "On", "the", "other", "hand", ",", "glutaminolysis", "did", "not", "inhibit", "glycolysis", ".", "\n" ]

[ "Cell", "Gene_or_gene_product", "Amino_acid", "Simple_chemical" ]

Glutamine is a Amino_acid, glucose is a Simple_chemical, Ehrlich ascites tumour cells is a Cell, Ehrlich ascites tumour cells is a Cell, glucose is a Simple_chemical, glutamine is a Amino_acid, oxygen is a Simple_chemical, glutamine is a Amino_acid, glucose is a Simple_chemical, glucose is a Simple_chemical, glutamine is a Amino_acid, oxygen is a Simple_chemical, CO2 is a Simple_chemical, cytochromes is a Gene_or_gene_product, glucose is a Simple_chemical, Ehrlich ascites tumour cells is a Cell, Glucose is a Simple_chemical, glutamine is a Amino_acid

281_task1

Sentence: Glutamine and glucose as energy substrates for Ehrlich ascites tumour cells. Energy metabolism of freshly harvested Ehrlich ascites tumour cells in the presence of 5 mM glucose and/or 0.5 mM glutamine was studied. The rate of oxygen utilization was not altered by the addition of 0.5 mM glutamine; 5 mM glucose induced an inhibition of respiration. In the presence of both glucose and glutamine, the Crabtree effect decreased. In these conditions, the rates of oxygen uptake, the CO2 evolution and the changes in the redox states of cytochromes indicate that glucose is preferred by Ehrlich ascites tumour cells as energy substrate. Glucose decreased the rate of glutamine utilization by 34%. On the other hand, glutaminolysis did not inhibit glycolysis. Instructions: please typing these entity words according to sentence: Glutamine, glucose, Ehrlich ascites tumour cells, Ehrlich ascites tumour cells, glucose, glutamine, oxygen, glutamine, glucose, glucose, glutamine, oxygen, CO2, cytochromes, glucose, Ehrlich ascites tumour cells, Glucose, glutamine Options: Simple_chemical, Amino_acid, Gene_or_gene_product, Cell

[ "B-Amino_acid", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "B-Amino_acid", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Amino_acid", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Amino_acid", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Amino_acid", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Glutamine and glucose as energy substrates for Ehrlich ascites tumour cells. Energy metabolism of freshly harvested Ehrlich ascites tumour cells in the presence of 5 mM glucose and/or 0.5 mM glutamine was studied. The rate of oxygen utilization was not altered by the addition of 0.5 mM glutamine; 5 mM glucose induced an inhibition of respiration. In the presence of both glucose and glutamine, the Crabtree effect decreased. In these conditions, the rates of oxygen uptake, the CO2 evolution and the changes in the redox states of cytochromes indicate that glucose is preferred by Ehrlich ascites tumour cells as energy substrate. Glucose decreased the rate of glutamine utilization by 34%. On the other hand, glutaminolysis did not inhibit glycolysis.

[ "Glutamine", "and", "glucose", "as", "energy", "substrates", "for", "Ehrlich", "ascites", "tumour", "cells", ".", "\n", "Energy", "metabolism", "of", "freshly", "harvested", "Ehrlich", "ascites", "tumour", "cells", "in", "the", "presence", "of", "5", "mM", "glucose", "and", "/", "or", "0.5", "mM", "glutamine", "was", "studied", ".", "The", "rate", "of", "oxygen", "utilization", "was", "not", "altered", "by", "the", "addition", "of", "0.5", "mM", "glutamine", ";", "5", "mM", "glucose", "induced", "an", "inhibition", "of", "respiration", ".", "In", "the", "presence", "of", "both", "glucose", "and", "glutamine", ",", "the", "Crabtree", "effect", "decreased", ".", "In", "these", "conditions", ",", "the", "rates", "of", "oxygen", "uptake", ",", "the", "CO2", "evolution", "and", "the", "changes", "in", "the", "redox", "states", "of", "cytochromes", "indicate", "that", "glucose", "is", "preferred", "by", "Ehrlich", "ascites", "tumour", "cells", "as", "energy", "substrate", ".", "Glucose", "decreased", "the", "rate", "of", "glutamine", "utilization", "by", "34", "%", ".", "On", "the", "other", "hand", ",", "glutaminolysis", "did", "not", "inhibit", "glycolysis", ".", "\n" ]

[ "Cell", "Gene_or_gene_product", "Amino_acid", "Simple_chemical" ]

Glutamine, glucose, Ehrlich ascites tumour cells, Ehrlich ascites tumour cells, glucose, glutamine, oxygen, glutamine, glucose, glucose, glutamine, oxygen, CO2, cytochromes, glucose, Ehrlich ascites tumour cells, Glucose, glutamine

281_task2

Sentence: Glutamine and glucose as energy substrates for Ehrlich ascites tumour cells. Energy metabolism of freshly harvested Ehrlich ascites tumour cells in the presence of 5 mM glucose and/or 0.5 mM glutamine was studied. The rate of oxygen utilization was not altered by the addition of 0.5 mM glutamine; 5 mM glucose induced an inhibition of respiration. In the presence of both glucose and glutamine, the Crabtree effect decreased. In these conditions, the rates of oxygen uptake, the CO2 evolution and the changes in the redox states of cytochromes indicate that glucose is preferred by Ehrlich ascites tumour cells as energy substrate. Glucose decreased the rate of glutamine utilization by 34%. On the other hand, glutaminolysis did not inhibit glycolysis. Instructions: please extract entity words from the input sentence

[ "B-Amino_acid", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "B-Amino_acid", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Amino_acid", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Amino_acid", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Amino_acid", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Glutamine and glucose as energy substrates for Ehrlich ascites tumour cells. Energy metabolism of freshly harvested Ehrlich ascites tumour cells in the presence of 5 mM glucose and/or 0.5 mM glutamine was studied. The rate of oxygen utilization was not altered by the addition of 0.5 mM glutamine; 5 mM glucose induced an inhibition of respiration. In the presence of both glucose and glutamine, the Crabtree effect decreased. In these conditions, the rates of oxygen uptake, the CO2 evolution and the changes in the redox states of cytochromes indicate that glucose is preferred by Ehrlich ascites tumour cells as energy substrate. Glucose decreased the rate of glutamine utilization by 34%. On the other hand, glutaminolysis did not inhibit glycolysis.

[ "Glutamine", "and", "glucose", "as", "energy", "substrates", "for", "Ehrlich", "ascites", "tumour", "cells", ".", "\n", "Energy", "metabolism", "of", "freshly", "harvested", "Ehrlich", "ascites", "tumour", "cells", "in", "the", "presence", "of", "5", "mM", "glucose", "and", "/", "or", "0.5", "mM", "glutamine", "was", "studied", ".", "The", "rate", "of", "oxygen", "utilization", "was", "not", "altered", "by", "the", "addition", "of", "0.5", "mM", "glutamine", ";", "5", "mM", "glucose", "induced", "an", "inhibition", "of", "respiration", ".", "In", "the", "presence", "of", "both", "glucose", "and", "glutamine", ",", "the", "Crabtree", "effect", "decreased", ".", "In", "these", "conditions", ",", "the", "rates", "of", "oxygen", "uptake", ",", "the", "CO2", "evolution", "and", "the", "changes", "in", "the", "redox", "states", "of", "cytochromes", "indicate", "that", "glucose", "is", "preferred", "by", "Ehrlich", "ascites", "tumour", "cells", "as", "energy", "substrate", ".", "Glucose", "decreased", "the", "rate", "of", "glutamine", "utilization", "by", "34", "%", ".", "On", "the", "other", "hand", ",", "glutaminolysis", "did", "not", "inhibit", "glycolysis", ".", "\n" ]

[ "Cell", "Gene_or_gene_product", "Amino_acid", "Simple_chemical" ]

Antofine is a CHEMICAL, connexin43 is a GENE-Y, protein kinase Cβ is a GENE-Y

23403203_task0

Sentence: Antofine-induced connexin43 gap junction disassembly in rat astrocytes involves protein kinase Cβ. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL

[ "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O" ]

Antofine-induced connexin43 gap junction disassembly in rat astrocytes involves protein kinase Cβ.

[ "Antofine", "-", "induced", "connexin43", "gap", "junction", "disassembly", "in", "rat", "astrocytes", "involves", "protein", "kinase", "Cβ", "." ]

[ "CHEMICAL", "GENE-N", "GENE-Y" ]

Antofine is a CHEMICAL, connexin43 is a GENE-Y, protein kinase Cβ is a GENE-Y

23403203_task1

Sentence: Antofine-induced connexin43 gap junction disassembly in rat astrocytes involves protein kinase Cβ. Instructions: please typing these entity words according to sentence: Antofine, connexin43, protein kinase Cβ Options: GENE-Y, CHEMICAL

[ "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O" ]

Antofine-induced connexin43 gap junction disassembly in rat astrocytes involves protein kinase Cβ.

[ "Antofine", "-", "induced", "connexin43", "gap", "junction", "disassembly", "in", "rat", "astrocytes", "involves", "protein", "kinase", "Cβ", "." ]

[ "CHEMICAL", "GENE-N", "GENE-Y" ]

Antofine, connexin43, protein kinase Cβ

23403203_task2

Sentence: Antofine-induced connexin43 gap junction disassembly in rat astrocytes involves protein kinase Cβ. Instructions: please extract entity words from the input sentence

[ "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O" ]

Antofine-induced connexin43 gap junction disassembly in rat astrocytes involves protein kinase Cβ.

[ "Antofine", "-", "induced", "connexin43", "gap", "junction", "disassembly", "in", "rat", "astrocytes", "involves", "protein", "kinase", "Cβ", "." ]

[ "CHEMICAL", "GENE-N", "GENE-Y" ]

primary prevention program is a Intervention_Educational, adolescents is a Participant_Age, school - based primary prevention psychological program is a Intervention_Educational, distress - coping is a Outcome_Mental, " gatekeepers " with regard to self - destructive behavior of peers is a Outcome_Mental, face validity and social validity is a Outcome_Mental, Two hundred and thirty - seven is a Participant_Sample-size, attitudes , emotions , knowledge and awareness of distress coping skills is a Outcome_Mental, cognitive - behavioral , school - based prevention program is a Intervention_Educational

85443_task0

Sentence: Coping with distress and self harm : the impact of a primary prevention program among adolescents . The effectiveness of a school-based primary prevention psychological program is assessed in the present study . The program was designed to ( a ) improve students ' distress-coping , ( b ) prepare them as " gatekeepers " with regard to self-destructive behavior of peers and ( c ) assess the program 's face validity and social validity . The program was primarily based on cognitive-behavioral modification principles , procedures and techniques . Two hundred and thirty-seven students , drawn from six homeroom grade eight classes were randomly assigned to experimental and control ( no intervention ) conditions . The program consisted of seven units passed during twelve weekly one-hour sessions . Overall , the program had a positive effect on attitudes , emotions , knowledge and awareness of distress coping skills . In addition , it had some degree of face validity and social validity from the students ' vantage point . These results lend support to the feasibility of a cognitive-behavioral , school-based prevention program for students ' distress-coping enhancement . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Educational, Participant_Age, Participant_Sample-size, Outcome_Mental

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O" ]

Coping with distress and self harm : the impact of a primary prevention program among adolescents . The effectiveness of a school-based primary prevention psychological program is assessed in the present study . The program was designed to ( a ) improve students ' distress-coping , ( b ) prepare them as " gatekeepers " with regard to self-destructive behavior of peers and ( c ) assess the program 's face validity and social validity . The program was primarily based on cognitive-behavioral modification principles , procedures and techniques . Two hundred and thirty-seven students , drawn from six homeroom grade eight classes were randomly assigned to experimental and control ( no intervention ) conditions . The program consisted of seven units passed during twelve weekly one-hour sessions . Overall , the program had a positive effect on attitudes , emotions , knowledge and awareness of distress coping skills . In addition , it had some degree of face validity and social validity from the students ' vantage point . These results lend support to the feasibility of a cognitive-behavioral , school-based prevention program for students ' distress-coping enhancement .

[ "Coping", "with", "distress", "and", "self", "harm", ":", "the", "impact", "of", "a", "primary", "prevention", "program", "among", "adolescents", ".", "The", "effectiveness", "of", "a", "school", "-", "based", "primary", "prevention", "psychological", "program", "is", "assessed", "in", "the", "present", "study", ".", "The", "program", "was", "designed", "to", "(", "a", ")", "improve", "students", "'", "distress", "-", "coping", ",", "(", "b", ")", "prepare", "them", "as", "\"", "gatekeepers", "\"", "with", "regard", "to", "self", "-", "destructive", "behavior", "of", "peers", "and", "(", "c", ")", "assess", "the", "program", "'", "s", "face", "validity", "and", "social", "validity", ".", "The", "program", "was", "primarily", "based", "on", "cognitive", "-", "behavioral", "modification", "principles", ",", "procedures", "and", "techniques", ".", "Two", "hundred", "and", "thirty", "-", "seven", "students", ",", "drawn", "from", "six", "homeroom", "grade", "eight", "classes", "were", "randomly", "assigned", "to", "experimental", "and", "control", "(", "no", "intervention", ")", "conditions", ".", "The", "program", "consisted", "of", "seven", "units", "passed", "during", "twelve", "weekly", "one", "-", "hour", "sessions", ".", "Overall", ",", "the", "program", "had", "a", "positive", "effect", "on", "attitudes", ",", "emotions", ",", "knowledge", "and", "awareness", "of", "distress", "coping", "skills", ".", "In", "addition", ",", "it", "had", "some", "degree", "of", "face", "validity", "and", "social", "validity", "from", "the", "students", "'", "vantage", "point", ".", "These", "results", "lend", "support", "to", "the", "feasibility", "of", "a", "cognitive", "-", "behavioral", ",", "school", "-", "based", "prevention", "program", "for", "students", "'", "distress", "-", "coping", "enhancement", "." ]

[ "Outcome_Mental", "Intervention_Educational", "Participant_Sample-size", "Participant_Age" ]

primary prevention program is a Intervention_Educational, adolescents is a Participant_Age, school - based primary prevention psychological program is a Intervention_Educational, distress - coping is a Outcome_Mental, " gatekeepers " with regard to self - destructive behavior of peers is a Outcome_Mental, face validity and social validity is a Outcome_Mental, Two hundred and thirty - seven is a Participant_Sample-size, attitudes , emotions , knowledge and awareness of distress coping skills is a Outcome_Mental, cognitive - behavioral , school - based prevention program is a Intervention_Educational

85443_task1

Sentence: Coping with distress and self harm : the impact of a primary prevention program among adolescents . The effectiveness of a school-based primary prevention psychological program is assessed in the present study . The program was designed to ( a ) improve students ' distress-coping , ( b ) prepare them as " gatekeepers " with regard to self-destructive behavior of peers and ( c ) assess the program 's face validity and social validity . The program was primarily based on cognitive-behavioral modification principles , procedures and techniques . Two hundred and thirty-seven students , drawn from six homeroom grade eight classes were randomly assigned to experimental and control ( no intervention ) conditions . The program consisted of seven units passed during twelve weekly one-hour sessions . Overall , the program had a positive effect on attitudes , emotions , knowledge and awareness of distress coping skills . In addition , it had some degree of face validity and social validity from the students ' vantage point . These results lend support to the feasibility of a cognitive-behavioral , school-based prevention program for students ' distress-coping enhancement . Instructions: please typing these entity words according to sentence: primary prevention program, adolescents, school - based primary prevention psychological program, distress - coping, " gatekeepers " with regard to self - destructive behavior of peers, face validity and social validity, Two hundred and thirty - seven, attitudes , emotions , knowledge and awareness of distress coping skills, cognitive - behavioral , school - based prevention program Options: Intervention_Educational, Participant_Age, Participant_Sample-size, Outcome_Mental

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O" ]

Coping with distress and self harm : the impact of a primary prevention program among adolescents . The effectiveness of a school-based primary prevention psychological program is assessed in the present study . The program was designed to ( a ) improve students ' distress-coping , ( b ) prepare them as " gatekeepers " with regard to self-destructive behavior of peers and ( c ) assess the program 's face validity and social validity . The program was primarily based on cognitive-behavioral modification principles , procedures and techniques . Two hundred and thirty-seven students , drawn from six homeroom grade eight classes were randomly assigned to experimental and control ( no intervention ) conditions . The program consisted of seven units passed during twelve weekly one-hour sessions . Overall , the program had a positive effect on attitudes , emotions , knowledge and awareness of distress coping skills . In addition , it had some degree of face validity and social validity from the students ' vantage point . These results lend support to the feasibility of a cognitive-behavioral , school-based prevention program for students ' distress-coping enhancement .

[ "Coping", "with", "distress", "and", "self", "harm", ":", "the", "impact", "of", "a", "primary", "prevention", "program", "among", "adolescents", ".", "The", "effectiveness", "of", "a", "school", "-", "based", "primary", "prevention", "psychological", "program", "is", "assessed", "in", "the", "present", "study", ".", "The", "program", "was", "designed", "to", "(", "a", ")", "improve", "students", "'", "distress", "-", "coping", ",", "(", "b", ")", "prepare", "them", "as", "\"", "gatekeepers", "\"", "with", "regard", "to", "self", "-", "destructive", "behavior", "of", "peers", "and", "(", "c", ")", "assess", "the", "program", "'", "s", "face", "validity", "and", "social", "validity", ".", "The", "program", "was", "primarily", "based", "on", "cognitive", "-", "behavioral", "modification", "principles", ",", "procedures", "and", "techniques", ".", "Two", "hundred", "and", "thirty", "-", "seven", "students", ",", "drawn", "from", "six", "homeroom", "grade", "eight", "classes", "were", "randomly", "assigned", "to", "experimental", "and", "control", "(", "no", "intervention", ")", "conditions", ".", "The", "program", "consisted", "of", "seven", "units", "passed", "during", "twelve", "weekly", "one", "-", "hour", "sessions", ".", "Overall", ",", "the", "program", "had", "a", "positive", "effect", "on", "attitudes", ",", "emotions", ",", "knowledge", "and", "awareness", "of", "distress", "coping", "skills", ".", "In", "addition", ",", "it", "had", "some", "degree", "of", "face", "validity", "and", "social", "validity", "from", "the", "students", "'", "vantage", "point", ".", "These", "results", "lend", "support", "to", "the", "feasibility", "of", "a", "cognitive", "-", "behavioral", ",", "school", "-", "based", "prevention", "program", "for", "students", "'", "distress", "-", "coping", "enhancement", "." ]

[ "Outcome_Mental", "Intervention_Educational", "Participant_Sample-size", "Participant_Age" ]

primary prevention program, adolescents, school - based primary prevention psychological program, distress - coping, " gatekeepers " with regard to self - destructive behavior of peers, face validity and social validity, Two hundred and thirty - seven, attitudes , emotions , knowledge and awareness of distress coping skills, cognitive - behavioral , school - based prevention program

85443_task2

Sentence: Coping with distress and self harm : the impact of a primary prevention program among adolescents . The effectiveness of a school-based primary prevention psychological program is assessed in the present study . The program was designed to ( a ) improve students ' distress-coping , ( b ) prepare them as " gatekeepers " with regard to self-destructive behavior of peers and ( c ) assess the program 's face validity and social validity . The program was primarily based on cognitive-behavioral modification principles , procedures and techniques . Two hundred and thirty-seven students , drawn from six homeroom grade eight classes were randomly assigned to experimental and control ( no intervention ) conditions . The program consisted of seven units passed during twelve weekly one-hour sessions . Overall , the program had a positive effect on attitudes , emotions , knowledge and awareness of distress coping skills . In addition , it had some degree of face validity and social validity from the students ' vantage point . These results lend support to the feasibility of a cognitive-behavioral , school-based prevention program for students ' distress-coping enhancement . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O" ]

Coping with distress and self harm : the impact of a primary prevention program among adolescents . The effectiveness of a school-based primary prevention psychological program is assessed in the present study . The program was designed to ( a ) improve students ' distress-coping , ( b ) prepare them as " gatekeepers " with regard to self-destructive behavior of peers and ( c ) assess the program 's face validity and social validity . The program was primarily based on cognitive-behavioral modification principles , procedures and techniques . Two hundred and thirty-seven students , drawn from six homeroom grade eight classes were randomly assigned to experimental and control ( no intervention ) conditions . The program consisted of seven units passed during twelve weekly one-hour sessions . Overall , the program had a positive effect on attitudes , emotions , knowledge and awareness of distress coping skills . In addition , it had some degree of face validity and social validity from the students ' vantage point . These results lend support to the feasibility of a cognitive-behavioral , school-based prevention program for students ' distress-coping enhancement .

[ "Coping", "with", "distress", "and", "self", "harm", ":", "the", "impact", "of", "a", "primary", "prevention", "program", "among", "adolescents", ".", "The", "effectiveness", "of", "a", "school", "-", "based", "primary", "prevention", "psychological", "program", "is", "assessed", "in", "the", "present", "study", ".", "The", "program", "was", "designed", "to", "(", "a", ")", "improve", "students", "'", "distress", "-", "coping", ",", "(", "b", ")", "prepare", "them", "as", "\"", "gatekeepers", "\"", "with", "regard", "to", "self", "-", "destructive", "behavior", "of", "peers", "and", "(", "c", ")", "assess", "the", "program", "'", "s", "face", "validity", "and", "social", "validity", ".", "The", "program", "was", "primarily", "based", "on", "cognitive", "-", "behavioral", "modification", "principles", ",", "procedures", "and", "techniques", ".", "Two", "hundred", "and", "thirty", "-", "seven", "students", ",", "drawn", "from", "six", "homeroom", "grade", "eight", "classes", "were", "randomly", "assigned", "to", "experimental", "and", "control", "(", "no", "intervention", ")", "conditions", ".", "The", "program", "consisted", "of", "seven", "units", "passed", "during", "twelve", "weekly", "one", "-", "hour", "sessions", ".", "Overall", ",", "the", "program", "had", "a", "positive", "effect", "on", "attitudes", ",", "emotions", ",", "knowledge", "and", "awareness", "of", "distress", "coping", "skills", ".", "In", "addition", ",", "it", "had", "some", "degree", "of", "face", "validity", "and", "social", "validity", "from", "the", "students", "'", "vantage", "point", ".", "These", "results", "lend", "support", "to", "the", "feasibility", "of", "a", "cognitive", "-", "behavioral", ",", "school", "-", "based", "prevention", "program", "for", "students", "'", "distress", "-", "coping", "enhancement", "." ]

[ "Outcome_Mental", "Intervention_Educational", "Participant_Sample-size", "Participant_Age" ]

profilin is a Individual_protein, actin is a Individual_protein

347_task0

Sentence: High levels of profilin suppress the lethality caused by overproduction of actin in yeast cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein

[ "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O" ]

High levels of profilin suppress the lethality caused by overproduction of actin in yeast cells.

[ "High", "levels", "of", "profilin", "suppress", "the", "lethality", "caused", "by", "overproduction", "of", "actin", "in", "yeast", "cells", "." ]

[ "Individual_protein" ]

profilin is a Individual_protein, actin is a Individual_protein

347_task1

Sentence: High levels of profilin suppress the lethality caused by overproduction of actin in yeast cells. Instructions: please typing these entity words according to sentence: profilin, actin Options: Individual_protein

[ "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O" ]

High levels of profilin suppress the lethality caused by overproduction of actin in yeast cells.

[ "High", "levels", "of", "profilin", "suppress", "the", "lethality", "caused", "by", "overproduction", "of", "actin", "in", "yeast", "cells", "." ]

[ "Individual_protein" ]

profilin, actin

347_task2

Sentence: High levels of profilin suppress the lethality caused by overproduction of actin in yeast cells. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O" ]

High levels of profilin suppress the lethality caused by overproduction of actin in yeast cells.

[ "High", "levels", "of", "profilin", "suppress", "the", "lethality", "caused", "by", "overproduction", "of", "actin", "in", "yeast", "cells", "." ]

[ "Individual_protein" ]

Fragebogenaktion is an umlsterm, Gesellschaft is an umlsterm, Pneumologie is an umlsterm, Aerzten is an umlsterm, Intensivbettenzahl is an umlsterm, Intensivbetten is an umlsterm, Betten is an umlsterm, Universitaetskliniken is an umlsterm, Lungenkliniken is an umlsterm, Universitaetskliniken is an umlsterm, Intensivbetten is an umlsterm, selbst is an umlsterm, Lungenkliniken is an umlsterm, Intensivstationen is an umlsterm, Deutschland is an umlsterm, Intensivbetten is an umlsterm, Deutschland is an umlsterm, Pneumologie is an umlsterm, Krankenhaeusern is an umlsterm, Intensivmedizin is an umlsterm

IntensiveMedizin.90360190.ger.abstr_task0

Sentence: Im Rahmen einer Fragebogenaktion wurde der Stand der Intensiv-Versorgung an Kliniken mit in der Deutschen Gesellschaft fuer Pneumologie ( DGP ) organisierten Pneumologen untersucht . Dazu wurden saemtliche eingetragenen Mitglieder der DGP zur Situation an der Klinik , an der sie arbeiten , befragt . Von mehr als 1600 angeschriebenen Aerzten antworteten 240 , die 145 verschiedene Kliniken repraesentieren ( Ruecklaufquote 14,4% ) . : Analysiert wurden die Anzahl und Art der Einrichtungen , die pneumologische Gesamt- und Intensivbettenzahl und das pneumologisch-intensivmedizinische Leistungsspektrum . Auch wenn der Anteil pneumologischer Intensivbetten an der Gesamtzahl pneumologischer Betten an Universitaetskliniken genau so hoch liegt wie an Lungenkliniken , finden sich weder an Universitaetskliniken ( 8% ) noch an Versorgungskrankenhaeusern ( 2% ) eine akzeptable Anzahl pneumologisch verantworteter Intensivbetten , und selbst an Lungenkliniken ( 50% ) wird nur ein Teil der Intensivstationen durch Pneumologen geleitet . Pneumologen haben in Deutschland bezogen auf die Gesamtzahl der internistischen Intensivbetten so gut wie nichts mit der Intensiv-Versorgung zu tun . Das in Deutschland bestehende Defizit in der Praesenz von Pneumologie an Universitaetsklinika und an den anderen Krankenhaeusern spiegelt sich - im Gegensatz zu anderen Laendern - in besonderer Weise in der internistischen Intensivmedizin wider . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Im Rahmen einer Fragebogenaktion wurde der Stand der Intensiv-Versorgung an Kliniken mit in der Deutschen Gesellschaft fuer Pneumologie ( DGP ) organisierten Pneumologen untersucht . Dazu wurden saemtliche eingetragenen Mitglieder der DGP zur Situation an der Klinik , an der sie arbeiten , befragt . Von mehr als 1600 angeschriebenen Aerzten antworteten 240 , die 145 verschiedene Kliniken repraesentieren ( Ruecklaufquote 14,4% ) . : Analysiert wurden die Anzahl und Art der Einrichtungen , die pneumologische Gesamt- und Intensivbettenzahl und das pneumologisch-intensivmedizinische Leistungsspektrum . Auch wenn der Anteil pneumologischer Intensivbetten an der Gesamtzahl pneumologischer Betten an Universitaetskliniken genau so hoch liegt wie an Lungenkliniken , finden sich weder an Universitaetskliniken ( 8% ) noch an Versorgungskrankenhaeusern ( 2% ) eine akzeptable Anzahl pneumologisch verantworteter Intensivbetten , und selbst an Lungenkliniken ( 50% ) wird nur ein Teil der Intensivstationen durch Pneumologen geleitet . Pneumologen haben in Deutschland bezogen auf die Gesamtzahl der internistischen Intensivbetten so gut wie nichts mit der Intensiv-Versorgung zu tun . Das in Deutschland bestehende Defizit in der Praesenz von Pneumologie an Universitaetsklinika und an den anderen Krankenhaeusern spiegelt sich - im Gegensatz zu anderen Laendern - in besonderer Weise in der internistischen Intensivmedizin wider .

[ "Im", "Rahmen", "einer", "Fragebogenaktion", "wurde", "der", "Stand", "der", "Intensiv", "-", "Versorgung", "an", "Kliniken", "mit", "in", "der", "Deutschen", "Gesellschaft", "fuer", "Pneumologie", "(", "DGP", ")", "organisierten", "Pneumologen", "untersucht", ".", "Dazu", "wurden", "saemtliche", "eingetragenen", "Mitglieder", "der", "DGP", "zur", "Situation", "an", "der", "Klinik", ",", "an", "der", "sie", "arbeiten", ",", "befragt", ".", "Von", "mehr", "als", "1600", "angeschriebenen", "Aerzten", "antworteten", "240", ",", "die", "145", "verschiedene", "Kliniken", "repraesentieren", "(", "Ruecklaufquote", "14,4", "%", ")", ".", ":", "Analysiert", "wurden", "die", "Anzahl", "und", "Art", "der", "Einrichtungen", ",", "die", "pneumologische", "Gesamt-", "und", "Intensivbettenzahl", "und", "das", "pneumologisch", "-", "intensivmedizinische", "Leistungsspektrum", ".", "Auch", "wenn", "der", "Anteil", "pneumologischer", "Intensivbetten", "an", "der", "Gesamtzahl", "pneumologischer", "Betten", "an", "Universitaetskliniken", "genau", "so", "hoch", "liegt", "wie", "an", "Lungenkliniken", ",", "finden", "sich", "weder", "an", "Universitaetskliniken", "(", "8", "%", ")", "noch", "an", "Versorgungskrankenhaeusern", "(", "2", "%", ")", "eine", "akzeptable", "Anzahl", "pneumologisch", "verantworteter", "Intensivbetten", ",", "und", "selbst", "an", "Lungenkliniken", "(", "50", "%", ")", "wird", "nur", "ein", "Teil", "der", "Intensivstationen", "durch", "Pneumologen", "geleitet", ".", "Pneumologen", "haben", "in", "Deutschland", "bezogen", "auf", "die", "Gesamtzahl", "der", "internistischen", "Intensivbetten", "so", "gut", "wie", "nichts", "mit", "der", "Intensiv", "-", "Versorgung", "zu", "tun", ".", "Das", "in", "Deutschland", "bestehende", "Defizit", "in", "der", "Praesenz", "von", "Pneumologie", "an", "Universitaetsklinika", "und", "an", "den", "anderen", "Krankenhaeusern", "spiegelt", "sich", "-", "im", "Gegensatz", "zu", "anderen", "Laendern", "-", "in", "besonderer", "Weise", "in", "der", "internistischen", "Intensivmedizin", "wider", "." ]

[ "umlsterm" ]

Fragebogenaktion is an umlsterm, Gesellschaft is an umlsterm, Pneumologie is an umlsterm, Aerzten is an umlsterm, Intensivbettenzahl is an umlsterm, Intensivbetten is an umlsterm, Betten is an umlsterm, Universitaetskliniken is an umlsterm, Lungenkliniken is an umlsterm, Universitaetskliniken is an umlsterm, Intensivbetten is an umlsterm, selbst is an umlsterm, Lungenkliniken is an umlsterm, Intensivstationen is an umlsterm, Deutschland is an umlsterm, Intensivbetten is an umlsterm, Deutschland is an umlsterm, Pneumologie is an umlsterm, Krankenhaeusern is an umlsterm, Intensivmedizin is an umlsterm

IntensiveMedizin.90360190.ger.abstr_task1

Sentence: Im Rahmen einer Fragebogenaktion wurde der Stand der Intensiv-Versorgung an Kliniken mit in der Deutschen Gesellschaft fuer Pneumologie ( DGP ) organisierten Pneumologen untersucht . Dazu wurden saemtliche eingetragenen Mitglieder der DGP zur Situation an der Klinik , an der sie arbeiten , befragt . Von mehr als 1600 angeschriebenen Aerzten antworteten 240 , die 145 verschiedene Kliniken repraesentieren ( Ruecklaufquote 14,4% ) . : Analysiert wurden die Anzahl und Art der Einrichtungen , die pneumologische Gesamt- und Intensivbettenzahl und das pneumologisch-intensivmedizinische Leistungsspektrum . Auch wenn der Anteil pneumologischer Intensivbetten an der Gesamtzahl pneumologischer Betten an Universitaetskliniken genau so hoch liegt wie an Lungenkliniken , finden sich weder an Universitaetskliniken ( 8% ) noch an Versorgungskrankenhaeusern ( 2% ) eine akzeptable Anzahl pneumologisch verantworteter Intensivbetten , und selbst an Lungenkliniken ( 50% ) wird nur ein Teil der Intensivstationen durch Pneumologen geleitet . Pneumologen haben in Deutschland bezogen auf die Gesamtzahl der internistischen Intensivbetten so gut wie nichts mit der Intensiv-Versorgung zu tun . Das in Deutschland bestehende Defizit in der Praesenz von Pneumologie an Universitaetsklinika und an den anderen Krankenhaeusern spiegelt sich - im Gegensatz zu anderen Laendern - in besonderer Weise in der internistischen Intensivmedizin wider . Instructions: please typing these entity words according to sentence: Fragebogenaktion, Gesellschaft, Pneumologie, Aerzten, Intensivbettenzahl, Intensivbetten, Betten, Universitaetskliniken, Lungenkliniken, Universitaetskliniken, Intensivbetten, selbst, Lungenkliniken, Intensivstationen, Deutschland, Intensivbetten, Deutschland, Pneumologie, Krankenhaeusern, Intensivmedizin Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Im Rahmen einer Fragebogenaktion wurde der Stand der Intensiv-Versorgung an Kliniken mit in der Deutschen Gesellschaft fuer Pneumologie ( DGP ) organisierten Pneumologen untersucht . Dazu wurden saemtliche eingetragenen Mitglieder der DGP zur Situation an der Klinik , an der sie arbeiten , befragt . Von mehr als 1600 angeschriebenen Aerzten antworteten 240 , die 145 verschiedene Kliniken repraesentieren ( Ruecklaufquote 14,4% ) . : Analysiert wurden die Anzahl und Art der Einrichtungen , die pneumologische Gesamt- und Intensivbettenzahl und das pneumologisch-intensivmedizinische Leistungsspektrum . Auch wenn der Anteil pneumologischer Intensivbetten an der Gesamtzahl pneumologischer Betten an Universitaetskliniken genau so hoch liegt wie an Lungenkliniken , finden sich weder an Universitaetskliniken ( 8% ) noch an Versorgungskrankenhaeusern ( 2% ) eine akzeptable Anzahl pneumologisch verantworteter Intensivbetten , und selbst an Lungenkliniken ( 50% ) wird nur ein Teil der Intensivstationen durch Pneumologen geleitet . Pneumologen haben in Deutschland bezogen auf die Gesamtzahl der internistischen Intensivbetten so gut wie nichts mit der Intensiv-Versorgung zu tun . Das in Deutschland bestehende Defizit in der Praesenz von Pneumologie an Universitaetsklinika und an den anderen Krankenhaeusern spiegelt sich - im Gegensatz zu anderen Laendern - in besonderer Weise in der internistischen Intensivmedizin wider .

[ "Im", "Rahmen", "einer", "Fragebogenaktion", "wurde", "der", "Stand", "der", "Intensiv", "-", "Versorgung", "an", "Kliniken", "mit", "in", "der", "Deutschen", "Gesellschaft", "fuer", "Pneumologie", "(", "DGP", ")", "organisierten", "Pneumologen", "untersucht", ".", "Dazu", "wurden", "saemtliche", "eingetragenen", "Mitglieder", "der", "DGP", "zur", "Situation", "an", "der", "Klinik", ",", "an", "der", "sie", "arbeiten", ",", "befragt", ".", "Von", "mehr", "als", "1600", "angeschriebenen", "Aerzten", "antworteten", "240", ",", "die", "145", "verschiedene", "Kliniken", "repraesentieren", "(", "Ruecklaufquote", "14,4", "%", ")", ".", ":", "Analysiert", "wurden", "die", "Anzahl", "und", "Art", "der", "Einrichtungen", ",", "die", "pneumologische", "Gesamt-", "und", "Intensivbettenzahl", "und", "das", "pneumologisch", "-", "intensivmedizinische", "Leistungsspektrum", ".", "Auch", "wenn", "der", "Anteil", "pneumologischer", "Intensivbetten", "an", "der", "Gesamtzahl", "pneumologischer", "Betten", "an", "Universitaetskliniken", "genau", "so", "hoch", "liegt", "wie", "an", "Lungenkliniken", ",", "finden", "sich", "weder", "an", "Universitaetskliniken", "(", "8", "%", ")", "noch", "an", "Versorgungskrankenhaeusern", "(", "2", "%", ")", "eine", "akzeptable", "Anzahl", "pneumologisch", "verantworteter", "Intensivbetten", ",", "und", "selbst", "an", "Lungenkliniken", "(", "50", "%", ")", "wird", "nur", "ein", "Teil", "der", "Intensivstationen", "durch", "Pneumologen", "geleitet", ".", "Pneumologen", "haben", "in", "Deutschland", "bezogen", "auf", "die", "Gesamtzahl", "der", "internistischen", "Intensivbetten", "so", "gut", "wie", "nichts", "mit", "der", "Intensiv", "-", "Versorgung", "zu", "tun", ".", "Das", "in", "Deutschland", "bestehende", "Defizit", "in", "der", "Praesenz", "von", "Pneumologie", "an", "Universitaetsklinika", "und", "an", "den", "anderen", "Krankenhaeusern", "spiegelt", "sich", "-", "im", "Gegensatz", "zu", "anderen", "Laendern", "-", "in", "besonderer", "Weise", "in", "der", "internistischen", "Intensivmedizin", "wider", "." ]

[ "umlsterm" ]

Fragebogenaktion, Gesellschaft, Pneumologie, Aerzten, Intensivbettenzahl, Intensivbetten, Betten, Universitaetskliniken, Lungenkliniken, Universitaetskliniken, Intensivbetten, selbst, Lungenkliniken, Intensivstationen, Deutschland, Intensivbetten, Deutschland, Pneumologie, Krankenhaeusern, Intensivmedizin

IntensiveMedizin.90360190.ger.abstr_task2

Sentence: Im Rahmen einer Fragebogenaktion wurde der Stand der Intensiv-Versorgung an Kliniken mit in der Deutschen Gesellschaft fuer Pneumologie ( DGP ) organisierten Pneumologen untersucht . Dazu wurden saemtliche eingetragenen Mitglieder der DGP zur Situation an der Klinik , an der sie arbeiten , befragt . Von mehr als 1600 angeschriebenen Aerzten antworteten 240 , die 145 verschiedene Kliniken repraesentieren ( Ruecklaufquote 14,4% ) . : Analysiert wurden die Anzahl und Art der Einrichtungen , die pneumologische Gesamt- und Intensivbettenzahl und das pneumologisch-intensivmedizinische Leistungsspektrum . Auch wenn der Anteil pneumologischer Intensivbetten an der Gesamtzahl pneumologischer Betten an Universitaetskliniken genau so hoch liegt wie an Lungenkliniken , finden sich weder an Universitaetskliniken ( 8% ) noch an Versorgungskrankenhaeusern ( 2% ) eine akzeptable Anzahl pneumologisch verantworteter Intensivbetten , und selbst an Lungenkliniken ( 50% ) wird nur ein Teil der Intensivstationen durch Pneumologen geleitet . Pneumologen haben in Deutschland bezogen auf die Gesamtzahl der internistischen Intensivbetten so gut wie nichts mit der Intensiv-Versorgung zu tun . Das in Deutschland bestehende Defizit in der Praesenz von Pneumologie an Universitaetsklinika und an den anderen Krankenhaeusern spiegelt sich - im Gegensatz zu anderen Laendern - in besonderer Weise in der internistischen Intensivmedizin wider . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Im Rahmen einer Fragebogenaktion wurde der Stand der Intensiv-Versorgung an Kliniken mit in der Deutschen Gesellschaft fuer Pneumologie ( DGP ) organisierten Pneumologen untersucht . Dazu wurden saemtliche eingetragenen Mitglieder der DGP zur Situation an der Klinik , an der sie arbeiten , befragt . Von mehr als 1600 angeschriebenen Aerzten antworteten 240 , die 145 verschiedene Kliniken repraesentieren ( Ruecklaufquote 14,4% ) . : Analysiert wurden die Anzahl und Art der Einrichtungen , die pneumologische Gesamt- und Intensivbettenzahl und das pneumologisch-intensivmedizinische Leistungsspektrum . Auch wenn der Anteil pneumologischer Intensivbetten an der Gesamtzahl pneumologischer Betten an Universitaetskliniken genau so hoch liegt wie an Lungenkliniken , finden sich weder an Universitaetskliniken ( 8% ) noch an Versorgungskrankenhaeusern ( 2% ) eine akzeptable Anzahl pneumologisch verantworteter Intensivbetten , und selbst an Lungenkliniken ( 50% ) wird nur ein Teil der Intensivstationen durch Pneumologen geleitet . Pneumologen haben in Deutschland bezogen auf die Gesamtzahl der internistischen Intensivbetten so gut wie nichts mit der Intensiv-Versorgung zu tun . Das in Deutschland bestehende Defizit in der Praesenz von Pneumologie an Universitaetsklinika und an den anderen Krankenhaeusern spiegelt sich - im Gegensatz zu anderen Laendern - in besonderer Weise in der internistischen Intensivmedizin wider .

[ "Im", "Rahmen", "einer", "Fragebogenaktion", "wurde", "der", "Stand", "der", "Intensiv", "-", "Versorgung", "an", "Kliniken", "mit", "in", "der", "Deutschen", "Gesellschaft", "fuer", "Pneumologie", "(", "DGP", ")", "organisierten", "Pneumologen", "untersucht", ".", "Dazu", "wurden", "saemtliche", "eingetragenen", "Mitglieder", "der", "DGP", "zur", "Situation", "an", "der", "Klinik", ",", "an", "der", "sie", "arbeiten", ",", "befragt", ".", "Von", "mehr", "als", "1600", "angeschriebenen", "Aerzten", "antworteten", "240", ",", "die", "145", "verschiedene", "Kliniken", "repraesentieren", "(", "Ruecklaufquote", "14,4", "%", ")", ".", ":", "Analysiert", "wurden", "die", "Anzahl", "und", "Art", "der", "Einrichtungen", ",", "die", "pneumologische", "Gesamt-", "und", "Intensivbettenzahl", "und", "das", "pneumologisch", "-", "intensivmedizinische", "Leistungsspektrum", ".", "Auch", "wenn", "der", "Anteil", "pneumologischer", "Intensivbetten", "an", "der", "Gesamtzahl", "pneumologischer", "Betten", "an", "Universitaetskliniken", "genau", "so", "hoch", "liegt", "wie", "an", "Lungenkliniken", ",", "finden", "sich", "weder", "an", "Universitaetskliniken", "(", "8", "%", ")", "noch", "an", "Versorgungskrankenhaeusern", "(", "2", "%", ")", "eine", "akzeptable", "Anzahl", "pneumologisch", "verantworteter", "Intensivbetten", ",", "und", "selbst", "an", "Lungenkliniken", "(", "50", "%", ")", "wird", "nur", "ein", "Teil", "der", "Intensivstationen", "durch", "Pneumologen", "geleitet", ".", "Pneumologen", "haben", "in", "Deutschland", "bezogen", "auf", "die", "Gesamtzahl", "der", "internistischen", "Intensivbetten", "so", "gut", "wie", "nichts", "mit", "der", "Intensiv", "-", "Versorgung", "zu", "tun", ".", "Das", "in", "Deutschland", "bestehende", "Defizit", "in", "der", "Praesenz", "von", "Pneumologie", "an", "Universitaetsklinika", "und", "an", "den", "anderen", "Krankenhaeusern", "spiegelt", "sich", "-", "im", "Gegensatz", "zu", "anderen", "Laendern", "-", "in", "besonderer", "Weise", "in", "der", "internistischen", "Intensivmedizin", "wider", "." ]

[ "umlsterm" ]

liver cancer cell Bel-7402 ] is a Cell, liver cancer cell Bel-7402 is a Cell, cell is a Cell, tumor is a Cancer, Bel-7402 is a Cell, Bel-7402 is a Cell, chromatin is a Cellular_component, cell is a Cell, tumor cell is a Cell

PMID-11255762_task0

Sentence: [Study of fungus polysaccharides compounds (FPC) in inducing the apoptosis of liver cancer cell Bel-7402]. To observe the influence of fungus polysaccharides compounds (FPC) in inducing human liver cancer cell Bel-7402 apoptosis in cell cultivating in vitro, the authors analyzed tumor inhibitive gene P53 expression in Bel-7402 apoptosis by applying double immuno-marker. The result showed that the multilevel of FPC could all apparently induce Bel-7402 apoptosis. With the enhancement of FPC concentration, the authors observed chromatin condensation in some phases companying with the characteristic apoptosis. In the meantime, it could also greatly reduce the G1 and S, with obviously dose-response relationship. The percentage of cell apoptosis increased with the enhancing of concentration. In the high-level group the authors found typical DNA ladder eletrophoresis stripe. The result showed that the mechanism of the FPC antineoplastic effect had an intimate relation with its induction to apoptosis and that the result of FPC inducing tumor cell apoptosis had the character of P53 independence. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Cancer, Cellular_component, Cell

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

[Study of fungus polysaccharides compounds (FPC) in inducing the apoptosis of liver cancer cell Bel-7402]. To observe the influence of fungus polysaccharides compounds (FPC) in inducing human liver cancer cell Bel-7402 apoptosis in cell cultivating in vitro, the authors analyzed tumor inhibitive gene P53 expression in Bel-7402 apoptosis by applying double immuno-marker. The result showed that the multilevel of FPC could all apparently induce Bel-7402 apoptosis. With the enhancement of FPC concentration, the authors observed chromatin condensation in some phases companying with the characteristic apoptosis. In the meantime, it could also greatly reduce the G1 and S, with obviously dose-response relationship. The percentage of cell apoptosis increased with the enhancing of concentration. In the high-level group the authors found typical DNA ladder eletrophoresis stripe. The result showed that the mechanism of the FPC antineoplastic effect had an intimate relation with its induction to apoptosis and that the result of FPC inducing tumor cell apoptosis had the character of P53 independence.

[ "[", "Study", "of", "fungus", "polysaccharides", "compounds", "(", "FPC", ")", "in", "inducing", "the", "apoptosis", "of", "liver", "cancer", "cell", "Bel-7402", "]", ".", "\n", "To", "observe", "the", "influence", "of", "fungus", "polysaccharides", "compounds", "(", "FPC", ")", "in", "inducing", "human", "liver", "cancer", "cell", "Bel-7402", "apoptosis", "in", "cell", "cultivating", "in", "vitro", ",", "the", "authors", "analyzed", "tumor", "inhibitive", "gene", "P53", "expression", "in", "Bel-7402", "apoptosis", "by", "applying", "double", "immuno", "-", "marker", ".", "The", "result", "showed", "that", "the", "multilevel", "of", "FPC", "could", "all", "apparently", "induce", "Bel-7402", "apoptosis", ".", "With", "the", "enhancement", "of", "FPC", "concentration", ",", "the", "authors", "observed", "chromatin", "condensation", "in", "some", "phases", "companying", "with", "the", "characteristic", "apoptosis", ".", "In", "the", "meantime", ",", "it", "could", "also", "greatly", "reduce", "the", "G1", "and", "S", ",", "with", "obviously", "dose", "-", "response", "relationship", ".", "The", "percentage", "of", "cell", "apoptosis", "increased", "with", "the", "enhancing", "of", "concentration", ".", "In", "the", "high", "-", "level", "group", "the", "authors", "found", "typical", "DNA", "ladder", "eletrophoresis", "stripe", ".", "The", "result", "showed", "that", "the", "mechanism", "of", "the", "FPC", "antineoplastic", "effect", "had", "an", "intimate", "relation", "with", "its", "induction", "to", "apoptosis", "and", "that", "the", "result", "of", "FPC", "inducing", "tumor", "cell", "apoptosis", "had", "the", "character", "of", "P53", "independence", ".", "\n" ]

[ "Cell", "Cancer", "Cellular_component" ]

liver cancer cell Bel-7402 ] is a Cell, liver cancer cell Bel-7402 is a Cell, cell is a Cell, tumor is a Cancer, Bel-7402 is a Cell, Bel-7402 is a Cell, chromatin is a Cellular_component, cell is a Cell, tumor cell is a Cell

PMID-11255762_task1

Sentence: [Study of fungus polysaccharides compounds (FPC) in inducing the apoptosis of liver cancer cell Bel-7402]. To observe the influence of fungus polysaccharides compounds (FPC) in inducing human liver cancer cell Bel-7402 apoptosis in cell cultivating in vitro, the authors analyzed tumor inhibitive gene P53 expression in Bel-7402 apoptosis by applying double immuno-marker. The result showed that the multilevel of FPC could all apparently induce Bel-7402 apoptosis. With the enhancement of FPC concentration, the authors observed chromatin condensation in some phases companying with the characteristic apoptosis. In the meantime, it could also greatly reduce the G1 and S, with obviously dose-response relationship. The percentage of cell apoptosis increased with the enhancing of concentration. In the high-level group the authors found typical DNA ladder eletrophoresis stripe. The result showed that the mechanism of the FPC antineoplastic effect had an intimate relation with its induction to apoptosis and that the result of FPC inducing tumor cell apoptosis had the character of P53 independence. Instructions: please typing these entity words according to sentence: liver cancer cell Bel-7402 ], liver cancer cell Bel-7402, cell, tumor, Bel-7402, Bel-7402, chromatin, cell, tumor cell Options: Cancer, Cellular_component, Cell

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

[Study of fungus polysaccharides compounds (FPC) in inducing the apoptosis of liver cancer cell Bel-7402]. To observe the influence of fungus polysaccharides compounds (FPC) in inducing human liver cancer cell Bel-7402 apoptosis in cell cultivating in vitro, the authors analyzed tumor inhibitive gene P53 expression in Bel-7402 apoptosis by applying double immuno-marker. The result showed that the multilevel of FPC could all apparently induce Bel-7402 apoptosis. With the enhancement of FPC concentration, the authors observed chromatin condensation in some phases companying with the characteristic apoptosis. In the meantime, it could also greatly reduce the G1 and S, with obviously dose-response relationship. The percentage of cell apoptosis increased with the enhancing of concentration. In the high-level group the authors found typical DNA ladder eletrophoresis stripe. The result showed that the mechanism of the FPC antineoplastic effect had an intimate relation with its induction to apoptosis and that the result of FPC inducing tumor cell apoptosis had the character of P53 independence.

[ "[", "Study", "of", "fungus", "polysaccharides", "compounds", "(", "FPC", ")", "in", "inducing", "the", "apoptosis", "of", "liver", "cancer", "cell", "Bel-7402", "]", ".", "\n", "To", "observe", "the", "influence", "of", "fungus", "polysaccharides", "compounds", "(", "FPC", ")", "in", "inducing", "human", "liver", "cancer", "cell", "Bel-7402", "apoptosis", "in", "cell", "cultivating", "in", "vitro", ",", "the", "authors", "analyzed", "tumor", "inhibitive", "gene", "P53", "expression", "in", "Bel-7402", "apoptosis", "by", "applying", "double", "immuno", "-", "marker", ".", "The", "result", "showed", "that", "the", "multilevel", "of", "FPC", "could", "all", "apparently", "induce", "Bel-7402", "apoptosis", ".", "With", "the", "enhancement", "of", "FPC", "concentration", ",", "the", "authors", "observed", "chromatin", "condensation", "in", "some", "phases", "companying", "with", "the", "characteristic", "apoptosis", ".", "In", "the", "meantime", ",", "it", "could", "also", "greatly", "reduce", "the", "G1", "and", "S", ",", "with", "obviously", "dose", "-", "response", "relationship", ".", "The", "percentage", "of", "cell", "apoptosis", "increased", "with", "the", "enhancing", "of", "concentration", ".", "In", "the", "high", "-", "level", "group", "the", "authors", "found", "typical", "DNA", "ladder", "eletrophoresis", "stripe", ".", "The", "result", "showed", "that", "the", "mechanism", "of", "the", "FPC", "antineoplastic", "effect", "had", "an", "intimate", "relation", "with", "its", "induction", "to", "apoptosis", "and", "that", "the", "result", "of", "FPC", "inducing", "tumor", "cell", "apoptosis", "had", "the", "character", "of", "P53", "independence", ".", "\n" ]

[ "Cell", "Cancer", "Cellular_component" ]

liver cancer cell Bel-7402 ], liver cancer cell Bel-7402, cell, tumor, Bel-7402, Bel-7402, chromatin, cell, tumor cell

PMID-11255762_task2

Sentence: [Study of fungus polysaccharides compounds (FPC) in inducing the apoptosis of liver cancer cell Bel-7402]. To observe the influence of fungus polysaccharides compounds (FPC) in inducing human liver cancer cell Bel-7402 apoptosis in cell cultivating in vitro, the authors analyzed tumor inhibitive gene P53 expression in Bel-7402 apoptosis by applying double immuno-marker. The result showed that the multilevel of FPC could all apparently induce Bel-7402 apoptosis. With the enhancement of FPC concentration, the authors observed chromatin condensation in some phases companying with the characteristic apoptosis. In the meantime, it could also greatly reduce the G1 and S, with obviously dose-response relationship. The percentage of cell apoptosis increased with the enhancing of concentration. In the high-level group the authors found typical DNA ladder eletrophoresis stripe. The result showed that the mechanism of the FPC antineoplastic effect had an intimate relation with its induction to apoptosis and that the result of FPC inducing tumor cell apoptosis had the character of P53 independence. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

[Study of fungus polysaccharides compounds (FPC) in inducing the apoptosis of liver cancer cell Bel-7402]. To observe the influence of fungus polysaccharides compounds (FPC) in inducing human liver cancer cell Bel-7402 apoptosis in cell cultivating in vitro, the authors analyzed tumor inhibitive gene P53 expression in Bel-7402 apoptosis by applying double immuno-marker. The result showed that the multilevel of FPC could all apparently induce Bel-7402 apoptosis. With the enhancement of FPC concentration, the authors observed chromatin condensation in some phases companying with the characteristic apoptosis. In the meantime, it could also greatly reduce the G1 and S, with obviously dose-response relationship. The percentage of cell apoptosis increased with the enhancing of concentration. In the high-level group the authors found typical DNA ladder eletrophoresis stripe. The result showed that the mechanism of the FPC antineoplastic effect had an intimate relation with its induction to apoptosis and that the result of FPC inducing tumor cell apoptosis had the character of P53 independence.

[ "[", "Study", "of", "fungus", "polysaccharides", "compounds", "(", "FPC", ")", "in", "inducing", "the", "apoptosis", "of", "liver", "cancer", "cell", "Bel-7402", "]", ".", "\n", "To", "observe", "the", "influence", "of", "fungus", "polysaccharides", "compounds", "(", "FPC", ")", "in", "inducing", "human", "liver", "cancer", "cell", "Bel-7402", "apoptosis", "in", "cell", "cultivating", "in", "vitro", ",", "the", "authors", "analyzed", "tumor", "inhibitive", "gene", "P53", "expression", "in", "Bel-7402", "apoptosis", "by", "applying", "double", "immuno", "-", "marker", ".", "The", "result", "showed", "that", "the", "multilevel", "of", "FPC", "could", "all", "apparently", "induce", "Bel-7402", "apoptosis", ".", "With", "the", "enhancement", "of", "FPC", "concentration", ",", "the", "authors", "observed", "chromatin", "condensation", "in", "some", "phases", "companying", "with", "the", "characteristic", "apoptosis", ".", "In", "the", "meantime", ",", "it", "could", "also", "greatly", "reduce", "the", "G1", "and", "S", ",", "with", "obviously", "dose", "-", "response", "relationship", ".", "The", "percentage", "of", "cell", "apoptosis", "increased", "with", "the", "enhancing", "of", "concentration", ".", "In", "the", "high", "-", "level", "group", "the", "authors", "found", "typical", "DNA", "ladder", "eletrophoresis", "stripe", ".", "The", "result", "showed", "that", "the", "mechanism", "of", "the", "FPC", "antineoplastic", "effect", "had", "an", "intimate", "relation", "with", "its", "induction", "to", "apoptosis", "and", "that", "the", "result", "of", "FPC", "inducing", "tumor", "cell", "apoptosis", "had", "the", "character", "of", "P53", "independence", ".", "\n" ]

[ "Cell", "Cancer", "Cellular_component" ]

Salmonella typhimurium is a Microorganism, Escherichia coli is a Microorganism

4_task0

Sentence: A new purification method for overproduced proteins sensitive to endogenous proteases. Proteolysisis a major problem in purification of overproduced proteins for structural studies. We developed a new method to avoid proteolysis of the products even in cases where popular protease inhibitors do not work effectively. When we cloned FlgF, a flagellar rod protein, from Salmonella typhimurium and overproduced it in Escherichia coli, FlgF was highly susceptible to cleavage by endogenous proteases after cell disruption even in the presence of various protease inhibitors. However, FlgF was not digested when the cells were disrupted in the presence of urea, which allowed us to develop the following new purification procedure. After cell disruption in the presence of urea and removal of the cell debris, the supernatant was passed through tandem-connected cation- and anion-exchange columns. Proteases were trapped in the cation-exchange column, and protease-free FlgF was eluted from the disconnected anion-exchange column. This gave a stable full-length product suitable for crystallization trials. The key procedures are cell disruption in the presence of urea and linked ion-exchange chromatography to quickly remove proteases as well as urea. This fast and simple method can be applied to purification of other overproduced proteins that are very sensitive to proteolysis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Microorganism

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A new purification method for overproduced proteins sensitive to endogenous proteases. Proteolysisis a major problem in purification of overproduced proteins for structural studies. We developed a new method to avoid proteolysis of the products even in cases where popular protease inhibitors do not work effectively. When we cloned FlgF, a flagellar rod protein, from Salmonella typhimurium and overproduced it in Escherichia coli, FlgF was highly susceptible to cleavage by endogenous proteases after cell disruption even in the presence of various protease inhibitors. However, FlgF was not digested when the cells were disrupted in the presence of urea, which allowed us to develop the following new purification procedure. After cell disruption in the presence of urea and removal of the cell debris, the supernatant was passed through tandem-connected cation- and anion-exchange columns. Proteases were trapped in the cation-exchange column, and protease-free FlgF was eluted from the disconnected anion-exchange column. This gave a stable full-length product suitable for crystallization trials. The key procedures are cell disruption in the presence of urea and linked ion-exchange chromatography to quickly remove proteases as well as urea. This fast and simple method can be applied to purification of other overproduced proteins that are very sensitive to proteolysis.

[ "A", "new", "purification", "method", "for", "overproduced", "proteins", "sensitive", "to", "endogenous", "proteases", ".", "Proteolysisis", "a", "major", "problem", "in", "purification", "of", "overproduced", "proteins", "for", "structural", "studies", ".", "We", "developed", "a", "new", "method", "to", "avoid", "proteolysis", "of", "the", "products", "even", "in", "cases", "where", "popular", "protease", "inhibitors", "do", "not", "work", "effectively", ".", "When", "we", "cloned", "FlgF", ",", "a", "flagellar", "rod", "protein", ",", "from", "Salmonella", "typhimurium", "and", "overproduced", "it", "in", "Escherichia", "coli", ",", "FlgF", "was", "highly", "susceptible", "to", "cleavage", "by", "endogenous", "proteases", "after", "cell", "disruption", "even", "in", "the", "presence", "of", "various", "protease", "inhibitors", ".", "However", ",", "FlgF", "was", "not", "digested", "when", "the", "cells", "were", "disrupted", "in", "the", "presence", "of", "urea", ",", "which", "allowed", "us", "to", "develop", "the", "following", "new", "purification", "procedure", ".", "After", "cell", "disruption", "in", "the", "presence", "of", "urea", "and", "removal", "of", "the", "cell", "debris", ",", "the", "supernatant", "was", "passed", "through", "tandem", "-", "connected", "cation-", "and", "anion", "-", "exchange", "columns", ".", "Proteases", "were", "trapped", "in", "the", "cation", "-", "exchange", "column", ",", "and", "protease", "-", "free", "FlgF", "was", "eluted", "from", "the", "disconnected", "anion", "-", "exchange", "column", ".", "This", "gave", "a", "stable", "full", "-", "length", "product", "suitable", "for", "crystallization", "trials", ".", "The", "key", "procedures", "are", "cell", "disruption", "in", "the", "presence", "of", "urea", "and", "linked", "ion", "-", "exchange", "chromatography", "to", "quickly", "remove", "proteases", "as", "well", "as", "urea", ".", "This", "fast", "and", "simple", "method", "can", "be", "applied", "to", "purification", "of", "other", "overproduced", "proteins", "that", "are", "very", "sensitive", "to", "proteolysis", ".", " " ]

[ "Microorganism" ]

Salmonella typhimurium is a Microorganism, Escherichia coli is a Microorganism

4_task1

Sentence: A new purification method for overproduced proteins sensitive to endogenous proteases. Proteolysisis a major problem in purification of overproduced proteins for structural studies. We developed a new method to avoid proteolysis of the products even in cases where popular protease inhibitors do not work effectively. When we cloned FlgF, a flagellar rod protein, from Salmonella typhimurium and overproduced it in Escherichia coli, FlgF was highly susceptible to cleavage by endogenous proteases after cell disruption even in the presence of various protease inhibitors. However, FlgF was not digested when the cells were disrupted in the presence of urea, which allowed us to develop the following new purification procedure. After cell disruption in the presence of urea and removal of the cell debris, the supernatant was passed through tandem-connected cation- and anion-exchange columns. Proteases were trapped in the cation-exchange column, and protease-free FlgF was eluted from the disconnected anion-exchange column. This gave a stable full-length product suitable for crystallization trials. The key procedures are cell disruption in the presence of urea and linked ion-exchange chromatography to quickly remove proteases as well as urea. This fast and simple method can be applied to purification of other overproduced proteins that are very sensitive to proteolysis. Instructions: please typing these entity words according to sentence: Salmonella typhimurium, Escherichia coli Options: Microorganism

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A new purification method for overproduced proteins sensitive to endogenous proteases. Proteolysisis a major problem in purification of overproduced proteins for structural studies. We developed a new method to avoid proteolysis of the products even in cases where popular protease inhibitors do not work effectively. When we cloned FlgF, a flagellar rod protein, from Salmonella typhimurium and overproduced it in Escherichia coli, FlgF was highly susceptible to cleavage by endogenous proteases after cell disruption even in the presence of various protease inhibitors. However, FlgF was not digested when the cells were disrupted in the presence of urea, which allowed us to develop the following new purification procedure. After cell disruption in the presence of urea and removal of the cell debris, the supernatant was passed through tandem-connected cation- and anion-exchange columns. Proteases were trapped in the cation-exchange column, and protease-free FlgF was eluted from the disconnected anion-exchange column. This gave a stable full-length product suitable for crystallization trials. The key procedures are cell disruption in the presence of urea and linked ion-exchange chromatography to quickly remove proteases as well as urea. This fast and simple method can be applied to purification of other overproduced proteins that are very sensitive to proteolysis.

[ "A", "new", "purification", "method", "for", "overproduced", "proteins", "sensitive", "to", "endogenous", "proteases", ".", "Proteolysisis", "a", "major", "problem", "in", "purification", "of", "overproduced", "proteins", "for", "structural", "studies", ".", "We", "developed", "a", "new", "method", "to", "avoid", "proteolysis", "of", "the", "products", "even", "in", "cases", "where", "popular", "protease", "inhibitors", "do", "not", "work", "effectively", ".", "When", "we", "cloned", "FlgF", ",", "a", "flagellar", "rod", "protein", ",", "from", "Salmonella", "typhimurium", "and", "overproduced", "it", "in", "Escherichia", "coli", ",", "FlgF", "was", "highly", "susceptible", "to", "cleavage", "by", "endogenous", "proteases", "after", "cell", "disruption", "even", "in", "the", "presence", "of", "various", "protease", "inhibitors", ".", "However", ",", "FlgF", "was", "not", "digested", "when", "the", "cells", "were", "disrupted", "in", "the", "presence", "of", "urea", ",", "which", "allowed", "us", "to", "develop", "the", "following", "new", "purification", "procedure", ".", "After", "cell", "disruption", "in", "the", "presence", "of", "urea", "and", "removal", "of", "the", "cell", "debris", ",", "the", "supernatant", "was", "passed", "through", "tandem", "-", "connected", "cation-", "and", "anion", "-", "exchange", "columns", ".", "Proteases", "were", "trapped", "in", "the", "cation", "-", "exchange", "column", ",", "and", "protease", "-", "free", "FlgF", "was", "eluted", "from", "the", "disconnected", "anion", "-", "exchange", "column", ".", "This", "gave", "a", "stable", "full", "-", "length", "product", "suitable", "for", "crystallization", "trials", ".", "The", "key", "procedures", "are", "cell", "disruption", "in", "the", "presence", "of", "urea", "and", "linked", "ion", "-", "exchange", "chromatography", "to", "quickly", "remove", "proteases", "as", "well", "as", "urea", ".", "This", "fast", "and", "simple", "method", "can", "be", "applied", "to", "purification", "of", "other", "overproduced", "proteins", "that", "are", "very", "sensitive", "to", "proteolysis", ".", " " ]

[ "Microorganism" ]

Salmonella typhimurium, Escherichia coli

4_task2

Sentence: A new purification method for overproduced proteins sensitive to endogenous proteases. Proteolysisis a major problem in purification of overproduced proteins for structural studies. We developed a new method to avoid proteolysis of the products even in cases where popular protease inhibitors do not work effectively. When we cloned FlgF, a flagellar rod protein, from Salmonella typhimurium and overproduced it in Escherichia coli, FlgF was highly susceptible to cleavage by endogenous proteases after cell disruption even in the presence of various protease inhibitors. However, FlgF was not digested when the cells were disrupted in the presence of urea, which allowed us to develop the following new purification procedure. After cell disruption in the presence of urea and removal of the cell debris, the supernatant was passed through tandem-connected cation- and anion-exchange columns. Proteases were trapped in the cation-exchange column, and protease-free FlgF was eluted from the disconnected anion-exchange column. This gave a stable full-length product suitable for crystallization trials. The key procedures are cell disruption in the presence of urea and linked ion-exchange chromatography to quickly remove proteases as well as urea. This fast and simple method can be applied to purification of other overproduced proteins that are very sensitive to proteolysis. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A new purification method for overproduced proteins sensitive to endogenous proteases. Proteolysisis a major problem in purification of overproduced proteins for structural studies. We developed a new method to avoid proteolysis of the products even in cases where popular protease inhibitors do not work effectively. When we cloned FlgF, a flagellar rod protein, from Salmonella typhimurium and overproduced it in Escherichia coli, FlgF was highly susceptible to cleavage by endogenous proteases after cell disruption even in the presence of various protease inhibitors. However, FlgF was not digested when the cells were disrupted in the presence of urea, which allowed us to develop the following new purification procedure. After cell disruption in the presence of urea and removal of the cell debris, the supernatant was passed through tandem-connected cation- and anion-exchange columns. Proteases were trapped in the cation-exchange column, and protease-free FlgF was eluted from the disconnected anion-exchange column. This gave a stable full-length product suitable for crystallization trials. The key procedures are cell disruption in the presence of urea and linked ion-exchange chromatography to quickly remove proteases as well as urea. This fast and simple method can be applied to purification of other overproduced proteins that are very sensitive to proteolysis.

[ "A", "new", "purification", "method", "for", "overproduced", "proteins", "sensitive", "to", "endogenous", "proteases", ".", "Proteolysisis", "a", "major", "problem", "in", "purification", "of", "overproduced", "proteins", "for", "structural", "studies", ".", "We", "developed", "a", "new", "method", "to", "avoid", "proteolysis", "of", "the", "products", "even", "in", "cases", "where", "popular", "protease", "inhibitors", "do", "not", "work", "effectively", ".", "When", "we", "cloned", "FlgF", ",", "a", "flagellar", "rod", "protein", ",", "from", "Salmonella", "typhimurium", "and", "overproduced", "it", "in", "Escherichia", "coli", ",", "FlgF", "was", "highly", "susceptible", "to", "cleavage", "by", "endogenous", "proteases", "after", "cell", "disruption", "even", "in", "the", "presence", "of", "various", "protease", "inhibitors", ".", "However", ",", "FlgF", "was", "not", "digested", "when", "the", "cells", "were", "disrupted", "in", "the", "presence", "of", "urea", ",", "which", "allowed", "us", "to", "develop", "the", "following", "new", "purification", "procedure", ".", "After", "cell", "disruption", "in", "the", "presence", "of", "urea", "and", "removal", "of", "the", "cell", "debris", ",", "the", "supernatant", "was", "passed", "through", "tandem", "-", "connected", "cation-", "and", "anion", "-", "exchange", "columns", ".", "Proteases", "were", "trapped", "in", "the", "cation", "-", "exchange", "column", ",", "and", "protease", "-", "free", "FlgF", "was", "eluted", "from", "the", "disconnected", "anion", "-", "exchange", "column", ".", "This", "gave", "a", "stable", "full", "-", "length", "product", "suitable", "for", "crystallization", "trials", ".", "The", "key", "procedures", "are", "cell", "disruption", "in", "the", "presence", "of", "urea", "and", "linked", "ion", "-", "exchange", "chromatography", "to", "quickly", "remove", "proteases", "as", "well", "as", "urea", ".", "This", "fast", "and", "simple", "method", "can", "be", "applied", "to", "purification", "of", "other", "overproduced", "proteins", "that", "are", "very", "sensitive", "to", "proteolysis", ".", " " ]

[ "Microorganism" ]

Gesichtshaelfte is an umlsterm, Patienten is an umlsterm, wachsende is an umlsterm, Tumoren is an umlsterm, Schilddruesenlaborparameter is an umlsterm, antinukleaere Antikoerper is an umlsterm, Kontaktallergien is an umlsterm, Angiosarkom is an umlsterm, Therapie is an umlsterm, Radiotherapie is an umlsterm, rezidivfreies is an umlsterm

DerHautarzt.00510419.ger.abstr_task0

Sentence: Kutane Angiosarkome entwickeln sich am Kapillitium und der oberen Gesichtshaelfte aelterer Patienten als schnell wachsende , roetlich-livide Infiltrate und Knoten , die bluten und exulzerieren koennen . Die Tumoren sind aggressiv , rezidivieren haeufig und metastasieren haematogen und lymphogen . Wir berichten ueber eine 48jaehrige Patientin mit einer einseitigen Lidschwellung als Erstmanifestation eines kutanen Angiosarkoms . Trotz der ungewoehnlichen Klinik und zunaechst nicht-Malignom-verdaechtiger Befunde wie pathologische Schilddruesenlaborparameter , antinukleaere Antikoerper und multiple Kontaktallergien wurde ein hochdifferenziertes Angiosarkom bioptisch gesichert . Nach radikaler chirurgischer Therapie und postoperativer Radiotherapie konnte in einem Nachbeobachtungszeitraum von 26 Monaten ein rezidivfreies Ergebnis ohne Anhaltspunkt fuer Metastasierung erzielt werden . Das Fallbeispiel soll veranschaulichen , dass bei einseitigen Lid- bzw. Periorbitalschwellungen differential-diagnostisch immer ein neoplastischer Prozess in Erwaegung gezogen werden sollte . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Kutane Angiosarkome entwickeln sich am Kapillitium und der oberen Gesichtshaelfte aelterer Patienten als schnell wachsende , roetlich-livide Infiltrate und Knoten , die bluten und exulzerieren koennen . Die Tumoren sind aggressiv , rezidivieren haeufig und metastasieren haematogen und lymphogen . Wir berichten ueber eine 48jaehrige Patientin mit einer einseitigen Lidschwellung als Erstmanifestation eines kutanen Angiosarkoms . Trotz der ungewoehnlichen Klinik und zunaechst nicht-Malignom-verdaechtiger Befunde wie pathologische Schilddruesenlaborparameter , antinukleaere Antikoerper und multiple Kontaktallergien wurde ein hochdifferenziertes Angiosarkom bioptisch gesichert . Nach radikaler chirurgischer Therapie und postoperativer Radiotherapie konnte in einem Nachbeobachtungszeitraum von 26 Monaten ein rezidivfreies Ergebnis ohne Anhaltspunkt fuer Metastasierung erzielt werden . Das Fallbeispiel soll veranschaulichen , dass bei einseitigen Lid- bzw. Periorbitalschwellungen differential-diagnostisch immer ein neoplastischer Prozess in Erwaegung gezogen werden sollte .

[ "Kutane", "Angiosarkome", "entwickeln", "sich", "am", "Kapillitium", "und", "der", "oberen", "Gesichtshaelfte", "aelterer", "Patienten", "als", "schnell", "wachsende", ",", "roetlich", "-", "livide", "Infiltrate", "und", "Knoten", ",", "die", "bluten", "und", "exulzerieren", "koennen", ".", "Die", "Tumoren", "sind", "aggressiv", ",", "rezidivieren", "haeufig", "und", "metastasieren", "haematogen", "und", "lymphogen", ".", "Wir", "berichten", "ueber", "eine", "48jaehrige", "Patientin", "mit", "einer", "einseitigen", "Lidschwellung", "als", "Erstmanifestation", "eines", "kutanen", "Angiosarkoms", ".", "Trotz", "der", "ungewoehnlichen", "Klinik", "und", "zunaechst", "nicht", "-", "Malignom", "-", "verdaechtiger", "Befunde", "wie", "pathologische", "Schilddruesenlaborparameter", ",", "antinukleaere", "Antikoerper", "und", "multiple", "Kontaktallergien", "wurde", "ein", "hochdifferenziertes", "Angiosarkom", "bioptisch", "gesichert", ".", "Nach", "radikaler", "chirurgischer", "Therapie", "und", "postoperativer", "Radiotherapie", "konnte", "in", "einem", "Nachbeobachtungszeitraum", "von", "26", "Monaten", "ein", "rezidivfreies", "Ergebnis", "ohne", "Anhaltspunkt", "fuer", "Metastasierung", "erzielt", "werden", ".", "Das", "Fallbeispiel", "soll", "veranschaulichen", ",", "dass", "bei", "einseitigen", "Lid-", "bzw", ".", "Periorbitalschwellungen", "differential", "-", "diagnostisch", "immer", "ein", "neoplastischer", "Prozess", "in", "Erwaegung", "gezogen", "werden", "sollte", "." ]

[ "umlsterm" ]

Gesichtshaelfte is an umlsterm, Patienten is an umlsterm, wachsende is an umlsterm, Tumoren is an umlsterm, Schilddruesenlaborparameter is an umlsterm, antinukleaere Antikoerper is an umlsterm, Kontaktallergien is an umlsterm, Angiosarkom is an umlsterm, Therapie is an umlsterm, Radiotherapie is an umlsterm, rezidivfreies is an umlsterm

DerHautarzt.00510419.ger.abstr_task1

Sentence: Kutane Angiosarkome entwickeln sich am Kapillitium und der oberen Gesichtshaelfte aelterer Patienten als schnell wachsende , roetlich-livide Infiltrate und Knoten , die bluten und exulzerieren koennen . Die Tumoren sind aggressiv , rezidivieren haeufig und metastasieren haematogen und lymphogen . Wir berichten ueber eine 48jaehrige Patientin mit einer einseitigen Lidschwellung als Erstmanifestation eines kutanen Angiosarkoms . Trotz der ungewoehnlichen Klinik und zunaechst nicht-Malignom-verdaechtiger Befunde wie pathologische Schilddruesenlaborparameter , antinukleaere Antikoerper und multiple Kontaktallergien wurde ein hochdifferenziertes Angiosarkom bioptisch gesichert . Nach radikaler chirurgischer Therapie und postoperativer Radiotherapie konnte in einem Nachbeobachtungszeitraum von 26 Monaten ein rezidivfreies Ergebnis ohne Anhaltspunkt fuer Metastasierung erzielt werden . Das Fallbeispiel soll veranschaulichen , dass bei einseitigen Lid- bzw. Periorbitalschwellungen differential-diagnostisch immer ein neoplastischer Prozess in Erwaegung gezogen werden sollte . Instructions: please typing these entity words according to sentence: Gesichtshaelfte, Patienten, wachsende, Tumoren, Schilddruesenlaborparameter, antinukleaere Antikoerper, Kontaktallergien, Angiosarkom, Therapie, Radiotherapie, rezidivfreies Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Kutane Angiosarkome entwickeln sich am Kapillitium und der oberen Gesichtshaelfte aelterer Patienten als schnell wachsende , roetlich-livide Infiltrate und Knoten , die bluten und exulzerieren koennen . Die Tumoren sind aggressiv , rezidivieren haeufig und metastasieren haematogen und lymphogen . Wir berichten ueber eine 48jaehrige Patientin mit einer einseitigen Lidschwellung als Erstmanifestation eines kutanen Angiosarkoms . Trotz der ungewoehnlichen Klinik und zunaechst nicht-Malignom-verdaechtiger Befunde wie pathologische Schilddruesenlaborparameter , antinukleaere Antikoerper und multiple Kontaktallergien wurde ein hochdifferenziertes Angiosarkom bioptisch gesichert . Nach radikaler chirurgischer Therapie und postoperativer Radiotherapie konnte in einem Nachbeobachtungszeitraum von 26 Monaten ein rezidivfreies Ergebnis ohne Anhaltspunkt fuer Metastasierung erzielt werden . Das Fallbeispiel soll veranschaulichen , dass bei einseitigen Lid- bzw. Periorbitalschwellungen differential-diagnostisch immer ein neoplastischer Prozess in Erwaegung gezogen werden sollte .

[ "Kutane", "Angiosarkome", "entwickeln", "sich", "am", "Kapillitium", "und", "der", "oberen", "Gesichtshaelfte", "aelterer", "Patienten", "als", "schnell", "wachsende", ",", "roetlich", "-", "livide", "Infiltrate", "und", "Knoten", ",", "die", "bluten", "und", "exulzerieren", "koennen", ".", "Die", "Tumoren", "sind", "aggressiv", ",", "rezidivieren", "haeufig", "und", "metastasieren", "haematogen", "und", "lymphogen", ".", "Wir", "berichten", "ueber", "eine", "48jaehrige", "Patientin", "mit", "einer", "einseitigen", "Lidschwellung", "als", "Erstmanifestation", "eines", "kutanen", "Angiosarkoms", ".", "Trotz", "der", "ungewoehnlichen", "Klinik", "und", "zunaechst", "nicht", "-", "Malignom", "-", "verdaechtiger", "Befunde", "wie", "pathologische", "Schilddruesenlaborparameter", ",", "antinukleaere", "Antikoerper", "und", "multiple", "Kontaktallergien", "wurde", "ein", "hochdifferenziertes", "Angiosarkom", "bioptisch", "gesichert", ".", "Nach", "radikaler", "chirurgischer", "Therapie", "und", "postoperativer", "Radiotherapie", "konnte", "in", "einem", "Nachbeobachtungszeitraum", "von", "26", "Monaten", "ein", "rezidivfreies", "Ergebnis", "ohne", "Anhaltspunkt", "fuer", "Metastasierung", "erzielt", "werden", ".", "Das", "Fallbeispiel", "soll", "veranschaulichen", ",", "dass", "bei", "einseitigen", "Lid-", "bzw", ".", "Periorbitalschwellungen", "differential", "-", "diagnostisch", "immer", "ein", "neoplastischer", "Prozess", "in", "Erwaegung", "gezogen", "werden", "sollte", "." ]

[ "umlsterm" ]

Gesichtshaelfte, Patienten, wachsende, Tumoren, Schilddruesenlaborparameter, antinukleaere Antikoerper, Kontaktallergien, Angiosarkom, Therapie, Radiotherapie, rezidivfreies

DerHautarzt.00510419.ger.abstr_task2

Sentence: Kutane Angiosarkome entwickeln sich am Kapillitium und der oberen Gesichtshaelfte aelterer Patienten als schnell wachsende , roetlich-livide Infiltrate und Knoten , die bluten und exulzerieren koennen . Die Tumoren sind aggressiv , rezidivieren haeufig und metastasieren haematogen und lymphogen . Wir berichten ueber eine 48jaehrige Patientin mit einer einseitigen Lidschwellung als Erstmanifestation eines kutanen Angiosarkoms . Trotz der ungewoehnlichen Klinik und zunaechst nicht-Malignom-verdaechtiger Befunde wie pathologische Schilddruesenlaborparameter , antinukleaere Antikoerper und multiple Kontaktallergien wurde ein hochdifferenziertes Angiosarkom bioptisch gesichert . Nach radikaler chirurgischer Therapie und postoperativer Radiotherapie konnte in einem Nachbeobachtungszeitraum von 26 Monaten ein rezidivfreies Ergebnis ohne Anhaltspunkt fuer Metastasierung erzielt werden . Das Fallbeispiel soll veranschaulichen , dass bei einseitigen Lid- bzw. Periorbitalschwellungen differential-diagnostisch immer ein neoplastischer Prozess in Erwaegung gezogen werden sollte . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Kutane Angiosarkome entwickeln sich am Kapillitium und der oberen Gesichtshaelfte aelterer Patienten als schnell wachsende , roetlich-livide Infiltrate und Knoten , die bluten und exulzerieren koennen . Die Tumoren sind aggressiv , rezidivieren haeufig und metastasieren haematogen und lymphogen . Wir berichten ueber eine 48jaehrige Patientin mit einer einseitigen Lidschwellung als Erstmanifestation eines kutanen Angiosarkoms . Trotz der ungewoehnlichen Klinik und zunaechst nicht-Malignom-verdaechtiger Befunde wie pathologische Schilddruesenlaborparameter , antinukleaere Antikoerper und multiple Kontaktallergien wurde ein hochdifferenziertes Angiosarkom bioptisch gesichert . Nach radikaler chirurgischer Therapie und postoperativer Radiotherapie konnte in einem Nachbeobachtungszeitraum von 26 Monaten ein rezidivfreies Ergebnis ohne Anhaltspunkt fuer Metastasierung erzielt werden . Das Fallbeispiel soll veranschaulichen , dass bei einseitigen Lid- bzw. Periorbitalschwellungen differential-diagnostisch immer ein neoplastischer Prozess in Erwaegung gezogen werden sollte .

[ "Kutane", "Angiosarkome", "entwickeln", "sich", "am", "Kapillitium", "und", "der", "oberen", "Gesichtshaelfte", "aelterer", "Patienten", "als", "schnell", "wachsende", ",", "roetlich", "-", "livide", "Infiltrate", "und", "Knoten", ",", "die", "bluten", "und", "exulzerieren", "koennen", ".", "Die", "Tumoren", "sind", "aggressiv", ",", "rezidivieren", "haeufig", "und", "metastasieren", "haematogen", "und", "lymphogen", ".", "Wir", "berichten", "ueber", "eine", "48jaehrige", "Patientin", "mit", "einer", "einseitigen", "Lidschwellung", "als", "Erstmanifestation", "eines", "kutanen", "Angiosarkoms", ".", "Trotz", "der", "ungewoehnlichen", "Klinik", "und", "zunaechst", "nicht", "-", "Malignom", "-", "verdaechtiger", "Befunde", "wie", "pathologische", "Schilddruesenlaborparameter", ",", "antinukleaere", "Antikoerper", "und", "multiple", "Kontaktallergien", "wurde", "ein", "hochdifferenziertes", "Angiosarkom", "bioptisch", "gesichert", ".", "Nach", "radikaler", "chirurgischer", "Therapie", "und", "postoperativer", "Radiotherapie", "konnte", "in", "einem", "Nachbeobachtungszeitraum", "von", "26", "Monaten", "ein", "rezidivfreies", "Ergebnis", "ohne", "Anhaltspunkt", "fuer", "Metastasierung", "erzielt", "werden", ".", "Das", "Fallbeispiel", "soll", "veranschaulichen", ",", "dass", "bei", "einseitigen", "Lid-", "bzw", ".", "Periorbitalschwellungen", "differential", "-", "diagnostisch", "immer", "ein", "neoplastischer", "Prozess", "in", "Erwaegung", "gezogen", "werden", "sollte", "." ]

[ "umlsterm" ]

p27Kip1 is a Protein, p27Kip1 is a Protein, p27Kip1 is a Protein, p27Kip1 is a Protein, p27Kip1 is a Protein, p27Kip1 is a Protein, Sp1 is a Protein, Myb is a Protein, p27Kip1 is a Protein

653_task0

Sentence: Characterization of the murine cyclin-dependent kinase inhibitor gene p27Kip1. The cyclin-dependent kinase inhibitor p27Kip1 plays an important role in regulating cell-cycle progression. p27Kip1 directly inhibits the catalytic activity of cyclin/cdks (cyclin-dependent kinase) complexes and/or interferes physically with cyclin/cdks activation by CAK. Interestingly, the expression level of p27Kip1 mRNA was maximal in resting Go T-cells and rapidly declined following anti-CD3 activation. We report here the cloning of p27Kip1 gene from murine genomic DNA and the functional analysis of the promoter of the p27Kip1 gene. The gene consists of at least three exons and spans more than 5.6 kb of DNA. Primer extension and nuclease S1 protection analysis revealed two major transcription initiation sites. The promoter region lacked a TATA box but contained potential binding sites for the transcriptional factors including two Sp1, CRE, Myb and NFkB located at positions -153, -178, -286, -875, and -1011, respectively. To analyze the regulatory mechanisms controlling p27Kip1 gene expression, we characterized the 5'-flanking region from nt -1609 to +178. The -326 to -615 region contained positive regulatory elements. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Characterization of the murine cyclin-dependent kinase inhibitor gene p27Kip1. The cyclin-dependent kinase inhibitor p27Kip1 plays an important role in regulating cell-cycle progression. p27Kip1 directly inhibits the catalytic activity of cyclin/cdks (cyclin-dependent kinase) complexes and/or interferes physically with cyclin/cdks activation by CAK. Interestingly, the expression level of p27Kip1 mRNA was maximal in resting Go T-cells and rapidly declined following anti-CD3 activation. We report here the cloning of p27Kip1 gene from murine genomic DNA and the functional analysis of the promoter of the p27Kip1 gene. The gene consists of at least three exons and spans more than 5.6 kb of DNA. Primer extension and nuclease S1 protection analysis revealed two major transcription initiation sites. The promoter region lacked a TATA box but contained potential binding sites for the transcriptional factors including two Sp1, CRE, Myb and NFkB located at positions -153, -178, -286, -875, and -1011, respectively. To analyze the regulatory mechanisms controlling p27Kip1 gene expression, we characterized the 5'-flanking region from nt -1609 to +178. The -326 to -615 region contained positive regulatory elements.

[ "Characterization", "of", "the", "murine", "cyclin", "-", "dependent", "kinase", "inhibitor", "gene", "p27Kip1", ".", "\n", "The", "cyclin", "-", "dependent", "kinase", "inhibitor", "p27Kip1", "plays", "an", "important", "role", "in", "regulating", "cell", "-", "cycle", "progression", ".", "p27Kip1", "directly", "inhibits", "the", "catalytic", "activity", "of", "cyclin", "/", "cdks", "(", "cyclin", "-", "dependent", "kinase", ")", "complexes", "and", "/", "or", "interferes", "physically", "with", "cyclin", "/", "cdks", "activation", "by", "CAK", ".", "Interestingly", ",", "the", "expression", "level", "of", "p27Kip1", "mRNA", "was", "maximal", "in", "resting", "Go", "T", "-", "cells", "and", "rapidly", "declined", "following", "anti", "-", "CD3", "activation", ".", "We", "report", "here", "the", "cloning", "of", "p27Kip1", "gene", "from", "murine", "genomic", "DNA", "and", "the", "functional", "analysis", "of", "the", "promoter", "of", "the", "p27Kip1", "gene", ".", "The", "gene", "consists", "of", "at", "least", "three", "exons", "and", "spans", "more", "than", "5.6", "kb", "of", "DNA", ".", "Primer", "extension", "and", "nuclease", "S1", "protection", "analysis", "revealed", "two", "major", "transcription", "initiation", "sites", ".", "The", "promoter", "region", "lacked", "a", "TATA", "box", "but", "contained", "potential", "binding", "sites", "for", "the", "transcriptional", "factors", "including", "two", "Sp1", ",", "CRE", ",", "Myb", "and", "NFkB", "located", "at", "positions", "-153", ",", "-178", ",", "-286", ",", "-875", ",", "and", "-1011", ",", "respectively", ".", "To", "analyze", "the", "regulatory", "mechanisms", "controlling", "p27Kip1", "gene", "expression", ",", "we", "characterized", "the", "5'-flanking", "region", "from", "nt", "-1609", "to", "+178", ".", "The", "-326", "to", "-615", "region", "contained", "positive", "regulatory", "elements", "." ]

[ "Protein" ]

p27Kip1 is a Protein, p27Kip1 is a Protein, p27Kip1 is a Protein, p27Kip1 is a Protein, p27Kip1 is a Protein, p27Kip1 is a Protein, Sp1 is a Protein, Myb is a Protein, p27Kip1 is a Protein

653_task1

Sentence: Characterization of the murine cyclin-dependent kinase inhibitor gene p27Kip1. The cyclin-dependent kinase inhibitor p27Kip1 plays an important role in regulating cell-cycle progression. p27Kip1 directly inhibits the catalytic activity of cyclin/cdks (cyclin-dependent kinase) complexes and/or interferes physically with cyclin/cdks activation by CAK. Interestingly, the expression level of p27Kip1 mRNA was maximal in resting Go T-cells and rapidly declined following anti-CD3 activation. We report here the cloning of p27Kip1 gene from murine genomic DNA and the functional analysis of the promoter of the p27Kip1 gene. The gene consists of at least three exons and spans more than 5.6 kb of DNA. Primer extension and nuclease S1 protection analysis revealed two major transcription initiation sites. The promoter region lacked a TATA box but contained potential binding sites for the transcriptional factors including two Sp1, CRE, Myb and NFkB located at positions -153, -178, -286, -875, and -1011, respectively. To analyze the regulatory mechanisms controlling p27Kip1 gene expression, we characterized the 5'-flanking region from nt -1609 to +178. The -326 to -615 region contained positive regulatory elements. Instructions: please typing these entity words according to sentence: p27Kip1, p27Kip1, p27Kip1, p27Kip1, p27Kip1, p27Kip1, Sp1, Myb, p27Kip1 Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Characterization of the murine cyclin-dependent kinase inhibitor gene p27Kip1. The cyclin-dependent kinase inhibitor p27Kip1 plays an important role in regulating cell-cycle progression. p27Kip1 directly inhibits the catalytic activity of cyclin/cdks (cyclin-dependent kinase) complexes and/or interferes physically with cyclin/cdks activation by CAK. Interestingly, the expression level of p27Kip1 mRNA was maximal in resting Go T-cells and rapidly declined following anti-CD3 activation. We report here the cloning of p27Kip1 gene from murine genomic DNA and the functional analysis of the promoter of the p27Kip1 gene. The gene consists of at least three exons and spans more than 5.6 kb of DNA. Primer extension and nuclease S1 protection analysis revealed two major transcription initiation sites. The promoter region lacked a TATA box but contained potential binding sites for the transcriptional factors including two Sp1, CRE, Myb and NFkB located at positions -153, -178, -286, -875, and -1011, respectively. To analyze the regulatory mechanisms controlling p27Kip1 gene expression, we characterized the 5'-flanking region from nt -1609 to +178. The -326 to -615 region contained positive regulatory elements.

[ "Characterization", "of", "the", "murine", "cyclin", "-", "dependent", "kinase", "inhibitor", "gene", "p27Kip1", ".", "\n", "The", "cyclin", "-", "dependent", "kinase", "inhibitor", "p27Kip1", "plays", "an", "important", "role", "in", "regulating", "cell", "-", "cycle", "progression", ".", "p27Kip1", "directly", "inhibits", "the", "catalytic", "activity", "of", "cyclin", "/", "cdks", "(", "cyclin", "-", "dependent", "kinase", ")", "complexes", "and", "/", "or", "interferes", "physically", "with", "cyclin", "/", "cdks", "activation", "by", "CAK", ".", "Interestingly", ",", "the", "expression", "level", "of", "p27Kip1", "mRNA", "was", "maximal", "in", "resting", "Go", "T", "-", "cells", "and", "rapidly", "declined", "following", "anti", "-", "CD3", "activation", ".", "We", "report", "here", "the", "cloning", "of", "p27Kip1", "gene", "from", "murine", "genomic", "DNA", "and", "the", "functional", "analysis", "of", "the", "promoter", "of", "the", "p27Kip1", "gene", ".", "The", "gene", "consists", "of", "at", "least", "three", "exons", "and", "spans", "more", "than", "5.6", "kb", "of", "DNA", ".", "Primer", "extension", "and", "nuclease", "S1", "protection", "analysis", "revealed", "two", "major", "transcription", "initiation", "sites", ".", "The", "promoter", "region", "lacked", "a", "TATA", "box", "but", "contained", "potential", "binding", "sites", "for", "the", "transcriptional", "factors", "including", "two", "Sp1", ",", "CRE", ",", "Myb", "and", "NFkB", "located", "at", "positions", "-153", ",", "-178", ",", "-286", ",", "-875", ",", "and", "-1011", ",", "respectively", ".", "To", "analyze", "the", "regulatory", "mechanisms", "controlling", "p27Kip1", "gene", "expression", ",", "we", "characterized", "the", "5'-flanking", "region", "from", "nt", "-1609", "to", "+178", ".", "The", "-326", "to", "-615", "region", "contained", "positive", "regulatory", "elements", "." ]

[ "Protein" ]

p27Kip1, p27Kip1, p27Kip1, p27Kip1, p27Kip1, p27Kip1, Sp1, Myb, p27Kip1

653_task2

Sentence: Characterization of the murine cyclin-dependent kinase inhibitor gene p27Kip1. The cyclin-dependent kinase inhibitor p27Kip1 plays an important role in regulating cell-cycle progression. p27Kip1 directly inhibits the catalytic activity of cyclin/cdks (cyclin-dependent kinase) complexes and/or interferes physically with cyclin/cdks activation by CAK. Interestingly, the expression level of p27Kip1 mRNA was maximal in resting Go T-cells and rapidly declined following anti-CD3 activation. We report here the cloning of p27Kip1 gene from murine genomic DNA and the functional analysis of the promoter of the p27Kip1 gene. The gene consists of at least three exons and spans more than 5.6 kb of DNA. Primer extension and nuclease S1 protection analysis revealed two major transcription initiation sites. The promoter region lacked a TATA box but contained potential binding sites for the transcriptional factors including two Sp1, CRE, Myb and NFkB located at positions -153, -178, -286, -875, and -1011, respectively. To analyze the regulatory mechanisms controlling p27Kip1 gene expression, we characterized the 5'-flanking region from nt -1609 to +178. The -326 to -615 region contained positive regulatory elements. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Characterization of the murine cyclin-dependent kinase inhibitor gene p27Kip1. The cyclin-dependent kinase inhibitor p27Kip1 plays an important role in regulating cell-cycle progression. p27Kip1 directly inhibits the catalytic activity of cyclin/cdks (cyclin-dependent kinase) complexes and/or interferes physically with cyclin/cdks activation by CAK. Interestingly, the expression level of p27Kip1 mRNA was maximal in resting Go T-cells and rapidly declined following anti-CD3 activation. We report here the cloning of p27Kip1 gene from murine genomic DNA and the functional analysis of the promoter of the p27Kip1 gene. The gene consists of at least three exons and spans more than 5.6 kb of DNA. Primer extension and nuclease S1 protection analysis revealed two major transcription initiation sites. The promoter region lacked a TATA box but contained potential binding sites for the transcriptional factors including two Sp1, CRE, Myb and NFkB located at positions -153, -178, -286, -875, and -1011, respectively. To analyze the regulatory mechanisms controlling p27Kip1 gene expression, we characterized the 5'-flanking region from nt -1609 to +178. The -326 to -615 region contained positive regulatory elements.

[ "Characterization", "of", "the", "murine", "cyclin", "-", "dependent", "kinase", "inhibitor", "gene", "p27Kip1", ".", "\n", "The", "cyclin", "-", "dependent", "kinase", "inhibitor", "p27Kip1", "plays", "an", "important", "role", "in", "regulating", "cell", "-", "cycle", "progression", ".", "p27Kip1", "directly", "inhibits", "the", "catalytic", "activity", "of", "cyclin", "/", "cdks", "(", "cyclin", "-", "dependent", "kinase", ")", "complexes", "and", "/", "or", "interferes", "physically", "with", "cyclin", "/", "cdks", "activation", "by", "CAK", ".", "Interestingly", ",", "the", "expression", "level", "of", "p27Kip1", "mRNA", "was", "maximal", "in", "resting", "Go", "T", "-", "cells", "and", "rapidly", "declined", "following", "anti", "-", "CD3", "activation", ".", "We", "report", "here", "the", "cloning", "of", "p27Kip1", "gene", "from", "murine", "genomic", "DNA", "and", "the", "functional", "analysis", "of", "the", "promoter", "of", "the", "p27Kip1", "gene", ".", "The", "gene", "consists", "of", "at", "least", "three", "exons", "and", "spans", "more", "than", "5.6", "kb", "of", "DNA", ".", "Primer", "extension", "and", "nuclease", "S1", "protection", "analysis", "revealed", "two", "major", "transcription", "initiation", "sites", ".", "The", "promoter", "region", "lacked", "a", "TATA", "box", "but", "contained", "potential", "binding", "sites", "for", "the", "transcriptional", "factors", "including", "two", "Sp1", ",", "CRE", ",", "Myb", "and", "NFkB", "located", "at", "positions", "-153", ",", "-178", ",", "-286", ",", "-875", ",", "and", "-1011", ",", "respectively", ".", "To", "analyze", "the", "regulatory", "mechanisms", "controlling", "p27Kip1", "gene", "expression", ",", "we", "characterized", "the", "5'-flanking", "region", "from", "nt", "-1609", "to", "+178", ".", "The", "-326", "to", "-615", "region", "contained", "positive", "regulatory", "elements", "." ]

[ "Protein" ]

p75 tumor necrosis factor receptor is a Protein, p75TNF - R is a Protein, lymphotoxin alpha is a Protein, p75 tumor necrosis factor receptor is a Protein, p75TNF - R is a Protein, p75TNF - R is a Protein, NF - kappaB is a Entity, lymphotoxin alpha is a Protein, p55TNF - R is a Protein, human TNF transgene is a Entity, p75TNF - R is a Protein

341_task0

Sentence: A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNF-R. Despite overwhelming evidence that enhanced production of the p75 tumor necrosis factor receptor (p75TNF-R) accompanies development of specific human inflammatory pathologies such as multi-organ failure during sepsis, inflammatory liver disease, pancreatitis, respiratory distress syndrome, or AIDS, the function of this receptor remains poorly defined in vivo. We show here that at levels relevant to human disease, production of the human p75TNF-R in transgenic mice results in a severe inflammatory syndrome involving mainly the pancreas, liver, kidney, and lung, and characterized by constitutively increased NF-kappaB activity in the peripheral blood mononuclear cell compartment. This process is shown to evolve independently of the presence of TNF, lymphotoxin alpha, or the p55TNF-R, although coexpression of a human TNF transgene accelerated pathology. These results establish an independent role for enhanced p75TNF-R production in the pathogenesis of inflammatory disease and implicate the direct involvement of this receptor in a wide range of human inflammatory pathologies. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNF-R. Despite overwhelming evidence that enhanced production of the p75 tumor necrosis factor receptor (p75TNF-R) accompanies development of specific human inflammatory pathologies such as multi-organ failure during sepsis, inflammatory liver disease, pancreatitis, respiratory distress syndrome, or AIDS, the function of this receptor remains poorly defined in vivo. We show here that at levels relevant to human disease, production of the human p75TNF-R in transgenic mice results in a severe inflammatory syndrome involving mainly the pancreas, liver, kidney, and lung, and characterized by constitutively increased NF-kappaB activity in the peripheral blood mononuclear cell compartment. This process is shown to evolve independently of the presence of TNF, lymphotoxin alpha, or the p55TNF-R, although coexpression of a human TNF transgene accelerated pathology. These results establish an independent role for enhanced p75TNF-R production in the pathogenesis of inflammatory disease and implicate the direct involvement of this receptor in a wide range of human inflammatory pathologies.

[ "A", "critical", "role", "of", "the", "p75", "tumor", "necrosis", "factor", "receptor", "(", "p75TNF", "-", "R", ")", "in", "organ", "inflammation", "independent", "of", "TNF", ",", "lymphotoxin", "alpha", ",", "or", "the", "p55TNF", "-", "R.", "\n", "Despite", "overwhelming", "evidence", "that", "enhanced", "production", "of", "the", "p75", "tumor", "necrosis", "factor", "receptor", "(", "p75TNF", "-", "R", ")", "accompanies", "development", "of", "specific", "human", "inflammatory", "pathologies", "such", "as", "multi", "-", "organ", "failure", "during", "sepsis", ",", "inflammatory", "liver", "disease", ",", "pancreatitis", ",", "respiratory", "distress", "syndrome", ",", "or", "AIDS", ",", "the", "function", "of", "this", "receptor", "remains", "poorly", "defined", "in", "vivo", ".", "We", "show", "here", "that", "at", "levels", "relevant", "to", "human", "disease", ",", "production", "of", "the", "human", "p75TNF", "-", "R", "in", "transgenic", "mice", "results", "in", "a", "severe", "inflammatory", "syndrome", "involving", "mainly", "the", "pancreas", ",", "liver", ",", "kidney", ",", "and", "lung", ",", "and", "characterized", "by", "constitutively", "increased", "NF", "-", "kappaB", "activity", "in", "the", "peripheral", "blood", "mononuclear", "cell", "compartment", ".", "This", "process", "is", "shown", "to", "evolve", "independently", "of", "the", "presence", "of", "TNF", ",", "lymphotoxin", "alpha", ",", "or", "the", "p55TNF", "-", "R", ",", "although", "coexpression", "of", "a", "human", "TNF", "transgene", "accelerated", "pathology", ".", "These", "results", "establish", "an", "independent", "role", "for", "enhanced", "p75TNF", "-", "R", "production", "in", "the", "pathogenesis", "of", "inflammatory", "disease", "and", "implicate", "the", "direct", "involvement", "of", "this", "receptor", "in", "a", "wide", "range", "of", "human", "inflammatory", "pathologies", ".", "\n" ]

[ "Protein", "Entity" ]

p75 tumor necrosis factor receptor is a Protein, p75TNF - R is a Protein, lymphotoxin alpha is a Protein, p75 tumor necrosis factor receptor is a Protein, p75TNF - R is a Protein, p75TNF - R is a Protein, NF - kappaB is a Entity, lymphotoxin alpha is a Protein, p55TNF - R is a Protein, human TNF transgene is a Entity, p75TNF - R is a Protein

341_task1

Sentence: A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNF-R. Despite overwhelming evidence that enhanced production of the p75 tumor necrosis factor receptor (p75TNF-R) accompanies development of specific human inflammatory pathologies such as multi-organ failure during sepsis, inflammatory liver disease, pancreatitis, respiratory distress syndrome, or AIDS, the function of this receptor remains poorly defined in vivo. We show here that at levels relevant to human disease, production of the human p75TNF-R in transgenic mice results in a severe inflammatory syndrome involving mainly the pancreas, liver, kidney, and lung, and characterized by constitutively increased NF-kappaB activity in the peripheral blood mononuclear cell compartment. This process is shown to evolve independently of the presence of TNF, lymphotoxin alpha, or the p55TNF-R, although coexpression of a human TNF transgene accelerated pathology. These results establish an independent role for enhanced p75TNF-R production in the pathogenesis of inflammatory disease and implicate the direct involvement of this receptor in a wide range of human inflammatory pathologies. Instructions: please typing these entity words according to sentence: p75 tumor necrosis factor receptor, p75TNF - R, lymphotoxin alpha, p75 tumor necrosis factor receptor, p75TNF - R, p75TNF - R, NF - kappaB, lymphotoxin alpha, p55TNF - R, human TNF transgene, p75TNF - R Options: Entity, Protein

[ "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNF-R. Despite overwhelming evidence that enhanced production of the p75 tumor necrosis factor receptor (p75TNF-R) accompanies development of specific human inflammatory pathologies such as multi-organ failure during sepsis, inflammatory liver disease, pancreatitis, respiratory distress syndrome, or AIDS, the function of this receptor remains poorly defined in vivo. We show here that at levels relevant to human disease, production of the human p75TNF-R in transgenic mice results in a severe inflammatory syndrome involving mainly the pancreas, liver, kidney, and lung, and characterized by constitutively increased NF-kappaB activity in the peripheral blood mononuclear cell compartment. This process is shown to evolve independently of the presence of TNF, lymphotoxin alpha, or the p55TNF-R, although coexpression of a human TNF transgene accelerated pathology. These results establish an independent role for enhanced p75TNF-R production in the pathogenesis of inflammatory disease and implicate the direct involvement of this receptor in a wide range of human inflammatory pathologies.

[ "A", "critical", "role", "of", "the", "p75", "tumor", "necrosis", "factor", "receptor", "(", "p75TNF", "-", "R", ")", "in", "organ", "inflammation", "independent", "of", "TNF", ",", "lymphotoxin", "alpha", ",", "or", "the", "p55TNF", "-", "R.", "\n", "Despite", "overwhelming", "evidence", "that", "enhanced", "production", "of", "the", "p75", "tumor", "necrosis", "factor", "receptor", "(", "p75TNF", "-", "R", ")", "accompanies", "development", "of", "specific", "human", "inflammatory", "pathologies", "such", "as", "multi", "-", "organ", "failure", "during", "sepsis", ",", "inflammatory", "liver", "disease", ",", "pancreatitis", ",", "respiratory", "distress", "syndrome", ",", "or", "AIDS", ",", "the", "function", "of", "this", "receptor", "remains", "poorly", "defined", "in", "vivo", ".", "We", "show", "here", "that", "at", "levels", "relevant", "to", "human", "disease", ",", "production", "of", "the", "human", "p75TNF", "-", "R", "in", "transgenic", "mice", "results", "in", "a", "severe", "inflammatory", "syndrome", "involving", "mainly", "the", "pancreas", ",", "liver", ",", "kidney", ",", "and", "lung", ",", "and", "characterized", "by", "constitutively", "increased", "NF", "-", "kappaB", "activity", "in", "the", "peripheral", "blood", "mononuclear", "cell", "compartment", ".", "This", "process", "is", "shown", "to", "evolve", "independently", "of", "the", "presence", "of", "TNF", ",", "lymphotoxin", "alpha", ",", "or", "the", "p55TNF", "-", "R", ",", "although", "coexpression", "of", "a", "human", "TNF", "transgene", "accelerated", "pathology", ".", "These", "results", "establish", "an", "independent", "role", "for", "enhanced", "p75TNF", "-", "R", "production", "in", "the", "pathogenesis", "of", "inflammatory", "disease", "and", "implicate", "the", "direct", "involvement", "of", "this", "receptor", "in", "a", "wide", "range", "of", "human", "inflammatory", "pathologies", ".", "\n" ]

[ "Protein", "Entity" ]

p75 tumor necrosis factor receptor, p75TNF - R, lymphotoxin alpha, p75 tumor necrosis factor receptor, p75TNF - R, p75TNF - R, NF - kappaB, lymphotoxin alpha, p55TNF - R, human TNF transgene, p75TNF - R

341_task2

Sentence: A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNF-R. Despite overwhelming evidence that enhanced production of the p75 tumor necrosis factor receptor (p75TNF-R) accompanies development of specific human inflammatory pathologies such as multi-organ failure during sepsis, inflammatory liver disease, pancreatitis, respiratory distress syndrome, or AIDS, the function of this receptor remains poorly defined in vivo. We show here that at levels relevant to human disease, production of the human p75TNF-R in transgenic mice results in a severe inflammatory syndrome involving mainly the pancreas, liver, kidney, and lung, and characterized by constitutively increased NF-kappaB activity in the peripheral blood mononuclear cell compartment. This process is shown to evolve independently of the presence of TNF, lymphotoxin alpha, or the p55TNF-R, although coexpression of a human TNF transgene accelerated pathology. These results establish an independent role for enhanced p75TNF-R production in the pathogenesis of inflammatory disease and implicate the direct involvement of this receptor in a wide range of human inflammatory pathologies. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNF-R. Despite overwhelming evidence that enhanced production of the p75 tumor necrosis factor receptor (p75TNF-R) accompanies development of specific human inflammatory pathologies such as multi-organ failure during sepsis, inflammatory liver disease, pancreatitis, respiratory distress syndrome, or AIDS, the function of this receptor remains poorly defined in vivo. We show here that at levels relevant to human disease, production of the human p75TNF-R in transgenic mice results in a severe inflammatory syndrome involving mainly the pancreas, liver, kidney, and lung, and characterized by constitutively increased NF-kappaB activity in the peripheral blood mononuclear cell compartment. This process is shown to evolve independently of the presence of TNF, lymphotoxin alpha, or the p55TNF-R, although coexpression of a human TNF transgene accelerated pathology. These results establish an independent role for enhanced p75TNF-R production in the pathogenesis of inflammatory disease and implicate the direct involvement of this receptor in a wide range of human inflammatory pathologies.

[ "A", "critical", "role", "of", "the", "p75", "tumor", "necrosis", "factor", "receptor", "(", "p75TNF", "-", "R", ")", "in", "organ", "inflammation", "independent", "of", "TNF", ",", "lymphotoxin", "alpha", ",", "or", "the", "p55TNF", "-", "R.", "\n", "Despite", "overwhelming", "evidence", "that", "enhanced", "production", "of", "the", "p75", "tumor", "necrosis", "factor", "receptor", "(", "p75TNF", "-", "R", ")", "accompanies", "development", "of", "specific", "human", "inflammatory", "pathologies", "such", "as", "multi", "-", "organ", "failure", "during", "sepsis", ",", "inflammatory", "liver", "disease", ",", "pancreatitis", ",", "respiratory", "distress", "syndrome", ",", "or", "AIDS", ",", "the", "function", "of", "this", "receptor", "remains", "poorly", "defined", "in", "vivo", ".", "We", "show", "here", "that", "at", "levels", "relevant", "to", "human", "disease", ",", "production", "of", "the", "human", "p75TNF", "-", "R", "in", "transgenic", "mice", "results", "in", "a", "severe", "inflammatory", "syndrome", "involving", "mainly", "the", "pancreas", ",", "liver", ",", "kidney", ",", "and", "lung", ",", "and", "characterized", "by", "constitutively", "increased", "NF", "-", "kappaB", "activity", "in", "the", "peripheral", "blood", "mononuclear", "cell", "compartment", ".", "This", "process", "is", "shown", "to", "evolve", "independently", "of", "the", "presence", "of", "TNF", ",", "lymphotoxin", "alpha", ",", "or", "the", "p55TNF", "-", "R", ",", "although", "coexpression", "of", "a", "human", "TNF", "transgene", "accelerated", "pathology", ".", "These", "results", "establish", "an", "independent", "role", "for", "enhanced", "p75TNF", "-", "R", "production", "in", "the", "pathogenesis", "of", "inflammatory", "disease", "and", "implicate", "the", "direct", "involvement", "of", "this", "receptor", "in", "a", "wide", "range", "of", "human", "inflammatory", "pathologies", ".", "\n" ]

[ "Protein", "Entity" ]

Acyl - CoA synthetase isoforms 1 , 4 , and 5 is a GENE-N, acyl - CoA synthetase is a GENE-N, ACS is a GENE-N, acyl - CoAs is a CHEMICAL, ACSs is a GENE-N, ACS1 is a GENE-Y, ACS4 is a GENE-Y, ACS5 is a GENE-Y, ACS1 is a GENE-Y, ACS4 is a GENE-Y, ACS5 is a GENE-Y, N - ethylmaleimide is a CHEMICAL, ACS4 is a GENE-Y, ACS is a GENE-N, Troglitazone is a CHEMICAL, ACS4 is a GENE-Y, ACS is a GENE-N, Triacsin C is a CHEMICAL, ACS1 is a GENE-Y, ACS4 is a GENE-Y, ACS is a GENE-N, triacsin is a CHEMICAL, ACS is a GENE-N, ACS1 is a GENE-Y, ACS4 is a GENE-Y, ACS5 is a GENE-Y, ACS4 is a GENE-Y, ACS5 is a GENE-Y, sucrose is a CHEMICAL, ACS1 is a GENE-Y, ACS4 is a GENE-Y, ACS1 is a GENE-Y, ACS4 is a GENE-Y, triacylglycerol is a CHEMICAL, acyl - CoAs is a CHEMICAL, ACS is a GENE-N

8550_task0

Sentence: Acyl-CoA synthetase isoforms 1, 4, and 5 are present in different subcellular membranes in rat liver and can be inhibited independently. Inhibition studies have suggested that acyl-CoA synthetase (ACS, EC ) isoforms might regulate the use of acyl-CoAs by different metabolic pathways. In order to determine whether the subcellular locations differed for each of the three ACSs present in liver and whether these isoforms were regulated independently, non-cross-reacting peptide antibodies were raised against ACS1, ACS4, and ACS5. ACS1 was identified in endoplasmic reticulum, mitochondria-associated membrane (MAM), and cytosol, but not in mitochondria. ACS4 was present primarily in MAM, and the 76-kDa ACS5 protein was located in mitochondrial membrane. Consistent with these locations, N-ethylmaleimide, an inhibitor of ACS4, inhibited ACS activity 47% in MAM and 28% in endoplasmic reticulum. Troglitazone, a second ACS4 inhibitor, inhibited ACS activity <10% in microsomes and mitochondria and 45% in MAM. Triacsin C, a competitive inhibitor of both ACS1 and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria. ACS1, ACS4, and ACS5 were regulated independently by fasting and re-feeding. Fasting rats for 48 h resulted in a decrease in ACS4 protein, and an increase in ACS5. Re-feeding normal chow or a high sucrose diet for 24 h after a 48-h fast increased both ACS1 and ACS4 protein expression 1.5-2.0-fold, consistent with inhibition studies. These results suggest that ACS1 and ACS4 may be linked to triacylglycerol synthesis. Taken together, the data suggest that acyl-CoAs may be functionally channeled to specific metabolic pathways through different ACS isoforms in unique subcellular locations. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N, CHEMICAL

[ "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O" ]

Acyl-CoA synthetase isoforms 1, 4, and 5 are present in different subcellular membranes in rat liver and can be inhibited independently. Inhibition studies have suggested that acyl-CoA synthetase (ACS, EC ) isoforms might regulate the use of acyl-CoAs by different metabolic pathways. In order to determine whether the subcellular locations differed for each of the three ACSs present in liver and whether these isoforms were regulated independently, non-cross-reacting peptide antibodies were raised against ACS1, ACS4, and ACS5. ACS1 was identified in endoplasmic reticulum, mitochondria-associated membrane (MAM), and cytosol, but not in mitochondria. ACS4 was present primarily in MAM, and the 76-kDa ACS5 protein was located in mitochondrial membrane. Consistent with these locations, N-ethylmaleimide, an inhibitor of ACS4, inhibited ACS activity 47% in MAM and 28% in endoplasmic reticulum. Troglitazone, a second ACS4 inhibitor, inhibited ACS activity <10% in microsomes and mitochondria and 45% in MAM. Triacsin C, a competitive inhibitor of both ACS1 and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria. ACS1, ACS4, and ACS5 were regulated independently by fasting and re-feeding. Fasting rats for 48 h resulted in a decrease in ACS4 protein, and an increase in ACS5. Re-feeding normal chow or a high sucrose diet for 24 h after a 48-h fast increased both ACS1 and ACS4 protein expression 1.5-2.0-fold, consistent with inhibition studies. These results suggest that ACS1 and ACS4 may be linked to triacylglycerol synthesis. Taken together, the data suggest that acyl-CoAs may be functionally channeled to specific metabolic pathways through different ACS isoforms in unique subcellular locations.

[ "Acyl", "-", "CoA", "synthetase", "isoforms", "1", ",", "4", ",", "and", "5", "are", "present", "in", "different", "subcellular", "membranes", "in", "rat", "liver", "and", "can", "be", "inhibited", "independently", ".", "\n", "Inhibition", "studies", "have", "suggested", "that", "acyl", "-", "CoA", "synthetase", "(", "ACS", ",", "EC", ")", "isoforms", "might", "regulate", "the", "use", "of", "acyl", "-", "CoAs", "by", "different", "metabolic", "pathways", ".", "In", "order", "to", "determine", "whether", "the", "subcellular", "locations", "differed", "for", "each", "of", "the", "three", "ACSs", "present", "in", "liver", "and", "whether", "these", "isoforms", "were", "regulated", "independently", ",", "non", "-", "cross", "-", "reacting", "peptide", "antibodies", "were", "raised", "against", "ACS1", ",", "ACS4", ",", "and", "ACS5", ".", "ACS1", "was", "identified", "in", "endoplasmic", "reticulum", ",", "mitochondria", "-", "associated", "membrane", "(", "MAM", ")", ",", "and", "cytosol", ",", "but", "not", "in", "mitochondria", ".", "ACS4", "was", "present", "primarily", "in", "MAM", ",", "and", "the", "76-kDa", "ACS5", "protein", "was", "located", "in", "mitochondrial", "membrane", ".", "Consistent", "with", "these", "locations", ",", "N", "-", "ethylmaleimide", ",", "an", "inhibitor", "of", "ACS4", ",", "inhibited", "ACS", "activity", "47", "%", "in", "MAM", "and", "28", "%", "in", "endoplasmic", "reticulum", ".", "Troglitazone", ",", "a", "second", "ACS4", "inhibitor", ",", "inhibited", "ACS", "activity", "<", "10", "%", "in", "microsomes", "and", "mitochondria", "and", "45", "%", "in", "MAM", ".", "Triacsin", "C", ",", "a", "competitive", "inhibitor", "of", "both", "ACS1", "and", "ACS4", ",", "inhibited", "ACS", "activity", "similarly", "in", "endoplasmic", "reticulum", ",", "MAM", ",", "and", "mitochondria", ",", "suggesting", "that", "a", "hitherto", "unidentified", "triacsin", "-", "sensitive", "ACS", "is", "present", "in", "mitochondria", ".", "ACS1", ",", "ACS4", ",", "and", "ACS5", "were", "regulated", "independently", "by", "fasting", "and", "re", "-", "feeding", ".", "Fasting", "rats", "for", "48", "h", "resulted", "in", "a", "decrease", "in", "ACS4", "protein", ",", "and", "an", "increase", "in", "ACS5", ".", "Re", "-", "feeding", "normal", "chow", "or", "a", "high", "sucrose", "diet", "for", "24", "h", "after", "a", "48-h", "fast", "increased", "both", "ACS1", "and", "ACS4", "protein", "expression", "1.5", "-", "2.0-fold", ",", "consistent", "with", "inhibition", "studies", ".", "These", "results", "suggest", "that", "ACS1", "and", "ACS4", "may", "be", "linked", "to", "triacylglycerol", "synthesis", ".", "Taken", "together", ",", "the", "data", "suggest", "that", "acyl", "-", "CoAs", "may", "be", "functionally", "channeled", "to", "specific", "metabolic", "pathways", "through", "different", "ACS", "isoforms", "in", "unique", "subcellular", "locations", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

Acyl - CoA synthetase isoforms 1 , 4 , and 5 is a GENE-N, acyl - CoA synthetase is a GENE-N, ACS is a GENE-N, acyl - CoAs is a CHEMICAL, ACSs is a GENE-N, ACS1 is a GENE-Y, ACS4 is a GENE-Y, ACS5 is a GENE-Y, ACS1 is a GENE-Y, ACS4 is a GENE-Y, ACS5 is a GENE-Y, N - ethylmaleimide is a CHEMICAL, ACS4 is a GENE-Y, ACS is a GENE-N, Troglitazone is a CHEMICAL, ACS4 is a GENE-Y, ACS is a GENE-N, Triacsin C is a CHEMICAL, ACS1 is a GENE-Y, ACS4 is a GENE-Y, ACS is a GENE-N, triacsin is a CHEMICAL, ACS is a GENE-N, ACS1 is a GENE-Y, ACS4 is a GENE-Y, ACS5 is a GENE-Y, ACS4 is a GENE-Y, ACS5 is a GENE-Y, sucrose is a CHEMICAL, ACS1 is a GENE-Y, ACS4 is a GENE-Y, ACS1 is a GENE-Y, ACS4 is a GENE-Y, triacylglycerol is a CHEMICAL, acyl - CoAs is a CHEMICAL, ACS is a GENE-N

8550_task1

Sentence: Acyl-CoA synthetase isoforms 1, 4, and 5 are present in different subcellular membranes in rat liver and can be inhibited independently. Inhibition studies have suggested that acyl-CoA synthetase (ACS, EC ) isoforms might regulate the use of acyl-CoAs by different metabolic pathways. In order to determine whether the subcellular locations differed for each of the three ACSs present in liver and whether these isoforms were regulated independently, non-cross-reacting peptide antibodies were raised against ACS1, ACS4, and ACS5. ACS1 was identified in endoplasmic reticulum, mitochondria-associated membrane (MAM), and cytosol, but not in mitochondria. ACS4 was present primarily in MAM, and the 76-kDa ACS5 protein was located in mitochondrial membrane. Consistent with these locations, N-ethylmaleimide, an inhibitor of ACS4, inhibited ACS activity 47% in MAM and 28% in endoplasmic reticulum. Troglitazone, a second ACS4 inhibitor, inhibited ACS activity <10% in microsomes and mitochondria and 45% in MAM. Triacsin C, a competitive inhibitor of both ACS1 and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria. ACS1, ACS4, and ACS5 were regulated independently by fasting and re-feeding. Fasting rats for 48 h resulted in a decrease in ACS4 protein, and an increase in ACS5. Re-feeding normal chow or a high sucrose diet for 24 h after a 48-h fast increased both ACS1 and ACS4 protein expression 1.5-2.0-fold, consistent with inhibition studies. These results suggest that ACS1 and ACS4 may be linked to triacylglycerol synthesis. Taken together, the data suggest that acyl-CoAs may be functionally channeled to specific metabolic pathways through different ACS isoforms in unique subcellular locations. Instructions: please typing these entity words according to sentence: Acyl - CoA synthetase isoforms 1 , 4 , and 5, acyl - CoA synthetase, ACS, acyl - CoAs, ACSs, ACS1, ACS4, ACS5, ACS1, ACS4, ACS5, N - ethylmaleimide, ACS4, ACS, Troglitazone, ACS4, ACS, Triacsin C, ACS1, ACS4, ACS, triacsin, ACS, ACS1, ACS4, ACS5, ACS4, ACS5, sucrose, ACS1, ACS4, ACS1, ACS4, triacylglycerol, acyl - CoAs, ACS Options: GENE-Y, GENE-N, CHEMICAL

[ "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O" ]

Acyl-CoA synthetase isoforms 1, 4, and 5 are present in different subcellular membranes in rat liver and can be inhibited independently. Inhibition studies have suggested that acyl-CoA synthetase (ACS, EC ) isoforms might regulate the use of acyl-CoAs by different metabolic pathways. In order to determine whether the subcellular locations differed for each of the three ACSs present in liver and whether these isoforms were regulated independently, non-cross-reacting peptide antibodies were raised against ACS1, ACS4, and ACS5. ACS1 was identified in endoplasmic reticulum, mitochondria-associated membrane (MAM), and cytosol, but not in mitochondria. ACS4 was present primarily in MAM, and the 76-kDa ACS5 protein was located in mitochondrial membrane. Consistent with these locations, N-ethylmaleimide, an inhibitor of ACS4, inhibited ACS activity 47% in MAM and 28% in endoplasmic reticulum. Troglitazone, a second ACS4 inhibitor, inhibited ACS activity <10% in microsomes and mitochondria and 45% in MAM. Triacsin C, a competitive inhibitor of both ACS1 and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria. ACS1, ACS4, and ACS5 were regulated independently by fasting and re-feeding. Fasting rats for 48 h resulted in a decrease in ACS4 protein, and an increase in ACS5. Re-feeding normal chow or a high sucrose diet for 24 h after a 48-h fast increased both ACS1 and ACS4 protein expression 1.5-2.0-fold, consistent with inhibition studies. These results suggest that ACS1 and ACS4 may be linked to triacylglycerol synthesis. Taken together, the data suggest that acyl-CoAs may be functionally channeled to specific metabolic pathways through different ACS isoforms in unique subcellular locations.

[ "Acyl", "-", "CoA", "synthetase", "isoforms", "1", ",", "4", ",", "and", "5", "are", "present", "in", "different", "subcellular", "membranes", "in", "rat", "liver", "and", "can", "be", "inhibited", "independently", ".", "\n", "Inhibition", "studies", "have", "suggested", "that", "acyl", "-", "CoA", "synthetase", "(", "ACS", ",", "EC", ")", "isoforms", "might", "regulate", "the", "use", "of", "acyl", "-", "CoAs", "by", "different", "metabolic", "pathways", ".", "In", "order", "to", "determine", "whether", "the", "subcellular", "locations", "differed", "for", "each", "of", "the", "three", "ACSs", "present", "in", "liver", "and", "whether", "these", "isoforms", "were", "regulated", "independently", ",", "non", "-", "cross", "-", "reacting", "peptide", "antibodies", "were", "raised", "against", "ACS1", ",", "ACS4", ",", "and", "ACS5", ".", "ACS1", "was", "identified", "in", "endoplasmic", "reticulum", ",", "mitochondria", "-", "associated", "membrane", "(", "MAM", ")", ",", "and", "cytosol", ",", "but", "not", "in", "mitochondria", ".", "ACS4", "was", "present", "primarily", "in", "MAM", ",", "and", "the", "76-kDa", "ACS5", "protein", "was", "located", "in", "mitochondrial", "membrane", ".", "Consistent", "with", "these", "locations", ",", "N", "-", "ethylmaleimide", ",", "an", "inhibitor", "of", "ACS4", ",", "inhibited", "ACS", "activity", "47", "%", "in", "MAM", "and", "28", "%", "in", "endoplasmic", "reticulum", ".", "Troglitazone", ",", "a", "second", "ACS4", "inhibitor", ",", "inhibited", "ACS", "activity", "<", "10", "%", "in", "microsomes", "and", "mitochondria", "and", "45", "%", "in", "MAM", ".", "Triacsin", "C", ",", "a", "competitive", "inhibitor", "of", "both", "ACS1", "and", "ACS4", ",", "inhibited", "ACS", "activity", "similarly", "in", "endoplasmic", "reticulum", ",", "MAM", ",", "and", "mitochondria", ",", "suggesting", "that", "a", "hitherto", "unidentified", "triacsin", "-", "sensitive", "ACS", "is", "present", "in", "mitochondria", ".", "ACS1", ",", "ACS4", ",", "and", "ACS5", "were", "regulated", "independently", "by", "fasting", "and", "re", "-", "feeding", ".", "Fasting", "rats", "for", "48", "h", "resulted", "in", "a", "decrease", "in", "ACS4", "protein", ",", "and", "an", "increase", "in", "ACS5", ".", "Re", "-", "feeding", "normal", "chow", "or", "a", "high", "sucrose", "diet", "for", "24", "h", "after", "a", "48-h", "fast", "increased", "both", "ACS1", "and", "ACS4", "protein", "expression", "1.5", "-", "2.0-fold", ",", "consistent", "with", "inhibition", "studies", ".", "These", "results", "suggest", "that", "ACS1", "and", "ACS4", "may", "be", "linked", "to", "triacylglycerol", "synthesis", ".", "Taken", "together", ",", "the", "data", "suggest", "that", "acyl", "-", "CoAs", "may", "be", "functionally", "channeled", "to", "specific", "metabolic", "pathways", "through", "different", "ACS", "isoforms", "in", "unique", "subcellular", "locations", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

Acyl - CoA synthetase isoforms 1 , 4 , and 5, acyl - CoA synthetase, ACS, acyl - CoAs, ACSs, ACS1, ACS4, ACS5, ACS1, ACS4, ACS5, N - ethylmaleimide, ACS4, ACS, Troglitazone, ACS4, ACS, Triacsin C, ACS1, ACS4, ACS, triacsin, ACS, ACS1, ACS4, ACS5, ACS4, ACS5, sucrose, ACS1, ACS4, ACS1, ACS4, triacylglycerol, acyl - CoAs, ACS

8550_task2

Sentence: Acyl-CoA synthetase isoforms 1, 4, and 5 are present in different subcellular membranes in rat liver and can be inhibited independently. Inhibition studies have suggested that acyl-CoA synthetase (ACS, EC ) isoforms might regulate the use of acyl-CoAs by different metabolic pathways. In order to determine whether the subcellular locations differed for each of the three ACSs present in liver and whether these isoforms were regulated independently, non-cross-reacting peptide antibodies were raised against ACS1, ACS4, and ACS5. ACS1 was identified in endoplasmic reticulum, mitochondria-associated membrane (MAM), and cytosol, but not in mitochondria. ACS4 was present primarily in MAM, and the 76-kDa ACS5 protein was located in mitochondrial membrane. Consistent with these locations, N-ethylmaleimide, an inhibitor of ACS4, inhibited ACS activity 47% in MAM and 28% in endoplasmic reticulum. Troglitazone, a second ACS4 inhibitor, inhibited ACS activity <10% in microsomes and mitochondria and 45% in MAM. Triacsin C, a competitive inhibitor of both ACS1 and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria. ACS1, ACS4, and ACS5 were regulated independently by fasting and re-feeding. Fasting rats for 48 h resulted in a decrease in ACS4 protein, and an increase in ACS5. Re-feeding normal chow or a high sucrose diet for 24 h after a 48-h fast increased both ACS1 and ACS4 protein expression 1.5-2.0-fold, consistent with inhibition studies. These results suggest that ACS1 and ACS4 may be linked to triacylglycerol synthesis. Taken together, the data suggest that acyl-CoAs may be functionally channeled to specific metabolic pathways through different ACS isoforms in unique subcellular locations. Instructions: please extract entity words from the input sentence

[ "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O" ]

Acyl-CoA synthetase isoforms 1, 4, and 5 are present in different subcellular membranes in rat liver and can be inhibited independently. Inhibition studies have suggested that acyl-CoA synthetase (ACS, EC ) isoforms might regulate the use of acyl-CoAs by different metabolic pathways. In order to determine whether the subcellular locations differed for each of the three ACSs present in liver and whether these isoforms were regulated independently, non-cross-reacting peptide antibodies were raised against ACS1, ACS4, and ACS5. ACS1 was identified in endoplasmic reticulum, mitochondria-associated membrane (MAM), and cytosol, but not in mitochondria. ACS4 was present primarily in MAM, and the 76-kDa ACS5 protein was located in mitochondrial membrane. Consistent with these locations, N-ethylmaleimide, an inhibitor of ACS4, inhibited ACS activity 47% in MAM and 28% in endoplasmic reticulum. Troglitazone, a second ACS4 inhibitor, inhibited ACS activity <10% in microsomes and mitochondria and 45% in MAM. Triacsin C, a competitive inhibitor of both ACS1 and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria. ACS1, ACS4, and ACS5 were regulated independently by fasting and re-feeding. Fasting rats for 48 h resulted in a decrease in ACS4 protein, and an increase in ACS5. Re-feeding normal chow or a high sucrose diet for 24 h after a 48-h fast increased both ACS1 and ACS4 protein expression 1.5-2.0-fold, consistent with inhibition studies. These results suggest that ACS1 and ACS4 may be linked to triacylglycerol synthesis. Taken together, the data suggest that acyl-CoAs may be functionally channeled to specific metabolic pathways through different ACS isoforms in unique subcellular locations.

[ "Acyl", "-", "CoA", "synthetase", "isoforms", "1", ",", "4", ",", "and", "5", "are", "present", "in", "different", "subcellular", "membranes", "in", "rat", "liver", "and", "can", "be", "inhibited", "independently", ".", "\n", "Inhibition", "studies", "have", "suggested", "that", "acyl", "-", "CoA", "synthetase", "(", "ACS", ",", "EC", ")", "isoforms", "might", "regulate", "the", "use", "of", "acyl", "-", "CoAs", "by", "different", "metabolic", "pathways", ".", "In", "order", "to", "determine", "whether", "the", "subcellular", "locations", "differed", "for", "each", "of", "the", "three", "ACSs", "present", "in", "liver", "and", "whether", "these", "isoforms", "were", "regulated", "independently", ",", "non", "-", "cross", "-", "reacting", "peptide", "antibodies", "were", "raised", "against", "ACS1", ",", "ACS4", ",", "and", "ACS5", ".", "ACS1", "was", "identified", "in", "endoplasmic", "reticulum", ",", "mitochondria", "-", "associated", "membrane", "(", "MAM", ")", ",", "and", "cytosol", ",", "but", "not", "in", "mitochondria", ".", "ACS4", "was", "present", "primarily", "in", "MAM", ",", "and", "the", "76-kDa", "ACS5", "protein", "was", "located", "in", "mitochondrial", "membrane", ".", "Consistent", "with", "these", "locations", ",", "N", "-", "ethylmaleimide", ",", "an", "inhibitor", "of", "ACS4", ",", "inhibited", "ACS", "activity", "47", "%", "in", "MAM", "and", "28", "%", "in", "endoplasmic", "reticulum", ".", "Troglitazone", ",", "a", "second", "ACS4", "inhibitor", ",", "inhibited", "ACS", "activity", "<", "10", "%", "in", "microsomes", "and", "mitochondria", "and", "45", "%", "in", "MAM", ".", "Triacsin", "C", ",", "a", "competitive", "inhibitor", "of", "both", "ACS1", "and", "ACS4", ",", "inhibited", "ACS", "activity", "similarly", "in", "endoplasmic", "reticulum", ",", "MAM", ",", "and", "mitochondria", ",", "suggesting", "that", "a", "hitherto", "unidentified", "triacsin", "-", "sensitive", "ACS", "is", "present", "in", "mitochondria", ".", "ACS1", ",", "ACS4", ",", "and", "ACS5", "were", "regulated", "independently", "by", "fasting", "and", "re", "-", "feeding", ".", "Fasting", "rats", "for", "48", "h", "resulted", "in", "a", "decrease", "in", "ACS4", "protein", ",", "and", "an", "increase", "in", "ACS5", ".", "Re", "-", "feeding", "normal", "chow", "or", "a", "high", "sucrose", "diet", "for", "24", "h", "after", "a", "48-h", "fast", "increased", "both", "ACS1", "and", "ACS4", "protein", "expression", "1.5", "-", "2.0-fold", ",", "consistent", "with", "inhibition", "studies", ".", "These", "results", "suggest", "that", "ACS1", "and", "ACS4", "may", "be", "linked", "to", "triacylglycerol", "synthesis", ".", "Taken", "together", ",", "the", "data", "suggest", "that", "acyl", "-", "CoAs", "may", "be", "functionally", "channeled", "to", "specific", "metabolic", "pathways", "through", "different", "ACS", "isoforms", "in", "unique", "subcellular", "locations", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

use is an umlsterm, non - biologic is an umlsterm, head is an umlsterm, neck is an umlsterm, surgery is an umlsterm, tissue compatibility is an umlsterm, epithelial cells is an umlsterm, mesenchymatic is an umlsterm, cells is an umlsterm, human is an umlsterm, fibroblasts is an umlsterm, keratinocytes is an umlsterm, oral mucosa is an umlsterm, cell culture is an umlsterm, tissue culture is an umlsterm, keratinocyte is an umlsterm, flaps is an umlsterm, histology is an umlsterm, scanning electron microscopy is an umlsterm, Cellulose - ester is an umlsterm, polyglactin is an umlsterm, fibroblasts is an umlsterm, keratinocytes is an umlsterm, cell cultures is an umlsterm, tissue culture is an umlsterm, flaps is an umlsterm, keratinocytes is an umlsterm, polytetrafluor - ethylene is an umlsterm, fibroblasts is an umlsterm, keratinocytes is an umlsterm, cell culture is an umlsterm, cell is an umlsterm, tissue culture is an umlsterm, flaps is an umlsterm, mesenchymatic is an umlsterm, cell is an umlsterm, tissue cultures is an umlsterm, growth is an umlsterm, non - biologic is an umlsterm, implants is an umlsterm, method is an umlsterm, development is an umlsterm, non - biologic is an umlsterm, implantation is an umlsterm

HNO.00480430.eng.abstr_task0

Sentence: Successful use of non-biologic implants in reconstructive head and neck surgery is dependent on tissue compatibility and epithelization . This is true not only for epithelial cells , but also for mesenchymatic cells . Therefore we tested several substrates with human fibroblasts or keratinocytes from the oral mucosa in cell culture . In tissue culture keratinocyte outgrowth from small mucosal flaps onto the surface was observed . Preparations were evaluated by histology and scanning electron microscopy . Cellulose-ester , polyvinylidene-difluoride and polyglactin developed monolayers of fibroblasts and keratinocytes in cell cultures . In tissue culture mucosal flaps showed good adherence to the surface of these materials and a fine outgrowth of keratinocytes . Expanded polytetrafluor-ethylene ( ePTFE ) was partially covered by a layer of fibroblasts and keratinocytes in cell culture , but cell adherence was not sufficient . In tissue culture the mucosal flaps failed to attach on ePTFE . These results illustrate that the mesenchymatic and epithelial component of cell and tissue cultures show different qualities of cellular adherence and growth on the surface of non-biologic implants . We propose our method for the development of an in-vitro model for the epithelization of non-biologic implantation materials . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O" ]

Successful use of non-biologic implants in reconstructive head and neck surgery is dependent on tissue compatibility and epithelization . This is true not only for epithelial cells , but also for mesenchymatic cells . Therefore we tested several substrates with human fibroblasts or keratinocytes from the oral mucosa in cell culture . In tissue culture keratinocyte outgrowth from small mucosal flaps onto the surface was observed . Preparations were evaluated by histology and scanning electron microscopy . Cellulose-ester , polyvinylidene-difluoride and polyglactin developed monolayers of fibroblasts and keratinocytes in cell cultures . In tissue culture mucosal flaps showed good adherence to the surface of these materials and a fine outgrowth of keratinocytes . Expanded polytetrafluor-ethylene ( ePTFE ) was partially covered by a layer of fibroblasts and keratinocytes in cell culture , but cell adherence was not sufficient . In tissue culture the mucosal flaps failed to attach on ePTFE . These results illustrate that the mesenchymatic and epithelial component of cell and tissue cultures show different qualities of cellular adherence and growth on the surface of non-biologic implants . We propose our method for the development of an in-vitro model for the epithelization of non-biologic implantation materials .

[ "Successful", "use", "of", "non", "-", "biologic", "implants", "in", "reconstructive", "head", "and", "neck", "surgery", "is", "dependent", "on", "tissue", "compatibility", "and", "epithelization", ".", "This", "is", "true", "not", "only", "for", "epithelial", "cells", ",", "but", "also", "for", "mesenchymatic", "cells", ".", "Therefore", "we", "tested", "several", "substrates", "with", "human", "fibroblasts", "or", "keratinocytes", "from", "the", "oral", "mucosa", "in", "cell", "culture", ".", "In", "tissue", "culture", "keratinocyte", "outgrowth", "from", "small", "mucosal", "flaps", "onto", "the", "surface", "was", "observed", ".", "Preparations", "were", "evaluated", "by", "histology", "and", "scanning", "electron", "microscopy", ".", "Cellulose", "-", "ester", ",", "polyvinylidene", "-", "difluoride", "and", "polyglactin", "developed", "monolayers", "of", "fibroblasts", "and", "keratinocytes", "in", "cell", "cultures", ".", "In", "tissue", "culture", "mucosal", "flaps", "showed", "good", "adherence", "to", "the", "surface", "of", "these", "materials", "and", "a", "fine", "outgrowth", "of", "keratinocytes", ".", "Expanded", "polytetrafluor", "-", "ethylene", "(", "ePTFE", ")", "was", "partially", "covered", "by", "a", "layer", "of", "fibroblasts", "and", "keratinocytes", "in", "cell", "culture", ",", "but", "cell", "adherence", "was", "not", "sufficient", ".", "In", "tissue", "culture", "the", "mucosal", "flaps", "failed", "to", "attach", "on", "ePTFE", ".", "These", "results", "illustrate", "that", "the", "mesenchymatic", "and", "epithelial", "component", "of", "cell", "and", "tissue", "cultures", "show", "different", "qualities", "of", "cellular", "adherence", "and", "growth", "on", "the", "surface", "of", "non", "-", "biologic", "implants", ".", "We", "propose", "our", "method", "for", "the", "development", "of", "an", "in", "-", "vitro", "model", "for", "the", "epithelization", "of", "non", "-", "biologic", "implantation", "materials", "." ]

[ "umlsterm" ]

use is an umlsterm, non - biologic is an umlsterm, head is an umlsterm, neck is an umlsterm, surgery is an umlsterm, tissue compatibility is an umlsterm, epithelial cells is an umlsterm, mesenchymatic is an umlsterm, cells is an umlsterm, human is an umlsterm, fibroblasts is an umlsterm, keratinocytes is an umlsterm, oral mucosa is an umlsterm, cell culture is an umlsterm, tissue culture is an umlsterm, keratinocyte is an umlsterm, flaps is an umlsterm, histology is an umlsterm, scanning electron microscopy is an umlsterm, Cellulose - ester is an umlsterm, polyglactin is an umlsterm, fibroblasts is an umlsterm, keratinocytes is an umlsterm, cell cultures is an umlsterm, tissue culture is an umlsterm, flaps is an umlsterm, keratinocytes is an umlsterm, polytetrafluor - ethylene is an umlsterm, fibroblasts is an umlsterm, keratinocytes is an umlsterm, cell culture is an umlsterm, cell is an umlsterm, tissue culture is an umlsterm, flaps is an umlsterm, mesenchymatic is an umlsterm, cell is an umlsterm, tissue cultures is an umlsterm, growth is an umlsterm, non - biologic is an umlsterm, implants is an umlsterm, method is an umlsterm, development is an umlsterm, non - biologic is an umlsterm, implantation is an umlsterm

HNO.00480430.eng.abstr_task1

Sentence: Successful use of non-biologic implants in reconstructive head and neck surgery is dependent on tissue compatibility and epithelization . This is true not only for epithelial cells , but also for mesenchymatic cells . Therefore we tested several substrates with human fibroblasts or keratinocytes from the oral mucosa in cell culture . In tissue culture keratinocyte outgrowth from small mucosal flaps onto the surface was observed . Preparations were evaluated by histology and scanning electron microscopy . Cellulose-ester , polyvinylidene-difluoride and polyglactin developed monolayers of fibroblasts and keratinocytes in cell cultures . In tissue culture mucosal flaps showed good adherence to the surface of these materials and a fine outgrowth of keratinocytes . Expanded polytetrafluor-ethylene ( ePTFE ) was partially covered by a layer of fibroblasts and keratinocytes in cell culture , but cell adherence was not sufficient . In tissue culture the mucosal flaps failed to attach on ePTFE . These results illustrate that the mesenchymatic and epithelial component of cell and tissue cultures show different qualities of cellular adherence and growth on the surface of non-biologic implants . We propose our method for the development of an in-vitro model for the epithelization of non-biologic implantation materials . Instructions: please typing these entity words according to sentence: use, non - biologic, head, neck, surgery, tissue compatibility, epithelial cells, mesenchymatic, cells, human, fibroblasts, keratinocytes, oral mucosa, cell culture, tissue culture, keratinocyte, flaps, histology, scanning electron microscopy, Cellulose - ester, polyglactin, fibroblasts, keratinocytes, cell cultures, tissue culture, flaps, keratinocytes, polytetrafluor - ethylene, fibroblasts, keratinocytes, cell culture, cell, tissue culture, flaps, mesenchymatic, cell, tissue cultures, growth, non - biologic, implants, method, development, non - biologic, implantation Options: umlsterm

[ "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O" ]

Successful use of non-biologic implants in reconstructive head and neck surgery is dependent on tissue compatibility and epithelization . This is true not only for epithelial cells , but also for mesenchymatic cells . Therefore we tested several substrates with human fibroblasts or keratinocytes from the oral mucosa in cell culture . In tissue culture keratinocyte outgrowth from small mucosal flaps onto the surface was observed . Preparations were evaluated by histology and scanning electron microscopy . Cellulose-ester , polyvinylidene-difluoride and polyglactin developed monolayers of fibroblasts and keratinocytes in cell cultures . In tissue culture mucosal flaps showed good adherence to the surface of these materials and a fine outgrowth of keratinocytes . Expanded polytetrafluor-ethylene ( ePTFE ) was partially covered by a layer of fibroblasts and keratinocytes in cell culture , but cell adherence was not sufficient . In tissue culture the mucosal flaps failed to attach on ePTFE . These results illustrate that the mesenchymatic and epithelial component of cell and tissue cultures show different qualities of cellular adherence and growth on the surface of non-biologic implants . We propose our method for the development of an in-vitro model for the epithelization of non-biologic implantation materials .

[ "Successful", "use", "of", "non", "-", "biologic", "implants", "in", "reconstructive", "head", "and", "neck", "surgery", "is", "dependent", "on", "tissue", "compatibility", "and", "epithelization", ".", "This", "is", "true", "not", "only", "for", "epithelial", "cells", ",", "but", "also", "for", "mesenchymatic", "cells", ".", "Therefore", "we", "tested", "several", "substrates", "with", "human", "fibroblasts", "or", "keratinocytes", "from", "the", "oral", "mucosa", "in", "cell", "culture", ".", "In", "tissue", "culture", "keratinocyte", "outgrowth", "from", "small", "mucosal", "flaps", "onto", "the", "surface", "was", "observed", ".", "Preparations", "were", "evaluated", "by", "histology", "and", "scanning", "electron", "microscopy", ".", "Cellulose", "-", "ester", ",", "polyvinylidene", "-", "difluoride", "and", "polyglactin", "developed", "monolayers", "of", "fibroblasts", "and", "keratinocytes", "in", "cell", "cultures", ".", "In", "tissue", "culture", "mucosal", "flaps", "showed", "good", "adherence", "to", "the", "surface", "of", "these", "materials", "and", "a", "fine", "outgrowth", "of", "keratinocytes", ".", "Expanded", "polytetrafluor", "-", "ethylene", "(", "ePTFE", ")", "was", "partially", "covered", "by", "a", "layer", "of", "fibroblasts", "and", "keratinocytes", "in", "cell", "culture", ",", "but", "cell", "adherence", "was", "not", "sufficient", ".", "In", "tissue", "culture", "the", "mucosal", "flaps", "failed", "to", "attach", "on", "ePTFE", ".", "These", "results", "illustrate", "that", "the", "mesenchymatic", "and", "epithelial", "component", "of", "cell", "and", "tissue", "cultures", "show", "different", "qualities", "of", "cellular", "adherence", "and", "growth", "on", "the", "surface", "of", "non", "-", "biologic", "implants", ".", "We", "propose", "our", "method", "for", "the", "development", "of", "an", "in", "-", "vitro", "model", "for", "the", "epithelization", "of", "non", "-", "biologic", "implantation", "materials", "." ]

[ "umlsterm" ]

use, non - biologic, head, neck, surgery, tissue compatibility, epithelial cells, mesenchymatic, cells, human, fibroblasts, keratinocytes, oral mucosa, cell culture, tissue culture, keratinocyte, flaps, histology, scanning electron microscopy, Cellulose - ester, polyglactin, fibroblasts, keratinocytes, cell cultures, tissue culture, flaps, keratinocytes, polytetrafluor - ethylene, fibroblasts, keratinocytes, cell culture, cell, tissue culture, flaps, mesenchymatic, cell, tissue cultures, growth, non - biologic, implants, method, development, non - biologic, implantation

HNO.00480430.eng.abstr_task2

Sentence: Successful use of non-biologic implants in reconstructive head and neck surgery is dependent on tissue compatibility and epithelization . This is true not only for epithelial cells , but also for mesenchymatic cells . Therefore we tested several substrates with human fibroblasts or keratinocytes from the oral mucosa in cell culture . In tissue culture keratinocyte outgrowth from small mucosal flaps onto the surface was observed . Preparations were evaluated by histology and scanning electron microscopy . Cellulose-ester , polyvinylidene-difluoride and polyglactin developed monolayers of fibroblasts and keratinocytes in cell cultures . In tissue culture mucosal flaps showed good adherence to the surface of these materials and a fine outgrowth of keratinocytes . Expanded polytetrafluor-ethylene ( ePTFE ) was partially covered by a layer of fibroblasts and keratinocytes in cell culture , but cell adherence was not sufficient . In tissue culture the mucosal flaps failed to attach on ePTFE . These results illustrate that the mesenchymatic and epithelial component of cell and tissue cultures show different qualities of cellular adherence and growth on the surface of non-biologic implants . We propose our method for the development of an in-vitro model for the epithelization of non-biologic implantation materials . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O" ]

Successful use of non-biologic implants in reconstructive head and neck surgery is dependent on tissue compatibility and epithelization . This is true not only for epithelial cells , but also for mesenchymatic cells . Therefore we tested several substrates with human fibroblasts or keratinocytes from the oral mucosa in cell culture . In tissue culture keratinocyte outgrowth from small mucosal flaps onto the surface was observed . Preparations were evaluated by histology and scanning electron microscopy . Cellulose-ester , polyvinylidene-difluoride and polyglactin developed monolayers of fibroblasts and keratinocytes in cell cultures . In tissue culture mucosal flaps showed good adherence to the surface of these materials and a fine outgrowth of keratinocytes . Expanded polytetrafluor-ethylene ( ePTFE ) was partially covered by a layer of fibroblasts and keratinocytes in cell culture , but cell adherence was not sufficient . In tissue culture the mucosal flaps failed to attach on ePTFE . These results illustrate that the mesenchymatic and epithelial component of cell and tissue cultures show different qualities of cellular adherence and growth on the surface of non-biologic implants . We propose our method for the development of an in-vitro model for the epithelization of non-biologic implantation materials .

[ "Successful", "use", "of", "non", "-", "biologic", "implants", "in", "reconstructive", "head", "and", "neck", "surgery", "is", "dependent", "on", "tissue", "compatibility", "and", "epithelization", ".", "This", "is", "true", "not", "only", "for", "epithelial", "cells", ",", "but", "also", "for", "mesenchymatic", "cells", ".", "Therefore", "we", "tested", "several", "substrates", "with", "human", "fibroblasts", "or", "keratinocytes", "from", "the", "oral", "mucosa", "in", "cell", "culture", ".", "In", "tissue", "culture", "keratinocyte", "outgrowth", "from", "small", "mucosal", "flaps", "onto", "the", "surface", "was", "observed", ".", "Preparations", "were", "evaluated", "by", "histology", "and", "scanning", "electron", "microscopy", ".", "Cellulose", "-", "ester", ",", "polyvinylidene", "-", "difluoride", "and", "polyglactin", "developed", "monolayers", "of", "fibroblasts", "and", "keratinocytes", "in", "cell", "cultures", ".", "In", "tissue", "culture", "mucosal", "flaps", "showed", "good", "adherence", "to", "the", "surface", "of", "these", "materials", "and", "a", "fine", "outgrowth", "of", "keratinocytes", ".", "Expanded", "polytetrafluor", "-", "ethylene", "(", "ePTFE", ")", "was", "partially", "covered", "by", "a", "layer", "of", "fibroblasts", "and", "keratinocytes", "in", "cell", "culture", ",", "but", "cell", "adherence", "was", "not", "sufficient", ".", "In", "tissue", "culture", "the", "mucosal", "flaps", "failed", "to", "attach", "on", "ePTFE", ".", "These", "results", "illustrate", "that", "the", "mesenchymatic", "and", "epithelial", "component", "of", "cell", "and", "tissue", "cultures", "show", "different", "qualities", "of", "cellular", "adherence", "and", "growth", "on", "the", "surface", "of", "non", "-", "biologic", "implants", ".", "We", "propose", "our", "method", "for", "the", "development", "of", "an", "in", "-", "vitro", "model", "for", "the", "epithelization", "of", "non", "-", "biologic", "implantation", "materials", "." ]

[ "umlsterm" ]

interleukin-1alpha is a Protein, promoter is a Entity, Tax is a Protein, interleukin-1alpha is a Protein, IL-1alpha is a Protein, IL-1alpha is a Protein, IL-1alpha is a Protein, IL-1alpha is a Protein, IL-1alpha is a Protein, chloramphenicol acetyltransferase is a Protein, CAT is a Protein, IL-1alpha is a Protein, Tax is a Protein, IL-1alpha is a Protein, Tax is a Protein, IL-1alpha is a Protein, CAT is a Protein, p65 is a Protein, p50 is a Protein, IL-1alpha is a Protein, IL-1alpha is a Protein, IL-1alpha is a Protein, promoter is a Entity, Tax is a Protein, Tax is a Protein, IL-1alpha is a Protein, IL-1alpha is a Protein

8605359_task0

Sentence: Transactivation of the interleukin-1alpha promoter by human T-cell leukemia virus type I and type II Tax proteins. Human T-cell leukemia virus type I (HTLV-I)-infected T-cell lines constitutively produce high levels of interleukin-1alpha (IL-1alpha). To analyze the mechanisms that lead to the expression of IL-1alpha in HTLV-I-infected cell lines, we studied regulatory regions of the human IL-1alpha promoter involved in activation of the IL-1alpha gene. IL-1alpha promoter constructs drive transcription of the chloramphenicol acetyltransferase (CAT) reporter gene in HTLV-I-positive MT-2 cells, which constitutively produce IL-1alpha. In a cotransfection assay, the Tax protein of both HTLV-I and HTLV-II specifically activated transcription from the IL-1alpha promoter in an uninfected Jurkat cell line. A mutant Tax protein deficient in transactivation of genes by the nuclear factor (NF)-kappaB pathway was unable to induce transcriptional activity of IL-1alpha promoter-CAT constructs, but was rescued by exogenous provision of p65/p50 NF-kappaB. We found that two IL-1alpha kappaB-like sites (positions -1,065 to -1,056 and +646 to +655) specifically formed a complex with NF-kappaB-containing nuclear extract from MT-2 cells and that NF-kappaB bound with higher affinity to the 3' NF-kappaB binding site than to the 5' NF-kappaB site. Moreover, deletion of either 5' or 3' NF-kappaB sites reduced IL-1alpha promoter activity in MT-2 cells and transactivation of the IL-1alpha promoter by exogenous NF-kappaB and Tax in Jurkat cells. These data suggest a general role for Tax induction of IL-1alpha gene transcription by the NF-kappaB pathway. Expression of IL-1alpha by HTLV-I productively infected cells may be important in the hypercalcemia, osteolytic bone lesions, neutrophilia, elevation of C-reactive protein, and fever frequently seen in patients with HTLV-I-induced adult T-cell leukemia/lymphoma. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Transactivation of the interleukin-1alpha promoter by human T-cell leukemia virus type I and type II Tax proteins. Human T-cell leukemia virus type I (HTLV-I)-infected T-cell lines constitutively produce high levels of interleukin-1alpha (IL-1alpha). To analyze the mechanisms that lead to the expression of IL-1alpha in HTLV-I-infected cell lines, we studied regulatory regions of the human IL-1alpha promoter involved in activation of the IL-1alpha gene. IL-1alpha promoter constructs drive transcription of the chloramphenicol acetyltransferase (CAT) reporter gene in HTLV-I-positive MT-2 cells, which constitutively produce IL-1alpha. In a cotransfection assay, the Tax protein of both HTLV-I and HTLV-II specifically activated transcription from the IL-1alpha promoter in an uninfected Jurkat cell line. A mutant Tax protein deficient in transactivation of genes by the nuclear factor (NF)-kappaB pathway was unable to induce transcriptional activity of IL-1alpha promoter-CAT constructs, but was rescued by exogenous provision of p65/p50 NF-kappaB. We found that two IL-1alpha kappaB-like sites (positions -1,065 to -1,056 and +646 to +655) specifically formed a complex with NF-kappaB-containing nuclear extract from MT-2 cells and that NF-kappaB bound with higher affinity to the 3' NF-kappaB binding site than to the 5' NF-kappaB site. Moreover, deletion of either 5' or 3' NF-kappaB sites reduced IL-1alpha promoter activity in MT-2 cells and transactivation of the IL-1alpha promoter by exogenous NF-kappaB and Tax in Jurkat cells. These data suggest a general role for Tax induction of IL-1alpha gene transcription by the NF-kappaB pathway. Expression of IL-1alpha by HTLV-I productively infected cells may be important in the hypercalcemia, osteolytic bone lesions, neutrophilia, elevation of C-reactive protein, and fever frequently seen in patients with HTLV-I-induced adult T-cell leukemia/lymphoma.

[ "Transactivation", "of", "the", "interleukin-1alpha", "promoter", "by", "human", "T", "-", "cell", "leukemia", "virus", "type", "I", "and", "type", "II", "Tax", "proteins", ".", "\n", "Human", "T", "-", "cell", "leukemia", "virus", "type", "I", "(", "HTLV", "-", "I)-infected", "T", "-", "cell", "lines", "constitutively", "produce", "high", "levels", "of", "interleukin-1alpha", "(", "IL-1alpha", ")", ".", "To", "analyze", "the", "mechanisms", "that", "lead", "to", "the", "expression", "of", "IL-1alpha", "in", "HTLV", "-", "I", "-", "infected", "cell", "lines", ",", "we", "studied", "regulatory", "regions", "of", "the", "human", "IL-1alpha", "promoter", "involved", "in", "activation", "of", "the", "IL-1alpha", "gene", ".", "IL-1alpha", "promoter", "constructs", "drive", "transcription", "of", "the", "chloramphenicol", "acetyltransferase", "(", "CAT", ")", "reporter", "gene", "in", "HTLV", "-", "I", "-", "positive", "MT-2", "cells", ",", "which", "constitutively", "produce", "IL-1alpha", ".", "In", "a", "cotransfection", "assay", ",", "the", "Tax", "protein", "of", "both", "HTLV", "-", "I", "and", "HTLV", "-", "II", "specifically", "activated", "transcription", "from", "the", "IL-1alpha", "promoter", "in", "an", "uninfected", "Jurkat", "cell", "line", ".", "A", "mutant", "Tax", "protein", "deficient", "in", "transactivation", "of", "genes", "by", "the", "nuclear", "factor", "(", "NF)-kappaB", "pathway", "was", "unable", "to", "induce", "transcriptional", "activity", "of", "IL-1alpha", "promoter", "-", "CAT", "constructs", ",", "but", "was", "rescued", "by", "exogenous", "provision", "of", "p65", "/", "p50", "NF", "-", "kappaB.", "We", "found", "that", "two", "IL-1alpha", "kappaB", "-", "like", "sites", "(", "positions", "-1,065", "to", "-1,056", "and", "+646", "to", "+655", ")", "specifically", "formed", "a", "complex", "with", "NF", "-", "kappaB", "-", "containing", "nuclear", "extract", "from", "MT-2", "cells", "and", "that", "NF", "-", "kappaB", "bound", "with", "higher", "affinity", "to", "the", "3", "'", "NF", "-", "kappaB", "binding", "site", "than", "to", "the", "5", "'", "NF", "-", "kappaB", "site", ".", "Moreover", ",", "deletion", "of", "either", "5", "'", "or", "3", "'", "NF", "-", "kappaB", "sites", "reduced", "IL-1alpha", "promoter", "activity", "in", "MT-2", "cells", "and", "transactivation", "of", "the", "IL-1alpha", "promoter", "by", "exogenous", "NF", "-", "kappaB", "and", "Tax", "in", "Jurkat", "cells", ".", "These", "data", "suggest", "a", "general", "role", "for", "Tax", "induction", "of", "IL-1alpha", "gene", "transcription", "by", "the", "NF", "-", "kappaB", "pathway", ".", "Expression", "of", "IL-1alpha", "by", "HTLV", "-", "I", "productively", "infected", "cells", "may", "be", "important", "in", "the", "hypercalcemia", ",", "osteolytic", "bone", "lesions", ",", "neutrophilia", ",", "elevation", "of", "C", "-", "reactive", "protein", ",", "and", "fever", "frequently", "seen", "in", "patients", "with", "HTLV", "-", "I", "-", "induced", "adult", "T", "-", "cell", "leukemia", "/", "lymphoma", "." ]

[ "Protein", "Entity" ]

interleukin-1alpha is a Protein, promoter is a Entity, Tax is a Protein, interleukin-1alpha is a Protein, IL-1alpha is a Protein, IL-1alpha is a Protein, IL-1alpha is a Protein, IL-1alpha is a Protein, IL-1alpha is a Protein, chloramphenicol acetyltransferase is a Protein, CAT is a Protein, IL-1alpha is a Protein, Tax is a Protein, IL-1alpha is a Protein, Tax is a Protein, IL-1alpha is a Protein, CAT is a Protein, p65 is a Protein, p50 is a Protein, IL-1alpha is a Protein, IL-1alpha is a Protein, IL-1alpha is a Protein, promoter is a Entity, Tax is a Protein, Tax is a Protein, IL-1alpha is a Protein, IL-1alpha is a Protein

8605359_task1

Sentence: Transactivation of the interleukin-1alpha promoter by human T-cell leukemia virus type I and type II Tax proteins. Human T-cell leukemia virus type I (HTLV-I)-infected T-cell lines constitutively produce high levels of interleukin-1alpha (IL-1alpha). To analyze the mechanisms that lead to the expression of IL-1alpha in HTLV-I-infected cell lines, we studied regulatory regions of the human IL-1alpha promoter involved in activation of the IL-1alpha gene. IL-1alpha promoter constructs drive transcription of the chloramphenicol acetyltransferase (CAT) reporter gene in HTLV-I-positive MT-2 cells, which constitutively produce IL-1alpha. In a cotransfection assay, the Tax protein of both HTLV-I and HTLV-II specifically activated transcription from the IL-1alpha promoter in an uninfected Jurkat cell line. A mutant Tax protein deficient in transactivation of genes by the nuclear factor (NF)-kappaB pathway was unable to induce transcriptional activity of IL-1alpha promoter-CAT constructs, but was rescued by exogenous provision of p65/p50 NF-kappaB. We found that two IL-1alpha kappaB-like sites (positions -1,065 to -1,056 and +646 to +655) specifically formed a complex with NF-kappaB-containing nuclear extract from MT-2 cells and that NF-kappaB bound with higher affinity to the 3' NF-kappaB binding site than to the 5' NF-kappaB site. Moreover, deletion of either 5' or 3' NF-kappaB sites reduced IL-1alpha promoter activity in MT-2 cells and transactivation of the IL-1alpha promoter by exogenous NF-kappaB and Tax in Jurkat cells. These data suggest a general role for Tax induction of IL-1alpha gene transcription by the NF-kappaB pathway. Expression of IL-1alpha by HTLV-I productively infected cells may be important in the hypercalcemia, osteolytic bone lesions, neutrophilia, elevation of C-reactive protein, and fever frequently seen in patients with HTLV-I-induced adult T-cell leukemia/lymphoma. Instructions: please typing these entity words according to sentence: interleukin-1alpha, promoter, Tax, interleukin-1alpha, IL-1alpha, IL-1alpha, IL-1alpha, IL-1alpha, IL-1alpha, chloramphenicol acetyltransferase, CAT, IL-1alpha, Tax, IL-1alpha, Tax, IL-1alpha, CAT, p65, p50, IL-1alpha, IL-1alpha, IL-1alpha, promoter, Tax, Tax, IL-1alpha, IL-1alpha Options: Entity, Protein

[ "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Transactivation of the interleukin-1alpha promoter by human T-cell leukemia virus type I and type II Tax proteins. Human T-cell leukemia virus type I (HTLV-I)-infected T-cell lines constitutively produce high levels of interleukin-1alpha (IL-1alpha). To analyze the mechanisms that lead to the expression of IL-1alpha in HTLV-I-infected cell lines, we studied regulatory regions of the human IL-1alpha promoter involved in activation of the IL-1alpha gene. IL-1alpha promoter constructs drive transcription of the chloramphenicol acetyltransferase (CAT) reporter gene in HTLV-I-positive MT-2 cells, which constitutively produce IL-1alpha. In a cotransfection assay, the Tax protein of both HTLV-I and HTLV-II specifically activated transcription from the IL-1alpha promoter in an uninfected Jurkat cell line. A mutant Tax protein deficient in transactivation of genes by the nuclear factor (NF)-kappaB pathway was unable to induce transcriptional activity of IL-1alpha promoter-CAT constructs, but was rescued by exogenous provision of p65/p50 NF-kappaB. We found that two IL-1alpha kappaB-like sites (positions -1,065 to -1,056 and +646 to +655) specifically formed a complex with NF-kappaB-containing nuclear extract from MT-2 cells and that NF-kappaB bound with higher affinity to the 3' NF-kappaB binding site than to the 5' NF-kappaB site. Moreover, deletion of either 5' or 3' NF-kappaB sites reduced IL-1alpha promoter activity in MT-2 cells and transactivation of the IL-1alpha promoter by exogenous NF-kappaB and Tax in Jurkat cells. These data suggest a general role for Tax induction of IL-1alpha gene transcription by the NF-kappaB pathway. Expression of IL-1alpha by HTLV-I productively infected cells may be important in the hypercalcemia, osteolytic bone lesions, neutrophilia, elevation of C-reactive protein, and fever frequently seen in patients with HTLV-I-induced adult T-cell leukemia/lymphoma.

[ "Transactivation", "of", "the", "interleukin-1alpha", "promoter", "by", "human", "T", "-", "cell", "leukemia", "virus", "type", "I", "and", "type", "II", "Tax", "proteins", ".", "\n", "Human", "T", "-", "cell", "leukemia", "virus", "type", "I", "(", "HTLV", "-", "I)-infected", "T", "-", "cell", "lines", "constitutively", "produce", "high", "levels", "of", "interleukin-1alpha", "(", "IL-1alpha", ")", ".", "To", "analyze", "the", "mechanisms", "that", "lead", "to", "the", "expression", "of", "IL-1alpha", "in", "HTLV", "-", "I", "-", "infected", "cell", "lines", ",", "we", "studied", "regulatory", "regions", "of", "the", "human", "IL-1alpha", "promoter", "involved", "in", "activation", "of", "the", "IL-1alpha", "gene", ".", "IL-1alpha", "promoter", "constructs", "drive", "transcription", "of", "the", "chloramphenicol", "acetyltransferase", "(", "CAT", ")", "reporter", "gene", "in", "HTLV", "-", "I", "-", "positive", "MT-2", "cells", ",", "which", "constitutively", "produce", "IL-1alpha", ".", "In", "a", "cotransfection", "assay", ",", "the", "Tax", "protein", "of", "both", "HTLV", "-", "I", "and", "HTLV", "-", "II", "specifically", "activated", "transcription", "from", "the", "IL-1alpha", "promoter", "in", "an", "uninfected", "Jurkat", "cell", "line", ".", "A", "mutant", "Tax", "protein", "deficient", "in", "transactivation", "of", "genes", "by", "the", "nuclear", "factor", "(", "NF)-kappaB", "pathway", "was", "unable", "to", "induce", "transcriptional", "activity", "of", "IL-1alpha", "promoter", "-", "CAT", "constructs", ",", "but", "was", "rescued", "by", "exogenous", "provision", "of", "p65", "/", "p50", "NF", "-", "kappaB.", "We", "found", "that", "two", "IL-1alpha", "kappaB", "-", "like", "sites", "(", "positions", "-1,065", "to", "-1,056", "and", "+646", "to", "+655", ")", "specifically", "formed", "a", "complex", "with", "NF", "-", "kappaB", "-", "containing", "nuclear", "extract", "from", "MT-2", "cells", "and", "that", "NF", "-", "kappaB", "bound", "with", "higher", "affinity", "to", "the", "3", "'", "NF", "-", "kappaB", "binding", "site", "than", "to", "the", "5", "'", "NF", "-", "kappaB", "site", ".", "Moreover", ",", "deletion", "of", "either", "5", "'", "or", "3", "'", "NF", "-", "kappaB", "sites", "reduced", "IL-1alpha", "promoter", "activity", "in", "MT-2", "cells", "and", "transactivation", "of", "the", "IL-1alpha", "promoter", "by", "exogenous", "NF", "-", "kappaB", "and", "Tax", "in", "Jurkat", "cells", ".", "These", "data", "suggest", "a", "general", "role", "for", "Tax", "induction", "of", "IL-1alpha", "gene", "transcription", "by", "the", "NF", "-", "kappaB", "pathway", ".", "Expression", "of", "IL-1alpha", "by", "HTLV", "-", "I", "productively", "infected", "cells", "may", "be", "important", "in", "the", "hypercalcemia", ",", "osteolytic", "bone", "lesions", ",", "neutrophilia", ",", "elevation", "of", "C", "-", "reactive", "protein", ",", "and", "fever", "frequently", "seen", "in", "patients", "with", "HTLV", "-", "I", "-", "induced", "adult", "T", "-", "cell", "leukemia", "/", "lymphoma", "." ]

[ "Protein", "Entity" ]

interleukin-1alpha, promoter, Tax, interleukin-1alpha, IL-1alpha, IL-1alpha, IL-1alpha, IL-1alpha, IL-1alpha, chloramphenicol acetyltransferase, CAT, IL-1alpha, Tax, IL-1alpha, Tax, IL-1alpha, CAT, p65, p50, IL-1alpha, IL-1alpha, IL-1alpha, promoter, Tax, Tax, IL-1alpha, IL-1alpha

8605359_task2

Sentence: Transactivation of the interleukin-1alpha promoter by human T-cell leukemia virus type I and type II Tax proteins. Human T-cell leukemia virus type I (HTLV-I)-infected T-cell lines constitutively produce high levels of interleukin-1alpha (IL-1alpha). To analyze the mechanisms that lead to the expression of IL-1alpha in HTLV-I-infected cell lines, we studied regulatory regions of the human IL-1alpha promoter involved in activation of the IL-1alpha gene. IL-1alpha promoter constructs drive transcription of the chloramphenicol acetyltransferase (CAT) reporter gene in HTLV-I-positive MT-2 cells, which constitutively produce IL-1alpha. In a cotransfection assay, the Tax protein of both HTLV-I and HTLV-II specifically activated transcription from the IL-1alpha promoter in an uninfected Jurkat cell line. A mutant Tax protein deficient in transactivation of genes by the nuclear factor (NF)-kappaB pathway was unable to induce transcriptional activity of IL-1alpha promoter-CAT constructs, but was rescued by exogenous provision of p65/p50 NF-kappaB. We found that two IL-1alpha kappaB-like sites (positions -1,065 to -1,056 and +646 to +655) specifically formed a complex with NF-kappaB-containing nuclear extract from MT-2 cells and that NF-kappaB bound with higher affinity to the 3' NF-kappaB binding site than to the 5' NF-kappaB site. Moreover, deletion of either 5' or 3' NF-kappaB sites reduced IL-1alpha promoter activity in MT-2 cells and transactivation of the IL-1alpha promoter by exogenous NF-kappaB and Tax in Jurkat cells. These data suggest a general role for Tax induction of IL-1alpha gene transcription by the NF-kappaB pathway. Expression of IL-1alpha by HTLV-I productively infected cells may be important in the hypercalcemia, osteolytic bone lesions, neutrophilia, elevation of C-reactive protein, and fever frequently seen in patients with HTLV-I-induced adult T-cell leukemia/lymphoma. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Transactivation of the interleukin-1alpha promoter by human T-cell leukemia virus type I and type II Tax proteins. Human T-cell leukemia virus type I (HTLV-I)-infected T-cell lines constitutively produce high levels of interleukin-1alpha (IL-1alpha). To analyze the mechanisms that lead to the expression of IL-1alpha in HTLV-I-infected cell lines, we studied regulatory regions of the human IL-1alpha promoter involved in activation of the IL-1alpha gene. IL-1alpha promoter constructs drive transcription of the chloramphenicol acetyltransferase (CAT) reporter gene in HTLV-I-positive MT-2 cells, which constitutively produce IL-1alpha. In a cotransfection assay, the Tax protein of both HTLV-I and HTLV-II specifically activated transcription from the IL-1alpha promoter in an uninfected Jurkat cell line. A mutant Tax protein deficient in transactivation of genes by the nuclear factor (NF)-kappaB pathway was unable to induce transcriptional activity of IL-1alpha promoter-CAT constructs, but was rescued by exogenous provision of p65/p50 NF-kappaB. We found that two IL-1alpha kappaB-like sites (positions -1,065 to -1,056 and +646 to +655) specifically formed a complex with NF-kappaB-containing nuclear extract from MT-2 cells and that NF-kappaB bound with higher affinity to the 3' NF-kappaB binding site than to the 5' NF-kappaB site. Moreover, deletion of either 5' or 3' NF-kappaB sites reduced IL-1alpha promoter activity in MT-2 cells and transactivation of the IL-1alpha promoter by exogenous NF-kappaB and Tax in Jurkat cells. These data suggest a general role for Tax induction of IL-1alpha gene transcription by the NF-kappaB pathway. Expression of IL-1alpha by HTLV-I productively infected cells may be important in the hypercalcemia, osteolytic bone lesions, neutrophilia, elevation of C-reactive protein, and fever frequently seen in patients with HTLV-I-induced adult T-cell leukemia/lymphoma.

[ "Transactivation", "of", "the", "interleukin-1alpha", "promoter", "by", "human", "T", "-", "cell", "leukemia", "virus", "type", "I", "and", "type", "II", "Tax", "proteins", ".", "\n", "Human", "T", "-", "cell", "leukemia", "virus", "type", "I", "(", "HTLV", "-", "I)-infected", "T", "-", "cell", "lines", "constitutively", "produce", "high", "levels", "of", "interleukin-1alpha", "(", "IL-1alpha", ")", ".", "To", "analyze", "the", "mechanisms", "that", "lead", "to", "the", "expression", "of", "IL-1alpha", "in", "HTLV", "-", "I", "-", "infected", "cell", "lines", ",", "we", "studied", "regulatory", "regions", "of", "the", "human", "IL-1alpha", "promoter", "involved", "in", "activation", "of", "the", "IL-1alpha", "gene", ".", "IL-1alpha", "promoter", "constructs", "drive", "transcription", "of", "the", "chloramphenicol", "acetyltransferase", "(", "CAT", ")", "reporter", "gene", "in", "HTLV", "-", "I", "-", "positive", "MT-2", "cells", ",", "which", "constitutively", "produce", "IL-1alpha", ".", "In", "a", "cotransfection", "assay", ",", "the", "Tax", "protein", "of", "both", "HTLV", "-", "I", "and", "HTLV", "-", "II", "specifically", "activated", "transcription", "from", "the", "IL-1alpha", "promoter", "in", "an", "uninfected", "Jurkat", "cell", "line", ".", "A", "mutant", "Tax", "protein", "deficient", "in", "transactivation", "of", "genes", "by", "the", "nuclear", "factor", "(", "NF)-kappaB", "pathway", "was", "unable", "to", "induce", "transcriptional", "activity", "of", "IL-1alpha", "promoter", "-", "CAT", "constructs", ",", "but", "was", "rescued", "by", "exogenous", "provision", "of", "p65", "/", "p50", "NF", "-", "kappaB.", "We", "found", "that", "two", "IL-1alpha", "kappaB", "-", "like", "sites", "(", "positions", "-1,065", "to", "-1,056", "and", "+646", "to", "+655", ")", "specifically", "formed", "a", "complex", "with", "NF", "-", "kappaB", "-", "containing", "nuclear", "extract", "from", "MT-2", "cells", "and", "that", "NF", "-", "kappaB", "bound", "with", "higher", "affinity", "to", "the", "3", "'", "NF", "-", "kappaB", "binding", "site", "than", "to", "the", "5", "'", "NF", "-", "kappaB", "site", ".", "Moreover", ",", "deletion", "of", "either", "5", "'", "or", "3", "'", "NF", "-", "kappaB", "sites", "reduced", "IL-1alpha", "promoter", "activity", "in", "MT-2", "cells", "and", "transactivation", "of", "the", "IL-1alpha", "promoter", "by", "exogenous", "NF", "-", "kappaB", "and", "Tax", "in", "Jurkat", "cells", ".", "These", "data", "suggest", "a", "general", "role", "for", "Tax", "induction", "of", "IL-1alpha", "gene", "transcription", "by", "the", "NF", "-", "kappaB", "pathway", ".", "Expression", "of", "IL-1alpha", "by", "HTLV", "-", "I", "productively", "infected", "cells", "may", "be", "important", "in", "the", "hypercalcemia", ",", "osteolytic", "bone", "lesions", ",", "neutrophilia", ",", "elevation", "of", "C", "-", "reactive", "protein", ",", "and", "fever", "frequently", "seen", "in", "patients", "with", "HTLV", "-", "I", "-", "induced", "adult", "T", "-", "cell", "leukemia", "/", "lymphoma", "." ]

[ "Protein", "Entity" ]

cyclooxygenase is a GENE-N, ketorolac tromethamine is a CHEMICAL, bromfenac sodium is a CHEMICAL, cyclooxygenase is a GENE-N, COX is a GENE-N, ketorolac tromethamine is a CHEMICAL, ketorolac is a CHEMICAL, bromfenac sodium is a CHEMICAL, bromfenac is a CHEMICAL, Cyclooxygenase is a GENE-N, prostaglandin E(2 ) is a CHEMICAL, PGE(2 ) is a CHEMICAL, human recombinant COX-1 is a GENE-Y, COX-2 is a GENE-Y, arachidonic acid is a CHEMICAL, ( + /- ) ketorolac is a CHEMICAL, Acular LS is a CHEMICAL, bromfenac is a CHEMICAL, Xibrom is a CHEMICAL, PGE(2 ) is a CHEMICAL, fluorescein isothiocyanate is a CHEMICAL, PGE(2 ) is a CHEMICAL, Ketorolac is a CHEMICAL, COX-1 is a GENE-Y, COX-2 is a GENE-Y, bromfenac is a CHEMICAL, COX-2 is a GENE-Y, COX-1 is a GENE-Y, FITC is a CHEMICAL, PGE(2 ) is a CHEMICAL, FITC is a CHEMICAL, bromfenac is a CHEMICAL, ketorolac is a CHEMICAL, Ketorolac is a CHEMICAL, COX-1 is a GENE-Y, bromfenac is a CHEMICAL, COX-2 is a GENE-Y, COX-1 is a GENE-Y, ketorolac is a CHEMICAL, bromfenac is a CHEMICAL, bromfenac is a CHEMICAL

19386_task0

Sentence: Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. OBJECTIVE: To compare the cyclooxygenase (COX) activity and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs (NSAIDs) ketorolac tromethamine (ketorolac) and bromfenac sodium (bromfenac). METHODS: Cyclooxygenase activity and selectivity was determined in vitro by measuring prostaglandin E(2) (PGE(2)) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid. Anti-inflammatory effects were evaluated in a rabbit model in which an ocular inflammatory response was induced by intravenous injection of 10 microg/kg lipopolysaccharide (LPS). In study animals, one eye was treated with 50 microL (+/-) ketorolac 0.4% (Acular LS) or bromfenac 0.09% (Xibrom) and the other eye with 50 microL buffered saline. In control animals, both eyes were treated with vehicle. All animals were treated twice: 2 hours and 1 hour before LPS. MAIN OUTCOME MEASURES: PGE(2) production in vitro, measured by enzyme immunoassay; fluorescein isothiocyanate (FITC)-dextran leakage into the anterior chamber, measured by fluorophotometry; aqueous PGE(2) levels in vivo, measured by ELISA immunoassay. RESULTS: Ketorolac was six times more active against COX-1 (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM). In the animal model, both drugs resulted in nearly complete inhibition of FITC-dextran leakage and PGE(2) production in the anterior chamber of treated eyes. There was also a 79% inhibition (p < 0.001) of FITC-dextran leakage in the contralateral eyes of bromfenac-treated rabbits, and a 22.5% inhibition (not statistically significant) in the contralateral eyes of ketorolac-treated rabbits. CONCLUSIONS: Ketorolac is relatively COX-1 selective while bromfenac is potently selective for COX-2 over COX-1. In the animal model, both ketorolac 0.4% and bromfenac 0.09% demonstrated maximal anti-inflammatory activity in treated eyes. Only bromfenac 0.09% had a significant effect on the contralateral eye, suggesting possible systemic absorption of this drug. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N, CHEMICAL

[ "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. OBJECTIVE: To compare the cyclooxygenase (COX) activity and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs (NSAIDs) ketorolac tromethamine (ketorolac) and bromfenac sodium (bromfenac). METHODS: Cyclooxygenase activity and selectivity was determined in vitro by measuring prostaglandin E(2) (PGE(2)) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid. Anti-inflammatory effects were evaluated in a rabbit model in which an ocular inflammatory response was induced by intravenous injection of 10 microg/kg lipopolysaccharide (LPS). In study animals, one eye was treated with 50 microL (+/-) ketorolac 0.4% (Acular LS) or bromfenac 0.09% (Xibrom) and the other eye with 50 microL buffered saline. In control animals, both eyes were treated with vehicle. All animals were treated twice: 2 hours and 1 hour before LPS. MAIN OUTCOME MEASURES: PGE(2) production in vitro, measured by enzyme immunoassay; fluorescein isothiocyanate (FITC)-dextran leakage into the anterior chamber, measured by fluorophotometry; aqueous PGE(2) levels in vivo, measured by ELISA immunoassay. RESULTS: Ketorolac was six times more active against COX-1 (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM). In the animal model, both drugs resulted in nearly complete inhibition of FITC-dextran leakage and PGE(2) production in the anterior chamber of treated eyes. There was also a 79% inhibition (p < 0.001) of FITC-dextran leakage in the contralateral eyes of bromfenac-treated rabbits, and a 22.5% inhibition (not statistically significant) in the contralateral eyes of ketorolac-treated rabbits. CONCLUSIONS: Ketorolac is relatively COX-1 selective while bromfenac is potently selective for COX-2 over COX-1. In the animal model, both ketorolac 0.4% and bromfenac 0.09% demonstrated maximal anti-inflammatory activity in treated eyes. Only bromfenac 0.09% had a significant effect on the contralateral eye, suggesting possible systemic absorption of this drug.

[ "Comparison", "of", "cyclooxygenase", "inhibitory", "activity", "and", "ocular", "anti", "-", "inflammatory", "effects", "of", "ketorolac", "tromethamine", "and", "bromfenac", "sodium", ".", "\n", "OBJECTIVE", ":", "To", "compare", "the", "cyclooxygenase", "(", "COX", ")", "activity", "and", "anti", "-", "inflammatory", "effects", "of", "the", "nonsteroidal", "anti", "-", "inflammatory", "drugs", "(", "NSAIDs", ")", "ketorolac", "tromethamine", "(", "ketorolac", ")", "and", "bromfenac", "sodium", "(", "bromfenac", ")", ".", "METHODS", ":", "Cyclooxygenase", "activity", "and", "selectivity", "was", "determined", "in", "vitro", "by", "measuring", "prostaglandin", "E(2", ")", "(", "PGE(2", ")", ")", "production", "following", "incubation", "of", "varying", "concentrations", "of", "NSAID", "with", "human", "recombinant", "COX-1", "or", "COX-2", "and", "arachidonic", "acid", ".", "Anti", "-", "inflammatory", "effects", "were", "evaluated", "in", "a", "rabbit", "model", "in", "which", "an", "ocular", "inflammatory", "response", "was", "induced", "by", "intravenous", "injection", "of", "10", "microg", "/", "kg", "lipopolysaccharide", "(", "LPS", ")", ".", "In", "study", "animals", ",", "one", "eye", "was", "treated", "with", "50", "microL", "(", "+", "/-", ")", "ketorolac", "0.4", "%", "(", "Acular", "LS", ")", "or", "bromfenac", "0.09", "%", "(", "Xibrom", ")", "and", "the", "other", "eye", "with", "50", "microL", "buffered", "saline", ".", "In", "control", "animals", ",", "both", "eyes", "were", "treated", "with", "vehicle", ".", "All", "animals", "were", "treated", "twice", ":", "2", "hours", "and", "1", "hour", "before", "LPS", ".", "MAIN", "OUTCOME", "MEASURES", ":", "PGE(2", ")", "production", "in", "vitro", ",", "measured", "by", "enzyme", "immunoassay", ";", "fluorescein", "isothiocyanate", "(", "FITC)-dextran", "leakage", "into", "the", "anterior", "chamber", ",", "measured", "by", "fluorophotometry", ";", "aqueous", "PGE(2", ")", "levels", "in", "vivo", ",", "measured", "by", "ELISA", "immunoassay", ".", "RESULTS", ":", "Ketorolac", "was", "six", "times", "more", "active", "against", "COX-1", "(", "IC(50", ")", "=", "0.02", "microM", ")", "than", "COX-2", "(", "IC(50", ")", "=", "0.12", "microM", ")", "while", "bromfenac", "was", "approximately", "32", "times", "more", "active", "against", "COX-2", "(", "IC(50", ")", "=", "0.0066", "microM", ")", "than", "COX-1", "(", "IC(50", ")", "=", "0.210", "microM", ")", ".", "In", "the", "animal", "model", ",", "both", "drugs", "resulted", "in", "nearly", "complete", "inhibition", "of", "FITC", "-", "dextran", "leakage", "and", "PGE(2", ")", "production", "in", "the", "anterior", "chamber", "of", "treated", "eyes", ".", "There", "was", "also", "a", "79", "%", "inhibition", "(", "p", "<", "0.001", ")", "of", "FITC", "-", "dextran", "leakage", "in", "the", "contralateral", "eyes", "of", "bromfenac", "-", "treated", "rabbits", ",", "and", "a", "22.5", "%", "inhibition", "(", "not", "statistically", "significant", ")", "in", "the", "contralateral", "eyes", "of", "ketorolac", "-", "treated", "rabbits", ".", "CONCLUSIONS", ":", "Ketorolac", "is", "relatively", "COX-1", "selective", "while", "bromfenac", "is", "potently", "selective", "for", "COX-2", "over", "COX-1", ".", "In", "the", "animal", "model", ",", "both", "ketorolac", "0.4", "%", "and", "bromfenac", "0.09", "%", "demonstrated", "maximal", "anti", "-", "inflammatory", "activity", "in", "treated", "eyes", ".", "Only", "bromfenac", "0.09", "%", "had", "a", "significant", "effect", "on", "the", "contralateral", "eye", ",", "suggesting", "possible", "systemic", "absorption", "of", "this", "drug", "." ]

[ "CHEMICAL", "GENE-Y", "GENE-N" ]

cyclooxygenase is a GENE-N, ketorolac tromethamine is a CHEMICAL, bromfenac sodium is a CHEMICAL, cyclooxygenase is a GENE-N, COX is a GENE-N, ketorolac tromethamine is a CHEMICAL, ketorolac is a CHEMICAL, bromfenac sodium is a CHEMICAL, bromfenac is a CHEMICAL, Cyclooxygenase is a GENE-N, prostaglandin E(2 ) is a CHEMICAL, PGE(2 ) is a CHEMICAL, human recombinant COX-1 is a GENE-Y, COX-2 is a GENE-Y, arachidonic acid is a CHEMICAL, ( + /- ) ketorolac is a CHEMICAL, Acular LS is a CHEMICAL, bromfenac is a CHEMICAL, Xibrom is a CHEMICAL, PGE(2 ) is a CHEMICAL, fluorescein isothiocyanate is a CHEMICAL, PGE(2 ) is a CHEMICAL, Ketorolac is a CHEMICAL, COX-1 is a GENE-Y, COX-2 is a GENE-Y, bromfenac is a CHEMICAL, COX-2 is a GENE-Y, COX-1 is a GENE-Y, FITC is a CHEMICAL, PGE(2 ) is a CHEMICAL, FITC is a CHEMICAL, bromfenac is a CHEMICAL, ketorolac is a CHEMICAL, Ketorolac is a CHEMICAL, COX-1 is a GENE-Y, bromfenac is a CHEMICAL, COX-2 is a GENE-Y, COX-1 is a GENE-Y, ketorolac is a CHEMICAL, bromfenac is a CHEMICAL, bromfenac is a CHEMICAL

19386_task1

Sentence: Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. OBJECTIVE: To compare the cyclooxygenase (COX) activity and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs (NSAIDs) ketorolac tromethamine (ketorolac) and bromfenac sodium (bromfenac). METHODS: Cyclooxygenase activity and selectivity was determined in vitro by measuring prostaglandin E(2) (PGE(2)) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid. Anti-inflammatory effects were evaluated in a rabbit model in which an ocular inflammatory response was induced by intravenous injection of 10 microg/kg lipopolysaccharide (LPS). In study animals, one eye was treated with 50 microL (+/-) ketorolac 0.4% (Acular LS) or bromfenac 0.09% (Xibrom) and the other eye with 50 microL buffered saline. In control animals, both eyes were treated with vehicle. All animals were treated twice: 2 hours and 1 hour before LPS. MAIN OUTCOME MEASURES: PGE(2) production in vitro, measured by enzyme immunoassay; fluorescein isothiocyanate (FITC)-dextran leakage into the anterior chamber, measured by fluorophotometry; aqueous PGE(2) levels in vivo, measured by ELISA immunoassay. RESULTS: Ketorolac was six times more active against COX-1 (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM). In the animal model, both drugs resulted in nearly complete inhibition of FITC-dextran leakage and PGE(2) production in the anterior chamber of treated eyes. There was also a 79% inhibition (p < 0.001) of FITC-dextran leakage in the contralateral eyes of bromfenac-treated rabbits, and a 22.5% inhibition (not statistically significant) in the contralateral eyes of ketorolac-treated rabbits. CONCLUSIONS: Ketorolac is relatively COX-1 selective while bromfenac is potently selective for COX-2 over COX-1. In the animal model, both ketorolac 0.4% and bromfenac 0.09% demonstrated maximal anti-inflammatory activity in treated eyes. Only bromfenac 0.09% had a significant effect on the contralateral eye, suggesting possible systemic absorption of this drug. Instructions: please typing these entity words according to sentence: cyclooxygenase, ketorolac tromethamine, bromfenac sodium, cyclooxygenase, COX, ketorolac tromethamine, ketorolac, bromfenac sodium, bromfenac, Cyclooxygenase, prostaglandin E(2 ), PGE(2 ), human recombinant COX-1, COX-2, arachidonic acid, ( + /- ) ketorolac, Acular LS, bromfenac, Xibrom, PGE(2 ), fluorescein isothiocyanate, PGE(2 ), Ketorolac, COX-1, COX-2, bromfenac, COX-2, COX-1, FITC, PGE(2 ), FITC, bromfenac, ketorolac, Ketorolac, COX-1, bromfenac, COX-2, COX-1, ketorolac, bromfenac, bromfenac Options: GENE-Y, GENE-N, CHEMICAL

[ "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. OBJECTIVE: To compare the cyclooxygenase (COX) activity and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs (NSAIDs) ketorolac tromethamine (ketorolac) and bromfenac sodium (bromfenac). METHODS: Cyclooxygenase activity and selectivity was determined in vitro by measuring prostaglandin E(2) (PGE(2)) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid. Anti-inflammatory effects were evaluated in a rabbit model in which an ocular inflammatory response was induced by intravenous injection of 10 microg/kg lipopolysaccharide (LPS). In study animals, one eye was treated with 50 microL (+/-) ketorolac 0.4% (Acular LS) or bromfenac 0.09% (Xibrom) and the other eye with 50 microL buffered saline. In control animals, both eyes were treated with vehicle. All animals were treated twice: 2 hours and 1 hour before LPS. MAIN OUTCOME MEASURES: PGE(2) production in vitro, measured by enzyme immunoassay; fluorescein isothiocyanate (FITC)-dextran leakage into the anterior chamber, measured by fluorophotometry; aqueous PGE(2) levels in vivo, measured by ELISA immunoassay. RESULTS: Ketorolac was six times more active against COX-1 (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM). In the animal model, both drugs resulted in nearly complete inhibition of FITC-dextran leakage and PGE(2) production in the anterior chamber of treated eyes. There was also a 79% inhibition (p < 0.001) of FITC-dextran leakage in the contralateral eyes of bromfenac-treated rabbits, and a 22.5% inhibition (not statistically significant) in the contralateral eyes of ketorolac-treated rabbits. CONCLUSIONS: Ketorolac is relatively COX-1 selective while bromfenac is potently selective for COX-2 over COX-1. In the animal model, both ketorolac 0.4% and bromfenac 0.09% demonstrated maximal anti-inflammatory activity in treated eyes. Only bromfenac 0.09% had a significant effect on the contralateral eye, suggesting possible systemic absorption of this drug.

[ "Comparison", "of", "cyclooxygenase", "inhibitory", "activity", "and", "ocular", "anti", "-", "inflammatory", "effects", "of", "ketorolac", "tromethamine", "and", "bromfenac", "sodium", ".", "\n", "OBJECTIVE", ":", "To", "compare", "the", "cyclooxygenase", "(", "COX", ")", "activity", "and", "anti", "-", "inflammatory", "effects", "of", "the", "nonsteroidal", "anti", "-", "inflammatory", "drugs", "(", "NSAIDs", ")", "ketorolac", "tromethamine", "(", "ketorolac", ")", "and", "bromfenac", "sodium", "(", "bromfenac", ")", ".", "METHODS", ":", "Cyclooxygenase", "activity", "and", "selectivity", "was", "determined", "in", "vitro", "by", "measuring", "prostaglandin", "E(2", ")", "(", "PGE(2", ")", ")", "production", "following", "incubation", "of", "varying", "concentrations", "of", "NSAID", "with", "human", "recombinant", "COX-1", "or", "COX-2", "and", "arachidonic", "acid", ".", "Anti", "-", "inflammatory", "effects", "were", "evaluated", "in", "a", "rabbit", "model", "in", "which", "an", "ocular", "inflammatory", "response", "was", "induced", "by", "intravenous", "injection", "of", "10", "microg", "/", "kg", "lipopolysaccharide", "(", "LPS", ")", ".", "In", "study", "animals", ",", "one", "eye", "was", "treated", "with", "50", "microL", "(", "+", "/-", ")", "ketorolac", "0.4", "%", "(", "Acular", "LS", ")", "or", "bromfenac", "0.09", "%", "(", "Xibrom", ")", "and", "the", "other", "eye", "with", "50", "microL", "buffered", "saline", ".", "In", "control", "animals", ",", "both", "eyes", "were", "treated", "with", "vehicle", ".", "All", "animals", "were", "treated", "twice", ":", "2", "hours", "and", "1", "hour", "before", "LPS", ".", "MAIN", "OUTCOME", "MEASURES", ":", "PGE(2", ")", "production", "in", "vitro", ",", "measured", "by", "enzyme", "immunoassay", ";", "fluorescein", "isothiocyanate", "(", "FITC)-dextran", "leakage", "into", "the", "anterior", "chamber", ",", "measured", "by", "fluorophotometry", ";", "aqueous", "PGE(2", ")", "levels", "in", "vivo", ",", "measured", "by", "ELISA", "immunoassay", ".", "RESULTS", ":", "Ketorolac", "was", "six", "times", "more", "active", "against", "COX-1", "(", "IC(50", ")", "=", "0.02", "microM", ")", "than", "COX-2", "(", "IC(50", ")", "=", "0.12", "microM", ")", "while", "bromfenac", "was", "approximately", "32", "times", "more", "active", "against", "COX-2", "(", "IC(50", ")", "=", "0.0066", "microM", ")", "than", "COX-1", "(", "IC(50", ")", "=", "0.210", "microM", ")", ".", "In", "the", "animal", "model", ",", "both", "drugs", "resulted", "in", "nearly", "complete", "inhibition", "of", "FITC", "-", "dextran", "leakage", "and", "PGE(2", ")", "production", "in", "the", "anterior", "chamber", "of", "treated", "eyes", ".", "There", "was", "also", "a", "79", "%", "inhibition", "(", "p", "<", "0.001", ")", "of", "FITC", "-", "dextran", "leakage", "in", "the", "contralateral", "eyes", "of", "bromfenac", "-", "treated", "rabbits", ",", "and", "a", "22.5", "%", "inhibition", "(", "not", "statistically", "significant", ")", "in", "the", "contralateral", "eyes", "of", "ketorolac", "-", "treated", "rabbits", ".", "CONCLUSIONS", ":", "Ketorolac", "is", "relatively", "COX-1", "selective", "while", "bromfenac", "is", "potently", "selective", "for", "COX-2", "over", "COX-1", ".", "In", "the", "animal", "model", ",", "both", "ketorolac", "0.4", "%", "and", "bromfenac", "0.09", "%", "demonstrated", "maximal", "anti", "-", "inflammatory", "activity", "in", "treated", "eyes", ".", "Only", "bromfenac", "0.09", "%", "had", "a", "significant", "effect", "on", "the", "contralateral", "eye", ",", "suggesting", "possible", "systemic", "absorption", "of", "this", "drug", "." ]

[ "CHEMICAL", "GENE-Y", "GENE-N" ]

cyclooxygenase, ketorolac tromethamine, bromfenac sodium, cyclooxygenase, COX, ketorolac tromethamine, ketorolac, bromfenac sodium, bromfenac, Cyclooxygenase, prostaglandin E(2 ), PGE(2 ), human recombinant COX-1, COX-2, arachidonic acid, ( + /- ) ketorolac, Acular LS, bromfenac, Xibrom, PGE(2 ), fluorescein isothiocyanate, PGE(2 ), Ketorolac, COX-1, COX-2, bromfenac, COX-2, COX-1, FITC, PGE(2 ), FITC, bromfenac, ketorolac, Ketorolac, COX-1, bromfenac, COX-2, COX-1, ketorolac, bromfenac, bromfenac

19386_task2

Sentence: Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. OBJECTIVE: To compare the cyclooxygenase (COX) activity and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs (NSAIDs) ketorolac tromethamine (ketorolac) and bromfenac sodium (bromfenac). METHODS: Cyclooxygenase activity and selectivity was determined in vitro by measuring prostaglandin E(2) (PGE(2)) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid. Anti-inflammatory effects were evaluated in a rabbit model in which an ocular inflammatory response was induced by intravenous injection of 10 microg/kg lipopolysaccharide (LPS). In study animals, one eye was treated with 50 microL (+/-) ketorolac 0.4% (Acular LS) or bromfenac 0.09% (Xibrom) and the other eye with 50 microL buffered saline. In control animals, both eyes were treated with vehicle. All animals were treated twice: 2 hours and 1 hour before LPS. MAIN OUTCOME MEASURES: PGE(2) production in vitro, measured by enzyme immunoassay; fluorescein isothiocyanate (FITC)-dextran leakage into the anterior chamber, measured by fluorophotometry; aqueous PGE(2) levels in vivo, measured by ELISA immunoassay. RESULTS: Ketorolac was six times more active against COX-1 (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM). In the animal model, both drugs resulted in nearly complete inhibition of FITC-dextran leakage and PGE(2) production in the anterior chamber of treated eyes. There was also a 79% inhibition (p < 0.001) of FITC-dextran leakage in the contralateral eyes of bromfenac-treated rabbits, and a 22.5% inhibition (not statistically significant) in the contralateral eyes of ketorolac-treated rabbits. CONCLUSIONS: Ketorolac is relatively COX-1 selective while bromfenac is potently selective for COX-2 over COX-1. In the animal model, both ketorolac 0.4% and bromfenac 0.09% demonstrated maximal anti-inflammatory activity in treated eyes. Only bromfenac 0.09% had a significant effect on the contralateral eye, suggesting possible systemic absorption of this drug. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. OBJECTIVE: To compare the cyclooxygenase (COX) activity and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs (NSAIDs) ketorolac tromethamine (ketorolac) and bromfenac sodium (bromfenac). METHODS: Cyclooxygenase activity and selectivity was determined in vitro by measuring prostaglandin E(2) (PGE(2)) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid. Anti-inflammatory effects were evaluated in a rabbit model in which an ocular inflammatory response was induced by intravenous injection of 10 microg/kg lipopolysaccharide (LPS). In study animals, one eye was treated with 50 microL (+/-) ketorolac 0.4% (Acular LS) or bromfenac 0.09% (Xibrom) and the other eye with 50 microL buffered saline. In control animals, both eyes were treated with vehicle. All animals were treated twice: 2 hours and 1 hour before LPS. MAIN OUTCOME MEASURES: PGE(2) production in vitro, measured by enzyme immunoassay; fluorescein isothiocyanate (FITC)-dextran leakage into the anterior chamber, measured by fluorophotometry; aqueous PGE(2) levels in vivo, measured by ELISA immunoassay. RESULTS: Ketorolac was six times more active against COX-1 (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM). In the animal model, both drugs resulted in nearly complete inhibition of FITC-dextran leakage and PGE(2) production in the anterior chamber of treated eyes. There was also a 79% inhibition (p < 0.001) of FITC-dextran leakage in the contralateral eyes of bromfenac-treated rabbits, and a 22.5% inhibition (not statistically significant) in the contralateral eyes of ketorolac-treated rabbits. CONCLUSIONS: Ketorolac is relatively COX-1 selective while bromfenac is potently selective for COX-2 over COX-1. In the animal model, both ketorolac 0.4% and bromfenac 0.09% demonstrated maximal anti-inflammatory activity in treated eyes. Only bromfenac 0.09% had a significant effect on the contralateral eye, suggesting possible systemic absorption of this drug.

[ "Comparison", "of", "cyclooxygenase", "inhibitory", "activity", "and", "ocular", "anti", "-", "inflammatory", "effects", "of", "ketorolac", "tromethamine", "and", "bromfenac", "sodium", ".", "\n", "OBJECTIVE", ":", "To", "compare", "the", "cyclooxygenase", "(", "COX", ")", "activity", "and", "anti", "-", "inflammatory", "effects", "of", "the", "nonsteroidal", "anti", "-", "inflammatory", "drugs", "(", "NSAIDs", ")", "ketorolac", "tromethamine", "(", "ketorolac", ")", "and", "bromfenac", "sodium", "(", "bromfenac", ")", ".", "METHODS", ":", "Cyclooxygenase", "activity", "and", "selectivity", "was", "determined", "in", "vitro", "by", "measuring", "prostaglandin", "E(2", ")", "(", "PGE(2", ")", ")", "production", "following", "incubation", "of", "varying", "concentrations", "of", "NSAID", "with", "human", "recombinant", "COX-1", "or", "COX-2", "and", "arachidonic", "acid", ".", "Anti", "-", "inflammatory", "effects", "were", "evaluated", "in", "a", "rabbit", "model", "in", "which", "an", "ocular", "inflammatory", "response", "was", "induced", "by", "intravenous", "injection", "of", "10", "microg", "/", "kg", "lipopolysaccharide", "(", "LPS", ")", ".", "In", "study", "animals", ",", "one", "eye", "was", "treated", "with", "50", "microL", "(", "+", "/-", ")", "ketorolac", "0.4", "%", "(", "Acular", "LS", ")", "or", "bromfenac", "0.09", "%", "(", "Xibrom", ")", "and", "the", "other", "eye", "with", "50", "microL", "buffered", "saline", ".", "In", "control", "animals", ",", "both", "eyes", "were", "treated", "with", "vehicle", ".", "All", "animals", "were", "treated", "twice", ":", "2", "hours", "and", "1", "hour", "before", "LPS", ".", "MAIN", "OUTCOME", "MEASURES", ":", "PGE(2", ")", "production", "in", "vitro", ",", "measured", "by", "enzyme", "immunoassay", ";", "fluorescein", "isothiocyanate", "(", "FITC)-dextran", "leakage", "into", "the", "anterior", "chamber", ",", "measured", "by", "fluorophotometry", ";", "aqueous", "PGE(2", ")", "levels", "in", "vivo", ",", "measured", "by", "ELISA", "immunoassay", ".", "RESULTS", ":", "Ketorolac", "was", "six", "times", "more", "active", "against", "COX-1", "(", "IC(50", ")", "=", "0.02", "microM", ")", "than", "COX-2", "(", "IC(50", ")", "=", "0.12", "microM", ")", "while", "bromfenac", "was", "approximately", "32", "times", "more", "active", "against", "COX-2", "(", "IC(50", ")", "=", "0.0066", "microM", ")", "than", "COX-1", "(", "IC(50", ")", "=", "0.210", "microM", ")", ".", "In", "the", "animal", "model", ",", "both", "drugs", "resulted", "in", "nearly", "complete", "inhibition", "of", "FITC", "-", "dextran", "leakage", "and", "PGE(2", ")", "production", "in", "the", "anterior", "chamber", "of", "treated", "eyes", ".", "There", "was", "also", "a", "79", "%", "inhibition", "(", "p", "<", "0.001", ")", "of", "FITC", "-", "dextran", "leakage", "in", "the", "contralateral", "eyes", "of", "bromfenac", "-", "treated", "rabbits", ",", "and", "a", "22.5", "%", "inhibition", "(", "not", "statistically", "significant", ")", "in", "the", "contralateral", "eyes", "of", "ketorolac", "-", "treated", "rabbits", ".", "CONCLUSIONS", ":", "Ketorolac", "is", "relatively", "COX-1", "selective", "while", "bromfenac", "is", "potently", "selective", "for", "COX-2", "over", "COX-1", ".", "In", "the", "animal", "model", ",", "both", "ketorolac", "0.4", "%", "and", "bromfenac", "0.09", "%", "demonstrated", "maximal", "anti", "-", "inflammatory", "activity", "in", "treated", "eyes", ".", "Only", "bromfenac", "0.09", "%", "had", "a", "significant", "effect", "on", "the", "contralateral", "eye", ",", "suggesting", "possible", "systemic", "absorption", "of", "this", "drug", "." ]

[ "CHEMICAL", "GENE-Y", "GENE-N" ]

O - linked N - acetylglucosaminyltransferase is a Protein, O - linked N - acetylglucosaminyltransferase is a Protein, OGT is a Protein, OGT is a Protein, O - GlcNAcase is a Protein, O - GlcNAcase is a Protein

293_task0

Sentence: Glucose deprivation stimulates O-GlcNAc modification of proteins through up-regulation of O-linked N-acetylglucosaminyltransferase. O-Linked N-acetylglucosamine (O-GlcNAc) is a post-translational modification of proteins that functions as a nutrient sensing mechanism. Here we report on regulation of O-GlcNAcylation over a broad range of glucose concentrations. We have discovered a significant induction of O-GlcNAc modification of a limited number of proteins under conditions of glucose deprivation. Beginning 12 h after treatment, glucose-deprived human hepatocellular carcinoma (HepG2) cells demonstrate a 7.8-fold increase in total O-GlcNAc modification compared with cells cultured in normal glucose (5 mm; p = 0.008). Some of the targets of glucose deprivation-induced O-GlcNAcylation are distinct from those modified in response to high glucose (20 mm) or glucosamine (10 mm) treatment, suggesting differential targeting with glucose deprivation and glucose excess. O-GlcNAcylation of glycogen synthase is significantly increased with glucose deprivation, and this O-GlcNAc increase contributes to a 60% decrease (p = 0.004) in glycogen synthase activity. Increased O-GlcNAc modification is not mediated by increased UDP-GlcNAc, the rate-limiting substrate for O-GlcNAcylation. Rather, the mRNA for nucleocytoplasmic O-linked N-acetylglucosaminyltransferase (OGT) increases 3.4-fold within 6 h of glucose deprivation (p = 0.006). Within 12 h, OGT protein increases 1.7-fold (p = 0.01) compared with normal glucose-treated cells. In addition, 12-h glucose deprivation leads to a 49% decrease in O-GlcNAcase protein levels (p = 0.03). We conclude that increased O-GlcNAc modification stimulated by glucose deprivation results from increased OGT and decreased O-GlcNAcase levels and that these changes affect cell metabolism, thus inactivating glycogen synthase. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Glucose deprivation stimulates O-GlcNAc modification of proteins through up-regulation of O-linked N-acetylglucosaminyltransferase. O-Linked N-acetylglucosamine (O-GlcNAc) is a post-translational modification of proteins that functions as a nutrient sensing mechanism. Here we report on regulation of O-GlcNAcylation over a broad range of glucose concentrations. We have discovered a significant induction of O-GlcNAc modification of a limited number of proteins under conditions of glucose deprivation. Beginning 12 h after treatment, glucose-deprived human hepatocellular carcinoma (HepG2) cells demonstrate a 7.8-fold increase in total O-GlcNAc modification compared with cells cultured in normal glucose (5 mm; p = 0.008). Some of the targets of glucose deprivation-induced O-GlcNAcylation are distinct from those modified in response to high glucose (20 mm) or glucosamine (10 mm) treatment, suggesting differential targeting with glucose deprivation and glucose excess. O-GlcNAcylation of glycogen synthase is significantly increased with glucose deprivation, and this O-GlcNAc increase contributes to a 60% decrease (p = 0.004) in glycogen synthase activity. Increased O-GlcNAc modification is not mediated by increased UDP-GlcNAc, the rate-limiting substrate for O-GlcNAcylation. Rather, the mRNA for nucleocytoplasmic O-linked N-acetylglucosaminyltransferase (OGT) increases 3.4-fold within 6 h of glucose deprivation (p = 0.006). Within 12 h, OGT protein increases 1.7-fold (p = 0.01) compared with normal glucose-treated cells. In addition, 12-h glucose deprivation leads to a 49% decrease in O-GlcNAcase protein levels (p = 0.03). We conclude that increased O-GlcNAc modification stimulated by glucose deprivation results from increased OGT and decreased O-GlcNAcase levels and that these changes affect cell metabolism, thus inactivating glycogen synthase.

[ "Glucose", "deprivation", "stimulates", "O", "-", "GlcNAc", "modification", "of", "proteins", "through", "up", "-", "regulation", "of", "O", "-", "linked", "N", "-", "acetylglucosaminyltransferase", ".", "\n", "O", "-", "Linked", "N", "-", "acetylglucosamine", "(", "O", "-", "GlcNAc", ")", "is", "a", "post", "-", "translational", "modification", "of", "proteins", "that", "functions", "as", "a", "nutrient", "sensing", "mechanism", ".", "Here", "we", "report", "on", "regulation", "of", "O", "-", "GlcNAcylation", "over", "a", "broad", "range", "of", "glucose", "concentrations", ".", "We", "have", "discovered", "a", "significant", "induction", "of", "O", "-", "GlcNAc", "modification", "of", "a", "limited", "number", "of", "proteins", "under", "conditions", "of", "glucose", "deprivation", ".", "Beginning", "12", "h", "after", "treatment", ",", "glucose", "-", "deprived", "human", "hepatocellular", "carcinoma", "(", "HepG2", ")", "cells", "demonstrate", "a", "7.8-fold", "increase", "in", "total", "O", "-", "GlcNAc", "modification", "compared", "with", "cells", "cultured", "in", "normal", "glucose", "(", "5", "mm", ";", "p", "=", "0.008", ")", ".", "Some", "of", "the", "targets", "of", "glucose", "deprivation", "-", "induced", "O", "-", "GlcNAcylation", "are", "distinct", "from", "those", "modified", "in", "response", "to", "high", "glucose", "(", "20", "mm", ")", "or", "glucosamine", "(", "10", "mm", ")", "treatment", ",", "suggesting", "differential", "targeting", "with", "glucose", "deprivation", "and", "glucose", "excess", ".", "O", "-", "GlcNAcylation", "of", "glycogen", "synthase", "is", "significantly", "increased", "with", "glucose", "deprivation", ",", "and", "this", "O", "-", "GlcNAc", "increase", "contributes", "to", "a", "60", "%", "decrease", "(", "p", "=", "0.004", ")", "in", "glycogen", "synthase", "activity", ".", "Increased", "O", "-", "GlcNAc", "modification", "is", "not", "mediated", "by", "increased", "UDP", "-", "GlcNAc", ",", "the", "rate", "-", "limiting", "substrate", "for", "O", "-", "GlcNAcylation", ".", "Rather", ",", "the", "mRNA", "for", "nucleocytoplasmic", "O", "-", "linked", "N", "-", "acetylglucosaminyltransferase", "(", "OGT", ")", "increases", "3.4-fold", "within", "6", "h", "of", "glucose", "deprivation", "(", "p", "=", "0.006", ")", ".", "Within", "12", "h", ",", "OGT", "protein", "increases", "1.7-fold", "(", "p", "=", "0.01", ")", "compared", "with", "normal", "glucose", "-", "treated", "cells", ".", "In", "addition", ",", "12-h", "glucose", "deprivation", "leads", "to", "a", "49", "%", "decrease", "in", "O", "-", "GlcNAcase", "protein", "levels", "(", "p", "=", "0.03", ")", ".", "We", "conclude", "that", "increased", "O", "-", "GlcNAc", "modification", "stimulated", "by", "glucose", "deprivation", "results", "from", "increased", "OGT", "and", "decreased", "O", "-", "GlcNAcase", "levels", "and", "that", "these", "changes", "affect", "cell", "metabolism", ",", "thus", "inactivating", "glycogen", "synthase", ".", "\n" ]

[ "Protein" ]

O - linked N - acetylglucosaminyltransferase is a Protein, O - linked N - acetylglucosaminyltransferase is a Protein, OGT is a Protein, OGT is a Protein, O - GlcNAcase is a Protein, O - GlcNAcase is a Protein

293_task1

Sentence: Glucose deprivation stimulates O-GlcNAc modification of proteins through up-regulation of O-linked N-acetylglucosaminyltransferase. O-Linked N-acetylglucosamine (O-GlcNAc) is a post-translational modification of proteins that functions as a nutrient sensing mechanism. Here we report on regulation of O-GlcNAcylation over a broad range of glucose concentrations. We have discovered a significant induction of O-GlcNAc modification of a limited number of proteins under conditions of glucose deprivation. Beginning 12 h after treatment, glucose-deprived human hepatocellular carcinoma (HepG2) cells demonstrate a 7.8-fold increase in total O-GlcNAc modification compared with cells cultured in normal glucose (5 mm; p = 0.008). Some of the targets of glucose deprivation-induced O-GlcNAcylation are distinct from those modified in response to high glucose (20 mm) or glucosamine (10 mm) treatment, suggesting differential targeting with glucose deprivation and glucose excess. O-GlcNAcylation of glycogen synthase is significantly increased with glucose deprivation, and this O-GlcNAc increase contributes to a 60% decrease (p = 0.004) in glycogen synthase activity. Increased O-GlcNAc modification is not mediated by increased UDP-GlcNAc, the rate-limiting substrate for O-GlcNAcylation. Rather, the mRNA for nucleocytoplasmic O-linked N-acetylglucosaminyltransferase (OGT) increases 3.4-fold within 6 h of glucose deprivation (p = 0.006). Within 12 h, OGT protein increases 1.7-fold (p = 0.01) compared with normal glucose-treated cells. In addition, 12-h glucose deprivation leads to a 49% decrease in O-GlcNAcase protein levels (p = 0.03). We conclude that increased O-GlcNAc modification stimulated by glucose deprivation results from increased OGT and decreased O-GlcNAcase levels and that these changes affect cell metabolism, thus inactivating glycogen synthase. Instructions: please typing these entity words according to sentence: O - linked N - acetylglucosaminyltransferase, O - linked N - acetylglucosaminyltransferase, OGT, OGT, O - GlcNAcase, O - GlcNAcase Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Glucose deprivation stimulates O-GlcNAc modification of proteins through up-regulation of O-linked N-acetylglucosaminyltransferase. O-Linked N-acetylglucosamine (O-GlcNAc) is a post-translational modification of proteins that functions as a nutrient sensing mechanism. Here we report on regulation of O-GlcNAcylation over a broad range of glucose concentrations. We have discovered a significant induction of O-GlcNAc modification of a limited number of proteins under conditions of glucose deprivation. Beginning 12 h after treatment, glucose-deprived human hepatocellular carcinoma (HepG2) cells demonstrate a 7.8-fold increase in total O-GlcNAc modification compared with cells cultured in normal glucose (5 mm; p = 0.008). Some of the targets of glucose deprivation-induced O-GlcNAcylation are distinct from those modified in response to high glucose (20 mm) or glucosamine (10 mm) treatment, suggesting differential targeting with glucose deprivation and glucose excess. O-GlcNAcylation of glycogen synthase is significantly increased with glucose deprivation, and this O-GlcNAc increase contributes to a 60% decrease (p = 0.004) in glycogen synthase activity. Increased O-GlcNAc modification is not mediated by increased UDP-GlcNAc, the rate-limiting substrate for O-GlcNAcylation. Rather, the mRNA for nucleocytoplasmic O-linked N-acetylglucosaminyltransferase (OGT) increases 3.4-fold within 6 h of glucose deprivation (p = 0.006). Within 12 h, OGT protein increases 1.7-fold (p = 0.01) compared with normal glucose-treated cells. In addition, 12-h glucose deprivation leads to a 49% decrease in O-GlcNAcase protein levels (p = 0.03). We conclude that increased O-GlcNAc modification stimulated by glucose deprivation results from increased OGT and decreased O-GlcNAcase levels and that these changes affect cell metabolism, thus inactivating glycogen synthase.

[ "Glucose", "deprivation", "stimulates", "O", "-", "GlcNAc", "modification", "of", "proteins", "through", "up", "-", "regulation", "of", "O", "-", "linked", "N", "-", "acetylglucosaminyltransferase", ".", "\n", "O", "-", "Linked", "N", "-", "acetylglucosamine", "(", "O", "-", "GlcNAc", ")", "is", "a", "post", "-", "translational", "modification", "of", "proteins", "that", "functions", "as", "a", "nutrient", "sensing", "mechanism", ".", "Here", "we", "report", "on", "regulation", "of", "O", "-", "GlcNAcylation", "over", "a", "broad", "range", "of", "glucose", "concentrations", ".", "We", "have", "discovered", "a", "significant", "induction", "of", "O", "-", "GlcNAc", "modification", "of", "a", "limited", "number", "of", "proteins", "under", "conditions", "of", "glucose", "deprivation", ".", "Beginning", "12", "h", "after", "treatment", ",", "glucose", "-", "deprived", "human", "hepatocellular", "carcinoma", "(", "HepG2", ")", "cells", "demonstrate", "a", "7.8-fold", "increase", "in", "total", "O", "-", "GlcNAc", "modification", "compared", "with", "cells", "cultured", "in", "normal", "glucose", "(", "5", "mm", ";", "p", "=", "0.008", ")", ".", "Some", "of", "the", "targets", "of", "glucose", "deprivation", "-", "induced", "O", "-", "GlcNAcylation", "are", "distinct", "from", "those", "modified", "in", "response", "to", "high", "glucose", "(", "20", "mm", ")", "or", "glucosamine", "(", "10", "mm", ")", "treatment", ",", "suggesting", "differential", "targeting", "with", "glucose", "deprivation", "and", "glucose", "excess", ".", "O", "-", "GlcNAcylation", "of", "glycogen", "synthase", "is", "significantly", "increased", "with", "glucose", "deprivation", ",", "and", "this", "O", "-", "GlcNAc", "increase", "contributes", "to", "a", "60", "%", "decrease", "(", "p", "=", "0.004", ")", "in", "glycogen", "synthase", "activity", ".", "Increased", "O", "-", "GlcNAc", "modification", "is", "not", "mediated", "by", "increased", "UDP", "-", "GlcNAc", ",", "the", "rate", "-", "limiting", "substrate", "for", "O", "-", "GlcNAcylation", ".", "Rather", ",", "the", "mRNA", "for", "nucleocytoplasmic", "O", "-", "linked", "N", "-", "acetylglucosaminyltransferase", "(", "OGT", ")", "increases", "3.4-fold", "within", "6", "h", "of", "glucose", "deprivation", "(", "p", "=", "0.006", ")", ".", "Within", "12", "h", ",", "OGT", "protein", "increases", "1.7-fold", "(", "p", "=", "0.01", ")", "compared", "with", "normal", "glucose", "-", "treated", "cells", ".", "In", "addition", ",", "12-h", "glucose", "deprivation", "leads", "to", "a", "49", "%", "decrease", "in", "O", "-", "GlcNAcase", "protein", "levels", "(", "p", "=", "0.03", ")", ".", "We", "conclude", "that", "increased", "O", "-", "GlcNAc", "modification", "stimulated", "by", "glucose", "deprivation", "results", "from", "increased", "OGT", "and", "decreased", "O", "-", "GlcNAcase", "levels", "and", "that", "these", "changes", "affect", "cell", "metabolism", ",", "thus", "inactivating", "glycogen", "synthase", ".", "\n" ]

[ "Protein" ]

O - linked N - acetylglucosaminyltransferase, O - linked N - acetylglucosaminyltransferase, OGT, OGT, O - GlcNAcase, O - GlcNAcase

293_task2

Sentence: Glucose deprivation stimulates O-GlcNAc modification of proteins through up-regulation of O-linked N-acetylglucosaminyltransferase. O-Linked N-acetylglucosamine (O-GlcNAc) is a post-translational modification of proteins that functions as a nutrient sensing mechanism. Here we report on regulation of O-GlcNAcylation over a broad range of glucose concentrations. We have discovered a significant induction of O-GlcNAc modification of a limited number of proteins under conditions of glucose deprivation. Beginning 12 h after treatment, glucose-deprived human hepatocellular carcinoma (HepG2) cells demonstrate a 7.8-fold increase in total O-GlcNAc modification compared with cells cultured in normal glucose (5 mm; p = 0.008). Some of the targets of glucose deprivation-induced O-GlcNAcylation are distinct from those modified in response to high glucose (20 mm) or glucosamine (10 mm) treatment, suggesting differential targeting with glucose deprivation and glucose excess. O-GlcNAcylation of glycogen synthase is significantly increased with glucose deprivation, and this O-GlcNAc increase contributes to a 60% decrease (p = 0.004) in glycogen synthase activity. Increased O-GlcNAc modification is not mediated by increased UDP-GlcNAc, the rate-limiting substrate for O-GlcNAcylation. Rather, the mRNA for nucleocytoplasmic O-linked N-acetylglucosaminyltransferase (OGT) increases 3.4-fold within 6 h of glucose deprivation (p = 0.006). Within 12 h, OGT protein increases 1.7-fold (p = 0.01) compared with normal glucose-treated cells. In addition, 12-h glucose deprivation leads to a 49% decrease in O-GlcNAcase protein levels (p = 0.03). We conclude that increased O-GlcNAc modification stimulated by glucose deprivation results from increased OGT and decreased O-GlcNAcase levels and that these changes affect cell metabolism, thus inactivating glycogen synthase. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Glucose deprivation stimulates O-GlcNAc modification of proteins through up-regulation of O-linked N-acetylglucosaminyltransferase. O-Linked N-acetylglucosamine (O-GlcNAc) is a post-translational modification of proteins that functions as a nutrient sensing mechanism. Here we report on regulation of O-GlcNAcylation over a broad range of glucose concentrations. We have discovered a significant induction of O-GlcNAc modification of a limited number of proteins under conditions of glucose deprivation. Beginning 12 h after treatment, glucose-deprived human hepatocellular carcinoma (HepG2) cells demonstrate a 7.8-fold increase in total O-GlcNAc modification compared with cells cultured in normal glucose (5 mm; p = 0.008). Some of the targets of glucose deprivation-induced O-GlcNAcylation are distinct from those modified in response to high glucose (20 mm) or glucosamine (10 mm) treatment, suggesting differential targeting with glucose deprivation and glucose excess. O-GlcNAcylation of glycogen synthase is significantly increased with glucose deprivation, and this O-GlcNAc increase contributes to a 60% decrease (p = 0.004) in glycogen synthase activity. Increased O-GlcNAc modification is not mediated by increased UDP-GlcNAc, the rate-limiting substrate for O-GlcNAcylation. Rather, the mRNA for nucleocytoplasmic O-linked N-acetylglucosaminyltransferase (OGT) increases 3.4-fold within 6 h of glucose deprivation (p = 0.006). Within 12 h, OGT protein increases 1.7-fold (p = 0.01) compared with normal glucose-treated cells. In addition, 12-h glucose deprivation leads to a 49% decrease in O-GlcNAcase protein levels (p = 0.03). We conclude that increased O-GlcNAc modification stimulated by glucose deprivation results from increased OGT and decreased O-GlcNAcase levels and that these changes affect cell metabolism, thus inactivating glycogen synthase.

[ "Glucose", "deprivation", "stimulates", "O", "-", "GlcNAc", "modification", "of", "proteins", "through", "up", "-", "regulation", "of", "O", "-", "linked", "N", "-", "acetylglucosaminyltransferase", ".", "\n", "O", "-", "Linked", "N", "-", "acetylglucosamine", "(", "O", "-", "GlcNAc", ")", "is", "a", "post", "-", "translational", "modification", "of", "proteins", "that", "functions", "as", "a", "nutrient", "sensing", "mechanism", ".", "Here", "we", "report", "on", "regulation", "of", "O", "-", "GlcNAcylation", "over", "a", "broad", "range", "of", "glucose", "concentrations", ".", "We", "have", "discovered", "a", "significant", "induction", "of", "O", "-", "GlcNAc", "modification", "of", "a", "limited", "number", "of", "proteins", "under", "conditions", "of", "glucose", "deprivation", ".", "Beginning", "12", "h", "after", "treatment", ",", "glucose", "-", "deprived", "human", "hepatocellular", "carcinoma", "(", "HepG2", ")", "cells", "demonstrate", "a", "7.8-fold", "increase", "in", "total", "O", "-", "GlcNAc", "modification", "compared", "with", "cells", "cultured", "in", "normal", "glucose", "(", "5", "mm", ";", "p", "=", "0.008", ")", ".", "Some", "of", "the", "targets", "of", "glucose", "deprivation", "-", "induced", "O", "-", "GlcNAcylation", "are", "distinct", "from", "those", "modified", "in", "response", "to", "high", "glucose", "(", "20", "mm", ")", "or", "glucosamine", "(", "10", "mm", ")", "treatment", ",", "suggesting", "differential", "targeting", "with", "glucose", "deprivation", "and", "glucose", "excess", ".", "O", "-", "GlcNAcylation", "of", "glycogen", "synthase", "is", "significantly", "increased", "with", "glucose", "deprivation", ",", "and", "this", "O", "-", "GlcNAc", "increase", "contributes", "to", "a", "60", "%", "decrease", "(", "p", "=", "0.004", ")", "in", "glycogen", "synthase", "activity", ".", "Increased", "O", "-", "GlcNAc", "modification", "is", "not", "mediated", "by", "increased", "UDP", "-", "GlcNAc", ",", "the", "rate", "-", "limiting", "substrate", "for", "O", "-", "GlcNAcylation", ".", "Rather", ",", "the", "mRNA", "for", "nucleocytoplasmic", "O", "-", "linked", "N", "-", "acetylglucosaminyltransferase", "(", "OGT", ")", "increases", "3.4-fold", "within", "6", "h", "of", "glucose", "deprivation", "(", "p", "=", "0.006", ")", ".", "Within", "12", "h", ",", "OGT", "protein", "increases", "1.7-fold", "(", "p", "=", "0.01", ")", "compared", "with", "normal", "glucose", "-", "treated", "cells", ".", "In", "addition", ",", "12-h", "glucose", "deprivation", "leads", "to", "a", "49", "%", "decrease", "in", "O", "-", "GlcNAcase", "protein", "levels", "(", "p", "=", "0.03", ")", ".", "We", "conclude", "that", "increased", "O", "-", "GlcNAc", "modification", "stimulated", "by", "glucose", "deprivation", "results", "from", "increased", "OGT", "and", "decreased", "O", "-", "GlcNAcase", "levels", "and", "that", "these", "changes", "affect", "cell", "metabolism", ",", "thus", "inactivating", "glycogen", "synthase", ".", "\n" ]

[ "Protein" ]

knowledge gain is a Outcome_Mental, structured is a Intervention_Other, student - directed learning is a Intervention_Educational, Health is a Participant_Condition, students is a Participant_Age, versus is a Intervention_Educational, 138 is a Participant_Sample-size, structured learning is a Intervention_Other, Pre- and post - course tests is a Outcome_Other, 129 is a Participant_Sample-size, gain in knowledge is a Outcome_Mental, pre - course scores is a Outcome_Mental, post - course scores is a Outcome_Mental, Knowledge gain is a Outcome_Mental

26561_task0

Sentence: Greater knowledge gain with structured than student-directed learning in Child Health : cluster randomized trial . The aim of this study was to detect a difference in knowledge gain between students receiving structured versus student-directed learning for the two-week Child Health outpatient module . A total of 138 phase 3 ( year 4 ) medical students in 10 two-week paediatric outpatient blocks at the Department of Child Health , University of Dundee , Scotland , were randomized to student-directed or structured learning between January and December 2002 . Pre- and post-course tests were administered at the start and the end of the attachment ; 129 students sat both tests . Results are presented as mean scores with standard deviations or 95 % confidence intervals ( CI ) in parentheses . The primary outcome measure was gain in knowledge of the Child Health core curriculum that is covered in the outpatient setting . Although pre-course scores were similar ( student-directed 25.3 ( 7.3 ) ; structured 24.8 ( 7.5 ) ) the structured approach resulted in higher post-course scores in comparison with the student-directed approach ( student-directed 41.8 ( 9.4 ) ; structured 53.8 ( 8.8 ) ; p < 0.01 ) . Knowledge gain showed significant differences between the two learning approaches ( student-directed 16.5 ( 3.7 ) ; structured 29.1 ( 3.8 ) , difference = 12.6 ( 95 % CI 11.3 to 13.9 ) ) . Low pre-course scores or gender did not affect knowledge gain . In the Child Health outpatient setting , the 'traditional ' structured approach led to significantly greater knowledge gain in comparison with the 'novel ' student-directed approach . The findings emphasize the importance of careful evaluation of novel medical education strategies before their implementation in medical schools , and the need for further research to define the effective methods for delivering medical education in Child Health . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Participant_Condition, Intervention_Educational, Intervention_Other, Participant_Age, Participant_Sample-size, Outcome_Other, Outcome_Mental

[ "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Intervention_Other", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "O", "B-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Greater knowledge gain with structured than student-directed learning in Child Health : cluster randomized trial . The aim of this study was to detect a difference in knowledge gain between students receiving structured versus student-directed learning for the two-week Child Health outpatient module . A total of 138 phase 3 ( year 4 ) medical students in 10 two-week paediatric outpatient blocks at the Department of Child Health , University of Dundee , Scotland , were randomized to student-directed or structured learning between January and December 2002 . Pre- and post-course tests were administered at the start and the end of the attachment ; 129 students sat both tests . Results are presented as mean scores with standard deviations or 95 % confidence intervals ( CI ) in parentheses . The primary outcome measure was gain in knowledge of the Child Health core curriculum that is covered in the outpatient setting . Although pre-course scores were similar ( student-directed 25.3 ( 7.3 ) ; structured 24.8 ( 7.5 ) ) the structured approach resulted in higher post-course scores in comparison with the student-directed approach ( student-directed 41.8 ( 9.4 ) ; structured 53.8 ( 8.8 ) ; p < 0.01 ) . Knowledge gain showed significant differences between the two learning approaches ( student-directed 16.5 ( 3.7 ) ; structured 29.1 ( 3.8 ) , difference = 12.6 ( 95 % CI 11.3 to 13.9 ) ) . Low pre-course scores or gender did not affect knowledge gain . In the Child Health outpatient setting , the 'traditional ' structured approach led to significantly greater knowledge gain in comparison with the 'novel ' student-directed approach . The findings emphasize the importance of careful evaluation of novel medical education strategies before their implementation in medical schools , and the need for further research to define the effective methods for delivering medical education in Child Health .

[ "Greater", "knowledge", "gain", "with", "structured", "than", "student", "-", "directed", "learning", "in", "Child", "Health", ":", "cluster", "randomized", "trial", ".", "The", "aim", "of", "this", "study", "was", "to", "detect", "a", "difference", "in", "knowledge", "gain", "between", "students", "receiving", "structured", "versus", "student", "-", "directed", "learning", "for", "the", "two", "-", "week", "Child", "Health", "outpatient", "module", ".", "A", "total", "of", "138", "phase", "3", "(", "year", "4", ")", "medical", "students", "in", "10", "two", "-", "week", "paediatric", "outpatient", "blocks", "at", "the", "Department", "of", "Child", "Health", ",", "University", "of", "Dundee", ",", "Scotland", ",", "were", "randomized", "to", "student", "-", "directed", "or", "structured", "learning", "between", "January", "and", "December", "2002", ".", "Pre-", "and", "post", "-", "course", "tests", "were", "administered", "at", "the", "start", "and", "the", "end", "of", "the", "attachment", ";", "129", "students", "sat", "both", "tests", ".", "Results", "are", "presented", "as", "mean", "scores", "with", "standard", "deviations", "or", "95", "%", "confidence", "intervals", "(", "CI", ")", "in", "parentheses", ".", "The", "primary", "outcome", "measure", "was", "gain", "in", "knowledge", "of", "the", "Child", "Health", "core", "curriculum", "that", "is", "covered", "in", "the", "outpatient", "setting", ".", "Although", "pre", "-", "course", "scores", "were", "similar", "(", "student", "-", "directed", "25.3", "(", "7.3", ")", ";", "structured", "24.8", "(", "7.5", ")", ")", "the", "structured", "approach", "resulted", "in", "higher", "post", "-", "course", "scores", "in", "comparison", "with", "the", "student", "-", "directed", "approach", "(", "student", "-", "directed", "41.8", "(", "9.4", ")", ";", "structured", "53.8", "(", "8.8", ")", ";", "p", "<", "0.01", ")", ".", "Knowledge", "gain", "showed", "significant", "differences", "between", "the", "two", "learning", "approaches", "(", "student", "-", "directed", "16.5", "(", "3.7", ")", ";", "structured", "29.1", "(", "3.8", ")", ",", "difference", "=", "12.6", "(", "95", "%", "CI", "11.3", "to", "13.9", ")", ")", ".", "Low", "pre", "-", "course", "scores", "or", "gender", "did", "not", "affect", "knowledge", "gain", ".", "In", "the", "Child", "Health", "outpatient", "setting", ",", "the", "'", "traditional", "'", "structured", "approach", "led", "to", "significantly", "greater", "knowledge", "gain", "in", "comparison", "with", "the", "'", "novel", "'", "student", "-", "directed", "approach", ".", "The", "findings", "emphasize", "the", "importance", "of", "careful", "evaluation", "of", "novel", "medical", "education", "strategies", "before", "their", "implementation", "in", "medical", "schools", ",", "and", "the", "need", "for", "further", "research", "to", "define", "the", "effective", "methods", "for", "delivering", "medical", "education", "in", "Child", "Health", "." ]

[ "Outcome_Other", "Intervention_Educational", "Intervention_Other", "Outcome_Mental", "Intervention_Control", "Participant_Age", "Participant_Condition", "Participant_Sample-size" ]

knowledge gain is a Outcome_Mental, structured is a Intervention_Other, student - directed learning is a Intervention_Educational, Health is a Participant_Condition, students is a Participant_Age, versus is a Intervention_Educational, 138 is a Participant_Sample-size, structured learning is a Intervention_Other, Pre- and post - course tests is a Outcome_Other, 129 is a Participant_Sample-size, gain in knowledge is a Outcome_Mental, pre - course scores is a Outcome_Mental, post - course scores is a Outcome_Mental, Knowledge gain is a Outcome_Mental

26561_task1

Sentence: Greater knowledge gain with structured than student-directed learning in Child Health : cluster randomized trial . The aim of this study was to detect a difference in knowledge gain between students receiving structured versus student-directed learning for the two-week Child Health outpatient module . A total of 138 phase 3 ( year 4 ) medical students in 10 two-week paediatric outpatient blocks at the Department of Child Health , University of Dundee , Scotland , were randomized to student-directed or structured learning between January and December 2002 . Pre- and post-course tests were administered at the start and the end of the attachment ; 129 students sat both tests . Results are presented as mean scores with standard deviations or 95 % confidence intervals ( CI ) in parentheses . The primary outcome measure was gain in knowledge of the Child Health core curriculum that is covered in the outpatient setting . Although pre-course scores were similar ( student-directed 25.3 ( 7.3 ) ; structured 24.8 ( 7.5 ) ) the structured approach resulted in higher post-course scores in comparison with the student-directed approach ( student-directed 41.8 ( 9.4 ) ; structured 53.8 ( 8.8 ) ; p < 0.01 ) . Knowledge gain showed significant differences between the two learning approaches ( student-directed 16.5 ( 3.7 ) ; structured 29.1 ( 3.8 ) , difference = 12.6 ( 95 % CI 11.3 to 13.9 ) ) . Low pre-course scores or gender did not affect knowledge gain . In the Child Health outpatient setting , the 'traditional ' structured approach led to significantly greater knowledge gain in comparison with the 'novel ' student-directed approach . The findings emphasize the importance of careful evaluation of novel medical education strategies before their implementation in medical schools , and the need for further research to define the effective methods for delivering medical education in Child Health . Instructions: please typing these entity words according to sentence: knowledge gain, structured, student - directed learning, Health, students, versus, 138, structured learning, Pre- and post - course tests, 129, gain in knowledge, pre - course scores, post - course scores, Knowledge gain Options: Participant_Condition, Intervention_Educational, Intervention_Other, Participant_Age, Participant_Sample-size, Outcome_Other, Outcome_Mental

[ "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Intervention_Other", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "O", "B-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Greater knowledge gain with structured than student-directed learning in Child Health : cluster randomized trial . The aim of this study was to detect a difference in knowledge gain between students receiving structured versus student-directed learning for the two-week Child Health outpatient module . A total of 138 phase 3 ( year 4 ) medical students in 10 two-week paediatric outpatient blocks at the Department of Child Health , University of Dundee , Scotland , were randomized to student-directed or structured learning between January and December 2002 . Pre- and post-course tests were administered at the start and the end of the attachment ; 129 students sat both tests . Results are presented as mean scores with standard deviations or 95 % confidence intervals ( CI ) in parentheses . The primary outcome measure was gain in knowledge of the Child Health core curriculum that is covered in the outpatient setting . Although pre-course scores were similar ( student-directed 25.3 ( 7.3 ) ; structured 24.8 ( 7.5 ) ) the structured approach resulted in higher post-course scores in comparison with the student-directed approach ( student-directed 41.8 ( 9.4 ) ; structured 53.8 ( 8.8 ) ; p < 0.01 ) . Knowledge gain showed significant differences between the two learning approaches ( student-directed 16.5 ( 3.7 ) ; structured 29.1 ( 3.8 ) , difference = 12.6 ( 95 % CI 11.3 to 13.9 ) ) . Low pre-course scores or gender did not affect knowledge gain . In the Child Health outpatient setting , the 'traditional ' structured approach led to significantly greater knowledge gain in comparison with the 'novel ' student-directed approach . The findings emphasize the importance of careful evaluation of novel medical education strategies before their implementation in medical schools , and the need for further research to define the effective methods for delivering medical education in Child Health .

[ "Greater", "knowledge", "gain", "with", "structured", "than", "student", "-", "directed", "learning", "in", "Child", "Health", ":", "cluster", "randomized", "trial", ".", "The", "aim", "of", "this", "study", "was", "to", "detect", "a", "difference", "in", "knowledge", "gain", "between", "students", "receiving", "structured", "versus", "student", "-", "directed", "learning", "for", "the", "two", "-", "week", "Child", "Health", "outpatient", "module", ".", "A", "total", "of", "138", "phase", "3", "(", "year", "4", ")", "medical", "students", "in", "10", "two", "-", "week", "paediatric", "outpatient", "blocks", "at", "the", "Department", "of", "Child", "Health", ",", "University", "of", "Dundee", ",", "Scotland", ",", "were", "randomized", "to", "student", "-", "directed", "or", "structured", "learning", "between", "January", "and", "December", "2002", ".", "Pre-", "and", "post", "-", "course", "tests", "were", "administered", "at", "the", "start", "and", "the", "end", "of", "the", "attachment", ";", "129", "students", "sat", "both", "tests", ".", "Results", "are", "presented", "as", "mean", "scores", "with", "standard", "deviations", "or", "95", "%", "confidence", "intervals", "(", "CI", ")", "in", "parentheses", ".", "The", "primary", "outcome", "measure", "was", "gain", "in", "knowledge", "of", "the", "Child", "Health", "core", "curriculum", "that", "is", "covered", "in", "the", "outpatient", "setting", ".", "Although", "pre", "-", "course", "scores", "were", "similar", "(", "student", "-", "directed", "25.3", "(", "7.3", ")", ";", "structured", "24.8", "(", "7.5", ")", ")", "the", "structured", "approach", "resulted", "in", "higher", "post", "-", "course", "scores", "in", "comparison", "with", "the", "student", "-", "directed", "approach", "(", "student", "-", "directed", "41.8", "(", "9.4", ")", ";", "structured", "53.8", "(", "8.8", ")", ";", "p", "<", "0.01", ")", ".", "Knowledge", "gain", "showed", "significant", "differences", "between", "the", "two", "learning", "approaches", "(", "student", "-", "directed", "16.5", "(", "3.7", ")", ";", "structured", "29.1", "(", "3.8", ")", ",", "difference", "=", "12.6", "(", "95", "%", "CI", "11.3", "to", "13.9", ")", ")", ".", "Low", "pre", "-", "course", "scores", "or", "gender", "did", "not", "affect", "knowledge", "gain", ".", "In", "the", "Child", "Health", "outpatient", "setting", ",", "the", "'", "traditional", "'", "structured", "approach", "led", "to", "significantly", "greater", "knowledge", "gain", "in", "comparison", "with", "the", "'", "novel", "'", "student", "-", "directed", "approach", ".", "The", "findings", "emphasize", "the", "importance", "of", "careful", "evaluation", "of", "novel", "medical", "education", "strategies", "before", "their", "implementation", "in", "medical", "schools", ",", "and", "the", "need", "for", "further", "research", "to", "define", "the", "effective", "methods", "for", "delivering", "medical", "education", "in", "Child", "Health", "." ]

[ "Outcome_Other", "Intervention_Educational", "Intervention_Other", "Outcome_Mental", "Intervention_Control", "Participant_Age", "Participant_Condition", "Participant_Sample-size" ]

knowledge gain, structured, student - directed learning, Health, students, versus, 138, structured learning, Pre- and post - course tests, 129, gain in knowledge, pre - course scores, post - course scores, Knowledge gain

26561_task2

Sentence: Greater knowledge gain with structured than student-directed learning in Child Health : cluster randomized trial . The aim of this study was to detect a difference in knowledge gain between students receiving structured versus student-directed learning for the two-week Child Health outpatient module . A total of 138 phase 3 ( year 4 ) medical students in 10 two-week paediatric outpatient blocks at the Department of Child Health , University of Dundee , Scotland , were randomized to student-directed or structured learning between January and December 2002 . Pre- and post-course tests were administered at the start and the end of the attachment ; 129 students sat both tests . Results are presented as mean scores with standard deviations or 95 % confidence intervals ( CI ) in parentheses . The primary outcome measure was gain in knowledge of the Child Health core curriculum that is covered in the outpatient setting . Although pre-course scores were similar ( student-directed 25.3 ( 7.3 ) ; structured 24.8 ( 7.5 ) ) the structured approach resulted in higher post-course scores in comparison with the student-directed approach ( student-directed 41.8 ( 9.4 ) ; structured 53.8 ( 8.8 ) ; p < 0.01 ) . Knowledge gain showed significant differences between the two learning approaches ( student-directed 16.5 ( 3.7 ) ; structured 29.1 ( 3.8 ) , difference = 12.6 ( 95 % CI 11.3 to 13.9 ) ) . Low pre-course scores or gender did not affect knowledge gain . In the Child Health outpatient setting , the 'traditional ' structured approach led to significantly greater knowledge gain in comparison with the 'novel ' student-directed approach . The findings emphasize the importance of careful evaluation of novel medical education strategies before their implementation in medical schools , and the need for further research to define the effective methods for delivering medical education in Child Health . Instructions: please extract entity words from the input sentence

[ "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Intervention_Other", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "O", "B-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Greater knowledge gain with structured than student-directed learning in Child Health : cluster randomized trial . The aim of this study was to detect a difference in knowledge gain between students receiving structured versus student-directed learning for the two-week Child Health outpatient module . A total of 138 phase 3 ( year 4 ) medical students in 10 two-week paediatric outpatient blocks at the Department of Child Health , University of Dundee , Scotland , were randomized to student-directed or structured learning between January and December 2002 . Pre- and post-course tests were administered at the start and the end of the attachment ; 129 students sat both tests . Results are presented as mean scores with standard deviations or 95 % confidence intervals ( CI ) in parentheses . The primary outcome measure was gain in knowledge of the Child Health core curriculum that is covered in the outpatient setting . Although pre-course scores were similar ( student-directed 25.3 ( 7.3 ) ; structured 24.8 ( 7.5 ) ) the structured approach resulted in higher post-course scores in comparison with the student-directed approach ( student-directed 41.8 ( 9.4 ) ; structured 53.8 ( 8.8 ) ; p < 0.01 ) . Knowledge gain showed significant differences between the two learning approaches ( student-directed 16.5 ( 3.7 ) ; structured 29.1 ( 3.8 ) , difference = 12.6 ( 95 % CI 11.3 to 13.9 ) ) . Low pre-course scores or gender did not affect knowledge gain . In the Child Health outpatient setting , the 'traditional ' structured approach led to significantly greater knowledge gain in comparison with the 'novel ' student-directed approach . The findings emphasize the importance of careful evaluation of novel medical education strategies before their implementation in medical schools , and the need for further research to define the effective methods for delivering medical education in Child Health .

[ "Greater", "knowledge", "gain", "with", "structured", "than", "student", "-", "directed", "learning", "in", "Child", "Health", ":", "cluster", "randomized", "trial", ".", "The", "aim", "of", "this", "study", "was", "to", "detect", "a", "difference", "in", "knowledge", "gain", "between", "students", "receiving", "structured", "versus", "student", "-", "directed", "learning", "for", "the", "two", "-", "week", "Child", "Health", "outpatient", "module", ".", "A", "total", "of", "138", "phase", "3", "(", "year", "4", ")", "medical", "students", "in", "10", "two", "-", "week", "paediatric", "outpatient", "blocks", "at", "the", "Department", "of", "Child", "Health", ",", "University", "of", "Dundee", ",", "Scotland", ",", "were", "randomized", "to", "student", "-", "directed", "or", "structured", "learning", "between", "January", "and", "December", "2002", ".", "Pre-", "and", "post", "-", "course", "tests", "were", "administered", "at", "the", "start", "and", "the", "end", "of", "the", "attachment", ";", "129", "students", "sat", "both", "tests", ".", "Results", "are", "presented", "as", "mean", "scores", "with", "standard", "deviations", "or", "95", "%", "confidence", "intervals", "(", "CI", ")", "in", "parentheses", ".", "The", "primary", "outcome", "measure", "was", "gain", "in", "knowledge", "of", "the", "Child", "Health", "core", "curriculum", "that", "is", "covered", "in", "the", "outpatient", "setting", ".", "Although", "pre", "-", "course", "scores", "were", "similar", "(", "student", "-", "directed", "25.3", "(", "7.3", ")", ";", "structured", "24.8", "(", "7.5", ")", ")", "the", "structured", "approach", "resulted", "in", "higher", "post", "-", "course", "scores", "in", "comparison", "with", "the", "student", "-", "directed", "approach", "(", "student", "-", "directed", "41.8", "(", "9.4", ")", ";", "structured", "53.8", "(", "8.8", ")", ";", "p", "<", "0.01", ")", ".", "Knowledge", "gain", "showed", "significant", "differences", "between", "the", "two", "learning", "approaches", "(", "student", "-", "directed", "16.5", "(", "3.7", ")", ";", "structured", "29.1", "(", "3.8", ")", ",", "difference", "=", "12.6", "(", "95", "%", "CI", "11.3", "to", "13.9", ")", ")", ".", "Low", "pre", "-", "course", "scores", "or", "gender", "did", "not", "affect", "knowledge", "gain", ".", "In", "the", "Child", "Health", "outpatient", "setting", ",", "the", "'", "traditional", "'", "structured", "approach", "led", "to", "significantly", "greater", "knowledge", "gain", "in", "comparison", "with", "the", "'", "novel", "'", "student", "-", "directed", "approach", ".", "The", "findings", "emphasize", "the", "importance", "of", "careful", "evaluation", "of", "novel", "medical", "education", "strategies", "before", "their", "implementation", "in", "medical", "schools", ",", "and", "the", "need", "for", "further", "research", "to", "define", "the", "effective", "methods", "for", "delivering", "medical", "education", "in", "Child", "Health", "." ]

[ "Outcome_Other", "Intervention_Educational", "Intervention_Other", "Outcome_Mental", "Intervention_Control", "Participant_Age", "Participant_Condition", "Participant_Sample-size" ]

aconitine is a CHEMICAL, cytochrome P450 3A is a GENE-N, buspirone is a CHEMICAL, paclitaxel is a CHEMICAL, Aconitine is a CHEMICAL, CYP3A is a GENE-N, CYP3A is a GENE-N, buspirone is a CHEMICAL, buspirone is a CHEMICAL, CYP3A is a GENE-N, buspirone is a CHEMICAL, Buspirone is a CHEMICAL, 1-(2-pyrimidinyl)piperazine is a CHEMICAL, 6'-hydroxybuspirone is a CHEMICAL, CYP3A is a GENE-N, 1-(2-pyrimidinyl)piperazine is a CHEMICAL, 6'-hydroxybuspirone is a CHEMICAL, CYP3A is a GENE-N, CYP3A is a GENE-N, CYP3A is a GENE-N

10737_task0

Sentence: The exposure of highly toxic aconitine does not significantly impact the activity and expression of cytochrome P450 3A in rats determined by a novel ultra performance liquid chromatography-tandem mass spectrometric method of a specific probe buspirone. Aconitum species are widely used to treat rheumatism, cardiovascular diseases, and tumors in China and other Asian countries. The herbs are always used with drugs such as paclitaxel. Aconitine (AC) is one of the main bioactive/high-toxic alkaloids of Aconitum roots. AC is metabolized by cytochrome P450 (CYP) 3A. However, whether AC inhibits/induces CYP3A, which causes drug-drug interaction (DDI) is unclear. Our study aims to explore the potent effects of AC, as a marker component of Aconitum, on CYP3A using the probe buspirone in rats. The effects of oral AC on pharmacokinetics of buspirone were evaluated. CYP3A activity and protein levels in rat liver microsomes pretreated with oral AC were also measured using in vitro buspirone metabolism and Western blot. Buspirone and its major metabolites 1-(2-pyrimidinyl)piperazine and 6'-hydroxybuspirone were determined using a newly validated UPLC-MS/MS method. Single dose and 7-day AC administration at 0.125mg/kg had no effect on CYP3A activity since no change in the formation of 1-(2-pyrimidinyl)piperazine and 6'-hydroxybuspirone. CYP3A activity and protein levels in liver microsomes were also not affected by 7-day AC pretreatment at 0.125mg/kg. Therefore, AC neither inhibits nor induces CYP3A in rats, indicating AC does not cause CYP3A-related DDI in the liver. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, CHEMICAL

[ "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O" ]

The exposure of highly toxic aconitine does not significantly impact the activity and expression of cytochrome P450 3A in rats determined by a novel ultra performance liquid chromatography-tandem mass spectrometric method of a specific probe buspirone. Aconitum species are widely used to treat rheumatism, cardiovascular diseases, and tumors in China and other Asian countries. The herbs are always used with drugs such as paclitaxel. Aconitine (AC) is one of the main bioactive/high-toxic alkaloids of Aconitum roots. AC is metabolized by cytochrome P450 (CYP) 3A. However, whether AC inhibits/induces CYP3A, which causes drug-drug interaction (DDI) is unclear. Our study aims to explore the potent effects of AC, as a marker component of Aconitum, on CYP3A using the probe buspirone in rats. The effects of oral AC on pharmacokinetics of buspirone were evaluated. CYP3A activity and protein levels in rat liver microsomes pretreated with oral AC were also measured using in vitro buspirone metabolism and Western blot. Buspirone and its major metabolites 1-(2-pyrimidinyl)piperazine and 6'-hydroxybuspirone were determined using a newly validated UPLC-MS/MS method. Single dose and 7-day AC administration at 0.125mg/kg had no effect on CYP3A activity since no change in the formation of 1-(2-pyrimidinyl)piperazine and 6'-hydroxybuspirone. CYP3A activity and protein levels in liver microsomes were also not affected by 7-day AC pretreatment at 0.125mg/kg. Therefore, AC neither inhibits nor induces CYP3A in rats, indicating AC does not cause CYP3A-related DDI in the liver.

[ "The", "exposure", "of", "highly", "toxic", "aconitine", "does", "not", "significantly", "impact", "the", "activity", "and", "expression", "of", "cytochrome", "P450", "3A", "in", "rats", "determined", "by", "a", "novel", "ultra", "performance", "liquid", "chromatography", "-", "tandem", "mass", "spectrometric", "method", "of", "a", "specific", "probe", "buspirone", ".", "\n", "Aconitum", "species", "are", "widely", "used", "to", "treat", "rheumatism", ",", "cardiovascular", "diseases", ",", "and", "tumors", "in", "China", "and", "other", "Asian", "countries", ".", "The", "herbs", "are", "always", "used", "with", "drugs", "such", "as", "paclitaxel", ".", "Aconitine", "(", "AC", ")", "is", "one", "of", "the", "main", "bioactive", "/", "high", "-", "toxic", "alkaloids", "of", "Aconitum", "roots", ".", "AC", "is", "metabolized", "by", "cytochrome", "P450", "(", "CYP", ")", "3A.", "However", ",", "whether", "AC", "inhibits", "/", "induces", "CYP3A", ",", "which", "causes", "drug", "-", "drug", "interaction", "(", "DDI", ")", "is", "unclear", ".", "Our", "study", "aims", "to", "explore", "the", "potent", "effects", "of", "AC", ",", "as", "a", "marker", "component", "of", "Aconitum", ",", "on", "CYP3A", "using", "the", "probe", "buspirone", "in", "rats", ".", "The", "effects", "of", "oral", "AC", "on", "pharmacokinetics", "of", "buspirone", "were", "evaluated", ".", "CYP3A", "activity", "and", "protein", "levels", "in", "rat", "liver", "microsomes", "pretreated", "with", "oral", "AC", "were", "also", "measured", "using", "in", "vitro", "buspirone", "metabolism", "and", "Western", "blot", ".", "Buspirone", "and", "its", "major", "metabolites", "1-(2-pyrimidinyl)piperazine", "and", "6'-hydroxybuspirone", "were", "determined", "using", "a", "newly", "validated", "UPLC", "-", "MS", "/", "MS", "method", ".", "Single", "dose", "and", "7-day", "AC", "administration", "at", "0.125mg", "/", "kg", "had", "no", "effect", "on", "CYP3A", "activity", "since", "no", "change", "in", "the", "formation", "of", "1-(2-pyrimidinyl)piperazine", "and", "6'-hydroxybuspirone", ".", "CYP3A", "activity", "and", "protein", "levels", "in", "liver", "microsomes", "were", "also", "not", "affected", "by", "7-day", "AC", "pretreatment", "at", "0.125mg", "/", "kg", ".", "Therefore", ",", "AC", "neither", "inhibits", "nor", "induces", "CYP3A", "in", "rats", ",", "indicating", "AC", "does", "not", "cause", "CYP3A", "-", "related", "DDI", "in", "the", "liver", "." ]

[ "CHEMICAL", "GENE-N" ]

aconitine is a CHEMICAL, cytochrome P450 3A is a GENE-N, buspirone is a CHEMICAL, paclitaxel is a CHEMICAL, Aconitine is a CHEMICAL, CYP3A is a GENE-N, CYP3A is a GENE-N, buspirone is a CHEMICAL, buspirone is a CHEMICAL, CYP3A is a GENE-N, buspirone is a CHEMICAL, Buspirone is a CHEMICAL, 1-(2-pyrimidinyl)piperazine is a CHEMICAL, 6'-hydroxybuspirone is a CHEMICAL, CYP3A is a GENE-N, 1-(2-pyrimidinyl)piperazine is a CHEMICAL, 6'-hydroxybuspirone is a CHEMICAL, CYP3A is a GENE-N, CYP3A is a GENE-N, CYP3A is a GENE-N

10737_task1

Sentence: The exposure of highly toxic aconitine does not significantly impact the activity and expression of cytochrome P450 3A in rats determined by a novel ultra performance liquid chromatography-tandem mass spectrometric method of a specific probe buspirone. Aconitum species are widely used to treat rheumatism, cardiovascular diseases, and tumors in China and other Asian countries. The herbs are always used with drugs such as paclitaxel. Aconitine (AC) is one of the main bioactive/high-toxic alkaloids of Aconitum roots. AC is metabolized by cytochrome P450 (CYP) 3A. However, whether AC inhibits/induces CYP3A, which causes drug-drug interaction (DDI) is unclear. Our study aims to explore the potent effects of AC, as a marker component of Aconitum, on CYP3A using the probe buspirone in rats. The effects of oral AC on pharmacokinetics of buspirone were evaluated. CYP3A activity and protein levels in rat liver microsomes pretreated with oral AC were also measured using in vitro buspirone metabolism and Western blot. Buspirone and its major metabolites 1-(2-pyrimidinyl)piperazine and 6'-hydroxybuspirone were determined using a newly validated UPLC-MS/MS method. Single dose and 7-day AC administration at 0.125mg/kg had no effect on CYP3A activity since no change in the formation of 1-(2-pyrimidinyl)piperazine and 6'-hydroxybuspirone. CYP3A activity and protein levels in liver microsomes were also not affected by 7-day AC pretreatment at 0.125mg/kg. Therefore, AC neither inhibits nor induces CYP3A in rats, indicating AC does not cause CYP3A-related DDI in the liver. Instructions: please typing these entity words according to sentence: aconitine, cytochrome P450 3A, buspirone, paclitaxel, Aconitine, CYP3A, CYP3A, buspirone, buspirone, CYP3A, buspirone, Buspirone, 1-(2-pyrimidinyl)piperazine, 6'-hydroxybuspirone, CYP3A, 1-(2-pyrimidinyl)piperazine, 6'-hydroxybuspirone, CYP3A, CYP3A, CYP3A Options: GENE-N, CHEMICAL

[ "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O" ]

The exposure of highly toxic aconitine does not significantly impact the activity and expression of cytochrome P450 3A in rats determined by a novel ultra performance liquid chromatography-tandem mass spectrometric method of a specific probe buspirone. Aconitum species are widely used to treat rheumatism, cardiovascular diseases, and tumors in China and other Asian countries. The herbs are always used with drugs such as paclitaxel. Aconitine (AC) is one of the main bioactive/high-toxic alkaloids of Aconitum roots. AC is metabolized by cytochrome P450 (CYP) 3A. However, whether AC inhibits/induces CYP3A, which causes drug-drug interaction (DDI) is unclear. Our study aims to explore the potent effects of AC, as a marker component of Aconitum, on CYP3A using the probe buspirone in rats. The effects of oral AC on pharmacokinetics of buspirone were evaluated. CYP3A activity and protein levels in rat liver microsomes pretreated with oral AC were also measured using in vitro buspirone metabolism and Western blot. Buspirone and its major metabolites 1-(2-pyrimidinyl)piperazine and 6'-hydroxybuspirone were determined using a newly validated UPLC-MS/MS method. Single dose and 7-day AC administration at 0.125mg/kg had no effect on CYP3A activity since no change in the formation of 1-(2-pyrimidinyl)piperazine and 6'-hydroxybuspirone. CYP3A activity and protein levels in liver microsomes were also not affected by 7-day AC pretreatment at 0.125mg/kg. Therefore, AC neither inhibits nor induces CYP3A in rats, indicating AC does not cause CYP3A-related DDI in the liver.

[ "The", "exposure", "of", "highly", "toxic", "aconitine", "does", "not", "significantly", "impact", "the", "activity", "and", "expression", "of", "cytochrome", "P450", "3A", "in", "rats", "determined", "by", "a", "novel", "ultra", "performance", "liquid", "chromatography", "-", "tandem", "mass", "spectrometric", "method", "of", "a", "specific", "probe", "buspirone", ".", "\n", "Aconitum", "species", "are", "widely", "used", "to", "treat", "rheumatism", ",", "cardiovascular", "diseases", ",", "and", "tumors", "in", "China", "and", "other", "Asian", "countries", ".", "The", "herbs", "are", "always", "used", "with", "drugs", "such", "as", "paclitaxel", ".", "Aconitine", "(", "AC", ")", "is", "one", "of", "the", "main", "bioactive", "/", "high", "-", "toxic", "alkaloids", "of", "Aconitum", "roots", ".", "AC", "is", "metabolized", "by", "cytochrome", "P450", "(", "CYP", ")", "3A.", "However", ",", "whether", "AC", "inhibits", "/", "induces", "CYP3A", ",", "which", "causes", "drug", "-", "drug", "interaction", "(", "DDI", ")", "is", "unclear", ".", "Our", "study", "aims", "to", "explore", "the", "potent", "effects", "of", "AC", ",", "as", "a", "marker", "component", "of", "Aconitum", ",", "on", "CYP3A", "using", "the", "probe", "buspirone", "in", "rats", ".", "The", "effects", "of", "oral", "AC", "on", "pharmacokinetics", "of", "buspirone", "were", "evaluated", ".", "CYP3A", "activity", "and", "protein", "levels", "in", "rat", "liver", "microsomes", "pretreated", "with", "oral", "AC", "were", "also", "measured", "using", "in", "vitro", "buspirone", "metabolism", "and", "Western", "blot", ".", "Buspirone", "and", "its", "major", "metabolites", "1-(2-pyrimidinyl)piperazine", "and", "6'-hydroxybuspirone", "were", "determined", "using", "a", "newly", "validated", "UPLC", "-", "MS", "/", "MS", "method", ".", "Single", "dose", "and", "7-day", "AC", "administration", "at", "0.125mg", "/", "kg", "had", "no", "effect", "on", "CYP3A", "activity", "since", "no", "change", "in", "the", "formation", "of", "1-(2-pyrimidinyl)piperazine", "and", "6'-hydroxybuspirone", ".", "CYP3A", "activity", "and", "protein", "levels", "in", "liver", "microsomes", "were", "also", "not", "affected", "by", "7-day", "AC", "pretreatment", "at", "0.125mg", "/", "kg", ".", "Therefore", ",", "AC", "neither", "inhibits", "nor", "induces", "CYP3A", "in", "rats", ",", "indicating", "AC", "does", "not", "cause", "CYP3A", "-", "related", "DDI", "in", "the", "liver", "." ]

[ "CHEMICAL", "GENE-N" ]

aconitine, cytochrome P450 3A, buspirone, paclitaxel, Aconitine, CYP3A, CYP3A, buspirone, buspirone, CYP3A, buspirone, Buspirone, 1-(2-pyrimidinyl)piperazine, 6'-hydroxybuspirone, CYP3A, 1-(2-pyrimidinyl)piperazine, 6'-hydroxybuspirone, CYP3A, CYP3A, CYP3A

10737_task2

Sentence: The exposure of highly toxic aconitine does not significantly impact the activity and expression of cytochrome P450 3A in rats determined by a novel ultra performance liquid chromatography-tandem mass spectrometric method of a specific probe buspirone. Aconitum species are widely used to treat rheumatism, cardiovascular diseases, and tumors in China and other Asian countries. The herbs are always used with drugs such as paclitaxel. Aconitine (AC) is one of the main bioactive/high-toxic alkaloids of Aconitum roots. AC is metabolized by cytochrome P450 (CYP) 3A. However, whether AC inhibits/induces CYP3A, which causes drug-drug interaction (DDI) is unclear. Our study aims to explore the potent effects of AC, as a marker component of Aconitum, on CYP3A using the probe buspirone in rats. The effects of oral AC on pharmacokinetics of buspirone were evaluated. CYP3A activity and protein levels in rat liver microsomes pretreated with oral AC were also measured using in vitro buspirone metabolism and Western blot. Buspirone and its major metabolites 1-(2-pyrimidinyl)piperazine and 6'-hydroxybuspirone were determined using a newly validated UPLC-MS/MS method. Single dose and 7-day AC administration at 0.125mg/kg had no effect on CYP3A activity since no change in the formation of 1-(2-pyrimidinyl)piperazine and 6'-hydroxybuspirone. CYP3A activity and protein levels in liver microsomes were also not affected by 7-day AC pretreatment at 0.125mg/kg. Therefore, AC neither inhibits nor induces CYP3A in rats, indicating AC does not cause CYP3A-related DDI in the liver. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O" ]

The exposure of highly toxic aconitine does not significantly impact the activity and expression of cytochrome P450 3A in rats determined by a novel ultra performance liquid chromatography-tandem mass spectrometric method of a specific probe buspirone. Aconitum species are widely used to treat rheumatism, cardiovascular diseases, and tumors in China and other Asian countries. The herbs are always used with drugs such as paclitaxel. Aconitine (AC) is one of the main bioactive/high-toxic alkaloids of Aconitum roots. AC is metabolized by cytochrome P450 (CYP) 3A. However, whether AC inhibits/induces CYP3A, which causes drug-drug interaction (DDI) is unclear. Our study aims to explore the potent effects of AC, as a marker component of Aconitum, on CYP3A using the probe buspirone in rats. The effects of oral AC on pharmacokinetics of buspirone were evaluated. CYP3A activity and protein levels in rat liver microsomes pretreated with oral AC were also measured using in vitro buspirone metabolism and Western blot. Buspirone and its major metabolites 1-(2-pyrimidinyl)piperazine and 6'-hydroxybuspirone were determined using a newly validated UPLC-MS/MS method. Single dose and 7-day AC administration at 0.125mg/kg had no effect on CYP3A activity since no change in the formation of 1-(2-pyrimidinyl)piperazine and 6'-hydroxybuspirone. CYP3A activity and protein levels in liver microsomes were also not affected by 7-day AC pretreatment at 0.125mg/kg. Therefore, AC neither inhibits nor induces CYP3A in rats, indicating AC does not cause CYP3A-related DDI in the liver.

[ "The", "exposure", "of", "highly", "toxic", "aconitine", "does", "not", "significantly", "impact", "the", "activity", "and", "expression", "of", "cytochrome", "P450", "3A", "in", "rats", "determined", "by", "a", "novel", "ultra", "performance", "liquid", "chromatography", "-", "tandem", "mass", "spectrometric", "method", "of", "a", "specific", "probe", "buspirone", ".", "\n", "Aconitum", "species", "are", "widely", "used", "to", "treat", "rheumatism", ",", "cardiovascular", "diseases", ",", "and", "tumors", "in", "China", "and", "other", "Asian", "countries", ".", "The", "herbs", "are", "always", "used", "with", "drugs", "such", "as", "paclitaxel", ".", "Aconitine", "(", "AC", ")", "is", "one", "of", "the", "main", "bioactive", "/", "high", "-", "toxic", "alkaloids", "of", "Aconitum", "roots", ".", "AC", "is", "metabolized", "by", "cytochrome", "P450", "(", "CYP", ")", "3A.", "However", ",", "whether", "AC", "inhibits", "/", "induces", "CYP3A", ",", "which", "causes", "drug", "-", "drug", "interaction", "(", "DDI", ")", "is", "unclear", ".", "Our", "study", "aims", "to", "explore", "the", "potent", "effects", "of", "AC", ",", "as", "a", "marker", "component", "of", "Aconitum", ",", "on", "CYP3A", "using", "the", "probe", "buspirone", "in", "rats", ".", "The", "effects", "of", "oral", "AC", "on", "pharmacokinetics", "of", "buspirone", "were", "evaluated", ".", "CYP3A", "activity", "and", "protein", "levels", "in", "rat", "liver", "microsomes", "pretreated", "with", "oral", "AC", "were", "also", "measured", "using", "in", "vitro", "buspirone", "metabolism", "and", "Western", "blot", ".", "Buspirone", "and", "its", "major", "metabolites", "1-(2-pyrimidinyl)piperazine", "and", "6'-hydroxybuspirone", "were", "determined", "using", "a", "newly", "validated", "UPLC", "-", "MS", "/", "MS", "method", ".", "Single", "dose", "and", "7-day", "AC", "administration", "at", "0.125mg", "/", "kg", "had", "no", "effect", "on", "CYP3A", "activity", "since", "no", "change", "in", "the", "formation", "of", "1-(2-pyrimidinyl)piperazine", "and", "6'-hydroxybuspirone", ".", "CYP3A", "activity", "and", "protein", "levels", "in", "liver", "microsomes", "were", "also", "not", "affected", "by", "7-day", "AC", "pretreatment", "at", "0.125mg", "/", "kg", ".", "Therefore", ",", "AC", "neither", "inhibits", "nor", "induces", "CYP3A", "in", "rats", ",", "indicating", "AC", "does", "not", "cause", "CYP3A", "-", "related", "DDI", "in", "the", "liver", "." ]

[ "CHEMICAL", "GENE-N" ]

Ezequiel is a NOMBRE_SUJETO_ASISTENCIA, Lopez Pereira is a NOMBRE_SUJETO_ASISTENCIA, 7856544 is a ID_SUJETO_ASISTENCIA, 78 45678567 05 is a ID_ASEGURAMIENTO, Madrid is a TERRITORIO, 28029 is a TERRITORIO, 23/08/1957 is a FECHAS, España is a PAIS, 60 años is a EDAD_SUJETO_ASISTENCIA, 29/12/2017 is a FECHAS, Luis Roberto León is a NOMBRE_PERSONAL_SANITARIO, 28 28 57103 is a ID_TITULACION_PERSONAL_SANITARIO, varón is a SEXO_SUJETO_ASISTENCIA, 60 años is a EDAD_SUJETO_ASISTENCIA, 1995 is a FECHAS, Hermano mayor is a FAMILIARES_SUJETO_ASISTENCIA, 65 años is a FAMILIARES_SUJETO_ASISTENCIA, Hermano menor is a FAMILIARES_SUJETO_ASISTENCIA, 58 años is a FAMILIARES_SUJETO_ASISTENCIA, Hermana is a FAMILIARES_SUJETO_ASISTENCIA, 55 años is a FAMILIARES_SUJETO_ASISTENCIA, Tío materno is a FAMILIARES_SUJETO_ASISTENCIA, 60 años is a FAMILIARES_SUJETO_ASISTENCIA, hijo varón is a FAMILIARES_SUJETO_ASISTENCIA, Madre is a FAMILIARES_SUJETO_ASISTENCIA, dos primos hermanos is a FAMILIARES_SUJETO_ASISTENCIA, 67 años is a FAMILIARES_SUJETO_ASISTENCIA, 62 años is a FAMILIARES_SUJETO_ASISTENCIA, Luis Roberto León is a NOMBRE_PERSONAL_SANITARIO, lleon@intramed.com is a CORREO_ELECTRONICO

111_task0

Sentence: Datos del paciente. Nombre: Ezequiel. Apellidos: Lopez Pereira. NHC: 7856544. NASS: 78 45678567 05. Domicilio: C/ Vinuesa, 4, 6 A. Localidad/ Provincia: Madrid. CP: 28029. Datos asistenciales. Fecha de nacimiento: 23/08/1957. País de nacimiento: España. Edad: 60 años Sexo: H. Fecha de Ingreso: 29/12/2017. Médico: Luis Roberto León NºCol: 28 28 57103. Informe clínico del paciente: Paciente varón de 60 años, con síndrome de Alport, microhematuria y proteinuria de 4 g/día, creatinina de 2 mg/dl, urea 123 mg/dl, pérdida moderada de la audición, hipertensión arterial tratada con enalapril 20 mg, obesidad con IMC = 36,26 (P 120 kg, h 1,81 m), glucemias en ayunas alteradas (menor a 126 mg/dl), Hb glucosilada normal, dislipidemia e hiperuricemia en tratamiento. Ex-fumador de un paquete al día. Normotiroideo. Biopsia renal (realizada en 1995): MO (12 glomérulos) esclerosis focal y segmentaria glomerular en evolución a glomerulopatía esclerosante, IF con Ig M de leve intensidad en mesangio e IgA y M en cilindros tubulares. ME 2 glomérulos. MB capilar con engrosamiento irregular y desdoblamiento focal de la lámina densa. Podocitos con fusión total de pedicelos. En un sector, borramiento de la estructura glomerular con depósito de abundante material amorfo, electrón denso. Las alteraciones de la lámina densa son compatibles con enfermedad de Alport, el resto de los hallazgos con glomerulonefritis esclerosante focal. Ecografía renal: RD 95,6 x 52 x 53, RI 99 x 51 x 52. Doppler renal sin alteraciones. Se indica dieta baja en proteínas, hipocalórica y se agrega al tratamiento losartán en dosis de 75 mg/día (máxima tolerada por el paciente). Se observa reducción muy leve de proteinuria a 3,6 g/día. Se realiza cirugía de by-pass gástrico, y presenta en su evolución disminución de 35 kg en total, llegando a IMC de 25,6. Control nefrológico: creatinina 1,56 mg/dl, proteinuria 0,3 g/día, urea 65 mg/dl y normotensión con enalapril 5 mg/d; se mantiene dosis mínima de hipolipemiantes, normouricemia y normoglucemias. Antecedentes familiares: Hermano mayor de 65 años con nefropatía e hipoacusia neurosensorial bilateral y síndrome de Alport. Hermano menor de 58 años también con nefropatía e hipoacusia y síndrome de Alport. Hermana de 55 años de edad con nefropatía sin hipoacusia. Tío materno fallecido a los 60 años de edad por nefropatía de causa no aclarada y sin hipoacusia, que además ha tenido un hijo varón y una nieta con nefropatía sin hipoacusia. Madre con nefropatía desde la infancia con posible síndrome de Alport. Según comenta, dos primos hermanos de 67 años y 62 años de edad respectivamente, con diagnóstico clínico de hemocromatosis hereditaria. Tres años después de la cirugía, la buena evolución del paciente está relacionada con el cumplimento del tratamiento (dieta), ejercicio aeróbico y apoyo clínico-psicológico. Responsable clínico: Dr. Luis Roberto León, Email: lleon@intramed.com Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, FAMILIARES_SUJETO_ASISTENCIA, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Datos del paciente. Nombre: Ezequiel. Apellidos: Lopez Pereira. NHC: 7856544. NASS: 78 45678567 05. Domicilio: C/ Vinuesa, 4, 6 A. Localidad/ Provincia: Madrid. CP: 28029. Datos asistenciales. Fecha de nacimiento: 23/08/1957. País de nacimiento: España. Edad: 60 años Sexo: H. Fecha de Ingreso: 29/12/2017. Médico: Luis Roberto León NºCol: 28 28 57103. Informe clínico del paciente: Paciente varón de 60 años, con síndrome de Alport, microhematuria y proteinuria de 4 g/día, creatinina de 2 mg/dl, urea 123 mg/dl, pérdida moderada de la audición, hipertensión arterial tratada con enalapril 20 mg, obesidad con IMC = 36,26 (P 120 kg, h 1,81 m), glucemias en ayunas alteradas (menor a 126 mg/dl), Hb glucosilada normal, dislipidemia e hiperuricemia en tratamiento. Ex-fumador de un paquete al día. Normotiroideo. Biopsia renal (realizada en 1995): MO (12 glomérulos) esclerosis focal y segmentaria glomerular en evolución a glomerulopatía esclerosante, IF con Ig M de leve intensidad en mesangio e IgA y M en cilindros tubulares. ME 2 glomérulos. MB capilar con engrosamiento irregular y desdoblamiento focal de la lámina densa. Podocitos con fusión total de pedicelos. En un sector, borramiento de la estructura glomerular con depósito de abundante material amorfo, electrón denso. Las alteraciones de la lámina densa son compatibles con enfermedad de Alport, el resto de los hallazgos con glomerulonefritis esclerosante focal. Ecografía renal: RD 95,6 x 52 x 53, RI 99 x 51 x 52. Doppler renal sin alteraciones. Se indica dieta baja en proteínas, hipocalórica y se agrega al tratamiento losartán en dosis de 75 mg/día (máxima tolerada por el paciente). Se observa reducción muy leve de proteinuria a 3,6 g/día. Se realiza cirugía de by-pass gástrico, y presenta en su evolución disminución de 35 kg en total, llegando a IMC de 25,6. Control nefrológico: creatinina 1,56 mg/dl, proteinuria 0,3 g/día, urea 65 mg/dl y normotensión con enalapril 5 mg/d; se mantiene dosis mínima de hipolipemiantes, normouricemia y normoglucemias. Antecedentes familiares: Hermano mayor de 65 años con nefropatía e hipoacusia neurosensorial bilateral y síndrome de Alport. Hermano menor de 58 años también con nefropatía e hipoacusia y síndrome de Alport. Hermana de 55 años de edad con nefropatía sin hipoacusia. Tío materno fallecido a los 60 años de edad por nefropatía de causa no aclarada y sin hipoacusia, que además ha tenido un hijo varón y una nieta con nefropatía sin hipoacusia. Madre con nefropatía desde la infancia con posible síndrome de Alport. Según comenta, dos primos hermanos de 67 años y 62 años de edad respectivamente, con diagnóstico clínico de hemocromatosis hereditaria. Tres años después de la cirugía, la buena evolución del paciente está relacionada con el cumplimento del tratamiento (dieta), ejercicio aeróbico y apoyo clínico-psicológico. Responsable clínico: Dr. Luis Roberto León, Email: lleon@intramed.com

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Ezequiel", ".", "\n", "Apellidos", ":", "Lopez", "Pereira", ".", "\n", "NHC", ":", "7856544", ".", "\n", "NASS", ":", "78", "45678567", "05", ".", "\n", "Domicilio", ":", "C/", "Vinuesa", ",", "4", ",", "6", "A.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "28029", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "23/08/1957", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "60", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "29/12/2017", ".", "\n", "Médico", ":", "Luis", "Roberto", "León", " ", "NºCol", ":", "28", "28", "57103", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Paciente", "varón", "de", "60", "años", ",", "con", "síndrome", "de", "Alport", ",", "microhematuria", "y", "proteinuria", "de", "4", "g", "/", "día", ",", "creatinina", "de", "2", "mg", "/", "dl", ",", "urea", "123", "mg", "/", "dl", ",", "pérdida", "moderada", "de", "la", "audición", ",", "hipertensión", "arterial", "tratada", "con", "enalapril", "20", "mg", ",", "obesidad", "con", "IMC", "=", "36,26", "(", "P", "120", "kg", ",", "h", "1,81", "m", ")", ",", "glucemias", "en", "ayunas", "alteradas", "(", "menor", "a", "126", "mg", "/", "dl", ")", ",", "Hb", "glucosilada", "normal", ",", "dislipidemia", "e", "hiperuricemia", "en", "tratamiento", ".", "Ex", "-", "fumador", "de", "un", "paquete", "al", "día", ".", "Normotiroideo", ".", "Biopsia", "renal", "(", "realizada", "en", "1995", "):", "MO", "(", "12", "glomérulos", ")", "esclerosis", "focal", "y", "segmentaria", "glomerular", "en", "evolución", "a", "glomerulopatía", "esclerosante", ",", "IF", "con", "Ig", "M", "de", "leve", "intensidad", "en", "mesangio", "e", "IgA", "y", "M", "en", "cilindros", "tubulares", ".", "ME", "2", "glomérulos", ".", "MB", "capilar", "con", "engrosamiento", "irregular", "y", "desdoblamiento", "focal", "de", "la", "lámina", "densa", ".", "Podocitos", "con", "fusión", "total", "de", "pedicelos", ".", "En", "un", "sector", ",", "borramiento", "de", "la", "estructura", "glomerular", "con", "depósito", "de", "abundante", "material", "amorfo", ",", "electrón", "denso", ".", "Las", "alteraciones", "de", "la", "lámina", "densa", "son", "compatibles", "con", "enfermedad", "de", "Alport", ",", "el", "resto", "de", "los", "hallazgos", "con", "glomerulonefritis", "esclerosante", "focal", ".", "Ecografía", "renal", ":", "RD", "95,6", "x", "52", "x", "53", ",", "RI", "99", "x", "51", "x", "52", ".", "Doppler", "renal", "sin", "alteraciones", ".", "\n", "Se", "indica", "dieta", "baja", "en", "proteínas", ",", "hipocalórica", "y", "se", "agrega", "al", "tratamiento", "losartán", "en", "dosis", "de", "75", "mg", "/", "día", "(", "máxima", "tolerada", "por", "el", "paciente", ")", ".", "Se", "observa", "reducción", "muy", "leve", "de", "proteinuria", "a", "3,6", "g", "/", "día", ".", "Se", "realiza", "cirugía", "de", "by", "-", "pass", "gástrico", ",", "y", "presenta", "en", "su", "evolución", "disminución", "de", "35", "kg", "en", "total", ",", "llegando", "a", "IMC", "de", "25,6", ".", "Control", "nefrológico", ":", "creatinina", "1,56", "mg", "/", "dl", ",", "proteinuria", "0,3", "g", "/", "día", ",", "urea", "65", "mg", "/", "dl", "y", "normotensión", "con", "enalapril", "5", "mg", "/", "d", ";", "se", "mantiene", "dosis", "mínima", "de", "hipolipemiantes", ",", "normouricemia", "y", "normoglucemias", ".", "\n", "Antecedentes", "familiares", ":", "\n", "Hermano", "mayor", "de", "65", "años", "con", "nefropatía", "e", "hipoacusia", "neurosensorial", "bilateral", "y", "síndrome", "de", "Alport", ".", "\n", "Hermano", "menor", "de", "58", "años", "también", "con", "nefropatía", "e", "hipoacusia", "y", "síndrome", "de", "Alport", ".", "\n", "Hermana", "de", "55", "años", "de", "edad", "con", "nefropatía", "sin", "hipoacusia", ".", "\n", "Tío", "materno", "fallecido", "a", "los", "60", "años", "de", "edad", "por", "nefropatía", "de", "causa", "no", "aclarada", "y", "sin", "hipoacusia", ",", "que", "además", "ha", "tenido", "un", "hijo", "varón", "y", "una", "nieta", "con", "nefropatía", "sin", "hipoacusia", ".", "\n", "Madre", "con", "nefropatía", "desde", "la", "infancia", "con", "posible", "síndrome", "de", "Alport", ".", "\n", "Según", "comenta", ",", "dos", "primos", "hermanos", "de", "67", "años", "y", "62", "años", "de", "edad", "respectivamente", ",", "con", "diagnóstico", "clínico", "de", "hemocromatosis", "hereditaria", ".", "\n", "Tres", "años", "después", "de", "la", "cirugía", ",", "la", "buena", "evolución", "del", "paciente", "está", "relacionada", "con", "el", "cumplimento", "del", "tratamiento", "(", "dieta", ")", ",", "ejercicio", "aeróbico", "y", "apoyo", "clínico", "-", "psicológico", ".", "\n", "Responsable", "clínico", ":", "Dr", ".", "Luis", "Roberto", "León", ",", "Email", ":", "lleon@intramed.com", "\n" ]

[ "FAMILIARES_SUJETO_ASISTENCIA", "CORREO_ELECTRONICO", "CALLE", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]

Ezequiel is a NOMBRE_SUJETO_ASISTENCIA, Lopez Pereira is a NOMBRE_SUJETO_ASISTENCIA, 7856544 is a ID_SUJETO_ASISTENCIA, 78 45678567 05 is a ID_ASEGURAMIENTO, Madrid is a TERRITORIO, 28029 is a TERRITORIO, 23/08/1957 is a FECHAS, España is a PAIS, 60 años is a EDAD_SUJETO_ASISTENCIA, 29/12/2017 is a FECHAS, Luis Roberto León is a NOMBRE_PERSONAL_SANITARIO, 28 28 57103 is a ID_TITULACION_PERSONAL_SANITARIO, varón is a SEXO_SUJETO_ASISTENCIA, 60 años is a EDAD_SUJETO_ASISTENCIA, 1995 is a FECHAS, Hermano mayor is a FAMILIARES_SUJETO_ASISTENCIA, 65 años is a FAMILIARES_SUJETO_ASISTENCIA, Hermano menor is a FAMILIARES_SUJETO_ASISTENCIA, 58 años is a FAMILIARES_SUJETO_ASISTENCIA, Hermana is a FAMILIARES_SUJETO_ASISTENCIA, 55 años is a FAMILIARES_SUJETO_ASISTENCIA, Tío materno is a FAMILIARES_SUJETO_ASISTENCIA, 60 años is a FAMILIARES_SUJETO_ASISTENCIA, hijo varón is a FAMILIARES_SUJETO_ASISTENCIA, Madre is a FAMILIARES_SUJETO_ASISTENCIA, dos primos hermanos is a FAMILIARES_SUJETO_ASISTENCIA, 67 años is a FAMILIARES_SUJETO_ASISTENCIA, 62 años is a FAMILIARES_SUJETO_ASISTENCIA, Luis Roberto León is a NOMBRE_PERSONAL_SANITARIO, lleon@intramed.com is a CORREO_ELECTRONICO

111_task1

Sentence: Datos del paciente. Nombre: Ezequiel. Apellidos: Lopez Pereira. NHC: 7856544. NASS: 78 45678567 05. Domicilio: C/ Vinuesa, 4, 6 A. Localidad/ Provincia: Madrid. CP: 28029. Datos asistenciales. Fecha de nacimiento: 23/08/1957. País de nacimiento: España. Edad: 60 años Sexo: H. Fecha de Ingreso: 29/12/2017. Médico: Luis Roberto León NºCol: 28 28 57103. Informe clínico del paciente: Paciente varón de 60 años, con síndrome de Alport, microhematuria y proteinuria de 4 g/día, creatinina de 2 mg/dl, urea 123 mg/dl, pérdida moderada de la audición, hipertensión arterial tratada con enalapril 20 mg, obesidad con IMC = 36,26 (P 120 kg, h 1,81 m), glucemias en ayunas alteradas (menor a 126 mg/dl), Hb glucosilada normal, dislipidemia e hiperuricemia en tratamiento. Ex-fumador de un paquete al día. Normotiroideo. Biopsia renal (realizada en 1995): MO (12 glomérulos) esclerosis focal y segmentaria glomerular en evolución a glomerulopatía esclerosante, IF con Ig M de leve intensidad en mesangio e IgA y M en cilindros tubulares. ME 2 glomérulos. MB capilar con engrosamiento irregular y desdoblamiento focal de la lámina densa. Podocitos con fusión total de pedicelos. En un sector, borramiento de la estructura glomerular con depósito de abundante material amorfo, electrón denso. Las alteraciones de la lámina densa son compatibles con enfermedad de Alport, el resto de los hallazgos con glomerulonefritis esclerosante focal. Ecografía renal: RD 95,6 x 52 x 53, RI 99 x 51 x 52. Doppler renal sin alteraciones. Se indica dieta baja en proteínas, hipocalórica y se agrega al tratamiento losartán en dosis de 75 mg/día (máxima tolerada por el paciente). Se observa reducción muy leve de proteinuria a 3,6 g/día. Se realiza cirugía de by-pass gástrico, y presenta en su evolución disminución de 35 kg en total, llegando a IMC de 25,6. Control nefrológico: creatinina 1,56 mg/dl, proteinuria 0,3 g/día, urea 65 mg/dl y normotensión con enalapril 5 mg/d; se mantiene dosis mínima de hipolipemiantes, normouricemia y normoglucemias. Antecedentes familiares: Hermano mayor de 65 años con nefropatía e hipoacusia neurosensorial bilateral y síndrome de Alport. Hermano menor de 58 años también con nefropatía e hipoacusia y síndrome de Alport. Hermana de 55 años de edad con nefropatía sin hipoacusia. Tío materno fallecido a los 60 años de edad por nefropatía de causa no aclarada y sin hipoacusia, que además ha tenido un hijo varón y una nieta con nefropatía sin hipoacusia. Madre con nefropatía desde la infancia con posible síndrome de Alport. Según comenta, dos primos hermanos de 67 años y 62 años de edad respectivamente, con diagnóstico clínico de hemocromatosis hereditaria. Tres años después de la cirugía, la buena evolución del paciente está relacionada con el cumplimento del tratamiento (dieta), ejercicio aeróbico y apoyo clínico-psicológico. Responsable clínico: Dr. Luis Roberto León, Email: lleon@intramed.com Instructions: please typing these entity words according to sentence: Ezequiel, Lopez Pereira, 7856544, 78 45678567 05, Madrid, 28029, 23/08/1957, España, 60 años, 29/12/2017, Luis Roberto León, 28 28 57103, varón, 60 años, 1995, Hermano mayor, 65 años, Hermano menor, 58 años, Hermana, 55 años, Tío materno, 60 años, hijo varón, Madre, dos primos hermanos, 67 años, 62 años, Luis Roberto León, lleon@intramed.com Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, FAMILIARES_SUJETO_ASISTENCIA, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Datos del paciente. Nombre: Ezequiel. Apellidos: Lopez Pereira. NHC: 7856544. NASS: 78 45678567 05. Domicilio: C/ Vinuesa, 4, 6 A. Localidad/ Provincia: Madrid. CP: 28029. Datos asistenciales. Fecha de nacimiento: 23/08/1957. País de nacimiento: España. Edad: 60 años Sexo: H. Fecha de Ingreso: 29/12/2017. Médico: Luis Roberto León NºCol: 28 28 57103. Informe clínico del paciente: Paciente varón de 60 años, con síndrome de Alport, microhematuria y proteinuria de 4 g/día, creatinina de 2 mg/dl, urea 123 mg/dl, pérdida moderada de la audición, hipertensión arterial tratada con enalapril 20 mg, obesidad con IMC = 36,26 (P 120 kg, h 1,81 m), glucemias en ayunas alteradas (menor a 126 mg/dl), Hb glucosilada normal, dislipidemia e hiperuricemia en tratamiento. Ex-fumador de un paquete al día. Normotiroideo. Biopsia renal (realizada en 1995): MO (12 glomérulos) esclerosis focal y segmentaria glomerular en evolución a glomerulopatía esclerosante, IF con Ig M de leve intensidad en mesangio e IgA y M en cilindros tubulares. ME 2 glomérulos. MB capilar con engrosamiento irregular y desdoblamiento focal de la lámina densa. Podocitos con fusión total de pedicelos. En un sector, borramiento de la estructura glomerular con depósito de abundante material amorfo, electrón denso. Las alteraciones de la lámina densa son compatibles con enfermedad de Alport, el resto de los hallazgos con glomerulonefritis esclerosante focal. Ecografía renal: RD 95,6 x 52 x 53, RI 99 x 51 x 52. Doppler renal sin alteraciones. Se indica dieta baja en proteínas, hipocalórica y se agrega al tratamiento losartán en dosis de 75 mg/día (máxima tolerada por el paciente). Se observa reducción muy leve de proteinuria a 3,6 g/día. Se realiza cirugía de by-pass gástrico, y presenta en su evolución disminución de 35 kg en total, llegando a IMC de 25,6. Control nefrológico: creatinina 1,56 mg/dl, proteinuria 0,3 g/día, urea 65 mg/dl y normotensión con enalapril 5 mg/d; se mantiene dosis mínima de hipolipemiantes, normouricemia y normoglucemias. Antecedentes familiares: Hermano mayor de 65 años con nefropatía e hipoacusia neurosensorial bilateral y síndrome de Alport. Hermano menor de 58 años también con nefropatía e hipoacusia y síndrome de Alport. Hermana de 55 años de edad con nefropatía sin hipoacusia. Tío materno fallecido a los 60 años de edad por nefropatía de causa no aclarada y sin hipoacusia, que además ha tenido un hijo varón y una nieta con nefropatía sin hipoacusia. Madre con nefropatía desde la infancia con posible síndrome de Alport. Según comenta, dos primos hermanos de 67 años y 62 años de edad respectivamente, con diagnóstico clínico de hemocromatosis hereditaria. Tres años después de la cirugía, la buena evolución del paciente está relacionada con el cumplimento del tratamiento (dieta), ejercicio aeróbico y apoyo clínico-psicológico. Responsable clínico: Dr. Luis Roberto León, Email: lleon@intramed.com

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Ezequiel", ".", "\n", "Apellidos", ":", "Lopez", "Pereira", ".", "\n", "NHC", ":", "7856544", ".", "\n", "NASS", ":", "78", "45678567", "05", ".", "\n", "Domicilio", ":", "C/", "Vinuesa", ",", "4", ",", "6", "A.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "28029", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "23/08/1957", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "60", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "29/12/2017", ".", "\n", "Médico", ":", "Luis", "Roberto", "León", " ", "NºCol", ":", "28", "28", "57103", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Paciente", "varón", "de", "60", "años", ",", "con", "síndrome", "de", "Alport", ",", "microhematuria", "y", "proteinuria", "de", "4", "g", "/", "día", ",", "creatinina", "de", "2", "mg", "/", "dl", ",", "urea", "123", "mg", "/", "dl", ",", "pérdida", "moderada", "de", "la", "audición", ",", "hipertensión", "arterial", "tratada", "con", "enalapril", "20", "mg", ",", "obesidad", "con", "IMC", "=", "36,26", "(", "P", "120", "kg", ",", "h", "1,81", "m", ")", ",", "glucemias", "en", "ayunas", "alteradas", "(", "menor", "a", "126", "mg", "/", "dl", ")", ",", "Hb", "glucosilada", "normal", ",", "dislipidemia", "e", "hiperuricemia", "en", "tratamiento", ".", "Ex", "-", "fumador", "de", "un", "paquete", "al", "día", ".", "Normotiroideo", ".", "Biopsia", "renal", "(", "realizada", "en", "1995", "):", "MO", "(", "12", "glomérulos", ")", "esclerosis", "focal", "y", "segmentaria", "glomerular", "en", "evolución", "a", "glomerulopatía", "esclerosante", ",", "IF", "con", "Ig", "M", "de", "leve", "intensidad", "en", "mesangio", "e", "IgA", "y", "M", "en", "cilindros", "tubulares", ".", "ME", "2", "glomérulos", ".", "MB", "capilar", "con", "engrosamiento", "irregular", "y", "desdoblamiento", "focal", "de", "la", "lámina", "densa", ".", "Podocitos", "con", "fusión", "total", "de", "pedicelos", ".", "En", "un", "sector", ",", "borramiento", "de", "la", "estructura", "glomerular", "con", "depósito", "de", "abundante", "material", "amorfo", ",", "electrón", "denso", ".", "Las", "alteraciones", "de", "la", "lámina", "densa", "son", "compatibles", "con", "enfermedad", "de", "Alport", ",", "el", "resto", "de", "los", "hallazgos", "con", "glomerulonefritis", "esclerosante", "focal", ".", "Ecografía", "renal", ":", "RD", "95,6", "x", "52", "x", "53", ",", "RI", "99", "x", "51", "x", "52", ".", "Doppler", "renal", "sin", "alteraciones", ".", "\n", "Se", "indica", "dieta", "baja", "en", "proteínas", ",", "hipocalórica", "y", "se", "agrega", "al", "tratamiento", "losartán", "en", "dosis", "de", "75", "mg", "/", "día", "(", "máxima", "tolerada", "por", "el", "paciente", ")", ".", "Se", "observa", "reducción", "muy", "leve", "de", "proteinuria", "a", "3,6", "g", "/", "día", ".", "Se", "realiza", "cirugía", "de", "by", "-", "pass", "gástrico", ",", "y", "presenta", "en", "su", "evolución", "disminución", "de", "35", "kg", "en", "total", ",", "llegando", "a", "IMC", "de", "25,6", ".", "Control", "nefrológico", ":", "creatinina", "1,56", "mg", "/", "dl", ",", "proteinuria", "0,3", "g", "/", "día", ",", "urea", "65", "mg", "/", "dl", "y", "normotensión", "con", "enalapril", "5", "mg", "/", "d", ";", "se", "mantiene", "dosis", "mínima", "de", "hipolipemiantes", ",", "normouricemia", "y", "normoglucemias", ".", "\n", "Antecedentes", "familiares", ":", "\n", "Hermano", "mayor", "de", "65", "años", "con", "nefropatía", "e", "hipoacusia", "neurosensorial", "bilateral", "y", "síndrome", "de", "Alport", ".", "\n", "Hermano", "menor", "de", "58", "años", "también", "con", "nefropatía", "e", "hipoacusia", "y", "síndrome", "de", "Alport", ".", "\n", "Hermana", "de", "55", "años", "de", "edad", "con", "nefropatía", "sin", "hipoacusia", ".", "\n", "Tío", "materno", "fallecido", "a", "los", "60", "años", "de", "edad", "por", "nefropatía", "de", "causa", "no", "aclarada", "y", "sin", "hipoacusia", ",", "que", "además", "ha", "tenido", "un", "hijo", "varón", "y", "una", "nieta", "con", "nefropatía", "sin", "hipoacusia", ".", "\n", "Madre", "con", "nefropatía", "desde", "la", "infancia", "con", "posible", "síndrome", "de", "Alport", ".", "\n", "Según", "comenta", ",", "dos", "primos", "hermanos", "de", "67", "años", "y", "62", "años", "de", "edad", "respectivamente", ",", "con", "diagnóstico", "clínico", "de", "hemocromatosis", "hereditaria", ".", "\n", "Tres", "años", "después", "de", "la", "cirugía", ",", "la", "buena", "evolución", "del", "paciente", "está", "relacionada", "con", "el", "cumplimento", "del", "tratamiento", "(", "dieta", ")", ",", "ejercicio", "aeróbico", "y", "apoyo", "clínico", "-", "psicológico", ".", "\n", "Responsable", "clínico", ":", "Dr", ".", "Luis", "Roberto", "León", ",", "Email", ":", "lleon@intramed.com", "\n" ]

[ "FAMILIARES_SUJETO_ASISTENCIA", "CORREO_ELECTRONICO", "CALLE", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]

Ezequiel, Lopez Pereira, 7856544, 78 45678567 05, Madrid, 28029, 23/08/1957, España, 60 años, 29/12/2017, Luis Roberto León, 28 28 57103, varón, 60 años, 1995, Hermano mayor, 65 años, Hermano menor, 58 años, Hermana, 55 años, Tío materno, 60 años, hijo varón, Madre, dos primos hermanos, 67 años, 62 años, Luis Roberto León, lleon@intramed.com

111_task2

Sentence: Datos del paciente. Nombre: Ezequiel. Apellidos: Lopez Pereira. NHC: 7856544. NASS: 78 45678567 05. Domicilio: C/ Vinuesa, 4, 6 A. Localidad/ Provincia: Madrid. CP: 28029. Datos asistenciales. Fecha de nacimiento: 23/08/1957. País de nacimiento: España. Edad: 60 años Sexo: H. Fecha de Ingreso: 29/12/2017. Médico: Luis Roberto León NºCol: 28 28 57103. Informe clínico del paciente: Paciente varón de 60 años, con síndrome de Alport, microhematuria y proteinuria de 4 g/día, creatinina de 2 mg/dl, urea 123 mg/dl, pérdida moderada de la audición, hipertensión arterial tratada con enalapril 20 mg, obesidad con IMC = 36,26 (P 120 kg, h 1,81 m), glucemias en ayunas alteradas (menor a 126 mg/dl), Hb glucosilada normal, dislipidemia e hiperuricemia en tratamiento. Ex-fumador de un paquete al día. Normotiroideo. Biopsia renal (realizada en 1995): MO (12 glomérulos) esclerosis focal y segmentaria glomerular en evolución a glomerulopatía esclerosante, IF con Ig M de leve intensidad en mesangio e IgA y M en cilindros tubulares. ME 2 glomérulos. MB capilar con engrosamiento irregular y desdoblamiento focal de la lámina densa. Podocitos con fusión total de pedicelos. En un sector, borramiento de la estructura glomerular con depósito de abundante material amorfo, electrón denso. Las alteraciones de la lámina densa son compatibles con enfermedad de Alport, el resto de los hallazgos con glomerulonefritis esclerosante focal. Ecografía renal: RD 95,6 x 52 x 53, RI 99 x 51 x 52. Doppler renal sin alteraciones. Se indica dieta baja en proteínas, hipocalórica y se agrega al tratamiento losartán en dosis de 75 mg/día (máxima tolerada por el paciente). Se observa reducción muy leve de proteinuria a 3,6 g/día. Se realiza cirugía de by-pass gástrico, y presenta en su evolución disminución de 35 kg en total, llegando a IMC de 25,6. Control nefrológico: creatinina 1,56 mg/dl, proteinuria 0,3 g/día, urea 65 mg/dl y normotensión con enalapril 5 mg/d; se mantiene dosis mínima de hipolipemiantes, normouricemia y normoglucemias. Antecedentes familiares: Hermano mayor de 65 años con nefropatía e hipoacusia neurosensorial bilateral y síndrome de Alport. Hermano menor de 58 años también con nefropatía e hipoacusia y síndrome de Alport. Hermana de 55 años de edad con nefropatía sin hipoacusia. Tío materno fallecido a los 60 años de edad por nefropatía de causa no aclarada y sin hipoacusia, que además ha tenido un hijo varón y una nieta con nefropatía sin hipoacusia. Madre con nefropatía desde la infancia con posible síndrome de Alport. Según comenta, dos primos hermanos de 67 años y 62 años de edad respectivamente, con diagnóstico clínico de hemocromatosis hereditaria. Tres años después de la cirugía, la buena evolución del paciente está relacionada con el cumplimento del tratamiento (dieta), ejercicio aeróbico y apoyo clínico-psicológico. Responsable clínico: Dr. Luis Roberto León, Email: lleon@intramed.com Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Datos del paciente. Nombre: Ezequiel. Apellidos: Lopez Pereira. NHC: 7856544. NASS: 78 45678567 05. Domicilio: C/ Vinuesa, 4, 6 A. Localidad/ Provincia: Madrid. CP: 28029. Datos asistenciales. Fecha de nacimiento: 23/08/1957. País de nacimiento: España. Edad: 60 años Sexo: H. Fecha de Ingreso: 29/12/2017. Médico: Luis Roberto León NºCol: 28 28 57103. Informe clínico del paciente: Paciente varón de 60 años, con síndrome de Alport, microhematuria y proteinuria de 4 g/día, creatinina de 2 mg/dl, urea 123 mg/dl, pérdida moderada de la audición, hipertensión arterial tratada con enalapril 20 mg, obesidad con IMC = 36,26 (P 120 kg, h 1,81 m), glucemias en ayunas alteradas (menor a 126 mg/dl), Hb glucosilada normal, dislipidemia e hiperuricemia en tratamiento. Ex-fumador de un paquete al día. Normotiroideo. Biopsia renal (realizada en 1995): MO (12 glomérulos) esclerosis focal y segmentaria glomerular en evolución a glomerulopatía esclerosante, IF con Ig M de leve intensidad en mesangio e IgA y M en cilindros tubulares. ME 2 glomérulos. MB capilar con engrosamiento irregular y desdoblamiento focal de la lámina densa. Podocitos con fusión total de pedicelos. En un sector, borramiento de la estructura glomerular con depósito de abundante material amorfo, electrón denso. Las alteraciones de la lámina densa son compatibles con enfermedad de Alport, el resto de los hallazgos con glomerulonefritis esclerosante focal. Ecografía renal: RD 95,6 x 52 x 53, RI 99 x 51 x 52. Doppler renal sin alteraciones. Se indica dieta baja en proteínas, hipocalórica y se agrega al tratamiento losartán en dosis de 75 mg/día (máxima tolerada por el paciente). Se observa reducción muy leve de proteinuria a 3,6 g/día. Se realiza cirugía de by-pass gástrico, y presenta en su evolución disminución de 35 kg en total, llegando a IMC de 25,6. Control nefrológico: creatinina 1,56 mg/dl, proteinuria 0,3 g/día, urea 65 mg/dl y normotensión con enalapril 5 mg/d; se mantiene dosis mínima de hipolipemiantes, normouricemia y normoglucemias. Antecedentes familiares: Hermano mayor de 65 años con nefropatía e hipoacusia neurosensorial bilateral y síndrome de Alport. Hermano menor de 58 años también con nefropatía e hipoacusia y síndrome de Alport. Hermana de 55 años de edad con nefropatía sin hipoacusia. Tío materno fallecido a los 60 años de edad por nefropatía de causa no aclarada y sin hipoacusia, que además ha tenido un hijo varón y una nieta con nefropatía sin hipoacusia. Madre con nefropatía desde la infancia con posible síndrome de Alport. Según comenta, dos primos hermanos de 67 años y 62 años de edad respectivamente, con diagnóstico clínico de hemocromatosis hereditaria. Tres años después de la cirugía, la buena evolución del paciente está relacionada con el cumplimento del tratamiento (dieta), ejercicio aeróbico y apoyo clínico-psicológico. Responsable clínico: Dr. Luis Roberto León, Email: lleon@intramed.com

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Ezequiel", ".", "\n", "Apellidos", ":", "Lopez", "Pereira", ".", "\n", "NHC", ":", "7856544", ".", "\n", "NASS", ":", "78", "45678567", "05", ".", "\n", "Domicilio", ":", "C/", "Vinuesa", ",", "4", ",", "6", "A.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "28029", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "23/08/1957", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "60", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "29/12/2017", ".", "\n", "Médico", ":", "Luis", "Roberto", "León", " ", "NºCol", ":", "28", "28", "57103", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Paciente", "varón", "de", "60", "años", ",", "con", "síndrome", "de", "Alport", ",", "microhematuria", "y", "proteinuria", "de", "4", "g", "/", "día", ",", "creatinina", "de", "2", "mg", "/", "dl", ",", "urea", "123", "mg", "/", "dl", ",", "pérdida", "moderada", "de", "la", "audición", ",", "hipertensión", "arterial", "tratada", "con", "enalapril", "20", "mg", ",", "obesidad", "con", "IMC", "=", "36,26", "(", "P", "120", "kg", ",", "h", "1,81", "m", ")", ",", "glucemias", "en", "ayunas", "alteradas", "(", "menor", "a", "126", "mg", "/", "dl", ")", ",", "Hb", "glucosilada", "normal", ",", "dislipidemia", "e", "hiperuricemia", "en", "tratamiento", ".", "Ex", "-", "fumador", "de", "un", "paquete", "al", "día", ".", "Normotiroideo", ".", "Biopsia", "renal", "(", "realizada", "en", "1995", "):", "MO", "(", "12", "glomérulos", ")", "esclerosis", "focal", "y", "segmentaria", "glomerular", "en", "evolución", "a", "glomerulopatía", "esclerosante", ",", "IF", "con", "Ig", "M", "de", "leve", "intensidad", "en", "mesangio", "e", "IgA", "y", "M", "en", "cilindros", "tubulares", ".", "ME", "2", "glomérulos", ".", "MB", "capilar", "con", "engrosamiento", "irregular", "y", "desdoblamiento", "focal", "de", "la", "lámina", "densa", ".", "Podocitos", "con", "fusión", "total", "de", "pedicelos", ".", "En", "un", "sector", ",", "borramiento", "de", "la", "estructura", "glomerular", "con", "depósito", "de", "abundante", "material", "amorfo", ",", "electrón", "denso", ".", "Las", "alteraciones", "de", "la", "lámina", "densa", "son", "compatibles", "con", "enfermedad", "de", "Alport", ",", "el", "resto", "de", "los", "hallazgos", "con", "glomerulonefritis", "esclerosante", "focal", ".", "Ecografía", "renal", ":", "RD", "95,6", "x", "52", "x", "53", ",", "RI", "99", "x", "51", "x", "52", ".", "Doppler", "renal", "sin", "alteraciones", ".", "\n", "Se", "indica", "dieta", "baja", "en", "proteínas", ",", "hipocalórica", "y", "se", "agrega", "al", "tratamiento", "losartán", "en", "dosis", "de", "75", "mg", "/", "día", "(", "máxima", "tolerada", "por", "el", "paciente", ")", ".", "Se", "observa", "reducción", "muy", "leve", "de", "proteinuria", "a", "3,6", "g", "/", "día", ".", "Se", "realiza", "cirugía", "de", "by", "-", "pass", "gástrico", ",", "y", "presenta", "en", "su", "evolución", "disminución", "de", "35", "kg", "en", "total", ",", "llegando", "a", "IMC", "de", "25,6", ".", "Control", "nefrológico", ":", "creatinina", "1,56", "mg", "/", "dl", ",", "proteinuria", "0,3", "g", "/", "día", ",", "urea", "65", "mg", "/", "dl", "y", "normotensión", "con", "enalapril", "5", "mg", "/", "d", ";", "se", "mantiene", "dosis", "mínima", "de", "hipolipemiantes", ",", "normouricemia", "y", "normoglucemias", ".", "\n", "Antecedentes", "familiares", ":", "\n", "Hermano", "mayor", "de", "65", "años", "con", "nefropatía", "e", "hipoacusia", "neurosensorial", "bilateral", "y", "síndrome", "de", "Alport", ".", "\n", "Hermano", "menor", "de", "58", "años", "también", "con", "nefropatía", "e", "hipoacusia", "y", "síndrome", "de", "Alport", ".", "\n", "Hermana", "de", "55", "años", "de", "edad", "con", "nefropatía", "sin", "hipoacusia", ".", "\n", "Tío", "materno", "fallecido", "a", "los", "60", "años", "de", "edad", "por", "nefropatía", "de", "causa", "no", "aclarada", "y", "sin", "hipoacusia", ",", "que", "además", "ha", "tenido", "un", "hijo", "varón", "y", "una", "nieta", "con", "nefropatía", "sin", "hipoacusia", ".", "\n", "Madre", "con", "nefropatía", "desde", "la", "infancia", "con", "posible", "síndrome", "de", "Alport", ".", "\n", "Según", "comenta", ",", "dos", "primos", "hermanos", "de", "67", "años", "y", "62", "años", "de", "edad", "respectivamente", ",", "con", "diagnóstico", "clínico", "de", "hemocromatosis", "hereditaria", ".", "\n", "Tres", "años", "después", "de", "la", "cirugía", ",", "la", "buena", "evolución", "del", "paciente", "está", "relacionada", "con", "el", "cumplimento", "del", "tratamiento", "(", "dieta", ")", ",", "ejercicio", "aeróbico", "y", "apoyo", "clínico", "-", "psicológico", ".", "\n", "Responsable", "clínico", ":", "Dr", ".", "Luis", "Roberto", "León", ",", "Email", ":", "lleon@intramed.com", "\n" ]

[ "FAMILIARES_SUJETO_ASISTENCIA", "CORREO_ELECTRONICO", "CALLE", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]

Symptomatic treatment is a Intervention_Physical, combination chemotherapy is a Intervention_Pharmacological, patients with extensive non - small cell lung cancer . is a Participant_Condition, 87 is a Participant_Sample-size, patients with inoperable , extensive non - small cell lung cancer ( NSCLC ) is a Participant_Condition, combination chemotherapy ( cisplatin is a Intervention_Pharmacological, etoposide is a Intervention_Pharmacological, symptomatic treatment is a Intervention_Physical, survival time is a Outcome_Mortality, Three long - term survivors is a Outcome_Mortality

35790_task0

Sentence: Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer . In a randomized clinical trial , 87 patients with inoperable , extensive non-small cell lung cancer ( NSCLC ) were randomized to receive either combination chemotherapy ( cisplatin at 70 mg/m2 intravenously [ i.v . ] on day 1 and etoposide at 100 mg/m2 i.v . on day 1 and 200 mg/m2 orally on days 2 and 3 ) or symptomatic treatment . No statistically significant differences in survival time were found between the two treatment techniques . A major problem in the interpretation of the results was the use of semicurative radiation therapy ( 3000 to 4200 cGy ) to the primary tumor and mediastinum , which was given with symptomatic intent . Three long-term survivors were seen in the latter group . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Outcome_Mortality, Participant_Sample-size

[ "B-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O" ]

Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer . In a randomized clinical trial , 87 patients with inoperable , extensive non-small cell lung cancer ( NSCLC ) were randomized to receive either combination chemotherapy ( cisplatin at 70 mg/m2 intravenously [ i.v . ] on day 1 and etoposide at 100 mg/m2 i.v . on day 1 and 200 mg/m2 orally on days 2 and 3 ) or symptomatic treatment . No statistically significant differences in survival time were found between the two treatment techniques . A major problem in the interpretation of the results was the use of semicurative radiation therapy ( 3000 to 4200 cGy ) to the primary tumor and mediastinum , which was given with symptomatic intent . Three long-term survivors were seen in the latter group .

[ "Symptomatic", "treatment", "versus", "combination", "chemotherapy", "for", "patients", "with", "extensive", "non", "-", "small", "cell", "lung", "cancer", ".", "In", "a", "randomized", "clinical", "trial", ",", "87", "patients", "with", "inoperable", ",", "extensive", "non", "-", "small", "cell", "lung", "cancer", "(", "NSCLC", ")", "were", "randomized", "to", "receive", "either", "combination", "chemotherapy", "(", "cisplatin", "at", "70", "mg", "/", "m2", "intravenously", "[", "i.v", ".", "]", "on", "day", "1", "and", "etoposide", "at", "100", "mg", "/", "m2", "i.v", ".", "on", "day", "1", "and", "200", "mg", "/", "m2", "orally", "on", "days", "2", "and", "3", ")", "or", "symptomatic", "treatment", ".", "No", "statistically", "significant", "differences", "in", "survival", "time", "were", "found", "between", "the", "two", "treatment", "techniques", ".", "A", "major", "problem", "in", "the", "interpretation", "of", "the", "results", "was", "the", "use", "of", "semicurative", "radiation", "therapy", "(", "3000", "to", "4200", "cGy", ")", "to", "the", "primary", "tumor", "and", "mediastinum", ",", "which", "was", "given", "with", "symptomatic", "intent", ".", "Three", "long", "-", "term", "survivors", "were", "seen", "in", "the", "latter", "group", "." ]

[ "Participant_Condition", "Intervention_Pharmacological", "Outcome_Mortality", "Intervention_Physical", "Participant_Sample-size" ]

Symptomatic treatment is a Intervention_Physical, combination chemotherapy is a Intervention_Pharmacological, patients with extensive non - small cell lung cancer . is a Participant_Condition, 87 is a Participant_Sample-size, patients with inoperable , extensive non - small cell lung cancer ( NSCLC ) is a Participant_Condition, combination chemotherapy ( cisplatin is a Intervention_Pharmacological, etoposide is a Intervention_Pharmacological, symptomatic treatment is a Intervention_Physical, survival time is a Outcome_Mortality, Three long - term survivors is a Outcome_Mortality

35790_task1

Sentence: Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer . In a randomized clinical trial , 87 patients with inoperable , extensive non-small cell lung cancer ( NSCLC ) were randomized to receive either combination chemotherapy ( cisplatin at 70 mg/m2 intravenously [ i.v . ] on day 1 and etoposide at 100 mg/m2 i.v . on day 1 and 200 mg/m2 orally on days 2 and 3 ) or symptomatic treatment . No statistically significant differences in survival time were found between the two treatment techniques . A major problem in the interpretation of the results was the use of semicurative radiation therapy ( 3000 to 4200 cGy ) to the primary tumor and mediastinum , which was given with symptomatic intent . Three long-term survivors were seen in the latter group . Instructions: please typing these entity words according to sentence: Symptomatic treatment, combination chemotherapy, patients with extensive non - small cell lung cancer ., 87, patients with inoperable , extensive non - small cell lung cancer ( NSCLC ), combination chemotherapy ( cisplatin, etoposide, symptomatic treatment, survival time, Three long - term survivors Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Outcome_Mortality, Participant_Sample-size

[ "B-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O" ]

Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer . In a randomized clinical trial , 87 patients with inoperable , extensive non-small cell lung cancer ( NSCLC ) were randomized to receive either combination chemotherapy ( cisplatin at 70 mg/m2 intravenously [ i.v . ] on day 1 and etoposide at 100 mg/m2 i.v . on day 1 and 200 mg/m2 orally on days 2 and 3 ) or symptomatic treatment . No statistically significant differences in survival time were found between the two treatment techniques . A major problem in the interpretation of the results was the use of semicurative radiation therapy ( 3000 to 4200 cGy ) to the primary tumor and mediastinum , which was given with symptomatic intent . Three long-term survivors were seen in the latter group .

[ "Symptomatic", "treatment", "versus", "combination", "chemotherapy", "for", "patients", "with", "extensive", "non", "-", "small", "cell", "lung", "cancer", ".", "In", "a", "randomized", "clinical", "trial", ",", "87", "patients", "with", "inoperable", ",", "extensive", "non", "-", "small", "cell", "lung", "cancer", "(", "NSCLC", ")", "were", "randomized", "to", "receive", "either", "combination", "chemotherapy", "(", "cisplatin", "at", "70", "mg", "/", "m2", "intravenously", "[", "i.v", ".", "]", "on", "day", "1", "and", "etoposide", "at", "100", "mg", "/", "m2", "i.v", ".", "on", "day", "1", "and", "200", "mg", "/", "m2", "orally", "on", "days", "2", "and", "3", ")", "or", "symptomatic", "treatment", ".", "No", "statistically", "significant", "differences", "in", "survival", "time", "were", "found", "between", "the", "two", "treatment", "techniques", ".", "A", "major", "problem", "in", "the", "interpretation", "of", "the", "results", "was", "the", "use", "of", "semicurative", "radiation", "therapy", "(", "3000", "to", "4200", "cGy", ")", "to", "the", "primary", "tumor", "and", "mediastinum", ",", "which", "was", "given", "with", "symptomatic", "intent", ".", "Three", "long", "-", "term", "survivors", "were", "seen", "in", "the", "latter", "group", "." ]

[ "Participant_Condition", "Intervention_Pharmacological", "Outcome_Mortality", "Intervention_Physical", "Participant_Sample-size" ]

Symptomatic treatment, combination chemotherapy, patients with extensive non - small cell lung cancer ., 87, patients with inoperable , extensive non - small cell lung cancer ( NSCLC ), combination chemotherapy ( cisplatin, etoposide, symptomatic treatment, survival time, Three long - term survivors

35790_task2

Sentence: Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer . In a randomized clinical trial , 87 patients with inoperable , extensive non-small cell lung cancer ( NSCLC ) were randomized to receive either combination chemotherapy ( cisplatin at 70 mg/m2 intravenously [ i.v . ] on day 1 and etoposide at 100 mg/m2 i.v . on day 1 and 200 mg/m2 orally on days 2 and 3 ) or symptomatic treatment . No statistically significant differences in survival time were found between the two treatment techniques . A major problem in the interpretation of the results was the use of semicurative radiation therapy ( 3000 to 4200 cGy ) to the primary tumor and mediastinum , which was given with symptomatic intent . Three long-term survivors were seen in the latter group . Instructions: please extract entity words from the input sentence

[ "B-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O" ]

Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer . In a randomized clinical trial , 87 patients with inoperable , extensive non-small cell lung cancer ( NSCLC ) were randomized to receive either combination chemotherapy ( cisplatin at 70 mg/m2 intravenously [ i.v . ] on day 1 and etoposide at 100 mg/m2 i.v . on day 1 and 200 mg/m2 orally on days 2 and 3 ) or symptomatic treatment . No statistically significant differences in survival time were found between the two treatment techniques . A major problem in the interpretation of the results was the use of semicurative radiation therapy ( 3000 to 4200 cGy ) to the primary tumor and mediastinum , which was given with symptomatic intent . Three long-term survivors were seen in the latter group .

[ "Symptomatic", "treatment", "versus", "combination", "chemotherapy", "for", "patients", "with", "extensive", "non", "-", "small", "cell", "lung", "cancer", ".", "In", "a", "randomized", "clinical", "trial", ",", "87", "patients", "with", "inoperable", ",", "extensive", "non", "-", "small", "cell", "lung", "cancer", "(", "NSCLC", ")", "were", "randomized", "to", "receive", "either", "combination", "chemotherapy", "(", "cisplatin", "at", "70", "mg", "/", "m2", "intravenously", "[", "i.v", ".", "]", "on", "day", "1", "and", "etoposide", "at", "100", "mg", "/", "m2", "i.v", ".", "on", "day", "1", "and", "200", "mg", "/", "m2", "orally", "on", "days", "2", "and", "3", ")", "or", "symptomatic", "treatment", ".", "No", "statistically", "significant", "differences", "in", "survival", "time", "were", "found", "between", "the", "two", "treatment", "techniques", ".", "A", "major", "problem", "in", "the", "interpretation", "of", "the", "results", "was", "the", "use", "of", "semicurative", "radiation", "therapy", "(", "3000", "to", "4200", "cGy", ")", "to", "the", "primary", "tumor", "and", "mediastinum", ",", "which", "was", "given", "with", "symptomatic", "intent", ".", "Three", "long", "-", "term", "survivors", "were", "seen", "in", "the", "latter", "group", "." ]

[ "Participant_Condition", "Intervention_Pharmacological", "Outcome_Mortality", "Intervention_Physical", "Participant_Sample-size" ]

progesterone is a compound, low - density lipoprotein receptor is a protein, VLDLR is a protein, low - density lipoprotein receptor is a protein, SR - BI is a protein

DS.d1451_task0

Sentence: The use of lipoproteins as a substrate for progesterone synthesis remains unclear, and the expression of lipoprotein receptors (very-low-density lipoprotein receptor (VLDLR), low-density lipoprotein receptor (LDLR), and scavenger receptor-BI (SR-BI 12 h) has not been characterized. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "I-protein", "O", "B-protein", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O" ]

The use of lipoproteins as a substrate for progesterone synthesis remains unclear, and the expression of lipoprotein receptors (very-low-density lipoprotein receptor (VLDLR), low-density lipoprotein receptor (LDLR), and scavenger receptor-BI (SR-BI 12 h) has not been characterized.

[ "The", "use", "of", "lipoproteins", "as", "a", "substrate", "for", "progesterone", "synthesis", "remains", "unclear", ",", "and", "the", "expression", "of", "lipoprotein", "receptors", "(", "very", "-", "low", "-", "density", "lipoprotein", "receptor", "(", "VLDLR", ")", ",", "low", "-", "density", "lipoprotein", "receptor", "(", "LDLR", ")", ",", "and", "scavenger", "receptor", "-", "BI", "(", "SR", "-", "BI", "12", "h", ")", "has", "not", "been", "characterized", "." ]

[ "protein", "compound" ]

progesterone is a compound, low - density lipoprotein receptor is a protein, VLDLR is a protein, low - density lipoprotein receptor is a protein, SR - BI is a protein

DS.d1451_task1

Sentence: The use of lipoproteins as a substrate for progesterone synthesis remains unclear, and the expression of lipoprotein receptors (very-low-density lipoprotein receptor (VLDLR), low-density lipoprotein receptor (LDLR), and scavenger receptor-BI (SR-BI 12 h) has not been characterized. Instructions: please typing these entity words according to sentence: progesterone, low - density lipoprotein receptor, VLDLR, low - density lipoprotein receptor, SR - BI Options: compound, protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "I-protein", "O", "B-protein", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O" ]

The use of lipoproteins as a substrate for progesterone synthesis remains unclear, and the expression of lipoprotein receptors (very-low-density lipoprotein receptor (VLDLR), low-density lipoprotein receptor (LDLR), and scavenger receptor-BI (SR-BI 12 h) has not been characterized.

[ "The", "use", "of", "lipoproteins", "as", "a", "substrate", "for", "progesterone", "synthesis", "remains", "unclear", ",", "and", "the", "expression", "of", "lipoprotein", "receptors", "(", "very", "-", "low", "-", "density", "lipoprotein", "receptor", "(", "VLDLR", ")", ",", "low", "-", "density", "lipoprotein", "receptor", "(", "LDLR", ")", ",", "and", "scavenger", "receptor", "-", "BI", "(", "SR", "-", "BI", "12", "h", ")", "has", "not", "been", "characterized", "." ]

[ "protein", "compound" ]

progesterone, low - density lipoprotein receptor, VLDLR, low - density lipoprotein receptor, SR - BI

DS.d1451_task2

Sentence: The use of lipoproteins as a substrate for progesterone synthesis remains unclear, and the expression of lipoprotein receptors (very-low-density lipoprotein receptor (VLDLR), low-density lipoprotein receptor (LDLR), and scavenger receptor-BI (SR-BI 12 h) has not been characterized. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "I-protein", "O", "B-protein", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O" ]

The use of lipoproteins as a substrate for progesterone synthesis remains unclear, and the expression of lipoprotein receptors (very-low-density lipoprotein receptor (VLDLR), low-density lipoprotein receptor (LDLR), and scavenger receptor-BI (SR-BI 12 h) has not been characterized.

[ "The", "use", "of", "lipoproteins", "as", "a", "substrate", "for", "progesterone", "synthesis", "remains", "unclear", ",", "and", "the", "expression", "of", "lipoprotein", "receptors", "(", "very", "-", "low", "-", "density", "lipoprotein", "receptor", "(", "VLDLR", ")", ",", "low", "-", "density", "lipoprotein", "receptor", "(", "LDLR", ")", ",", "and", "scavenger", "receptor", "-", "BI", "(", "SR", "-", "BI", "12", "h", ")", "has", "not", "been", "characterized", "." ]

[ "protein", "compound" ]

lysine - rich histones is a Protein, lysine - rich histone is a Protein, histone is a Protein, NH2 terminus is a Entity, histone is a Protein, lysine - rich histone is a Protein, lysine - rich is a Protein, arginine - rich histones is a Protein, lysine - rich histones is a Protein

2_task0

Sentence: Amino acid sequence and sequence variability of the amino-terminal regions of lysine-rich histones. The amino acid sequence has been determined for the first 72 residues of a lysine-rich histone from rabbit thymus. These are the residues contained in a fragment released from the histone by treatment with N-bromosuccinimide. Peptides derived by tryptic, thermolysin, and chymotryptic digestion of this 72-residue fragment were used to reconstruct the total sequence. Analysis of the sequence revealed some unusual aspects of the structure of the fragment, which comprises about one-third of the histone molecule. Thirty of the first 40 residues are accounted for by lysine, alanine, and proline; this portion of the fragment includes sequences of 4,2, and 3 consecutive basic residues. The last 32 residues contain all the hydrophobic amino acids (valine, isoleucine, leucine, tyrosine) of the fragment but have few basic residues and no prolines. The NH2 terminus of the histone is acetylated. Comparison of the sequence of the NH2-terminal half of this lysine-rich histone with the entire sequences of the slightly lysine-rich and arginine-rich histones shows that all three have similar characteristics, that is, an NH2-terminal region rich in basic amino acids and a COOH-terminal portion rich in hydrophobic residues. Tryptic peptides from the NH2-terminal N-bromosuccinimide fragment of two other thymus lysine-rich histones have been isolated. These peptides (with partial sequences) were aligned by direct identity or analogy with the complete amino acid sequence of the NH2-terminal N-bromosuccinimide fragment of the lysine-rich histone studied previously. It was found that there were from 7 to 14 amino acid differences between fractions. One of the amino acid interchanges eliminates a major phosphorylation site. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Amino acid sequence and sequence variability of the amino-terminal regions of lysine-rich histones. The amino acid sequence has been determined for the first 72 residues of a lysine-rich histone from rabbit thymus. These are the residues contained in a fragment released from the histone by treatment with N-bromosuccinimide. Peptides derived by tryptic, thermolysin, and chymotryptic digestion of this 72-residue fragment were used to reconstruct the total sequence. Analysis of the sequence revealed some unusual aspects of the structure of the fragment, which comprises about one-third of the histone molecule. Thirty of the first 40 residues are accounted for by lysine, alanine, and proline; this portion of the fragment includes sequences of 4,2, and 3 consecutive basic residues. The last 32 residues contain all the hydrophobic amino acids (valine, isoleucine, leucine, tyrosine) of the fragment but have few basic residues and no prolines. The NH2 terminus of the histone is acetylated. Comparison of the sequence of the NH2-terminal half of this lysine-rich histone with the entire sequences of the slightly lysine-rich and arginine-rich histones shows that all three have similar characteristics, that is, an NH2-terminal region rich in basic amino acids and a COOH-terminal portion rich in hydrophobic residues. Tryptic peptides from the NH2-terminal N-bromosuccinimide fragment of two other thymus lysine-rich histones have been isolated. These peptides (with partial sequences) were aligned by direct identity or analogy with the complete amino acid sequence of the NH2-terminal N-bromosuccinimide fragment of the lysine-rich histone studied previously. It was found that there were from 7 to 14 amino acid differences between fractions. One of the amino acid interchanges eliminates a major phosphorylation site.

[ "Amino", "acid", "sequence", "and", "sequence", "variability", "of", "the", "amino", "-", "terminal", "regions", "of", "lysine", "-", "rich", "histones", ".", "\n", "The", "amino", "acid", "sequence", "has", "been", "determined", "for", "the", "first", "72", "residues", "of", "a", "lysine", "-", "rich", "histone", "from", "rabbit", "thymus", ".", "These", "are", "the", "residues", "contained", "in", "a", "fragment", "released", "from", "the", "histone", "by", "treatment", "with", "N", "-", "bromosuccinimide", ".", "Peptides", "derived", "by", "tryptic", ",", "thermolysin", ",", "and", "chymotryptic", "digestion", "of", "this", "72-residue", "fragment", "were", "used", "to", "reconstruct", "the", "total", "sequence", ".", "Analysis", "of", "the", "sequence", "revealed", "some", "unusual", "aspects", "of", "the", "structure", "of", "the", "fragment", ",", "which", "comprises", "about", "one", "-", "third", "of", "the", "histone", "molecule", ".", "Thirty", "of", "the", "first", "40", "residues", "are", "accounted", "for", "by", "lysine", ",", "alanine", ",", "and", "proline", ";", "this", "portion", "of", "the", "fragment", "includes", "sequences", "of", "4,2", ",", "and", "3", "consecutive", "basic", "residues", ".", "The", "last", "32", "residues", "contain", "all", "the", "hydrophobic", "amino", "acids", "(", "valine", ",", "isoleucine", ",", "leucine", ",", "tyrosine", ")", "of", "the", "fragment", "but", "have", "few", "basic", "residues", "and", "no", "prolines", ".", "The", "NH2", "terminus", "of", "the", "histone", "is", "acetylated", ".", "Comparison", "of", "the", "sequence", "of", "the", "NH2-terminal", "half", "of", "this", "lysine", "-", "rich", "histone", "with", "the", "entire", "sequences", "of", "the", "slightly", "lysine", "-", "rich", "and", "arginine", "-", "rich", "histones", "shows", "that", "all", "three", "have", "similar", "characteristics", ",", "that", "is", ",", "an", "NH2-terminal", "region", "rich", "in", "basic", "amino", "acids", "and", "a", "COOH", "-", "terminal", "portion", "rich", "in", "hydrophobic", "residues", ".", "Tryptic", "peptides", "from", "the", "NH2-terminal", "N", "-", "bromosuccinimide", "fragment", "of", "two", "other", "thymus", "lysine", "-", "rich", "histones", "have", "been", "isolated", ".", "These", "peptides", "(", "with", "partial", "sequences", ")", "were", "aligned", "by", "direct", "identity", "or", "analogy", "with", "the", "complete", "amino", "acid", "sequence", "of", "the", "NH2-terminal", "N", "-", "bromosuccinimide", "fragment", "of", "the", "lysine", "-", "rich", "histone", "studied", "previously", ".", "It", "was", "found", "that", "there", "were", "from", "7", "to", "14", "amino", "acid", "differences", "between", "fractions", ".", "One", "of", "the", "amino", "acid", "interchanges", "eliminates", "a", "major", "phosphorylation", "site", "." ]

[ "Protein", "Entity" ]

lysine - rich histones is a Protein, lysine - rich histone is a Protein, histone is a Protein, NH2 terminus is a Entity, histone is a Protein, lysine - rich histone is a Protein, lysine - rich is a Protein, arginine - rich histones is a Protein, lysine - rich histones is a Protein

2_task1

Sentence: Amino acid sequence and sequence variability of the amino-terminal regions of lysine-rich histones. The amino acid sequence has been determined for the first 72 residues of a lysine-rich histone from rabbit thymus. These are the residues contained in a fragment released from the histone by treatment with N-bromosuccinimide. Peptides derived by tryptic, thermolysin, and chymotryptic digestion of this 72-residue fragment were used to reconstruct the total sequence. Analysis of the sequence revealed some unusual aspects of the structure of the fragment, which comprises about one-third of the histone molecule. Thirty of the first 40 residues are accounted for by lysine, alanine, and proline; this portion of the fragment includes sequences of 4,2, and 3 consecutive basic residues. The last 32 residues contain all the hydrophobic amino acids (valine, isoleucine, leucine, tyrosine) of the fragment but have few basic residues and no prolines. The NH2 terminus of the histone is acetylated. Comparison of the sequence of the NH2-terminal half of this lysine-rich histone with the entire sequences of the slightly lysine-rich and arginine-rich histones shows that all three have similar characteristics, that is, an NH2-terminal region rich in basic amino acids and a COOH-terminal portion rich in hydrophobic residues. Tryptic peptides from the NH2-terminal N-bromosuccinimide fragment of two other thymus lysine-rich histones have been isolated. These peptides (with partial sequences) were aligned by direct identity or analogy with the complete amino acid sequence of the NH2-terminal N-bromosuccinimide fragment of the lysine-rich histone studied previously. It was found that there were from 7 to 14 amino acid differences between fractions. One of the amino acid interchanges eliminates a major phosphorylation site. Instructions: please typing these entity words according to sentence: lysine - rich histones, lysine - rich histone, histone, NH2 terminus, histone, lysine - rich histone, lysine - rich, arginine - rich histones, lysine - rich histones Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Amino acid sequence and sequence variability of the amino-terminal regions of lysine-rich histones. The amino acid sequence has been determined for the first 72 residues of a lysine-rich histone from rabbit thymus. These are the residues contained in a fragment released from the histone by treatment with N-bromosuccinimide. Peptides derived by tryptic, thermolysin, and chymotryptic digestion of this 72-residue fragment were used to reconstruct the total sequence. Analysis of the sequence revealed some unusual aspects of the structure of the fragment, which comprises about one-third of the histone molecule. Thirty of the first 40 residues are accounted for by lysine, alanine, and proline; this portion of the fragment includes sequences of 4,2, and 3 consecutive basic residues. The last 32 residues contain all the hydrophobic amino acids (valine, isoleucine, leucine, tyrosine) of the fragment but have few basic residues and no prolines. The NH2 terminus of the histone is acetylated. Comparison of the sequence of the NH2-terminal half of this lysine-rich histone with the entire sequences of the slightly lysine-rich and arginine-rich histones shows that all three have similar characteristics, that is, an NH2-terminal region rich in basic amino acids and a COOH-terminal portion rich in hydrophobic residues. Tryptic peptides from the NH2-terminal N-bromosuccinimide fragment of two other thymus lysine-rich histones have been isolated. These peptides (with partial sequences) were aligned by direct identity or analogy with the complete amino acid sequence of the NH2-terminal N-bromosuccinimide fragment of the lysine-rich histone studied previously. It was found that there were from 7 to 14 amino acid differences between fractions. One of the amino acid interchanges eliminates a major phosphorylation site.

[ "Amino", "acid", "sequence", "and", "sequence", "variability", "of", "the", "amino", "-", "terminal", "regions", "of", "lysine", "-", "rich", "histones", ".", "\n", "The", "amino", "acid", "sequence", "has", "been", "determined", "for", "the", "first", "72", "residues", "of", "a", "lysine", "-", "rich", "histone", "from", "rabbit", "thymus", ".", "These", "are", "the", "residues", "contained", "in", "a", "fragment", "released", "from", "the", "histone", "by", "treatment", "with", "N", "-", "bromosuccinimide", ".", "Peptides", "derived", "by", "tryptic", ",", "thermolysin", ",", "and", "chymotryptic", "digestion", "of", "this", "72-residue", "fragment", "were", "used", "to", "reconstruct", "the", "total", "sequence", ".", "Analysis", "of", "the", "sequence", "revealed", "some", "unusual", "aspects", "of", "the", "structure", "of", "the", "fragment", ",", "which", "comprises", "about", "one", "-", "third", "of", "the", "histone", "molecule", ".", "Thirty", "of", "the", "first", "40", "residues", "are", "accounted", "for", "by", "lysine", ",", "alanine", ",", "and", "proline", ";", "this", "portion", "of", "the", "fragment", "includes", "sequences", "of", "4,2", ",", "and", "3", "consecutive", "basic", "residues", ".", "The", "last", "32", "residues", "contain", "all", "the", "hydrophobic", "amino", "acids", "(", "valine", ",", "isoleucine", ",", "leucine", ",", "tyrosine", ")", "of", "the", "fragment", "but", "have", "few", "basic", "residues", "and", "no", "prolines", ".", "The", "NH2", "terminus", "of", "the", "histone", "is", "acetylated", ".", "Comparison", "of", "the", "sequence", "of", "the", "NH2-terminal", "half", "of", "this", "lysine", "-", "rich", "histone", "with", "the", "entire", "sequences", "of", "the", "slightly", "lysine", "-", "rich", "and", "arginine", "-", "rich", "histones", "shows", "that", "all", "three", "have", "similar", "characteristics", ",", "that", "is", ",", "an", "NH2-terminal", "region", "rich", "in", "basic", "amino", "acids", "and", "a", "COOH", "-", "terminal", "portion", "rich", "in", "hydrophobic", "residues", ".", "Tryptic", "peptides", "from", "the", "NH2-terminal", "N", "-", "bromosuccinimide", "fragment", "of", "two", "other", "thymus", "lysine", "-", "rich", "histones", "have", "been", "isolated", ".", "These", "peptides", "(", "with", "partial", "sequences", ")", "were", "aligned", "by", "direct", "identity", "or", "analogy", "with", "the", "complete", "amino", "acid", "sequence", "of", "the", "NH2-terminal", "N", "-", "bromosuccinimide", "fragment", "of", "the", "lysine", "-", "rich", "histone", "studied", "previously", ".", "It", "was", "found", "that", "there", "were", "from", "7", "to", "14", "amino", "acid", "differences", "between", "fractions", ".", "One", "of", "the", "amino", "acid", "interchanges", "eliminates", "a", "major", "phosphorylation", "site", "." ]

[ "Protein", "Entity" ]

lysine - rich histones, lysine - rich histone, histone, NH2 terminus, histone, lysine - rich histone, lysine - rich, arginine - rich histones, lysine - rich histones

2_task2

Sentence: Amino acid sequence and sequence variability of the amino-terminal regions of lysine-rich histones. The amino acid sequence has been determined for the first 72 residues of a lysine-rich histone from rabbit thymus. These are the residues contained in a fragment released from the histone by treatment with N-bromosuccinimide. Peptides derived by tryptic, thermolysin, and chymotryptic digestion of this 72-residue fragment were used to reconstruct the total sequence. Analysis of the sequence revealed some unusual aspects of the structure of the fragment, which comprises about one-third of the histone molecule. Thirty of the first 40 residues are accounted for by lysine, alanine, and proline; this portion of the fragment includes sequences of 4,2, and 3 consecutive basic residues. The last 32 residues contain all the hydrophobic amino acids (valine, isoleucine, leucine, tyrosine) of the fragment but have few basic residues and no prolines. The NH2 terminus of the histone is acetylated. Comparison of the sequence of the NH2-terminal half of this lysine-rich histone with the entire sequences of the slightly lysine-rich and arginine-rich histones shows that all three have similar characteristics, that is, an NH2-terminal region rich in basic amino acids and a COOH-terminal portion rich in hydrophobic residues. Tryptic peptides from the NH2-terminal N-bromosuccinimide fragment of two other thymus lysine-rich histones have been isolated. These peptides (with partial sequences) were aligned by direct identity or analogy with the complete amino acid sequence of the NH2-terminal N-bromosuccinimide fragment of the lysine-rich histone studied previously. It was found that there were from 7 to 14 amino acid differences between fractions. One of the amino acid interchanges eliminates a major phosphorylation site. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Amino acid sequence and sequence variability of the amino-terminal regions of lysine-rich histones. The amino acid sequence has been determined for the first 72 residues of a lysine-rich histone from rabbit thymus. These are the residues contained in a fragment released from the histone by treatment with N-bromosuccinimide. Peptides derived by tryptic, thermolysin, and chymotryptic digestion of this 72-residue fragment were used to reconstruct the total sequence. Analysis of the sequence revealed some unusual aspects of the structure of the fragment, which comprises about one-third of the histone molecule. Thirty of the first 40 residues are accounted for by lysine, alanine, and proline; this portion of the fragment includes sequences of 4,2, and 3 consecutive basic residues. The last 32 residues contain all the hydrophobic amino acids (valine, isoleucine, leucine, tyrosine) of the fragment but have few basic residues and no prolines. The NH2 terminus of the histone is acetylated. Comparison of the sequence of the NH2-terminal half of this lysine-rich histone with the entire sequences of the slightly lysine-rich and arginine-rich histones shows that all three have similar characteristics, that is, an NH2-terminal region rich in basic amino acids and a COOH-terminal portion rich in hydrophobic residues. Tryptic peptides from the NH2-terminal N-bromosuccinimide fragment of two other thymus lysine-rich histones have been isolated. These peptides (with partial sequences) were aligned by direct identity or analogy with the complete amino acid sequence of the NH2-terminal N-bromosuccinimide fragment of the lysine-rich histone studied previously. It was found that there were from 7 to 14 amino acid differences between fractions. One of the amino acid interchanges eliminates a major phosphorylation site.

[ "Amino", "acid", "sequence", "and", "sequence", "variability", "of", "the", "amino", "-", "terminal", "regions", "of", "lysine", "-", "rich", "histones", ".", "\n", "The", "amino", "acid", "sequence", "has", "been", "determined", "for", "the", "first", "72", "residues", "of", "a", "lysine", "-", "rich", "histone", "from", "rabbit", "thymus", ".", "These", "are", "the", "residues", "contained", "in", "a", "fragment", "released", "from", "the", "histone", "by", "treatment", "with", "N", "-", "bromosuccinimide", ".", "Peptides", "derived", "by", "tryptic", ",", "thermolysin", ",", "and", "chymotryptic", "digestion", "of", "this", "72-residue", "fragment", "were", "used", "to", "reconstruct", "the", "total", "sequence", ".", "Analysis", "of", "the", "sequence", "revealed", "some", "unusual", "aspects", "of", "the", "structure", "of", "the", "fragment", ",", "which", "comprises", "about", "one", "-", "third", "of", "the", "histone", "molecule", ".", "Thirty", "of", "the", "first", "40", "residues", "are", "accounted", "for", "by", "lysine", ",", "alanine", ",", "and", "proline", ";", "this", "portion", "of", "the", "fragment", "includes", "sequences", "of", "4,2", ",", "and", "3", "consecutive", "basic", "residues", ".", "The", "last", "32", "residues", "contain", "all", "the", "hydrophobic", "amino", "acids", "(", "valine", ",", "isoleucine", ",", "leucine", ",", "tyrosine", ")", "of", "the", "fragment", "but", "have", "few", "basic", "residues", "and", "no", "prolines", ".", "The", "NH2", "terminus", "of", "the", "histone", "is", "acetylated", ".", "Comparison", "of", "the", "sequence", "of", "the", "NH2-terminal", "half", "of", "this", "lysine", "-", "rich", "histone", "with", "the", "entire", "sequences", "of", "the", "slightly", "lysine", "-", "rich", "and", "arginine", "-", "rich", "histones", "shows", "that", "all", "three", "have", "similar", "characteristics", ",", "that", "is", ",", "an", "NH2-terminal", "region", "rich", "in", "basic", "amino", "acids", "and", "a", "COOH", "-", "terminal", "portion", "rich", "in", "hydrophobic", "residues", ".", "Tryptic", "peptides", "from", "the", "NH2-terminal", "N", "-", "bromosuccinimide", "fragment", "of", "two", "other", "thymus", "lysine", "-", "rich", "histones", "have", "been", "isolated", ".", "These", "peptides", "(", "with", "partial", "sequences", ")", "were", "aligned", "by", "direct", "identity", "or", "analogy", "with", "the", "complete", "amino", "acid", "sequence", "of", "the", "NH2-terminal", "N", "-", "bromosuccinimide", "fragment", "of", "the", "lysine", "-", "rich", "histone", "studied", "previously", ".", "It", "was", "found", "that", "there", "were", "from", "7", "to", "14", "amino", "acid", "differences", "between", "fractions", ".", "One", "of", "the", "amino", "acid", "interchanges", "eliminates", "a", "major", "phosphorylation", "site", "." ]

[ "Protein", "Entity" ]

tRNA is a RNA, HisRS - like is a protein-domain, eIF2alpha is a protein

1.0alpha7.train.646_task0

Sentence: Accordingly, it was proposed that binding of uncharged tRNA to the HisRS-like domain stimulates the ability of the kinase domain to phosphorylate eIF2alpha ( 51). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: RNA, protein-domain, protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-RNA", "O", "O", "O", "B-protein-domain", "I-protein-domain", "I-protein-domain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O" ]

Accordingly, it was proposed that binding of uncharged tRNA to the HisRS-like domain stimulates the ability of the kinase domain to phosphorylate eIF2alpha ( 51).

[ " ", "Accordingly", ",", "it", "was", "proposed", "that", "binding", "of", "uncharged", " ", "tRNA", "to", "the", " ", "HisRS", "-", "like", "domain", "stimulates", "the", "ability", "of", "the", "kinase", "domain", "to", "phosphorylate", " ", "eIF2alpha", "(", "51", ")", ".", " " ]

[ "protein-domain", "protein", "RNA" ]

tRNA is a RNA, HisRS - like is a protein-domain, eIF2alpha is a protein

1.0alpha7.train.646_task1

Sentence: Accordingly, it was proposed that binding of uncharged tRNA to the HisRS-like domain stimulates the ability of the kinase domain to phosphorylate eIF2alpha ( 51). Instructions: please typing these entity words according to sentence: tRNA, HisRS - like, eIF2alpha Options: RNA, protein-domain, protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-RNA", "O", "O", "O", "B-protein-domain", "I-protein-domain", "I-protein-domain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O" ]

Accordingly, it was proposed that binding of uncharged tRNA to the HisRS-like domain stimulates the ability of the kinase domain to phosphorylate eIF2alpha ( 51).

[ " ", "Accordingly", ",", "it", "was", "proposed", "that", "binding", "of", "uncharged", " ", "tRNA", "to", "the", " ", "HisRS", "-", "like", "domain", "stimulates", "the", "ability", "of", "the", "kinase", "domain", "to", "phosphorylate", " ", "eIF2alpha", "(", "51", ")", ".", " " ]

[ "protein-domain", "protein", "RNA" ]

tRNA, HisRS - like, eIF2alpha

1.0alpha7.train.646_task2

Sentence: Accordingly, it was proposed that binding of uncharged tRNA to the HisRS-like domain stimulates the ability of the kinase domain to phosphorylate eIF2alpha ( 51). Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-RNA", "O", "O", "O", "B-protein-domain", "I-protein-domain", "I-protein-domain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O" ]

Accordingly, it was proposed that binding of uncharged tRNA to the HisRS-like domain stimulates the ability of the kinase domain to phosphorylate eIF2alpha ( 51).

[ " ", "Accordingly", ",", "it", "was", "proposed", "that", "binding", "of", "uncharged", " ", "tRNA", "to", "the", " ", "HisRS", "-", "like", "domain", "stimulates", "the", "ability", "of", "the", "kinase", "domain", "to", "phosphorylate", " ", "eIF2alpha", "(", "51", ")", ".", " " ]

[ "protein-domain", "protein", "RNA" ]

ubiquitin is a protein, methamphetamine is a compound

DS.d1022_task0

Sentence: Quinone formation is closely linked to other representative hypotheses such as mitochondrial dysfunction, inflammation, oxidative stress, and dysfunction of the ubiquitin-proteasome system, in the pathogenesis of neurodegenerative diseases such as Parkinson's disease and methamphetamine-induced neurotoxicity. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O" ]

Quinone formation is closely linked to other representative hypotheses such as mitochondrial dysfunction, inflammation, oxidative stress, and dysfunction of the ubiquitin-proteasome system, in the pathogenesis of neurodegenerative diseases such as Parkinson's disease and methamphetamine-induced neurotoxicity.

[ "Quinone", "formation", "is", "closely", "linked", "to", "other", "representative", "hypotheses", "such", "as", "mitochondrial", "dysfunction", ",", "inflammation", ",", "oxidative", "stress", ",", "and", "dysfunction", "of", "the", "ubiquitin", "-", "proteasome", "system", ",", "in", "the", "pathogenesis", "of", "neurodegenerative", "diseases", "such", "as", "Parkinson", "'s", "disease", "and", "methamphetamine", "-", "induced", "neurotoxicity", "." ]

[ "compound", "protein" ]

ubiquitin is a protein, methamphetamine is a compound

DS.d1022_task1

Sentence: Quinone formation is closely linked to other representative hypotheses such as mitochondrial dysfunction, inflammation, oxidative stress, and dysfunction of the ubiquitin-proteasome system, in the pathogenesis of neurodegenerative diseases such as Parkinson's disease and methamphetamine-induced neurotoxicity. Instructions: please typing these entity words according to sentence: ubiquitin, methamphetamine Options: compound, protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O" ]

Quinone formation is closely linked to other representative hypotheses such as mitochondrial dysfunction, inflammation, oxidative stress, and dysfunction of the ubiquitin-proteasome system, in the pathogenesis of neurodegenerative diseases such as Parkinson's disease and methamphetamine-induced neurotoxicity.

[ "Quinone", "formation", "is", "closely", "linked", "to", "other", "representative", "hypotheses", "such", "as", "mitochondrial", "dysfunction", ",", "inflammation", ",", "oxidative", "stress", ",", "and", "dysfunction", "of", "the", "ubiquitin", "-", "proteasome", "system", ",", "in", "the", "pathogenesis", "of", "neurodegenerative", "diseases", "such", "as", "Parkinson", "'s", "disease", "and", "methamphetamine", "-", "induced", "neurotoxicity", "." ]

[ "compound", "protein" ]

ubiquitin, methamphetamine

DS.d1022_task2

Sentence: Quinone formation is closely linked to other representative hypotheses such as mitochondrial dysfunction, inflammation, oxidative stress, and dysfunction of the ubiquitin-proteasome system, in the pathogenesis of neurodegenerative diseases such as Parkinson's disease and methamphetamine-induced neurotoxicity. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O" ]

Quinone formation is closely linked to other representative hypotheses such as mitochondrial dysfunction, inflammation, oxidative stress, and dysfunction of the ubiquitin-proteasome system, in the pathogenesis of neurodegenerative diseases such as Parkinson's disease and methamphetamine-induced neurotoxicity.

[ "Quinone", "formation", "is", "closely", "linked", "to", "other", "representative", "hypotheses", "such", "as", "mitochondrial", "dysfunction", ",", "inflammation", ",", "oxidative", "stress", ",", "and", "dysfunction", "of", "the", "ubiquitin", "-", "proteasome", "system", ",", "in", "the", "pathogenesis", "of", "neurodegenerative", "diseases", "such", "as", "Parkinson", "'s", "disease", "and", "methamphetamine", "-", "induced", "neurotoxicity", "." ]

[ "compound", "protein" ]

microRNA is a Non-Specific_miRNAs, modulate adenoviral protein expression is a Relation_Trigger, tumor is a Diseases

4501_task0

Sentence: Additionally, several research groups have established that inserting microRNA (miRNA)-targeted sequences into the adenoviral genome can modulate adenoviral protein expression to confer tissue and tumor selectivity. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Relation_Trigger, Diseases, Non-Specific_miRNAs

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Non-Specific_miRNAs", "O", "O", "O", "O", "O", "O", "O", "O", "B-Relation_Trigger", "I-Relation_Trigger", "I-Relation_Trigger", "I-Relation_Trigger", "O", "O", "O", "O", "B-Diseases", "O", "O" ]

Additionally, several research groups have established that inserting microRNA (miRNA)-targeted sequences into the adenoviral genome can modulate adenoviral protein expression to confer tissue and tumor selectivity.

[ "Additionally", ",", "several", "research", "groups", "have", "established", "that", "inserting", "microRNA", "(", "miRNA)-targeted", "sequences", "into", "the", "adenoviral", "genome", "can", "modulate", "adenoviral", "protein", "expression", "to", "confer", "tissue", "and", "tumor", "selectivity", "." ]

[ "Relation_Trigger", "Diseases", "Non-Specific_miRNAs", "Genes/Proteins" ]

microRNA is a Non-Specific_miRNAs, modulate adenoviral protein expression is a Relation_Trigger, tumor is a Diseases

4501_task1

Sentence: Additionally, several research groups have established that inserting microRNA (miRNA)-targeted sequences into the adenoviral genome can modulate adenoviral protein expression to confer tissue and tumor selectivity. Instructions: please typing these entity words according to sentence: microRNA, modulate adenoviral protein expression, tumor Options: Relation_Trigger, Diseases, Non-Specific_miRNAs

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Non-Specific_miRNAs", "O", "O", "O", "O", "O", "O", "O", "O", "B-Relation_Trigger", "I-Relation_Trigger", "I-Relation_Trigger", "I-Relation_Trigger", "O", "O", "O", "O", "B-Diseases", "O", "O" ]

Additionally, several research groups have established that inserting microRNA (miRNA)-targeted sequences into the adenoviral genome can modulate adenoviral protein expression to confer tissue and tumor selectivity.

[ "Additionally", ",", "several", "research", "groups", "have", "established", "that", "inserting", "microRNA", "(", "miRNA)-targeted", "sequences", "into", "the", "adenoviral", "genome", "can", "modulate", "adenoviral", "protein", "expression", "to", "confer", "tissue", "and", "tumor", "selectivity", "." ]

[ "Relation_Trigger", "Diseases", "Non-Specific_miRNAs", "Genes/Proteins" ]

microRNA, modulate adenoviral protein expression, tumor

4501_task2

Sentence: Additionally, several research groups have established that inserting microRNA (miRNA)-targeted sequences into the adenoviral genome can modulate adenoviral protein expression to confer tissue and tumor selectivity. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Non-Specific_miRNAs", "O", "O", "O", "O", "O", "O", "O", "O", "B-Relation_Trigger", "I-Relation_Trigger", "I-Relation_Trigger", "I-Relation_Trigger", "O", "O", "O", "O", "B-Diseases", "O", "O" ]

Additionally, several research groups have established that inserting microRNA (miRNA)-targeted sequences into the adenoviral genome can modulate adenoviral protein expression to confer tissue and tumor selectivity.

[ "Additionally", ",", "several", "research", "groups", "have", "established", "that", "inserting", "microRNA", "(", "miRNA)-targeted", "sequences", "into", "the", "adenoviral", "genome", "can", "modulate", "adenoviral", "protein", "expression", "to", "confer", "tissue", "and", "tumor", "selectivity", "." ]

[ "Relation_Trigger", "Diseases", "Non-Specific_miRNAs", "Genes/Proteins" ]

sialic acid is a compound, peroxidase is a protein

DS.d1286_task0

Sentence: After 2 and 6 weeks of treatment, parotid gland was removed and total protein and sialic acid (free and total) concentration and amylase and peroxidase activities were determined. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O" ]

After 2 and 6 weeks of treatment, parotid gland was removed and total protein and sialic acid (free and total) concentration and amylase and peroxidase activities were determined.

[ "After", "2", "and", "6", "weeks", "of", "treatment", ",", "parotid", "gland", "was", "removed", "and", "total", "protein", "and", "sialic", "acid", "(", "free", "and", "total", ")", "concentration", "and", "amylase", "and", "peroxidase", "activities", "were", "determined", "." ]

[ "compound", "protein" ]

sialic acid is a compound, peroxidase is a protein

DS.d1286_task1

Sentence: After 2 and 6 weeks of treatment, parotid gland was removed and total protein and sialic acid (free and total) concentration and amylase and peroxidase activities were determined. Instructions: please typing these entity words according to sentence: sialic acid, peroxidase Options: compound, protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O" ]

After 2 and 6 weeks of treatment, parotid gland was removed and total protein and sialic acid (free and total) concentration and amylase and peroxidase activities were determined.

[ "After", "2", "and", "6", "weeks", "of", "treatment", ",", "parotid", "gland", "was", "removed", "and", "total", "protein", "and", "sialic", "acid", "(", "free", "and", "total", ")", "concentration", "and", "amylase", "and", "peroxidase", "activities", "were", "determined", "." ]

[ "compound", "protein" ]

sialic acid, peroxidase

DS.d1286_task2

Sentence: After 2 and 6 weeks of treatment, parotid gland was removed and total protein and sialic acid (free and total) concentration and amylase and peroxidase activities were determined. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O" ]

After 2 and 6 weeks of treatment, parotid gland was removed and total protein and sialic acid (free and total) concentration and amylase and peroxidase activities were determined.

[ "After", "2", "and", "6", "weeks", "of", "treatment", ",", "parotid", "gland", "was", "removed", "and", "total", "protein", "and", "sialic", "acid", "(", "free", "and", "total", ")", "concentration", "and", "amylase", "and", "peroxidase", "activities", "were", "determined", "." ]

[ "compound", "protein" ]

4-Hydroxyphenylpyruvate dioxygenase is a Protein, 4-Hydroxyphenylpyruvate dioxygenase is a Protein, HPPD is a Protein, HPPD is a Protein, HPPD is a Protein, HPPD is a Protein, HPPD is a Protein, HPPD is a Protein, HPPD is a Protein

141_task0

Sentence: 4-Hydroxyphenylpyruvate dioxygenase. 4-Hydroxyphenylpyruvate dioxygenase (HPPD) is an Fe(II)-dependent, non-heme oxygenase that catalyzes the conversion of 4-hydroxyphenylpyruvate to homogentisate. This reaction involves decarboxylation, substituent migration and aromatic oxygenation in a single catalytic cycle. HPPD is a member of the alpha-keto acid dependent oxygenases that typically require an alpha-keto acid (almost exclusively alpha-ketoglutarate) and molecular oxygen to either oxygenate or oxidize a third molecule. As an exception in this class of enzymes HPPD has only two substrates, does not use alpha-ketoglutarate, and incorporates both atoms of dioxygen into the aromatic product, homogentisate. The tertiary structure of the enzyme would suggest that its mechanism converged with that of other alpha-keto acid enzymes from an extradiol dioxygenase progenitor. The transformation catalyzed by HPPD has both agricultural and therapeutic significance. HPPD catalyzes the second step in the pathway for the catabolism of tyrosine, that is common to essentially all aerobic forms of life. In plants this pathway has an anabolic branch from homogentisate that forms essential isoprenoid redox cofactors such as plastoquinone and tocopherol. Naturally occurring multi-ketone molecules act as allelopathic agents by inhibiting HPPD and preventing the production of homogentisate and hence required redox cofactors. This has been the basis for the development of a range of very effective herbicides that are currently used commercially. In humans, deficiencies of specific enzymes of the tyrosine catabolism pathway give rise to a number of severe metabolic disorders. Interestingly, HPPD inhibitor/herbicide molecules act also as therapeutic agents for a number of debilitating and lethal inborn defects in tyrosine catabolism by preventing the accumulation of toxic metabolites. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "B-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

4-Hydroxyphenylpyruvate dioxygenase. 4-Hydroxyphenylpyruvate dioxygenase (HPPD) is an Fe(II)-dependent, non-heme oxygenase that catalyzes the conversion of 4-hydroxyphenylpyruvate to homogentisate. This reaction involves decarboxylation, substituent migration and aromatic oxygenation in a single catalytic cycle. HPPD is a member of the alpha-keto acid dependent oxygenases that typically require an alpha-keto acid (almost exclusively alpha-ketoglutarate) and molecular oxygen to either oxygenate or oxidize a third molecule. As an exception in this class of enzymes HPPD has only two substrates, does not use alpha-ketoglutarate, and incorporates both atoms of dioxygen into the aromatic product, homogentisate. The tertiary structure of the enzyme would suggest that its mechanism converged with that of other alpha-keto acid enzymes from an extradiol dioxygenase progenitor. The transformation catalyzed by HPPD has both agricultural and therapeutic significance. HPPD catalyzes the second step in the pathway for the catabolism of tyrosine, that is common to essentially all aerobic forms of life. In plants this pathway has an anabolic branch from homogentisate that forms essential isoprenoid redox cofactors such as plastoquinone and tocopherol. Naturally occurring multi-ketone molecules act as allelopathic agents by inhibiting HPPD and preventing the production of homogentisate and hence required redox cofactors. This has been the basis for the development of a range of very effective herbicides that are currently used commercially. In humans, deficiencies of specific enzymes of the tyrosine catabolism pathway give rise to a number of severe metabolic disorders. Interestingly, HPPD inhibitor/herbicide molecules act also as therapeutic agents for a number of debilitating and lethal inborn defects in tyrosine catabolism by preventing the accumulation of toxic metabolites.

[ "4-Hydroxyphenylpyruvate", "dioxygenase", ".", "\n", "4-Hydroxyphenylpyruvate", "dioxygenase", "(", "HPPD", ")", "is", "an", "Fe(II)-dependent", ",", "non", "-", "heme", "oxygenase", "that", "catalyzes", "the", "conversion", "of", "4-hydroxyphenylpyruvate", "to", "homogentisate", ".", "This", "reaction", "involves", "decarboxylation", ",", "substituent", "migration", "and", "aromatic", "oxygenation", "in", "a", "single", "catalytic", "cycle", ".", "HPPD", "is", "a", "member", "of", "the", "alpha", "-", "keto", "acid", "dependent", "oxygenases", "that", "typically", "require", "an", "alpha", "-", "keto", "acid", "(", "almost", "exclusively", "alpha", "-", "ketoglutarate", ")", "and", "molecular", "oxygen", "to", "either", "oxygenate", "or", "oxidize", "a", "third", "molecule", ".", "As", "an", "exception", "in", "this", "class", "of", "enzymes", "HPPD", "has", "only", "two", "substrates", ",", "does", "not", "use", "alpha", "-", "ketoglutarate", ",", "and", "incorporates", "both", "atoms", "of", "dioxygen", "into", "the", "aromatic", "product", ",", "homogentisate", ".", "The", "tertiary", "structure", "of", "the", "enzyme", "would", "suggest", "that", "its", "mechanism", "converged", "with", "that", "of", "other", "alpha", "-", "keto", "acid", "enzymes", "from", "an", "extradiol", "dioxygenase", "progenitor", ".", "The", "transformation", "catalyzed", "by", "HPPD", "has", "both", "agricultural", "and", "therapeutic", "significance", ".", "HPPD", "catalyzes", "the", "second", "step", "in", "the", "pathway", "for", "the", "catabolism", "of", "tyrosine", ",", "that", "is", "common", "to", "essentially", "all", "aerobic", "forms", "of", "life", ".", "In", "plants", "this", "pathway", "has", "an", "anabolic", "branch", "from", "homogentisate", "that", "forms", "essential", "isoprenoid", "redox", "cofactors", "such", "as", "plastoquinone", "and", "tocopherol", ".", "Naturally", "occurring", "multi", "-", "ketone", "molecules", "act", "as", "allelopathic", "agents", "by", "inhibiting", "HPPD", "and", "preventing", "the", "production", "of", "homogentisate", "and", "hence", "required", "redox", "cofactors", ".", "This", "has", "been", "the", "basis", "for", "the", "development", "of", "a", "range", "of", "very", "effective", "herbicides", "that", "are", "currently", "used", "commercially", ".", "In", "humans", ",", "deficiencies", "of", "specific", "enzymes", "of", "the", "tyrosine", "catabolism", "pathway", "give", "rise", "to", "a", "number", "of", "severe", "metabolic", "disorders", ".", "Interestingly", ",", "HPPD", "inhibitor", "/", "herbicide", "molecules", "act", "also", "as", "therapeutic", "agents", "for", "a", "number", "of", "debilitating", "and", "lethal", "inborn", "defects", "in", "tyrosine", "catabolism", "by", "preventing", "the", "accumulation", "of", "toxic", "metabolites", ".", "\n" ]

[ "Protein" ]

4-Hydroxyphenylpyruvate dioxygenase is a Protein, 4-Hydroxyphenylpyruvate dioxygenase is a Protein, HPPD is a Protein, HPPD is a Protein, HPPD is a Protein, HPPD is a Protein, HPPD is a Protein, HPPD is a Protein, HPPD is a Protein

141_task1

Sentence: 4-Hydroxyphenylpyruvate dioxygenase. 4-Hydroxyphenylpyruvate dioxygenase (HPPD) is an Fe(II)-dependent, non-heme oxygenase that catalyzes the conversion of 4-hydroxyphenylpyruvate to homogentisate. This reaction involves decarboxylation, substituent migration and aromatic oxygenation in a single catalytic cycle. HPPD is a member of the alpha-keto acid dependent oxygenases that typically require an alpha-keto acid (almost exclusively alpha-ketoglutarate) and molecular oxygen to either oxygenate or oxidize a third molecule. As an exception in this class of enzymes HPPD has only two substrates, does not use alpha-ketoglutarate, and incorporates both atoms of dioxygen into the aromatic product, homogentisate. The tertiary structure of the enzyme would suggest that its mechanism converged with that of other alpha-keto acid enzymes from an extradiol dioxygenase progenitor. The transformation catalyzed by HPPD has both agricultural and therapeutic significance. HPPD catalyzes the second step in the pathway for the catabolism of tyrosine, that is common to essentially all aerobic forms of life. In plants this pathway has an anabolic branch from homogentisate that forms essential isoprenoid redox cofactors such as plastoquinone and tocopherol. Naturally occurring multi-ketone molecules act as allelopathic agents by inhibiting HPPD and preventing the production of homogentisate and hence required redox cofactors. This has been the basis for the development of a range of very effective herbicides that are currently used commercially. In humans, deficiencies of specific enzymes of the tyrosine catabolism pathway give rise to a number of severe metabolic disorders. Interestingly, HPPD inhibitor/herbicide molecules act also as therapeutic agents for a number of debilitating and lethal inborn defects in tyrosine catabolism by preventing the accumulation of toxic metabolites. Instructions: please typing these entity words according to sentence: 4-Hydroxyphenylpyruvate dioxygenase, 4-Hydroxyphenylpyruvate dioxygenase, HPPD, HPPD, HPPD, HPPD, HPPD, HPPD, HPPD Options: Protein

[ "B-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

4-Hydroxyphenylpyruvate dioxygenase. 4-Hydroxyphenylpyruvate dioxygenase (HPPD) is an Fe(II)-dependent, non-heme oxygenase that catalyzes the conversion of 4-hydroxyphenylpyruvate to homogentisate. This reaction involves decarboxylation, substituent migration and aromatic oxygenation in a single catalytic cycle. HPPD is a member of the alpha-keto acid dependent oxygenases that typically require an alpha-keto acid (almost exclusively alpha-ketoglutarate) and molecular oxygen to either oxygenate or oxidize a third molecule. As an exception in this class of enzymes HPPD has only two substrates, does not use alpha-ketoglutarate, and incorporates both atoms of dioxygen into the aromatic product, homogentisate. The tertiary structure of the enzyme would suggest that its mechanism converged with that of other alpha-keto acid enzymes from an extradiol dioxygenase progenitor. The transformation catalyzed by HPPD has both agricultural and therapeutic significance. HPPD catalyzes the second step in the pathway for the catabolism of tyrosine, that is common to essentially all aerobic forms of life. In plants this pathway has an anabolic branch from homogentisate that forms essential isoprenoid redox cofactors such as plastoquinone and tocopherol. Naturally occurring multi-ketone molecules act as allelopathic agents by inhibiting HPPD and preventing the production of homogentisate and hence required redox cofactors. This has been the basis for the development of a range of very effective herbicides that are currently used commercially. In humans, deficiencies of specific enzymes of the tyrosine catabolism pathway give rise to a number of severe metabolic disorders. Interestingly, HPPD inhibitor/herbicide molecules act also as therapeutic agents for a number of debilitating and lethal inborn defects in tyrosine catabolism by preventing the accumulation of toxic metabolites.

[ "4-Hydroxyphenylpyruvate", "dioxygenase", ".", "\n", "4-Hydroxyphenylpyruvate", "dioxygenase", "(", "HPPD", ")", "is", "an", "Fe(II)-dependent", ",", "non", "-", "heme", "oxygenase", "that", "catalyzes", "the", "conversion", "of", "4-hydroxyphenylpyruvate", "to", "homogentisate", ".", "This", "reaction", "involves", "decarboxylation", ",", "substituent", "migration", "and", "aromatic", "oxygenation", "in", "a", "single", "catalytic", "cycle", ".", "HPPD", "is", "a", "member", "of", "the", "alpha", "-", "keto", "acid", "dependent", "oxygenases", "that", "typically", "require", "an", "alpha", "-", "keto", "acid", "(", "almost", "exclusively", "alpha", "-", "ketoglutarate", ")", "and", "molecular", "oxygen", "to", "either", "oxygenate", "or", "oxidize", "a", "third", "molecule", ".", "As", "an", "exception", "in", "this", "class", "of", "enzymes", "HPPD", "has", "only", "two", "substrates", ",", "does", "not", "use", "alpha", "-", "ketoglutarate", ",", "and", "incorporates", "both", "atoms", "of", "dioxygen", "into", "the", "aromatic", "product", ",", "homogentisate", ".", "The", "tertiary", "structure", "of", "the", "enzyme", "would", "suggest", "that", "its", "mechanism", "converged", "with", "that", "of", "other", "alpha", "-", "keto", "acid", "enzymes", "from", "an", "extradiol", "dioxygenase", "progenitor", ".", "The", "transformation", "catalyzed", "by", "HPPD", "has", "both", "agricultural", "and", "therapeutic", "significance", ".", "HPPD", "catalyzes", "the", "second", "step", "in", "the", "pathway", "for", "the", "catabolism", "of", "tyrosine", ",", "that", "is", "common", "to", "essentially", "all", "aerobic", "forms", "of", "life", ".", "In", "plants", "this", "pathway", "has", "an", "anabolic", "branch", "from", "homogentisate", "that", "forms", "essential", "isoprenoid", "redox", "cofactors", "such", "as", "plastoquinone", "and", "tocopherol", ".", "Naturally", "occurring", "multi", "-", "ketone", "molecules", "act", "as", "allelopathic", "agents", "by", "inhibiting", "HPPD", "and", "preventing", "the", "production", "of", "homogentisate", "and", "hence", "required", "redox", "cofactors", ".", "This", "has", "been", "the", "basis", "for", "the", "development", "of", "a", "range", "of", "very", "effective", "herbicides", "that", "are", "currently", "used", "commercially", ".", "In", "humans", ",", "deficiencies", "of", "specific", "enzymes", "of", "the", "tyrosine", "catabolism", "pathway", "give", "rise", "to", "a", "number", "of", "severe", "metabolic", "disorders", ".", "Interestingly", ",", "HPPD", "inhibitor", "/", "herbicide", "molecules", "act", "also", "as", "therapeutic", "agents", "for", "a", "number", "of", "debilitating", "and", "lethal", "inborn", "defects", "in", "tyrosine", "catabolism", "by", "preventing", "the", "accumulation", "of", "toxic", "metabolites", ".", "\n" ]

[ "Protein" ]

4-Hydroxyphenylpyruvate dioxygenase, 4-Hydroxyphenylpyruvate dioxygenase, HPPD, HPPD, HPPD, HPPD, HPPD, HPPD, HPPD

141_task2

Sentence: 4-Hydroxyphenylpyruvate dioxygenase. 4-Hydroxyphenylpyruvate dioxygenase (HPPD) is an Fe(II)-dependent, non-heme oxygenase that catalyzes the conversion of 4-hydroxyphenylpyruvate to homogentisate. This reaction involves decarboxylation, substituent migration and aromatic oxygenation in a single catalytic cycle. HPPD is a member of the alpha-keto acid dependent oxygenases that typically require an alpha-keto acid (almost exclusively alpha-ketoglutarate) and molecular oxygen to either oxygenate or oxidize a third molecule. As an exception in this class of enzymes HPPD has only two substrates, does not use alpha-ketoglutarate, and incorporates both atoms of dioxygen into the aromatic product, homogentisate. The tertiary structure of the enzyme would suggest that its mechanism converged with that of other alpha-keto acid enzymes from an extradiol dioxygenase progenitor. The transformation catalyzed by HPPD has both agricultural and therapeutic significance. HPPD catalyzes the second step in the pathway for the catabolism of tyrosine, that is common to essentially all aerobic forms of life. In plants this pathway has an anabolic branch from homogentisate that forms essential isoprenoid redox cofactors such as plastoquinone and tocopherol. Naturally occurring multi-ketone molecules act as allelopathic agents by inhibiting HPPD and preventing the production of homogentisate and hence required redox cofactors. This has been the basis for the development of a range of very effective herbicides that are currently used commercially. In humans, deficiencies of specific enzymes of the tyrosine catabolism pathway give rise to a number of severe metabolic disorders. Interestingly, HPPD inhibitor/herbicide molecules act also as therapeutic agents for a number of debilitating and lethal inborn defects in tyrosine catabolism by preventing the accumulation of toxic metabolites. Instructions: please extract entity words from the input sentence

[ "B-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

4-Hydroxyphenylpyruvate dioxygenase. 4-Hydroxyphenylpyruvate dioxygenase (HPPD) is an Fe(II)-dependent, non-heme oxygenase that catalyzes the conversion of 4-hydroxyphenylpyruvate to homogentisate. This reaction involves decarboxylation, substituent migration and aromatic oxygenation in a single catalytic cycle. HPPD is a member of the alpha-keto acid dependent oxygenases that typically require an alpha-keto acid (almost exclusively alpha-ketoglutarate) and molecular oxygen to either oxygenate or oxidize a third molecule. As an exception in this class of enzymes HPPD has only two substrates, does not use alpha-ketoglutarate, and incorporates both atoms of dioxygen into the aromatic product, homogentisate. The tertiary structure of the enzyme would suggest that its mechanism converged with that of other alpha-keto acid enzymes from an extradiol dioxygenase progenitor. The transformation catalyzed by HPPD has both agricultural and therapeutic significance. HPPD catalyzes the second step in the pathway for the catabolism of tyrosine, that is common to essentially all aerobic forms of life. In plants this pathway has an anabolic branch from homogentisate that forms essential isoprenoid redox cofactors such as plastoquinone and tocopherol. Naturally occurring multi-ketone molecules act as allelopathic agents by inhibiting HPPD and preventing the production of homogentisate and hence required redox cofactors. This has been the basis for the development of a range of very effective herbicides that are currently used commercially. In humans, deficiencies of specific enzymes of the tyrosine catabolism pathway give rise to a number of severe metabolic disorders. Interestingly, HPPD inhibitor/herbicide molecules act also as therapeutic agents for a number of debilitating and lethal inborn defects in tyrosine catabolism by preventing the accumulation of toxic metabolites.

[ "4-Hydroxyphenylpyruvate", "dioxygenase", ".", "\n", "4-Hydroxyphenylpyruvate", "dioxygenase", "(", "HPPD", ")", "is", "an", "Fe(II)-dependent", ",", "non", "-", "heme", "oxygenase", "that", "catalyzes", "the", "conversion", "of", "4-hydroxyphenylpyruvate", "to", "homogentisate", ".", "This", "reaction", "involves", "decarboxylation", ",", "substituent", "migration", "and", "aromatic", "oxygenation", "in", "a", "single", "catalytic", "cycle", ".", "HPPD", "is", "a", "member", "of", "the", "alpha", "-", "keto", "acid", "dependent", "oxygenases", "that", "typically", "require", "an", "alpha", "-", "keto", "acid", "(", "almost", "exclusively", "alpha", "-", "ketoglutarate", ")", "and", "molecular", "oxygen", "to", "either", "oxygenate", "or", "oxidize", "a", "third", "molecule", ".", "As", "an", "exception", "in", "this", "class", "of", "enzymes", "HPPD", "has", "only", "two", "substrates", ",", "does", "not", "use", "alpha", "-", "ketoglutarate", ",", "and", "incorporates", "both", "atoms", "of", "dioxygen", "into", "the", "aromatic", "product", ",", "homogentisate", ".", "The", "tertiary", "structure", "of", "the", "enzyme", "would", "suggest", "that", "its", "mechanism", "converged", "with", "that", "of", "other", "alpha", "-", "keto", "acid", "enzymes", "from", "an", "extradiol", "dioxygenase", "progenitor", ".", "The", "transformation", "catalyzed", "by", "HPPD", "has", "both", "agricultural", "and", "therapeutic", "significance", ".", "HPPD", "catalyzes", "the", "second", "step", "in", "the", "pathway", "for", "the", "catabolism", "of", "tyrosine", ",", "that", "is", "common", "to", "essentially", "all", "aerobic", "forms", "of", "life", ".", "In", "plants", "this", "pathway", "has", "an", "anabolic", "branch", "from", "homogentisate", "that", "forms", "essential", "isoprenoid", "redox", "cofactors", "such", "as", "plastoquinone", "and", "tocopherol", ".", "Naturally", "occurring", "multi", "-", "ketone", "molecules", "act", "as", "allelopathic", "agents", "by", "inhibiting", "HPPD", "and", "preventing", "the", "production", "of", "homogentisate", "and", "hence", "required", "redox", "cofactors", ".", "This", "has", "been", "the", "basis", "for", "the", "development", "of", "a", "range", "of", "very", "effective", "herbicides", "that", "are", "currently", "used", "commercially", ".", "In", "humans", ",", "deficiencies", "of", "specific", "enzymes", "of", "the", "tyrosine", "catabolism", "pathway", "give", "rise", "to", "a", "number", "of", "severe", "metabolic", "disorders", ".", "Interestingly", ",", "HPPD", "inhibitor", "/", "herbicide", "molecules", "act", "also", "as", "therapeutic", "agents", "for", "a", "number", "of", "debilitating", "and", "lethal", "inborn", "defects", "in", "tyrosine", "catabolism", "by", "preventing", "the", "accumulation", "of", "toxic", "metabolites", ".", "\n" ]

[ "Protein" ]

Diagnostik is an umlsterm, Interviewtechnik is an umlsterm, Selbsterleben is an umlsterm, Psychotherapiemotivation is an umlsterm, Diagnostik is an umlsterm, Erstinterview is an umlsterm

Psychotherapeut.60410297.ger.abstr_task0

Sentence: Auf der Grundlage der bisherigen Modelle zur psychodynamischen Diagnostik und der psychoanalytischen Interviewtechnik sowie den theoretischen Konzepten der fuenf Achsen der OPD-Diagnostik wird eine psychodynamisch-diagnostische Untersuchung konzeptualisiert . Die Untersuchung ist in fuenf Phasen strukturiert : Eroeffnung Ermittlung , von Beziehungsepisoden , von Selbsterleben , von Objekterleben und der Psychotherapiemotivation sowie Behandlungsvoraussetzungen und Einsichtsfaehigkeit . Die syndromale Diagnostik nach ICD 10 wird in einer abschliessenden Phase ermittelt . Die entwickelte psychodynamisch-diagnostische Untersuchung kann als Erstinterview oder auch in spaeteren Phasen eingesetzt werden . Sie wird ueber die OPD-Diagnostik hinaus auch zur klinischen Anwendung empfohlen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Auf der Grundlage der bisherigen Modelle zur psychodynamischen Diagnostik und der psychoanalytischen Interviewtechnik sowie den theoretischen Konzepten der fuenf Achsen der OPD-Diagnostik wird eine psychodynamisch-diagnostische Untersuchung konzeptualisiert . Die Untersuchung ist in fuenf Phasen strukturiert : Eroeffnung Ermittlung , von Beziehungsepisoden , von Selbsterleben , von Objekterleben und der Psychotherapiemotivation sowie Behandlungsvoraussetzungen und Einsichtsfaehigkeit . Die syndromale Diagnostik nach ICD 10 wird in einer abschliessenden Phase ermittelt . Die entwickelte psychodynamisch-diagnostische Untersuchung kann als Erstinterview oder auch in spaeteren Phasen eingesetzt werden . Sie wird ueber die OPD-Diagnostik hinaus auch zur klinischen Anwendung empfohlen .

[ "Auf", "der", "Grundlage", "der", "bisherigen", "Modelle", "zur", "psychodynamischen", "Diagnostik", "und", "der", "psychoanalytischen", "Interviewtechnik", "sowie", "den", "theoretischen", "Konzepten", "der", "fuenf", "Achsen", "der", "OPD", "-", "Diagnostik", "wird", "eine", "psychodynamisch", "-", "diagnostische", "Untersuchung", "konzeptualisiert", ".", "Die", "Untersuchung", "ist", "in", "fuenf", "Phasen", "strukturiert", ":", "Eroeffnung", "Ermittlung", ",", "von", "Beziehungsepisoden", ",", "von", "Selbsterleben", ",", "von", "Objekterleben", "und", "der", "Psychotherapiemotivation", "sowie", "Behandlungsvoraussetzungen", "und", "Einsichtsfaehigkeit", ".", "Die", "syndromale", "Diagnostik", "nach", "ICD", "10", "wird", "in", "einer", "abschliessenden", "Phase", "ermittelt", ".", "Die", "entwickelte", "psychodynamisch", "-", "diagnostische", "Untersuchung", "kann", "als", "Erstinterview", "oder", "auch", "in", "spaeteren", "Phasen", "eingesetzt", "werden", ".", "Sie", "wird", "ueber", "die", "OPD", "-", "Diagnostik", "hinaus", "auch", "zur", "klinischen", "Anwendung", "empfohlen", "." ]

[ "umlsterm" ]

Diagnostik is an umlsterm, Interviewtechnik is an umlsterm, Selbsterleben is an umlsterm, Psychotherapiemotivation is an umlsterm, Diagnostik is an umlsterm, Erstinterview is an umlsterm

Psychotherapeut.60410297.ger.abstr_task1

Sentence: Auf der Grundlage der bisherigen Modelle zur psychodynamischen Diagnostik und der psychoanalytischen Interviewtechnik sowie den theoretischen Konzepten der fuenf Achsen der OPD-Diagnostik wird eine psychodynamisch-diagnostische Untersuchung konzeptualisiert . Die Untersuchung ist in fuenf Phasen strukturiert : Eroeffnung Ermittlung , von Beziehungsepisoden , von Selbsterleben , von Objekterleben und der Psychotherapiemotivation sowie Behandlungsvoraussetzungen und Einsichtsfaehigkeit . Die syndromale Diagnostik nach ICD 10 wird in einer abschliessenden Phase ermittelt . Die entwickelte psychodynamisch-diagnostische Untersuchung kann als Erstinterview oder auch in spaeteren Phasen eingesetzt werden . Sie wird ueber die OPD-Diagnostik hinaus auch zur klinischen Anwendung empfohlen . Instructions: please typing these entity words according to sentence: Diagnostik, Interviewtechnik, Selbsterleben, Psychotherapiemotivation, Diagnostik, Erstinterview Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Auf der Grundlage der bisherigen Modelle zur psychodynamischen Diagnostik und der psychoanalytischen Interviewtechnik sowie den theoretischen Konzepten der fuenf Achsen der OPD-Diagnostik wird eine psychodynamisch-diagnostische Untersuchung konzeptualisiert . Die Untersuchung ist in fuenf Phasen strukturiert : Eroeffnung Ermittlung , von Beziehungsepisoden , von Selbsterleben , von Objekterleben und der Psychotherapiemotivation sowie Behandlungsvoraussetzungen und Einsichtsfaehigkeit . Die syndromale Diagnostik nach ICD 10 wird in einer abschliessenden Phase ermittelt . Die entwickelte psychodynamisch-diagnostische Untersuchung kann als Erstinterview oder auch in spaeteren Phasen eingesetzt werden . Sie wird ueber die OPD-Diagnostik hinaus auch zur klinischen Anwendung empfohlen .

[ "Auf", "der", "Grundlage", "der", "bisherigen", "Modelle", "zur", "psychodynamischen", "Diagnostik", "und", "der", "psychoanalytischen", "Interviewtechnik", "sowie", "den", "theoretischen", "Konzepten", "der", "fuenf", "Achsen", "der", "OPD", "-", "Diagnostik", "wird", "eine", "psychodynamisch", "-", "diagnostische", "Untersuchung", "konzeptualisiert", ".", "Die", "Untersuchung", "ist", "in", "fuenf", "Phasen", "strukturiert", ":", "Eroeffnung", "Ermittlung", ",", "von", "Beziehungsepisoden", ",", "von", "Selbsterleben", ",", "von", "Objekterleben", "und", "der", "Psychotherapiemotivation", "sowie", "Behandlungsvoraussetzungen", "und", "Einsichtsfaehigkeit", ".", "Die", "syndromale", "Diagnostik", "nach", "ICD", "10", "wird", "in", "einer", "abschliessenden", "Phase", "ermittelt", ".", "Die", "entwickelte", "psychodynamisch", "-", "diagnostische", "Untersuchung", "kann", "als", "Erstinterview", "oder", "auch", "in", "spaeteren", "Phasen", "eingesetzt", "werden", ".", "Sie", "wird", "ueber", "die", "OPD", "-", "Diagnostik", "hinaus", "auch", "zur", "klinischen", "Anwendung", "empfohlen", "." ]

[ "umlsterm" ]

Diagnostik, Interviewtechnik, Selbsterleben, Psychotherapiemotivation, Diagnostik, Erstinterview

Psychotherapeut.60410297.ger.abstr_task2

Sentence: Auf der Grundlage der bisherigen Modelle zur psychodynamischen Diagnostik und der psychoanalytischen Interviewtechnik sowie den theoretischen Konzepten der fuenf Achsen der OPD-Diagnostik wird eine psychodynamisch-diagnostische Untersuchung konzeptualisiert . Die Untersuchung ist in fuenf Phasen strukturiert : Eroeffnung Ermittlung , von Beziehungsepisoden , von Selbsterleben , von Objekterleben und der Psychotherapiemotivation sowie Behandlungsvoraussetzungen und Einsichtsfaehigkeit . Die syndromale Diagnostik nach ICD 10 wird in einer abschliessenden Phase ermittelt . Die entwickelte psychodynamisch-diagnostische Untersuchung kann als Erstinterview oder auch in spaeteren Phasen eingesetzt werden . Sie wird ueber die OPD-Diagnostik hinaus auch zur klinischen Anwendung empfohlen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Auf der Grundlage der bisherigen Modelle zur psychodynamischen Diagnostik und der psychoanalytischen Interviewtechnik sowie den theoretischen Konzepten der fuenf Achsen der OPD-Diagnostik wird eine psychodynamisch-diagnostische Untersuchung konzeptualisiert . Die Untersuchung ist in fuenf Phasen strukturiert : Eroeffnung Ermittlung , von Beziehungsepisoden , von Selbsterleben , von Objekterleben und der Psychotherapiemotivation sowie Behandlungsvoraussetzungen und Einsichtsfaehigkeit . Die syndromale Diagnostik nach ICD 10 wird in einer abschliessenden Phase ermittelt . Die entwickelte psychodynamisch-diagnostische Untersuchung kann als Erstinterview oder auch in spaeteren Phasen eingesetzt werden . Sie wird ueber die OPD-Diagnostik hinaus auch zur klinischen Anwendung empfohlen .

[ "Auf", "der", "Grundlage", "der", "bisherigen", "Modelle", "zur", "psychodynamischen", "Diagnostik", "und", "der", "psychoanalytischen", "Interviewtechnik", "sowie", "den", "theoretischen", "Konzepten", "der", "fuenf", "Achsen", "der", "OPD", "-", "Diagnostik", "wird", "eine", "psychodynamisch", "-", "diagnostische", "Untersuchung", "konzeptualisiert", ".", "Die", "Untersuchung", "ist", "in", "fuenf", "Phasen", "strukturiert", ":", "Eroeffnung", "Ermittlung", ",", "von", "Beziehungsepisoden", ",", "von", "Selbsterleben", ",", "von", "Objekterleben", "und", "der", "Psychotherapiemotivation", "sowie", "Behandlungsvoraussetzungen", "und", "Einsichtsfaehigkeit", ".", "Die", "syndromale", "Diagnostik", "nach", "ICD", "10", "wird", "in", "einer", "abschliessenden", "Phase", "ermittelt", ".", "Die", "entwickelte", "psychodynamisch", "-", "diagnostische", "Untersuchung", "kann", "als", "Erstinterview", "oder", "auch", "in", "spaeteren", "Phasen", "eingesetzt", "werden", ".", "Sie", "wird", "ueber", "die", "OPD", "-", "Diagnostik", "hinaus", "auch", "zur", "klinischen", "Anwendung", "empfohlen", "." ]

[ "umlsterm" ]

B - domain deleted recombinant factor VIII preparations is a Intervention_Pharmacological, bioequivalent is a Outcome_Other, BDDrFVIII formulations ( one reconstituted with 5 mL of sterile water , the other reconstituted with 4 mL sodium chloride 0.9 % USP ) is a Intervention_Pharmacological, full - length FVIII preparation ( Hemofil M ) is a Intervention_Control, haemophilia A is a Participant_Condition, blood samples is a Outcome_Physical, FVIII preparations is a Intervention_Pharmacological, Plasma FVIII activity is a Outcome_Physical, time curves is a Outcome_Other, maximum plasma concentration ( Cmax ) and the area under plasma concentration vs . time curves ( AUCs is a Outcome_Physical, ratio of geometric means for Cmax and AUCs is a Outcome_Physical

21167_task0

Sentence: B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate : a randomized , three-way crossover study . BACKGROUND Deletion of the B-domain of recombinant blood coagulation factor VIII ( BDDrFVIII ) increases the manufacturing yield of the product but does not impair in vitro or in vivo functionality . BDDrFVIII ( ReFacto ) has been developed with the additional benefit of being formulated without human albumin . OBJECTIVE The primary objective of this three-way crossover-design study was to compare the pharmacokinetic ( PK ) parameters of two BDDrFVIII formulations ( one reconstituted with 5 mL of sterile water , the other reconstituted with 4 mL sodium chloride 0.9 % USP ) with those of a plasma-derived , full-length FVIII preparation ( Hemofil M ) in patients with haemophilia A to determine bioequivalence . METHODS A series of blood samples were collected over a period of 48 h after i.v . administration of each of the FVIII preparations . Plasma FVIII activity was determined using a validated chromogenic substrate assay . Plasma FVIII activity vs. time curves was characterized for a standard set of PK parameter estimates . Two parameter estimates , the maximum plasma concentration ( Cmax ) and the area under plasma concentration vs. time curves ( AUCs ) , were used to evaluate bioequivalence . The two preparations were considered bioequivalent if the 90 % confidence intervals for the ratio of geometric means for Cmax and AUCs fell within the bioequivalence window of 80 % to 125 % . RESULTS/CONCLUSION Results show that each BDDrFVIII formulation is bioequivalent to Hemofil M and the two formulations of BDDrFVIII are bioequivalent to each other . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Outcome_Other

[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate : a randomized , three-way crossover study . BACKGROUND Deletion of the B-domain of recombinant blood coagulation factor VIII ( BDDrFVIII ) increases the manufacturing yield of the product but does not impair in vitro or in vivo functionality . BDDrFVIII ( ReFacto ) has been developed with the additional benefit of being formulated without human albumin . OBJECTIVE The primary objective of this three-way crossover-design study was to compare the pharmacokinetic ( PK ) parameters of two BDDrFVIII formulations ( one reconstituted with 5 mL of sterile water , the other reconstituted with 4 mL sodium chloride 0.9 % USP ) with those of a plasma-derived , full-length FVIII preparation ( Hemofil M ) in patients with haemophilia A to determine bioequivalence . METHODS A series of blood samples were collected over a period of 48 h after i.v . administration of each of the FVIII preparations . Plasma FVIII activity was determined using a validated chromogenic substrate assay . Plasma FVIII activity vs. time curves was characterized for a standard set of PK parameter estimates . Two parameter estimates , the maximum plasma concentration ( Cmax ) and the area under plasma concentration vs. time curves ( AUCs ) , were used to evaluate bioequivalence . The two preparations were considered bioequivalent if the 90 % confidence intervals for the ratio of geometric means for Cmax and AUCs fell within the bioequivalence window of 80 % to 125 % . RESULTS/CONCLUSION Results show that each BDDrFVIII formulation is bioequivalent to Hemofil M and the two formulations of BDDrFVIII are bioequivalent to each other .

[ "B", "-", "domain", "deleted", "recombinant", "factor", "VIII", "preparations", "are", "bioequivalent", "to", "a", "monoclonal", "antibody", "purified", "plasma", "-", "derived", "factor", "VIII", "concentrate", ":", "a", "randomized", ",", "three", "-", "way", "crossover", "study", ".", "BACKGROUND", "Deletion", "of", "the", "B", "-", "domain", "of", "recombinant", "blood", "coagulation", "factor", "VIII", "(", "BDDrFVIII", ")", "increases", "the", "manufacturing", "yield", "of", "the", "product", "but", "does", "not", "impair", "in", "vitro", "or", "in", "vivo", "functionality", ".", "BDDrFVIII", "(", "ReFacto", ")", "has", "been", "developed", "with", "the", "additional", "benefit", "of", "being", "formulated", "without", "human", "albumin", ".", "OBJECTIVE", "The", "primary", "objective", "of", "this", "three", "-", "way", "crossover", "-", "design", "study", "was", "to", "compare", "the", "pharmacokinetic", "(", "PK", ")", "parameters", "of", "two", "BDDrFVIII", "formulations", "(", "one", "reconstituted", "with", "5", "mL", "of", "sterile", "water", ",", "the", "other", "reconstituted", "with", "4", "mL", "sodium", "chloride", "0.9", "%", "USP", ")", "with", "those", "of", "a", "plasma", "-", "derived", ",", "full", "-", "length", "FVIII", "preparation", "(", "Hemofil", "M", ")", "in", "patients", "with", "haemophilia", "A", "to", "determine", "bioequivalence", ".", "METHODS", "A", "series", "of", "blood", "samples", "were", "collected", "over", "a", "period", "of", "48", "h", "after", "i.v", ".", "administration", "of", "each", "of", "the", "FVIII", "preparations", ".", "Plasma", "FVIII", "activity", "was", "determined", "using", "a", "validated", "chromogenic", "substrate", "assay", ".", "Plasma", "FVIII", "activity", "vs", ".", "time", "curves", "was", "characterized", "for", "a", "standard", "set", "of", "PK", "parameter", "estimates", ".", "Two", "parameter", "estimates", ",", "the", "maximum", "plasma", "concentration", "(", "Cmax", ")", "and", "the", "area", "under", "plasma", "concentration", "vs", ".", "time", "curves", "(", "AUCs", ")", ",", "were", "used", "to", "evaluate", "bioequivalence", ".", "The", "two", "preparations", "were", "considered", "bioequivalent", "if", "the", "90", "%", "confidence", "intervals", "for", "the", "ratio", "of", "geometric", "means", "for", "Cmax", "and", "AUCs", "fell", "within", "the", "bioequivalence", "window", "of", "80", "%", "to", "125", "%", ".", "RESULTS", "/", "CONCLUSION", "Results", "show", "that", "each", "BDDrFVIII", "formulation", "is", "bioequivalent", "to", "Hemofil", "M", "and", "the", "two", "formulations", "of", "BDDrFVIII", "are", "bioequivalent", "to", "each", "other", "." ]

[ "Intervention_Pharmacological", "Outcome_Physical", "Intervention_Control", "Outcome_Other", "Participant_Condition" ]

B - domain deleted recombinant factor VIII preparations is a Intervention_Pharmacological, bioequivalent is a Outcome_Other, BDDrFVIII formulations ( one reconstituted with 5 mL of sterile water , the other reconstituted with 4 mL sodium chloride 0.9 % USP ) is a Intervention_Pharmacological, full - length FVIII preparation ( Hemofil M ) is a Intervention_Control, haemophilia A is a Participant_Condition, blood samples is a Outcome_Physical, FVIII preparations is a Intervention_Pharmacological, Plasma FVIII activity is a Outcome_Physical, time curves is a Outcome_Other, maximum plasma concentration ( Cmax ) and the area under plasma concentration vs . time curves ( AUCs is a Outcome_Physical, ratio of geometric means for Cmax and AUCs is a Outcome_Physical

21167_task1

Sentence: B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate : a randomized , three-way crossover study . BACKGROUND Deletion of the B-domain of recombinant blood coagulation factor VIII ( BDDrFVIII ) increases the manufacturing yield of the product but does not impair in vitro or in vivo functionality . BDDrFVIII ( ReFacto ) has been developed with the additional benefit of being formulated without human albumin . OBJECTIVE The primary objective of this three-way crossover-design study was to compare the pharmacokinetic ( PK ) parameters of two BDDrFVIII formulations ( one reconstituted with 5 mL of sterile water , the other reconstituted with 4 mL sodium chloride 0.9 % USP ) with those of a plasma-derived , full-length FVIII preparation ( Hemofil M ) in patients with haemophilia A to determine bioequivalence . METHODS A series of blood samples were collected over a period of 48 h after i.v . administration of each of the FVIII preparations . Plasma FVIII activity was determined using a validated chromogenic substrate assay . Plasma FVIII activity vs. time curves was characterized for a standard set of PK parameter estimates . Two parameter estimates , the maximum plasma concentration ( Cmax ) and the area under plasma concentration vs. time curves ( AUCs ) , were used to evaluate bioequivalence . The two preparations were considered bioequivalent if the 90 % confidence intervals for the ratio of geometric means for Cmax and AUCs fell within the bioequivalence window of 80 % to 125 % . RESULTS/CONCLUSION Results show that each BDDrFVIII formulation is bioequivalent to Hemofil M and the two formulations of BDDrFVIII are bioequivalent to each other . Instructions: please typing these entity words according to sentence: B - domain deleted recombinant factor VIII preparations, bioequivalent, BDDrFVIII formulations ( one reconstituted with 5 mL of sterile water , the other reconstituted with 4 mL sodium chloride 0.9 % USP ), full - length FVIII preparation ( Hemofil M ), haemophilia A, blood samples, FVIII preparations, Plasma FVIII activity, time curves, maximum plasma concentration ( Cmax ) and the area under plasma concentration vs . time curves ( AUCs, ratio of geometric means for Cmax and AUCs Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Outcome_Other

[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate : a randomized , three-way crossover study . BACKGROUND Deletion of the B-domain of recombinant blood coagulation factor VIII ( BDDrFVIII ) increases the manufacturing yield of the product but does not impair in vitro or in vivo functionality . BDDrFVIII ( ReFacto ) has been developed with the additional benefit of being formulated without human albumin . OBJECTIVE The primary objective of this three-way crossover-design study was to compare the pharmacokinetic ( PK ) parameters of two BDDrFVIII formulations ( one reconstituted with 5 mL of sterile water , the other reconstituted with 4 mL sodium chloride 0.9 % USP ) with those of a plasma-derived , full-length FVIII preparation ( Hemofil M ) in patients with haemophilia A to determine bioequivalence . METHODS A series of blood samples were collected over a period of 48 h after i.v . administration of each of the FVIII preparations . Plasma FVIII activity was determined using a validated chromogenic substrate assay . Plasma FVIII activity vs. time curves was characterized for a standard set of PK parameter estimates . Two parameter estimates , the maximum plasma concentration ( Cmax ) and the area under plasma concentration vs. time curves ( AUCs ) , were used to evaluate bioequivalence . The two preparations were considered bioequivalent if the 90 % confidence intervals for the ratio of geometric means for Cmax and AUCs fell within the bioequivalence window of 80 % to 125 % . RESULTS/CONCLUSION Results show that each BDDrFVIII formulation is bioequivalent to Hemofil M and the two formulations of BDDrFVIII are bioequivalent to each other .

[ "B", "-", "domain", "deleted", "recombinant", "factor", "VIII", "preparations", "are", "bioequivalent", "to", "a", "monoclonal", "antibody", "purified", "plasma", "-", "derived", "factor", "VIII", "concentrate", ":", "a", "randomized", ",", "three", "-", "way", "crossover", "study", ".", "BACKGROUND", "Deletion", "of", "the", "B", "-", "domain", "of", "recombinant", "blood", "coagulation", "factor", "VIII", "(", "BDDrFVIII", ")", "increases", "the", "manufacturing", "yield", "of", "the", "product", "but", "does", "not", "impair", "in", "vitro", "or", "in", "vivo", "functionality", ".", "BDDrFVIII", "(", "ReFacto", ")", "has", "been", "developed", "with", "the", "additional", "benefit", "of", "being", "formulated", "without", "human", "albumin", ".", "OBJECTIVE", "The", "primary", "objective", "of", "this", "three", "-", "way", "crossover", "-", "design", "study", "was", "to", "compare", "the", "pharmacokinetic", "(", "PK", ")", "parameters", "of", "two", "BDDrFVIII", "formulations", "(", "one", "reconstituted", "with", "5", "mL", "of", "sterile", "water", ",", "the", "other", "reconstituted", "with", "4", "mL", "sodium", "chloride", "0.9", "%", "USP", ")", "with", "those", "of", "a", "plasma", "-", "derived", ",", "full", "-", "length", "FVIII", "preparation", "(", "Hemofil", "M", ")", "in", "patients", "with", "haemophilia", "A", "to", "determine", "bioequivalence", ".", "METHODS", "A", "series", "of", "blood", "samples", "were", "collected", "over", "a", "period", "of", "48", "h", "after", "i.v", ".", "administration", "of", "each", "of", "the", "FVIII", "preparations", ".", "Plasma", "FVIII", "activity", "was", "determined", "using", "a", "validated", "chromogenic", "substrate", "assay", ".", "Plasma", "FVIII", "activity", "vs", ".", "time", "curves", "was", "characterized", "for", "a", "standard", "set", "of", "PK", "parameter", "estimates", ".", "Two", "parameter", "estimates", ",", "the", "maximum", "plasma", "concentration", "(", "Cmax", ")", "and", "the", "area", "under", "plasma", "concentration", "vs", ".", "time", "curves", "(", "AUCs", ")", ",", "were", "used", "to", "evaluate", "bioequivalence", ".", "The", "two", "preparations", "were", "considered", "bioequivalent", "if", "the", "90", "%", "confidence", "intervals", "for", "the", "ratio", "of", "geometric", "means", "for", "Cmax", "and", "AUCs", "fell", "within", "the", "bioequivalence", "window", "of", "80", "%", "to", "125", "%", ".", "RESULTS", "/", "CONCLUSION", "Results", "show", "that", "each", "BDDrFVIII", "formulation", "is", "bioequivalent", "to", "Hemofil", "M", "and", "the", "two", "formulations", "of", "BDDrFVIII", "are", "bioequivalent", "to", "each", "other", "." ]

[ "Intervention_Pharmacological", "Outcome_Physical", "Intervention_Control", "Outcome_Other", "Participant_Condition" ]

B - domain deleted recombinant factor VIII preparations, bioequivalent, BDDrFVIII formulations ( one reconstituted with 5 mL of sterile water , the other reconstituted with 4 mL sodium chloride 0.9 % USP ), full - length FVIII preparation ( Hemofil M ), haemophilia A, blood samples, FVIII preparations, Plasma FVIII activity, time curves, maximum plasma concentration ( Cmax ) and the area under plasma concentration vs . time curves ( AUCs, ratio of geometric means for Cmax and AUCs

21167_task2

Sentence: B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate : a randomized , three-way crossover study . BACKGROUND Deletion of the B-domain of recombinant blood coagulation factor VIII ( BDDrFVIII ) increases the manufacturing yield of the product but does not impair in vitro or in vivo functionality . BDDrFVIII ( ReFacto ) has been developed with the additional benefit of being formulated without human albumin . OBJECTIVE The primary objective of this three-way crossover-design study was to compare the pharmacokinetic ( PK ) parameters of two BDDrFVIII formulations ( one reconstituted with 5 mL of sterile water , the other reconstituted with 4 mL sodium chloride 0.9 % USP ) with those of a plasma-derived , full-length FVIII preparation ( Hemofil M ) in patients with haemophilia A to determine bioequivalence . METHODS A series of blood samples were collected over a period of 48 h after i.v . administration of each of the FVIII preparations . Plasma FVIII activity was determined using a validated chromogenic substrate assay . Plasma FVIII activity vs. time curves was characterized for a standard set of PK parameter estimates . Two parameter estimates , the maximum plasma concentration ( Cmax ) and the area under plasma concentration vs. time curves ( AUCs ) , were used to evaluate bioequivalence . The two preparations were considered bioequivalent if the 90 % confidence intervals for the ratio of geometric means for Cmax and AUCs fell within the bioequivalence window of 80 % to 125 % . RESULTS/CONCLUSION Results show that each BDDrFVIII formulation is bioequivalent to Hemofil M and the two formulations of BDDrFVIII are bioequivalent to each other . Instructions: please extract entity words from the input sentence

[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate : a randomized , three-way crossover study . BACKGROUND Deletion of the B-domain of recombinant blood coagulation factor VIII ( BDDrFVIII ) increases the manufacturing yield of the product but does not impair in vitro or in vivo functionality . BDDrFVIII ( ReFacto ) has been developed with the additional benefit of being formulated without human albumin . OBJECTIVE The primary objective of this three-way crossover-design study was to compare the pharmacokinetic ( PK ) parameters of two BDDrFVIII formulations ( one reconstituted with 5 mL of sterile water , the other reconstituted with 4 mL sodium chloride 0.9 % USP ) with those of a plasma-derived , full-length FVIII preparation ( Hemofil M ) in patients with haemophilia A to determine bioequivalence . METHODS A series of blood samples were collected over a period of 48 h after i.v . administration of each of the FVIII preparations . Plasma FVIII activity was determined using a validated chromogenic substrate assay . Plasma FVIII activity vs. time curves was characterized for a standard set of PK parameter estimates . Two parameter estimates , the maximum plasma concentration ( Cmax ) and the area under plasma concentration vs. time curves ( AUCs ) , were used to evaluate bioequivalence . The two preparations were considered bioequivalent if the 90 % confidence intervals for the ratio of geometric means for Cmax and AUCs fell within the bioequivalence window of 80 % to 125 % . RESULTS/CONCLUSION Results show that each BDDrFVIII formulation is bioequivalent to Hemofil M and the two formulations of BDDrFVIII are bioequivalent to each other .

[ "B", "-", "domain", "deleted", "recombinant", "factor", "VIII", "preparations", "are", "bioequivalent", "to", "a", "monoclonal", "antibody", "purified", "plasma", "-", "derived", "factor", "VIII", "concentrate", ":", "a", "randomized", ",", "three", "-", "way", "crossover", "study", ".", "BACKGROUND", "Deletion", "of", "the", "B", "-", "domain", "of", "recombinant", "blood", "coagulation", "factor", "VIII", "(", "BDDrFVIII", ")", "increases", "the", "manufacturing", "yield", "of", "the", "product", "but", "does", "not", "impair", "in", "vitro", "or", "in", "vivo", "functionality", ".", "BDDrFVIII", "(", "ReFacto", ")", "has", "been", "developed", "with", "the", "additional", "benefit", "of", "being", "formulated", "without", "human", "albumin", ".", "OBJECTIVE", "The", "primary", "objective", "of", "this", "three", "-", "way", "crossover", "-", "design", "study", "was", "to", "compare", "the", "pharmacokinetic", "(", "PK", ")", "parameters", "of", "two", "BDDrFVIII", "formulations", "(", "one", "reconstituted", "with", "5", "mL", "of", "sterile", "water", ",", "the", "other", "reconstituted", "with", "4", "mL", "sodium", "chloride", "0.9", "%", "USP", ")", "with", "those", "of", "a", "plasma", "-", "derived", ",", "full", "-", "length", "FVIII", "preparation", "(", "Hemofil", "M", ")", "in", "patients", "with", "haemophilia", "A", "to", "determine", "bioequivalence", ".", "METHODS", "A", "series", "of", "blood", "samples", "were", "collected", "over", "a", "period", "of", "48", "h", "after", "i.v", ".", "administration", "of", "each", "of", "the", "FVIII", "preparations", ".", "Plasma", "FVIII", "activity", "was", "determined", "using", "a", "validated", "chromogenic", "substrate", "assay", ".", "Plasma", "FVIII", "activity", "vs", ".", "time", "curves", "was", "characterized", "for", "a", "standard", "set", "of", "PK", "parameter", "estimates", ".", "Two", "parameter", "estimates", ",", "the", "maximum", "plasma", "concentration", "(", "Cmax", ")", "and", "the", "area", "under", "plasma", "concentration", "vs", ".", "time", "curves", "(", "AUCs", ")", ",", "were", "used", "to", "evaluate", "bioequivalence", ".", "The", "two", "preparations", "were", "considered", "bioequivalent", "if", "the", "90", "%", "confidence", "intervals", "for", "the", "ratio", "of", "geometric", "means", "for", "Cmax", "and", "AUCs", "fell", "within", "the", "bioequivalence", "window", "of", "80", "%", "to", "125", "%", ".", "RESULTS", "/", "CONCLUSION", "Results", "show", "that", "each", "BDDrFVIII", "formulation", "is", "bioequivalent", "to", "Hemofil", "M", "and", "the", "two", "formulations", "of", "BDDrFVIII", "are", "bioequivalent", "to", "each", "other", "." ]

[ "Intervention_Pharmacological", "Outcome_Physical", "Intervention_Control", "Outcome_Other", "Participant_Condition" ]

E - cadherin is a Individual_protein, alpha - catenin is a Individual_protein, beta - catenin is a Individual_protein

133_task0

Sentence: These results suggest that the dysfunction of E-cadherin in these cell lines is due primarily to its failure to interact with alpha-catenin, and that this defect results from the mutation in beta-catenin. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein

[ "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O" ]

These results suggest that the dysfunction of E-cadherin in these cell lines is due primarily to its failure to interact with alpha-catenin, and that this defect results from the mutation in beta-catenin.

[ "These", "results", "suggest", "that", "the", "dysfunction", "of", "E", "-", "cadherin", "in", "these", "cell", "lines", "is", "due", "primarily", "to", "its", "failure", "to", "interact", "with", "alpha", "-", "catenin", ",", "and", "that", "this", "defect", "results", "from", "the", "mutation", "in", "beta", "-", "catenin", "." ]

[ "Individual_protein" ]

E - cadherin is a Individual_protein, alpha - catenin is a Individual_protein, beta - catenin is a Individual_protein

133_task1

Sentence: These results suggest that the dysfunction of E-cadherin in these cell lines is due primarily to its failure to interact with alpha-catenin, and that this defect results from the mutation in beta-catenin. Instructions: please typing these entity words according to sentence: E - cadherin, alpha - catenin, beta - catenin Options: Individual_protein

[ "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O" ]

These results suggest that the dysfunction of E-cadherin in these cell lines is due primarily to its failure to interact with alpha-catenin, and that this defect results from the mutation in beta-catenin.

[ "These", "results", "suggest", "that", "the", "dysfunction", "of", "E", "-", "cadherin", "in", "these", "cell", "lines", "is", "due", "primarily", "to", "its", "failure", "to", "interact", "with", "alpha", "-", "catenin", ",", "and", "that", "this", "defect", "results", "from", "the", "mutation", "in", "beta", "-", "catenin", "." ]

[ "Individual_protein" ]

E - cadherin, alpha - catenin, beta - catenin

133_task2

Sentence: These results suggest that the dysfunction of E-cadherin in these cell lines is due primarily to its failure to interact with alpha-catenin, and that this defect results from the mutation in beta-catenin. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O" ]

These results suggest that the dysfunction of E-cadherin in these cell lines is due primarily to its failure to interact with alpha-catenin, and that this defect results from the mutation in beta-catenin.

[ "These", "results", "suggest", "that", "the", "dysfunction", "of", "E", "-", "cadherin", "in", "these", "cell", "lines", "is", "due", "primarily", "to", "its", "failure", "to", "interact", "with", "alpha", "-", "catenin", ",", "and", "that", "this", "defect", "results", "from", "the", "mutation", "in", "beta", "-", "catenin", "." ]

[ "Individual_protein" ]

Stat3 is a protein_molecule, ligand - induced , tyrosine - phosphorylated docking sites is a protein_domain_or_region, interleukin-10 receptor intracellular domain is a protein_domain_or_region

20598_task0

Sentence: Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein_domain_or_region, protein_molecule

[ "B-protein_molecule", "O", "O", "O", "O", "B-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "O", "O", "B-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "O" ]

Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain.

[ "Stat3", "recruitment", "by", "two", "distinct", "ligand", "-", "induced", ",", "tyrosine", "-", "phosphorylated", "docking", "sites", "in", "the", "interleukin-10", "receptor", "intracellular", "domain", "." ]

[ "protein_molecule", "protein_domain_or_region", "other_name", "peptide", "protein_complex", "protein_family_or_group", "amino_acid_monomer", "cell_line" ]

Stat3 is a protein_molecule, ligand - induced , tyrosine - phosphorylated docking sites is a protein_domain_or_region, interleukin-10 receptor intracellular domain is a protein_domain_or_region

20598_task1

Sentence: Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. Instructions: please typing these entity words according to sentence: Stat3, ligand - induced , tyrosine - phosphorylated docking sites, interleukin-10 receptor intracellular domain Options: protein_domain_or_region, protein_molecule

[ "B-protein_molecule", "O", "O", "O", "O", "B-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "O", "O", "B-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "O" ]

Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain.

[ "Stat3", "recruitment", "by", "two", "distinct", "ligand", "-", "induced", ",", "tyrosine", "-", "phosphorylated", "docking", "sites", "in", "the", "interleukin-10", "receptor", "intracellular", "domain", "." ]

[ "protein_molecule", "protein_domain_or_region", "other_name", "peptide", "protein_complex", "protein_family_or_group", "amino_acid_monomer", "cell_line" ]

Stat3, ligand - induced , tyrosine - phosphorylated docking sites, interleukin-10 receptor intracellular domain

20598_task2

Sentence: Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. Instructions: please extract entity words from the input sentence

[ "B-protein_molecule", "O", "O", "O", "O", "B-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "O", "O", "B-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "O" ]

Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain.

[ "Stat3", "recruitment", "by", "two", "distinct", "ligand", "-", "induced", ",", "tyrosine", "-", "phosphorylated", "docking", "sites", "in", "the", "interleukin-10", "receptor", "intracellular", "domain", "." ]

[ "protein_molecule", "protein_domain_or_region", "other_name", "peptide", "protein_complex", "protein_family_or_group", "amino_acid_monomer", "cell_line" ]